GENETIC SYSTEMS THAT DEFEND AGAINST FOREIGN DNA

AND USES THEREOF

SEQUENCE LISTING STATEMENT

[001] The instant application contains a "lengthy" Sequence Listing which has been submitted via CD-R in lieu of a printed paper copy, and is hereby incorporated by reference in its entirety. Said CD-R, recorded on May 15, 2018, are labeled "CRF", "COPY 1 - SEQUENCE LISTING PART," "COPY 2 - SEQUENCE LISTING PART" and "COPY 3 - SEQUENCE LISTING PART," respectively, and each contains only one identical 350,356,650 bytes file (P-573737- PC_SL.txt).

FIELD OF DISCLOSURE

[002] Microbial defense systems providing host cells with anti-phage resistance or resistance against plasmid transformation, or both are disclosed. Methods of identifying these systems, and using these systems for example but not limited, for producing bacterial cells comprising defense systems, for producing food products, and for gene editing, are also disclosed.

BACKGROUND

[003] Bacteria and archaea are often being attacked by viruses (phages), and as a result have developed multiple, sophisticated lines of active defense that can collectively be referred to as the prokaryotic "immune system". Anti-phage defense strategies include restriction- modification (R/M) systems that target specific sequences on the invading phage, CRISPR-Cas that provides acquired immunity through memorization of past phage attacks, infection systems (Abi) that lead the cell to death or metabolic arrest upon infection, and additional systems whose mechanism of action is not yet clear such as BREX and DISARM. Different bacteria encode different sets of defense systems: CRISPR-Cas systems are found in about 40% of all sequenced bacteria, BREX appears in 10% of sequenced bacteria, and DISARM in about 1%. It has been suggested that many new, currently unknown defense systems reside in the genomes of non-model bacteria and archaea and await discovery.

[004] Anti-phage defense systems have been found to be frequently physically clustered in bacterial and archaeal genomes such that, for example, genes encoding restriction enzymes commonly reside in the vicinity of genes encoding infection systems and other phage resistance systems. The observation that defense systems are clustered in genomic "defense islands" has led to the suggestion that genes of unknown function residing within such defense islands may also participate in anti-phage defense. Indeed, recent studies that anecdotally examined individual genes enriched next to known defense genes yielded the discovery of new systems that protect bacteria against phages.

[005] Anti-phage defense systems are usually composed of multiple genes that work in concert to achieve defense - for example, casl, cas2, cas3 and the cascade genes in type I CRISPR-Cas systems, and the R, M and S genes in type I restriction systems. Genes functioning within the same defense system are very frequently encoded on the same operon, and the gene order within the operon is highly conserved among distantly related organisms sharing the same system.

[006] Some of these phage-resistance systems have been successfully adapted for biotechnological application; for example, the R/M and the CRISPR/Cas systems have been extensively used for genetic engineering purposes in general and gene therapy in particular.

[007] A broad array of food products, commodity chemicals, and biotechnology products are manufactured industrially by large-scale bacterial fermentation of various substrates. Enormous amounts of bacteria are being cultivated each day in large fermentation vats, thus foreign nucleic acid contamination, for example phage contamination can rapidly bring fermentations to a halt and cause economic setbacks, and is therefore considered a serious threat in these industries. The dairy fermentation industry has openly acknowledged the problem of phages and has been working with academia and starter culture companies to develop defense strategies and systems to curtail the propagation and evolution of phages for decades. There remains a need to provide bacteria that can defend against nucleic acid molecules from foreign sources.

[008] The use of defense systems, for example anti-phage may provide the necessary defense for bacteria in food, chemical, and biotechnology production. Thus, it would be advantageous to both the producers and the consumers to have bacteria resistant to nucleic acid molecules from foreign sources, for example with anti-phage, anti-conjugative element, and or anti-plasmid activity.

[009] Disclosed herein are newly identified anti-phage defense systems, anti-conjugative element systems, and an anti-plasmid system that show strong protection against nucleic acid molecules from foreign sources. These systems could provide protection for fermentation bacteria against phages, for protection of bacteria against viruses, and may also provide biotechnological tools for use with prokaryotic and eukaryotic cells. SUMMARY

[0010] In one aspect, disclosed herein is a method of protecting bacteria from foreign nucleic acid invasion comprising a step of introducing into the bacteria at least one defense system (a) to (o), said at least one defense system comprising:

(a) a Defense System IV comprising at least two different polypeptide components selected from

a HamA polypeptide comprising a pfam08878 domain or a DUF1837 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 12 rows 2-1782 columns H and I; and

a HamB polypeptide comprising COG1204 domain or a pfam00270 domain or a pfam00271 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 12 rows 2-1782 columnsL and M; or

(b) a Defense System la comprising at least two different polypeptide components selected from

a ZorA polypeptide comprising a pfam01618 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns J and K; a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns N and O;

a ZorC polypeptide comprising a pfaml5611 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1174 columns R and S; and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1174 columnsV and W;

or

(c) a Defense System lb comprising a ZorE polypeptide comprising a pfam01844 domain or a COG3183 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 1175-1830 columns Z and AA; and at least one other polypeptide component selected from

a ZorA polypeptide comprising a pfam01618 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns J and K; and a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns N and O; or

a Defense System II comprising at least two different polypeptide components selected from

a ThsA polypeptide comprising a pfaml3289 domain or a pfaml4519 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 9 rows 2-2100 columns I and J; and

a ThsB polypeptide comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 9 rows 2-2100 columns M and N, Q and R, U and V, Y and Z, and AC and AD; or

a Defense System Ilia comprising at least two different polypeptide components selected from

a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or a combination thereof; or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns J and K, or a combination thereof;

a DruB polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2- 123 columns N and O; a DruC polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2- 123 columns R and S;

a DruD polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2- 123 columns V and W; and

a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or

a Defense System Mb comprising at least two different polypeptide components selected from

a DruM polypeptide comprising a pfam00145 domain or a COG0270 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AD and AE;

a DruF polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AH and AI;

a DruG polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AL and AM; and

a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 column Z and AA; or

a Defense System IIIc comprising at least two different polypeptide components selected from

a DruH polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 296-1343 columns AP and AQ; and

a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or

a Defense System V comprising a SduA polypeptide comprising a pfam 14082 domain or a pfam01939 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 13 rows 2-1247 columns H and I; or

a Defense System VI comprising at least two different polypeptide components selected from

a GajA polypeptide comprising a pfaml3175 domain or a COG3593 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table

14 rows 2-4599 columns H and I; and

a GajB polypeptide comprising a pfam04257 domain or a pfam00580 domain or a pfaml3361 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 14 rows 2-4599 columns L and M; or

a Defense System VII comprising at least two different polypeptide components selected from

a PtuA polypeptide comprising a pfaml3304 domain or a pfam02463 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table

15 rows 2-12507 columns H and I; and

a PtuB polypeptide comprising pfaml3395 domain or a pfam 01844 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 15 rows 2-2507 columns L and M; or

a Defense System VIII comprising at least two different polypeptide components selected from

a LmuA polypeptide comprising a pfaml4130 domain or a DUF4297 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table

16 rows 2-698 columns H and I; and

a LmuB polypeptide comprising a pfam02463 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 16 rows 2-698 columns L and M; or a Defense System IX comprising at least two different polypeptide components selected from

a KwaA polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 17 rows 2- 935 columns H and I; and

a KwaB polypeptide comprising a pfaml6162 domain or a DUF4868 domain or a combination thereof; or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table

17 rows 2-935 columns L and M; or

) a Defense System Xa comprising at least two different polypeptide components selected from

a JetA polypeptide comprising a pfaml l855 domain or a DUF3375 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns J and K;

a JetB polypeptide comprising a pfaml3835 domain or a DUF4194 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns N and O;

a JetC polypeptide comprising a pfaml3555 domain or a pfaml3558 domain or a COG4913 domain or any combination thereof; or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns R and S; and

a JetD polypeptide comprising a pfaml l795 domain or a DUF3322 domain or a pfam09983 domain or a DUF2220 domain or a COG4924 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns V and W; or

(n) a Defense System Xb comprising at least two different polypeptide components selected from

a JetA ¹¹ polypeptide comprising a pfam09660 domain or a DUF2397 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns J and K;

a JetB ¹¹ polypeptide comprising a pfam09661 domain or a DUF2398 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns N and O;

a JetC ¹¹ polypeptide comprising a pfaml3558 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns R and S; and a JetD ¹¹ polypeptide comprising a pfaml l796 domain or a DUF3323 domain or a pfam09664 domain or a DUF2399 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns V and W; or

(o) a Defense System Xc comprising at least two different polypeptide components selected from

a JetA ¹¹¹ polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns and K;

a JetB ¹¹¹ polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns N and O;

a JetC ¹¹¹ polypeptide comprising a COG 1196 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns R and S; and a JetD ¹¹¹ polypeptide comprising a pfam09983 domain or a pfam09664 domain or a DUF2220 or a DUF2399 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns V and W; or

(p) any combination of Defense Systems Ia-Xc (a)-(o); wherein the introduction of said at least one defense system results in the bacteria being protected from foreign DNA invasion.

[0011] In a related aspect, methods of protecting bacteria from foreign nucleic acid invasion comprises protecting from phage infection, protection from plasmid transformation, or protecting from entry of conjugative elements, or any combination thereof. In another related aspect, a phage comprises a single stranded DNA (ssDNA) phage, a double stranded DNA (dsDNA) phage, a single stranded RNA (ssRNA) phage, a double stranded RNA (dsRNA) phage, a lytic phage, or a lysogenic phage, or a combination thereof. In another related aspect, at least one defense system comprises

(a) a Defense System IV comprising the HamA polypeptide and the HamB polypeptide; or

(b) a Defense System la comprising the ZorA polypeptide, the ZorB polypeptide, the ZorC polypeptide, and the ZorD polypeptide; or

(c) a Defense System lb comprising the ZorA polypeptide, the ZorB polypeptide, and the ZorE polypeptide; or

(d) a Defense System II comprising the ThsA polypeptide, and the ThsB polypeptide; or

(e) a Defense System Ilia comprising the DruA polypeptide, the DruB polypeptide, the DruC polypeptide, the DruD polypeptide, and the DruE polypeptide; or

(f) a Defense System Illb comprising the DruM polypeptide, the DruF polypeptide, the DruG polypeptide, and the DruE polypeptide; or

(g) a Defense System IIIc comprising the DruH polypeptide and the DruE polypeptide; or

(h) a Defense System V comprising the SduA polypeptide; or (i) a Defense System VI comprising the GajA polypeptide and the GajB polypeptide; or

j) a Defense System VII comprising the PtuA polypeptide and the PtuB polypeptide; or

(k) a Defense System VIII comprising the LmuA polypeptide and the LmuB polypeptide; or

(1) a Defense System IX comprising the KwaA polypeptide and the KwaB polypeptide; or

(m)a Defense System Xa comprising the JetA polypeptide, the JetB polypeptide, the JetC polypeptide, and the JetD polypeptide; or

(n) a Defense System Xb comprising the JetA ¹¹ polypeptide, the JetB ¹¹ polypeptide, the JetC ¹¹ polypeptide, and the JetD ¹¹ polypeptide; or (o) a Defense System Xc comprising the JetA ¹¹¹ polypeptide, the JetB ¹¹¹ polypeptide, the JetC ¹¹¹ polypeptide, and the JetD ¹¹¹ polypeptide; or

(p) any combination of Defense Systems Ia-Xc (a)-(o).

[0012] In another related aspect, defense systems disclosed herein may be encoded by a nucleic acid sequence, wherein

(a) said Defense System IV is encoded by

a nucleic acid sequence selected from the group referenced in Table 12, rows 2-1782, columns G, P, and Q or the nucleic acid sequence set forth in SEQ ID NO: 4; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the HamA polypeptide and HamB polypeptide as disclosed herein;

(b) said Defense System la is encoded by

a nucleic acid sequence selected from the group referenced in Table 8 rows 2- 1174 columns G, AD, and AE or the nucleic acid sequence set forth in SEQ ID NO: 14; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the ZorA polypeptide, the ZorB polypeptide, the ZorC polypeptide, and ZorD polypeptide as disclosed herein;

(c) said Defense System lb is encoded by

a nucleic acid sequence selected from the group referenced in Table 8 rows 1175-1830 columns G, AD, and AE or set forth in SEQ ID NO: 15; or a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the ZorA polypeptide, the ZorB polypeptide,and ZorE polypeptide as disclosed herein;

(d) said Defense System II is encoded by

a nucleic acid sequence selected from the group referenced in Table 9 rows 2- 2100 columns G, AG, and AH or set forth in the nucleic acid sequence set forth in SEQ ID NO: 10 or SEQ ID NO: 11; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the ThsA polypeptide and the ThsB polypeptide as disclosed herein;

(e) said Defense System Ilia is encoded by

a nucleic acid sequence selected from the group referenced in Table 10 rows 2-123 columns G, AT, and AU or set forth in SEQ ID NO: 16; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the DruA polypeptide, the DruB polypeptide, the DruC, the DruD, and the DruE polypeptide as disclosed herein;

(f) said Defense System Mb is encoded by

a nucleic acid sequence selected from the group referenced in Table 10 rows 124-295 columns G, AT, AU; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the DruM polypeptide, the DruF polypeptide, the DruG polypeptide, and the DruE polypeptide as disclosed herein; (g) said Defense System IIIc is encoded by

a nucleic acid sequence selected from the group referenced in Table 10 rows 296-1343 columns G, AT, and AU; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the DruH polypeptide and the DruE polypeptide as disclosed herein;

(h) said Defense System V is encoded by

a nucleic acid sequence selected from the group referenced in Table 13, rows 2-1247, columns H and J; or

a nucleic acid sequence encoding the SduA polypeptide as disclosed herein;

(i) said Defense System VI is encoded by

a nucleic acid sequence selected from the group referenced in Table 14, rows 2-4599, columns G, P, and Q or the sequences set forth in SEQ ID NO: 5 and SEQ ID NO: 6; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the GajA polypeptide and the GajB polypeptide as disclosed herein;

j) said Defense System VII is encoded by

a nucleic acid sequence selected from the group referenced in Table 15, rows 2-2507, columns G, P, and Q or the sequences set forth in SEQ ID NO: 12 and SEQ ID NO: 13; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the Ptu polypeptide and the PtuB polypeptide as disclosed herein;

(k) said Defense System VIII is encoded by

a nucleic acid sequence selected from the group referenced in Table 16, rows 2-698, columns G, P, and Q or the sequences set forth in SEQ ID NO: 7 and SEQ ID NO: 8; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the LmuA polypeptide and LmuB polypeptide as disclosed herein;

(1) said Defense System IX is encoded by

a nucleic acid sequence selected from the group referenced in Table 17, rows 2-935, columns G, P, and Q or the sequence set forth in SEQ ID NO: 3; or a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the KwaA polypeptide and the KwaB polypeptide as disclosed herein;

(m) said Defense System Xa is encoded by

a nucleic acid sequence selected from the group referenced in Table 11, rows 2-2322, columns G, Z, and AA or the sequence set forth in SEQ ID NO: 17; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the JetA polypeptide, the JetB polypeptide, the JetC polypeptide, and the JetD polypeptide as disclosed herein;

(n) said Defense System Xb is encoded by

a nucleic acid sequence having at least 80% homology to a sequence selected from the group referenced in Table 11, rows 2323-2844, columns G, Z, and AA or the sequence set forth in SEQ ID NO: 18; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the JetA ¹¹ polypeptide, the JetB ¹¹ polypeptide, the JetC ¹¹ polypeptide, and the JetD ¹¹ polypeptide as disclosed herein;

(o) said Defense System Xc is encoded by

a nucleic acid sequence selected from the group referenced in Table 11, rows 2845-3174, columns G, Z, and AA or the sequence set forth in SEQ ID NO: 19; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the JetA ¹¹¹ polypeptide, the JetB ¹¹¹ polypeptide, the JetC ¹¹¹ polypeptide, and the JetD ¹¹¹ polypeptide as disclosed herein.

[0013] In another related aspect, methods disclosed herein comprise use of a defense system as disclosed or use of a combination of defense systems wherein

(a) for said Defense system IV, said HamA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 12, rows 2-1782, columna H and J, or

said HamB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 12, rows 2-1782, columns L and N, or a combination thereof;

(b) for said Defense system la, said ZorA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 8 rows 2-1830 columns J and L,

said ZorB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 8 rows 2-1830 columns N and P, said ZorC polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 8 rows 2-1174 columns R and T, or said ZorD polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 8 rows 2-1174 columns V and X, or a combination thereof;

(c) for said Defense system lb, said ZorA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 8 rows 2-1830 columns J and L,

said ZorB polypeptide is encoded by a nucleic acid sequence sequence selected from the group Table 8 rows 2-1830 columns N and P, said ZorE polypeptide is encoded by a nucleic acid sequence sequence selected from the group referenced in Table 8 rows 1175-1830 columns Z and AB, or

a combination thereof;

(d) for said Defense system II, said ThsA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 9 rows 2-2100 columns I and K,

said ThsB polypeptide is encoded by a nucleic acid sequence sequence selected from the group referenced in Table 9 rows 2-2100 columns M and O, Q and S, U and W, Y and AA, and AC and AE, or

a combination thereof;

(e) for said Defense system Ilia, said DruA polypeptide is encoded by a nucleic acid sequence sequence selected from the group referenced in Table 10 rows 2-123 columns J and L, or

said DruB polypeptide is encoded by a nucleic acid sequence sequence selected from the group referenced in Table 10 rows 2-123 columns N and P, or

said DruC polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 2-123 columns R and T, or

said DruD polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 2-123 columns V and X, or

said DruE polypeptide is encoded by a nucleic acid sequence sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and

AB, or

a combination thereof;

(f) for said Defense system Illb, said DruM polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 124-295 columns AD and AF, or

said DruF polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 124-295 columns AH and AJ, or said DruG polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 124-295 columns AL and AN, or said DruE polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AB, or a combination thereof;

(g) for said Defense system IIIc, said DruH polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 296-1343 columns AP and AR, or

said DruE polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and ZB, or a combination thereof;

(h) for said Defense system V, said SduA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 13; rows 2-1247, columns H and J;

(i) for said Defense system VI, said GajA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 14, rows 2-4599, columns H and J, or

said GajB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 14, rows 2-4599, columns L and N, or a combination thereof;

j) for said Defense system VII, said PtuA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 15, rows 2-2507, columns H and J, or

said PtuB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 15, rows 2-2507, columns L and N, or

a combination thereof;

(k) for said Defense system VIII, said LmuA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 16, rows 2-698, columns H and J, or

said LmuB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 16, rows 2-698, columns L and N, or a combination thereof;

(1) for said Defense system IX, said KwaA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 17, rows 2-935, columns H and J, or

said KwaB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 17, rows 2-935, columns L and N, or a combination thereof;

(m) for said Defense system Xa, said JetA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2-2322, columns J and L, or

said JetB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2-2322, columns N and P, or said JetC polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2-2322, columns R and T, or said JetD polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2-2322, columns V and X, or a combination thereof;

(n) for said Defense system Xb, said JetA ¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2323- 2844, columns J and L, or

said JetB ¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2323-2844, columns N and P, or said JetC ¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2323-2844, columns R and T, or said JetD ¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2323-2844, columns V and X, or a combination thereof;

(o) for said Defense system Xc, said JetA ¹¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2845- 3174, columns J and L, or

said JetB ¹¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2845-3174, columns N and P, or said JetC ¹¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2845-3174, columns R and T, or said JetD ¹¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2845-3174, columns V and X, or a combination thereof.

[0014] In another aspect, disclosed herein are defense systems encoded by a nucleic acid sequence, comprising at least one defense system (a)-(o), wherein said at least one defense system comprises (a) a Defense System IV comprising at least two different polypeptide components selected from

a HamA polypeptide comprising a pfam08878 domain or a DUF1837 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 12 rows 2-1782 columns H and I; and

a HamB polypeptide comprising COG1204 domain or a pfam00270 domain or a pfam00271 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 12 rows 2-1782 columns L and M; or

(b) a Defense System la comprising at least two different polypeptide components selected from

a ZorA polypeptide comprising a pfam01618 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns J and K;

a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns N and O;

a ZorC polypeptide comprising a pfaml5611 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1174 columns R and S; and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1174 columns V and W;

or

(c) a Defense System lb comprising a ZorE polypeptide comprising a pfam01844 domain or a COG3183 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 1175-1830 columns Z and AA; and at least one other polypeptide component selected from

a ZorA polypeptide comprising a pfam01618 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns J and K; and a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns N and O; or

a Defense System II comprising at least two different polypeptide components selected from

a ThsA polypeptide comprising a pfaml3289 domain or a pfaml4519 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 9 rows 2-2100 columns I and J; and

a ThsB polypeptide comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 9 rows 2-2100 columns M and N, Q and R, U and V, Y and Z, and AC and AD; or

a Defense System Ilia comprising at least two different polypeptide components selected from

a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns Jand K, or a combination thereof;

a DruB polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2- 123 columns N and O;

a DruC polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2- 123 columns R and S;

a DruD polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2- 123 columns V and W; and

a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or

a Defense System Illb comprising at least two different polypeptide components selected from

a DruM polypeptide comprising a pfam00145 domain or a COG0270 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AD and AE;

a DruF polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AH and AI;

a DruG polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AL and AM; and

a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain, or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columnsZ and AA; or

a Defense System IIIc comprising at least two different polypeptide components selected from

a DruH polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 296-1343 columns AP and AQ; and

a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or

a Defense System V comprising a SduA polypeptide comprising a pfam 14082 domain or a pfam01939 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 13 rows 2-1247 columns H and I; or

a Defense System VI comprising at least two different polypeptide components selected from

a GajA polypeptide comprising a pfaml3175 domain or a COG3593 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table

14 rows 2-4599 columns H and I; and

a GajB polypeptide comprising a pfam04257 domain or a pfam00580 domain or a pfaml3361 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 14 rows 2-4599 columns L and M; or

a Defense System VII comprising at least two different polypeptide components selected from

a PtuA polypeptide comprising a pfaml3304 domain or a pfam02463 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table

15 rows 2-12507 columns H and I; and

a PtuB polypeptide comprising pfaml3395 domain or a pfam 01844 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 15 rows 2-2507 columns L and M; or

a Defense System VIII comprising at least two different polypeptide components selected from

a LmuA polypeptide comprising a pfaml4130 domain or a DUF4297 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 16 rows 2-698 columns H and I; and

a LmuB polypeptide comprising a pfam02463 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 16 rows 2-698 columns L and M; or a Defense System IX comprising at least two different polypeptide components selected from

a KwaA polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 17 rows 2- 935 columns H and I; and

a KwaB polypeptide comprising a pfaml6162 domain or a DUF4868 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table

17 rows 2-935 columns L and M; or

) a Defense System Xa comprising at least two different polypeptide components selected from

a JetA polypeptide comprising a pfaml l855 domain or a DUF3375 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns J and K;

a JetB polypeptide comprising a pfaml3835 domain or a DUF4194 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns N and O;

a JetC polypeptide comprising a pfaml3555 domain or a pfaml3558 domain or a COG4913 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns R and S; and

a JetD polypeptide comprising a pfaml l795 domain or a DUF3322 domain or a pfam09983 domain or a DUF2220 domain or a COG4924 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns V and W; or (n) a Defense System Xb comprising at least two different polypeptide components selected from

a JetA ¹¹ polypeptide comprising a pfam09660 domain or a DUF2397 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns J and K;

a JetB ¹¹ polypeptide comprising a pfam09661 domain or a DUF2398 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns N and O;

a JetC ¹¹ polypeptide comprising a pfaml3558 domain comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns R and S; and a JetD ¹¹ polypeptide comprising a pfaml l796 domain or a DUF3323 domain or a pfam09664 domain or a DUF2399 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns V and W; or

(o) a Defense System Xc comprising at least two different polypeptide components selected from

a JetA ¹¹¹ polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns J and K;

a JetB ¹¹¹ polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns N and O;

a JetC ¹¹¹ polypeptide comprising a COG 1196 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns R and S; and a JetD ¹¹¹ polypeptide comprising a pfam09983 domain or a pfam09664 domain or a DUF2220 or a DUF2399 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns V and W; or

(p) any combination of the Defense Systems Ia-Xc (a)-(o);

wherein said at least one defense system comprises a non-naturally occurring combination of components.

related aspect, a defense system disclosed wherein

(a) said Defense System IV comprises the HamA polypeptide and the HamB polypeptide; or

(b) said Defense System la comprises the ZorA polypeptide, the ZorB polypeptide, the ZorC polypeptide, and the ZorD polypeptide; or

(c) said Defense System lb comprises the ZorA polypeptide, the ZorB polypeptide, and the ZorE polypeptide; or

(d) said Defense System II comprises the ThsA polypeptide, and the ThsB polypeptide; or

(e) said Defense System Ilia comprises the DruA polypeptide, the DruB polypeptide, the DruC polypeptide, the DruD polypeptide, and the DruE polypeptide; or

(f) said Defense System Illb comprises the DruM polypeptide, the DruF polypeptide, the DruG polypeptide, and the DruE polypeptide; or

(g) said Defense System IIIc comprises the DruH polypeptide and the DruE polypeptide; or

(h) said Defense System V comprises the SduA polypeptide; or

(i) said Defense System VI comprises the GajA polypeptide and the GajB polypeptide; or

j) said Defense System VII comprises the PtuA polypeptide and the PtuB polypeptide; or

(k) said Defense System VIII comprises the LmuA polypeptide and the LmuB polypeptide; or

(1) said Defense System IX comprises the KwaA polypeptide and the KwaB polypeptide; or

(m) said Defense System Xa comprises the JetA polypeptide, the JetB polypeptide, the JetC polypeptide, and the JetD polypeptide; or (n) said Defense System Xb comprises the JetA ¹¹ polypeptide, the JetB ¹¹ polypeptide, the JetC ¹¹ polypeptide, and the JetD ¹¹ polypeptide; or (o) said Defense System Xc comprises the JetA ¹¹¹ polypeptide, the JetB ¹¹¹ polypeptide, the JetC ¹¹¹ polypeptide, and the JetD ¹¹¹ polypeptide.

[0016] In another related aspect, at least one defense system disclosed herein or a combination thereof, provides a host cell with resistance to foreign nucleic acid invasion. In another related aspect, the resistance to foreign nucleic acid invasion comprises resistance to at least one phage infection, or resistance to plasmid transformation,or resistance to entry of a conjugative element, or any combination thereof.

[0017] In another aspected, disclosed herein is a nucleic acid construct encoding an at least one defense system (a)-(o), said nucleic acid construct comprising

(a) a nucleic acid construct encoding a Defense System IV comprising at least two different polypeptide components selected from

a HamA polypeptide comprising a pfam08878 domain or a DUF1837 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 12 rows 2-1782 columns H and I; and

a HamB polypeptide comprising COG1204 domain or a pfam00270 domain or a pfam00271 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 12 rows 2-1782 columns L and M; or

(b) a nucleic acid construct encoding a Defense System la comprising at least two different polypeptide components selected from

a ZorA polypeptide comprising a pfam01618 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns J and K; a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns N and O;

a ZorC polypeptide comprising a pfaml5611 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1174 columns R and S; and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1174 columns V and W;

or

(c) a nucleic acid construct encoding a Defense System lb comprising a ZorE polypeptide comprising a pfam01844 domain or a COG3183 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 1175-1830 columns Z and AA; and at least one other polypeptide component selected from

a ZorA polypeptide comprising a pfam01618 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns J and K; and a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns N and O; or

(d) a nucleic acid construct encoding a Defense System II comprising at least two different polypeptide components selected from

a ThsA polypeptide comprising a pfaml3289 domain or a pfaml4519 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 9 rows 2-2100 columns I and J; and

a ThsB polypeptide comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 9 rows 2-2100 columns M and N, Q and R, U and V, Y and Z, and AC and AD; or

(e) a nucleic acid construct encoding a Defense System Ilia comprising at least two different polypeptide components selected from a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns J and K, or a combination thereof;

a DruB polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2- 123 columns N and O;

a DruC polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2- 123 columns R and S;

a DruD polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2- 123 columns V and W; and

a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or

(f) a nucleic acid construct encoding a Defense System Illb comprising at least two different polypeptide components selected from

a DruM polypeptide comprising a pfam00145 domain or a COG0270 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AD and AE;

a DruF polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AH and AI;

a DruG polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AL and AM; and

a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or

a nucleic acid construct encoding a Defense System IIIc comprising at least two different polypeptide components selected from

a DruH polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 296-1343 columns AP and AQ; and

a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or

a nucleic acid construct encoding a Defense System V comprising a SduA polypeptide comprising a pfam 14082 domain or a pfam01939 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 13 rows 2-1247 columns H and I; or

a nucleic acid construct encoding a Defense System VI comprising at least two different polypeptide components selected from

a GajA polypeptide comprising a pfaml3175 domain or a COG3593 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 14 rows 2-4599 columns H and I; and

a GajB polypeptide comprising a pfam04257 domain or a pfam00580 domain or a pfaml3361 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 14 rows 2-4599 columns L and M; or

a nucleic acid construct encoding a Defense System VII comprising at least two different polypeptide components selected from

a PtuA polypeptide comprising a pfaml3304 domain or a pfam02463 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 15 rows 2-12507 columns H and I; and

a PtuB polypeptide comprising pfaml3395 domain or a pfam 01844 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table

15 rows 2-2507 columns L and M; or

a nucleic acid construct encoding a Defense System VIII comprising at least two different polypeptide components selected from

a LmuA polypeptide comprising a pfaml4130 domain or a DUF4297 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table

16 rows 2-698 columns H and I; and

a LmuB polypeptide comprising a pfam02463 domain, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 16 rows 2-698 columns L and M; or a nucleic acid construct encoding a Defense System IX comprising at least two different polypeptide components selected from

a KwaA polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 17 rows 2- 935 columns H and I; and

a KwaB polypeptide comprising a pfaml6162 domain or a DUF4868 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table

17 rows 2-935 columns L and M; or

) a nucleic acid construct encoding a Defense System Xa comprising at least two different polypeptide components selected from

a JetA polypeptide comprising a pfaml l855 domain or a DUF3375 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns J and K;

a JetB polypeptide comprising a pfaml3835 domain or a DUF4194 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns N and O;

a JetC polypeptide comprising a pfaml3555 domain or a pfaml3558 domain or a COG4913 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns R and S; and

a JetD polypeptide comprising a pfaml l795 domain or a DUF3322 domain or a pfam09983 domain or a DUF2220 domain or a COG4924 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns V and W; or

(n) a nucleic acid construct encoding a Defense System Xb comprising at least two different polypeptide components selected from

a JetA ¹¹ polypeptide comprising a pfam09660 domain or a DUF2397 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns J and K;

a JetB ¹¹ polypeptide comprising a pfam09661 domain or a DUF2398 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns N and O;

a JetC ¹¹ polypeptide comprising a pfaml3558 domain comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns R and S; and a JetD ¹¹ polypeptide comprising a pfaml l796 domain or a DUF3323 domain or a pfam09664 domain or a DUF2399 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns V and W; or

(o) a nucleic acid construct encoding a Defense System Xc comprising at least two different polypeptide components selected from

a JetA ¹¹¹ polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns J and K;

a JetB ¹¹¹ polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns N and O;

a JetC ¹¹¹ polypeptide comprising a COG 1196 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns R and S; and a JetD ¹¹¹ polypeptide comprising a pfam09983 domain or a pfam09664 domain or a DUF2220 or a DUF2399 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns V and W; or

(p) any combination of nucleic acid constructs encoding a Defense Systems Ia- Xc (a)-(o);

wherein each nucleic acid construct of each Defense System (a)-(o) further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof.

related aspect, the expressed defense system comprises

(a) a Defense System IV comprising the HamA polypeptide, and the HamB polypeptide; or

(b) a Defense System la comprising the ZorA polypeptide, the ZorB polypeptide, the ZorC polypeptide, and the ZorD polypeptide; or

(c) a Defense System lb comprising the ZorA polypeptide, the ZorB polypeptide, and the ZorE polypeptide; or

(d) a Defense System II comprising the ThsA polypeptide, and the ThsB polypeptide; or (e) a Defense System Ilia comprising the DruA polypeptide, the DruB polypeptide, the DruC polypeptide, the DruD polypeptide, and the DruE polypeptide; or

(f) a Defense System Illb comprising the DruM polypeptide, the DruF polypeptide, the DruG polypeptide, and the DruE polypeptide; or

(g) a Defense System IIIc comprising the DruH polypeptide and the DruE polypeptide; or

(h) a Defense System V comprising the SduA polypeptide; or

(i) a Defense System VI comprising the GajA polypeptide and the GajB polypeptide; or

j) a Defense System VII comprising the PtuA polypeptide and the PtuB polypeptide; or

(k) a Defense System VIII comprising the LmuA polypeptide and the LmuB polypeptide; or

(1) a Defense System IX comprising the KwaA polypeptide and the KwaB polypeptide; or

(m)a Defense System Xa comprising the JetA polypeptide, the JetB polypeptide, the JetC polypeptide, and the JetD polypeptide; or

(n) a Defense System Xb comprising the JetA ¹¹ polypeptide, the JetB ¹¹ polypeptide, the JetC ¹¹ polypeptide, and the JetD ¹¹ polypeptide; or

(o) a Defense System Xc comprising the JetA ¹¹¹ polypeptide, the JetB ¹¹¹ polypeptide, the JetC ¹¹¹ polypeptide, and the JetD ¹¹¹ polypeptide.

other related aspect, the nucleic acid construct disclosed herein, wherein

(a) said Defense System IV is encoded by

a nucleic acid sequence selected from the group referenced in Table 12, rows 2-1782, columns G, P, and Q or the nucleic acid sequence set forth in SEQ ID NO: 4; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the HamA polypeptide and HamB polypeptide as disclosed herein;

(b) said Defense System la is encoded by a nucleic acid sequence selected from the group referenced in Table 8 rows 2- 1174 columns G, AD, and AE or the nucleic acid sequence set forth in SEQ ID NO: 14; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the ZorA polypeptide, the ZorB polypeptide, the ZorC polypeptide, and ZorD polypeptide as disclosed herein;

(c) said Defense System lb is encoded by

a nucleic acid sequence selected from the group referenced in Table 8 rows 1175-1830 columns G, AD, and AE or set forth in SEQ ID NO: 15; or a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the ZorA polypeptide, the ZorB polypeptide, and ZorE polypeptide as disclosed herein;

(d) said Defense System II is encoded by

a nucleic acid sequence selected from the group referenced in Table 9 rows 2- 2100 columns G, AG, and AH or set forth in the nucleic acid sequence set forth in SEQ ID NO: 10 or SEQ ID NO: 11; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the ThsA polypeptide and the ThsB polypeptide as disclosed herein;

(e) said Defense System Ilia is encoded by

a nucleic acid sequence selected from the group referenced in Table 10 rows 2-123 columns G, AT, and AU or set forth in SEQ ID NO: 16; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the DruA polypeptide, the DruB polypeptide, the DruC, the DruD, and the DruE polypeptide as disclosed herein;

(f) said Defense System Illb is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 124-295 columns G, AT, AU; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the DruM polypeptide, the DruF polypeptide, the DruG polypeptide, and the DruE polypeptide as disclosed herein;

(g) said Defense System IIIc is encoded by

a nucleic acid sequence selected from the group referenced in Table 10 rows 296-1343 columns G, AT, and AU; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the DruH polypeptide and the DruE polypeptide as disclosed herein;

(h) said Defense System V is encoded by

a nucleic acid sequence selected from the group referenced in Table 13; rows 2-1247, columns H and J; or

a nucleic acid sequence encoding the SduA polypeptide disclosed herein;

(i) said Defense System VI is encoded by

a nucleic acid sequence selected from the group referenced in Table 14, rows 2-4599, columns G, P, and Q or the sequences set forth in SEQ ID NO: 5 and SEQ ID NO: 6; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the GajA polypeptide and the GajB polypeptide as disclosed herein;

j) said Defense System VII is encoded by

a nucleic acid sequence selected from the group referenced in Table 15, rows 2-2507, columns G, P, and Q or the sequences set forth in SEQ ID NO: 12 and SEQ ID NO: 13; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or a nucleic acid sequence encoding the Ptu polypeptide and the PtuB polypeptide as disclosed herein;

(k) said Defense System VIII is encoded by

a nucleic acid sequence selected from the group referenced in Table 16, rows 2-698, columns G, P, and Q or the sequences set forth in SEQ ID NO: 7 and SEQ ID NO: 8; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the LmuA polypeptide and LmuB polypeptide as disclosed herein;

(1) said Defense System IX is encoded by

a nucleic acid sequence selected from the group referenced in Table 17, rows 2-935, columns G, P, and Q or the sequence set forth in SEQ ID NO: 3; or a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the KwaA polypeptide and the KwaB polypeptide as disclosed herein;

(m) said Defense System Xa is encoded by

a nucleic acid sequence selected from the group referenced in Table 11, rows 2-2322, columns G, Z, and AA or the sequence set forth in SEQ ID NO: 17; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the JetA polypeptide, the JetB polypeptide, the JetC polypeptide, and the JetD polypeptide as disclosed herein;

(n) said Defense System Xb is encoded by

a nucleic acid sequence having at least 80% homology to a sequence selected from the group referenced in Table 11, rows 2323-2844, columns G, Z, and AA or the sequence set forth in SEQ ID NO: 18; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the JetA ¹¹ polypeptide, the JetB ¹¹ polypeptide, the JetC ¹¹ polypeptide, and the JetD ¹¹ polypeptide as disclosed herein;

(o) said Defense System Xc is encoded by

a nucleic acid sequence selected from the group referenced in Table 11, rows 2845-3174, columns G, Z, and AA or the sequence set forth in SEQ ID NO: 19; or

a nucleic acid sequence encoding the at least two different polypeptide sequences as disclosed herein; or

a nucleic acid sequence encoding the JetA ¹¹¹ polypeptide, the JetB ¹¹¹ polypeptide, the JetC ¹¹¹ polypeptide, and the JetD ¹¹¹ polypeptide as disclosed herein.

[0020] Further, in another related aspect, a nucleic acid construct disclosed herein comprises a nucleic acid construct wherein

(a) said HamA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 12, rows 2-1782, columns H and J, or s aid HamB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 12, rows 2-1782, columns L and N, or a combination thereof;

(b) said ZorA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 8 rows 2-1830 columns J and L, said ZorB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 8 rows 2-1830 columns N and P, said ZorC polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 8 rows 2-1174 columnsR and T, or said ZorD polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 8 rows 2-1174 columns V and X, or a combination thereof;

(c) said ZorA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 8 rows 2-1830 columns J and L, said ZorB polypeptide is encoded by a nucleic acid sequence sequence selected from the group Table 8 rows 2-1830 columns N and P, said ZorE polypeptide is encoded by a nucleic acid sequence sequence selected from the group referenced in Table 8 rows 1175-1830 columns Z and AB, or

a combination thereof;

(d) said ThsA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 9 rows 2-2100 columns I and K,

said ThsB polypeptide is encoded by a nucleic acid sequence sequence selected from the group referenced in Table 9 rows 2-2100 columns M and O, Q and S, U and W, Y and AA, and AC and AE, or

a combination thereof;

(e) said DruA polypeptide is encoded by a nucleic acid sequence sequence selected from the group referenced in Table 10 rows 2-123 columns J and L, or

said DruB polypeptide is encoded by a nucleic acid sequence sequence selected from the group referenced in Table 10 rows 2-123 columns N and P, or

said DruC polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 2-123 columns R and T, or

said DruD polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 2-123 columns V and X, or

said DruE polypeptide is encoded by a nucleic acid sequence sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and

AB, or

a combination thereof;

(f) said DruM polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 124-295 columns AD and AF, or said DruF polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 124-295 columns AH and AJ, or said DruG polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 124-295 columns AL and AN, or said DruE polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AB, or a combination thereof; (g) said DruH polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 296-1343 columns AP and AR, or said DruE polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AB, or a combination thereof;

(h) said SduA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 13; rows 2-1247, columns H and J;

(i) said GajA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 14, rows 2-4599, columns H and J, or said GajB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 14, rows 2-4599, columns L and N, or a combination thereof;

(j) said PtuA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 15, rows 2-2507, columns H and J, or said PtuB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 15, rows 2-2507, columns L and N, or

a combination thereof;

(k) said LmuA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 16, rows 2-698, columns H and J, or said LmuB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 16, rows 2-698, columns L and N, or a combination thereof;

(1) said KwaA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 17, rows 2-935, columns H and J, or said KwaB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 17, rows 2-935, columns L and N, or a combination thereof;

(m) said JetA polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2-2322, columns J and L, or said JetB polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2-2322, columns N and P, or

said JetC polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2-2322, columns R and T, or said JetD polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2-2322, columns V and X, or a combination thereof;

(n) said JetA ¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2323-2844, columns J and L, or said JetB ¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2323-2844, columns N and P, or said JetC ¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2323-2844, columns R and T, or said JetD ¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2323-2844, columns V and X, or a combination thereof;

(o) said JetA ¹¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2845-3174, column J and L, or said JetB ¹¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2845-3174, columns N and O, or said JetC ¹¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2845-3174, columns R and T, or said JetD ¹¹¹ polypeptide is encoded by a nucleic acid sequence selected from the group referenced in Table 11, rows 2845-3174, columns V and X, or a combination thereof.

[0021] In another related aspect, disclosed herein is a nucleic acid construct wherein expression of said defense system from the nucleic acid construct in a host cells provides the host cell with resistance to foreign nucleic acid invasion. In another related aspect, resistance to foreign nucleic acid invasion comprises resistance to at least one phage infection, or resistance to plasmid transformation, or resistance to entry of a conjugation element, or any combination thereof

[0022] In another aspect, disclosed herein is a transmissible genetic element or an expression vector comprising a nucleic acid construct as disclosed herein.

[0023] In another aspect, disclosed herein is an isolated cell expressing a nucleic acid construct as disclosed herein. In a related aspect, the cell comprises a gram-positive bacterium or a gram- negative bacterium. In another related aspect, the cell comprises resistance to foreign nucleic acid invasion. In still another related aspect, the resistance to foreign nucleic acid invasion comprises resistance to at least one phage infection, or reduced plasmid transformation efficiency, or resistance to entry of a conjugation element, or a combination thereof.

[0024] In another aspect, disclosed herein is a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product, and or a veterinary product comprising any defense system or combination of defense systems as disclosed herein, or the nucleic acid construct or combination of constructs as disclosed herein, or the transmissible genetic element as disclosed herein, or the isolated cell as disclosed herein.

[0025] In a related aspect, the defense system or combination of defense systems included in a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product, and or a veterinary product disclosed herein, comprises a combination of Defense Systems selected from Defense Systems Ia-Xc (a)-(o).

[0026] In another aspect, disclosed herein is a method of preparing a food, a food additive, a feed, a nutritional supplements, a probiotic supplement, a personal care product, a health care product or a veterinary product, the method comprising adding to the food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product, or veterinary product at least one defense system as disclosed herein, or the nucleic acid construct as disclosed herein, or the transmissible genetic element disclosed herein, or the isolated cell disclosed herein.

[0027] In another aspect, disclosed herein is a method for identifying a defense system in a prokaryotic cell, comprising the steps of:

(a) selecting, in-silico, a family of genes that are preferentially located in close proximity to a known defense-related gene family present in a plurality of prokaryotic genomes; and

(b) analyzing, in-silico, the DNA upstream and downstream of said gene; and

(c) identifying, in-silico, a cassette of genes within the upstream and downstream DNA analyzed in step (b) comprising said gene of step (a), wherein said cassette of genes has conserved synteny in said plurality of prokaryotic genomes.

[0028] In a related aspect, in a method of identifying a defense system, the gene of step (a), located in close proximity to a known defense related gene family, is within 10 genes upstream and or 10 genes downstream of the known defense related gene family.

[0029] In another aspect, disclosed herein is a method gene editing, said method comprising contacting a nucleic acid sequence comprising a gene to be edited with at least one polypeptide component of a defense system, wherein said defense system component comprises a compononent selected from the components of the defense system disclosed herein, wherein said method results in the gene being edited.

BRIEF DESCRIPTION OF THE DRAWINGS

[0030] The subject matter disclosed herein is particularly pointed out and distinctly claimed in the concluding portion of the specification. The defense systems described, however, both as to organization and method of operation, together with objects, features, and advantages thereof, may best be understood by reference to the following detailed description when read with the accompanying drawings in which:

[0031] Figures 1A-1C presents the strategy and initial results for the discovery of new anti- phage defense systems in defense islands. Figure 1A illustrates the computational analysis employed for each pfam found to be enriched in defense islands. Pfams that are enriched in the vicinity of known defense genes are identified, and their neighboring genes are clustered based on sequence homology to identify conserved cassettes that represent putative defense systems. Figure IB presents a bar graph showing the tendency of protein families to occur next to defense genes. The genomic neighborhood for each member gene in each pfam is examined, and the fraction of member genes occurring in the vicinity (10 genes on each side) of one or more known defense genes is recorded. A set of 123 pfams known to participate in anti-phage defense ("positive set") are represented in pink; the remaining 13,960 pfams analyzed in this study are shown in blue. Figure 1C presents the neighborhood variability score for analyzed pfams. Scores represent the fraction of pfams members occurring in different defense neighborhoods out of total occurrences of pfam members. (Pink, the 123 positive pfams; blue, a set of 576 pfams that passed the 65% threshold for fraction of members occurring with defense genes in proximity.)

[0032] Figures 2A and 2B present the distribution of predicted functions for pfams genomically associated with known defense genes. Figure 2A presents the pfams retrieved from prediction cycle #1. Figure 2B presents the pfams retrieved from prediction cycle #2.

[0033] Figures 3A-3H show the flowchart and experimentally verified defense systems. (Figure 3A) Flowchart of the experimental verification strategy. (Figure 3B) Active defense systems cloned into B. subtilis. (Figure 3C) Active defense systems cloned into E. coli. For Figures 3B and 3C, the fold protection was measured using serial dilution plaque assays, comparing the system-containing strain to a control strain that lacks the system and has an empty vector instead. Data represents average of 3 replicates (Figures 3E and 3F). Numbers below phage names represent phage genome size. On the right of Figures 3B and 3C, gene organization of the defense systems, with identified domains indicated (DUF, domain of unknown function). Gene sizes are drawn to scale, scale bar represents 400 amino acids. Figure 3D presents the initial data demonstrating that the ZORYA type I system provides protection against phages as evaluated by serial dilution plaque assay. E. coli MG1655 strain (control) and E. coli MG1655 strain (control) transfected with the ZORYA system I of ZORYA locus of Escherichia coli (E. coli) E24377A and challenged with the indicated phages (phage T4, phage T7, phage lambda vir t [an obligatory lytic mutant of phage lambda], SECphi27, SECphil7, and SECphil8). Columns represent serial 10-fold dilutions of the initial phage stock concentration. The leftmost column represents 10 ^" (100 fold) dilution, the second column from the right represents 10 ^" (1000 fold dilution), and so on until the leftmost column that represents 10 million fold dilution. Figure 3E presents the efficiency of plating (EOP) of Bacillus phages on defense systems cloned into B. subtilis BEST7003. Data represent PFU/ml values, average of 3 replicates; error bars are STD. When two representations of the same system are indicated (e.g. Thoeris I and Thoeris II), order of systems is as in Figure 3B. Figure 3F presents efficiency of plating (EOP) of coliphages on defense systems cloned into E. coli MG1655. Data represent PFU/ml values, average of 3 replicates; error bars are STD. Order of defense systems in each graph is as in Figure 3C. Figure 3G presents efficiency of plating (EOP) of Bacillus phage SpBeta on defense systems mutated in individual genes. Data represent PFU/ml values of SpBeta phage infecting WT and mutated systems. Average of 3 replicates; error bars are STD. Gene deletion results for systems Zorya, Thoeris, Wadjet and Druantia appear in figures 4, 5, 7, and 6, respectively. Gene deletion attempts for the Kiwa system were not successful. Figure 3H presents distribution of defense systems in sequenced microbial genomes. For each system, phyla in which instances of the system were detected are indicated. Top left pie chart represents the entire set of microbial genomes analyzed, and is shown in order to provide a reference for the phylogenetic distribution of the species whose genomes were sequenced. Data on individual instances of each system are found in Tables 4 and 8-18. [0034] Figures 4A-4J present the identified members of the Type I and Type II ZORYA defense systems and analysis thereof. Figure 4A shows schematic representative instances of the Type I ZORYA system and their defense island context. In the last four embodiments, genes known to be involved in defense are orange. Mobilome genes are in dark grey. RM - restriction modification; TA - toxin-antitoxin; Abi - abortive infection; Wadjet and DISARM are other defense systems identified herein. Figure 4B presents the domain organization of the Type I ZORYA system comprising zorA (A), zorB (B), zorC (C) and zorD (D). Figure 4C presents a schematic of the ZORYA type I defense system locus of Escherichia coli (E. coli) E24377A used for cloning. Numbers represent position on the E. coli E24377A genome. Specifically, nucleotides 298890 - 307639 of the reverse strand were cloned into the E. coli MG1655 genome (SEQ ID NO: 14). Figure 4D shows multiple schematic representative instances of the Type II ZORYA system and their defense island context. Genes known to be involved in defense are orange. Mobilome genes are in dark grey. RM - restriction modification; TA - toxin-antitoxin; Druantia is another defense systems identified herein. Figure 4E presents the domain organization of theType II ZORYA system comprising zorA (A), zorB (B), and zorE (E). Domain organization of zorA and zorB are as in Figure 4B. Figure 4F presents a model of the flagellum base. The position of the MotAB complex is indicated. Figure 4G presents percent phage infection of Zorya-containing cells in solid cultures. Figure 4H presents optical density (O.D.) versus time post infection of phage infected Zorya Defense System la-containing baceteria in liquid cultures. Figure 41 presents optical density (O.D.) versus time post infection of phage infected Zorya Defense System Ib-containing baceteria in liquid cultures. Figure 4J presents the efficiency of plating (EOP) of phage SECphi27 infecting WT Type I ZORA, deletion strains, and strains with point mutations. Data represent PFU/ml, average of 3 replicates with error bars representing STD. ZorA:T147A/S184A and ZorB:D26N are predicted to abolish proton flux; ZorC:E400A/H443A are mutations in two conserved residues in pfaml5611 ("EH domain") whose function is unknown; ZorD:D730A/E731A are mutations in the Walker B motif, predicted to abolish ATP hydrolysis.

[0035] Figures 5A-5E present the identified members of the Thoeris system and analysis thereof. Figure 5A shows schematic representative instances of the Thoeris (SIR2-TIR) system and their defense island context. In each row of the top set of systems identified, the red gene is the thsA gene (Sir2-domain; pfaml3289) gene; the immediately downstream gene is the thsB gene (TIR domain; pfam08937 or pfaml3676) gene. In the last four systems presented, the Thoeris genes thsA (containing NAD-binding domain) and thsB (TIR domain) are marked dark and light green, respectively. Genes known to be involved in defense are orange. Mobilome genes are in dark grey. RM, restriction-modification; TA, toxin-antitoxin; Abi, abortive infection. Figure 5B presents schematic representations of two Thoeris systems identified and analyzed in this study, shown to protect against myophages. Locus tag accessions are indicated for the individual genes. Figure 5C presents the efficiency of plating (EOP) results of phage SBSphiJ infection with WT and mutated versions of the B. amyloliquefaciens Y2 Thoeris (Figure 5B top set) or B. cereus MSX-D12 Thoeris (Figure 5B bottom set) cloned into B. subtilis BEST7003. Average of 3 replicates, error bars represent STD. Figure 5D shows the initial results demonstrating that the Thoeris system (SIR2-TIR system) provides protection against phages as evaluated by plaque assay. Phage used were SBSphiC, SBSphiJ and SPOl. Figure 5E presents predictions of the active site in ThsB polypeptide. Shown is an alignment of the ThsB gene from Bacillus amyloliquefaciens Y2 to SARM1 and MliB. Numbers in the alignment represent position in the protein sequence. Positions of verified active sites for MliB and SARM1, and the predicted active site of ThsB, are indicated.

[0036] Figures 6A-6C present the identified members of the Druantia system and analysis thereof. Figure 6A presents representative instances of Druantia types I, II and III and their defense island context. The system is characterized by a gene encoding a large (1800aa-2100aa) polypeptide with a DUF1998 domain (druE), preceded by 3, 2, or 1 genes encoding hypothetical proteins with no domain annotation, for Types I, II and III, respectively. In some Type I cases, a gene encoding a polypeptide with a pfaml4236 (DUF4338) domain (druA gene; DruA polypeptide) is associated with the system. Type II systems are typically associated with a cytosine methylase gene (DruM). Genes known to be involved in defense are orange. Mobilome genes are in dark grey. RM, restriction-modification; TA, toxin-antitoxin; Zorya, a defense system identified in this study. Figure 6B presents the Druantia systems that was cloned (Example 6) and experimentally shown to protect against coliphages. Locus tag accessions are indicated for the individual genes. Figure 6C presents data showing gene deletions render the Druantia defense system inactive. DruA deletion was not tested due to technical reasons. Data represent EOP, average of 3 replicates; error bars are STD.

[0037] Figure 7A-7C present the identified members of the Wadjet system and analysis thereof. The Wadjet system was shown to provide protection against plasmid transformation in B. subtilis. (Figure 7A) Representative instances of the Wadjet system and their defense island context. Genes known to be involved in defense are orange. RM, restriction-modification; TA, toxin-antitoxin; Abi, abortive infection. (Figure 7B) Domain organization of the three types of Wadjet. (Figure 7C) Wadjet reduces plasmid transformation efficiency in B. subtilis. Wadjet systems were taken from B. cereus Ql (Type I), Bacillus vireti LMG 21834 (Type II) and Bacillus thuringiensis serovar finitimus YBT-020 (Type III) (Table 4) and cloned into B. subtilis BEST7003. Gene deletions and point mutations are of the B. cereus Ql Type I Wadjet. Transformation efficiency of plasmid pHCMC05 into Wadjet-containing strains is presented as a percentage of the transformation efficiency to B. subtilis BEST7003 carrying an empty vector instead of the Wadjet system. Average of 3 replicates; error bars represent STD.

DETAILED DESCRIPTION

[0038] In the following detailed description, numerous specific details are set forth in order to provide a thorough understanding of the defense systems disclosed herein, including cells comprising these systems, methods of producing cells comprising these systems, methods of identifying the defense systems, and products, for example but not limited to food products or probiotic supplements, that may comprise these the defense systems. In some instances, well- known methods, procedures, and components have not been described in detail so as not to obscure the present disclosure.

[0039] The evolutionary pressure imposed by phage predation on bacteria has resulted in the development of both anti-phage bacterial resistance systems and counter-resistance mechanisms developed by phages. Harnessing the anti-phage bacterial mechanisms to improve industrial processes by e.g. curtailing the propagation and evolution of phages in fermentation vats in the manufacturing of food products, commodity chemicals, and biotechnology products is a standing goal in biological research. On the counter arm, properly formulated and applied phages or their defense mechanisms have sufficient potential to cure bacterial infections.

[0040] In some embodiments, disclosed herein are the defense systems, including but not limited to anti-phage defense systems, methods for producing and using such defense systems, and methods of countering such defense systems. In some embodiments, disclosed herein are defense systems that provide a host cell with resistance to foreign nucleic acid invasion. In some embodiments, a defense system described herein, provides the host cell with resistance to a foreign nucleic acid invasion, wherein the foreign nucleic acid invasion comprises resistance to at least one phage infection, or resistance to plasmid transformation, or a combination of resistance to at least one phage infection and resistance to plasmid transformation. In some embodiments, it is the combination of defense systems that provides a host cell with resistance to a foreign nucleic acid invasion.

[0041] Taken together, the disclosure presented herein of anti-phage defense systems or functional portions thereof may in some embodiments be used for conferring phage resistance in microbial cells. Bacteria comprising these anti-phage defense systems can be utilized for example in the dairy industry, where phages cause serious annual losses, as well as in other industries that rely on large-scale bacterial fermentation for biotechnological production. Alternatively, an agent able to antagonize a defense system may in some embodiments can be used as an antibiotic or in conjunction with known antibiotics.

[0042] In addition, embodiments disclosed herein include methods of use of defense systems for gene editing, for example but not limited to, for cloning and cutting a nucleic acid sequence leading to specific deletion of a gene, repair of a gene, or replacement of a gene.

Genetic Systems That Defend Against Foreign Nucleic Acid (DNA and RNA)

[0043] In some embodiments, disclosed herein is a genetic system that defends a host cell against foreign nucleic acid invasion. One skilled in the art would appreciate that defense against a foreign nucleic acid invasion may encompass, defending against entry of a foreign nucleic acid into the host cell, as well as, defending against the actions of a foreign nucleic acid that has entered the host cell. In some embodiments, defense against a foreign nucleic acid invasion comprises defense from phage infection. In some embodiments, defense against a foreign nucleic acid invasion comprises defense from plasmid transformation. In some embodiments, defense against a foreign nucelci acid invasion comprises defense against entry of a conjugative element. In some embodiments, defense against a foreign nucelci acid invasion comprises defense against any combination of phage infection, plasmid transformation, and entry of a conjugative element.

[0044] In some embodiments a foreign nucleic acid comprises a foreign DNA. In some embodiments a foreign nucleic acid comprises a foreign RNA.

[0045] In some embodiments, disclosed herein is a genetic system that defends against foreign DNA. (Tables 4, and 6-17) The skilled artisan would appreciate that as used herein the term "defense system" encompasses genetic systems that defend against foreign nucleic acid elements, including foreign DNA elements and foreign RNA elements.

[0046] In some embodiments, a defense system described herein functions as an anti-phage defense system, wherein the system provides a microbial cell resistance to phage infection. In some embodiments, a defense system described herein functions as an anti-phage defense system, wherein the system provides bacteria resistance to phage infection. In some embodiments, the defense system functions as an anti-plasmid transformation defense system, wherein the system reduces the transformation of a host cell by plasmid vectors. In some embodiments, the defense system functions as an anti-plasmid transformation defense system, wherein the system reduces the transformation of a microbial cell by plasmid vectors. In some embodiments, the defense system functions as an anti-plasmid transformation defense system, wherein the system reduces the transformation of bacteria by plasmid vectors.

[0047] The skilled artisan would appreciate that a defense system may in some embodiments, be introduced into a microbial cell in which such a defense system is not present. In some embodiments, a defense system may be introduced into a bacterium cell in which such a defense system is not present. In some embodiments, a defense system may be introduced into a microbial cell in which such a defense system is not functional. In some embodiments, a defense system may be introduced into a bacterium cell in which such a defense system is not functional. In some embodiments, a defense system may be introduced into a microbial cell in which such a defense system is not expressed. In some embodiments, a defense system may be introduced into a bacterium cell in which such a defense system is not expressed.

[0048] In some embodiments, introduction of a defense system into a microbial cell in which such a defense system is not present, provides the microbial cell resistance to foreign nucleci acid invasion. In some embodiments, integration of a defense system into the genome of a microbial cell in which such the defense system is not present, provides the microbial cell resistance to foreign nucleci acid invasion. In some embodiments, integration of functional components of a defense system into the genome of a microbial cell in which such the defense system is not present, provides the microbial cell resistance to foreign nucleci acid invasion. In some embodiments, integration of at least one functional component of a defense system into the genome of a microbial cell in which such the defense system is not present, provides the microbial cell resistance to foreign nucleci acid invasion.

[0049] In some embodiments, introduction of a defense system into a microbial cell in which such a defense system is not present, provides the microbial cell resistance to phage infection. In some embodiments, integration of a defense system into the genome of a microbial cell in which such the defense system is not present, provides the microbial cell resistance to phage infection. In some embodiments, integration of functional components of a defense system into the genome of a microbial cell in which such the defense system is not present, provides the microbial cell resistance to phage infection. In some embodiments, integration of at least one functional component of a defense system into the genome of a microbial cell in which such the defense system is not present, provides the microbial cell resistance to phage infection.

[0050] In some embodiments, introduction of a defense system into a bacterium cell in which such a defense system is not present, provides the bacterium resistance to foreign nucleic acid invasion. In some embodiments, introduction of a defense system into a bacterium cell in which such a defense system is not present, provides the bacterium resistance to phage infection. In some embodiments, integration of a defense system into the genome of a bacterial cell in which such the defense system is not present, provides the bacterium cell resistance to phage infection. In some embodiments, integration of functional components of a defense system into the genome of a bacterium cell in which such the defense system is not present, provides the bacterium cell resistance to phage infection. In some embodiments, integration of at least one functional component of a defense system into the genome of a bacterium cell in which such the defense system is not present, provides the bacterial cell resistance to phage infection. Resistance to phage infection in bacteria may occur for example, but not limited to, abortive infection of a phage, blocking phage adsorption to the bacterium surface, acquired immunity, preventing phage lysogeny in bacteria, causing degradation of phage genome in bacteria, inhibition of phage replication, and inhibition of phage genome replication, not causing an abortive infection;

[0051] In some embodiments, a defense system disclosed herein is not present in a microbial cell species. In some embodiments, a defense system disclosed herein is not present in a bacterial cell species.

[0052] In some embodiments, a defense system disclosed herein is not functional in a microbial cell species. In some embodiments, a defense system disclosed herein is not functional in a bacterial cell species. Thus, in some embodiments, introduction of a defense system into a microbial cell lacking a functional version of the defense system disclosed herein, provides resistance to foreign nucleic acid invasion. In some embodiments, introduction of a defense system into a microbial cell lacking a functional version of the defense system disclosed herein, provides resistance to phage infection.

[0053] In some embodiments, introduction of a defense system into a microbial cell in which such a defense system is not present, provides the microbial cell resistance to plasmid transformation. In some embodiments, integration of a defense system into the genome of a microbial cell in which such the defense system is not present, provides the microbial cell resistance to plasmid transformation. In some embodiments, integration of functional components of a defense system into the genome of a microbial cell in which such the defense system is not present, provides the microbial cell resistance to plasmid transformation. In some embodiments, integration of at least one functional component of a defense system into the genome of a microbial cell in which such the defense system is not present, provides the microbial cell resistance to plasmid transformation.

[0054] In some embodiments, introduction of a defense system into a bacterium cell in which such a defense system is not present, provides the bacterium resistance to plasmid transformation. In some embodiments, integration of a defense system into the genome of a bacterial cell in which such the defense system is not present, provides the bacterium cell resistance to plasmid transformation. In some embodiments, integration of functional components of a defense system into the genome of a bacterium cell in which such the defense system is not present, provides the bacterium cell resistance to plasmid transformation. In some embodiments, integration of at least one functional component of a defense system into the genome of a bacterium cell in which such the defense system is not present, provides the bacterial cell resistance to plasmid transformation. Resistance to plasmid in bacteria may occur for example, but not limited to, reduced transformation efficiency, inhibition of plasmid establishment, and or inhibition of transformation.

[0055] In some embodiments, introduction of a defense system into a bacterium cell in which such a defense system is not present, provides the bacterium protection from conjugative elements. In some embodiments, integration of a defense system into the genome of a bacterial cell in which such the defense system is not present, provides the bacterium cell protection from conjugative elements. In some embodiments, integration of functional components of a defense system into the genome of a bacterium cell in which such the defense system is not present, provides the bacterium cell resistance to conjugation with another bacterium. In some embodiments, integration of at least one functional component of a defense system into the genome of a bacterium cell in which such the defense system is not present, provides the bacterial cell resistance to conjugation with another bacterium. The skilled artisan would appreciate that the term "conjugative elements" may encompass mobile genetic elements, plasmids, and transposons.

[0056] A skilled artisan would appreciate that a defense system includes but is not limited to a system that defends a cell from foreign nucleic acid. In some embodiments, a defense system includes but is not limited to a system that defends a cell from foreign DNA. In some embodiments, a defense system includes but is not limited to a system that defends a cell from foreign RNA. In some embodiments, a defense system includes but is not limited to an anti- plasmid system. In some embodiments, a defense system includes but is not limited to an anti- transposon system. In some embodiments, a defense system includes but is not limited to an anti-conjugation system. In some embodiments, a defense system includes but is not limited to an anti-phage system.

[0057] In some embodiments, the nucleic acid comprises a linear nucleic acid molecule. In some embodiments, the nucleic acid comprises circular nucleic acid molecule. In some embodiments, the nucleic acid comprises a single stranded nucleic acid molecule. In some embodiments, the nucleic acid comprises a double stranded nucleic acid molecule. The skilled artisan would appreciate that foreign nucleic acid may in some embodiments, encompass any nucleic acid molecule foreign to, for example, but not limited to a microbial cell, a bacterium cell, or an archaeal cell.

[0058] In some embodiments, a foreign nucleic acid comprises a foreign DNA or foreign RNA. In some embodiments, a foreign DNA or foreign RNA comprises a phage. In some embodiments, a foreign DNA or foreign RNA comprises a plasmid. In some embodiments, a foreign DNA or foreign RNA comprises a conjugative element. In some embodiments, a foreign DNA or foreign RNA comprises a mobile genetic element. In some embodiments, a foreign DNA or foreign RNA comprises a mobile genetic element.

[0059] In some embodiments, a defense system protects bacteria from phage infection. In some embodiments, a defense system protects bacteria from plasmid transformation. In some embodiments, a defense system protects bacteria from conjugative elements. In some embodiments, a defense system provides a bacteria resistance to phage infection. In some embodiments, a defense system provides a bacteria resistance to plasmid transformation. In some embodiments, a defense system provides a bacteria resistance to entry of conjugative elements.

[0060] Disclosed herein, is the identification of defense systems. In some embodiments, the components of a defense system are located in a gene cluster in a prokaryotic cell. The terms "gene cluster", "cassette of genes", "cassette", and "components of a system", may in some embodiments herein be used interchangeably having all the same meanings and qualities.

[0061] In some embodiments, each gene of a "cassette of genes" comprises a nucleic acid sequence encoding a polypeptide component of the defense system. In some embodiments, a "cassette of genes" comprises nucleic acid sequences encoding components of the defense system including open reading frames encoding defense system polypeptide components, regulatory sequences, and non-coding RNAs. A skilled artisan would appreciate that a "cassette of genes" may encompass an operon. In some embodiments, a cassette of genes comprises regulatory sequences. In some embodiments, a cassette of gene comprises non-coding RNAs.

[0062] In some embodiments, disclosed herein is a nucleic acid construct of a Defense System. In some embodiments, a nucleic acid construct of a Defense System comprises at least two nucleic acid constructs each expressing at least one of the polypeptide components of the Defense System. In some embodiments, disclosed herein is a nucleic acid construct of a Defense System comprising at least two nucleic acid constructs each expressing at least one functional polypeptide component of the Defense System.

[0063] In some embodiments, the nucleic acid construct comprises a plurality of constructs each expressing a single component of a Defense System described herein. In some embodiments, the nucleic acid construct comprises a plurality of constructs each expressing a single functional component of a Defense System described herein.

[0064] In some embodiments, a single nucleic acid construct encodes a number of polypeptide components of a Defense System described herein. In some embodiments, a single construct encodes a number of functional polypepdie components of a Defense System described herein.

[0065] A skilled artisan would recognize that the term "anti-phage activity" or "resistant to infection by at least one phage" encompasses an activity providing increased resistance of a host cell to infection by at least one phage in comparison to the host cell of the same species under the same developmental stage (e.g. culture state) which does not express the functional defense system. In some embodiments, a host cell may comprise a microbial cell. In some embodiments, a host comprises a bacterium. Anti-phage activity or resistance of a host cell to infection by at least one phage may be determined by, for example but not limited to, bacterial viability, phage lysogeny, phage genomic replication or phage genomic degradation, or a combination thereof.

[0066] A skilled artisan would appreciate that the term "abortive infection (Abi)" encompasses a controlled cell death of an infected bacterial cell which takes place prior to the production of phage progeny, thus protecting the culture from phage propagation. Methods of analyzing Abi include, but are not limited to cell survival assays using high multiplicity of infection, one step growth assays and determination of phage DNA replication by e.g. DNA sequencing and southern blot analysis as further described hereinbelow.

[0067] A skilled artisan would appreciate that the phrase "not affecting phage adsorption" encompasses a non-statistically significant difference in phage adsorption to bacteria expressing a functional defense system in comparison to bacteria of the same species under the same developmental stage (e.g. culture state) which does not express a functional defense system.

[0068] A skilled artisan would appreciate that the term "adsorption" encompasses the attachment to the host (e.g. bacteria) cell surface via plasma membrane proteins and glycoproteins. Methods of analyzing phage adsorption include, but are not limited to enumerating free phages in bacterial cultures infected with the phages immediately after phage addition and at early time points (e.g. 30 minutes) following phage addition as further described hereinbelow.

[0069] A skilled artisan would appreciate that the term "prevent" or "preventing" encompasses a decrease in activity (e.g. phage genomic replication, phage lysogeny, circularization of phage genome) in bacteria expressing a functional defense system in comparison to bacteria of the same species under the same developmental stage (e.g. culture state) which does not express a functional defense system. According to specific embodiments the decrease is at least 1.5 fold, at least 2 fold, at least 3 fold, at least 5 fold, at least 10 fold, or at least 20 fold as compared to same in the absence of the functional defense system.

[0070] A skilled artisan would appreciate that the term "resistance" to, for example, foreign nucleic acid invasion, encompasses a decrease in activity (e.g. phage genomic replication, phage lysogeny, circularization of phage genome) in bacteria expressing a functional defense system in comparison to bacteria of the same species under the same developmental stage (e.g. culture state) which does not express a functional defense system. According to specific embodiments the decrease provided by such resistance to foreign nucleic acid invasion is at least 1.5 fold, at least 2 fold, at least 3 fold, at least 5 fold, at least 10 fold, or at least 20 fold as compared to same in the absence of the functional defense system.

[0071] A skilled artisan would appreciate that the term "phage genomic replication" encompasses production of new copies of the phage genome which can be dsDNA or ssDNA. Methods of analyzing phage genomic replication are well known in the art, and in the Examples section which follows.

[0072] A skilled artisan would appreciate that the term "lysogeny" encompasses the incorporation of the phage genetic material inside the genome of the host (e.g. bacteria). Methods of analyzing phage lysogeny are well known in the art and include, but not limited to, DNA sequencing and PCR analysis. Typically, when a temperate phage infects a bacterium, its genetic material becomes circular before it incorporates into the bacterial genome. Circularization of phage genome can be analyzed by methods well known in the art including, but not limited to, PCR analysis as described e.g. in the Examples section which follows.

[0073] When referring to "degradation of phage genome" the meaning is the cleavage of the foreign phage genome by the host bacteria. Method of analyzing genomic degradation are well known in the art including, but not limited to, DNA sequencing and PCR analysis.

[0074] A skilled artisan would appreciate that the term "restriction modification system" may encompass a restriction entity having an activity of cleaving a genomic molecule (e.g. DNA) / DNA and a modification entity capable of protecting (e.g., by methylation) the host DNA from the cleavage by the restriction enzyme e.g. by methylating the host DNA. Analyzing restriction modification mode of action include, but is not limited to, evaluation of host specific methylation, presence of degraded foreign DNA and host cell death in the absence of the modification enzyme by methods described herein.

[0075] In some embodiments, a functional defense system leads to an abortive infection in bacteria expressing the defense system. In some embodiments, a functional defense system reduces affect phage adsorption to bacteria expressing the defense system. In some embodiments, a functional defense system prevents phage genomic replication in bacteria expressing the defense system. In some embodiments, a functional defense system prevents phage lysogeny in bacteria expressing the defense system. In some embodiments, a functional defense system prevents circularization of a phage genome in bacteria expressing the defense system. In some embodiments, a functional defense system leads to degradation of a phage genome in bacteria expressing the defense system. In some embodiments, a functional defense system comprises a restriction modification system. In some embodiments, a functional defense system comprises a gene editing system.

[0076] In some embodiments, a functional defense system does not lead to an abortive infection in bacteria expressing the defense system. In some embodiments, a functional defense system does not affect phage adsorption to bacteria expressing the defense system. In some embodiments, a functional defense system does not prevent phage genomic replication in bacteria expressing the defense system. In some embodiments, a functional defense system does not prevent phage lysogeny in bacteria expressing the defense system. In some embodiments, a functional defense system does not prevent circularization of a phage genome in bacteria expressing the defense system. In some embodiments, a functional defense system does not lead to degradation of a phage genome in bacteria expressing the defense system. In some embodiments, a functional defense system does not comprise a restriction modification system.

[0077] A skilled artisan would recognize that the term "anti-plasmid transformation" or "reducing the transformation of a host cell by a plasmid vector" encompasses an activity whereby a host cell, for example but not limited to bacteria, expressing a functional defense system as disclosed herein, has reduced transformation efficiency of an episomal plasmid, in comparison to the host cell of the same species under the same developmental stage (e.g. culture state) which does not express the functional defense system. Anti-plasmid transformation or reduction of transformation efficiency may be determined by, for example but not limited to, measuring plasmid transformation efficiency in the presence or absence of a defense system disclosed herein.

[0078] In some embodiments, a plasmid may undergo integration into the bacterial genome or may be episomal. In some embodiments, the plasmid is episomal. In some embodiments, the plasmid is integrative. In some embodiments, a Defense System disclosed herein, provides plasmid resistance.

[0079] The skilled artisan would appreciate that "plasmid resistance" or "anti-plasmid activity" encompasses an increase resistance of at least two-fold increased bacterial resistance towards plasmid transformation, in comparison to bacteria of the same species under the same developmental stage (culture state) which does not express the Defense System. In some embodiments, plasmid resistance may be manifested as viability of the bacteria. In some embodiments, plasmid resistance comprises decreased efficiency of transformation of the plasmid. According to a specific embodiment, the plasmid resistance is increased by at least two-fold, five-fold, ten-fold, twenty-fold, fifty-fold, one-hundred-fold, or one-thousand-fold.

[0080] Assays for testing plasmid resistance are well known in the art and include, but not limited to, a transformation assay such as described in Itaya and Tsuge [Methods Enzymol (2011) 498:427-47]. [0081] As used herein, the terms "the defense system" may in some embodiments be used interchangeably with the term "defense system" or "defense system" or "system", having all the same meanings and qualities.

[0082] In some embodiments, different defense systems may be combined. Combination of defense systems, may in certain embodiments, provide multiple types of defense against foreign nucleic acid. For example, but not limited to defense against phage infection of phage from different families, or defense against phage infection and protection against conjugative elements, or defense against phage infection and resistance to plasmid transformation.

[0083] In some embodiments, a nucleic acid construct encodes an at least one defense system, said nucleic acid construct comprising nucleic acid sequences encoding polypeptide components of a defense system. In some embodiments, a nucleic acid construct described herein, encodes at least one defense system described herein. In some embodiments, a nucleic acid construct described herein, encodes at least one functional defense system described herein. In some embodiments, a nucleic acid construct comprises a nucleic acid encoding at least two different polypeptide components of the defense system. In some embodiments, a nucleic acid construct comprises a nucleic acid encoding at least one polypeptide components of the defense system. In some embodiments, a nucleic acid construct comprises a nucleic acid encoding at least three different polypeptide components of the defense system. In some embodiments, a nucleic acid construct comprises a nucleic acid encoding at least four two different polypeptide components of the defense system. In some embodiments, a nucleic acid construct comprises a nucleic acid encoding at least five different polypeptide components of the defense system.

[0084] In some embodiments, a nucleic acid construct encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system. In some embodiments, a nucleic acid construct encodes more than one component of the defense system but less than all of the components required for a functionally active defense system, whereby multiple constructs may be used to assemble the functional defense system. In some embodiments, a nucleic acid construct encodes more than one copy of a signle component of the defense system, whereby multiple constructs may be used to assemble the functional defense system.

[0085] The skilled artisan would recognize that the "components" making up a functional defense system may in some embodiments, be also be referred to herein as the members of the "cassette of genes" identified to represent a defense system, wherein each component is encoded by a different gene. In some embodiments, a construct disclosed herein may comprise less than the full complement of polypeptides required for a functional defense system, whereby multiple constructs may be combined for expression of the functional defense system. In some embodiments, components comprise polypeptide molecules of a defense system. In some embodiments, components comprise non-coding RNAs. In some embodiments, components comprise promoters and other control elements.

[0086] In some embodiments, a defense system described herein comprises all of the polypeptide componenets as described herein. In some embodiments, a defense system comprises one of the polypeptide component as described herein. In some embodiments, a defense system comprises all of the polypeptide component as described herein. In some embodiments, a defense system comprises two of the polypeptide component as described herein. In some embodiments, a defense system comprises three of the polypeptide component as described herein. In some embodiments, a defense system comprises four of the polypeptide component as described herein. In some embodiments, a defense system comprises five of the polypeptide component as described herein. In some embodiments, a defense system comprises more than one copy of a particular polypeptide component of the defense system, as described herein.

[0087] A skilled artisan would appreciate that the term "nucleic acid sequence" and "polynucleotide", which are interchangeably used herein, may encompass a single or double stranded nucleic acid sequence which is isolated and provided in the form of an RNA sequence, a complementary polynucleotide sequence (cDNA), a genomic polynucleotide sequence, and/or a composite polynucleotide sequences (e.g., a combination of the above).

[0088] In some embodiments, a nucleic acid construct disclosed herein encodes no more than 20, no more than 15, no more the 10 genes expression products. In some embodiments, a gene expression product comprises a component of a Defense System. In some embodiments, a gene expression product comprises a functional component of a Defense System. In some embodiments, a gene expression product comprises a portion of a component that is functional in a Defense System disclosed herein. In some embodiments, a gene expression product or a portion thereof is isolated. In some embodiments, a gene expression product or a portion thereof is comprised in a Defense System disclosed herein.

[0089] A skilled artisan would appreciate that the term "isolated" encompasses an element being at least partially separated from the natural environment, physiological environment e.g., a microorganism e.g., bacteria, e.g., a polypeptide, eg., a nucleic acid sequence.

[0090] A skilled artisan would appreciate that the term "polypeptide" encompasses native peptides (either degradation products, synthetically synthesized peptides or recombinant peptides) and peptidomimetics (typically, synthetically synthesized peptides), as well as peptoids and semipeptoids which are peptide analogs, which may have, for example, modifications rendering the peptides more stable while in a body or more capable of penetrating into cells. Such modifications include, but are not limited to N terminus modification, C terminus modification, peptide bond modification, backbone modifications, and residue modification. Methods for preparing peptidomimetic compounds are well known in the art and are specified, for example, in Quantitative Drug Design, C.A. Ramsden Gd., Chapter 17.2, F. Choplin Pergamon Press (1992), which is incorporated by reference as if fully set forth herein.

[0091] The polypeptides disclosed herein may be synthesized by any techniques known to those skilled in the art of peptide synthesis, for example but not limited to recombinant DNA techniques or solid phase peptide synthesis.

[0092] In some embodiments, a defense system comprises multiple nucleic acid constructs comprising nucleic acid sequences encoding polypeptide components of two or more functional the defense system. In some embodiments, the two or more functional the defense system do not naturally occur together in a cell in nature.

[0093] In some embodiments, each nucleic acid construct encoding a defense system or components of a defense system, further comprises a regulatory element or elements operably linked to the construct. In some embodiments, regulatory elements comprise a cis-acting regulatory element for directing expression of said nucleic acid sequence. In some embodiments, regulatory elements comprise a transmissible element for directing transfer of said nucleic acid sequence from one cell to another. In some embodiments, regulatory elements comprise a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct. In some embodiments, regulatory elements comprise an element providing episomal maintenance of said construct within a cell transfected with said construct. In some embodiments, regulatory elements comprise a combination of a cis-acting regulatory element for directing expression of said nucleic acid sequence, a regulatory element comprising a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, a regulatory element comprising a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, a regulatory element comprising an element providing episomal maintenance of said construct within a cell transfected with said construct, in any combination.

[0094] Defense Systems

[0095] In some embodiments, the defense systems disclosed herein may be a combination of defense systems. In some embodiments, a combination of the defense systems comprises an anti-phage system and an anti-plasmid system. In some embodiments, a combination of the defense systems comprises an anti-phage system and an anti-conjugative element system. In some embodiments, a combination of the defense systems comprises an anti-plasmid system and an anti-conjugative element system. In some embodiments, a combination of the defense systems comprises an anti-phage system, an anti-plasmid system, and an anti-conjugative element system. In some embodiments, a combination of the defense systems comprises an anti- phage system, an anti-plasmid system, or an anti-conjugative element system, or any combination thereof.

[0096] In some embodiments, introducing any of the defense systems disclosed herein, into eukaryotic cells, for example but not limited to bacteria cells, where they are not naturally found (therefore the defense system is non-naturally occurring), provides the host cells protection against phage infection.

[0097] In some embodiments, nucleic acid sequences or nucleic acid constructs may further include nuclear targeting signals (NLS) so that a nucleic acid sequence encoding a non-naturally polypeptide component, may be directed to the nucleus for expression. In some embodiments, nucleic acid sequences or nucleic acid constructs may further include nuclear targeting signals (NLS) so that multiple nucleic acid sequences encoding non-naturally polypeptide components or a defense system described herein, may be directed to the nucleus for expression. In some embodiments, nucleic acid sequences or nucleic acid constructs may further include nuclear targeting signals (NLS) so that combinations of nucleic acids encoding defense systems (polypepitdes) described herein, may be directed to the nucleus for expression.

[0098] In some embodiments, introducing any of the defense systems disclosed herein, into eukaryotic cells, for example but not limited to bacteria cells, where they are not naturally found (therefore they are non-naturally occurring), provides the host cells protection against introduction of external DNA. In some embodiments, introducing any of the defense systems disclosed herein, into eukaryotic cells, for example but not limited to bacteria cells, where they are not naturally found, provides the host cells protection against introduction of external plasmid DNA. In some embodiments, introducing any of the defense systems disclosed herein, into eukaryotic cells, for example but not limited to bacteria cells, where they are not naturally found, provides the host cells protection against introduction of external conjugative elements.

[0099] In some embodiments, a combination of the defense systems comprises combining an anti-phage system and another anti-phage system. In some embodiments, a combination of the defense systems comprises combining an anti-phage system and more than one other anti-phage system. In some embodiments, a combination of the defense systems comprises combining an anti-phage system and two other anti-phage systems. In some embodiments, a combination of the defense systems comprises combining an anti-phage system and three other anti-phage systems. In some embodiments, a combination of the defense systems comprises combining an anti-phage system and four other anti-phage systems. In some embodiments, a combination of the defense systems comprises combining an anti-phage system and five other anti-phage systems. In some embodiments, a combination of the defense systems comprises combining an anti-phage system and six other anti-phage systems. In some embodiments, a combination of the defense systems comprises combining an anti-phage system and seven other anti-phage systems. In some embodiments, a combination of the defense systems comprises combining an anti-phage system and eight other anti-phage systems. In some embodiments, a combination of the defense systems comprises combining an anti-phage system and nine other anti-phage systems. In some embodiments, a combination of the defense systems comprises combining an anti-phage system and ten other anti-phage systems. In some embodiments, a combination of the defense systems comprises combining an anti-phage system and more than 10 other anti- phage systems. In some embodiments, a combination of the defense systems comprises combining an anti-phage system with between 2-15 other anti-phage systems. In some embodiments, a combination of the defense systems comprises combining an anti-phage system with between 2-7 other anti-phage systems. In some embodiments, a combination of the defense systems comprises combining an anti-phage system with between 7-15 other anti-phage systems.

[00100] In some embodiments, an at least one defense system comprises any of the defense systems described herein. In some embodiments, an at least one defense system comprises any combination of the defense systems described herein. In some embodiments, wherein a defense system comprises at least two different polypeptide components (See below and Table 18), an at least one defense system comprises at least two different polypeptide components of the defense system.

[00101] Below are non-limiting examples of defense systems, which in some embodiments may be used independently, and in other embodiments may be used in combinations.

[00102] The ZORYA Defense System

[00103] In some embodiments, a defense system disclosed herein comprises a ZORYA anti- phage defense system. In some embodiments, a ZORYA defense system (Defense System la or Defense system lb) provides a host cell with resistance to entry of foreign nucleic acid invasion. In some embodiments, a host cell expressing a functional ZORYA defense system (Defense System la; or Defense System lb) provides the host cell resistance foreign nucleic acid invasion.

[00104] In some embodiments, a ZORYA defense system provides a host cell with resistance to at least one phage. In some embodiments, a ZORYA Type I defense system provides a host cell with resistance to at least one phage. In some embodiments, a ZORYA Type II defense system provides a host cell with resistance to at least one phage. (Table 8)

[00105] In some embodiments, expression of a ZORYA defense system in bacteria protects the bacteria from phage infection. In some embodiments, expression of a ZORYA Type I defense system in bacteria protects the bacteria from phage infection. In some embodiments, expression of a ZORYA Type II defense system in bacteria protects the bacteria from phage infection.

[00106] In some embodiments, a ZORYA defense system (Defense System la or Defense system lb) provides a host cell with resistance to plasmid transformation. In some embodiments, a host cell expressing a functional ZORYA defense system (Defense System la or Defense System lb) provides a host cells with resistance to plasmid transformation.

[00107] In some embodiments, a ZORYA defense system(Defense system la or lb) provides a host cell with resistance to entry of conjugative elements. In some embodiments, a host cell expressing a function ZORYA defense system (Defense System la or lb) provides the host cell resistance from entry of conjugative elements.

[00108] As used herein, the term "a ZORYA anti-phage defense system" may be used interchangeably with the term "a Defense System Γ, having all the same meanings and qualities. Further, in some embodiments, the term "a ZORYA Type I defense system" may be used interchangeably with the term "a Defense System la", having all the same meanings and qualities. In some embodiments, the term "a ZORYA anti-phage defense system" may be used interchangeably with the term "a Defense System la", having all the same meanings and qualities. Further, in some embodiments, the term "a ZORYA Type I defense system" may be used interchangeably with the term "a Defense System la", having all the same meanings and qualities. In some embodiments, the term "a ZORYA anti-phage defense system" may be used interchangeably with the term "a Defense System lb", having all the same meanings and qualities. Further, in some embodiments, the term "a ZORYA Type I defense system" may be used interchangeably with the term "a Defense System lb", having all the same meanings and qualities.

[00109] In some embodiments, a ZORYA defense system provides a host cell with resistance to plasmid transformation. In some embodiments, a ZORYA Type I defense system provides a host cell with resistance to plasmid transformation. In some embodiments, a ZORYA Type II defense system provides a host cell with resistance to plasmid transformation.

[00110] As used herein, the term "ZORYA system" may be used interchangeably in some embodiments with "ZORYA defense system", "ZORYA the defense system", "ZORYA defense system", "ZORYA anti-phage system", "ZORYA Type I defense system", "ZORYA Type II defense system", "Defense System la" and "Defense System lb".

[00111] In some embodiments, a microbial species does not comprise an endogenous Defense System I. In some embodiments, a microbial species does not comprise an endogenous Defense System la. In some embodiments, a microbial species does not comprise an endogenous Defense System lb. In some embodiments, a microbial species does not express an endogenous Defense System I. In some embodiments, a microbial species does not express an endogenous Defense System la. In some embodiments, a microbial species does not express an endogenous Defense System lb. In some embodiments, a microbial species does not express an endogenous functional Defense System I. In some embodiments, a microbial species does not express an endogenous functional Defense System la. In some embodiments, a microbial species does not express an endogenous functional Defense System lb.

[00112] In some embodiments, a bacterial species does not comprise an endogenous Defense System I. In some embodiments, a bacterial species does not comprise an endogenous Defense System la. In some embodiments, a bacterial species does not comprise an endogenous Defense System lb. In some embodiments, a bacterial species does not express an endogenous Defense System I. In some embodiments, a bacterial species does not express an endogenous Defense System la. In some embodiments, a bacterial species does not express an endogenous Defense System lb. In some embodiments, a bacterial species does not express an endogenous functional Defense System I. In some embodiments, a bacterial species does not express an endogenous functional Defense System la. In some embodiments, a bacterial species does not express an endogenous functional Defense System lb.

[00113] A ZORYA Type I defense system (Defense System la) comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence encoding a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, a ZorC polypeptide comprising a pfaml5611 domain, and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof. In some embodiments, a ZORYA Type I defense system comprises a nucleic acid construct comprising a nucleic acid sequence encoding a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide. In some embodiments, a ZORYA Type I defense system comprises a nucleic acid construct comprising a nucleic acid sequence comprising a zorA gene, a zorB gene, a zorC gene, and a zorD gene.

[00114] In some embodiments, a ZORYA Type I defense system (Defense System la) comprises a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, a ZorC polypeptide comprising a pfaml5611 domain, and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof. In some embodiments, a ZORYA Type I defense system (Defense System la) having an anti-phage activity comprises a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, a ZorC polypeptide comprising a pfaml5611 domain, and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof.

[00115] In some embodiments, a ZORYA Type I defense system (Defense System la) comprises at least two polypeptide components selected from a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, a ZorC polypeptide comprising a pfaml5611 domain, and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof. In some embodiments, a ZORYA Type I defense system (Defense System la) having an anti-phage activity comprises at least two polypeptide components seclected from a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, a ZorC polypeptide comprising a pfaml5611 domain, and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof. In some embodiments, a ZORYA Type I defense system (Defense System la) comprises at least three polypeptide components selected from a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, a ZorC polypeptide comprising a pfaml5611 domain, and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof. In some embodiments, a ZORYA Type I defense system (Defense System la) having an anti-phage activity comprises at least three polypeptide components seclected from a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, a ZorC polypeptide comprising a pfaml5611 domain, and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof. In some embodiments, a ZORYA Type I defense system (Defense System la) comprises at least four polypeptide components selected from a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, a ZorC polypeptide comprising a pfaml5611 domain, and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof. In some embodiments, a ZORYA Type I defense system (Defense System la) having an anti-phage activity comprises at least four polypeptide components seclected from a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, a ZorC polypeptide comprising a pfaml5611 domain, and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof.

[00116] In some embodiments, a Defense System la comprises a ZorA polypeptide comprising a pfam01618 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns J and K; or a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns N and O; or a ZorC polypeptide comprising a pfaml5611 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2- 1174 columns R and S; or a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1174 columns V and W; or said Defense System la comprises any combination of polypeptide components ZorA, ZorB, ZorC, and ZorD.

[00117] A skilled artisan would appreciate that the term "comprising" encompasses inclusion of the recited elements, but not excluding others which may be optional. For example, but not limited to a defense system, a defense system may comprise a single polypeptide component, or may comprise multiple polypeptide components. For example, but not limited to a Defense System la, in some embodiments a Defense System la comprises at least two different polypeptide components selected from ZorA, ZorB, ZorC, and ZorD. In some embodiments, a Defense System la comprises at least three different polypeptide components selected from ZorA, ZorB, ZorC, and ZorD. In some embodiments, a Defense System la comprises polypeptide components ZorA, ZorB, ZorC, and ZorD.

[00118] A skilled artisan would appreciate that the phrase "consisting essentially of may encompass, for example but not limited to, a defense system that includes the recited elements but exclude other elements that may have an essential significant effect on the performance of the method. In some embodiments, a Defense System la consists essentially of polypeptide components ZorA, ZorB, ZorC, and ZorD.

[00119] A skilled artisan would appreciate that the term "consisting of may encompass, for example but not limited to, a defense system that includes the recited elements but not more than traces of other elements. Thus, in some embodiments, a Defense System la consists of a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide.

[00120] Embodiments defined by each of these transition terms are within the scope of this invention.

[00121] A ZORYA Type II defense system (Defense System lb) comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence encoding a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, and a ZorE polypeptide comprising a pfam01844 domain. In some embodiments, a ZORYA Type II defense system (Defense System lb) comprises a nucleic acid construct comprising a nucleic acid sequence encoding a ZorA polypeptide, a ZorB polypeptide, and a ZorE polypeptide. In some embodiments, a ZORYA Type II defense system (Defense System lb) comprises a nucleic acid construct comprising a nucleic acid sequence comprising a zorA gene, a zorB gene, and a zorE gene. [00122] In some embodiments, a ZORYA Type II defense system (Defense System lb) comprises a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, and a ZorE polypeptide comprising a pfam01844 domain. In some embodiments, a ZORYA Type II defense system (Defense System lb) having an anti-phage activity comprises a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, and a ZorE polypeptide comprising a pfam01844 domain.

[00123] In some embodiments, a Zorya Type II defense system (Defense System lb) comprises a ZorE polypeptide and ZorA polypeptide. In some embodiments, a Zorya Type II defense system (Defense System lb) comprises a ZorE polypeptide and ZorB polypeptide. In some embodiments, a Zorya Type II defense system (Defense System lb) comprises a ZorE polypeptide, ZorA polypeptide, and a ZorB polypeptide. In some embodiemnts, a Zorya Type II defense system (Defense System lb) comprises a ZorE polypeptide comprising a pfam01844 domain or a COG3183 domain or a combination thereof. In some embodiemnts, a Zorya Type II defense system (Defense System lb) having an anti-phage activity comprises a ZorE polypeptide comprising a pfam01844 domain or a COG3183 domain or a combination thereof.

[00124] In some embodiments, a Defense System lb comprises a ZorA polypeptide comprising a pfam01618 domain or comprises an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns J and K; or a ZorB polypeptide comprises a pfaml3677 domain or a pfam00691 domain or a combination thereof, or comprises an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rows 2-1830 columns N and O; or a ZorE polypeptide comprising a pfam01844 domain or a COG3183 domain or a combination thereof or comprises an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 8 rowsl 175-1830 columns Z and AA; or any combination thereof.

[00125] In some embodiments, a ZORYA Type I defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide. In some embodiments, a ZORYA Type I defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a zorA gene, a zorB gene, a zorC gene, and a zorD gene. In some embodiments, a ZORYA Type II defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a ZorA polypeptide, a ZorB polypeptide, and a ZorE polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a zorA gene, a zorB gene, and a zorE gene.

[00126] In some embodiments, the ZORYA anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising zorA, zorB, zorC, and zorD genes. In some embodiments, a construct comprising the ZORYA defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system. In some embodiments, the components of a ZORYA Type I defense system comprise genes zorA, zorB, zorC, and zorD. In some embodiments, the components of a ZORYA Type I defense system consist of genes zorA, zorB, zorC, and zorD. In some embodiments, the components of a ZORYA Type I defense system comprise nucleic acid sequences encoding a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide. In some embodiments, the components of a ZORYA Type I defense system consist of nucleic acid sequences encoding a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide.

[00127] In some embodiments, a Zorya Type I (Defense System la) gene cassette comprises the nucleic acid sequence:

1 tgtaaatcct cggggtagat cgcagcgaaa gagcaaccat gccttatcgc aaattcagtt 61 ttggaatgca gttcgcaaaa tgatacccgg tacacttacg attacaaatg cgcggtataa 121 agaagtttgc atttgatcgg tgaataatag gaaactcagt cactgtttcg tctgcaaaat 181 cagccatttc gccttcatac gtagttcttc ggttgaatag taaggtctat catgctgcat 241 cgaacggtga ttttgatgga tgttggaagt gagtagctgt acgtaatttt tgattaaaag 301 taatcaaaat gttgccaatg gttatgctat cgtgtgtttt ttgaatatat aacaggtaaa 361 actatgtcct ggcttaattc tgtcttattg gcgcttacct cggtgcaacc ttatatggta 421 ccggcaaccg ttatcggcct cgtcagtttt gcattcctct gttttatttt cttttatttt 481 tttagagcag ttaaaattat taacggcctg aaaaaatata ctcagtcaat taatggcatc 541 gaaaataatg agcctggtaa tcagcttcag catctgcaaa gtttgtttgt acagcctgag 601 ttaaagcacg cctggaatga attcgaagaa tcgttgcact cacaatatga actggaggac 661 ggggaagaga aaatcgtccg tattagggct actgcaccga gcgccagttt cttctcggag 721 caacaactgg tcgatattcc gctgaacacc gaatttttca aacacctgcc cggtattctg 781 accggtgtgg ggattatcgg taccttctac ggtctgatga ttggtctcaa ccacttcgac 841 cccagcacac cagagcaggt ctccagcagc gtcaataatc tgcttcgcga tgtgctgtac 901 gccttcctcg gttcagcatt tgcgattacg ttctctatcc ttatcacctg gctggagaaa 961 ttctgtctgg cgaaatgcta caaatatctg gaaaaattca ccgcagctct cgacgccctc 1021 tatgacagcg gtgttggcga ggagtacctt gcctcactgg taaaatccag taatgaaagc 1081 gcgacccagg cacgccatct gaaagagagc ctggttaccg atttacgcga tatgctgctg 1141 catctggcca acagccagaa agtggaaaac gagcggctag cgaccaccct cagcaccacc 1201 tatcgcgaaa caggacaaca gtttgccgag caagtcagcg gtgcgattga aaacagcctg 1261 aaatcaccgc tggataaaat agcgggcgcg gttcagaccg ccagtggcga tcaaagcggc 1321 atggtacaaa acatgctgca ggatgtgctg accgcgttta tggcgaaact cgacaccacc

1381 tttggtcagc agtttactaa tctcaacgaa atgatgggac aaaccgttgg cgctattcag

1441 acaatgcaaa ccggtttcgg cgcgttatta caggacatgc gtcaggtgag cgatgattcc

1501 cgccagggca gcgcgcagct catcgagcaa ctgttatcag agatgaaatc tggccagcaa

1561 gctatgcagg ctggcatgaa tgacatgctc accagccttc agacctcggt ggctaaaatt

1621 ggcgcagaag gtgaaggtgc cggcgagcga atggctcgcc aactagagaa aatgttcgct

1681 gatagcgagg cgcgagaaaa agcccaggca gaacatatga ccgcctttat tgaagccatt

1741 cagaattcag tgcagcaggg acaaagcgcc acaatggaaa aaatggcagc ctctgtcgag

1801 tcgcttggtg aacaactggg tagcctgttt gggcagattg ataagggtca gcaacagatt

1861 tcagcaaatc agcaagcgaa tcagcagtcc ctgcacgaac agactcagcg ggtaatgagt

1921 gaggtagacg atcagattaa acaattggtc gaaactgttg ccagccagca tcagggaaca

1981 actgaaacac ttcgtttact cgcagaacaa actaaccgcc agattcagga tatgcatacc

2041 ggcgcggaca aaatgcgtct ggcggccgag cgctttgaac atgccggtga tcgggtgtcg

2101 gaagcaaacc accttaccgc tgacgtgctg aataaagcgc aatcggcagg ttcatcactc

2161 tcccttgcca ccagcgaact cacctctgtg gtggctgatt atcgtaacaa tcgggaagcg

2221 gttagcaaat ccattgccat gctggagttg ctcgccgcaa atacgcagtc tgaacaaacc

2281 acgcgcaccc aattcatcgc cgaccttaag cagcacggtg agcgtctgca gagctataac

2341 cgggaagcac aggcctttat ggaaaatgtc agtgacgtgc tagggaaagg gtttgaagac

2401 ttctctgaag gtgtttcacg cagcctggat aaaacgctgg gcaaactgga cgttgaaatg

2461 gcgaaggctt ctactctgct cgcgggttct gtcgaacaga tcggagaaag cgtcagcgag

2521 cttgatgatg tcctgtcacg cgttcgtgcc taaggggtga cggctgatgt ttggaaatgc

2581 atttggcgtt aaaaaacgcc gcagcgatga agcagagaaa cccttctgga tctcctatgc

2641 cgatttgatg actgccatga tggtgttatt tctggtcgtt atggttgcgt cgctgagttc

2701 cgttacgcag cgtattcaac gtgcggagca aggtgaaaaa acacgggggc aggatatttc

2761 cagattgtgt gagcgcctgg aattgcatgc ccgcaacgtg aacaaaacca ttgtggtgga

2821 ttgccatgat aaccgtatca gttttggtga agccgggcgt ttcgatcaca accaattttt

2881 cctgaacgct gaggggcaaa aagccttgca ggatgtggtt cctcttgtgc tggaagcgtc

2941 caacagtgaa gaaggtaaaa aatggtttaa gcagatcgtt attgaagggt ttaccgacac

3001 cgacggttcg tacttataca acctacatct ctccctgcaa cgttctgagt gggtaatgtg

3061 tagtctgctc gatagccgca gccctctgca aaaaaatatc tccgcagaac agcagctcca

3121 aatccgtaaa cttttcctcg cgggtggtgt ctccttcaat aatgccaagg aaagcaagga

3181 agccagccgc cgcgtcgagt tgcgcatgca gttcttcggg cttaaagata aacgtgataa

3241 ggccgatgag gtggatttcc cccccgtcgt caataaagaa gtttgccagt tggtaatgcc

3301 cctatgacgc ctgcactgaa ttctctttct caacgcattg cagcgaggct ctcttccagc

3361 caacgggatg accattatct gcataatgat ttccacgcgc tggcctcagc tgctctcgac

3421 atggaaaagc ggtttgataa ggcagaaaaa atccctttac cgccacaaaa aatgcgactg

3481 gcagctctgc gtcgccttcg ccttgcacaa gaactcacgg agcgagagtg gcggatggtg

3541 ttttatggtc tcgccgataa tgatccgtca tatcctgacc agccagtact gctggaggat

3601 gatacgtttt tccctgaagt aaacaatgca atcaaaaagc ggcttgaaac taaaaccctg

3661 aaacgccgag actgggccgc actctgttca agctattttg cttaccagaa cccatcacct

3721 gagacaaacc cgcactggtg cgtactgcgt ggtcatatcg ctcagggtta catggtggtg

3781 aaagcggcta tacgacgaga aaaatcgtgg atgaaaacca ttgagtttta tcacgatatt

3841 tttaccccgc aggcgggagg cgtgatctcc agacagttac ttgcgggtga gagcaattca

3901 ctctcgtcat tagaaaaaat cgcgcaaatc cctgatagca gttggttgtg gaaacgtatt

3961 ttcacggtgc ttttagcgca actggacaca ctcgacgatc cccagtttct ggacaaaatt

4021 agctggttgt taggtctggc tgcccagtgg gtacgtttcc gtgatgacat catgactgcg

4081 accttgactc gctattacca ttctatttat cgcgatcagg ctcattcagc tttgaagcag

4141 gccgcgctgg aatactggga taacccgcaa ctgaaaagcc agcagaataa atggcatcag

4201 tatgtctctg agccggtggc tgcgatggtc cggggctggc tggcaaaaca agatctgatg

4261 catttctttg aattgctgcg cggtaatggc gatgttgacc aggcacgatt gcactattgg

4321 ctacgtttcg ccaatcagat gggatttacc cgtatcgtca tggggactga tgcctggcaa

4381 gaccgtggta gtgactttgt gaaattccgc gaggagaata agggacgatt gagttactta

4441 cgaggtggac gtaactttga taacgccatg attatgcaga tcaacgatta tctgttcgtt

4501 gagttttccg ggacagggaa tgcaatgtat gcctatcgaa taggtcacgc gccatttaac

4561 cctgaatcac gcacgcttga tatcaacatt catctaaaag ataaggggcg ctgcgtgctc

4621 cgactgcccc atacaccgcg cgcagaaggg tataacaaag tccggataac cggctggatg

4681 ttgaaatacg acgacgagct gcgtcagttg ggcattcggt ggatggcaga agaagccatc

4741 aagtttgtcg ataagaaagc gtcctctccc gcctctatgt ccgacattaa aatcatcaac

4801 ccgttgcgtg atacggctat acagcatctg gttgaaggta gttcatgtat cgtcagcgat 4861 aatcgacaaa aaggtggcgt actgtccgta caactcaata ctcctgacga caccatagaa 4921 agagagttgt tacggctagg ctttgcgccc gtggctaaag aaccgcatcg ttactggatc 4981 aaataatgct gaaacgtctg ttaagtaaac tgacgggaaa ccgtcagcag atagaacatc 5041 acctaaaaaa tcagtaccag gttgaggaaa acggacttag ctttccgcta tcgctggttg 5101 atgattcgca gctttgggca ctggcatcct ggctagaaca actggctgaa gaagactatc 5161 tgatatcact tacagaccgg tggttgttga gttgggacgc actgtatcgc ctgctggagg 5221 atgaggaaca tgccagcagc ctgcctctta tcggtgtacc tgacgtactg cctttacgcg 5281 caagcctgag ttcacgagga gcattaagcg atagcgattt tcgcgtctgg attgctgaat 5341 gggctacgct tccagcccgc aagccgatcc gtttcagtcg taccggtgcc attttaaccc 5401 atgaaaatca gcaatacctg ttatcgcgtg aaaactgggc actcttacag gcaacagaac 5461 aactcagtgc acagaaaaat cagactcctg gtgaaaccac taaccagttg ggatgggccg 5521 ctatccgcaa atgtgcgaag caagcagccg caaaatttga tgattattta gaaaaaacgc 5581 atgtcgtcaa accaacttca ttgtcattac gtctgcgtaa agcaacggtt gccgatactg 5641 ctgttatcga aattgagccc catttcgagg accagcctgc taactggcta ggcagttttg 5701 acaaaaactc gcaggttcac gatagctacc gcatccctgg agagaatggc gaactcagcc 5761 atgtcattat ccctcccgaa gtgaaagaag tcctgaattc aatacactcg attccaagcc 5821 gtcgagtggc cggaagcgaa gcgctttcct ttgttcgcaa tccttatacc ttcctgggtg 5881 aagatgccgc cagtgttatt gcccctgaag aacatgaaca ggcactgttt gatgccagga 5941 ttttctttca tcatttcagg ttgataccgc aactgaatgc ggaaaataag atcgcagaag 6001 ttacgctggt acttgagcct gtttcacctg ttccccagcc agaaatcact tttgggttct 6061 cagccccccg ggagctggat aaattcatac agcaactcgg tattagcgtc gctgcacaga 6121 tgcctgccgg ttcatggcaa ggttacgagc tggaattaag tcagttcact gaacagcagt 6181 ggcacgattg ccaggcactt ctaactcgct ggcagcaaga aatagaagga aaagaattta 6241 gcgatgtgct ggatattgcg aagtatggcg atcgcgtgat tggcattggt gaatttgaaa 6301 aaatctcctc tccctggctg accaaagcgc agagtgaaaa ctggcttcca gatgacatcg 6361 atttctccgc gttttcagtc gaaacactgt ctggctggca acctgaaaac cttcaccatt 6421 tcgatgaact gcaggagaga attactcagg cagaagctgt aggtgaaacg catatcaccg 6481 caccatggaa tgacagccaa ttaccgttgg atgctgctaa aaccttcagt aagaactggg 6541 aaaaacagca aagcactgca aatgaatctc aaggcaacgt tgcagataaa acggcccgag 6601 ccgtactcaa aattgagcag aatattgaag aaacggccta catcaaacag cgccgcaatt 6661 cactcctcaa tgcgcgtcat gccgagcctg aaattcctct gagccttaaa gagcatatcc 6721 gactcaaaga ccatcaacgt gaaggcgtag cctggctcca gcaactcttc cttcgttcac 6781 ctgaggaaac cgcaggttgc ctgctggcgg atgatatggg gcttgggaaa acgctgcaaa 6841 ttctgagctt cctggtatgg ttcattgaaa aattcccgca agaaccgcca agtctcattg 6901 ttgctcctgt ctctctttta gataactggg aacgtgaact ggacaatttc ttctataccg 6961 caggaatacc ggtattgaaa ttgtatggcg agaccattaa agcggtgaaa tatcccaaac 7021 aggctatccc tgctcatctg caatctcagg ggatcaaaaa cctgcttaaa cctggctggc 7081 agggtgaggc gaaaatcatc ctgacaacct acgaaacgct tcgcgaccag gagttttctc 7141 tggcacgcca gccgtggtcc attatggtgt gcgacgaggc acaaaaaata aaaaacccag 7201 ctgcgttaat cacacatgcg gccaacgcgg tacaagccag gtttaaagtg gcatgtacag 7261 gaacacctgt cgaaaacaca cttgtcgacc tgtggagctt atttgatttt gcccagccag 7321 gattgttagg ggcactaaat gaatttggta aacactatgt tcgccccatc gagaacgaag 7381 atggccgcga tacggaacgg ttggaaagcc tgcgagcgct gatagaacct cagactttac 7441 gccgaaccaa agaagaggtt gcgcgtgatt tacctcagaa aattgaagtg gaaagctgca 7501 agcaattgac gttgtctggc gtgcaaaaac agctctacct ttcgtccgtt gcaaattggc 7561 aacaacagca agcactgagc gaagggatgc agcaggccgg aaccggtatg ttaggtttgt 7621 tacaccgact gaaactcatc tgtgcacacc ctgcagtagt taatccagaa ccacgttttc 7681 gtgataactc acccaagctt aactggctgc tgaaaatact cgcagaacta aaacacacca 7741 cgaaagataa ggtcattatt tttacggagc ttcgagattt acagcgcgaa cttcaacatg 7801 cgatccacca aaagtttggt ttccgccctg tcattatcaa tggtgatacc agcactaaaa 7861 gtcaaagtca aaacagccgc cagcgcctga ttgatgattt tcaggctcag cctgggtttg 7921 gggtgattat tctctctacg gttgccgtcg gattcggcgt taacgtccag aaagccaatc 7981 atgttattca tttcactcgc tgctggaacc cagccaaaga agatcaggca acagaccggg 8041 cgtaccgaat tgggcaaact aaagatgtgt atgtctatta cccgacggtg aaggacactg 8101 aaatcaccac atttgaagaa acactggatg accttctgca gcgtcgacgt gcattggcca 8161 gagatatgct ctgcgctact cccgatttga gtggtgcgga ttttgaggcc attttgaagg 8221 gggcttaacc gatacgagtg gcaataccac cagcagtcga accgattcat ttgaaacgac 8281 acgtagccgc gatggatctg tatcacctac cgacagcttg ggaaagtccc gaattacaaa 8341 tgttcagggg aataccataa cctgccggac ttattcgttt ggaacgacgt gttacgactt 8401 agtccgaggg aaacatgcca ggtaaaaacc gaatatccat cctcagcttt agcaaatacc 8461 tccccatact cgctacttca tattgagaag atattgtgtt gctcatattg ctttgagcat 8521 gctcttcagc gtttacatgt ggatcgtact accctgatga tccgatgcgt tgtttactgc 8581 ttttaacctc tatatacaaa acccccacta aatatttttc tgagactaac ggtaaatcat 8641 tatctatcat gtagttacga tagaattgca tgtatctggc acaaaataag gtttcattac 8701 gttctatctt gttaaatata aagggatcat ttcctcccaa agtcacaatc (SEQ ID

NO: 14; Construct 49 Table 4)

[00128] The coding regions for each of the zorA, zorB, zorC, and zorD gene sequences within this embodiment of a Zorya Type I cassette (SEQ ID NO: 14) are as follows: nucleotides 364-2553 encode an embodiment of a ZorA polypeptide; nucleotides 2567-3307 encode an embodiment of a ZorB polypeptide; nucleotides 3304-4986 encode an embodiment of a ZorC polypeptide; and nucleotides 4986-8228 encode an embodiment of a ZorD polypeptide.

[00129] In some embodiments, a Defense System la comprising a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide, is encoded by the nucleic acid sequence set forth in SEQ ID NO: 14. In some embodiments, a Defense System la comprising a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 14. In some embodiments, a Defense System la comprising a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 14. In some embodiments, a Defense System la comprising a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 14. In some embodiments, a Defense System la comprising a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 14.

[00130] In some embodiments, the ZORYA anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising zorA, zorB, and zorE genes. In some embodiments, a construct comprising the ZORYA defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system. In some embodiments, the components of a ZORYA Type II defense system comprise genes zorA, zorB, and zorE. In some embodiments, the components of a ZORYA Type II defense system consist of genes zorA, zorB, and zorE. In some embodiments, the components of a ZORYA Type II defense system comprise nucleic acid sequences encoding a ZorA polypeptide, a ZorB polypeptide, and a ZorE polypeptide. In some embodiments, the components of a ZORYA Type II defense system consist of nucleic acid sequences encoding a ZorA polypeptide, a ZorB polypeptide, and a ZorE polypeptide.

[00131] In some embodiments, a Zorya Type II (Defense System lb) gene cassette comprises the nucleic acid sequence:

1 acctgccttc ctttgataca attcgtaaca ggttactatc atcataaaaa agctcaaccc 61 gatgaactcg ctaaaaatga gacaaatcat ttatatctcg aaaaaacttg ttacaatcat 121 gagcgctaca ccgaacttaa ccatataaat tatgtgtgtt ttgtttattt tttaaacgat 181 tacaactatc cattatttac acaggtatca aaatgttagc gcagcttttt gagcagttgt 241 ttcaatcgat agactctaca ctgatcacca atattttcat ctgggctgtt atattcgtat 301 ttttatcagc gtggtggtgt gacaaaaaaa atatacatag taagtttaga gaatatgctc 361 caaccttaat gggggcatta ggtattctgg gtactttcat tggtattatt attggtttac 421 tcaattttaa taccgaaagt attgatacca gcatccccgt attattaggt ggcctaaaaa 481 cagcattcat tacaagcatt gtaggtatgt tttttgccat tttatttaat ggaatggatg 541 ctttcttttt tgccaataaa cgaagtgcgt tagctgaaaa taaccctgaa tctgttacac 601 ctgaacatat ctatcatgaa ttaaaagagc agaaccagac tctgactaaa ttagtctcgg 661 gtattaacgg tgatagtgaa ggttctctta ttgctcaaat aaaattacta cgtactgaga 721 ttagcgattc ctcgcaggca caattagcta atcacactca tttcagtaat aagctttggg 781 aacaacttga acaatttgca gatctaatgg caaaaggtgc tacagaacaa attattgatg 841 ctttgcgaca agtcattatt gattttaatg aaaatttaac tgaacagttt ggtgaaaact 901 ttaaagctct tgatgcctct gtaaaaaaac ttgttgagtg gcagggaaat tataaaacgc 961 aaattgagca gatgtcagaa caatatcaac aaagtgtcga gtccctggtt gaaacaaaaa 1021 ctgcggttgc agggatttgg gaagaatgta aagaaattcc tctggctatg tctgaactgc 1081 gtgaagtgct tcaggtgaac caacatcaaa tcagcgaact ctcccgccat ttagaaacct 1141 ttgtcgccat ccgcgataaa gctacaaccg tattacctga aatacagaac aaaatggctg 1201 aagtgggtga actgctgaaa tccggagctg caaatgttag tgcatctctt gagcaaacca 1261 gccagcaaat acttcttaat gcagattcaa tgcgcgttgc cctggatgaa ggtaccgaag 1321 gattcagaca atcggttacc caaacacaac aagcatttgc ctcgatggcg catgatgtca 1381 gcaattcctc cgaaacccta accagcacgt taggtgaaac aattactgaa atgaaacaaa 1441 gtggtgaaga attcctgaaa tcactagagt cgcactcgaa agaattgcat agaaatatgg 1501 aacaaaatac gacgaatgtg attgatatgt tcagtaagac tggtgaaaag attaaccatc 1561 aactatccag taatgccgat aatatgtttg attcaatcca gacatcattt gataaggctg 1621 gtgcagggct gacttctcaa gtcagagaat caattgaaaa atttgctcta tccatcaacg 1681 agcagttaca tgcttttgag caagcaactg aacgtgaaat gaaccgtgaa atgcaatcat 1741 taggtaatgc tctgctttca atcagcaaag gttttgtcgg taactatgaa aaacttatta 1801 aagattacca aatagttatg gggcagttac aagcattaat ttctgctaat aaacatcgag 1861 ggtaatcgat catggataag attataggga aacaattacc taaaaaagat caagataatg 1921 aacattgggt atccatgtca gacctaatgg cagggctgat gatggttttt atgttcatat 1981 ctattgctta tatgcactac gtacgtattg aaaaagaaaa aattaaagaa gttgccgtag 2041 cctacgagaa tgctcagtta cagatttata atgctctgga tattgagttt gcaaaggatt 2101 tacaagactg ggatgcagag atcgataaac agactctgga ggttcgattt aaatcaccgg 2161 atgttttatt tggcttagga agcacagagc taaaaccaaa gtttaaactc attcttgacg 2221 acttctttcc tcgctaccta aaagttctag ataattatca ggaacatatt actgaagtcc 2281 gcattgaagg tcacacaagt actgactgga caggaacaac gaatcctgat attgcttatt 2341 ttaataatat ggcactatcg caaggtcgta cacgtgcagt attacaatac gtttatgaca 2401 taaaaaatat cgcgacacac caacaatggg ttaaaagtaa atttgccgca gtaggttatt 2461 catctgcaca tcccattctt gataaaaccg gcaaagagga ccctaatcgc tctcgtcgtg 2521 tcaccttcaa agttgtaaca aatgccgagt tgcagattag aaagattatt caggagtaag 2581 agatgaaatt atctatcgac atttcagaac ttattcaatt agggaagaaa atgttaccag 2641 aaggagtcga tttttttctg gatgaatccc ctattgactt tgatcctata gatattgagt 2701 tatccacggg taaagaagtt agtatcgaag atcttgaccc tggtagcggg cttatctctt 2761 atcatggccg ccaggttctt ttatatattc gggaccattc agggcgttat gatgcggcta

2821 tcgtagatgg cgaaaaagga aaacgttttc atattgcctg gtgcagaact cttgatgaaa

2881 tgcgccataa aaatcgattt gaaaggtatc atgcaactaa ccgcatagat ggtttattcg

2941 aaattgatga tggttcaggt cggagccagg atgttgattt acgggtatgt atgaattgcc

3001 tcgaacgact taattataaa ggaagtattg ataaacaacg aaaaagagag atttttaaat

3061 cattctcatt aaatgagttt ttttcagatt atagtacctg ttttcgtcat atgcctaagg

3121 gtatctatga caaaacaaat agtgggtatg tcgaaaactg gaaggaaata tctaaagaaa

3181 tacgagaaaa ggcaaattat gtttgtaatg attgtggcgt gaatttatca accgccaaaa

3241 acttgtgcca tgtccatcat aaaaatggca tcaaatatga taatcaccat gaaaaccttc

3301 ttgttctgtg caaggattgc catcgaaaac agcccctcca cgaaggtata ttcgttaccc

3361 aagcagagat ggctatcatt caacgtttac gttcccaaca agggttatta aaagcagaat

3421 cctggaatga aatatatgac ctgactgatc catcagtgca tggtgatatt aatatgatgc

3481 aacataaagg ctttcaacct cctgttcctg ggttagatct tcaaaactca gaacatgaaa

3541 ttattgcaac cgtagaagct gcatggccag gccttaaaat tgcagttaac cttactcccg

3601 ccgaagtcga aggatggaga atatataccg tgggtgagct ggttaaagaa atacaaaccg

3661 gagcctttac gccagcaaaa ttgtaaattc taaaactccg tgaaagttaa ggctttcacg

3721 gaagataaat aaagtttccc tgatttgtga ctcaaattac aaaagtagtt tatggcataa

3781 cttgtctgat ttttatggtg taacaggtat aaaagcatat gctatggttc gcctcatact

3841 taaaacttcc ctcatatggg tgaaggttaa agcttggtag acagaagaca gtcacaatga

3901 ataaagcaat aaattga (SEQ ID NO: 15; construct 51 from Table 4).

[00132] The coding regions for each of the zorA, zorB, and zorE gene sequences within this embodiment of a Zorya Type Π cassette (SEQ ID NO: 15) are as follows: nucleotides 213-1865 encode an embodiment of a ZorA polypeptide; nucleotides 1872-2579 encode an embodiment of a ZorB polypeptide; and nucleotides 2583-3686 encode an embodiment of a ZorE polypeptide.

[00133] In some embodiments, a Defense System lb comprising a ZorA polypeptide, a ZorB polypeptide, and a ZorE polypeptide, is encoded by the nucleic acid sequence set forth in SEQ ID NO: 15. In some embodiments, a Defense System lb comprising a ZorA polypeptide, a ZorB polypeptide, and a ZorE polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 15. In some embodiments, a Defense System lb comprising a ZorA polypeptide, a ZorB polypeptide, and a ZorE polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 15. In some embodiments, a Defense System lb comprising a ZorA polypeptide, a ZorB polypeptide, and a ZorE polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 15. In some embodiments, a Defense System lb comprising a ZorA polypeptide, a ZorB polypeptide, and a ZorE polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 15. [00134] In some embodiments, a construct comprising the ZORYA defense system encodes more than one component of the defense system but less than all of the components required for a functionally active defense system, whereby multiple constructs may be used to assemble the functional defense system. For example, in some embodiments each of ZorA, ZorB, ZorC, and ZorD may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional ZORYA Type I defense system. In some embodiments each of ZorA, ZorB, and ZorE may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional ZORYA Type II defense system.

[00135] In some embodiments, the components making up a functional ZORYA Type I anti- phage defense system comprise a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide, each encoded by a zorA, a zorB, a zorC, and a zorD gene, respectively.

[00136] In some embodiments, the components making up a functional ZORYA Type Π anti- phage defense system comprise a ZorA polypeptide, a ZorB polypeptide, and a ZorE polypeptide, each encoded by a zorA, a zorB, and a zorE gene, respectively.

[00137] In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorA polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorA polypeptide and a ZorB polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorA polypeptide and a ZorC polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorA polypeptide and a ZorD polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorA polypeptide and a ZorE polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorA polypeptide, a ZorB polypeptide, and a ZorC polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorA polypeptide, a ZorB polypeptide, and a ZorD polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorA polypeptide, a ZorC polypeptide, and a ZorD polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorB polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorB polypeptide and a ZorC polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorB polypeptide and a ZorD polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorB polypeptide and a ZorE polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorC polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorC polypeptide and a ZorD polypeptide. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid encoding a ZorE polypeptide.

[00138] In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorA gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorA gene and a zorB gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorA gene and a zorC gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorA gene and a zorD gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorA gene and a zorE gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorA gene, a zorB gene, and a zorC gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorA gene, a zorfi gene, and a zorD gene. In some embodiments, a ZORYA defense system having an anti- phage activity comprise a nucleic acid comprising a zorA gene, a zorC gene, and a zorZ) gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorB gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorB gene and a zorC gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorB gene and a zorZ) gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorB gene and a zorE gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorC gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorC gene and a zorZ) gene. In some embodiments, a ZORYA defense system having an anti-phage activity comprise a nucleic acid comprising a zorE gene.

[00139] In some embodiments, a ZORYA defense system having an anti-phage activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3' order of polypeptides encoded is ZorA, ZorB, ZorC, and ZorD. In one embodiment, the 5' to 3' order of polypeptides encoded is ZorA, ZorB, and ZorE. In some embodiments the 5' to 3' order of polypeptides does not affect the anti-phage activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti-phage activity.

[00140] In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of ZorA, ZorB, ZorC, ZorD, and ZorD. In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of ZorA, ZorB, and ZorE.

[00141] In some embodiments, a ZORYA defense system having an anti-phage activity comprises a nucleic acid construct comprising genes in a set order. In some embodiment, the 5' to 3' order of genes is zorA, zorB, zorC, and zorD (Defense System la). In some embodiment, the 5' to 3' order of genes is zorA, zorB, and zorE (Defense System lb). In some embodiment, the 5' to 3' order of genes in a Defense System la is not zorA, zorB, zorC, and zorD. In some embodiment, the 5' to 3' order of genes in a Defense System lb is not zorA, zorB, and zorE. In some embodiments the 5' to 3' order of genes does not affect the anti-phage activity. In some embodiments the 5' to 3' order of genes does affect the anti-phage activity.

[00142] In some embodiments, the 5' to 3' order of genes is random, for example any order of zorA, zorB, zorC, zorD, and zorD. In some embodiments, the 5' to 3' order of genes is random, for example any order of zorA, zorB, and zorE.

[00143] In some embodiments, the ZORYA Type I system (Defense System la) composition and order is as shown in Figure 3C, Figure 4A, and Figure 4B. In some embodiments, the ZORYA Type II system (Defense System lb) composition and order is as shown in Figure 3C, Figure 4D, and Figure 4E.

[00144] In some embodiments, a ZORYA defense system having an anti-phage activity originates from a microbial genome (Table 8).

[00145] In some embodiments, a functional ZORYA defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different microbial species. In some embodiments, a Zorya defense system (Defense system la; Defense system lb) comprises a non- naturally occurring combination of polypeptide components. In some embodiments, a Zorya defense system (Defense system la; Defense system lb) comprises a combination of at least two polypeptides that do not naturally occur together. In some embodiments, a Zorya defense system (Defense system la; Defense system lb) comprises a combination of at least three polypeptides that do not naturally occur together. In some embodiments, a Zorya defense system (Defense system la) comprises a combination of four polypeptides that do not naturally occur together. In some embodiments, a Zorya defense system (Defense system la; Defense system lb) comprises a non-naturally occurring combination of polypeptide components. In some embodiments, a functional Zorya defense system (Defense system la; Defense system lb) comprises a combination of at least two polypeptides that do not naturally occur together. In some embodiments, a functional Zorya defense system (Defense system la; Defense system lb) comprises a combination of at least three polypeptides that do not naturally occur together. In some embodiments, a functional Zorya defense system (Defense system la) comprises a combination of four polypeptides that do not naturally occur together.

[00146] A skilled artisan would appreciate that the term "non-naturally occurring" may encompass in one embodiment, polypeptide that do not naturally occur together in nature. For example, polypeptide components that do not naturally occur together, either because they are from the same defense system found in a different strain of bactieria or because they comprise polypeptide components from different defense systems. In some embodiments, polypeptide components that do not naturally occur together, either because they are from the same defense system found in a different strain of a microorganism, or because they comprise polypeptide components from different defense systems. In some embodiments, the term "non-naturally occurring" may encompass a defense system or a functional defense system that is not found within a particular micro-organism in nature. In some embodiments, the term "non-naturally occurring" may encompass a defense system or a functional defense system that is not found within a particular bacteria in nature. In some embodiments, the term "non-naturally occurring" may encompass a combination of defense systems disclosed herein or a functional defense system disclosed herein that are not found within a particular micro-organism in nature. In some embodiments, the term "non-naturally occurring" may encompass a combination of defense systems disclosed herein or a functional defense systems disclosed herein that are not found within a particular bacteria in nature.

[00147] In some embodiments, introducing a defense system disclosed herein, or any combination of defense systems, into a bacterial strain that naturally lacks the defense system or system may be advantageous for the bacteria. In some embodiments, introducing a defense system disclosed herein, or any combination of defense systems, into a bacterial strain that naturally lacks the defense system or system may be biotechnologically useful in maintaining healthy bacteria used for example but not limited to, the food industry.

[00148] In some embodiments, a functional ZORYA defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different bacterial species. For example, the source of the nucleic acid sequence encoding a ZorA polypeptide may be one bacterial species from Table 8, the source of the nucleic acid sequence encoding a ZorB polypeptide may be a different bacterial species from Table 8, the source of the nucleic acid sequence encoding a ZorC polypeptide may be yet a different bacterial species from Table 8, and the source of the nucleic acid sequence encoding a ZorD polypeptide may be still a different bacterial species from Table 8. Similarly, the source of the nucleic acid sequence encoding a ZorA polypeptide may be one bacterial species from Table 8, the source of the nucleic acid sequence encoding a ZorB polypeptide may be a different bacterial species from Table 8, and the source of the nucleic acid sequence encoding a ZorE polypeptide may be still a different bacterial species from Table 8.

[00149] In some embodiments, the source of the nucleic acid encoding a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide is the same. In some embodiments, the source of the nucleic acid encoding a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, and a ZorD polypeptide is the not the same. In some embodiments, the source of some of the components is the same, while the source of other components is not the same. In some embodiments, the source of the nucleic acid sequence of any of the components of a ZORYA Type I defense system comprises any of the species listed in Table 8.

[00150] In some embodiments, the source of the nucleic acid encoding a ZorA polypeptide, a ZorB polypeptide, and a ZorE polypeptide is the same. In some embodiments, the source of the nucleic acid encoding a ZorA polypeptide, a ZorB polypeptide, and a ZorE polypeptide is the not the same. In some embodiments, the source of some of the components is the same, while the source of other components is not the same. In some embodiments, the source of the nucleic acid sequence of any of the components of a ZORYA Type II defense system comprises any of the species listed in Table 8. [00151] In some embodiments, a ZORYA defense system having an anti-phage activity comprises a nucleic acid construct comprising non-coding regions between the nucleic acid sequences encoding the polypeptides. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence not naturally occurring in the microbial species of origin. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence is the naturally occurring in the microbial species of origin.

[00152] In some embodiments, a ZORYA system disclosed herein comprises a multi-gene phage resistance system broadly distributed in microbial genomes, for example but not limited to bacteria. A skilled artisan would appreciate that the ZORYA system is not present in the majority of bacterial species.

[00153] According to some embodiments, the ZORYA system components are located in a gene cluster in a microbial cell genome. According to some embodiments, the ZORYA system components are located in close proximity (e.g. positioned within 20 genes, 10 genes, 5 genes or less one from the other) in a genome of a prokaryotic cell. According to some embodiments the prokaryotic cell expresses an endogenous ZORYA defense system. According to some embodiments, the prokaryotic cell expresses an endogenous functional ZORYA defense system. According to some embodiments, the species of prokaryotic cell is selected from the group consisting of the species listed in Table 8. According to some embodiments, a prokaryotic cell expresses a non-endogenous ZORYA defense system. According to some embodiments, a prokaryotic cell expresses a non-endogenous functional ZORYA defense system. According to some embodiments, the species of prokaryotic cell expressing a non-endogenous functional ZORYA defense system is selected from the group consisting of the species listed in Table 8.

[00154] A skilled artisan would appreciate that the term "endogenous" may encompass the expression of a native gene in its natural location and with its natural expression level in the genome of an organism, for example a prokaryote. In some embodiments, an endogenous anti- nucleic acid defense system is found in bacterial or in archaeal cells. In some embodiments, an endogenous anti-nucleic acid defense system is found in bacterial cells. In some embodiments, an endogenous anti-nucleic acid defense system is found in archaeal cells.

[00155] In some embodiments, a ZORYA Type I defense system (Defense System la) components comprise ZorA, ZorB, ZorC and ZorD polypeptides. In some embodiments, a ZORYA Type I defense system components comprise functional portions of ZorA, ZorB, ZorC and ZorD polypeptides. In some embodiments, the ZORYA Type I defense system components are encoded by zorA, zorB, zorC and zorD genes.

[00156] In some embodiments, a ZORYA Type II defense system (Defense System lb) components comprise ZorA, ZorB, and ZorE polypeptides. In some embodiments, a ZORYA Type II defense system components comprise functional portions of ZorA, ZorB, and ZorE polypeptides. In some embodiments, the ZORYA Type II defense system components are encoded by zorA, zorB, and zorE genes.

[00157] Non-limiting embodiments of endogenous ZORYA systems and the respective location of their components are provided in Table 8 herein.

[00158] In some embodiments, the components of a ZORYA system may be identified by the presence of similar domains present within each component. In some embodiments, domains comprise pfam domains and or clusters of orthologous groups (COG) domains.

[00159] A skilled artisan would appreciate that the term "pfam" may encompass a large collection of protein domains and protein families maintained by the pfam consortium and available at several sponsored world wide web sites, including for example: pfam.sanger.ac.uk/ (Welcome Trust, Sanger Institute); pfam.sbc.su.se/ (Stockholm Bioinformatics Center); pfam(dot)janelia(dot)org/ (Janelia Farm, Howard Hughes Medical Institute); pfam(dot)jouy(dot)inra(dot)fr/ (Institut national de la Recherche Agronomique); and pfam.ccbb.re.kr/. pfam domains and families are identified using multiple sequence alignments and hidden Markov models (HMMs) (see e.g. R.D. Finnet et al. nucleic Acids Research Database (2010) Issue 38: D211-222). By accessing the pfam database, for example, using any of the above-reference websites, protein sequences can be queried against the hidden Markov models (HMMs) using HMMER homology search software (e.g., HMMER3, hmmer(dot)j anelia(dot)org/) .

[00160] A skilled artisan would appreciate that the term "COG (clusters of orthologous groups)" may encompass a large collection of protein families classified according to their homologous relationships available at e.g. the NCBI COG website (http://www(dot)ncbi(dot)nlm(dot)nih(dot)gov/COG). Each COG consists of a group of proteins found to be orthologous across at least three lineages and likely corresponds to an ancient conserved domain [see e.g. Tatusov et al. Science 1997 Oct 24;278(5338):631-7; and Tatusov et al. nucleic Acids Res. 2000 Jan 1; 28(1): 33-36].

[00161] In some embodiments, a Defense System la comprises a membrane associated complex. In some embodiments, a Defense System lb comprises a membrane associated complex.

[00162] In some embodiments, the term "ZorA " refers to the polynucleotide or expression product e.g., the polypeptide encoded by the zorA gene. In some embodiments, the term "ZorA" refers to a ZorA polypeptide. In some embodiments, the zorA gene encodes a polypeptide comprising a pfam01618 domain. In some embodiments, the zorA gene encodes a polypeptide comprising a COG0840 domain. In some embodiments, the zorA gene encodes a polypeptide comprising a pfam01618 domain and a COG0840 domain. In some embodiments, the ZorA polypeptide comprises a pfam01618 domain. In some embodiments, the ZorA polypeptide comprises a COG0840 domain. In some embodiments, the ZorA polypeptide comprises a pfam01618 domain and a COG0840 domain.

[00163] In some embodiments, the zorA gene encodes a polypeptide member of the MotA/TolQ/EXaB proton channel family. In some embodiments, the zorA gene encodes a polypeptide comprising 3 transmembrane helices.

[00164] In some embodiments, the ZorA polypeptide comprises a member of the MotA/TolQ/EXaB proton channel family. In some embodiments, the ZorA polypeptide comprises a member of a family comprising 3 transmembrane helices.

[00165] In some embodiments, ZorA polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a ZorB, ZorC, ZorD, and or a ZorE polypeptide in a genome of a prokaryotic cell. In some embodiments, ZorA polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a ZorB, ZorC, ZorD, and/or a ZorE polypeptide in a genome of a prokaryotic cell. In some embodiments, ZorA polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a ZorB, ZorC, ZorD, and or ZorE polypeptide, or any combination thereof, in a genome of a prokaryotic cell.

[00166] In some embodiments, ZorA and ZorB are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ZorA and ZorB are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ZorA, ZorB, and ZorC are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ZorA, ZorB, and ZorC are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ZorA, ZorB, and ZorE are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ZorA, ZorB, and ZorE are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ZorA, ZorB, ZorC, and ZorD are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ZorA, ZorB, ZorC, and ZorD are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00167] In some embodiments, zorA and zorB genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, zorA, and zorB, genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, zorA, zorB, and zorC genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, zorA, zorB, and zorC genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, zorA, zorB, and zorE genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, zorA, zorB, and zorE genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, zorA, zorB, zorC, and zorD genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, zorA, zorB, zorC, and zorD genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00168] In some embodiments, a ZorA polypeptide is about 550 amino acids long (Median gene size).

[00169] In some embodiments, the ZorA polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting the polypeptides referenced in Table 8, rows 2-1830 columns J and K. In some embodiments, the ZorA polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns J and K.

[00170] A skilled artisan would appreciate that the terms "similar domain regions" encompasses but is not limited to pfam domains, COG domains, helices, membrane binding domains, transmembrane domains, structural domains, and enzyme active site domains.

[00171] In some embodiments, the ZorA polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 8, rows 2- 1830 columns J and K. In some embodiments, a homolog of a ZorA polypeptide comprises a member of the MotA/TolQ/EXaB proton channel family. In some embodiments, a homolog of ZorA polypeptide comprises 3 transmembrane helices. In some embodiments, the ZorA polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns J and K.

[00172] A skilled artisan would appreciate that homology encompasses similarity of sequence attributed to descent from a common ancestor. Homologous biological components (genes, proteins, structures) are called homologs. The extent to which nucleotide or protein sequences are related. The similarity between two sequences (DNA, RNA, or amino acid) can be expressed as percent sequence identity and/or percent positive substitutions.

[00173] A skilled artisan would appreciate that the term "homolog" encompasses a gene or a polypeptide (a protein) that is related to a second gene or polypeptide (protein), respectively, by descent from a common ancestral DNA or polypeptide (protein) sequence, respectively. Thus, a homolog of a gene, in some embodiments, comprises a similar nucleotide sequence to the gene. In some embodiments, a gene homolog encodes an identical polypeptide as is encoded by the gene. In some embodiments, a gene homolog encodes a polypeptide with the same functional properties as is encoded by the gene. In some embodiments, a gene homolog encodes a polypeptide that comprises a similar amino acid sequence as the polypeptide encoded by the gene. In one embodiment, the polypeptide homolog comprises a similar amino acid sequence as the polypeptide. In some embodiments, the polypeptide homolog comprises the same functional properties as the polypeptide. In some embodiments, the polypeptide homolog comprises similar functional properties as the polypeptide. In some embodiments, the polypeptide homolog comprises a same domain(s) as the polypeptide. In some embodiments, the polypeptide homolog comprises a similar domain(s) as the polypeptide.

[00174] A skilled artisan would appreciate that percent homology or percent identity may be determined, for example but no limited to, using BlastP software of the National Center of Biotechnology Information (NCBI) using default parameters. The homolog may also refer to an ortholog, a deletion, insertion, or substitution variant, including an amino acid substitution. In some embodiments, sequence identity or homology can be determined using any protein or nucleic acid sequence alignment algorithm such as Blast, ClustalW, MUSCLE, and HHpred.

[00175] In some embodiments, gene homology and/or polypeptide homology can be based on shared motifs, for example but not limited to pfam domains, COG domains, DUF domains, transmembrane domains, and nuclease domains. In some embodiments, similarities of shared motifs are combined with the conserved size of the gene or the expression product in the different subtypes and the location of the gene in the gene cluster.

[00176] In some embodiments, the ZorA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns J and K. In some embodiments, the ZorA polypeptide comprises the amino acid sequence having at least 80%, at least 85%, at least 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2- 1830 columns J and K. In some embodiments, the ZorA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns J and K. In some embodiments, the ZorA polypeptide comprises the amino acid sequence having at least 80%, at least 85%, at least 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns J and K. In some embodiments, the ZorA polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns J and K.

[00177] In some embodiments, the ZorA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns J and L. In some embodiments, the ZorA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns J and L. In some embodiments, the ZorA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns J and L. In some embodiments, the ZorA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 95% identity within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns J and L. In some embodiments, the ZorA polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns J and L.

[00178] In some embodiments, the nucleic acid sequence of a zorA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns J and L. In some embodiments, the nucleic acid sequence of a zorA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns J and L. In some embodiments, the nucleic acid sequence of a zorA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology within the nucleotide sequence encoding similar domain regions as a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns J and L. In some embodiments, the nucleic acid sequence of a zorA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity within the nucleotide sequence encoding similar domain regions as a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns J and L. In some embodiments, the nucleic acid sequence of a zorA gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns J and L.

[00179] As used herein, the term "ZorB " refers to the polynucleotide or expression product e.g., polypeptide encoded by the zorB gene. In some embodiments, the term "ZorB" refers to a ZorB polypeptide. In some embodiments, the product of the zorB gene comprises a pfaml3677 domain. In some embodiments, the product of the zorB gene comprises a pfam00691 domain. In some embodiments, the product of the zorB gene comprises a pfaml3677 domain and a pfam00691 domain. In some embodiments, the zorB gene encodes a member of MotB proton channel family. In some embodiments, the zorB gene encodes a polypeptide comprising a transmembrane helix.

[00180] In some embodiments, ZorB polypeptide is encoded by a gene positioned within 5-60 genes of a gene encoding a ZorA, ZorC, ZorD, and or a ZorE polypeptide in a genome of a prokaryotic cell. In some embodiments, ZorB polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a ZorA, ZorC, ZorD, and/or a ZorE polypeptide in a genome of a prokaryotic cell.

[00181] In some embodiments, ZorA and ZorB are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments ZorA and ZorB are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ZorB and ZorC are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments ZorB and ZorC are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ZorB and ZorE are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments ZorB and ZorE are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ZorB, ZorC, and ZorD are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ZorB, ZorC, and ZorD are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00182] In some embodiments, ZorB polypeptide is encoded by a gene positioned within 5 genes upstream or downstream to a gene encoding zorA, zorC, and zorD, in a genome of a prokaryotic cell. In some embodiments, ZorB polypeptide is encoded by a gene positioned within 5 genes upstream or downstream to a gene encoding zorA and zorE, in a genome of a prokaryotic cell.

[00183] In some embodiments, a ZorB polypeptide is about 217 amino acids long (median gene size).

[00184] In some embodiments, the ZorB polypeptide comprises an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns N and O.

[00185] In some embodiments, the ZorB polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns N and O. In some embodiments, a homology of the ZorB polypeptide comprises a MotB proton channel family member. In some embodiments, the ZorB polypeptide comprises an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns N and O.

[00186] In some embodiments, the ZorB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns N and O. In some embodiments, the ZorB polypeptide comprises the amino acid sequence having at least 80%, at least 85%, at least 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2- 1830 columns N and O. In some embodiments, the ZorB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns N and O. In some embodiments, the ZorB polypeptide comprises the amino acid sequence having at least 80%, at least 85%, at least 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns N and O. In some embodiments, the ZorB polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1830 columns N and O.

[00187] In some embodiments, the ZorB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns N and P. In some embodiments, the ZorB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns N and P. In some embodiments, the ZorB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns N and P. In some embodiments, the ZorB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 95% identity within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns N and P. In some embodiments, the ZorB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns N and P.

[00188] In some embodiments, the nucleic acid sequence of a zorB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns N and P. In some embodiments, the nucleic acid sequence of a zorB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns N and P. In some embodiments, the nucleic acid sequence of a zorB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology within the nucleotide sequence encoding similar domain regions as a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns N and P. In some embodiments, the nucleic acid sequence of a zorB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity within the nucleotide sequence encoding similar domain regions as a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns N and P. In some embodiments, the nucleic acid sequence of a zorB gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1830 columns N and P.

[00189] As used herein, the term "ZorC " refers to the polynucleotide or expression product e.g., polypeptide encoded by the zorC gene. In some embodiments, the term "ZorC" refers to a ZorC polypeptide. In some embodiments, the product of a zorC gene comprises a pfaml5611 domain. In some embodiments, the product of a zorC gene comprises a EH signature domain.

[00190] In some embodiments, ZorC polypeptide is encoded by a gene positioned within 5-60 genes of a gene encoding ZorA, ZorB and/or ZorD in a genome of a prokaryotic cell. In some embodiments, ZorC polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding ZorA, ZorB and/or ZorD in a genome of a prokaryotic cell. In some embodiments, ZorC polypeptide is encoded by a gene positioned within 5 genes upstream and downstream to a gene encoding ZorA, ZorB and ZorD in a genome of a prokaryotic cell.

[00191] In some embodiments, ZorC and ZorD are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ZorC and ZorD are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00192] In some embodiments, zorC and zorD genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, zorC and zorD genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00193] In some embodiments, a ZorC polypeptide is about 470 amino acids long (median gene size). [00194] In some embodiments, the ZorC polypeptide comprises an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns R and S. In some embodiments, the ZorC polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns R and S. In some embodiments, the ZorC polypeptide comprises an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns R and S

[00195] In some embodiments, the ZorC polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns R and S. In some embodiments, the ZorC polypeptide comprises the amino acid sequence having at least 80%, at least 85%, at least 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2- 1174 columns R and S. In some embodiments, a ZorC homolog comprises an EH signature domain. In some embodiments, the ZorC polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns R and S. In some embodiments, the ZorC polypeptide comprises the amino acid sequence having at least 80%, at least 85%, at least 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 column N. In some embodiments, the ZorC polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: the polypeptides referenced in Table 8, rows 2-1174 columns R and S.

[00196] In some embodiments, the ZorC polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns R and T. In some embodiments, the ZorC polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns R and T. In some embodiments, the ZorC polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns R and T. In some embodiments, the ZorC polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 95% identity within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns R and T. In some embodiments, the ZorC polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns R and T.

[00197] In some embodiments, the zorC gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns R and T. In some embodiments, the zorC gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns R and T. In some embodiments, the nucleic acid sequence of a zorA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns R and T. In some embodiments, the nucleic acid sequence of a zorA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns R and T. In some embodiments, the nucleic acid sequence of a zorC gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology within the nucleotide sequence encoding similar domain regions as a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns R and T. In some embodiments, the nucleic acid sequence of a zorC gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity within the nucleotide sequence encoding similar domain regions as a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns R and T. In some embodiments, the zorC gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns R and T. [00198] As used herein, the term "ZorD " refers to the polynucleotide or expression product e.g., polypeptide encoded by the zorD gene. In some embodiments, the term "ZorD" refers to a ZorD polypeptide. In some embodiments, the product of the zorD gene comprises a pfam00176 domain. In some embodiments, the product of the zorD gene comprises a pfam00271 domain. In some embodiments, the product of the zorD gene contains a pfam00176 domain and a pfam00271 domain. In some embodiments, the product of the zorD gene comprises, a COG0553 domain. In some embodiments, the product of the zorD gene further contains a pfam04471 domain.

[00199] In some embodiments, a ZorD polypeptide comprises a pfam00176 domain. In some embodiments, a ZorD polypeptide comprises a pfam00271 domain. In some embodiments, a ZorD polypeptide comprises a pfam00176 domain and a pfam00271 domain. In some embodiments, a ZorD polypeptide comprises, a COG0553 domain. In some embodiments, a ZorD polypeptide comprises a pfam04471 domain. In some embodiments, a ZorD polypeptide comprises, a pfam00176 domain, a pfam00271 domain, a COG0553 domain, or a pfam04471 domain or any combination thereof. In some embodiments, a ZorD polypeptide comprises, a pfam00176 domain, a pfam00271 domain, a COG0553 domain, and a pfam04471 domain.

[00200] In some embodiments, a ZorD polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding ZorA, ZorB and/or ZorC in a genome of a prokaryotic cell. In some embodiments, a ZorD polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding ZorA, ZorB and/or ZorC in a genome of a prokaryotic cell. In some embodiments, ZorD polypeptide is encoded by a gene positioned within 5 genes upstream or downstream to a gene encoding ZorA, ZorB and ZorC in a genome of a prokaryotic cell.

[00201] In some embodiments, a ZorD polypeptide is about 1200 amino acids long (median gene size).

[00202] In some embodiments, the ZorD polypeptide comprises an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns V and W. In some embodiments, the ZorD polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns V and W. In some embodiments, a ZorD polypeptide homologue comprises a SW12/SNF2 helicase. In some embodiments, a ZorD polypeptide homologue comprises a Mrr-like nuclease domain. In some embodiments, the ZorD polypeptide comprises an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns V and W. In some embodiments, the ZorD polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns V and W.

[00203] In some embodiments, the ZorD polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns V and W. In some embodiments, the ZorD polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns V and W.

[00204] In some embodiments, the ZorD polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns V and W. In some embodiments, the ZorD polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns V and W. In some embodiments, the ZorD polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 columns V and W.

[00205] In some embodiments, the ZorD polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns V and X. In some embodiments, the ZorD polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns V and X. In some embodiments, the ZorD polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns V and X. In some embodiments, the ZorD polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns V and X. In some embodiments, the ZorD polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns V and X.

[00206] In some embodiments, the zorD gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns V and X. In some embodiments, the zorD gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns V and X. In some embodiments, the nucleic acid sequence of a zorD gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology within the nucleotide sequence encoding similar domain regions as a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns V and X. In some embodiments, the nucleic acid sequence of a zorD gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity within the nucleotide sequence encoding similar domain regions as a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 2-1174 column P. In some embodiments, the nucleic acid sequence of the zorD gene is selected from the group consisting of the polynucleotides referenced in Table 8, rows 2-1174 columns V and X.

[00207] As used herein, the term "ZorE " refers to the polynucleotide or expression product e.g., polypeptide encoded by the zorE gene. In some embodiments, the term "ZorE" refers to a ZorE polypeptide. In some embodiments, the product of the zorE gene comprises a pfam01844 domain. In some embodiments, the product of the zorE gene comprises a COG3183 domain. In some embodiments, the product of the zorE gene contains a pfam01844 domain and a COG3183 domain. In some embodiments, the product of the zorE gene comprises an HNH endonuclease.

[00208] In some embodiments, a ZorE polypeptide comprises a pfam01844 domain. In some embodiments, a ZorE polypeptide comprises a COG3183 domain. In some embodiments, a ZorE polypeptide comprises a pfam01844 domain and a COG31383 domain. In some embodiments, a ZorE polypeptide comprises a HNH endonuclease.

[00209] In some embodiments, a ZorE polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding ZorA and/or ZorB in a genome of a prokaryotic cell. In some embodiments, a ZorE polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding ZorA and/or ZorB in a genome of a prokaryotic cell. In some embodiments, ZorE polypeptide is encoded by a gene positioned within 5 genes upstream and downstream to a gene encoding ZorA and/or ZorB in a genome of a prokaryotic cell.

[00210] In some embodiments, a ZorE polypeptide is about 367 amino acids long (median gene size).

[00211] In some embodiments, the ZorE polypeptide comprises an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 1175-1830 columns Z and AA. In some embodiments, the ZorE polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 1175-1830 columns Z and AA. In some embodiments, a ZorE polypeptide homologue comprises a HNH endonuclease. In some embodiments, the ZorE polypeptide comprises an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 1175-1830 columns Z and AA. In some embodiments, the ZorE polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 1175-1830 columns Z and AA.

[00212] In some embodiments, the ZorE polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 1175-1830 columns Z and AA. In some embodiments, the ZorE polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 1175-1830 columns Z and AA. In some embodiments, the ZorE polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 1175-1830 columns Z and AA. In some embodiments, the ZorE polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 1175-1830 columns Z and AA. In some embodiments, the ZorE polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 8, rows 1175-1830 columns Z and AA.

[00213] In some embodiments, the ZorE polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 1175-1830 columns Z and AB. In some embodiments, the ZorE polypeptide comprises the amino acid sequence encoded from a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 1175-1830 columns Z and AB. In some embodiments, the ZorE polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 1175-1830 columns Z and AB. In some embodiments, the ZorE polypeptide comprises the amino acid sequence encoded from a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 1175-1830 columns Z and AB. In some embodiments, the ZorE polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 1175-1830 columns Z and AB.

[00214] In some embodiments, the zorE gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 1175-1830 columns Z and AB. In some embodiments, the zorE gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 1175-1830 columns Z and AB. In some embodiments, the nucleic acid sequence of a zorE gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology within the nucleotide sequence encoding similar domain regions as a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 1175-1830 columns Z and AB. In some embodiments, the nucleic acid sequence of a zorE gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity within the nucleotide sequence encoding similar domain regions as a sequence selected from the group consisting of the polynucleotides referenced in Table 8, rows 1175-1830 columns Z and AB. In some embodiments, the nucleic acid sequence of the zorE gene is selected from the group consisting of the polynucleotides referenced in Table 8, rows 1175-1830 columns Z and AB.

[00215] A skilled artisan would appreciate that a "functional portion of a Defense System I component" or "functional fragment of Defense System I component" or "functional portion of a ZORYA defense system component" or "functional fragment of ZORYA defense system component" refers to a functional portion of a ZORYA polynucleotide or polypeptide, as disclosed herein, which expression is sufficient to elicit an anti-phage activity alone or in combination with the at least one of the other ZORYA polynucleotides or polypeptides disclosed herein or functional portions thereof.

[00216] As used herein, the terms "ZorA", "ZorB", "ZorC", "ZorD", "ZorE", "zorA", "zorB", "zorC "zorD", and "zorE", also refer to functional ZorA, ZorB, ZorC, ZorD, ZorE, zorA, zorB, zorC, zorD, and zorE, homologs, which exhibit the desired activity (i.e., conferring phage resistance). Such homologs can be, for example, at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polypeptides referenced in Table 8, rows 2-1830 columns J and K; rows 2-1830 columns N and O; rows 2-1174 columns R and S; rows 2-1174 columns V and W; and rows 1175-1830 columns Z and AA, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical to the polynucleotide referenced in Table 8, rows 2- 1830 columns J and L; rows 2-1830 columns N and P; rows 2-1174 columns R and T; rows 2- 1174 columns V and X; and rows 1175-1830 column Z and AB, respectively. In some embodiments, such homologs comprise at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homology within similar domain regions of the polypeptide referenced in Table 8, rows 2-1830 columns J and K; rows 2-1830 columns N and O; rows 2-1174 columns R and S; rows 2-1174 column V and W; and rows 1175-1830 column Z and AA, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identity within nucleotide sequences encoding similar domain regions to the polynucleotide referenced in Table 8, rows 2-1830 columns J and L; rows 2-1830 columns N and P; rows 2-1174 columns R and S; rows 2-1174 columns V and X; and rows 1175-1830 columns Z and AB, respectively.

[00217] Table 8 presents embodiments of components of Defense System la and Defense System lb that may be found in a diverse array of bacteria and archaea genomes (referenced in Table 18). Table 8 presents embodiments of nucleic acid sequences encoding gene cassettes of Defense System la and Defense System lb (referenced in Table 18).

[00218] The Thoens Defense System

[00219] In some embodiments, a defense system disclosed herein comprises a Thoeris anti- phage defense system. (Table 9)

[00220] In some embodiments, a Thoeris defense system provides a host cell with resistance to entry of foreign nucleic acid invasion. In some embodiments, a host cell expressing a functional Thoeris defense system (Defense System II) provides the host cell resistance foreign nucleic acid invasion.

[00221] In some embodiments, a Thoeris defense system provides a host cell with resistance to at least one phage. In some embodiments, expression of a Thoeris defense system in bacteria protects the bacteria from phage infection. In some embodiments, expression of a Thoeris defense system in bacteria protects the bacteria from plasmid transformation. In some embodiments, expression of a Thoeris defense system in bacteria protects the bacteria from phage infection and from plasmid transformation.

[00222] In some embodiments, a Thoeris defense system provides a host cell with resistance to phage infection. In some embodiments, a Thoeris defense system provides a host cell with resistance to plasmid transformation.

[00223] In some embodiments, expression of a Thoeris defense system in bacteria protects the bacteria from phage infection. [00224] As used herein, the term "a Thoeris anti-phage defense system" may be used interchangeably with the term "a Defense System Π", having all the same meanings and qualities. A skilled artisan would appreciate that the term "Thoeris system" may be used interchangeably in some embodiments with "Thoeris defense system", "Thoeris the defense system", "Thoeris anti-phage system", and "Defense System ΙΓ, having all the same meanings and qualities.

[00225] In some embodiments, a Thoeris defense system (Defense System Π) provides a host cell with resistance to plasmid transformation. In some embodiments, a host cell expressing a functional Thoeris defense system (Defense System Π) provides a host cells with resistance to plasmid transformation.

[00226] In some embodiments, a Thoeris defense system (Defense system II) provides a host cell with resistance to entry of conjugative elements. In some embodiments, a host cell expressing a function Thoeris defense system (Defense System II) provides the host cell resistance from entry of conjugative elements.

[00227] In some embodiments, a microbial species does not comprise an endogenous Defense System Π. In some embodiments, a microbial species does not express an endogenous Defense System II. In some embodiments, a microbial species does not express an endogenous functional Defense System II.

[00228] In some embodiments, a bacterial species does not comprise an endogenous Defense System II. In some embodiments, a bacterial species does not express an endogenous Defense System Π. In some embodiments, a bacterial species does not express an endogenous functional Defense System Π.

[00229] A Thoeris defense system comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence encoding a ThsA polypeptide comprising a pfaml3289 domain, and a ThsB polypeptide comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or a pfaml3289, or a pfaml4519 or a pfam08357 domain or any combination thereof. In some embodiments, a Thoeris defense system comprises a nucleic acid construct comprising a nucleic acid sequence comprising a thsA gene and a thsB gene. In some embodiments, a Thoeris defense system comprises a nucleic acid construct comprising a nucleic acid sequence comprising a thsA gene and multiple copies of a thsB gene. In some embodiments, a Thoeris defense system comprises 2 copies of a thsB gene. In some embodiments, a Thoeris defense system comprises 3 copies of a thsB gene. In some embodiments, a Thoeris defense system comprises 4 copies of a thsB gene. In some embodiments, a Thoeris defense system comprises 5 copies of a thsB gene. In some embodiments, a Thoeris defense system comprises 6 copies of a thsB gene. In some embodiments, a Thoeris defense system comprises 7 copies of a i/zsfi gene. In some embodiments, a Thoeris defense system comprises 8 copies of a thsB gene. In some embodiments, a Thoeris defense system comprises 9 copies of a i/zsfi gene. In some embodiments, a Thoeris defense system comprises 9 copies of a i/zsfi gene. In some embodiments, a Thoeris defense system comprises 1-10 copies of a thsB gene.

[00230] In some embodiments, each copy of a thsB gene comprises the same nucleotide sequence. In some embodiments, each copy of a thsB gene comprises a different nucleotide sequence. In some embodiments, each copy of a thsB gene encodes a ThsB polypeptide having the same amino acid sequence. In some embodiments, each copy of a thsB gene encodes a ThsB polypeptide having a different amino acid sequence. In some embodiments, the source of the different nucleotide sequences comprises different donor species. In some embodiments, the source of the difference amino acid sequences comprises different donor species

[00231] A Thoeris defense system (Defense System II) comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence encoding a ThsA polypeptide comprising a pfaml3289 or a pfaml4519 domain or a combination thereof, and a ThsB polypeptide comprising a pfam08937 domain or a pfaml3676 domain or a pfam08357 domain or any combination thereof. In some embodiments, a Thoeris defense system comprises a nucleic acid construct comprising a nucleic acid sequence encoding a ThsA polypeptide and a ThsB polypeptide. In some embodiments, a Thoeris defense system comprises a nucleic acid construct comprising a nucleic acid sequence encoding a ThsA polypeptide and 1-10 ThsB polypeptides.

[00232] In some embodiments, a Thoeris defense system (Defense System Π) comprises a ThsA polypeptide comprising a pfaml3289 or a pfaml4519 domain or a combination thereof, and a ThsB polypeptide comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or a pfaml 3289 or a pfaml4519 or a pfam08357 domain or any combination thereof. In some embodiments, a Thoeris defense system (Defense System II) comprises a ThsA polypeptide comprising a pfaml3289 or a pfaml4519 domain or a combination thereof, and 1- 10 ThsB polypeptides comprising a pfaml 3676 domain or a pfam08937 domain or a pfam08357 domain or a pfaml3289 or a pfaml4519 or a pfam08357 domain or a combination thereof. In some embodiments, a Thoeris defense system (Defense System II) having an anti- phage activity comprises a ThsA polypeptide comprising a pfaml3289 or a pfaml4519 domain or a combination thereof, and a ThsB polypeptide comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or a pfaml3289 or a pfaml4519 or a pfam08357 domain or any combinaton thereof. In some embodiments, a Thoeris defense system (Defense System II) having an anti-phage activity comprises a ThsA polypeptide comprising a pfaml3289 or a pfaml4519 domain or a combination thereof, and 1-10 ThsB polypeptides comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or a pfaml3289, or a pfaml4519 or a pfam08357 domain or any combination thereof. In some embodiments, a Thoeris defense system (Defense System II) having an anti-phage activity comprises a ThsA polypeptide comprising a pfaml3289 or a pfaml4519 domain or a combination thereof, and 1-5 ThsB polypeptides comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or a pfaml3289 or a pfaml4519 or a pfam08357 domain or anycombination thereof. In some embodiments, a Thoeris defense system (Defense System II) having an anti-phage activity comprises a ThsA polypeptide comprising a pfaml3289 or a pfaml4519 domain or a combination thereof, and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 ThsB polypeptides comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or a pfaml3289 or a pfaml4519 or a pfam08357 domain or any combination thereof.

[00233] In some embodiemnts, a Thoeris defense system (Defense System Π) comprisesat least two different polypeptide components selected from a ThsA polypeptide comprising a pfaml3289 or a pfaml4519 domain or a combination thereof, and a ThsB polypeptide comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or a pfaml3289 or a pfaml4519 or a pfam08357 domain or any combination thereof. In some embodiemnts, a Thoeris defense system (Defense System II) comprisesat least two different polypeptide components selected from a ThsA polypeptide comprising a pfam 13289 or a pfaml4519 domain or a combination thereof, and 1-10 ThsB polypeptides comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or a pfaml3289 or a pfaml4519 or a pfam08357 domain or a combination thereof. In some embodiemnts, a Thoeris defense system (Defense System II) having an anti-phage activity comprisesat least two different polypeptide components selected from a ThsA polypeptide comprising a pfaml3289 or a pfaml4519 domain or a combination thereof, and a ThsB polypeptide comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or a pfaml3289 or a pfaml4519 or a pfam08357 domain or any combinaton thereof. In some embodiments, a Thoeris defense system (Defense System II) having an anti-phage activity comprisesat least two different polypeptide components selected from a ThsA polypeptide comprising a pfaml3289 or a pfaml4519 domain or a combination thereof, and 1-10 ThsB polypeptides comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or a pfaml3289, or a pfaml4519 or a pfam08357 domain or any combination thereof. In some embodiments, a Thoeris defense system (Defense System II) having an anti-phage activity comprisesat least two different polypeptide components selected from a ThsA polypeptide comprising a pfaml3289 or a pfaml4519 domain or a combination thereof, and 1-5 ThsB polypeptides comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or a pfaml3289 or a pfaml4519 or a pfam08357 domain or anycombination thereof. In some embodiments, a Thoeris defense system (Defense System II) having an anti-phage activity comprisesat least two different polypeptide components selected from a ThsA polypeptide comprising a pfaml3289 or a pfaml4519 domain or a combination thereof, and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 ThsB polypeptides comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain orapfaml3289 or a pfaml4519 or a pfam08357 domain or any combination thereof.

[00234] In some embodiments, a Defense System Π comprises a ThsA polypeptide comprising a pfaml3289 domain or a pfaml4519 domain or a combination therof, or comprises an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 9 rows 2-2100 columns I and J; or a ThsB polypeptide comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain or a combination thereof, or comprises an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 9 rows 2-2100 columns M and N, Q and R, U and V, Y and Z, and AC and AD, or a combination thereof; or a combination thereof.

[00235] In some embodiments, the amino acid sequences of more than one copy of a Thsb polypeptide present in a Defense System Π are identical. In some embodiments, the amino acid sequences of more than one copy of a Thsb polypeptide present in a Defense System II are homologous. In some embodiments, the amino acid sequences of more than one copy of a Thsb polypeptide present in a Defense System II are not identical. In some embodiments, the amino acid sequences of more than one copy of a Thsb polypeptide present in a Defense System Π comprise the same functional activity.

[00236] In some embodiments, a Thoeris defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a ThsA polypeptide and a ThsB polypeptide. In some embodiments, the Thoeris system having an anti- phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a ThsA polypeptide and encoding 1-10 copies of a ThsB polypeptide. In some embodiments, a Thoeris defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a thsA gene and a thsB gene. In some embodiments, a Thoeris defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a thsA gene and 1-10 copies of a thsB gene.

[00237] In some embodiments, the Thoeris anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising thsA and thsB genes. In some embodiments, the Thoeris anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising thsA and 1-10 copies of a thsB genes. In some embodiments, the Thoeris anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising thsA and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of a thsB genes.

[00238] In some embodiments, a Thoeris (Defense System II) gene cassette comprises the nucleic acid sequence:

1 atgtttttag aaatttataa ttaatttact aatatattgc gataattaga accatttgaa 61 ttacagaagt gccaccaacg aggaagcaat caattaaata gtaagtttaa taattttatt 121 aagaaattga tttgttatac gaaattttat tatatgataa aatatttatg taataaatgt 181 aaatttgtat attaggtaag gggaatgaaa atgaatccaa tagttgaact atttattaaa 241 gattttacaa aagaagttat ggaagagaat gctgcaattt ttgcaggagc gggtttatca 301 atgtctgttg ggtatgttag ttgggcgaag ttattggagc ctattgctca agaaattgga 361 ttagatgtaa ataaagaaaa tgatttagta agcttggcgc aatattattg taatgagaat 421 cagggtaata gaggtagaat taatcaaatt atcctagatg aattttctcg aaaagtagat 481 ttaactgaaa atcacaaaat tttagctcga ttaccaattc atacttattg gacgacaaat 541 tatgataggt taattgaaaa ggcattagaa gaagaaaata agattgctga tgtaaagtat 601 acggtaaaac aattagctac tacaaaggta aaaagagatg cagttgtata taaaatgcat 661 ggagacgtgg aacatccctc tgaggcagtt ttgattaaag atgattatga aaagtattct 721 ataaaaatgg atccgtatat taaggcgttg agtggggatc tagtttctaa gacattttta 781 tttgttggat ttagttttac tgatcccaat ctagattata tattaagtcg agtaaggagt 841 gcttatgaaa gggatcaaag aagacactat tgtttaataa aaaaagaaga gcgaagacca 901 gatgaattag aggcggattt tgagtataga gtaagaaaac aggaattatt tattagtgat 961 ttatcacgtt ttaatataaa gactattgta cttaataatt acaatgagat taccgagata 1021 ttacaacgaa ttgaaaataa tataaaaact aaaacagtat ttttatctgg tagtgcggtt 1081 gaatataatc attgggagac agaacatgct gaacaattca ttcatcagtt aagtaaagaa 1141 ttaattagaa aggattttaa tatagtatct ggttttggac ttggtgtagg gagttttgtt 1201 atcaatggag ttctagaaga attgtatatg aaccagggaa ctatagatga tgatagactt 1261 attctaagac cgtttccaca ggggaaaaag ggcgaagagc aatgggataa atatagacga 1321 gatatgatta caagaactgg ggtaagcatc tttttatatg gaaataaaat agacaaggga 1381 caggttgtta aggctaaggg tgtccaatct gaatttaata tttcttttga acaaaataat 1441 tacgttgttc cggtaggtgc aactggttat attgcaaaag atttatggaa taaagtaaat 1501 gaggaatttg aaacgtatta cccaggtgct gatgcaagga tgaaaaaatt gttcggagaa 1561 ttgaataatg aagcattatc aatagaggaa ctgattaaca ctataataga gtttgtagaa 1621 atcctatcca actaatcatt actgattatt aatcagagag gaactgttaa attatggcga 1681 aaagagtttt ttttagtttc cattatcaag atgtaattga ttttagagta aatgttgtaa 1741 gaaatcattg ggtaacaaaa ttaaatcaaa gtgctgcggg ggtctttgat gcatctcttt 1801 gggaagatgc aaaaaaaaca agtgatatag cacttaaaag attaataaat ggcgggctaa 1861 acaatacctc agttacatgt gttttaattg gatctcagac ttttaataga agatgggtga 1921 gatatgaaat tatgaaaagt atagaaaaag gaaataagat aataggaatt catattaatg 1981 cttttaaaga taaatatgga aatattaaaa gtaaagggcc taatcctttc gattatttag 2041 ggtatcaata tagttcagac ggcaaacagt tacatttgta tgagtggaca gggggaaaat 2101 gggaggaata taaggatttg gcaccatata gggtgaatca aattgctcca gaatcactta 2161 gaggaaaatt ctatagtttg tcatcggttt atcgtgtgta tgattgggtt gctgatgatg 2221 gatataacaa attttcctct tgggtgaact aattaagttt tggataaaat tataaataga 2281 attgctattg ggattagata caaaatgatt aaataagaaa agtacctata aaagtaggtg 2341 cttttttctt tgttatatag aaattacaca ttaatttata tttaggttat tttaaaaaga 2401 aaaagtgatg aatgatggta ttcttacaat taatagttac ttataactat atgtacatga

2461 aaaacatcta tatatgc (SEQ ID NO: 10; construct 31 Table 4).

[00239] The coding regions for each of the thsA and thsB gene sequences within this embodiment of a Thoeris cassette (SEQ ID NO: 10) are as follows: nucleotides 205-1635 encode a ThsA polypeptide; and nucleotides 1674-2252 encode a ThsB polypeptide.

[00240] In some embodiments, a Defense System Π comprising a ThsA polypeptide and a

ThsB polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 10. In some embodiments, a Defense System II comprising a ThsA polypeptide and a ThsB polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in

SEQ ID NO: 10. In some embodiments, a Defense System II comprising a ThsA polypeptide and a ThsB polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 10. In some embodiments, a Defense System II comprising a ThsA polypeptide and a ThsB polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 10. In some embodiments, a Defense System II comprising a ThsA polypeptide and a ThsB polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 10.

[00241] In some embodiments, a Thoeris (Defense System II) gene cassette comprises the nucleic acid sequence:

1 gttaagcttt aggcggacat cagcaacgat gtccgctttt atcatcttaa cagcaataca

61 aggaggttta cgtggcggat gaaactctga aacagtatat gggcctgtac aaatgttgtt 121 agcaatctca agaaagccca ggagtagata tgattcactg aacagatgtt caatttaaat 181 ctaataatga agagggccta gtcaaaggcg ctcttcatta ttagataaga cataatcatt 241 acacaagatt tatgtcatgg ttctatattc atattttcat tgtaataaat tgaaaatatg 301 aatataatag gtagtgatcg caatactaac attggaggtt ttatgtggaa gtttaaagaa 361 ttaataagag ataagacatt tagaaggtgg gctctgagta taattctgac tattccaact 421 agtgtgagta cattcatttc atttctagac ttggatgctc gttgtagatt aattatttta 481 cttatattag tagggttgtc gctagtcata ataattgttc aattcattag actacttttt 541 atgaataata tcactcttaa tctcaatggt tccgaagttg aaattaaaaa aggtgatatt 601 tttgaagtgc caagaaataa ttataaagtc attgcattta atgagtattt tgacactcaa 661 gtagatgacg taataatcgc ccgcgaaaca ttaaatggtc aatatataaa gcgttattat 721 tcacatcaag atatcactga gttggatcag aaaattaaag atgacgtaaa acttaaaatt 781 gaagaaaaaa atgttgaaag accttttgga ggaaaaacaa cacgttacag cttgggatca 841 gtctttaaag atatggattt ttttctagtt gctttttcga agtttgatag ggaaaatcgt 901 gcccaattaa aactaaatga atatgcaagc tgcatgctta atgtatggaa tgaaatcaat 961 acattacatg caagcaaaga agtgtttatc cccttattag gttctggaat aacaagacat 1021 gtggattctg atgttggagt caatgaacta ttacatataa tgttgtggac atttcagatc 1081 agtaaagtaa agtttagaga accagccaaa gttacaattc ttttgtacaa aaatgatcac 1141 aagaagatca atttttataa gttaaaggag tttgagaaga atgggttata ggaatggaaa 1201 ttatgctgct ttctatgtca gtgaaccgtt tagtgaaagt agtttagggg ctaatgcaac 1261 caaggatttt gtgtcgtata acatgttaag agcatggaaa ggaaaagata ataactaccc 1321 atttaatgac tcccacgata aaacatacaa tgtacgggac ggtagtgatt gggagaaaac 1381 attaaagcca agattaagaa aaagattaga tcaatcaaaa aatataatct tttttttaag 1441 taagcatact gaaaacagca aagctttgcg agaagaaatt gattacggta ttaatgtgaa 1501 ggggctacca gttatcgttg tataccctga actttccgaa aagagtgaca tcatcgactg 1561 cactacaaag gttttcagat cagaagtggt gaatttatgg agtcgagtcc ctgtttttaa 1621 agactctatg ctaaaggtac caactattca tattccttat aaaaaagacc aaattaaaaa 1681 agctttagag aacaaagatt ttatgattaa ttcaaagatt tctgcaggtt cggtttattt 1741 ttatccatgt taatctatta tgggtgaata taatttaaag agaaagaata gattttcagt 1801 ttcgtcctca tggtagctca ttaattcaaa aacctctatg accaatttaa tttattgagg 1861 aggtagaggt tttggtatta aaatgatgaa gatagattat tggatatgaa tttcatttta 1921 tctagtttac ataatatata ttctaggaag ttaaatcttt aatgaaaatt ctgtctcgtt 1981 atcttaagtg tacttagttg gtgagacaga attaaaaaaa taggatgtat tacgatttgt

2041 atttatttct (SEQ ID NO: 11 ; construct 32 Table 4).

[00242] The coding regions for each of the thsA and thsB gene sequences within this embodiment of a Thoeris cassette (SEQ ID NO: 11) are as follows: nucleotides 298-1191 encode a ThsA polypeptide; and nucleotides 1181-1753 encode a ThsB polypeptide.

[00243] In some embodiments, a Defense System Π comprising a ThsA polypeptide and a

ThsB polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 11. In some embodiments, a Defense System II comprising a ThsA polypeptide and a ThsB polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in

SEQ ID NO: 11. In some embodiments, a Defense System Π comprising a ThsA polypeptide and a ThsB polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 11. In some embodiments, a Defense System II comprising a ThsA polypeptide and a ThsB polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 11. In some embodiments, a Defense System II comprising a ThsA polypeptide and a ThsB polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 11.

[00244] In some embodiments, a construct comprising the Thoeris defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system. In some embodiments, the components of a Thoeris defense system comprise genes thsA and thsB. In some embodiments, multiple thsB genes are present in the gene cassette of the defense system locus. In some embodiments, the components of a Thoeris defense system consist of genes thsA and thsB, wherein the copy number of the thsB gene is between 1 and 10. In some embodiments, the components of a Thoeris defense system comprise nucleic acid sequences encoding a ThsA polypeptide and a ThsB polypeptide. In some embodiments, the components of a Thoeris defense system consist of nucleic acid sequences encoding a ThsA polypeptide and a ThsB polypeptide. In some embodiments, the components of a Thoeris defense system consist of nucleic acid sequences encoding a ThsA polypeptide and 1-10 copies of a ThsB polypeptide. In some embodiments, the components of a Thoeris defense system consist of nucleic acid sequences encoding a ThsA polypeptide and 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of a ThsB polypeptide.

[00245] In some embodiments, a construct comprising the Thoeris defense system encodes one component of the defense system, whereby a second construct may be used to assemble the functional defense system. In some embodiments, a construct comprising the Thoeris defense system encodes one component of the defense system, whereby additional constructs may be used to assemble the functional defense system. For example, in some embodiments each of ThsA and ThsB may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional Thoeris defense system.

[00246] In some embodiments, the components making up a functional Thoeris anti-phage defense system comprise a ThsA polypeptide and a ThsB polypeptide, each encoded by a thsA and a thsB gene, respectively.

[00247] In some embodiments, a Thoeris defense system having an anti-phage activity comprise a nucleic acid encoding a ThsA polypeptide. In some embodiments, a Thoeris defense system having an anti-phage activity comprise a nucleic acid encoding a ThsA polypeptide and a ThsB polypeptide.

[00248] In some embodiments, a Thoeris defense system having an anti-phage activity comprise a nucleic acid comprising a thsA gene. In some embodiments, a Thoeris defense system having an anti-phage activity comprise a nucleic acid comprising a thsA gene and a thsB gene. In some embodiments, a Thoeris defense system having an anti-phage activity comprise a nucleic acid comprising a thsA gene and 1-10 thsB genes. [00249] In some embodiments, a Thoeris defense system having an anti-phage activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3' order of polypeptides encoded is ThsA and ThsB. In some embodiments the 5' to 3' order of polypeptides does not affect the anti-phage activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti-phage activity.

[00250] In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of ThsA and ThsB. In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of ThsA and 1-10 copies of ThsB, wherein ThsB may be encoded both 5' and 3 ' of the gene encoding the ThsA.

[00251] In some embodiments, a Thoeris defense system having an anti-phage activity comprises a nucleic acid construct comprising genes in a set order. In some embodiment, the 5' to 3' order of genes is thsA and thsB. In some embodiment, the 5' to 3' order of genes in a Thoeris defense system is not thsA and thsB. In some embodiments the 5' to 3' order of genes does not affect the anti-phage activity. In some embodiments the 5' to 3' order of genes does affect the anti-phage activity.

[00252] In some embodiments, the 5' to 3' order of genes is random, for example any order of thsA and thsB. In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of thsA and 1-10 copies of thsB, wherein thsB may be both 5' and 3' of thsA.

[00253] In some embodiments, the Thoeris system (a Defense System II) composition and order is as shown in Figure 3B or Figure 5A.

[00254] In some embodiments, a Thoeris defense system having an anti-phage activity originates from a microbial genome (Table 9). A skilled artisan would appreciate that the Thoeris system is not present in the majority of bacteria and or archaea species.

[00255] In some embodiments, a functional Thoeris defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different microbial species. For example, the source of the nucleic acid sequence encoding a ThsA polypeptide may be one microbial species, while the source of the nucleic acid sequence encoding a ThsB polypeptide may be a different microbial species. In some embodiments, a functional Thoeris defense system (Defense system II) comprises a non-naturally occurring combination of polypeptide components. In some embodiments, a functional Thoeris defense system (Defense system Π) comprises a combination of at least two polypeptides that do not naturally occur together. In some embodiments, a functional Thoeris defense system (Defense system Π) comprises a combination of at least three polypeptides that do not naturally occur together.

[00256] In some embodiments, a functional Thoeris defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different bacterial species. For example, the source of the nucleic acid sequence encoding a ThsA polypeptide may be one bacterial species, while the source of the nucleic acid sequence encoding a ThsB polypeptide may be a different bacterial species.

[00257] In some embodiments, the source of the nucleic acid encoding a ThsA polypeptide and a ThsB polypeptide is the same. In some embodiments, the source of the nucleic acid encoding a ThsA polypeptide and a ThsB polypeptide is the not the same. A skilled artisan would appreciate that the term "ThsB polypeptide" may in some embodiments, be used interchangeably with "ThsB ¹ polypeptide", "ThsB" polypeptide", "ThsB^ polypeptide", "ThsB ^iv polypeptide", and "ThsB ^v polypeptide", wherein the supra numbers I, ii, iii, iv, and v, indicate additional copies of a ThsB polypeptide comprised in embodiments of a Defense System Π. Similarly, skilled artisan would appreciate that the term "thsB gene" may in some embodiments, be used interchangeably with "thsB ¹ gene", thsB ^u gene", thsB ^m gene", thsB ^lv gene", and ^u thsB ^v gene", wherein the supra numbers i, ii, iii, iv, and v, indicate additional copies of a thsB gene encoding ThsB polypeptides comprised in embodiments of a Defense System II.

[00258] In some embodiments, the source of the nucleic acid sequence of any of the components of a Thoeris defense system comprises any of the species listed in Table 9.

[00259] In some embodiments, a Thoeris defense system having an anti-phage activity comprises a nucleic acid construct comprising non-coding regions between the nucleic acid sequences encoding the polypeptides. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence not naturally occurring in the microbial species of origin. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence is the naturally occurring in the microbial species of origin.

[00260] In some embodiments, a Thoeris system disclosed herein comprises a multi-gene phage resistance system broadly distributed in microbial genomes, for example but not limited to Proteobacteria, Firmicutes, Bacteriodetes, and Actinobacteria.

[00261] According to some embodiments, the Thoeris system components are located in a gene cluster (a cassette of genes) in a microbial cell genome. According to some embodiments, the Thoeris system components are located in close proximity (e.g. positioned within 20 genes, 10 genes, 5 genes or less one from the other) in a genome of a prokaryotic cell. According to some embodiments the prokaryotic cell expresses an endogenous Thoeris defense system. According to some embodiments, the prokaryotic cell expresses an endogenous functional Thoeris defense system. According to some embodiments, the species of prokaryotic cell is selected from the group consisting of the species listed in Table 9. According to some embodiments a prokaryotic cell expresses a non-endogenous Thoeris defense system. According to some embodiments, a prokaryotic cell expresses a non-endogenous functional Thoeris defense system. According to some embodiments, the species of prokaryotic cell expressing a non-endogenous functional Thoeris defense system is selected from the group consisting of the species listed in Table 9.

[00262] In some embodiments, Thoeris defense system components comprise ThsA and ThsB polypeptides. In some embodiments, a Thoeris defense system components comprise functional portions of ThsA and ThsB polypeptides. In some embodiments, the Thoeris defense system components are encoded by thsA and thsB genes.

[00263] Non-limiting embodiments of endogenous Thoeris systems and the respective location of their components are provided in Table 9 herein.

[00264] In some embodiments, the components of a Thoeris system may be identified by the presence of similar domains present within each component. In some embodiments, domains comprise pfam domains and or clusters of orthologous groups (COG) domains.

[00265] In some embodiments, a Defense System II comprises a membrane associated complex.

[00266] In some embodiments, the term "ThsA" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the thsA gene. In some embodiments, the term "ThsA" refers to a ThsA polypeptide. In some embodiments, the thsA gene encodes a polypeptide comprising a pfam 13289 domain. In some embodiments, the thsA gene encodes a polypeptide comprising a pfaml4519 domain. In some embodiments, the thsA gene encodes a polypeptide comprising a pfaml3289 domain and a pfaml4519 domain. In some embodiments, the ThsA polypeptide comprises a pfaml3289 domain. In some embodiments, the ThsA polypeptide comprises a pfaml4519 domain. In some embodiments, the ThsA polypeptide comprises a pfaml3289 domain and a pfaml4519 domain. [00267] In some embodiments, the thsA gene encodes a polypeptide comprising a Sir2/Macro domain (NAD binding). In some embodiments, the thsA gene encodes a polypeptide comprising N-terminal transmembrane helices. In some embodiments, the thsA gene encodes a polypeptide comprising a Sirl/Macro domain (NAD binding) and N-terminal transmembrane helices.

[00268] In some embodiments, the ThsA polypeptide comprises a Sir2/Macro domain (NAD binding). In some embodiments, the ThsA polypeptide comprises N-terminal transmembrane helices. In some embodiments, the ThsA polypeptide comprises a Sirl/Macro domain (NAD binding) and N-terminal transmembrane helices.

[00269] In some embodiments, ThsA polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a ThsB polypeptide in a genome of a prokaryotic cell. In some embodiments, ThsA polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a ThsB polypeptide in a genome of a prokaryotic cell. In some embodiments, ThsA polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a ThsB polypeptide in a genome of a prokaryotic cell.

[00270] In some embodiments, ThsA and ThsB are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ThsA and ThsB are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, nucleic acid encoding additional copies of ThsB is positions 3' of the nucleic acid sequence first encoding a ThsB polypeptide.

[00271] In some embodiments, thsA and thsB genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, thsA and thsB, genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, additional thsB genes are positions 3' of the first thsB gene, e.g., the order of a gene cassette with 2 copies of a thsB gene would be thsA, thsB, thsB.

[00272] In some embodiments, a ThsA polypeptide is about 477 amino acids long (median gene size).

[00273] In some embodiments, the ThsA polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns I and J. In some embodiments, the ThsA polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns I and J. In some embodiments, the ThsA polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 9, rows 2-2100 columns I and J. In some embodiments, a homolog of a ThsA polypeptide comprises a Sir2/Macro domain (NAD binding). In some embodiments, a homolog of ThsA polypeptide comprises N-terminal transmembrane helices. In some embodiments, a homolog of a ThsA polypeptide comprises a Sirl/Macro domain (NAD binding) and N-terminal transmembrane helices.

[00274] In some embodiments, the ThsA polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns I and J. In some embodiments, the ThsA polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns I and J. In some embodiments, the ThsA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns I and J. In some embodiments, the ThsA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns I and J. In some embodiments, the ThsA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns I and J. In some embodiments, the ThsA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns I and J. In some embodiments, the ThsA polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns I and J.

[00275] In some embodiments, the ThsA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns I and K. In some embodiments, the ThsA polypeptide comprises the amino acid sequence encoded from a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns I and K. In some embodiments, the ThsA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns I and K. In some embodiments, the ThsA polypeptide comprises the amino acid sequence encoded from a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns I and K. In some embodiments, the ThsA polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns I and K.

[00276] In some embodiments, the nucleic acid sequence of a thsA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns I and K. In some embodiments, the nucleic acid sequence of a thsA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns I and K. In some embodiments, the nucleic acid sequence of a thsA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology within the nucleotide sequences encoding similar domain sequences with a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns I and K. In some embodiments, the nucleic acid sequence of a thsA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity within nucleotide sequences encoding similar domain regions with a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns I and K. In some embodiments, the nucleic acid sequence of a thsA gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns I and K.

[00277] As used herein, the term "ThsB " refers to the polynucleotide or expression product e.g., polypeptide encoded by the thsB gene. In some embodiments, the term "ThsB" refers to a ThsB polypeptide. In some embodiments, the product of the thsB gene comprises a pfam08937 domain or a pfam08357 domain. In some embodiments, the thsB gene encodes a Toll/interleukin-1 receptor (TIR) domain.

[00278] In some embodiments, ThsB polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a ThsA polypeptide in a genome of a prokaryotic cell. In some embodiments, ThsB polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a ThsA polypeptide in a genome of a prokaryotic cell. In some embodiments, ThsB polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a ThsA polypeptide in a genome of a prokaryotic cell.

[00279] In some embodiments, ThsA and ThsB are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments ThsA and ThsB are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, additional ThsB polypeptides are encoded by genes positioned 3' of the first gene encoding ThsB. In some embodiments ThsA and ThsB (1-10 copies) are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00280] In some embodiments, a ThsB polypeptide is about 195 amino acids long (median gene size).

[00281] In some embodiments, the ThsB polypeptide comprises an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns M and N, Q and R, U and V, Y and Z, and AC and AD. In some embodiments, the ThsB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2- 2100 columns M and N, Q and R, U and V, Y and Z, and AC and AD. In some embodiments, a homologue of the ThsB polypeptide comprises a TIR domain. In some embodiments, the ThsB polypeptide comprises an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns M and N, Q and R, U and V, Y and Z, and AC and AD.

[00282] In some embodiments, the ThsB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns M and N, Q and R, U and V, Y and Z, and AC and AD. In some embodiments, the ThsB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns M and N, Q and R, U and V, Y and Z, and AC and AD. In some embodiments, the ThsB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns M and N, Q and R, U and V, Y and Z, and AC and AD. In some embodiments, the ThsB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2-2100 columns M and N, Q and R, U and V, Y and Z, and AC and AD. In some embodiments, the ThsB polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 9, rows 2- 2100 columns M and N, Q and R, U and V, Y and Z, and AC and AD.

[00283] In some embodiments, the ThsB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns M and O, Q and S, U and W, Y and A A, and AC and AE. In some embodiments, the ThsB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns M and O, Q and S, U and W, Y and AA, and AC and AE. In some embodiments, the ThsB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns M and O, Q and S, U and W, Y and AA, and AC and AE. In some embodiments, the ThsB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns M and O, Q and S, U and W, Y and AA, and AC and AE. In some embodiments, the ThsB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns M and O, Q and S, U and W, Y and A A, and AC and AE.

[00284] In some embodiments, the nucleic acid sequence of a thsB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns M and O, Q and S, U and W, Y and AA, and AC and AE. In some embodiments, the nucleic acid sequence of a thsB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns M and O, Q and S, U and W, Y and AA, and AC and AE. In some embodiments, the nucleic acid sequence of a thsB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology within the nucleotide sequences encoding similar domain sequences with a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns M and O, Q and S, U and W, Y and AA, and AC and AE. In some embodiments, the nucleic acid sequence of a thsB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity within nucleotide sequences encoding similar domain regions with a sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns M and O, Q and S, U and W, Y and AA, and AC and AE. In some embodiments, the thsB gene homolog encodes a polypeptide comprising a helicase activity. In some embodiments, the thsB gene homolog encodes a polypeptide comprising a DEAx box helicase activity. In some embodiments, the nucleic acid sequence of a thsB gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 9, rows 2-2100 columns M and O, Q and S, U and W, Y and AA, and AC and AE.

[00285] A skilled artisan would appreciate that a "functional portion of a Defense System II component" or "functional fragment of Defense System II component" or "functional portion of a Thoeris defense system component" or "functional fragment of Thoeris defense system component" refers to a functional portion of a Thoeris polynucleotide or polypeptide, as disclosed herein, which expression is sufficient to elicit an anti-phage activity alone or in combination with the at least one of the other Thoeris polynucleotides or polypeptides disclosed herein or functional portions thereof.

[00286] The terms "ThsA", "ThsB", "thsA", and "thsBT, also refer to functional ThsA, ThsB, thsA, and thsB, homologs, which exhibit the desired activity (i.e., conferring phage resistance). Such homologs can be, for example, at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polypeptide sequences referenced in Table 9, rows 2-2100 columns I and J, M and N, Q and R, U and V, Y and Z, and SAC and AD, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical to the polynucleotide sequences referenced in Table 9, rows 2-2100 columns I and K, M and O, Q and S, U and W, Y and AA, and SAC and AE, respectively. In some embodiments, such homologs comprise at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homology within similar domain regions of the polypeptide sequences referenced in Table 9, rows 2-2100 columns I and J, M and N, Q and R, U and V, Y and Z, and AC and AD, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identity within nucleotide sequences encoding similar domain regions to the polynucleotide sequences referenced in Table 9, rows 2-2100 columns I and K, M and O, Q and S, U and W, Y and AA, and AC and AE, respectively.

[00287] Table 9 presents embodiments of components of Defense System II that may be found in a diverse array of bacteria and archaea genomes (referenced in Table 18). Table 9 presents embodiments of nucleic acid sequences encoding gene cassettes of Defense System II (referenced in Table 18).

[00288] The Druantia Defense System

[00289] In some embodiments, a defense system disclosed herein comprises an Druantia anti- phage defense system. (Table 10) In some embodiments, a Druantia defense system provides a host cell with resistance to entry of foreign nucleic acid invasion. In some embodiments, a host cell expressing a functional Durantia defense system (Defense System Ilia; Defense System Illb; or Defense System Hie) provides the host cell resistance foreign nucleic acid invasion. [00290] In some embodiments, a Druantia defense system provides a host cell with resistance to at least one phage.

[00291] In some embodiments, a Druantia defense system provides a host cell with resistance to phage infection. In some embodiments, expression of a Druantia defense system in bacteria protects the bacteria from phage infection.

[00292] As used herein, the term "a Druantia anti-phage defense system" may be used interchangeably with the term "a Defense System ΠΙ", having all the same meanings and qualities. A skilled artisan would appreciate that the term "Druantia system" may be used interchangeably in some embodiments with "Druantia defense system", "Druantia the defense system", "Druantia anti-phage system", and "Defense System III", having all the same meanings and qualities. Disclosed herein, the Druantia defense system (Defense System III) comprises a Type I Druantia defense system (Defense System Ilia), a Type II Druantia defense system (Defense System nib), and a Type III Druantia defense system (Defense system Hie), as described below.

[00293] In some embodiments, expression of a Druantia Type I defense system (Defense System Ilia) in bacteria protects the bacteria from phage infection. In some embodiments, expression of a Druantia Type II defense system (Defense System Illb) in bacteria protects the bacteria from phage infection. In some embodiments, expression of a Druantia Type III defense system (Defense System IIIc) in bacteria protects the bacteria from phage infection.

[00294] In some embodiments, expression of a Druantia defense system in bacteria protects the bacteria from phage infection.

[00295] In some embodiments, a Druantia defense system (Defense System Ilia or Defense system Illb or Defense System Hie) provides a host cell with resistance to plasmid transformation. In some embodiments, a host cell expressing a functional Druantia defense system (Defense System Ilia or Defense System nib or Defense System IIIc) provides a host cells with resistance to plasmid transformation.

[00296] In some embodiments, a Druantia defense system (Defense system Ilia or Illb or IIIc) provides a host cell with resistance to entry of conjugative elements. In some embodiments, a host cell expressing a function Druantia defense system (Defense System Ilia or nib or IIIc) provides the host cell resistance from entry of conjugative elements.

[00297] In some embodiments, a microbial species does not comprise an endogenous Defense System ΠΙ. In some embodiments, a microbial species does not express an endogenous Defense System III. In some embodiments, a microbial species does not express an endogenous functional Defense System III.

[00298] In some embodiments, a bacterial species does not comprise an endogenous Defense System III. In some embodiments, a bacterial species does not express an endogenous Defense System ΠΙ. In some embodiments, a bacterial species does not express an endogenous functional Defense System III.

[00299] In some embodiments, a microbial species does not comprise an endogenous Defense System Ilia. In some embodiments, a microbial species does not express an endogenous Defense System Ilia. In some embodiments, a microbial species does not express an endogenous functional Defense System Ilia.

[00300] In some embodiments, a bacterial species does not comprise an endogenous Defense System ΠΙΑ. In some embodiments, a bacterial species does not express an endogenous Defense System Ilia. In some embodiments, a bacterial species does not express an endogenous functional Defense System Ilia.

[00301] In some embodiments, a microbial species does not comprise an endogenous Defense System Illb. In some embodiments, a microbial species does not express an endogenous Defense System nib. In some embodiments, a microbial species does not express an endogenous functional Defense System Illb.

[00302] In some embodiments, a bacterial species does not comprise an endogenous Defense System Illb. In some embodiments, a bacterial species does not express an endogenous Defense System nib. In some embodiments, a bacterial species does not express an endogenous functional Defense System Illb.

[00303] In some embodiments, a microbial species does not comprise an endogenous Defense System IIIc. In some embodiments, a microbial species does not express an endogenous Defense System IIIc. In some embodiments, a microbial species does not express an endogenous functional Defense System IIIc.

[00304] In some embodiments, a bacterial species does not comprise an endogenous Defense System IIIc. In some embodiments, a bacterial species does not express an endogenous Defense System Hie. In some embodiments, a bacterial species does not express an endogenous functional Defense System IIIc.

[00305] In some embodiments, a Druantia Type I defense system (Defense System Ilia) having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or a combination thereof, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof. In some embodiments, a Druantia Type I defense system (Defense System Ilia) having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or a combination thereof, a DruB polypeptide wherein said DruB polypeptide is encoded by a gene positioned within 5 genes of a gene encoding said DruA polypeptide and said DruE polypeptide, a DruC polypeptide wherein said DruC polypeptide is encoded by a gene positioned within 5 genes of a gene encoding said DruA polypeptide and said DruE polypeptide, a DruD polypeptide wherein said DruD polypeptide is encoded by a gene positioned within 5 genes of a gene encoding said DruA polypeptide and said DruE polypeptide, and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof.

[00306] In some embodiments, a Druantia Type I defense system (Defense System Ilia) having an anti-phage activity comprises a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or a combination thereof, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof. In some embodiments, a Druantia Type I defense system (Defense System Ilia) having an anti-phage activity comprises a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or a combination thereof, a DruB polypeptide wherein said DruB polypeptide is encoded by a gene positioned within 5 genes of a gene encoding said DruA polypeptide and said DruE polypeptide, a DruC polypeptide wherein said DruC polypeptide is encoded by a gene positioned within 5 genes of a gene encoding said DruA polypeptide and said DruE polypeptide, a DruD polypeptide wherein said DruD polypeptide is encoded by a gene positioned within 5 genes of a gene encoding said DruA polypeptide and said DruE polypeptide, and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof.

[00307] In some embodiments, a Defense System Ilia comprises a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns J and K; or a DruB polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns N and O; or a DruC polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns R and S; or a DruD polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns V and W; and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or any combination thereof.

[00308] In some embodiments, a Defense System Ilia comprises at least two polypeptide components selected from a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns J and K; or a DruB polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns N and O; or a DruC polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns R and S; or a DruD polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns V and W; and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA. In some embodiments, a Defense System Ilia comprises at least three polypeptide components selected from a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns J and K; or a DruB polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns N and O; or a DruC polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns R and S; or a DruD polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns V and W; and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 column Z and AA. In some embodiments, a Defense System Ilia comprises at least four polypeptide components selected from a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns J and K; or a DruB polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns N and O; or a DruC polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns R and S; or a DruD polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns V and W; and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA. In some embodiments, a Defense System Ilia comprises five polypeptide components selected from a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns J and K; or a DruB polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns N and O; or a DruC polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns R and S; or a DruD polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns V and W; and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA.

[00309] In some embodiments, a functional Defense System Ilia comprises at least two polypeptide components selected from a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns J and K; or a DruB polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns N and O; or a DruC polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns r and S; or a DruD polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns V and W; and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA. In some embodiments, a functional Defense System Ilia comprises at least three polypeptide components selected from a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns J and K; or a DruB polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns N and O; or a DruC polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns R and S; or a DruD polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns V and W; and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA. In some embodiments, a functional Defense System Ilia comprises at least four polypeptide components selected from a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns J and K; or a DruB polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns N and O; or a DruC polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns R and S; or a DruD polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns V and W; and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA. In some embodiments, a functional Defense System Ilia comprises five polypeptide components selected from a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns J and K; or a DruB polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns N and O; or a DruC polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns R and S; or a DruD polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-123 columns V and W; and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA.

[00310] In some embodiments, a Druantia Type I defense system (Defense System Ilia) having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a druA gene, a druB gene, a druC gene, a druD gene, and a druE gene.

[00311] In some embodiments, the Druantia Type I anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a gene cassette comprising druA, druB, druC, druD, and druE genes. In some embodiments, a Druantia Type I (Defense System Ilia) gene cassette comprises the nucleic acid sequence:

1 tagtaaggca ttatagtgaa acgatgtcta tgaatcacac atctaatgtc cggtgaacgt 61 ttggttgata gggtagtaaa actagtaatc atcctataat tagctatatt cgtggttatt 121 agattgaaaa cagataacat taacaaaatc tataaatcta tttgaatgat ttttttcatc 181 aatgctgttg taacctcctg ctatcaaaag tttttcacaa aatctataag ctcccagaat 241 tgcttgtata aatgctatca ttggcgctgt cccgatcgag ggagcaagga ggggactctc 301 ttgtgccatg cgattaatca cttgggctct aagtgaaatt tagtgggact aaatactaat 361 tggaacgtga gataaaaatg cacaaagatc cctctataat agttaatatc aaccttcgag 421 aagccaaact gaaaaagaag gtacgtgagc atttacaatc cttgggtttt acaagatctg 481 attctggagc gctccaggcc ccgggaaata ccaaagatgt aatacgggct cttcatagtt 541 ctcaacgagc tgagcggata tttgcaaacc aaaagttcat aacgctaaga gcggcaaagc 601 ttattaaatt tttcgcatcc ggcaatgagg tcattccgga taaaatttca ccggtacttg 661 aacgtgtaaa gtcaggaacc tggcaaggag atctctttag gttagcagca ttaacttggt 721 ccgtacctgt ttcaagcgga tttggaaggc gtctccggta tcttgtatgg gatgaaagca 781 acggaaaatt gatagggctg atcgcaattg gtgaccctgt gttcaacctt gcagtccgag 841 ataatttgat tgggtgggat actcatgcca gaagttcccg gcttgttaat ttgatggatg 901 catacgtcct cggtgctctt cccccttata atgccctgct gggaggaaaa ttaattgcat 961 gtctgcttcg tagccgcgat ctttatgatg actttgcaaa ggtctatggt gataccgttg 1021 gagtaatatc tcaaaaaaag aaacaagcac gtcttttggc tattacaaca acatcgtcta 1081 tggggcgctc atcggtatat aaccgtttaa agctggatgg aattcaatat ttaaaatcga 1141 ttggatatac aggcggttgg gggcattttc atatacctga tagcttgttc attgaattac 1201 gtgattactt acgtgatatg gatcacgctt atgcagatca ttatatgttt ggtaatgggc 1261 ctaactggcg tttacgtaca actaaggcag ctttaaatgt actaggattt agagataatt 1321 tgatgaagca tggaattcaa cgtgaagttt ttatcagtca gctagcagaa aatgcaacta 1381 gtattctgca aacaggcaaa ggtgaaccag atctaacctc tttgctttct gctaaagaga 1441 tagctgagtg tgcgatggca cgatggatgg ttccacgatc aattcgcaat ccagaatatc 1501 ggctttggaa agcaagagat ctatttgatt ttattagtaa tgactcgcta aaatttcccc 1561 cgtctgacga gatagcgaaa acagttgtct aatcttaact gaagggggag taagtgaatt 1621 acgctattga taagttcacc gggacactga tattagcagc tcgagcaacg aaatatgctc 1681 aatatgtttg cccagtttgt aaaaaaggtg ttaacctccg taaagggaag gttatacccc 1741 catattttgc tcatttgccc ggacatggta cgtcagactg tgaaaatttt gttcccggaa 1801 attccatcat tatcgaaact attaaaacta tttcaaagcg atatatggat ttgcgcttat 1861 tgattcctgt cggaagtaat agtcgagagt ggtcattaga attagtgttg ccaacctgta 1921 atttatgtag agcaaagata acgttagatg taggaggcag aagccaaacg cttgatatga 1981 ggagtatggt aaagagtcgc cagattggtg ctgaattatc agtaaaatct taccgtattg 2041 tttcatatag tggtgaaccc gatccaaaat ttgtaacaga agttgaaaga gaatgccccg 2101 gtttaccttc tgagggagca gcagttttca ctgctttagg gcgtggggca tcgaagggat 2161 ttccacgagc acaagagtta agatgtactg aaacatttgc ctttctttgg cgacaccctg 2221 ttgctccaga ttttcctgat gaattagaaa taaaaagttt agctagtaaa cagggatgga 2281 atttagctct tgttacaatt cctgaagtcc cttctgtgga gagtatttca tggctaaaat 2341 cttttacata ccttcctgtt gttcctgcca gaacatctat tacagcaatt tggccgttcc 2401 taaatcaaaa aacaagtatt aatcatgtcg aatgtgttca ttctgacaca atattgttgt 2461 cagcaaatat ggcaccaaca tcatcagaaa atgttggacc aactatgtac gcacaaggtt 2521 cctctttatt actttcagcg gttggtgttg aaaaatcacc tgctttcttc attcttaatc 2581 ctggagaaaa tgactttgtg ggcgtttctg gctcaattga gcaggacgta aacttatttt 2641 tttctttcta taaaaaaaac gtttctgtac ccagaaaata tccctcaata gatttggttt 2701 ttactaagag gaataaagaa aagaccatcg tttccttaca tcaaagaaga tgcattgaag 2761 ttatgatgga agcacgaatg tttggccata aattagaata catgtctatg ccttctggtg 2821 ttgaaggagt ggcaagaatt caaagacaaa ctgaaagtag tgttattaag ttagtttcta 2881 atgatgacat tgcagctcat gataagagca tgcggttact atctcctgtt gcgttatctc 2941 aattatctga ttgcttagca aacttaacat gtcatgtaga aatagatttt ttaggtcttg 3001 gtaaaatatt tttacctagt tcttctatgt tatcattaga tgacggggaa tttattgaat 3061 tatctcctaa tcttcgctca cggatattaa gttttatact tcaaatgggg cacaccctcc 3121 atggttttag tttaaataat gattttttat tagttgagaa attagtggat ttgcagccgg 3181 aaccacactt attaccgcat tatagggcat tggtaaaaga agttaagacc aatggatttg 3241 aatgtaaccg ctttagataa ggtgccttcg aatgagttac caatatagcc aagaggcaaa 3301 ggaacggatc tctaagttgg gacaatccga aattgttaac tttatcaatg agatttctcc 3361 aactttacga cgtaaagctt ttggttgttt accaaaagta ccgggattca gggcaggaca 3421 tcccactgaa attaaagaaa aacagaaaag attgattggg tatatgttcc agtcacatcc 3481 ttcctctgag gagagaaaag catggaaaag tttttctctt ttttggcagt tttgggctga 3541 agagaaaatt gacaaatcat ttagtatgat tgataattta ggattaaaag aaaactctgg 3601 ctctattttt attagagagc ttgctaaaaa ctttcctaaa gttgctagag agaatatcga 3661 gcgcctgttt atctttagtg ggtttgctga tgatccagac gttataaatg catttaacct 3721 ttttcctcct gcagttgttc ttgcccgcga tatcgtggtt gatactcttc caattcgttt 3781 agatgagctt gaagcacgta ttagtttaat tgccgataat gtggagaaaa aaaataacca 3841 tattaaagag cttgagttaa aaatagatgc tttttccgaa cggttcgata attactttaa 3901 taatgaaaag agcaatttaa aaataattaa cgaactacaa tccttaataa actcagagac 3961 taaacaatct gatattgcta ataaatctat tgacgagctt tatcatttta atgaaaaaaa 4021 caaacagcta atattatctc ttcaagagaa attagatttt aatgctctgg ctatgaatga 4081 catttctgag catgaaaaat tgataaaaag tatggctaat gaaatttcag agttaaaaaa 4141 tgcattaact atcttgtgtg ataataaaag aaagaataac gagttagatt atatcaatga 4201 attaaaaaaa ctcactgaac gaatagatac acttgaaata aacacatctc aagctagcaa 4261 agtgagtgtc accaatagat ttacaaaatt ccatgaaata gcgcactatg aaaattatga 4321 atatctttca tcctccgaag acatatctaa tagaatttct ttaaatttac aggctgttgg 4381 gttaacaaaa aattcagcag aaacattggc tagattgaca ttagctacct tcgtttctgg 4441 acaaatcatt caattcagtg gctctttggc agatattatc gcggatgcaa ttgccattgc 4501 tattggtgca ccacgttatc acatatggag agttccagtt ggtattattt ctgacatgga 4561 ttcttttgat tttatagaga ctatagctga atcatctcgc tgtctccttt tgaaaggggc 4621 caatctttca gcatttgaga tttatggagc ggcaattaga gatatagttg ttcaacggca 4681 aatacatcca acaaattatg accatctggc attgatagct acttggaaac aaggccctgc 4741 tacattccct gatggaggaa tgttggccga gttgggacca gttattgata ctgatacatt 4801 aaaaatgcgt ggtttatctg ctattttacc ccaattgaaa ccaggttgtc ttgccaagga 4861 taaatggaca aatattgatg gactacagct tgatagtgtt gatgattatg tagatgaatt 4921 aagagcatta ctggacgaag ctggatttga tgggggaact ttgtggaaga gaatggttca 4981 tattttctat acttcactca taagagtccc taatggaaat tatatttatg atctttattc 5041 tgtcttgtct ttttatactc ttacatgggc aaaaattaaa ggtggccccg tccaaaagat 5101 agaagatatt gccaatcgtg aattaaaaaa ttatagtgca aaaatatctt cttgaggagg 5161 tggttaatgg agtggagagc agtatcacga gacaaagcac tggatatgtt atcaactgca 5221 ttaaattgtc gatttgatga tgaagggttg agaatttcag cagtttcaga atgcttaagg 5281 agcgtattat atcaatattc tatatctgaa acagaagaag ctaggcaaac tgtaacctcg 5341 cttcgactca ctagtgcagt aaggcgaaaa ttggtacctt tatggccaga cattgctgat 5401 attgataatg ctatacatcc gggcattatg tctatattga acagcttggc tgaattgggt 5461 gacatgatta agttagaagg tggtaattgg ctcacagctc ccccacatgc agtacgaatt 5521 gacaataaga tggctgtttt ttttggtgga gagccttcct gtacattttc aacgggcgtg 5581 gtagctaaat ctgctggaag agttcgcttg gttgaagaaa aagtgtgtac tggaagtgtt 5641 gaaatctggg atgcaaatga gtggattggt gccccagcag aaggcaatga agaatggtca 5701 tccagactac tatctggaac tatttccggc tttatcgatg cgcctagcaa tatgagtgaa 5761 acgactgcat atgtgcgggg aaaatggctc catttgtcag aactttcttt taataaaaag 5821 caaatctact tatgcagaat gtccgttgat aatcactttt cctattattt aggagaaatt 5881 gaagctggac gcttatgtag aatgaattcg ttagaatcgt ctgatgatgt cagaagatta 5941 cgtttttttc tcgatacaaa agataattgt ccgctaaaga tccgtatcaa aatatctaat 6001 gggctagcaa gattaagatt aaccagaaga ttaccaagac gagaaacgaa ggtactcctg 6061 ctaggctgga gagaatcagg ttttgaaaat gaacattcag gaataacaca ccatgtattc 6121 cccgaggaaa tattacccat agtgcgtagc gcttttgaag ggcttggtat tatttggatt 6181 aacgaattca cgcgacggaa tgaaatatga ttaataaaaa taaagtaact gaacgttcag 6241 gtatacatga taccgtgaaa agccttagtg agaatctgag aaaatacatt gaggcacaat 6301 atcatatccg ggatgaaggg ttaattgctg agcgacgagc gcttttacag caaaatgaaa 6361 ctattgctca agctccttat atagaagcaa ccccaattta tgaacctggt gcgccataca 6421 gtgaattacc tattcccgaa gcagcaagta atgtgctaac tcaactatca gaacttggaa 6481 ttggcctcta tcaacgcccc tataaacacc aatcacaggc acttgagtca tttcttggcg 6541 aagacgcttc tgatctggtc attgcaacag gtacaggctc cggtaagact gaaagctttc 6601 taatgccaat tattggtaaa ttggcgattg aatcttccga gagacctaaa tctgcatccc 6661 ttccaggttg tagagcaatt ttattatatc caatgaatgc attagttaac gatcaacttg 6721 ctcgtatcag acgtcttttt ggtgattctg aagcctctaa aatactgaga tctggaagat 6781 gtgcccctgt acgctttggc gcttatacgg gaagaacgcc ttaccctggt cgtcgtagct 6841 ctagacgaga cgagcttttt atcaaacccc ttttcgatga gttttacaat aaactcgcaa 6901 ataacgcccc tgtacgtgcg gaactgaacc gcattggtcg ctggccaagt aaagatcttg 6961 atgcttttta tgggcaaagc gcatctcagg ctaaaaccta cgtctcaggc aaaaaaacgg 7021 gtaagcaatt tgttttgaac aattgggggg agaggctaat tacccagcct gaggatcgtg 7081 agctaatgac ccggcatgaa atgcagaatc gctgtccaga attactgata acgaactact 7141 ccatgcttga gtatatgctg atgcgaccta tcgagcgtaa tatttttgag cagactaagg 7201 aatggctcaa agctgatgag atgaatgagc ttatcttagt gcttgatgaa gcgcatatgt 7261 atagaggagc agggggagca gaggtagccc ttttaatacg tcgcctctgt gctcggttgg 7321 atattccccg ggaacgtatg cgctgcatcc ttaccagtgc tagtctaggg tccattgagg 7381 atggagaacg ttttgcccaa gacttaactg gcttatcacc aacctcttcg aggaaatttc 7441 gaattattga gggtacaagg gaatcgcgtc ctgagtcaca aattgttacc agtaaagaag 7501 ctaatgcact ggctgaattc gacctaaatt catttcagtg cgtagctgag gatcttgaat 7561 ctgcatatgc agcaatagag tctcttgccg aacgaatggg ctggcaaaag ccgatgataa 7621 aagatcatag tacactacgt aattggttat ttgataattt gactggtttt ggtcctattg 7681 aaacgcttat tgaaatagtt tcaggtaaag cggttaagct aaatatcttg agtgaaaacc 7741 tttttccaga ctctccacag caaattgcag agcgagcgac agatgcatta ctcgcattgg 7801 gttgctatgc tcagagggca tccgatggca gagtgcttat tccaactcgc atgcatcttt 7861 tttatcgggg attaccaggt ctttatgcct gtatagatcc cgattgtaat caacgtttgg 7921 gtaaccatag tgggccaact atacttggcc gcctttatac gaaaccactg gatcaatgta 7981 aatgcgcttc aaaagggcga gtctacgaat tatttaccca ccgtgactgc ggtgcggctt 8041 ttattcgtgg atacgttagt tccgaaatgg actttgtatg gcaccagccg aacggaccat 8101 tatcagaaga tgaggatatc gatcttgttc ccatagatat attggtcgag gaaacacctc 8161 atgtacatag tgattaccag gacagatggc tacatatagc aacaggacgc ctttctaaac 8221 agtgtcaaga tgaggattct ggttatcgta aagtctttat acctgaccga gttaagtctg 8281 gatctgaaat tacatttgat gaatgccctg tttgtatgcg taagacaaga agtgctcaga 8341 atgaaccgtc taaaattatg gatcatgtta caaaagggga agcacctttt acaacgttag 8401 tacgtacaca gatatctcac cagccagcga gtcgtcctat tgatggtaaa catcccaatg 8461 ggggaaaaaa agtacttatt ttttctgatg gccgacaaaa agcagctcgg cttgcacgtg 8521 atattcctag agatattgag cttgatttgt ttcggcaatc cattgctctc gcctgttcta 8581 aactgaaaga tatcaatcgg gaacccaaac caacatcagt actttacctt gctttcctat 8641 cagtcctttc tgaacatgac ttgcttattt ttgatgggga agattcacga aaagttgtaa 8701 tggcccgtga tgaattttat cgtgattata atagcgatct ggctcaagct tttgatgata 8761 acttcagtcc ccaagagtca ccgtcacgat ataaaatagc gttgcttaaa cttttatgta 8821 gcaattacta ttctctttcc ggaacaacag ttggttttgt tgaaccatcg cagcttaaat 8881 caaaaaaaat gtgggaagat gtgcagtcca agaagctaaa tattgagagc aaggatgttc 8941 atgctttagc tgttgcttgg attgatacct tactcactga atttgctttt gatgaatcta 9001 ttgattcgac actacgaatc aaagccgctg gattctacaa acccacttgg ggtagtcaag 9061 gacggtttgg aaaagctctt aggaaaaccc tgatacagca tcctgctatg ggggagcttt 9121 atgtggaagt tttggaggag atttttcgta ctcatctgac attaggaaaa gatggtgtct 9181 actttcttgc tccaaatgca ctacgtctga aaatagatct cttgcatgtc tggaaacaat 9241 gtaatgactg cacggcacta atgccatttg ctttagaaca ttctacttgc cttgcttgtg 9301 gtagtaacag tgtcaaaaca gtcgagccgt cggaaagcag ctatattaat gcacgaaaag 9361 gattctggcg ttcgccggta gaagaagttt tggtttcaaa ttcgcggctt ctaaacctta 9421 gcgttgaaga gcatactgct caactctcac atagagatag ggccagcgtt catgccacta 9481 cagaactcta cgaactgaga ttccaagatg ttcttattaa tgataacgac aagcccattg 9541 atgtacttag ttgtacgacg acgatggaag tgggggttga tattggatct ctggttgctg 9601 ttgctttaag aaacgtccct ccgcaacgag aaaattatca gcaacgtgct gggcgagcag 9661 gccgccgtgg cgcatctgtt tcaacggtgg ttacatattc tcaaaatggc cctcatgata 9721 gttattattt ccttaatcct gaacgcattg ttgcaggttc tcctcgtaca cctgaagtga 9781 aagtaaataa tcccaaaata gccagaagac acgttcattc ttttttagtt cagacctttt 9841 ttcacgagtt aatggaacaa ggaatttata atcccacaga gaaaactgcc atacttgaga 9901 aagcacttgg tactacacga gatttttttc atggagcaaa agatactggc ctaaatctcg 9961 atagctttaa taattgggtt aaaaaccgta ttctatctac taatggtgat ttgagaacaa 10021 gtgttgcagc atggcttcct cctgttcttg aaactggagg gctttctgcc agtgactggt 10081 ttgctaaggt agcagaggaa tttttaaata cactccatgg gctggctgaa attgttccac 10141 aaattgccgc tcttgttgat gaggaaaatg aagatgatga gcagacttct ggtggaatga 10201 aatttgcaca agaagaatta cttgagttcc tgttttacca tggtttatta ccaagttatg 10261 catttcctac aagcctctgt agtttcttgg tagaaaaaat tgtaaagaat attagaggtt 10321 cttttgaggt gcgaacagta caacagcctc agcaatcaat ttctcaggct ctgagtgaat 10381 atgccccggg acgtttgatt gttattgata ggaaaaccta tcgctctggt ggtgtttttt 10441 ctaatgcatt gaaaggcgaa ctaaaccggg caagaaagct tttcaataat cccaaaaagt 10501 ttattcattg cgataagtgc tcttttgtcc gcgatcctca taataatcag aatagcgaaa 10561 atacttgtcc gatctgtggt ggcattctaa aagtagaaat aatgattcag cccgaagtct 10621 ttggacctga aaatgccaag gaacttaatg aggacgacag agagcaagaa atcacctatg 10681 taactgcggc acaatatcca caacctgttg atcctgaaga ttttaagttc aataatggag 10741 gtgctcatat tgtttttact cacgcaatag atcagaaact ggtgacggtg aaccgaggga

10801 aaaatgaggg ggggtccagt ggtttttcag tatgttgcga atgtggtgcg gcctccgttt

10861 atgattccta ctcaccggca aagggggcac atgaaagacc gtataaatat atagcaacta

10921 aggaaacgcc tcgcttatgc tctggcgagt ataaacgcgt ttttctcgga catgatttcc

10981 gtactgattt gcttttatta cgaataaccg ttgggtctcc gcttgtaact gatacttcaa

11041 atgctatcgt tttacggatg tatgaagatg cattatatac aatagcggaa gcactaaggc

11101 ttgcagctag tcgccataaa caactggatc ttgatcctgc tgagtttggc tctggtttca

11161 gaattttacc cactatagag gaagatactc aggcattgga tctcttcctt tatgatactt

11221 tatctggcgg tgcgggttat gcggaagtag cagcagcgaa tctagatgac attcttactg

11281 caacactcgc attgttagaa ggttgtgagt gcgatacctc ctgtacagat tgtctcaatc

11341 atttccacaa ccagcatata caaagccgtc tcgataggaa actaggtgca tctttacttc

11401 gttatgctct atacggaatg gttcctcgtt gtgcttcacc tgatattcag gtagaaaaat

11461 tgtctcaatt gagggcaagt ctggaattgg atggttttca atgcctaatt aagggaactc

11521 aggaggcacc tatgattgtg agtttgaatg accgttctgt tgcagtggga agttaccctg

11581 gtcttattga tcgacccgac tttcaacacg acgtatataa gtcaaagaat actaatgctc

11641 atatagcctt taatgaatat cttcttcgtt caaatctgcc acaagcgcat caaaatatta

11701 gaaaattgtt gcgctgatag cagtattgag tgccctaaag tcctataggg cactcaaggt

11761 tattctcttt taatatttgt taatagcatg tattttaagg ctttcagtcc ttgagctggc

11821 ttttacacaa cgagaaagag gtaattataa taccagccgg atatggcgag aaatggtggc

11881 ccgggggtgt aagtatcccg cataatcgtg ccattcatat ttagagatca tccggcataa

11941 tcaatctgct aacgaaggag atcgcta (SEQ ID NO: 16; construct 56 of Table 4).

[00312] The coding regions for each of the druA, drub, druC, druD, and druE gene sequences within this embodiment of a Druantia Type I cassette (SEQ ID NO: 16) are as follows: nucleotides 378-1592 encode an embodiment of a DruA polypeptide; nucleotides 16614-3260 encode an embodiment of a DruB polypeptide; nucleotides 3272-5155 encode an embodiment of a DruC polypeptide, nucleotides 5167-6210 encode an embodiment of a DruD polypeptide; and nucleotides 6207-11717 encode an embodiment of a DruE polypeptide.

[00313] In some embodiments, a Defense System Ilia comprising a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide and a DruE polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 16. In some embodiments, a Defense System Ilia comprising a aDruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide and a DruE polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 16. In some embodiments, a Defense System Ilia comprising a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide and a DruE polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 16. In some embodiments, a Defense System Ilia comprising a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide and a DruE polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 16. In some embodiments, a Defense System

Ilia comprising a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide and a DruE polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 16.

[00314] In some embodiments, the Type I Druantia anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a gene cassette comprising druB, druC, druD, and druE genes. In some embodiments, the Type I Druantia anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a gene cassette comprising druB, druC, druD, druE, and druA genes.

[00315] In some embodiments, a construct comprising the Type I Druantia anti-phage defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system. In some embodiments, the components of a Druantia defense system comprise polypeptides DruA, DruB, DruC, DruD, and DruE. In some embodiments, the components of a Druantia Type I defense system comprise polypeptides DruB, DruC, DruD, and DruE.

[00316] In some embodiments, a construct comprising the Druantia Type I anti-phage defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system. In some embodiments, the components of a Druantia defense system comprise genes druA, druB, druC, druD, and druE. In some embodiments, the components of a Druantia Type I defense system comprise genes druB, druC, druD, and druE.

[00317] In some embodiments, the components of a Druantia Type I defense system consists of genes druA, druB, druC, druD, and druE. In some embodiments, the components of a Druantia Type I defense system consist of genes druB, druC, druD, and druE.

[00318] In some embodiments, the components of a Druantia Type I defense system comprise nucleic acid sequences encoding a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, and a DruE polypeptide. In some embodiments, the components of a Druantia Type I defense system comprise nucleic acid sequences encoding a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, and a DruE polypeptide. In some embodiments, the components of a Druantia Type I defense system comprise nucleic acid sequences encoding a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, a DruE polypeptide, and a DruA polypeptide.

[00319] In some embodiments, the components of a Druantia Type I defense system consist of nucleic acid sequences encoding a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, and a DruE polypeptide. In some embodiments, the components of a Druantia Type I defense system consist of nucleic acid sequences encoding aDruB polypeptide, a DruC polypeptide, a DruD polypeptide, and a DruE polypeptide. In some embodiments, the components of a Druantia Type I defense system consist of nucleic acid sequences encoding a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, a DruE polypeptide, and a DruA polypeptide.

[00320] In some embodiments, a construct comprising the Druantia Type I defense system encodes one component of the defense system, whereby a second, third, fourth, or fifth construct may be used to assemble the functional defense system. In some embodiments, a construct comprising the Druantia defense system encodes one component of the defense system, whereby additional constructs may be used to assemble the functional defense system. For example, in some embodiments each of DruA, DruB, DruC, DruD, and DruE may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional Druantia defense system. In some embodiments each of DruB, DruC, DruD, and DruE may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional Druantia defense system.

[00321] In some embodiments, the components making up a functional Druantia Type I anti- phage defense system comprise a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, and a DruE polypeptide, each encoded by a druA, druB, druC, druD, or druE gene, respectively. In some embodiments, the components making up a functional Druantia Type I anti-phage defense system comprise a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, and a DruE polypeptide, each encoded by a druB, druC, druD, or druE gene, respectively.

[00322] In some embodiments, a Druantia Type I defense system having an anti-phage activity comprises a nucleic acid encoding a DruA polypeptide. In some embodiments, a Druantia Type I defense system having an anti-phage activity comprises a nucleic acid encoding a DruB polypeptide. In some embodiments, a Druantia Type I defense system having an anti- phage activity comprises a nucleic acid encoding a DruC polypeptide. In some embodiments, a Druantia Type I defense system having an anti-phage activity comprises a nucleic acid encoding a DruD polypeptide. In some embodiments, a Druantia Type I defense system having an anti- phage activity comprises a nucleic acid encoding a DruE polypeptide.

[00323] In some embodiments, a Druantia Type I defense system having an anti-phage activity comprises a nucleic acid encoding a DruB polypeptide and a DruE polypeptide. In some embodiments, a Druantia defense system having an anti-phage activity comprises a nucleic acid encoding a DruC polypeptide and a DruE polypeptide. In some embodiments, a Druantia Type I defense system having an anti-phage activity comprises a nucleic acid encoding a DruB polypeptide, a DruC polypeptide, and a DruE polypeptide.

[00324] In some embodiments, a Druantia Type I defense system having an anti-phage activity comprise a nucleic acid comprising a druA gene. In some embodiments, a Druantia Type I defense system having an anti-phage activity comprise a nucleic acid comprising a druB gene. In some embodiments, a Druantia Type I defense system having an anti-phage activity comprise a nucleic acid comprising a druC gene. In some embodiments, a Druantia Type I defense system having an anti-phage activity comprise a nucleic acid comprising a druD gene. In some embodiments, a Druantia Type I defense system having an anti-phage activity comprise a nucleic acid comprising a druE gene.

[00325] In some embodiments, a Druantia Type I defense system having an anti-phage activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3' order of polypeptides encoded is DruA, DruB, DruC, DruD, and DruE. In one embodiment, the 5' to 3' order of polypeptides encoded is DruB, DruC, DruD, and DruE. In one embodiment, the 5' to 3' order of polypeptides encoded is DruB, DruC, DruD, DruE, and DruA.

[00326] In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of DruA, DruB, DruC, DruD, and DruE. In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of DruB, DruC, DruD, and DruE.

[00327] In some embodiments the 5' to 3' order of polypeptides does not affect the anti- phage activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti- phage activity.

[00328] In some embodiments, a Druantia Type I defense system having an anti-phage activity comprises a nucleic acid construct comprising genes in a set order. In some embodiment, the 5' to 3' order of genes is druA, druB, druC, druD, and druE. In some embodiment, the 5' to 3' order of genes is druB, druC, druD, and druE. In some embodiment, the 5' to 3' order of genes is druB, druC, druD, druE, and druA. [00329] In some embodiments, the 5' to 3' order of genes is random, for example any order of druA, druB, druC, druD, and druE. In some embodiments, the 5' to 3' order of genes is random, for example any order of druB, druC, druD, and druE.

[00330] In some embodiments the 5' to 3' order of genes does not affect the anti-phage activity. In some embodiments the 5' to 3' order of genes does affect the anti-phage activity.

[00331] In some embodiments, a Druantia Type II defense system (Defense System nib) having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a DruM polypeptide comprising a COG0270 domain or a pfam00145 domain or a combination thereof, a DruF polypeptide, a DruG polypeptide, and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof. In some embodiments, a Druantia Type II defense system (Defense System Illb) having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a DruM polypeptide comprising a COG0270 domain or a pfam00145 domain or a combination thereof, a DruF polypeptide wherein said DruF polypeptide is encoded by a gene positioned within 5 genes of a gene encoding said DruM polypeptide and said DruE polypeptide, a DruG polypeptide wherein said DruG polypeptide is encoded by a gene positioned within 5 genes of a gene encoding said DruM polypeptide and said DruE polypeptide, and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof.

[00332] In some embodiments, a Druantia Type II defense system (Defense System nib) having an anti-phage activity comprises a DruM polypeptide comprising a COG0270 domain or a pfam00145 domain or a combination thereof, a DruF polypeptide, a DruG polypeptide, and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof. In some embodiments, a Druantia Type II defense system (Defense System Illb) having an anti-phage activity comprises a DruM polypeptide comprising a COG0270 domain or a pfam00145 domain or a combination thereof, a DruF polypeptide wherein said DruF polypeptide is encoded by a gene positioned within 5 genes of a gene encoding said DruM polypeptide and said DruE polypeptide, a DruG polypeptide wherein said DruG polypeptide is encoded by a gene positioned within 5 genes of a gene encoding said DruM polypeptide and said DruE polypeptide, and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof.

[00333] In some embodiments, a Defense System nib comprises a DruM polypeptide comprising a pfam00145 domain or a COG0270 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AD and AE; or a DruF polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AH and AI; or a DruG polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AL and AM; or a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or any combination thereof.

[00334] In some embodiments a Defense System Illb comprises at least two different polypeptide components selected from a DruM polypeptide comprising a pfam00145 domain or a COG0270 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AD and AE; or a DruF polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AH and AI; or a DruG polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AL and AM; or a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or any combination thereof. In some embodiments a Defense System Illb comprises at least three different polypeptide components selected from a DruM polypeptide comprising a pfam00145 domain or a COG0270 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AD and AE; or a DruF polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AH and AI; or a DruG polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AL and AM; or a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or any combination thereof. In some embodiments a Defense System Illb comprises four different polypeptide components selected from a DruM polypeptide comprising a pfam00145 domain or a COG0270 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AD and AE; or a DruF polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AH and AI; or a DruG polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AL and AM; or a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or any combination thereof.

[00335] In some embodiments, a functional Defense System nib comprises at least two different polypeptide components selected from a DruM polypeptide comprising a pfam00145 domain or a COG0270 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AD and AE; or a DruF polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AH and AI; or a DruG polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AL and AM; or a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or any combination thereof. In some embodiments, a functional Defense System Illb comprises at least three different polypeptide components selected from a DruM polypeptide comprising a pfam00145 domain or a COG0270 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AD and AE; or a DruF polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AH and AI; or a DruG polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AL and AM; or a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or any combination thereof. In some embodiments, a functional Defense System nib comprises four different polypeptide components selected from a DruM polypeptide comprising a pfam00145 domain or a COG0270 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AD and AE; or a DruF polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AH and AI; or a DruG polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 124-295 columns AL and AM; or a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z and AA; or any combination thereof.

[00336] In some embodiments, a Druantia Type II defense system (Defense System nib) having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a druM gene, a druF gene, a druG gene, and a druE gene.

[00337] In some embodiments, the Druantia Type II anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a gene cassette comprising druM, druF, druG, and druE genes. In some embodiments, the Type II Druantia anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a gene cassette comprising druM, druF, druG, and druE genes.

[00338] In some embodiments, a construct comprising the Type II Druantia anti-phage defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system. In some embodiments, the components of a Druantia defense system comprise polypeptides DruM, DruF, DruG, and DruE.

[00339] In some embodiments, a construct comprising the Druantia Type II anti-phage defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system. In some embodiments, the components of a Druantia defense system comprise genes druM, druF, druG, and druE.

[00340] In some embodiments, the components of a Druantia Type II defense system consists of genes druM, druF, druG, and druE.

[00341] In some embodiments, the components of a Druantia Type II defense system comprise nucleic acid sequences encoding a DruM polypeptide, a DruF polypeptide, a DruG polypeptide, and a DruE polypeptide.

[00342] In some embodiments, the components of a Druantia Type II defense system consist of nucleic acid sequences encoding a DruM polypeptide, a DruF polypeptide, a DruG polypeptide, and a DruE polypeptide.

[00343] In some embodiments, a construct comprising the Druantia Type II defense system encodes one component of the defense system, whereby a second, third, or fourth, construct may be used to assemble the functional defense system. In some embodiments, a construct comprising the Druantia defense system encodes one component of the defense system, whereby additional constructs may be used to assemble the functional defense system. For example, in some embodiments each of DruM, DruF, DruG, and DruE may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional Druantia Type II defense system.

[00344] In some embodiments, the components making up a functional Druantia Type II anti- phage defense system comprise a DruM polypeptide, a DruF polypeptide, a DruG polypeptide, and a DruE polypeptide, each encoded by a druM, druF, druG, or druE gene, respectively.

[00345] In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid encoding a DruM polypeptide. In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid encoding a DruF polypeptide. In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid encoding a DruG polypeptide. In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid encoding a DruE polypeptide.

[00346] In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid encoding a DruM polypeptide and a DruE polypeptide. In some embodiments, a Druantia defense system having an anti-phage activity comprises a nucleic acid encoding a DruF polypeptide and a DruE polypeptide. In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid encoding a DruG polypeptide and a DruE polypeptide. In some embodiments, a Druantia defense system having an anti-phage activity comprises a nucleic acid encoding a DruM polypeptide, a DruF polypeptide, and a DruE polypeptide. In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid encoding a DruM polypeptide, a DruG polypeptide, and a DruE polypeptide. In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid encoding a DruM polypeptide, a DruF polypeptide, and a DruG polypeptide. In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid encoding a DruF polypeptide, a DruG polypeptide, and a DruE polypeptide. In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid encoding a DruF polypeptide and a DruG polypeptide.

[00347] In some embodiments, a Druantia Type II defense system having an anti-phage activity comprise a nucleic acid comprising a druM gene. In some embodiments, a Druantia Type II defense system having an anti-phage activity comprise a nucleic acid comprising a druF gene. In some embodiments, a Druantia Type II defense system having an anti-phage activity comprise a nucleic acid comprising a druG gene. In some embodiments, a Druantia Type II defense system having an anti-phage activity comprise a nucleic acid comprising a druE gene.

[00348] In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3' order of polypeptides encoded is DruM, DruF, DruG, and DruE.

[00349] In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of DruM, DruF, DruG, and DruE.

[00350] In some embodiments the 5' to 3' order of polypeptides does not affect the anti- phage activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti- phage activity.

[00351] In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid construct comprising genes in a set order. Non-limiting examples of the 5' to 3' order or genes comprises druM, druF, druG, and druE; druF, druG, druE, and drum; druG, druE, druM, and druF; and druE, druM, druG, and druF.

[00352] In some embodiments, the 5' to 3' order of genes is random, for example any order of druM, druF, druG, and druE.

[00353] In some embodiments the 5' to 3' order of genes does not affect the anti-phage activity. In some embodiments the 5' to 3' order of genes does affect the anti-phage activity.

[00354] In some embodiments, a Druantia Type III defense system (Defense System IIIc) having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a DruH polypeptide and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof. In some embodiments, a Druantia Type III defense system (Defense System IIIc) having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a DruH polypeptide and said DruE polypeptide, wherein said DruH polypeptide is encoded by a gene positioned within 5 genes of a gene encoding said DruE polypeptide.

[00355] In some embodiments, a Druantia Type III defense system (Defense System IIIc) having an anti-phage activity comprises a DruH polypeptide and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof. In some embodiments, a Druantia Type III defense system (Defense System IIIc) having an anti-phage activity comprises a DruH polypeptide and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, wherein said DruH polypeptide is encoded by a gene positioned within 5 genes of a gene encoding said DruE polypeptide.

[00356] In some embodiments, a Defense System IIIc comprises a DruH polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 296-1343 columns AP and AQ; or a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 10 rows 2-1343 columns Z nd AA or a combination thereof; or any combination thereof.

[00357] In some embodiments, a Druantia Type IIII defense system (Defense System IIIc) having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a druH gene and a druE gene.

[00358] In some embodiments, the Druantia Type IIII anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a gene cassette comprising druH and druE genes.

[00359] In some embodiments, a construct comprising the Type III Druantia anti-phage defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system. In some embodiments, the components of a Druantia defense system comprise polypeptides DruH and DruE.

[00360] In some embodiments, a construct comprising the Druantia Type III anti-phage defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system. In some embodiments, the components of a Druantia defense system comprise genes druH and druE.

[00361] In some embodiments, the components of a Druantia Type III defense system consists of genes druH and druE.

[00362] In some embodiments, the components of a Druantia Type III defense system comprise nucleic acid sequences encoding a DruH polypeptide and a DruE polypeptide.

[00363] In some embodiments, the components of a Druantia Type III defense system consist of nucleic acid sequences encoding a DruH polypeptide and a DruE polypeptide.

[00364] In some embodiments, a construct comprising the Druantia Type III defense system encodes one component of the defense system, whereby a second construct may be used to assemble the functional defense system. In some embodiments, a construct comprising the Druantia Type III defense system encodes one component of the defense system, whereby an additional construct may be used to assemble the functional defense system. For example, in some embodiments each of DruH and DruE may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional Druantia defense system.

[00365] In some embodiments, the components making up a functional Druantia Type III anti-phage defense system (Defense System IIIc) comprise a DruH polypeptide and a DruE polypeptide, each encoded by a druH and druE gene, respectively. In some embodiments, a Defense System Hie comprises at least two different polypeptide components selected from DruH and DruE, as described herein. In some embodiments, a functional Defense System IIIc comprises at least two different polypeptide components selected from DruH and DruE, as described herein. In some embodiments, a functional Defense System Hie having anti-phage activity comprises at least two different polypeptide components selected from DruH and DruE, as described herein.

[00366] In some embodiments, a Druantia Type III defense system having an anti-phage activity comprises a nucleic acid encoding a DruH polypeptide. In some embodiments, a Druantia Type III defense system having an anti-phage activity comprises a nucleic acid encoding a DruE polypeptide.

[00367] In some embodiments, a Druantia Type III defense system having an anti-phage activity comprises a nucleic acid encoding a DruH polypeptide and a DruE polypeptide.

[00368] In some embodiments, a Druantia Type III defense system having an anti-phage activity comprise a nucleic acid comprising a druH gene. In some embodiments, a Druantia Type III defense system having an anti-phage activity comprise a nucleic acid comprising a druE gene.

[00369] In some embodiments, a Druantia Type III defense system having an anti-phage activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3' order of polypeptides encoded is DruH and DruE. In one embodiment, the 5' to 3' order of polypeptides encoded is DruE and DruH.

[00370] In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of DruH and DruE.

[00371] In some embodiments the 5' to 3' order of polypeptides does not affect the anti- phage activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti- phage activity.

[00372] In some embodiments, a Druantia Type III defense system having an anti-phage activity comprises a nucleic acid construct comprising genes in a set order. In some embodiment, the 5' to 3' order of genes is druH and druE.

[00373] In some embodiments, the 5' to 3' order of genes is random, for example any order of druH and druE.

[00374] In some embodiments the 5' to 3' order of genes does not affect the anti-phage activity. In some embodiments the 5' to 3' order of genes does affect the anti-phage activity.

[00375] In some embodiments, the Druantia system (Defense Systems Ilia, Illb, and Hie) composition and order is as shown in Figure 3C, Figure 6A, or Figure 6B. [00376] In some embodiments, a Druantia defense system having an anti-phage activity originates from a microbial genome, for example a bacterial or an archaeal genome (Table 10). A skilled artisan would appreciate that the Druantia system is not present in the majority of bacteria and or archaea species.

[00377] In some embodiments, a functional Druantia defense system (Defense System Ilia, Defense System Illb, and/or Defense System IIIc) comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different microbial species. In some embodiments, a functional Druantia defense system (Defense System Ilia, Defense System Illb, and/or Defense System IIIc) comprises a non-naturally occurring combination of polypeptide components. In some embodiments, a functional Druantia defense system (Defense System Ilia, Defense System nib, and/or Defense System IIIc) comprises a combination of at least two polypeptides that do not naturally occur together. In some embodiments, a functional Druantia defense system (Defense System Ilia, Defense System Illb, and/or Defense System IIIc) comprises a combination of at least three polypeptides that do not naturally occur together. In some embodiments, a functional Druantia defense system (Defense System Ilia, Defense System nib, and/or Defense System IIIc) comprises a combination of at least four polypeptides that do not naturally occur together. In some embodiments, a functional Druantia defense system (Defense System Ilia, Defense System Illb, and/or Defense System Hie) comprises a combination of at least five polypeptides that do not naturally occur together.

[00378] For example, the source of the nucleic acid sequence encoding a DruA polypeptide may be one microbial species, the source of the nucleic acid sequence encoding a DruB polypeptide may be a different microbial species, the source of the nucleic acid sequence encoding a DruC polypeptide may be a different microbial species, the source of the nucleic acid sequence encoding a DruD polypeptide may be a different microbial species, and the source of the nucleic acid sequence encoding a DruE polypeptide may be yet a different microbial species. In some embodiments, the source of the nucleic acid sequence encoding some of the components of the Druantia system Type I (Defense System Ilia; DruA, DruB, DruC, DruD, and DruE) are the same, while the source of others is different. In some embodiments, the source of the nucleic acid sequence encoding the components of the Druantia Type I system (DruA, DruB, DruC, DruD, and DruE) is the same.

[00379] In other embodiments, the source of the nucleic acid sequence encoding a DruM polypeptide may be one microbial species, the source of the nucleic acid sequence encoding a DruF polypeptide may be a different microbial species, the source of the nucleic acid sequence encoding a DruG polypeptide may be a different microbial species, and the source of the nucleic acid sequence encoding a DruE polypeptide may be a different microbial species. In some embodiments, the source of the nucleic acid sequence encoding some of the components of the Druantia Type II system (Defense System nib; DruM, DruF, DruG, and DruE) are the same, while the source of others is different. In some embodiments, the source of the nucleic acid sequence encoding the components of the Druantia Type II system (DruM, DruF, DruG, and DruE) is the same.

[00380] In other embodiments, the source of the nucleic acid sequence encoding a DruH polypeptide may be one microbial species, and the source of the nucleic acid sequence encoding a DruE polypeptide may be a different microbial species. In some embodiments, the source of the nucleic acid sequence encoding the components of the Druantia Type ΠΙ system (Defense System Hie; DruH and DruE) is the same.

[00381] In some embodiments, a functional Druantia Type I defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different bacterial species. For example, the source of the nucleic acid sequence encoding a DruA polypeptide may be one bacterial species, the source of the nucleic acid sequence encoding a DruB polypeptide may be a different bacterial species, the source of the nucleic acid sequence encoding a DruC polypeptide may be a different bacterial species, the source of the nucleic acid sequence encoding a DruD polypeptide may be a different bacterial species, and the source of the nucleic acid sequence encoding a DruE polypeptide may be yet a different bacterial species. In some embodiments, the source of the nucleic acid sequence encoding some of the components of the Druantia Type I system (DruA, DruB, DruC, DruD, and DruE) are the same, while the source of others is different. In some embodiments, the source of the nucleic acid sequence encoding the components of the Druantia Type I system (DruA, DruB, DruC, DruD, and DruE) is the same.

[00382] In other embodiments, the source of the nucleic acid sequence encoding a DruM polypeptide may be one bacterial species, the source of the nucleic acid sequence encoding a DruF polypeptide may be a different bacterial species, the source of the nucleic acid sequence encoding a DruG polypeptide may be a different bacterial species, and the source of the nucleic acid sequence encoding a DruE polypeptide may be a different bacterial species. In some embodiments, the source of the nucleic acid sequence encoding some of the components of a functional Druantia Type II system (DruM, DruF, DruG, and DruE) are the same, while the source of others is different. In some embodiments, the source of the nucleic acid sequence encoding the components of a functional Druantia Type II system (DruM, DruF, DruG, and DruE) is the same.

[00383] In other embodiments, in a functional Type III Druantia system, the source of the nucleic acid sequence encoding a DruH polypeptide may be one bacterial species, and the source of the nucleic acid sequence encoding a DruE polypeptide may be a different bacterial species. In some embodiments, the source of the nucleic acid sequence encoding the components of a functional Druantia Type ΠΙ system (DruH and DruE) is the same.

[00384] In some embodiments, the source of the nucleic acid sequence of any of the components of a Druantia defense system (Defense Systems Ilia [Druantia defense system I], Illb [Druantia defense system II], and IIIc [Druantia defense system III]) comprises any of the species listed in Table 10.

[00385] In some embodiments, a Druantia Type I defense system having an anti-phage activity comprises a nucleic acid construct comprising non-coding regions between the nucleic acid sequences encoding the polypeptides. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence not naturally occurring in the microbial species of origin. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence is the naturally occurring in the microbial species of origin.

[00386] In some embodiments, a Druantia Type II defense system having an anti-phage activity comprises a nucleic acid construct comprising non-coding regions between the nucleic acid sequences encoding the polypeptides. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence not naturally occurring in the microbial species of origin. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence is the naturally occurring in the microbial species of origin.

[00387] In some embodiments, a Druantia Type III defense system having an anti-phage activity comprises a nucleic acid construct comprising non-coding regions between the nucleic acid sequences encoding the polypeptides. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence not naturally occurring in the microbial species of origin. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence is the naturally occurring in the microbial species of origin.

[00388] In some embodiments, a Druantia Type I system disclosed herein comprises a multi- gene phage resistance system broadly distributed in microbial genomes, for example but not limited to bacteria and archaea. Yet, the majority of bacterial species do not express a Druantia Type I defense system.

[00389] In some embodiments, a Druantia Type II system disclosed herein comprises a multi- gene phage resistance system broadly distributed in microbial genomes, for example but not limited to bacteria and archaea. Yet, the majority of bacterial species do not express a Druantia Type II defense system.

[00390] In some embodiments, a Druantia Type III system disclosed herein comprises a multi-gene phage resistance system broadly distributed in microbial genomes, for example but not limited to bacteria and archaea. Yet, the majority of bacterial species do not express a Druantia Type III defense system.

[00391] According to some embodiments, the Druantia systems' (Type I) components are located in a gene cluster (a cassette of genes) in a microbial cell genome. According to some embodiments, the Druantia system components are located in close proximity (e.g. positioned within 20 genes, 10 genes, 5 genes or less one from the other) in a genome of a prokaryotic cell. According to some embodiments the prokaryotic cell expresses an endogenous Druantia Type I defense system. According to some embodiments, the prokaryotic cell expresses an endogenous functional Druantia Type I defense system. According to some embodiments, the species of prokaryotic cell is selected from the group consisting of the species listed in Table 10.

[00392] According to some embodiments a prokaryotic cell expresses a non-endogenous Druantia Type I defense system. According to some embodiments, a prokaryotic cell expresses a non-endogenous functional Druantia Type I defense system. According to some embodiments, the species of prokaryotic cell expressing a non-endogenous functional Druantia Type I defense system is selected from the group consisting of the species listed in Table 10.

[00393] According to some embodiments, the Druantia systems' (Type II) components are located in a gene cluster (a cassette of genes) in a microbial cell genome. According to some embodiments, the Druantia system components are located in close proximity (e.g. positioned within 20 genes, 10 genes, 5 genes or less one from the other) in a genome of a prokaryotic cell. According to some embodiments the prokaryotic cell expresses an endogenous Druantia Type II defense system. According to some embodiments, the prokaryotic cell expresses an endogenous functional Druantia Type II defense system. According to some embodiments, the species of prokaryotic cell is selected from the group consisting of the species listed in Table 10.

[00394] According to some embodiments a prokaryotic cell expresses a non-endogenous Druantia Type II defense system. According to some embodiments, a prokaryotic cell expresses a non-endogenous functional Druantia Type II defense system. According to some embodiments, the species of prokaryotic cell expressing a non-endogenous functional Druantia Type II defense system is selected from the group consisting of the species listed in Table 10.

[00395] According to some embodiments, the Druantia systems' (Type III) components are located in a gene cluster (a cassette of genes) in a microbial cell genome. According to some embodiments, the Druantia system components are located in close proximity (e.g. positioned within 20 genes, 10 genes, 5 genes or less one from the other) in a genome of a prokaryotic cell. According to some embodiments the prokaryotic cell expresses an endogenous Druantia Type IIII defense system. According to some embodiments, the prokaryotic cell expresses an endogenous functional Druantia Type IIII defense system. According to some embodiments, the species of prokaryotic cell is selected from the group consisting of the species listed in Table 10.

[00396] According to some embodiments a prokaryotic cell expresses a non-endogenous Druantia Type III defense system. According to some embodiments, a prokaryotic cell expresses a non-endogenous functional Druantia Type III defense system. According to some embodiments, the species of prokaryotic cell expressing a non-endogenous functional Druantia Type III defense system is selected from the group consisting of the species listed in Table 10.

[00397] In some embodiments, Druantia Type I defense system components comprise DruA, DruB, DruC, DruD, and DruE polypeptides. In some embodiments, a Druantia Type I defense system's components comprise functional portions of DruA, DruB, DruC, DruD, and DruE polypeptides.

[00398] In some embodiments, Druantia Type II defense system's components comprise DruM, DruF, DruG, and DruE polypeptides. In some embodiments, a Druantia Type II defense system's components comprise functional portions of DruM, DruF, DruG, and DruE polypeptides.

[00399] In some embodiments, Druantia Type III defense system components comprise DruH and DruE polypeptides. In some embodiments, a Druantia Type III defense system components comprise functional portions of DruH and DruE polypeptides.

[00400] In some embodiments, the Druantia Type I defense system components are encoded by druA, druB, druC, druD, and druE genes. In some embodiments, the Druantia Type I defense system components are encoded by a portion of druA, druB, druC, druD, and druE genes, where the portions of the gene encode functional portions of the respective polypeptides.

[00401] In some embodiments, the Druantia Type II defense system components are encoded by druM, druF, druG, and druE genes. In some embodiments, the Druantia Type II defense system components are encoded by a portion of druM, druF, druG, and druE genes, where the portions of the gene encode functional portions of the respective polypeptides.

[00402] In some embodiments, the Druantia Type III defense system components are encoded by druH and druE genes. In some embodiments, the Druantia Type III defense system components are encoded by a portion of druH and druE genes, where the portions of the gene encode functional portions of the respective polypeptides.

[00403] Non-limiting embodiments of endogenous Druantia systems (Defense Systems Ilia, Illb, and Hie) and the respective location of their components are provided in Table 10 herein.

[00404] In some embodiments, the components of a Druantia system may be identified by the presence of similar domains present within each component. In some embodiments, domains comprise pfam domains and or clusters of orthologous groups (COG) domains.

[00405] In some embodiments, the term "DruA" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the druA gene. In some embodiments, the term "DruA" refers to a DruA polypeptide. In some embodiments, the druA gene encodes a polypeptide comprising a pfaml4236 domain. In some embodiments, the druA gene encodes a polypeptide comprising a DUF4338 domain. In some embodiments, the druA gene encodes a polypeptide comprising a pfaml4236 domain and a DUF4338 domain. In some embodiments, the DruA polypeptide comprises a pfam 14236 domain. In some embodiments, the DruA polypeptide comprises a DUF4338 domain. In some embodiments, the DruA polypeptide comprises a pfaml4236 domain and a DUF4338domain.

[00406] In some embodiments, DruA polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a DruB, DruC, DruD, or DruE polypeptide, or any combination thereof, in a genome of a prokaryotic cell. In some embodiments, DruA polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a DruB, DruC, DruD, or DruE polypeptide, or any combination thereof, in a genome of a prokaryotic cell. In some embodiments, DruA polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a DruB, DruC, DruD, or DruE, or any combination thereof, polypeptide in a genome of a prokaryotic cell.

[00407] In some embodiments, DruA and DruB are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruA and DruB are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruA, DruB, and DruC are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruA, DruB, and DruC are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruA, DruB, DruC, and DruD are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruA, DruB, DruC, and DruD are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruA, DruB, DruC, DruD, and DruE are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruA, DruB, DruC, DruD, and DruE are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00408] In some embodiments, druA and druB genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druA and druB genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druA, druB, and druC genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druA, druB, and druC genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druA, druB, druC, and druD genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druA, druB, druC, and druD genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druA, druB, druC, druD, and druE genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druA, druB, druC, druD, and druE genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00409] In some embodiments, a DruA polypeptide is about 404 amino acids long (median gene size).

In some embodiments, the DruA polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns J and K. In some embodiments, the DruA polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns J and K. In some embodiments, the DruA polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 10, rows 2-123, columns J and K.

[00410] In some embodiments, the DruA polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns J and K. In some embodiments, the DruA polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns J and K.

[00411] In some embodiments, the DruA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns J and K. In some embodiments, the DruA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns J and K. In some embodiments, the DruA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns J and K. In some embodiments, the DruA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2- 123, columns J and K. In some embodiments, the DruA polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2- 123, columns J and K.

[00412] In some embodiments, the DruA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns J and L. In some embodiments, the DruA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns J and L. In some embodiments, the DruA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns J and L. In some embodiments, the DruA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns J and L. In some embodiments, the DruA polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns J and L.

[00413] In some embodiments, the nucleic acid sequence of a druA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns J and L. In some embodiments, the druA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns J and L. In some embodiments, the nucleic acid sequence of a druA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns J and L. In some embodiments, the druA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns J and L. In some embodiments, the nucleic acid sequence of a druA gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns J and L.

[00414] As used herein, the term "DruB" refers to the polynucleotide or expression product e.g., polypeptide encoded by the druB gene. In some embodiments, the term "DruB" refers to a DruB polypeptide. [00415] In some embodiments, DruB polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a DruC, a DruD, or a DruE polypeptide, or any combination thereof in a genome of a prokaryotic cell. In some embodiments, a DruB-DruC fusion polypeptide is encoded by a gene positioned within 5-60 genes of a gene encoding a DruD or a DruE polypeptide or a combination thereof. In some embodiments, DruB polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a DruC, a DruD, or a DruE polypeptide or any combination thereof in a genome of a prokaryotic cell. In some embodiments, DruB-DruC fusion polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a DruD or a DruE polypeptide or a combination thereof in a genome of a prokaryotic cell. In some embodiments, DruB polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a DruC, a DruD, or a DruE polypeptide or a combination thereof in a genome of a prokaryotic cell.

[00416] In some embodiments, DruB and DruC are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments DruB and DruC are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruB, DruC, and DruD are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments DruB, DruC, and DruD are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruB, DruC, DruD, and DruE are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments DruB, DruC, DruD, and DruE are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruB, DruC, and DruD are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments DruB, DruC, and DruD are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruB, DruC, DruD, DruE, and DruA are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments DruB, DruC, DruD, DruE, and DruA are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00417] In some embodiments, druB and druC genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druB and druC genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druB, druC, and druD genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druB, druC, and druD genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druB, druC, druD, and druE genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druB, druC, druD, and druE genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druB, druC, druD, druE, and druA genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druB, druC, druD, druE, and druA genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00418] In some embodiments, a DruB polypeptide is about 531 amino acids long (median gene size).

[00419] In some embodiments, the DruB polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns N and O. In some embodiments, the DruB polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns N and O. In some embodiments, the DruB polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 10, rows 2-123, columns N and O.

[00420] In some embodiments, the DruB polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns N and O. In some embodiments, the DruB polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns N and O.

[00421] In some embodiments, the DruB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns N and O. In some embodiments, the DruB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns N and O. In some embodiments, the DruB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns N and O. In some embodiments, the DruB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2- 123, columns N and O. In some embodiments, the DruB polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2- 123, columns N and O.

[00422] In some embodiments, the DruB polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns N and P. In some embodiments, the DruB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns N and P. In some embodiments, the DruB polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns N and P. In some embodiments, the DruB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns N and P. In some embodiments, the DruB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns N and P.

[00423] In some embodiments, the nucleic acid sequence of a druB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns N and P. In some embodiments, the druB gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns N and P. In some embodiments, the nucleic acid sequence of a druB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns N and P. In some embodiments, the druB gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, column L. In some embodiments, the nucleic acid sequence of a druB gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns N and P.

[00424] In some embodiments, the term "DruC" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the druC gene. In some embodiments, the term "DruC" refers to a DruC polypeptide.

[00425] In some embodiments, DruC polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a DruD or DruE polypeptide, or any combination thereof, in a genome of a prokaryotic cell. In some embodiments, DruC polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a DruD or DruE polypeptide, or any combination thereof, in a genome of a prokaryotic cell. In some embodiments, a DruC polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a DruD or DruE polypeptide in a genome of a prokaryotic cell.

[00426] In some embodiments, DruC and DruD are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruC and DruD are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruC, DruD, and DruE are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruC, DruD, and DruE are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruC, DruD, DruE, and DruA are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruC, DruD, DruE, and DruA are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00427] In some embodiments, DruC and DruE polypeptides are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruC and DruE polypeptides are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. [00428] In some embodiments, druC and druD genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druC and druD genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druC, druD, and druE genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druC, druD, and druE genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druC, druD, druE, and druA genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druC, druD, druE, and druA genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00429] In some embodiments, druC and druE genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druC and druE genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druC, druE, and druA genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druC, druE, and druA genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druC and druA genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druC and druA genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00430] In some embodiments, a DruC polypeptide is about 627 amino acids long (median gene size).

[00431] In some embodiments, the DruC polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns R and S. In some embodiments, the DruC polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns R and S. In some embodiments, the DruC polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 10, rows 2-123, columns R and S.

[00432] In some embodiments, the DruC polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns R and S. In some embodiments, the DruC polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns R and S. [00433] In some embodiments, the DruC polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns R and S. In some embodiments, the DruC polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns R and S. In some embodiments, the DruC polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns R and S. In some embodiments, the DruC polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2- 123, columns R and S. In some embodiments, the DruC polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2- 123, columns R and S.

[00434] In some embodiments, the DruC polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns R and T. In some embodiments, the DruC polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns R and T. In some embodiments, the DruC polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns R and T. In some embodiments, the DruC polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns R and T. In some embodiments, the DruC polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns R and T. [00435] In some embodiments, the nucleic acid sequence of a druC gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns R and T. In some embodiments, the druC gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns R and T. In some embodiments, the nucleic acid sequence of a druC gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns R and T. In some embodiments, the druC gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns R and T. In some embodiments, the nucleic acid sequence of a druC gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns R and T.

[00436] In some embodiments, the term "DruD" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the druD gene. In some embodiments, the term "DruD" refers to a DruD polypeptide.

[00437] In some embodiments, DruD polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a DruE or DruA polypeptide, or any combination thereof, in a genome of a prokaryotic cell. In some embodiments, DruD polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a DruE or DruA polypeptide, or any combination thereof, in a genome of a prokaryotic cell.

[00438] In some embodiments, DruD and DruE are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruD and DruE are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruD, DruE, and DruA are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruD, DruE, and DruA are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00439] In some embodiments, druD and druE genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druD and druE genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druD, druE, and druA genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druD, druE, and druA genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00440] In some embodiments, druD and druA genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druD and druA genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00441] In some embodiments, a DruD polypeptide is about 347 amino acids long (median gene size).

[00442] In some embodiments, the DruD polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns V and W. In some embodiments, the DruD polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns V and W. In some embodiments, the DruD polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 10, rows 2-123, columns V and W.

[00443] In some embodiments, the DruD polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns V and W. In some embodiments, the DruD polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns V and W.

[00444] In some embodiments, the DruD polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns V and W. In some embodiments, the DruD polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns V and W. In some embodiments, the DruD polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-123, columns V and W. In some embodiments, the DruD polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2- 123, columns V and W. In some embodiments, the DruD polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2- 123, columns V and W.

[00445] In some embodiments, the DruD polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns V and X. In some embodiments, the DruD polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns V and X. In some embodiments, the DruD polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns V and X. In some embodiments, the DruD polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns V and X. In some embodiments, the DruD polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns V and X.

[00446] In some embodiments, the nucleic acid sequence of a druD gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, column P. In some embodiments, the druD gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns V and X. In some embodiments, the nucleic acid sequence of a druD gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns V and X. In some embodiments, the druD gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns V and X. In some embodiments, the nucleic acid sequence of a druD gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-123, columns V and X.

[00447] In some embodiments, the term "DruE" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the druE gene. In some embodiments, the term "DruE" refers to a DruE polypeptide. In some embodiments, the druE gene encodes a polypeptide comprising a pfam00270 domain. In some embodiments, the druE gene encodes a polypeptide comprising a pfam00271 domain. In some embodiments, the druE gene encodes a polypeptide comprising a pfam09369 domain. In some embodiments, the druE gene encodes a polypeptide comprising a DUF1998 domain. In some embodiments, the druE gene encodes a polypeptide comprising a pfam00270 domain, a pfam00271 domain, a pfam09369 domain, or a DUF4338 domain, or any combination thereof. In some embodiments, the druE gene encodes a polypeptide comprising a pfam00270 domain, a pfam00271 domain, a pfam09369 domain, and a DUF4338 domain. In some embodiments, a druE gene encodes a polypeptide comprising a helicase activity. In some embodiments, a druE gene encodes a polypeptide comprising a DEAx box helicase activity.

[00448] In some embodiments, the DruE polypeptide comprises a pfam00270 domain. In some embodiments, the DruE polypeptide comprises a pfam00271 domain. In some embodiments, the DruE polypeptide comprises a pfam09369 domain. In some embodiments, the DruE polypeptide comprises a DUF1998 domain. In some embodiments, the DruE polypeptide comprises a pfam00270 domain, a pfam00271 domain, a pfam09369 domain, or a DUF4338 domain, or any combination thereof. In some embodiments, the DruE polypeptide comprises a pfam00270 domain, a pfam00271 domain, a pfam09369 domain, and a DUF4338 domain. In some embodiments, a DruE polypeptide comprises a helicase activity. In some embodiments, a DruE polypeptide comprises a DEAx box helicase activity.

[00449] In some embodiments, DruE polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a DruA polypeptide in a genome of a prokaryotic cell. In some embodiments, DruE polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a DruA polypeptide in a genome of a prokaryotic cell. In some embodiments, DruE polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a DruA polypeptide in a genome of a prokaryotic cell.

[00450] In some embodiments, DruE and DruA are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruE and DruA are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00451] In some embodiments, druE and druA genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druE and druA genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00452] In some embodiments, a DruE polypeptide is about 2104 amino acids long (median gene size).

[00453] In some embodiments, the DruE polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-1343, columns Z and AA. In some embodiments, the DruE polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-1343, columns Z and AA. In some embodiments, the DruE polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 10, rows 2-1343, columns Z and AA.

[00454] In some embodiments, a DruE polypeptide homolog comprises a helicase domain. In some embodiments, a DruE polypeptide comprises a helicase activity.

[00455] In some embodiments, the DruE polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-1343, columns Z and AA. In some embodiments, the DruE polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-1343, columns Z and AA.

[00456] In some embodiments, the DruE polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-1343, columns Z and AA. In some embodiments, the DruE polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2- 1343, columns Z and AA. In some embodiments, the DruE polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2- 1343, columns Z and AA. In some embodiments, the DruE polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-1343, columns Z and AA. In some embodiments, the DruE polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 2-1343, columns Z and AA.

[00457] In some embodiments, the DruE polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-1343, columns Z and AB. In some embodiments, the DruE polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-1343, columns Z and AB. In some embodiments, the DruE polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-1343, columns Z and AB. In some embodiments, the DruE polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-1343, columns Z and AB. In some embodiments, the DruE polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-1343, columns Z and AB.

[00458] In some embodiments, the nucleic acid sequence of a druE gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-1343, columns Z and AB. In some embodiments, the druE gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-1343, columns Z and AB. In some embodiments, the nucleic acid sequence of a druE gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-1343, columns Z and AB. In some embodiments, the druE gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-1343, columns Z and AB. In some embodiments, the nucleic acid sequence of a druE gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 2-1343, columns Z and AB.

[00459] In some embodiments, the term "DruM" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the druM gene. In some embodiments, the term "DruM" refers to a DruM polypeptide. In some embodiments, the druM gene encodes a polypeptide.

[00460] In some embodiments, DruM polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a DruF polypeptide, a DruG polypeptide, and/or a DruE polypeptide in a genome of a prokaryotic cell. In some embodiments, DruM polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a DruF polypeptide, a DruG polypeptide, and/or a DruE polypeptide in a genome of a prokaryotic cell. In some embodiments, DruM polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a DruF polypeptide, a DruG polypeptide, and/or a DruE polypeptide in a genome of a prokaryotic cell.

[00461] In some embodiments, DruM. DruF, DruG, and DruE are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruM, DruF, DruG, and DruE are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00462] In some embodiments, druM, druF, druG, and druE genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druM, druF, druG, and druE genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00463] In some embodiments, a DruM polypeptide is about 386 amino acids long (median gene size).

[00464] In some embodiments, the DruM polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AD and AE. In some embodiments, the DruM polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AD and AE. In some embodiments, the DruM polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 10, rows 124-295, columns AD and AE.

[00465] In some embodiments, a DruM polypeptide homolog comprises a cytosine methylase activity. In some embodiments, a DruM polypeptide homolog comprises a cytosine methylase.

[00466] In some embodiments, the DruM polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AD and AE. In some embodiments, the DruM polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AD and AE.

[00467] In some embodiments, the DruM polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AD and AE. In some embodiments, the DruM polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AD and AE. In some embodiments, the DruM polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AD and AE. In some embodiments, the DruM polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AD and AE. In some embodiments, the DruM polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AD and AE.

[00468] In some embodiments, the DruM polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AD and AF. In some embodiments, the DruM polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AD and AF. In some embodiments, the DruM polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AD and AF. In some embodiments, the DruM polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AD and AF. In some embodiments, the DruM polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AD and AF.

[00469] In some embodiments, the nucleic acid sequence of a druM gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AD and AF. In some embodiments, the druM gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AD and AF. In some embodiments, a druM gene homolog encodes a cytosine methylase. In some embodiments, the nucleic acid sequence of a druM gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AD and AF. In some embodiments, the druM gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AD and AF. In some embodiments, the nucleic acid sequence of a druM gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AD and AF.

[00470] In some embodiments, the term "DruF" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the druF gene. In some embodiments, the term "DruF" refers to a DruF polypeptide. In some embodiments, the druF gene encodes a polypeptide.

[00471] In some embodiments, DruF polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a DruM polypeptide, a DruG polypeptide, and or a DruE polypeptide in a genome of a prokaryotic cell. In some embodiments, DruF polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a DruM polypeptide, a DruG polypeptide, and or a DruE polypeptide in a genome of a prokaryotic cell. In some embodiments, DruF polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding DruM polypeptide, a DruG polypeptide, and or a DruE polypeptide in a genome of a prokaryotic cell.

[00472] In some embodiments, DruF, DruG, and DruE are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruF, DruG, and DruE are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00473] In some embodiments, druF, druG, and druE genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druF, druG, and druE genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00474] In some embodiments, a DruF polypeptide is about 852 amino acids long (median gene size).

[00475] In some embodiments, the DruF polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AH and AI. In some embodiments, the DruF polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AH and AI. In some embodiments, the DruF polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 10, rows 124-295, columns AH and AI.

[00476] In some embodiments, the DruF polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AH and AI. In some embodiments, the DruF polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AH and AI.

[00477] In some embodiments, the DruF polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AH and AI. In some embodiments, the DruF polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AH and AI. In some embodiments, the DruF polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AH and AI. In some embodiments, the DruF polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AH and AI. In some embodiments, the DruF polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AH and AI.

[00478] In some embodiments, the DruF polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AH and AJ. In some embodiments, the DruF polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AH and AJ. In some embodiments, the DruF polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AH and AJ. In some embodiments, the DruF polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AH and AJ. In some embodiments, the DruF polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AH and AJ.

[00479] In some embodiments, the nucleic acid sequence of a druF gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AH and AJ. In some embodiments, the druF gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AH and AJ. In some embodiments, the nucleic acid sequence of a druF gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AH and AJ. In some embodiments, the druF gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AH and AJ. In some embodiments, the nucleic acid sequence of a druF gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AH and AJ.

[00480] In some embodiments, the term "DruG" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the druG gene. In some embodiments, the term "DruG" refers to a DruG polypeptide. In some embodiments, the druG gene encodes a polypeptide.

[00481] In some embodiments, DruG polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a DruM polypeptide, a DruF polypeptide, and or a DruE polypeptide in a genome of a prokaryotic cell. In some embodiments, DruG polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a DruM polypeptide, a DruF polypeptide, and or a DruE polypeptide in a genome of a prokaryotic cell. In some embodiments, DruG polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding DruM polypeptide, a DruF polypeptide, and or a DruE polypeptide in a genome of a prokaryotic cell.

[00482] In some embodiments, DruG and DruE are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruG and DruE are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00483] In some embodiments, druG and druE genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druG, and druE genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00484] In some embodiments, a DruG polypeptide is about 711 amino acids long (median gene size).

[00485] In some embodiments, the DruG polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AL and AM. In some embodiments, the DruG polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AL and AM. In some embodiments, the DruG polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 10, rows 124-295, columns AL and AM.

[00486] In some embodiments, the DruG polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AL and AM. In some embodiments, the DruG polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AL and AM.

[00487] In some embodiments, the DruG polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AL and AM. In some embodiments, the DruG polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AL and AM. In some embodiments, the DruG polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AL and AM. In some embodiments, the DruG polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AL and AM. In some embodiments, the DruG polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 124-295, columns AL and AM.

[00488] In some embodiments, the DruG polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AL and AN. In some embodiments, the DruG polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AL and AN. In some embodiments, the DruG polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AL and AN. In some embodiments, the DruG polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AL and AN. In some embodiments, the DruG polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AL and AN.

[00489] In some embodiments, the nucleic acid sequence of a druG gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AL and AN. In some embodiments, the druG gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AL and AN. In some embodiments, the nucleic acid sequence of a druG gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AL and AN. In some embodiments, the druG gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AL and AN. In some embodiments, the nucleic acid sequence of a druG gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 124-295, columns AL and AN.

[00490] In some embodiments, the term "DruH" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the druH gene. In some embodiments, the term "DruH" refers to a DruH polypeptide. In some embodiments, the druH gene encodes a polypeptide.

[00491] In some embodiments, DruH polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a DruE polypeptide in a genome of a prokaryotic cell. In some embodiments, DruH polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a DruE polypeptide in a genome of a prokaryotic cell. In some embodiments, DruH polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a DruE polypeptide in a genome of a prokaryotic cell.

[00492] In some embodiments, DruH and DruE are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, DruH and DruE are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00493] In some embodiments, druH and druE genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, druH, and druE genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. [00494] In some embodiments, a DruH polypeptide is about 1079 amino acids long (median gene size).

[00495] In some embodiments, the DruH polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 296-1343, columns AP and AQ. In some embodiments, the DruH polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 296-1343, columns AP and AQ. In some embodiments, the DruH polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 10, rows 296-1343, columns AP and AQ.

[00496] In some embodiments, the DruH polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 296-1343, columns AP and AQ. In some embodiments, the DruH polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 296-1343, columns AP and AQ.

[00497] In some embodiments, the DruH polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 296-1343, columns AP and AQ. In some embodiments, the DruH polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 296-1343, columns AP and AQ. In some embodiments, the DruH polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 296-1343, columns AP and AQ. In some embodiments, the DruH polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 296-1343, columns AP and AQ. In some embodiments, the DruH polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 10, rows 296-1343, columns AP and AQ. [00498] In some embodiments, the DruH polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 296-1343, columns AP and AR. In some embodiments, the DruH polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 296-1343, columns AP and AR. In some embodiments, the DruH polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 296-1343, columns AP and AR. In some embodiments, the DruH polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 296-1343, columns AP and AR. In some embodiments, the DruH polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 296-1343, columns AP and AR.

[00499] In some embodiments, the nucleic acid sequence of a druH gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 296-1343, columns AP and AR. In some embodiments, the druH gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 296- 1343, columns AP and AR. In some embodiments, the nucleic acid sequence of a druH gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 296-1343, columns AP and AR. In some embodiments, the druH gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 296-1343, columns AP and AR. In some embodiments, the nucleic acid sequence of a druH gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 10, rows 296-1343, columns AP and AR.

[00500] A skilled artisan would appreciate that the terms a "functional portion of a Defense System Ilia component" or "functional fragment of Defense System Ilia component" or "functional portion of a Druantia Type I defense system component" or "functional fragment of Druantia Type I defense system component" refers to a functional portion of a Druantia polynucleotide or polypeptide, as disclosed herein, which expression is sufficient to elicit an anti-phage activity alone or in combination with the at least one of the other Druantia polynucleotides or polypeptides disclosed herein or functional portions thereof.

[00501] A skilled artisan would appreciate that the terms a "functional portion of a Defense System Illb component" or "functional fragment of Defense System Illb component" or "functional portion of a Druantia Type II defense system component" or "functional fragment of Druantia Type II defense system component" refers to a functional portion of a Druantia polynucleotide or polypeptide, as disclosed herein, which expression is sufficient to elicit an anti-phage activity alone or in combination with the at least one of the other Druantia polynucleotides or polypeptides disclosed herein or functional portions thereof.

[00502] A skilled artisan would appreciate that the terms a "functional portion of a Defense System Hie component" or "functional fragment of Defense System IIIc component" or "functional portion of a Druantia Type III defense system component" or "functional fragment of Druantia Type III defense system component" refers to a functional portion of a Druantia polynucleotide or polypeptide, as disclosed herein, which expression is sufficient to elicit an anti-phage activity alone or in combination with the at least one of the other Druantia polynucleotides or polypeptides disclosed herein or functional portions thereof.

[00503] The terms "DruA", "DruB", "DruC", "DruD", "DruE", "DruF", "DruG", "DruH", "DruM", "druA", "druB", "druC, druU "druE "druF', "druG', "druH", and "druM", also refer to functional DruA, DruB, DruC, DruD, DruE, DruF, DruG, DruH, DruM, druA, druB, druC, druD, druE, druF, druG, druH, and druM, homologs, which exhibit the desired activity {i.e., conferring phage resistance). Such homologs can be, for example, at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polypeptide referenced in Table 10 rows 2-123, columns J and K; rows 2- 123, columns N and O; rows 2-123, columns R and S; rows 2-123, columns V and W; rows 2- 1343, columns Z and AA; rows 124-295, columns AD and AE; rows 124-295, columns AH and AI; rows 124-295, columns AL and AM, and rows 296-1343, columns AP and AQ, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homologous or identical to the polynucleotide sequences referenced in Table 10 rows 2-123, columns J and L ; rows 2-123, columns N and P; rows 2-123, columns R and T; rows 2-123, columns V and X; rows 2-1343, columns Z and AB; rows 124-295, columns AD and AF; rows 124-295, columns AH and AJ; rows 124-295, columns AL and AN, and rows 296-1343, columns AP and AR, respectively. In some embodiments, such homologs comprise at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homology within similar domain regions of the polypeptide sequences referenced in Table 10 rows 2-123, columns J and K; rows 2-123, columns N and O; rows 2-123, columns R and S; rows 2-123, columnsV and W; rows 2-1343, columns Z and AA; rows 124-295, columns ad and AE; rows 124-295, columns AH and AI; rows 124-295, columns AL and AN, and rows 296-1343, columns AP and AQ, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identity within nucleotide sequences encoding similar domain regions to the polynucleotide sequences referenced in Table 10 rows 2-123, columns J and L; rows 2-123, columns N and P; rows 2-123, columns R and T; rows 2-123, columns V and X; rows 2-1343, columns Z and AB; rows 124-295, columns AD and AF; rows 124-295, columns AH and AJ; rows 124-295, columns AL and AN, and rows 296-1343, column AP and AR, respectively.

[00504] Table 10 presents embodiments of components of Defense System III (Ilia; Illb; and IIIc) that may be found in a diverse array of bacteria and archaea genomes (referenced in Table 18). Table 10 presents embodiments of nucleic acid sequences encoding gene cassettes of Defense System ΠΙ (Ilia; Illb; and IIIc; referenced in Table 18).

[00505] The Hachiman Defense System [00506] In some embodiments, a defense system disclosed herein comprises a Hachiman anti- phage defense system. (Table 12) In some embodiments, a Hachiman defense system provides a host cell with resistance to at least one phage.

[00507] In some embodiments, a Hachiman defense system provides a host cell with resistance to entry of foreign nucleic acid invasion. In some embodiments, a host cell expressing a functional Hachiman defense system (Defense System IV) provides the host cell resistance foreign nucleic acid invasion.

[00508] In some embodiments, a bacterial cell expressing a Hachiman defense system (Defense System IV) protects the bacteria from phage infection. In some embodiments, a bacterial cell expressing a functional Hachiman defense system (Defense System IV) protects the bacteria from phage infection.

[00509] In some embodiments, a Hachiman defense system provides a host cell with resistance to plasmid transformation. In some embodiments, a host cell expressing a functional Hachiman defense system (Defense System IV) provides a host cells with resistance to plasmid transformation.

[00510] In some embodiments, a Hachiman defense system provides a host cell with resistance to entry of conjugative elements. In some embodiments, a host cell expressing a function Hachiman defense system (Defense System IV) provides the host cell resistance from entry of conjugative elements.

[00511] As used herein, the term "a Hachiman anti-phage defense system" may be used interchangeably with the term "a Defense System IV", having all the same meanings and qualities. A skilled artisan would appreciate that the term "Hachiman system" may be used interchangeably in some embodiments with "Hachiman defense system", "Hachiman the defense system", "Hachiman anti-phage system", and "Defense System IV", having all the same meanings and qualities.

[00512] In some embodiments, a microbial species does not comprise an endogenous Defense System IV. In some embodiments, a microbial species does not express an endogenous Defense System IV. In some embodiments, a microbial species does not express a functional Defense System IV.

[00513] In some embodiments, a bacterial species does not comprise an endogenous Defense System IV. In some embodiments, a bacterial species does not express an endogenous Defense System IV. In some embodiments, a bacterial species does not endogenously express a functional Defense System IV.

[00514] A Hachiman defense system comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence encoding a HamA polypeptide comprising a pfam08878 domain or a DUF1837 domain or a combination thereof, and a HamB polypeptide comprising COG 1204 domain or a pfam00270 domain or a pfam00271 domain or any combination thereof. In some embodiments, a Hachiman defense system comprises a nucleic acid construct comprising a nucleic acid sequence comprising a hamA gene and a hamB gene.

[00515] A Hachiman defense system comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence encoding a HamA polypeptide comprising a pfam08878 or a DUF1837 domain or a combination thereof, and a HamB polypeptide comprising a COG 1204 domain or a pfam00270 domain or a pfam00271 domain, or any combination thereof. In some embodiments, a Hachiman defense system comprises a nucleic acid construct comprising a nucleic acid sequence encoding a HamA polypeptide and a HamB polypeptide.

[00516] In some embodiments, a Hachiman defense system comprises, a HamA polypeptide comprising a pfam08878 or a DUF1837 domain or a combination thereof, and a HamB polypeptide comprising a COG 1204 domain or a pfam00270 domain or a pfam00271 domain or any combination thereof. In some embodiments, a Hachiman defense system comprises a HamA polypeptide and a HamB polypeptide.

[00517] In some embodiments, a Defense System IV comprising a HamA polypeptide comprising a pfam08878 domain or a DUF1837 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 12 rows 2-1782 columns H and I; or a HamB polypeptide comprising COG 1204 domain or a pfam00270 domain or a pfam00271 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 12 rows 2-1782 columns L and M; any combination thereof.

[00518] In some embodiments, a Defense System IV comprises at least two different polypeptide compnonents selected from a HamA polypeptide comprising a pfam08878 domain or a DUF1837 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 12 rows 2-1782 columns H and I; and a HamB polypeptide comprising COG1204 domain or a pfam00270 domain or a pfam00271 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 12 rows 2-1782 columns L and M.

[00519] In some embodiments, a Hachiman defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a HamA polypeptide and a HamB polypeptide. In some embodiments, a Hachiman defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a hamA gene and a hamB gene.

[00520] In some embodiments, the Hachiman anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising hamA and hamB genes.

[00521] In some embodiments, a construct comprising the Hachiman defense system encodes one component of the defense system, whereby multiple constructs, for example but not limited to, two constructs may be used to assemble the functional defense system. In some embodiments, the components of a Hachiman defense system comprise genes hamA and hamB. In some embodiments, the components of a Hachiman defense system consist of genes hamA and hamB. In some embodiments, the components of a Hachiman defense system comprise nucleic acid sequences encoding a HamA polypeptide and a HamB polypeptide. In some embodiments, the components of a Hachiman defense system consist of nucleic acid sequences encoding a HamA polypeptide and a HamB polypeptide.

[00522] In some embodiments, a construct comprising the Hachiman defense system encodes one component of the defense system, whereby a second construct may be used to assemble the functional defense system. In some embodiments, a construct comprising the Hachiman defense system encodes one component of the defense system, whereby additional constructs may be used to assemble the functional defense system. For example, in some embodiments each of HamA and HamB may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional Hachiman defense system.

[00523] In some embodiments, the components making up a functional Hachiman anti-phage defense system comprise a HamA polypeptide and a HamB polypeptide, each encoded by a hamA and a hamB gene, respectively.

[00524] In some embodiments, a Hachiman defense system having an anti-phage activity comprises a nucleic acid encoding a HamA polypeptide. In some embodiments, a Hachiman defense system having an anti-phage activity comprises a nucleic acid encoding a HamA polypeptide and a HamB polypeptide. In some embodiments, a Hachiman defense system having an anti-phage activity comprises a nucleic acid encoding a HamB polypeptide.

[00525] In some embodiments, a Hachiman defense system having an anti-phage activity comprises a nucleic acid comprising a hamA gene. In some embodiments, a Hachiman defense system having an anti-phage activity comprises a nucleic acid comprising a hamA gene and a hamB gene. In some embodiments, a Hachiman defense system having an anti-phage activity comprises a nucleic acid comprising hamB gene.

[00526] In some embodiments, a Hachiman defense system having an anti-phage activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3' order of polypeptides encoded is HamA and HamB. In some embodiments the 5' to 3' order of polypeptides does not affect the anti-phage activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti-phage activity.

[00527] In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of nucleic acid sequences encoding HamA and HamB.

[00528] In some embodiments, a Hachiman defense system having an anti-phage activity comprises a nucleic acid construct comprising genes in a set order. In some embodiment, the 5' to 3' order of genes is hamA and hamB. In some embodiment, the 5' to 3' order of genes in a Hachiman defense system is not hamA and hamB. In some embodiments the 5' to 3' order of genes does not affect the anti-phage activity. In some embodiments the 5' to 3' order of genes does affect the anti-phage activity.

[00529] In some embodiments, the 5' to 3' order of genes is random, for example any order of hamA and hamB.

[00530] In some embodiments, the Hachiman system (Defense System IV) composition and order is as shown in Figure 3B.

[00531] In some embodiments, a Hachiman defense system having an anti-phage activity originates from a microbial genome, for example a bacterial and or an archaeal genome (Table 12). A skilled artisan would appreciate that the Hachiman system is not present in the majority of bacteria and or archaea species.

[00532] In some embodiments, introducing a combination of polypeptide components within a defense system disclosed herein, for example taking HamA from one bacterium and HamB from another bacterium and combining them into HamA-HamB functional defense system that defends against foreign elements that are not naturally occurring is advantageous to the host cell comprising the non-naturally occurring polypeptide components. In some embodiments, introducing a combination of polypeptide components within any defense system disclosed herein, and combining them to form a functional defense system that defends against foreign elements that are not naturally occurring, is advantageous to the host cell comprising the combination of non-naturally occurring polypeptide components.

[00533] In some embodiments, a functional Hachiman defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different microbial species. For example, the source of the nucleic acid sequence encoding a HamA polypeptide may be one microbial species, while the source of the nucleic acid sequence encoding a HamB polypeptide may be a different microbial species. In some embodiments, a functional Hachiman defense system comprises a non-naturally occurring combination of polypeptide components. In some embodiments, a functional Hachiman defense system comprises a combination of at least two polypeptides that do not naturally occur together.

[00534] In some embodiments, a functional Hachiman defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different bacterial species. For example, the source of the nucleic acid sequence encoding a HamA polypeptide may be one bacterial species, while the source of the nucleic acid sequence encoding a HamB polypeptide may be a different bacterial species.

[00535] In some embodiments, the source of the nucleic acid encoding a HamA polypeptide and a HamB polypeptide is the same. In some embodiments, the source of the nucleic acid encoding a HamA polypeptide and a HamB polypeptide is the not the same. In some embodiments, the source of the nucleic acid sequence of any of the components of a Hachiman defense system comprises any of the species listed in Table 12.

[00536] In some embodiments, a Hachiman defense system having an anti-phage activity comprises a nucleic acid construct comprising non-coding regions between the nucleic acid sequences encoding the polypeptides. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence not naturally occurring in the microbial species of origin. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence is the naturally occurring in the microbial species of origin.

[00537] In some embodiments, a Hachiman system disclosed herein comprises a multi-gene phage resistance system broadly distributed in microbial genomes, for example but not limited to bacteria and archaea. According to some embodiments, the Hachiman system components are located in a gene cluster (a cassette of genes) in a microbial cell genome. According to some embodiments, the Hachiman system components are located in close proximity (e.g. positioned within 20 genes, 10 genes, 5 genes or less one from the other) in a genome of a prokaryotic cell. According to some embodiments the prokaryotic cell expresses an endogenous Hachiman defense system. According to some embodiments, the prokaryotic cell expresses an endogenous functional Hachiman defense system. According to some embodiments, the species of prokaryotic cell is selected from the group consisting of the species listed in Table 12. According to some embodiments a prokaryotic cell expresses a non- endogenous Hachiman defense system. According to some embodiments, a prokaryotic cell expresses a non-endogenous functional Hachiman defense system. According to some embodiments, the species of prokaryotic cell expressing a non-endogenous functional Hachiman defense system is selected from the group consisting of the species listed in Table 12.

[00538] In some embodiments, a Hachiman (Defense System IV) gene cassette comprises the nucleic acid sequence:

1 taaaagctgc ttcaggtaaa tatcctgaag cagcttttgt ggttaaaaga gaaagtaggt 61 aatagtcatt tgtagtgtat taaagaagat ggaggtgaat aaaacgatgt aatttaagcc 121 ataagttggc cgctttggcc aatgttttct ttattttata tatggtaaaa ttataattag 181 tttagatagt acatttgctt agtaaagatg tactttaaaa aaaaataaat ttatttttgt 241 ggctcttaac gaaatgaata tgctattttg atgtatctta ggtagaaatc taaaaatatt 301 aagaagttgt taaacagcgt taagctagga ggaaatatat gactatacaa gatgatatgg 361 ttggaaaaca tcctatcgag aatgattttt ggaaatggtt gcagcatgaa gatacagaat 421 cctcggattt aaaacggcat cgttacttag aagtggattc tagtaatcgt gatgaagcta 481 ttaaatctgt tgcagcttgg ctaattaagt atcatttgtc ggaaggtaaa aagagagtga 541 taagaaaaaa acaagaaata cttgaaaaac atgattttgc tgaatatgca caatcgcttc 601 atgtttttcc taaaagtgat aaaacacaga aaggaaattt aggagaaata tttttatcgg 661 aatatttgag tcagacatca ggagttcaaa tcctagtgta taaattacac tacaacccca 721 acatagatca atcgatgaaa ggggatgacg ttttacttgt taacccagat aaagttttat 781 taggagaaag taaatttcgt tctactccaa ataaacgtgc tgttgaagag gcttctgaac 841 ttatgaaaga taagttaact ttgcctatgt ctcttggttt tattgcagat agattatttg 901 aacaaggaaa agatgaatta ggtgaagtga ttttcgatct tcaatttaag atgagtagta 961 tagaaataga tattaaaaat atagggtttt tattatctac taaaaaggtt cgtagtatcg 1021 tagaaaataa cctttcttct ccaaattctg attttatttt tatttcatta ggaatggatg 1081 acccagcagc ttttttgaaa agtgtatttg actatgcaga aagtaatctt ctggagggat 1141 cttatgaaac ttgaaacagc atataattat tttgaaaagc ttgaaaaaga tgaacgtctt 1201 caaaactata tttcacaggc taattcaaga tatatccttt acatagcaaa tgaaccattg 1261 gaaaatttcc cacattacac tgtaaatcta gatgaaaaat gtacacatat agcatttagt 1321 tatctcaatt gtggatggcg ctttttttta gagaaaatca gtgatgaagc tacaaaatgt 1381 atggaaaagg cttctgaaat attggagtat ttgtatgcct atagtgattg cgaaaagtta 1441 tataaagagt attaccgttt agtatgctca ttagcgtatt atatatctgc acagtattct 1501 aaatctttta ttatcttggg gaaatataat tctgattcat atatagggaa aataacaaaa 1561 ttatttttaa ctagaaactt tatagaatta gaaaggcaac tggaaattaa gtacttgaag 1621 aacgatgaag aaacttcaag tgagaataag gataacataa tatatgaaaa aattttatct 1681 aatgcatttt tacatataat taattttatt cgcacaggga agatggaatc tttggaaagt 1741 tctaaagata tggttcgaga tttaattact ttggctgata taaataatga accacatatg 1801 tggtggtact ttagactact atatttggtt tttgaagaat atgaagatgg gtctttgtgg 1861 aaagtggttc caccgctttt agataatgat gatatatcag ctaaatatat ttatgctaat 1921 ttatacaaaa agaagccaat aactgaattt tttaagtcgc aaagggaatg tttggacgga 1981 gagttattaa agaacgatgg tttcgtaatt ggaatgccta ctagttcagg aaaaacaaag 2041 gttgctgaag taacaatatt aaaaacttta actaaatctc caggtgcact ttgtatttat 2101 attgcacctt atcgatcttt ggctaatgaa gtggaattta gcctatctag tatgtttgag 2161 attatgggtt atcaggtttc gcagttatat gggggatctc aaacgtctcc gctggatcgg 2221 caattgacta agcaagctaa tgtcataatt gttactccgg aaaaagctaa atcgatgttg 2281 agatctaata aagacttaaa ggatagaatt caacttgtaa tcattgatga aggtcattta 2341 gtcgggtttc agccaagata tattacagga gaattgctta ttgaagaact aaagattgtt 2401 ttgaaaaaaa ataatggtca acttgtacta ctatctgctg ttcttcctaa tatttctgat 2461 ttttctttgt ggattggtga ggatgataaa gctaaaagaa tgtctgtctg gagaccatca 2521 agtcaaagat ttggagaatt atctttagca agaaatactg tgaatataaa ttgggaggga 2581 gaaacaccat catataataa gaactttata acaccaaaat tagtaaaacc agaacggatt 2641 acaaaaacag gaaggaaata tgcagctaaa tattttccag cagataaaaa agaaggtgtt 2701 gctgcaaccg caacaaaaat gctagatgtg ggatccgttt tgatttatgt aggaagatcg 2761 aatatggtat tgtctcaagc taggattgtt tcgaaactct ttgaggaaaa gggaatagaa 2821 catgagtgga ggaataaaaa cgattggttg tttgtggaat tagcttgtat agaagaatat 2881 ggggaagatt cagaaatatt atctttatta aaacaaggta tagtacccca tagttctaaa 2941 ttaccaacag aagtacgtca gagcatagag aaattaatgg ctaatgataa tcctaagata 3001 ataattgcga catccacact tggacaaggg gttaatattg gtgtttcgac agttattgta 3061 tctaatgttc gtttagatga gagtaatact gtaaaagtaa atgatttttg gaatattgct 3121 ggtagagcgg ggagggcatt tacagataca gagggtaaaa ttctatacgc aattgataga 3181 aataaaagcc agtggtctat ttataatcaa attcaaatga aagaaatgta tttcaaatat 3241 agaaatattg aaaaagctac aagtggtctc tatcttcttc ttcgttatct atttatatta 3301 tcggaagaat tcgagataga atacagctta tttttagaac ttctagcaga aaatagagaa 3361 tccattgatg aacagaaagc tgtggagttt ttttctgagg cagatcagtt ccttgagtta 3421 ttagatgata ctctaatttc catggatatt atgaatgagg caaacgtttt ggaaaattcc 3481 tcttcttgga tagacgatgt ctttcgttct tcgctagctt ttattcaagc aaaacaagat 3541 caatcatttt ctgaagaaaa aatgattgaa atcttaaaag caagaaattc aggtgtaata 3601 aagttggctg gagaagaaac aaaatggcat tcaatagcat catcaagtgt accattgaga 3661 gcaagtcttg taattgaaca taggatagat gagctactaa agtatgtacg aaaatacatt 3721 gactcagata agagttttga agagttatta tctcttgtga tggaacttga tatatttatt 3781 gatagtctac cgatatctaa aatagaagga atagaaatag gtgctaattt ttctgaaatt 3841 cgtgagggat ggtttagtgg tactagcata cacatattgg aaaaaaggca cgaaaatgta 3901 agaagtatct gtaatgaata ttattctttt cattttcctt ggattgtaaa tgcgatagct 3961 caaaagatca aattaattga ttgccaagag gaatcaaagg tgttggagca aatttcttta 4021 tttgctgaaa tagggttaaa caataataaa agtgtaaaaa tctatttggc aggtataaag 4081 tcaagaaatt gtgccactga attatctgag aaaataggca tggataatga tttggtgacg 4141 cctgttaagg agctacttct agagtttttc aatttatgtg tagtgaaaaa agaggattgt 4201 tcagaaattt gtttcaattg gttaaagctt ttaaatgatg aaaaagaagc taaagagtat 4261 gtaaaggtaa aaagacggtc tttccaattt aatattcctt ttgatttaca tgacaatctt 4321 ttatatataa agaaagtaca gagtgaaata tggctgtgct catttgatta taaaattaaa 4381 attcctgtat taaaagagaa ggcgttattt aatgagtgct cggatatacc tgatattttc 4441 ttgagaaagg aaaaaggaga tgtctggatt ttagattctc ataatcctta tattattttt 4501 tattaattta tttgaattta atattttgga taaggcagat tgttcaacta tttggaggaa 4561 ataaaaaaac ggattattaa gggtgaacta aatttaatca aactttttac aaatctgcat 4621 ctttctcatt ttcaccttta aaaatgccaa ggaactcaat gaaatttggt atgcagatac 4681 cttcaagagc caccaatcct aaagtgaaat ctccatagtt tttacgatat tcttcataaa 4741 ttaatctggc tatatcttca ccaaaagaaa acatttcttt tgttatttcg gaaagataag 4801 gtagaagtgg tatatactca tctggtttac ctttttcatt tgaaggtact tttactgcat 4861 acccttgatc aagtgtcata atgttaattt gatgaccact atgtacaata gaatcgcgta 4921 tttctctatt cttatgaaag ctttctataa tagataatag ttttttttct aaggattcag 4981 gtaatttatc cttggttgtt cctttttcaa cggaagtaat taaactattt aaggaatcaa 5041 aactgagttg tccaacaaat ttaggagcta ctgttaatcg taggattttt gccatgaaat 5101 cataaattga acgaatatcc at (SEQ ID NO: 4; construct 3 Table 4).

[00539] The coding regions for each of the hamA and hamB gene sequences within this embodiment of a Hachiman cassette (SEQ ID NO: 4) are as follows: nucleotides 339-1154 encode an embodiment of a HamA polypeptide, and nucleotides 1114-4506 encode an embodiment of a HamB polypeptide.

[00540] In some embodiments, a Defense System IV comprising a HamA polypeptide and a HamB polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 4. In some embodiments, a Defense System IV comprising a HamA polypeptide and a HamB polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 4. In some embodiments, a Defense System IV comprising a HamA polypeptide and a HamB polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 4. In some embodiments, a Defense System IV comprising a HamA polypeptide and a HamB polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 4. In some embodiments, a Defense System IV comprising a HamA polypeptide and a HamB polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 4.

[00541] In some embodiments, Hachiman defense system components comprise HamA and HamB polypeptides. In some embodiments, Hachiman defense system components comprise functional portions of HamA and HamB polypeptides. In some embodiments, the Hachiman defense system components are encoded by hamA and hamB genes.

[00542] Non-limiting embodiments of endogenous Hachiman systems and the respective location of their components are provided in Table 12 herein.

[00543] In some embodiments, the components of a Hachiman system may be identified by the presence of similar domains present within each component. In some embodiments, domains comprise pfam domains and or clusters of orthologous groups (COG) domains.

[00544] In some embodiments, the term "HamA" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the hamA gene. In some embodiments, the term "HamA" refers to a HamA polypeptide. In some embodiments, the hamA gene encodes a polypeptide comprising a pfam08878 domain. In some embodiments, the hamA gene encodes a polypeptide comprising a DUF1837 domain. In some embodiments, the hamA gene encodes a polypeptide comprising a pfam08878 domain and a DUF1837 domain. In some embodiments, the HamA polypeptide comprises a pfam08878 domain. In some embodiments, the HamA polypeptide comprises a DUF1837 domain. In some embodiments, the HamA polypeptide comprises a pfam08878 domain and a DUF1837 domain.

[00545] In some embodiments, HamA polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a HamB polypeptide in a genome of a prokaryotic cell. In some embodiments, HamA polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a HamB polypeptide in a genome of a prokaryotic cell. In some embodiments, HamA polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a HamB polypeptide in a genome of a prokaryotic cell.

[00546] In some embodiments, HamA and HamB are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, HamA and HamB are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00547] In some embodiments, hamA and hamB genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, hamA and hamB, genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00548] In some embodiments, a HamA polypeptide is about 269 amino acids long (median gene size).

[00549] In some embodiments, the HamA polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns H and I. In some embodiments, the HamA polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns H and I. In some embodiments, the HamA polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 12, rows 2-1782, columns H and I.

[00550] In some embodiments, the HamA polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns H and I. In some embodiments, the HamA polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns H and I.

[00551] In some embodiments, the HamA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns H and I. In some embodiments, the HamA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns H and I. In some embodiments, the HamA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns H and I. In some embodiments, the HamA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2- 1782, columns H and I. In some embodiments, the HamA polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2- 1782, columns H and I.

[00552] In some embodiments, the HamA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns H and J. In some embodiments, the HamA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns H and J. In some embodiments, the HamA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns H and J. In some embodiments, the HamA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns H and J. In some embodiments, the HamA polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns H and J.

[00553] In some embodiments, the nucleic acid sequence of a hamA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns H and J. In some embodiments, the hamA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns H and J. In some embodiments, the nucleic acid sequence of a hamA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns H and J. In some embodiments, the hamA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns H and J. In some embodiments, the nucleic acid sequence of a hamA gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns H and J.

[00554] As used herein, the term "HamB" refers to the polynucleotide or expression product e.g., polypeptide encoded by the hamB gene. In some embodiments, the term "HamB" refers to a HamB polypeptide. In some embodiments, the product of the hamB gene comprises a COG 1204 domain. In some embodiments, the hamB gene encodes a pfam00270 domain. In some embodiments, the hamB gene encodes a pfam00271 domain. In some embodiments, the hamB gene encodes a helicase.

[00555] In some embodiments, HamB polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a HamA polypeptide in a genome of a prokaryotic cell. In some embodiments, HamB polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a HamA polypeptide in a genome of a prokaryotic cell. In some embodiments, HamB polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a HamA polypeptide in a genome of a prokaryotic cell. [00556] In some embodiments, HamA and HamB are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments HamA and HamB are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00557] In some embodiments, a HamB polypeptide is about 867 amino acids long (median gene size).

[00558] In some embodiments, the HamB polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns L and M. In some embodiments, the HamB polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns L and M. In some embodiments, the HamB polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 12, rows 2-1782, columns L and M.

[00559] In some embodiments, a HamB polypeptide homolog comprises a helicase domain. In some embodiments, a HamB polypeptide homolog comprises a helicase activity.

[00560] In some embodiments, the HamB polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns L and M. In some embodiments, the HamB polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns L and M.

[00561] In some embodiments, the HamB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns L and M. In some embodiments, the HamB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2- 1782, columns L and M. In some embodiments, the HamB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2- 1782, columns L and M. In some embodiments, the HamB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns L and M. In some embodiments, the HamB polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 12, rows 2-1782, columns L and M.

[00562] In some embodiments, the HamB polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns L and N. In some embodiments, the HamB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns L and N. In some embodiments, the HamB polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns L and N. In some embodiments, the HamB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns L and N. In some embodiments, the HamB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns L and N.

[00563] In some embodiments, the nucleic acid sequence of a hamB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns L and N. In some embodiments, the hamB gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns L and N. In some embodiments, the nucleic acid sequence of a hamB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns L and N. In some embodiments, the hamB gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns L and N. In some embodiments, the nucleic acid sequence of a hamB gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 12, rows 2-1782, columns L and N.

[00564] A skilled artisan would appreciate that the terms a "functional portion of a Defense System IV component" or "functional fragment of Defense System IV component" or "functional portion of a Hachiman defense system component" or "functional fragment of Hachiman defense system component" refers to a functional portion of a Hachiman polynucleotide or polypeptide, as disclosed herein, which expression is sufficient to elicit an anti-phage activity alone or in combination with the at least one of the other Hachiman polynucleotides or polypeptides disclosed herein or functional portions thereof.

[00565] The terms "HamA", "HamB", "hamA", and "hamB", also refer to functional HamA, HamB, hamA, and hamB, homologs, which exhibit the desired activity (i.e., conferring phage resistance). Such homologs can be, for example, at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polypeptide sequences referenced in Table 12 rows 2-1782 columns H and I and L and M, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homologous or identical to the polynucleotide sequences referenced in Table 12 rows 2-1782 columns H and J and L and N, respectively. In some embodiments, such homologs comprise at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homology or identity within similar domain regions of the polypeptide sequences referenced in Table 12 rows 2-1782 columns H and I and L and M, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homology or identity within nucleotide sequences encoding similar domain regions to the polynucleotide sequences referenced in Table 12 rows 2-1782 columns H and J and L and N, respectively.

[00566] Table 12 presents embodiments of components of Defense System IV that may be found in a diverse array of bacteria and archaea genomes (referenced in Table 18). Table 12 presents embodiments of nucleic acid sequences encoding gene cassettes of Defense System IV (referenced in Table 18).

[00567] The Shedu Defense System

[00568] In some embodiments, a defense system disclosed herein comprises a Shedu anti- phage defense system. (Table 13)

[00569] In some embodiments, a Shedu defense system provides a host cell with resistance to entry of foreign nucleic acid invasion. In some embodiments, a host cell expressing a functional Shedu defense system (Defense System V) provides the host cell resistance foreign nucleic acid invasion.

[00570] In some embodiments, a Shedu defense system provides a host cell with resistance to at least one phage. In some embodiments, a microbial cell comprising a Shedu defense system is protected from phage infection. In some embodiments, a microbial cell expressing a Shedu defense system is protected from phage infection. In some embodiments, a microbial cell expressing a functional Shedu defense system is protected from phage infection. In some embodiments, a bacterial cell comprising a Shedu defense system is protected from phage infection. In some embodiments, a bacterial cell expressing a Shedu defense system is protected from phage infection. In some embodiments, a bacterial cell expressing a functional Shedu defense system is protected from phage infection.

[00571] In some embodiments, a Shedu defense system provides a host cell with resistance to a plasmid.

[00572] In some embodiments, a Shedu defense system (Defense System V) provides a host cell with resistance to plasmid transformation. In some embodiments, a host cell expressing a functional Shedu defense system (Defense System V) provides a host cells with resistance to plasmid transformation.

[00573] In some embodiments, a Shedu defense system(Defense system V) provides a host cell with resistance to entry of conjugative elements. In some embodiments, a host cell expressing a function Shedu defense system (Defense System V) provides the host cell resistance from entry of conjugative elements.

[00574] As used herein, the term "a Shedu anti-phage defense system" may be used interchangeably with the term "a Defense System V", having all the same meanings and qualities. A skilled artisan would appreciate that the term "Shedu system" may be used interchangeably in some embodiments with "Shedu defense system", "Shedu the defense system", "Shedu anti-phage system", and "Defense System V", having all the same meanings and qualities.

[00575] In some embodiments, a microbial species does not comprise an endogenous Defense System V. In some embodiments, a microbial species does not express an endogenous Defense System V. In some embodiments, a microbial species does not express a functional Defense System V.

[00576] In some embodiments, a bacterial species does not comprise an endogenous Defense System V. In some embodiments, a bacterial species does not express an endogenous Defense System V. In some embodiments, a bacterial species does not express an endogenous functional Defense System V.

[00577] A Shedu defense system comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence encoding a SduA polypeptide comprising a pfaml4082 domain or a DUF4263 domain or a pfam01939 domain, or a combination thereof. In some embodiments, a Shedu defense system comprises a SduA polypeptide comprising an endonuclease NucS activity. A skilled artisan would appreciate that an endonuclease NucS activity encompasses an enzymatic activity cleaving both 3' and 5' ssDNA extremities of branched DNA structures, wherein the NucS endonuclease may bind to ssDNA. In some embodiments, a Shedu defense system comprises a nucleic acid construct comprising a nucleic acid sequence comprising a sduA gene.

[00578] A Shedu defense system comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence comprising a sduA gene encoding a pfaml4082 domain or a DUF4263 domain or a pfam01939 domain, or a combination thereof. In some embodiments, a Shedu defense system comprising a sduA gene encodes a polypeptide comprising an endonuclease NucS activity.

[00579] In some embodiments, a Defense System V comprises a SduA polypeptide comprising a pfaml4082 domain or a pfam01939 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 13 rows 2-1247 columns H and I or a combination thereof.

[00580] In some embodiments, a Shedu defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a SduA polypeptide. In some embodiments, a Shedu defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a sduA gene.

[00581] In some embodiments, the Shedu anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising a sduA gene.

[00582] In some embodiments, a construct comprising the Shedu defense system encodes one component of the defense system. In some embodiments, the components of a Shedu defense system comprise a sduA gene. In some embodiments, the components of a Shedu defense system consist of a sduA gene. In some embodiments, the components of a Shedu defense system comprise nucleic acid sequences encoding a SduA polypeptide. In some embodiments, the components of a Shedu defense system consist of nucleic acid sequences encoding a SduA polypeptide.

[00583] In some embodiments, a construct comprising the Shedu defense system encodes one component of the defense system, whereby a second construct may be used to assemble the functional defense system. In some embodiments, a construct comprising the Shedu defense system encodes one component of the defense system, whereby additional constructs may be used to assemble the functional defense system. In some embodiments, the Shedu defense system comprises non-coding RNA.

[00584] In some embodiments, the components making up a functional Shedu anti-phage defense system comprise a SduA polypeptide encoded by a sduA gene.

[00585] In some embodiments, a Shedu defense system having an anti-phage activity comprises a nucleic acid encoding a SduA polypeptide.

[00586] In some embodiments, a Shedu defense system having an anti-phage activity comprises a nucleic acid comprising a sduA gene.

[00587] In some embodiments, the Shedu system (Defense System V) composition and order is as shown in Figure 3B.

[00588] In some embodiments, a Shedu defense system having an anti-phage activity originates from a microbial genome, for example a bacterial and or an archaeal genome (Table 13). A skilled artisan would appreciate that the Shedu system is not present in the majority of bacteria and or archaea species.

[00589] In some embodiments, a Shedu defense system having an anti-phage activity comprises a nucleic acid construct comprising non-coding regions. In some embodiments, the non-coding regions comprises nucleic acid sequence not naturally occurring in the microbial species of origin. In some embodiments, the non-coding regions comprises nucleic acid sequence is the naturally occurring in the microbial species of origin.

[00590] In some embodiments, Shedu defense system components comprise functional portions of a SduA polypeptides. In some embodiments, the Shedu defense system functional portions of a SduA polypeptide component is encoded by a sduA gene.

[00591] Non-limiting embodiments of endogenous Shedu systems and the respective location of their component are provided in Table 13 herein. In some embodiments, a Shedu (Defense

System V) gene cassette comprises the nucleic acid sequence:

1 aatgaaattt gaacgccttt cggcagtgat atttgtacac ctcattttta cgtgccagcg 61 tgatgtacat gaaaagtggt gaaaagattc ctattgtggc tgagagtagt agcatgatga 121 tggtgtttct tttttctttt ttgatggttt tcatgagtga tttggccccc tttttgtttt 181 gtcttcttta aattaggggt gacgttgggg gagatgcaag gggaatctgt agaaaaattg 241 attgagaccg atatagataa attccatatt tttatttatg aaatcctata ctgtcaatat 301 taatcaaaac aattaatgag atcaaatttt tttgttcatc agacattaat agaatgattg 361 tatggataat agtagtttct ttatcacaac aacgcattat catgaagctc cacaatagga 421 ttgtagaata acctcaaatt caatcctatg ttcattgaaa agggggcggg gaactcttta 481 aacatctcca cgaggtattt tgagtgtatg tgctttatta attctacatg cttaggctaa 541 ctaatcatta atagactaca aaaaacattc atgcctagta cagaaacaca cccttctcat 601 tgaagaagac taaccagtgg tattcgcaaa agaagaaaag aggattacct caacagccac 661 ctaccttttt atattgtaaa tatgtcctat ttaattcgga gtagtgtata ctattagtag 721 aaaattccaa gcgtagctat cgaggagtgt taacaaaata tgagtgacaa aattaatgta 781 tggacaacat caagagactc tgctgtatgt ggtgacattg aattaaaaaa aacatctact 841 actagactta tttttaggcc tgaaatagtg aacaataata aaaatcctaa ggcatctgtt 901 agaggatgct ttatctttca aaagaaaggt agaaatgccc tttgggatga ttataaggaa 961 ttagatatga ataagttaaa agcagaggaa tggattaaac tagagataaa ctctgatgct 1021 atgctgactc ttactaaaga aattcagaag cattatgcag tgcatgaaaa gtatggggtt 1081 aggtatggag catttcacct tttcaaggat aaccctgata tcgagaaact gattgaaatg 1141 tttgagagta acactgattt gcttactcaa ttaatggagg atgacaagag tgaagctcta 1201 gagaaaacat tagaatggat tgttacaaat gataatccag ataaaataat tgacaggctt 1261 aaaaatctaa aagagcaaga tttagaccaa cttaatactc ttattgggat agctaatcta 1321 aaaaaggtat tgtctgtttg ggaaagcaac aaactcacta atacctctga gaagttttgg 1381 caaagtgtct taaaagaaaa cacttggatt ttgagtcaga ttttctctaa cccgactgtt 1441 ttgataaatg atgaagccta tgtaggcgga aagactgtca aaaatgatag tggtaagtta 1501 gtagatttct tatatgcaaa ccctttctca aaagatgctg tacttattga gattaagact 1561 ccatcaacgc ctctaattac tcccactgaa tacagaacag gagtatattc cgcacataaa 1621 gacttgacag gagcagttac gcaagtgttg acttataaga caaccctaca gagggagtat 1681 cagaatatag actataacaa ttatagacag ggaatcaaaa ctgattttga cattattact 1741 ccttgttgtg ttgttatagc aggcatgttt gatacattaa ctgatacagc tcatagacat 1801 tcctttgaac tgtacagaaa agagttaaaa aatgtaactg taattacttt tgatgaactg 1861 tttgaaaggg ttaaggggtt aatcaagcta ttggaaggat aaacccttgc cttctttttt 1921 tactgcctct aaatttatag aatgcatccg ttaaagctaa gtagaaatat tagaagaaag 1981 ggcaaaattt aaagagagaa atttgccttt tctttttatc aaactgatca aaaaatttta 2041 tatttcaatc actttatttc gccacctgaa tttttttatt ttttaaaagt gccttgcctc 2101 tcaccaattc aggtcattat aaaacaaaaa aagaaccgtt tatcaacaac aaacggtccg 2161 attaaaaatc ttgtgcgtat ctattaaaaa taacttaata aaacatgctt att (SEQ

ID NO: 9; construct 28 Table 4).

[00592] The coding region for the sduA gene sequence within this embodiment of a Shedu cassette (SEQ ID NO: 9) is as follows: nucleotides 760-1902 encode an embodiment of a SduA polypeptide.

[00593] In some embodiments, a Defense System V comprising a SduA polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 9. In some embodiments, a Defense System V comprising a SduA polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 9. In some embodiments, a Defense System V comprising a SduA polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 9. In some embodiments, a Defense System V comprising a SduA polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 9. In some embodiments, a Defense System V comprising a SduA polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 9.

[00594] In some embodiments, the components of a Shedu system may be identified by the presence of similar domains present within each component. In some embodiments, domains comprise pfam domains and or clusters of orthologous groups (COG) domains.

[00595] In some embodiments, the term "SduA" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the sduA gene. In some embodiments, the term "SduA" refers to a SduA polypeptide. In some embodiments, the sduA gene encodes a polypeptide comprising a pfaml4082 domain. In some embodiments, the sduA gene encodes a polypeptide comprising a DUF4263 domain. In some embodiments, the sduA gene encodes a polypeptide comprising a pfam01939 domain. In some embodiments, the sduA gene encodes a polypeptide comprising a pfaml4082 domain, a DUF4236 domain, or a pfam01939 domain, or any combination thereof. In some embodiments, the SduA polypeptide comprises a pfaml4082 domain. In some embodiments, the SduA polypeptide comprises a DUF4263 domain. In some embodiments, the SduA polypeptide comprises a pfam01939 domain. In some embodiments, the SduA polypeptide comprises a pfaml4082 domain, a DUF4263 domain, or pfam01939 domain, or any combination thereof. [00596] In some embodiments, a SduA polypeptide is about 367 amino acids long (median gene size).

[00597] In some embodiments, the SduA polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 13, rows 2-1247, columns H and I. In some embodiments, the SduA polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 13, rows 2-1247, columns H and I. In some embodiments, the SduA polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 13, rows 2-1247, columns H and I.

[00598] In some embodiments, a SduA polypeptide homolog comprises an endonuclease NucS domain. In some embodiments, a SduA polypeptide homolog comprises an endonuclease NucS activity. In some embodiments, a SduA polypeptide homolog comprises an activity that cleaves both 3' and 5' ssDNA extremities of branched DNA structures. In some embodiments, a SduA polypeptide homolog binds to ssDNA. In some embodiments, a SduA polypeptide homolog comprises an activity that cleaves both 3' and 5' ssDNA extremities of branched DNA structures and it binds to ssDNA. In some embodiments, an SduA polypeptide comprises a member of the PD-(D/E)XK superfamily.

[00599] In some embodiments, the SduA polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 13, rows 2-1247, columns H and I. In some embodiments, the SduA polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 13, rows 2-1247, columns H and I.

[00600] In some embodiments, the SduA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 13, rows 2-1247, columns H and I. In some embodiments, the SduA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 13, rows 2-1247, columns H and I. In some embodiments, the SduA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 13, rows 2-1247, columns H and I. In some embodiments, the SduA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 13, rows 2- 1247, columns H and I. In some embodiments, the SduA polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 13, rows 2- 1247, columns H and I.

[00601] In some embodiments, the SduA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 13, rows 2-1247, columns H and J. In some embodiments, the SduA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 13, rows 2-1247, columns H and J. In some embodiments, the SduA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 13, rows 2-1247, columns H and J. In some embodiments, the SduA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 13, rows 2-1247, columns H and J. In some embodiments, the SduA polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 13, rows 2-1247, columns H and J.

[00602] In some embodiments, the nucleic acid sequence of a sduA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 13, rows 2-1247, columns H and J. In some embodiments, the sduA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 13, rows 2-1247, columns H and J. In some embodiments, the nucleic acid sequence of a sduA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 13, rows 2-1247, columns H and J. In some embodiments, the sduA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 13, rows 2-1247, columns H and J. In some embodiments, the nucleic acid sequence of a sduA gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 13, rows 2-1247, columns H and J.

[00603] A skilled artisan would appreciate that the terms a "functional portion of a Defense System V component" or "functional fragment of Defense System V component" or "functional portion of a Shedu defense system component" or "functional fragment of Shedu defense system component" refers to a functional portion of a Shedu polynucleotide or polypeptide, as disclosed herein, which expression is sufficient to elicit an anti-phage activity alone.

[00604] The terms "SduA" and "sduA", also refer to functional SduA and sduA, homologs, which exhibit the desired activity (i.e., conferring phage resistance). Such homologs can be, for example, at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polypeptide sequences referenced in Table 13 rows 2-1247 columns H and I , respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polynucleotide sequences referenced in Table 13 rows 2-1247 columns H and J, respectively. In some embodiments, such homologs comprise at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homology or identity within similar domain regions of the polypeptide sequences referenced in Table 13 rows 2-1247 columns H and I , respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identity or homology within nucleotide sequences encoding similar domain regions to the sequences referenced in Table 13 rows 2-1247 columns H and J , respectively.

[00605] Table 13 presents embodiments of components of Defense System V that may be found in a diverse array of bacteria and archaea genomes (referenced in Table 18). Table 13 presents embodiments of nucleic acid sequences encoding gene cassettes of Defense System V (referenced in Table 18).

[00606] The Gabija Defense System

[00607] In some embodiments, a defense system disclosed herein comprises a Gabija anti- phage defense system. (Table 14)

[00608] In some embodiments, a Gabija defense system provides a host cell with resistance to entry of foreign nucleic acid invasion. In some embodiments, a host cell expressing a functional Gabija defense system (Defense System VI) provides the host cell resistance foreign nucleic acid invasion.

[00609] In some embodiments, a Gabija defense system provides a host cell with resistance to at least one phage.

[00610] In some embodiments, a microbial cell comprising a Gabija defense system protects the microbial cell from phage infection. In some embodiments, a microbial cell expressing a Gabija defense system protects the microbial cell from phage infection. In some embodiments, a microbial cell expressing a functional Gabija defense system protects the microbial cell from phage infection. In some embodiments, a bacterial cell comprising a Gabija defense system protects the bacterial cell from phage infection. In some embodiments, a bacterial cell expressing a Gabija defense system protects the bacterial cell from phage infection. In some embodiments, a bacterial cell expressing a functional Gabija defense system protects the bacterial cell from phage infection.

[00611] In some embodiments, a Gabija defense system (Defense System VI) provides a host cell with resistance to plasmid transformationin some embodiments, a host cell expressing a functional Gabija defense system (Defense System VI) provides a host cells with resistance to plasmid transformation.

[00612] In some embodiments, a Gabija defense system (Defense system VI) provides a host cell with resistance to entry of conjugative elements. In some embodiments, a host cell expressing a function Gabija defense system (Defense System VI) provides the host cell resistance from entry of conjugative elements.

[00613] As used herein, the term "a Gabija anti-phage defense system" may be used interchangeably with the term "a Defense System VP', having all the same meanings and qualities. A skilled artisan would appreciate that the term "Gabija system" may be used interchangeably in some embodiments with "Gabija defense system", "Gabija defense system", "Gabija anti-phage system", and "Defense System VP', having all the same meanings and qualities.

[00614] In some embodiments, a microbial species does not comprise an endogenous Defense System VI. In some embodiments, a microbial species does not express an endogenous Defense System VI. In some embodiments, a microbial species does not express an endogenous functional Defense System VI.

[00615] In some embodiments, a bacterial species does not comprise an endogenous Defense System VI. In some embodiments, a bacterial species does not express an endogenous Defense System VI. In some embodiments, a bacterial species does not express an endogenous functional Defense System VI.

[00616] A Gabija defense system comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence encoding a GajA polypeptide comprising a pfaml3175 domain or a COG3593 domain or a combination thereof, and a GajB polypeptide comprising a pfam04257 domain or a pfam00580 domain or a pfaml3361 domain or a combination thereof. In some embodiments, a Gabija defense system comprises a nucleic acid construct comprising a nucleic acid sequence comprising a gajA gene and a gajB gene.

[00617] In some embodiments, a Gabija defense system comprises, a GajA polypeptide comprising a pfaml3175 domain or a COG3593 domain or a combination thereof, and a GajB polypeptide comprising a pfam04257 domain or a pfam00580 domain or a pfaml3361 domain or any combination thereof. In some embodiments, a Gabija defense system comprises a GajA polypeptide and a GajB polypeptide.

[00618] In some embodiments, a Defense System VI comprises a GajA polypeptide comprising a pfaml3175 domain or a COG3593 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 14 rows 2-4599 columns H and I; or a GajB polypeptide comprising a pfam04257 domain or a pfam00580 domain or a pfaml3361 domain or any combination thereof or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 14 rows 2-4599 columns L and M; or a combination thereof.

[00619] In some embodiments, a Defense System VI comprises at least two different polypeptide components selected from a GajA polypeptide comprising a pfaml3175 domain or a COG3593 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 14 rows 2-4599 columns H and I; and a GajB polypeptide comprising a pfam04257 domain or a pfam00580 domain or a pfaml3361 domain or any combination thereof or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 14 rows 2-4599 columns L and M.

[00620] In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a GajA polypeptide and a GajB polypeptide. In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a GajA polypeptide comprising an ATPase domain, and a GajB polypeptide comprising a helicase activity. In some embodiments, a Gabija defense system having an anti- phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a GajA polypeptide comprising an ATPase domain. In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a GajB polypeptide comprising a helicase activity. In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a GajA polypeptide comprising an ATP- dependent endonuclease, and a GajB polypeptide comprising a UvrD helicase activity. In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a GajA polypeptide comprising an ATP- dependent endonuclease activity. In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a GajB polypeptide comprising a UvrD helicase activity.

[00621] In some embodiments, the Gabija anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising gajA and gajB genes.

[00622] In some embodiments, a Gabija (Defense System VI) gene cassette comprises the nucleic acid sequence:

1 gatcaaacaa tttattccta ttggaatggg ggaagagtcc caaactctca aagagctagt

61 tgatattgtt tggctgctgt gatggattta tttctaagaa aatagtgtgg gctattcatt

121 tttatgttgg atgtttgcag acttaataat gatagcttta gggaacactt actctgtaaa

181 atcggttatt ccctaaaccg ggatttaggt tcacagtata caagctctgg ggttacagaa

241 tacacttaat cttacagcat cattcaacca aaagagtctc tttatgataa tgcctgtgtc

301 gagtcatttt acggtattaa aaaaagaaga agtaaattat gtgcaatatc tagactacca

361 attttccaag ataagaaata tatgttttac gtttcggaaa tattagttgt atcaatggtt

421 tatagagcat tctacatttt cttgtgcaaa tcatgtaaca cagaaaaatg aagtttatga

481 aaaatattta tttatttttc actggtgaat actgaaatag tattcattta ttttttgttt

541 attttacaaa tttttttgaa agtcgttcaa tagcagagaa tttctagtat aattttggta

601 aataattcta tagattgatc ggaattatga atttaattta cagatatttt agagtaacat

661 tggagctatt atattaaaaa agaatgcttc aagattgagc gaacgatagc tttgggataa

721 attagctttt tggcggatag tgaagcagta acgagtaagt tagtaaataa agtgttaaat

781 agaataacag aagaatagga gagggcttta tgtatttaaa aagtttaaaa atctacaact

841 ttagaaaatt tggaacaaat aacaacaaga tagaatttgt tgatgctaaa agttttcaag

901 aacaaagaaa taaaaaagaa gtaaatattg ctccaacaac aactttaatt gtaggaaaga

961 ataactgtgg aaaaacaacg attattaaat cgttagataa tcttattaat aataataaag

1021 acgcttttaa agcaaatgat tttaattttt tatacttaaa aaaactaatt gagtattatg

1081 aacaagcaat tccaaaatta gatgatgaat taaaagaaaa aattaaaaca ccgtatcttc

1141 aatttaatat ttgtattgga attgagaata atagtaatga cttagttacc aatatagttc

1201 gttttatgaa attagatgat attaataatt ctgaattaaa aattgttata aaagtagaat

1261 tggagaacga agaagttttc attagagatg tgaaaaaact gttagagaaa aatgataatt

1321 cgagtcttcg gtttaatagc tttttggaat tgataaatga ttcggatttt aaaataaatt

1381 attataatac agataatgat aaaatagata attttaacat aaaaaattta attgaattga

1441 gaccgattaa agcaaataac attgaaagcg aaaaatgcct ttcaaaagct tttagtaaaa

1501 taattgaata tcgctataaa acattattcg aagaggaaag cgataatctt aattcgacaa

1561 tcataaatat taatcgaaca cttaccaaat taattagtga aaaacatacg gttagtataa

1621 ataagtcttt agaagaaatt gaatcaaatg aaaaacttca agtattgcta agggcagatt

1681 tgacttttca aaatgtgatg aataatttaa tcaaatatga atacgtcgaa cgtaatatga

1741 atatacctga gaatcaattt ggtttaggtt atacaaattt gatgatgata atagcggatt

1801 taattgatta tatggaaaaa tacccagaaa actcatttaa cagtaaggtt aatttaattt

1861 caattgaaga acctgaaaca tttatgcatc cacaaatgca ggagttattt ataaaaaata

1921 taaatgaagc gattgcttct ttattgaaaa gtaaaaataa aaacgtaaat agccagttga

1981 taattacaac acactcatca catatactaa atagtaaaat acacagtggt aatactttta

2041 ataatataaa ttacgttact accaaaaata attatactca tgtagtgaat ttgcatgatg

2101 atataattat ccctaaaagt gaaaaaaaag ctcataaaag agagcaggat cttaagttct

2161 taaaaaaaca tattaagtat aaagtttctg agttgttttt ttcagatgct attatttttg

2221 ttgaaggtgt gactgaagaa acgcttctta aatattatat tgatgataat aataagctca

2281 ataaatatta tatatcggtt ttcaatattg atggggctca cggaatggtt tatcacaatt

2341 taattgaaat actacaagta cctgctttga taattacgga tttagatata gaaagagatg

2401 atgatgaaaa gaaaaatttc aagcaaatct ctgatttaac gggaaaattc acaactaata

2461 aaacaattaa aaagtataat gatgactcta atagtttaga ggaattacag catgagcagc

2521 ttaaaataaa taatatgtat attgcatatc aaggtaaaat cgaagaatat tatgcaacaa

2581 gttttgaaga agcatttatc ttaacaaatt acaaaaatga acttttaaat agtgtactaa

2641 aaaaaatgaa acctcagatt tatgaaaata ttatgggtga gggagatgat ttcacaaaga

2701 taaaggaaaa ttcctataaa ctccaaaaaa agttatcaaa tgataaaagt gattttgcga

2761 atgagctact ctataagttt ataacggagg atataacaat tccttctttg ccaaagtata

2821 ttaagagtgg cctttcatgg ttagctaaaa aattagaagg ggaggaataa gggtgagttt

2881 atccaaaata atcccatcta ataagaaaga agagcagaaa tcaataaatg caatttttaa

2941 ttctattgat aaaagtgaag gtatcatttt taattctggt gctggtgctg gaaaaacata

3001 cgctcttatt gaaagtttga aatacataat aagaaactac gagaagagct taaaacaaca

3061 taatcaacaa attatctgta tcacatatac gaatgttgca actaaagaag taaaagagag

3121 attaggaaac acagatttag tattagtttc tacaattcat gaaagaatgt ggggactcat

3181 taaagattat caaaaagaat tagttgagat tcacaaagaa aagttggaag atgaaatctc

3241 aagtttaaaa caaaaattag aaaaaggtca gggatacgaa aaatttcaag aattagaaga

3301 ggacttaaag ggaaatttta aaaaaataat gattgagaat agggaactat tttttcaaaa

3361 ttatagtgct aaagcagcag aggtaaaaaa atcatttaaa atactcttaa acgattaccc 3421 taatatgctg aaaaatgttg gaaattttaa gagaatagta aatgcaattt acaaattaga 3481 tcagtatagt aaatgctatg aaaatataag cttaaataaa cagggttata aatctgtaga 3541 gtacaattcg atttataata acgatcaact ttataaaatg agaataagcc atgatacttt 3601 gttagattat ggtctgaaaa taattaagaa atatgacttg ttaaaacaaa taatcattga 3661 taaatatcca tttattttta ttgatgagta tcaggatacg gatgaaaaag ttatattaat 3721 aatgagttat ttagagcaat atgcaaaaaa aattgatcac aaaattttta taggttattt 3781 tggtgatact gctcaaaata tttatgatga tggagtagga agtgaaataa caaagattca 3841 ctcaggatta aaacagatag ataaagtgtt taatagaaga tctacaaaag aagtcattga 3901 ggttataaac aaaattagaa acgatagcat cgaacaaata tcaatttatg atgattgtga 3961 aggcggtagt gtaaagtttt ataaagggac ttcaggtaat gttaaggact taatagagcg 4021 gtatatatat gaatggaaaa taactacgga aaatcaacta cattgtctag ttttaactaa 4081 taagattgtt gcagaatata gtggttttaa aaacatatac gaagctttca aagagacaga 4141 taaatataaa gggagcaatt ataatcaact taatacggaa ctcttaagta atgatttatc 4201 taagcttggt gaaattccta agttgttatt taatatagtt agattacaga ataatcttgt 4261 ggataaaacg acttcagtta ttgatattac acctaaagaa agcctattcg atgagatgag 4321 tatagaaggg ttaaggaatt taattaaact attaaaacaa taccaaggga aaacattagg 4381 tgaatatata gaatcgatat caactgttta ttctcaagtt aatgatgaaa attataaaaa 4441 aataatagat tggacttttg gttttgaaaa tatcacattc gaactattta aaaatcatct 4501 tatagaaaag ttatttaata atatattaga tgatgatgtt gatcgtgcaa ccgcaactat 4561 acaaaaaata ctagaagttg atattgttga gtatggattg tggtataaat ttattatgga 4621 taaacaagaa gagaaggtta tttatcatac ttatcatggt acaaagggac gagagtttga 4681 taatgttatt attattatgg aaaatgcttt tggaagaaat cacaattatt ttaatttctt 4741 ttttgaaaat ttcttgcatc cagatgtatt agaaggtgaa aagaaactga acttcgagaa 4801 aataaagaat ttgttatatg tttcttgctc tagagctatt aagaatttaa gagttttata 4861 tattgatgat gttaccgatt ttgaaagtga aattaaggaa atgtttggag aagtatatcc 4921 tttttagtaa taattgaatg aagatatttt tcatgaataa aaaaatgttg tgttgatggg 4981 aagcatcata aaaaaacact cttaaccttt ttacaaagaa acaccccact cgttaggctt 5041 aattattaag tttatgtatt attttattat tcaaaacctt atttttgcta ttgattagcc 5101 gctcataata tttaattatg agcggtttta taacatccga gcacaagttt taaaaatgaa 5161 aattcaggac taggtttatt attcaagacg atgattacat atcatttaag gtgcaggaaa 5221 ataattaaag cattataagt aatatcgata tttcagtttg ttaagatttt ctaagggaaa

5281 tttgttcttt tatctagaaa ataattggat tatctaattc atcat (SE 3 ID NO: 5; construct 7 of Table 4).

[00623] The coding regions for each of the gajA and gajB gene sequences within this embodiment of a Gabija cassette (SEQ ID NO: 5) are as follows: nucleotides 810-2870 encode an embodiment of a GajA polypeptide, and nucleotides 2873-4927 encode an embodiment of a GajB polypeptide.

[00624] In some embodiments, a Defense System VI comprising a GajA polypeptide and a GajB polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 5. In some embodiments, a Defense System VI comprising a GajA polypeptide and a GajB polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 5. In some embodiments, a Defense System VI comprising a GajA polypeptide and a GajB polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 5. In some embodiments, a Defense System VI comprising a GajA polypeptide and a GajB polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 5. In some embodiments, a Defense System VI comprising a GajA polypeptide and a GajB polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 5.

[00625] In some embodiments, a Gabija (Defense System VI) gene cassette comprises the nucleic acid sequence:

1 ataatagtac tatttaacga tacctgtcaa aaaacataat cgatatttta tcaaaattaa 61 aaaaagaaac cattttattt aacttttctt taaaatggtt tcttggatta tgggacttag 121 ttttttgtct ggaaaatata atgggaattt attgtataat aaaactatgt agaaatacat 181 ggttttttta tttattgagg atgggattct agtgaagggg aacagcttgc ttaactattt 241 ataaaataca gggataagaa cagaattaaa gaaggtatat gttaaaagta aaataattaa 301 gaagataagg tgatgaataa tgaaattcag taatattaca ataaagaact tcaggaattt 361 tgaaaaagta aatataaatt tagataataa aaatgtgatt ttcgggatga atgatattgg 421 aaaaacaaat tttttatatg cattgagatt tcttttagat aaagagataa gaaaattcgg 481 ttttaataaa tctgattatc ataaacatga cacttctaaa aaaattgaaa ttattttaac 541 acttgatttg tctaattatg aaaaggatga agatacaaaa aaacttattt cagtggttaa 601 gggtgctaga acatcggcaa atgcagatgt tttttatatc gcactagaat ctaaatatga 661 tgataaagaa ttatatggga acataatttt aaaatgggga tcggaactag ataatttaat 721 agatatacca gggagaggga acataaacgc gttagataat gtatttaagg tgatttatat 781 aaatccgctt gttgatttag acaaattgtt cgcacaaaat aaaaaatata tttttgaaga 841 gtcacagggt aatgaatcag atgaagggat tttaaataat attaaatctt taacagatca 901 agtaaatcaa caaataggag aaatgacaat tattaagggt ttccagcaag agataacaag 961 tgaatatagg tctttaaaaa aagaagaggt ttctattgag ctgaagtccg aaatggcaat 1021 taaaggattt ttctcagata ttattccata tataaaaaaa gacggtgatt ctaattacta 1081 tccaacctca ggggatggta gaagaaaaat gctttcttac tctatatata actatctggc 1141 taagaaaaaa tatgaggata aaattgttat ttatttaatt gaggaacccg aaattagtct 1201 acatagatca atgcaaattg ctttatcaaa acagttattt gaacaatcta catataaata 1261 ttttttctta tccactcact ctcctgaact tctttatgaa atggataata caagattaat 1321 aagagtgcat tcaactgaaa aggttgtatg ttcttcccat atgtataatg tggaagaagc 1381 ctatggaagt gtcaagaaaa agctaaataa agctttatca tcggctctat ttgctgaaag 1441 agtactttta atagaaggtc cttcagaaaa aatattattt gaaaaggttt tagacgaagt 1501 agaaccagaa tatgaattaa atggaggttt cttgcttgaa gtaggaggga cgtactttaa 1561 tcattatgtg tgtacattaa atgatttagg tataacccat ataattaaaa cagataatga 1621 tttgaaatca aaaaaaggta aaaaaggtgt atacgaatta ctaggattaa atagatgctt 1681 aaacttatta ggacgtgaaa atctagatga gattactatt gacatccctg aagatataaa 1741 aggtaagaag aaaaaagaga gacttaatga aagaaaaaaa gagattttta aacaatataa 1801 aaatgaggta ggggaattct taggggaacg aatatattta tcggaaatcg atctggaaaa 1861 tgatttatat tctgcaattg gtgaaagcat gaaaagaatt tttgaaaacg aagatcccgt 1921 gcactattta cagaaaagta aactatttaa catggtcgag ctagtaaata atttaagtac 1981 taaagattgt tttgatgttt ttgagcacga aaaatttgca tgcctaaagg agttggtggg 2041 tagtgataga ggatgaaatg tctagagaac aaataataaa ggatgggggt aatattcttg 2101 ttaccgctgg agcaggttcg ggtaaaacaa caatattagt tagtaaaatt gaagctgatt 2161 taaaagaaaa taaaactcat tactcaattg cagctgttac ttttacaaat aaggcagcaa 2221 aagaaatcga gggaagatta gggtattcat caagagggaa ttttattggc actaacgatg 2281 gttttgtcga gtctgaaatt attaggccgt ttattaaaga tgcatttgga aatgattatc 2341 cagacaattt cactgctgaa tattttgata accaatttgc ttcatacgat aagggattgc 2401 aagtgctaaa atatcaaaat atattaggga cttatagtaa tcctaaaaag aattttaagt 2461 ttcaattggc tttagatatt ttaaaaaaat cacttgtcgc tagacaatat atattttcaa 2521 aatacttcaa gatatttata gacgagtacc aagattcgga taaggatatg cataatttat 2581 ttatgtattt aaaggatcag cttaaaatta agttatttat tgttggtgac ccaaaacaat 2641 ctatttatat ctggagggga gcagaacctg aaaattttaa tggtcttata gaaaattcta 2701 cggattttaa taaatatcat ttaacttcca actttcgatg ctgtcaggat attcaaaatt 2761 actctaattt atttaatgaa gaaactagaa gcttaattaa agaaaaaaat gaggttcaaa 2821 atgtaatcag tatagcagac gatatgccaa tttcagatat tttattaaaa ttaacagaag 2881 aaaagcaggt attaaacata gaagcggaat tagtgatttt agtccggaga cgtaatcaag 2941 ccattgaaat aatgaaagaa ctaaatgaag aagggtttaa ttttattttt attccccaaa 3001 ccccattaga tagggcaact ccaaatgcaa ctcttttaaa agaggtaatt aaatatgtta 3061 aaaatgatag atattcaata tatgatttag ctgctgaaat tgtaggtaat ctaagttcac 3121 gagaaattaa ggagatacaa aaaataatta atgaattact agtacctaat attaatcagg 3181 tactaattaa tcaggtatta attaatttat ttgctaaatt agaaattact ttagatacta 3241 gagaaattac agcatttaca gaagtaatga tgacgaatga atttgacata gcatttgata 3301 caaatgaata tttacataaa atatttactg tacattctgc aaaaggatta gaatttaatc 3361 aagtcattat tactgcaagt gattacaatg tacactataa tagagatact aacgaacatt 3421 atgttgctac aactagagca aaagataaat taattgtcat tatggataat aagaagtact 3481 cagattatat tgagacgcta atgaaagaac ttaaaattaa aaatattatt aagtcaatat 3541 aaggaaactt aagtttgaca taataacgat gaaatataaa agtttgtttt cgtaaatagc 3601 caatgtcact aagttatcaa gacttaaatt ttaaaacctt taaaaataaa gactctaaca 3661 tattagtcat aattaatatg ttagggtctt ttgttttatt tgaaatgtta ttttcaactt 3721 tataagacaa tgaatattat ttttgtttaa taatatccag agtgctcaaa ataaatatca 3781 gaaggtaatt cctaataata ttgcgtgtgt agttaatagt taaaataata aaataaaaaa

3841 agatggtata atttagtata ccatcttttt ttattttatt aggaggttca aaa (SEQ

ID NO: 6; construct 8 of Table 4).

[00626] The coding regions for each of the gajA and gajB gene sequences within this embodiment of a Gabija cassette (SEQ ID NO: 6) are as follows: nucleotides 320-2056 encode an embodiment of a GajA polypeptide, and nucleotides 2058-3542 encode an embodiment of a GajB polypeptide.

[00627] In some embodiments, a Defense System VI comprising a GajA polypeptide and a GajB polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 6. In some embodiments, a Defense System VI comprising a GajA polypeptide and a GajB polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 6. In some embodiments, a Defense System VI comprising a GajA polypeptide and a GajB polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 6. In some embodiments, a Defense System VI comprising a GajA polypeptide and a GajB polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 6. In some embodiments, a Defense System VI comprising a GajA polypeptide and a GajB polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 6.

[00628] In some embodiments, a construct comprising the Gabija defense system encodes one component of the defense system, whereby multiple constructs, for example but not limited to, two constructs may be used to assemble the functional defense system. In some embodiments, the components of a Gabija defense system comprise genes gajA and gajB. In some embodiments, the components of a Gabija defense system consist of genes gajA and gajB. In some embodiments, the components of a Gabija defense system comprise nucleic acid sequences encoding a GajA polypeptide and a GajB polypeptide. In some embodiments, the components of a Gabija defense system consist of nucleic acid sequences encoding a GajA polypeptide and a GajB polypeptide.

[00629] In some embodiments, a construct comprising the Gabija defense system encodes one component of the defense system, whereby a second construct may be used to assemble the functional defense system. In some embodiments, a construct comprising the Gabija defense system encodes one component of the defense system, whereby additional constructs may be used to assemble the functional defense system. For example, in some embodiments each of GajA and GajB may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional Gabija defense system.

[00630] In some embodiments, the components making up a functional Gabija anti-phage defense system comprise a GajA polypeptide and a GajB polypeptide, each encoded by a gajA and a gajB gene, respectively. In some embodiments, a gajA gene encodes a polypeptide comprising an ATPase activity. In some embodiments, a gajB gene encodes a polypeptide comprising a helicase activity.

[00631] In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid encoding a GajA polypeptide. In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid encoding a GajA polypeptide and a GajB polypeptide. In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid encoding a GajB polypeptide.

[00632] In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid comprising a gajA gene. In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid comprising a gajA gene and a gajB gene. In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid comprising gajB gene.

[00633] In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3 ' order of polypeptides encoded is GajA and GajB. In some embodiments the 5' to 3' order of polypeptides does not affect the anti-phage activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti -phage activity.

[00634] In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of nucleic acid sequences encoding GajA and GajB.

[00635] In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid construct comprising genes in a set order. In some embodiment, the 5' to 3 ' order of genes is gajA and gajB. In some embodiment, the 5' to 3 ' order of genes in a Gabija defense system is not gajA and gajB. In some embodiments the 5' to 3 ' order of genes does not affect the anti-phage activity. In some embodiments the 5' to 3' order of genes does affect the anti-phage activity.

[00636] In some embodiments, the 5' to 3 ' order of genes is random, for example any order of gajA and gajB.

[00637] In some embodiments, the Gabija system (Defense System VI) composition and order is as shown in Figure 3B.

[00638] In some embodiments, a Gabija defense system having an anti-phage activity originates from a microbial genome, for example a bacterial or an archaeal genome (Table 14). A skilled artisan would appreciate that the Gabija system is not present in the majority of bacteria and or archaea species.

[00639] In some embodiments, a functional Gabija defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different microbial species. For example, the source of the nucleic acid sequence encoding a GajA polypeptide may be one microbial species, while the source of the nucleic acid sequence encoding a GajB polypeptide may be a different microbial species. In some embodiments, a functional Gabija defense system comprises a non- naturally occurring combination of polypeptide components. In some embodiments, a functional Gabija defense system comprises a combination of at least two polypeptides that do not naturally occur together.

[00640] In some embodiments, a functional Gabija defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different bacterial species. For example, the source of the nucleic acid sequence encoding a GajA polypeptide may be one bacterial species, while the source of the nucleic acid sequence encoding a GajB polypeptide may be a different bacterial species. [00641] In some embodiments, the source of the nucleic acid encoding a GajA polypeptide and a GajB polypeptide is the same. In some embodiments, the source of the nucleic acid encoding a GajA polypeptide and a GajB polypeptide is the not the same. In some embodiments, the source of the nucleic acid sequence of any of the components of a Gabija defense system comprises any of the species listed in Table 14.

[00642] In some embodiments, a Gabija defense system having an anti-phage activity comprises a nucleic acid construct comprising non-coding regions between the nucleic acid sequences encoding the polypeptides. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence not naturally occurring in the microbial species of origin. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence is the naturally occurring in the microbial species of origin.

[00643] In some embodiments, a Gabija system disclosed herein comprises a multi-gene phage resistance system broadly distributed in microbial genomes, for example but not limited to bacteria and archaea. According to some embodiments, the Gabija system components are located in a gene cluster (a cassette of genes) in a microbial cell genome. According to some embodiments, the Gabija system components are located in close proximity (e.g. positioned within 20 genes, 10 genes, 5 genes or less one from the other) in a genome of a prokaryotic cell. According to some embodiments the prokaryotic cell expresses an endogenous Gabija defense system. According to some embodiments, the prokaryotic cell expresses an endogenous functional Gabija defense system. According to some embodiments, the species of prokaryotic cell is selected from the group consisting of the species listed in Table 14. According to some embodiments a prokaryotic cell expresses a non-endogenous Gabija defense system. According to some embodiments, a prokaryotic cell expresses a non-endogenous functional Gabija defense system. According to some embodiments, the species of prokaryotic cell expressing a non- endogenous functional Gabija defense system is selected from the group consisting of the species listed in Table 14.

[00644] In some embodiments, Gabija defense system components comprise GajA and GajB polypeptides. In some embodiments, Gabija defense system components comprise functional portions of GajA and GajB polypeptides. In some embodiments, the Gabija defense system functional components are encoded by gajA and gajB genes.

[00645] Non-limiting embodiments of endogenous Gabija systems and the respective location of their components are provided in Table 14 herein.

[00646] In some embodiments, the components of a Gabija system may be identified by the presence of similar domains present within each component. In some embodiments, domains comprise pfam domains and or clusters of orthologous groups (COG) domains.

[00647] In some embodiments, the term "GajA" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the gajA gene. In some embodiments, the term "GajA" refers to a GajA polypeptide. In some embodiments, the gajA gene encodes a polypeptide comprising a pfaml3175 domain. In some embodiments, the gajA gene encodes a polypeptide comprising a COG3593 domain. In some embodiments, the gajA gene encodes a polypeptide comprising a pfaml3175 domain and a COG3593 domain. In some embodiments, the GajA polypeptide comprises a pfaml3175 domain. In some embodiments, the GajA polypeptide comprises a COG3593 domain. In some embodiments, the GajA polypeptide comprises a pfaml3175 domain and a COG3593 domain.

[00648] In some embodiments, GajA polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a GajB polypeptide in a genome of a prokaryotic cell. In some embodiments, GajA polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3 ') to a gene encoding a GajB polypeptide in a genome of a prokaryotic cell. In some embodiments, GajA polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3 ') to a gene encoding a GajB polypeptide in a genome of a prokaryotic cell.

[00649] In some embodiments, GajA and GajB are encoded by genes positioned sequentially 5' to 3 ' in a genome of a prokaryotic cell. In some embodiments, GajA and GajB are encoded by genes positioned contiguously 5' to 3 ' in a genome of a prokaryotic cell.

[00650] In some embodiments, gajA and gajB genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, gajA and gajB, genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00651] In some embodiments, a GajA polypeptide is about 670 amino acids long (median gene size).

[00652] In some embodiments, the GajA polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns H and I. In some embodiments, the GajA polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, column H. In some embodiments, the GajA polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 14, rows 2-4599, columns H and I.

[00653] In some embodiments, a GajA polypeptide homolog comprises an ATPase domain. In some embodiments, a GajA polypeptide homolog comprises an ATPase activity. In some embodiments, a GajA polypeptide homolog comprises an ATP-dependent endonuclease domain. In some embodiments, a GajA polypeptide homolog comprises an ATP-dependent endonuclease activity.

[00654] In some embodiments, the GajA polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns H and I. In some embodiments, the GajA polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns H and I.

[00655] In some embodiments, the GajA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns H and I. In some embodiments, the GajA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns H and I. In some embodiments, the GajA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns H and I. In some embodiments, the GajA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2- 4599, columns H and I. In some embodiments, the GajA polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2- 4599, columns H and I.

[00656] In some embodiments, the GajA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns H and J. In some embodiments, the GajA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns H and J. In some embodiments, the GajA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns H and J. In some embodiments, the GajA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns H and J. In some embodiments, the GajA polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns H and J.

[00657] In some embodiments, the nucleic acid sequence of a gajA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns H and J. In some embodiments, the gajA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns H and J. In some embodiments, the nucleic acid sequence of a gajA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns H and J. In some embodiments, the gajA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns H and J. In some embodiments, the nucleic acid sequence of a gajA gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns H and J. [00658] As used herein, the term "GajB" refers to the polynucleotide or expression product e.g., polypeptide encoded by the gajB gene. In some embodiments, the term "GajB" refers to a GajB polypeptide. In some embodiments, the product of the gajB gene comprises a pfam04257 domain. In some embodiments, the gajB gene encodes a pfam00580 domain. In some embodiments, the gajB gene encodes a pfaml3361 domain. In some embodiments, the product of the gajB gene comprises a pfam04257 domain or a pfam00580 domain or a pfaml3361 domain, or any combination thereof. In some embodiments, the product of the gajB gene comprises a pfam04257 domain, a pfam00580 domain, and a pfaml3361 domain. In some embodiments, the gajB gene encodes a helicase. In some embodiments, the gajB gene encodes a UvrD helicase.

[00659] In some embodiments, GajB polypeptide is encoded by a gene positioned within 5-60 genes of a gene encoding a GajA polypeptide in a genome of a prokaryotic cell. In some embodiments, GajB polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a GajA polypeptide in a genome of a prokaryotic cell. In some embodiments, GajB polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a GajA polypeptide in a genome of a prokaryotic cell.

[00660] In some embodiments, a GajB polypeptide is about 598 amino acids long (median gene size).

[00661] In some embodiments, the GajB polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns L and M. In some embodiments, the GajB polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns L and M. In some embodiments, the GajB polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 14, rows 2-4599, columns L and M.

[00662] In some embodiments, a GajB polypeptide homolog comprises a UvrD helicase domain. In some embodiments, a GajB polypeptide homolog comprises a UvrD helicase activity.

[00663] In some embodiments, the GajB polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns L and M. In some embodiments, the GajB polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns L and M.

[00664] In some embodiments, the GajB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns L and M. In some embodiments, the GajB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns L and M. In some embodiments, the GajB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2-4599, columns L and M. In some embodiments, the GajB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2- 4599, columns L and M. In some embodiments, the GajB polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 14, rows 2- 4599, columns L and M.

[00665] In some embodiments, the GajB polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns L and N. In some embodiments, the GajB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns L and N. In some embodiments, the GajB polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns L and N. In some embodiments, the GajB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns L and N. In some embodiments, the GajB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns L and N.

[00666] In some embodiments, the nucleic acid sequence of a gajB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns L and N. In some embodiments, the gajB gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns L and N. In some embodiments, the nucleic acid sequence of a gajB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns L and N. In some embodiments, the gajB gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns L and N. In some embodiments, the nucleic acid sequence of a gajB gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 14, rows 2-4599, columns L and N.

[00667] A skilled artisan would appreciate that the terms a "functional portion of a Defense System VI component" or "functional fragment of Defense System VI component" or "functional portion of a Gabija defense system component" or "functional fragment of Gabija defense system component" refers to a functional portion of a Gabija polynucleotide or polypeptide, as disclosed herein, which expression is sufficient to elicit an anti-phage activity alone or in combination with the at least one of the other Gabija polynucleotides or polypeptides disclosed herein or functional portions thereof.

[00668] The terms "GajA", "GajB", "gajA" and "gajff also refer to functional GajA, GajB, gajA and gajB, homologs, which exhibit the desired activity {i.e., conferring phage resistance). Such homologs can be, for example, at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polypeptide sequences references in Table 14 rows 2-4599 columns H and I and L and M, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polynucleotide sequences references in Table 14 rows 2-4599 columns H and J and L and N, respectively. In some embodiments, such homologs comprise at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homology or identity within similar domain regions of the polypeptide sequences references in Table 14 rows 2-4599 columns H and I and L and M, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identity or homology within nucleotide sequences encoding similar domain regions to the polynucleotide sequences references in Table 14 rows 2-4599 columns H and J and L and N, respectively.

[00669] Table 14 presents embodiments of components of Defense System VI that may be found in a diverse array of bacteria and archaea genomes (referenced in Table 18). Table 14 presents embodiments of nucleic acid sequences encoding gene cassettes of Defense System VI (referenced in Table 18).

[00670] The Septu Defense System

[00671] In some embodiments, a defense system disclosed herein comprises a Septu anti- phage defense system (Table 15).

[00672] In some embodiments, a Septu defense system provides a host cell with resistance to entry of foreign nucleic acid invasion. In some embodiments, a host cell expressing a functional Septu defense system (Defense System VII) provides the host cell resistance foreign nucleic acid invasion.

[00673] In some embodiments, a Septu defense system provides a host cell with resistance to at least one phage.

[00674] In some embodiments, a microbial cell comprising a Septu defense system protects the microbial cell from phage infection. In some embodiments, a microbial cell expressing a Septu defense system protects the microbial cell from phage infection. In some embodiments, a microbial cell expressing a functional Septu defense system protects the microbial cell from phage infection. In some embodiments, a bacterial cell comprising a Septu defense system protects the bacterial cell from phage infection. In some embodiments, a bacterial cell expressing a Septu defense system protects the bacterial cell from phage infection. In some embodiments, a bacterial cell expressing a functional Septu defense system protects the bacterial cell from phage infection.

[00675] In some embodiments, a Septu defense system provides a host cell with resistance to plasmid transformation. In some embodiments, a Septu defense system (Defense System VII) provides a host cell with resistance to plasmid transformation. In some embodiments, a host cell expressing a functional Septu defense system (Defense System VII) provides a host cells with resistance to plasmid transformation.

[00676] In some embodiments, a Septu defense system (Defense system VII) provides a host cell with resistance to entry of conjugative elements. In some embodiments, a host cell expressing a function Septu defense system (Defense System VII) provides the host cell resistance from entry of conjugative elements.

[00677] As used herein, the term "a Septu anti-phage defense system" may be used interchangeably with the term "a Defense System VII", having all the same meanings and qualities. A skilled artisan would appreciate that the term "Septu system" may be used interchangeably in some embodiments with "Septu defense system", "Septu the defense system", "Septu anti-phage system", and "Defense System VII", having all the same meanings and qualities.

[00678] In some embodiments, a microbial species does not comprise an endogenous Defense System VII. In some embodiments, a microbial species does not express an endogenous Defense System VII. In some embodiments, a microbial species does not express an endogenous functional Defense System VII.

[00679] In some embodiments, a bacterial species does not comprise an endogenous Defense System VII. In some embodiments, a bacterial species does not express an endogenous Defense System VII. In some embodiments, a bacterial species does not express an endogenous functional Defense System VII.

[00680] A Septu defense system comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence encoding a PtuA polypeptide comprising a pfaml3304 domain or a pfam02463 domain or a combination thereof, and a PtuB polypeptide comprising pfaml3395 domain or a pfam01844 domain or a combination thereof. In some embodiments, a Septu defense system comprises a nucleic acid construct comprising a nucleic acid sequence comprising a ptuA gene and a ptuB gene.

[00681] In some embodiments, a Septu defense system comprises, a PtuA polypeptide comprising a pfaml3304 domain or a pfam02463 domain or a combination thereof, and a PtuB polypeptide comprising pfaml3395 domain or a pfam01844 domain or a combination thereof. In some embodiments, a Septu defense system comprising anti-phage activity comprises a PtuA polypeptide and a PtuB polypeptide.

[00682] In some embodiments, a Defense System VII comprises a PtuA polypeptide comprising a pfaml3304 domain or a pfam02463 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 15 rows 2-12507 columns H and I; or a PtuB polypeptide comprising pfaml3395 domain or a pfam 01844 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 15 rows 2-2507 columns L and M; or combination thereof.

[00683] In some embodiments, a Defense System VII comprises at least two different polypeptides selected from a PtuA polypeptide comprising a pfaml3304 domain or a pfam02463 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 15 rows 2-12507 columns H and I; and a PtuB polypeptide comprising pfaml3395 domain or a pfam 01844 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 15 rows 2-2507 columns L and M.

[00684] In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a PtuA polypeptide and a PtuB polypeptide. In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a PtuA polypeptide comprising an AAA domain ("ATPases Associated with diverse cellular Activities" domain) or a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins) or an N-terminal HNH nuclease domain, or any combination thereof, and a PtuB polypeptide comprising a HNH endonuclease activity.

[00685] In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a PtuA polypeptide comprising an AAA domain (" ATPases Associated with diverse cellular Activities" domain). In some embodiments a PtuA polypeptide comprises a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins). In some embodiments, a PtuA polypeptide comprises an N-terminal HNH nuclease domain. In some embodiments, a PtuA polypeptide comprises an AAA domain ("ATPases Associated with diverse cellular Activities" domain) and a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins) and an N-terminal HNH nuclease domain. In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a PtuB polypeptide comprising a HNH endonuclease. In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a PtuA polypeptide comprising an AAA domain ("ATPases Associated with diverse cellular Activities" domain) and a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins). In some embodiments, a Septu defense system having an anti- phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a PtuA polypeptide comprising an AAA domain ("ATPases Associated with diverse cellular Activities" domain) and a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins) and an N-terminal HNH nuclease domain, and a PtuB polypeptide comprising a HNH endonuclease. In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a PtuA polypeptide comprising an AAA domain ("ATPases Associated with diverse cellular Activities" domain) and a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins), and a PtuB polypeptide comprising a HNH endonuclease.

[00686] In some embodiments, the Septu anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising ptuA and ptuB genes. [00687] In some embodiments, a Septu (Defense System VII) gene cassette comprises the nucleic acid sequence:

1 gggaatgcaa aaaggaggcg ggacttgagt gcgagttctg cctctttttt gctgaattta 61 gaaatctttt aagttttatc taaaaaagca ttcactttat tgttatttat gtagtaagag 121 taaaatttta ttaaaaattc taaagctgta ttggtttata agctagtgct atatctacta 181 tttgttctgg agtaagatct tcatcattaa aagaaaggca ttattatttt tggtgaatgt 241 tatttagtat aaaccatagg ggaatggaat attttatgat aaaattgagt ggagtaaata 301 attgtaaaga taaataaacg gatagcatgt aaaaaaaggg ttgaccttga gccttattaa 361 gacgggtgtt gtagtaataa atgaattaag agaaaaacat ttgtaattag tcaacaaaaa 421 gggagttgct tgaatgttag ttataaaaga attaaaaatt gatgggattg gcggtattaa 481 tagccttaaa cttaatttta acgaggggtt aaatttgatt tgcggtccaa atggtgtagg 541 gaaaaccaca attcttgaaa gtattggcca tatgtttagt aatggtagtc gtagtaaggt 601 taagagaaat gttaaatttg atcaggggag ttgtgaaatt agctattcaa cattcctaga 661 tactatacat acacagtcat gtattttaag gaattatgaa gaaaatgatt cgctggattg 721 gcatggtgga aatgcaaatt tggctaaaga ggtcattgtc ttcaaagctc aaagatcatt 781 cacttatacg caattagatt ctcttcgtaa agatacggaa acaagtgatg gtaaatttct 841 ggatgattct atgaatggaa ttcaattttt cgactttaag aattggttta tccatcgttt 901 tttatttagt catgtagata atgaattaac aacagtacaa aaagagaatt ttaaacttgc 961 gacagattgt tttggtattt tagataatag cattcgtttt agtagtgtta aaagtgatac 1021 attcgatata attataagta cctcaaatgg tgaaatctat tttgagtatc tatcatcagg 1081 attcaaatca tgtatctata ttattcatgg gttaattaaa gaaatagagt atcgttttaa 1141 aaacgatggt ggtattaaag ttcaagatta tgaagggcta atactaatcg atgagttgga 1201 ccttcattta catccacagt ggcaagcgaa aatgatttat ttaataaagc atatattacc 1261 taaagctcaa attattgcaa caacacatag tcctcatatg gtacaagctg cagcaattaa 1321 tgaacttata gctttaggaa tcgatgaaga tgcggatgta tatgtaagac aactacctaa 1381 tgttcaatat ggatttcagg gatggactgt tgaggaaata ttggaagacg ttatggggtt 1441 agatgaaaca cggtctccaa tgtacataga ggctataact gaatttgaaa aatctctaga 1501 tgaagaaaat gaggagaaga tatttgaagc ttattataag ttagatttaa tgctacaccc 1561 aagtaatcca cttcgcaagt tgttaaagtt acaagtagct caattcggga gggttataga 1621 gtgattcatt taaaacgccc taatagtcct agtaaactta taaatgaaga agcaaaacta 1681 actcaagaat ttcttcaaaa tggtaatagt gtttggggaa agccttatat taagcttgct 1741 cttctagaga tgtcaaataa caaatgtgta tactgtgaat gtagactaga tgaagagagt 1801 aagtatatgg aggtagagca ctttctacca aaagatactt atcctaatct agttgtcaat 1861 tggagaaatt tattaccaag ttgtaaaaga tgtaatggaa aaaaagggac acatgattca 1921 aaaaaagaac ctattatcaa tcctactgtt gatactccaa gtaatcatat aaaaatgttt 1981 aactattgcc taaagggaaa agatttaaaa gggaaaacaa cagttgatgt attgcaccta 2041 aaccaacttg atagattagt atacccaaga atgttaattg gaacaaaaac tatagaaaca 2101 gtagaaaaac ttttagaaat ggcagagaac tttaatttga atattaatgc tactgggcgt 2161 atcaaaagtc gtattataca tggcactaca cagttgctca tagaagctca accgcattcc 2221 gaatattctg cgacagttgc ctcggtttta tttaacaatg aagattttgt taagttaaaa 2281 gagattatga ttaagtgcac aatctggaat acagaacatc aaaagttact gtctaatgca 2341 gaaagaaata ttttggtaga gccactttac aattgcctca ataataagaa ttaatgattc 2401 taacgtatac tctagctgaa agtatatagt tagtgtattc cttggggtag cttcaaccta 2461 tttgatatta gatgtagaat tagagttaca attgatgtga aagtaagtgt caatggttca 2521 caaattataa agtacacaac agtaaaggta agccatacta tgtaacagca aatgaggtct 2581 atgtatatgg gaagtaaaaa aagcggtctg ctcaaattat gagtagaccg cttttttact 2641 taagtatgct atttatcact tcataaatat aaaattacat atcaattact tttttacgac 2701 tttaccggca acacctgttt accgaattag ttgatgaaga ctcatcaatt aattcaatgc 2761 ttttatttgc aatatattgc ctcgcgttct tattaaaatc aatcagtgta gagaaaagaa 2821 gctggaagag ttagagggga tatatgatgt gtttgtgaag ggatatataa tagaggaaat 2881 ataaaaagtg ctaacaagtt tgcaaacgaa cttgctaaca cctatacaga atagacataa 2941 aatatcgctg atatgtcatc tttgaaatag ctttaatcag ttaaatcaca cttatacgaa 3001 atgcttatag taacagtctt aatatcaaga atataatcat ccagatattc ctttactttt

3061 cagacgaaaa cgagggatga tat (SEQ ID NO: 12; Table 4 construct 42).

[00688] The coding regions for each of the ptuA and ptuB gene sequences within this embodiment of a Septu cassette (SEQ ID NO: 12) are as follows: nucleotides 434-1624 encode an embodiment of a PtuA polypeptide, and nucleotides 1621-2394 encode an embodiment of a PtuB polypeptide.

[00689] In some embodiments, a Defense System VII comprising a PtuA polypeptide and a PtuB polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 12. In some embodiments, a Defense System VII comprising a PtuA polypeptide and a PtuB polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 12. In some embodiments, a Defense System VII comprising a PtuA polypeptide and a PtuB polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 12. In some embodiments, a Defense System VII comprising a PtuA polypeptide and a PtuB polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 12. In some embodiments, a Defense System VII comprising a PtuA polypeptide and a PtuB polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 12.

[00690] In some embodiments, a Septu (Defense System VII) gene cassette comprises the nucleic acid sequence:

1 ggctttttaa gtgtacattt ttattgaaga ttggatagaa ttcaacaaga tgaatttgat 61 gtttattaaa cataagatgg aaaggctatg tgttaaataa aaagatgaaa taattaccat 121 tagtgtataa aataataagt aactagtttg gtaatgattt taaggatatg aagtatatta 181 accgtgacat attatagttg aaattcagtt ttatatcatg tgaaaatatg cttttgagga 241 gggtaaagat atgattcgaa tacataaaga taaatatttt gattcaatat atgatgaatt 301 gttagaacaa gcaactcaag aaaagtatat ggatgagtat ttactagaaa agtttatgaa 361 aagatacttt aatggtaaat gttcatactg tgaaattcga atgaaagagt tacgactaac 421 aattgacttt tatagaccta taaatggatc gttaaacacg atggatggtg aatttcatcc 481 tgatcattat aaatggttaa aaaatgaaga tgataatata ctttcaattt gtgtagaatg 541 taagcgagcg aaaagtaatc gttttccagt agatggcgat gtcgcttcta ttaatgctga 601 taagaataaa ttagtgaaag aaagacgttt attgatacat ccttgtagag attatcctga 661 aaggcatttt gattacgatg aaagtggaat ggtttattat aaaagtaaaa aaggcgaggt 721 tactgtagat gttttaaatt tgaatcgcgg tatgttggta gaaatgcgtg cccaagtata 781 tagtgaattt aataatcttt gttatttatt ctcaatggag caaagtccct actatttaaa 841 gcaaattcta caagaagttc agttggattc aatatttatt ggtttaaaaa agtttatact 901 ttctgaatgg gtaatcttaa atgagaaaat tccatttctt caagaatttg agccattatt 961 aggtaagaga ttgcaggaag aagaagtgag agttttatca gttagaaata ataagattag 1021 tcaaattgat attgataata atatccttta tgttgataat gataagcgga gaaagcgtgt 1081 tcctgcaagg aaaattaatg attattacga tgtatccgac gagaacgctt tagaaaaata 1141 ttatggaaaa cagcgtttta ttgaaaaaat tgaaatttat aactttaaaa gtattagaaa 1201 tatgaaaatt gattttactc tcagtaaaag cagtaatgct ccttggctaa tgttattagg 1261 agaaaatggt gtgggcaaaa gctcaatttt acaagcaatt gcattaacac taatgggaaa 1321 cgaacaacgg caaaaaatta taaaaaagaa accttatgaa tatttaacaa aaggctttga 1381 tgaaggttct ataaagataa aattatcagg catgcaagag cctattagta tttatttaaa 1441 ttcgaattca tttgaattta caggtgaaaa tcatcaaagg cctagggttc taattttagg 1501 ttatggctca acgcgattac ttcctagaga agaaatgtta tcaaattata aggtgacttg 1561 ggcaagaata gaaaatctat ttaatccttt tattccatta gttaatgtaa gagagtatct

1621 cttatcttta aataatgaag attttaataa tgttaaaaaa gctattgagt ccttattttt

1681 agatgaagta ataattgatc gggatcagat atatgaagaa gtatattttg gatttgcgaa

1741 ttcttacagt aaactagaag atttaagtga tggctatcag acaattattg ctctggctac

1801 tgatattatg atggttatga agaatagatg gcgaaatttt gatgctgaag gaattgtttt

1861 aatagatgaa attgatgcac atcttcatcc aaggtggaat atagaaattg tttctcgatt

1921 aaaaaatgct tttccgaaaa ttcaatttat tgcaactacc cataacccgc tatcacttcg

1981 tggtttaata gatggagaag ttgcagtatt actagaaaat gaggaaagag aagcgtatat

2041 tactcaaaag ttaccttctc aaaaaggatt taatgtagaa ggattattaa cttctaaatt

2101 ttttggattg tatgacacca tgccagattt aaatgaatta tttgatcgat attatttact

2161 tttatctaat cctagtccta atgaaaggca aaaggaagaa ataaaaaatt tacaagataa

2221 attgtcaaaa tatgaaaaag taggtaccac attaagagaa caaaaattct atgaagcagt

2281 ggattactat tttgcacagt acagaaaaaa taatgtggaa ttaagtgatg aagagtttaa

2341 caatattata gaagatgcta ttaaatattt tgaaaggtaa gattttttat gataaaagtt

2401 caaagagaag cagaaccagc tgtattaaat ctaactgact cagattctat tggttttaaa

2461 gaattggaag cggcaaaaaa aactactttt acaaaagata cgaaatttcc gttcgaggca

2521 tataaggatg aaagtgtaaa aaatctttta aaaaaaatgt ttaatggtaa atgtggatat

2581 tgtgaaagta ttattaatgt gacttcgtat gaagaaattg aacattttag acctaaaaaa

2641 gctattaata tagaaggtat acaaggattg acttatcctg gttactattg gttggctatg

2701 agttggaata atttgttgat ttcttgtcaa aggtgcaata ggtcgcataa aaaaaattat

2761 tttccaatag aaaacgaaag taatcgtgca aaagctcccg gtgaagaaag tggagaggag

2821 gtattactat taaacccttg tgaagatgac ccgagtgaac atttggaatt taaggataca

2881 ggtattattg aatttaaaga gggatctaaa aagggagaaa aatctataaa agtttatgct

2941 cttcatagga gagaacttac tgaagaaaga gcgaaagttg ctaaggatat tgagctgaag

3001 aaagtacaaa tacttgacgg attaagtact ctaaaggtgc ttttacgcta tcaagaagat

3061 agtgatcttc aaaaagagat tgaaaaaact gtatcaaata taatatcatt atatgatttt

3121 atatttgaat atgaaaatga tcctaacagg ccttatcagg caatggtaac tcagattact

3181 tcggattttc tgagtgaacg taaagaatta atcaataaat tgaagacaac atccaatcgg

3241 aaaaattcct gtgaacaaag tcatatttca agttaagtta atttaggata agagctataa

3301 aaaagctctt atcctattta ttatgaagtt tagcgagata gtaaaagtaa cataattaat

3361 atttaaaaaa ttattttttc ttgagtaacg gtattaactc tgctacattt aatatttttt

3421 gtctttataa aatgccttat gtcaattata aaaaaatcat gatgctttct aatttagtcc

3481 tagcgtcttc tttaaattaa gatactataa atatgaggtc cctcaatgct gttgtttata

3541 aagtattttt gctaactgga ttactttgtt gttacgttca tctgacttag tgttccagct

3601 ccacctaact caattaatat ttctatgttt atcatcagtc tatcttttta aaattagtat

3661 atctaaattt ttgcaatgga agcaattggt tttatataat tgtagaagga tttaccaatg

3721 gacaatagcg ggaggattca aaaaa (SEQ ID NO: 13; construct 43 of Table 4).

[00691] The coding regions for each of the ptuA and ptuB gene sequences within this embodiment of a Septu cassette (SEQ ID NO: 13) are as follows: nucleotides 251-2380 encode an embodiment of a PtuA polypeptide, and nucleotides 2389-3276 encode an embodiment of a PtuB polypeptide.

[00692] In some embodiments, a Defense System VII comprising a PtuA polypeptide and a PtuB polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 13. In some embodiments, a Defense System VII comprising a PtuA polypeptide and a PtuB polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 13. In some embodiments, a Defense System VII comprising a PtuA polypeptide and a PtuB polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 13. In some embodiments, a Defense System VII comprising a PtuA polypeptide and a PtuB polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 13. In some embodiments, a Defense System VII comprising a PtuA polypeptide and a PtuB polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 13.

[00693] In some embodiments, a construct comprising the Septu defense system encodes one component of the defense system, whereby multiple constructs, for example but not limited to, two constructs may be used to assemble the functional defense system. In some embodiments, the components of a Septu defense system comprise genes ptuA and ptuB. In some embodiments, the components of a Septu defense system consist of genes ptuA and ptuB. In some embodiments, the components of a Septu defense system comprise nucleic acid sequences encoding a PtuA polypeptide and a PtuB polypeptide. In some embodiments, the components of a Septu defense system consist of nucleic acid sequences encoding a PtuA polypeptide and a PtuB polypeptide.

[00694] In some embodiments, a construct comprising the Septu defense system encodes one component of the defense system, whereby a second construct may be used to assemble the functional defense system. In some embodiments, a construct comprising the Septu defense system encodes one component of the defense system, whereby additional constructs may be used to assemble the functional defense system. For example, in some embodiments each of PtuA and PtuB may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional Septu defense system.

[00695] In some embodiments, the components making up a functional Septu anti-phage defense system comprise a PtuA polypeptide and a PtuB polypeptide, each encoded by a ptuA and a ptuB gene, respectively. In some embodiments, a ptuA gene encodes a polypeptide comprising an AAA domain ("ATPases Associated with diverse cellular Activities" domain). In some embodiments, a ptuA gene encodes a polypeptide comprising a RecF/RecN/SMC N- terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins). In some embodiments, a ptuA gene encodes a polypeptide comprising an N- terminal HNH nuclease domain. In some embodiments, a ptuA gene encodes a polypeptide comprising a AAA domain ("ATPases Associated with diverse cellular Activities" domain) or a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins) or an N-terminal HNH nuclease domain, or any combination thereof. In some embodiments, a ptuA gene encodes a polypeptide comprising a AAA domain ("ATPases Associated with diverse cellular Activities" domain) and a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins). In some embodiments, a ptuA gene encodes a polypeptide comprising a AAA domain ("ATPases Associated with diverse cellular Activities" domain) and a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins) and an N-terminal HNH nuclease domain.

[00696] In some embodiments, a ptuB gene encodes a polypeptide comprising a HNH endonuclease.

[00697] In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid encoding a PtuA polypeptide. In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid encoding a PtuA polypeptide and a PtuB polypeptide. In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid encoding a PtuB polypeptide.

[00698] In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid comprising a ptuA gene. In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid comprising a ptuA gene and a ptuB gene. In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid comprising ptuB gene.

[00699] In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3' order of polypeptides encoded is PtuA and PtuB. In some embodiments the 5' to 3' order of polypeptides does not affect the anti-phage activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti-phage activity.

[00700] In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of nucleic acid sequences encoding PtuA and PtuB.

[00701] In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid construct comprising genes in a set order. In some embodiment, the 5' to 3' order of genes is ptuA and ptuB. In some embodiment, the 5' to 3' order of genes in a Septu defense system is not ptuA and ptuB. In some embodiments the 5' to 3' order of genes does not affect the anti-phage activity. In some embodiments the 5' to 3' order of genes does affect the anti-phage activity.

[00702] In some embodiments, the 5' to 3' order of genes is random, for example any order of ptuA and ptuB.

[00703] In some embodiments, the Septu system (Defense System VII) composition and order is as shown in Figure 3B.

[00704] In some embodiments, a Septu defense system having an anti-phage activity originates from a microbial genome, for example a bacterial or an archaeal genome (Table 15). A skilled artisan would appreciate that the Septu system is not present in the majority of bacteria and or archaea species.

[00705] In some embodiments, a functional Septu defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different microbial species. For example, the source of the nucleic acid sequence encoding a PtuA polypeptide may be one microbial species, while the source of the nucleic acid sequence encoding a PtuB polypeptide may be a different microbial species.In some embodiments, a functional Septu defense system comprises a non- naturally occurring combination of polypeptide components. In some embodiments, a functional Septu defense system comprises a combination of at least two polypeptides that do not naturally occur together.

[00706] In some embodiments, a functional Septu defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different bacterial species. For example, the source of the nucleic acid sequence encoding PtuA polypeptide may be one bacterial species, while the source of the nucleic acid sequence encoding a PtuB polypeptide may be a different bacterial species.

[00707] In some embodiments, the source of the nucleic acid encoding a PtuA polypeptide and a PtuB polypeptide is the same. In some embodiments, the source of the nucleic acid encoding a PtuA polypeptide and a PtuB polypeptide is the not the same. In some embodiments, the source of the nucleic acid sequence of any of the components of a Septu defense system comprises any of the species listed in Table 15.

[00708] In some embodiments, a Septu defense system having an anti-phage activity comprises a nucleic acid construct comprising non-coding regions between the nucleic acid sequences encoding the polypeptides. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence not naturally occurring in the microbial species of origin. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence is the naturally occurring in the microbial species of origin.

[00709] In some embodiments, a Septu system disclosed herein comprises a multi-gene phage resistance system broadly distributed in microbial genomes, for example but not limited to bacteria and archaea. According to some embodiments, the Septu system components are located in a gene cluster (a cassette of genes) in a microbial cell genome. According to some embodiments, the Septu system components are located in close proximity (e.g. positioned within 20 genes, 10 genes, 5 genes or less one from the other) in a genome of a prokaryotic cell. According to some embodiments the prokaryotic cell expresses an endogenous Septu defense system. According to some embodiments, the prokaryotic cell expresses an endogenous functional Septu defense system. According to some embodiments, the species of prokaryotic cell is selected from the group consisting of the species listed in Table 15. According to some embodiments a prokaryotic cell expresses a non-endogenous Septu defense system. According to some embodiments, a prokaryotic cell expresses a non-endogenous functional Septu defense system. According to some embodiments, the species of prokaryotic cell expressing a non- endogenous functional Septu defense system is selected from the group consisting of the species listed in Table 15.

[00710] In some embodiments, Septu defense system components comprise PtuA and PtuB polypeptides. In some embodiments, Septu defense system components comprise functional portions of PtuA and PtuB polypeptides. In some embodiments, the Septu defense system functional components are encoded by ptuA and ptuB genes.

[00711] Non-limiting embodiments of endogenous Septu systems and the respective location of their components are provided in Table 15 herein.

[00712] In some embodiments, the components of a Septu system may be identified by the presence of similar domains present within each component. In some embodiments, domains comprise pfam domains and or clusters of orthologous groups (COG) domains.

[00713] In some embodiments, the term "PtuA" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the ptuA gene. In some embodiments, the term "PtuA" refers to a PtuA polypeptide. In some embodiments, the ptuA gene encodes a polypeptide comprising a pfaml3304 domain. In some embodiments, the ptuA gene encodes a polypeptide comprising a pfam02463 domain. In some embodiments, the ptuA gene encodes a polypeptide comprising a pfaml3304 domain and a pfam02463 domain. In some embodiments, the PtuA polypeptide comprises a pfaml3304 domain. In some embodiments, the PtuA polypeptide comprises a pfam02463 domain. In some embodiments, the PtuA polypeptide comprises a pfaml3304 domain and a pfam02463 domain.

[00714] In some embodiments, PtuA polypeptide is encoded by a gene positioned within 5-60 genes of a gene encoding a PtuB polypeptide in a genome of a prokaryotic cell. In some embodiments, PtuA polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a PtuB polypeptide in a genome of a prokaryotic cell. In some embodiments, PtuA polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a PtuB polypeptide in a genome of a prokaryotic cell.

[00715] In some embodiments, PtuA and PtuB are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, PtuA and PtuB are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00716] In some embodiments, ptuA and ptuB genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, ptuA and ptuB, genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00717] As used herein, the term "PtuA" refers to the polynucleotide or expression product e.g., polypeptide encoded by the ptuA gene. In some embodiments, the term "PtuA" refers to a PtuA polypeptide. In some embodiments, the product of the ptuA gene comprises a pfaml3304 domain. In some embodiments, the ptuA gene encodes a pfam02463 domain. In some embodiments, the product of the ptuA gene comprises a pfaml3304 domain or a pfam02463 domain, or any combination thereof. In some embodiments, the product of the ptuA gene comprises a pfaml3304 domain and a pfam02463 domain. In some embodiments, the ptuA gene encodes a AAA domain. In some embodiments, the ptuA gene encodes a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins). In some embodiments, the ptuA gene encodes an N-terminal HNH nuclease domain. In some embodiments, the ptuA gene encodes a AAA domain, or a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins), or an N-terminal HNH nuclease domain, or any combination thereof. In some embodiments, the ptuA gene encodes a AAA domain and a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins) and an N-terminal HNH nuclease domain. In some embodiments, the ptuA gene encodes a AAA domain and a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins). In some embodiments, the ptuA gene encodes a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins) and an N-terminal HNH nuclease domain.

[00718] In some embodiments, PtuA polypeptide is encoded by a gene positioned within 5-60 genes of a gene encoding a PtuB polypeptide in a genome of a prokaryotic cell. In some embodiments, PtuA polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a PtuB polypeptide in a genome of a prokaryotic cell. In some embodiments, PtuA polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a PtuB polypeptide in a genome of a prokaryotic cell.

[00719] In some embodiments, a PtuA polypeptide is about 452 amino acids long (median gene size).

[00720] In some embodiments, the PtuA polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns H and I. In some embodiments, the PtuA polypeptide comprises the amino acid sequence having at least 80% homology to similar domain regions in a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns H and I. In some embodiments, a PtuA polypeptide homologue comprises an AAA domain ("ATPases Associated with diverse cellular Activities" domain). In some embodiments, a PtuA polypeptide homologue comprises a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins). In some embodiments, a PtuA polypeptide homologue comprises an N-terminal HNH nuclease domain. In some embodiments, a PtuA polypeptide homologue comprises an AAA domain ("ATPases Associated with diverse cellular Activities" domain) and a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins). In some embodiments, a PtuA polypeptide homologue comprises an AAA domain ("ATPases Associated with diverse cellular Activities" domain) and a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins) and an HNH nuclease domain. In some embodiments, the PtuA polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 15, rows 2- 2507, columns H and I.

[00721] In some embodiments, the PtuA polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns H and I. In some embodiments, the PtuA polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2- 2507, columns H and I. In some embodiments, the PtuA polypeptide comprises the amino acid sequence having at least 80% homology to similar domain regions in a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns H and I. In some embodiments, the PtuA polypeptide comprises the amino acid sequence having at least 80% identity to similar domain regions in a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns H and I.

[00722] In some embodiments, the PtuA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns H and I. In some embodiments, the PtuA polypeptide comprises the amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95%, homology to similar domain regions in a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns H and I. In some embodiments, the PtuA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2- 2507, columns H and I. In some embodiments, the PtuA polypeptide comprises the amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95% identity to similar domain regions in a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns H and I. In some embodiments, the PtuA polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns H and I. [00723] In some embodiments, the PtuA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns H and J. In some embodiments, the PtuA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95%, homology to similar domain regions in a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns H and J. In some embodiments, the PtuA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns H and J. In some embodiments, the PtuA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95%, homology to similar domain regions in a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns H and J. In some embodiments, the PtuA polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns H and J.

[00724] In some embodiments, the nucleic acid sequence of a ptuA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns H and J. In some embodiments, the nucleic acid sequence of a ptuA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology within regions encoding similar domain sequences to a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns H and J.

[00725] In some embodiments, the nucleic acid sequence of a ptuA gene encodes a polypeptide comprising an AAA domain ("ATPases Associated with diverse cellular Activities" domain). In some embodiments, the nucleic acid sequence of a ptuA gene encodes a polypeptide comprising a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins). In some embodiments, the nucleic acid sequence of a ptuA gene encodes a polypeptide comprising an HNH nuclease domain. In some embodiments, the nucleic acid sequence of a ptuA gene encodes a polypeptide comprising an AAA domain ("ATPases Associated with diverse cellular Activities" domain) and a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins). In some embodiments, the nucleic acid sequence of a ptuA gene encodes a polypeptide comprising an AAA domain ("ATPases Associated with diverse cellular Activities" domain) and a RecF/RecN/SMC N-terminal domain (a domain found at the N terminus of structural maintenance of chromosomes (SMC) proteins) and an HNH nuclease domain. In some embodiments, the nucleic acid sequence of a ptuA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns H and J. In some embodiments, the nucleic acid sequence of a ptuA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity within regions encoding similar domain sequences to a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns H and J. In some embodiments, the nucleic acid sequence of a ptuA gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns H and J.

[00726] As used herein, the term "PtuB" refers to the polynucleotide or expression product e.g., polypeptide encoded by the ptuB gene. In some embodiments, the term "PtuB" refers to a PtuB polypeptide. In some embodiments, the product of the ptuB gene comprises a pfaml3395 domain. In some embodiments, the ptuB gene encodes a pfam01844 domain. In some embodiments, the product of the ptuB gene comprises a pfaml3395domain or a pfam01844 domain, or any combination thereof. In some embodiments, the product of the ptuB gene comprises a pfaml3395 domain and a pfam01844 domain. In some embodiments, the ptuB gene encodes a HNH endonuclease.

[00727] In some embodiments, PtuB polypeptide is encoded by a gene positioned within 5-60 genes of a gene encoding a PtuA polypeptide in a genome of a prokaryotic cell. In some embodiments, PtuB polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a PtuA polypeptide in a genome of a prokaryotic cell. In some embodiments, PtuB polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a PtuA polypeptide in a genome of a prokaryotic cell.

[00728] In some embodiments, a PtuB polypeptide is about 219 amino acids long (median gene size).

[00729] In some embodiments, the PtuB polypeptide comprises an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns L and M. In some embodiments, the PtuB polypeptide comprises the amino acid sequence having at least 80% homology to similar domain regions in a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns L and M. In some embodiments, a homologue of the PtuB polypeptide comprises an HNH endonuclease. In some embodiments, the PtuB polypeptide comprises an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columnsL and M. In some embodiments, the PtuB polypeptide comprises the amino acid sequence having at least 80% identity to similar domain regions in a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns L and M.

[00730] In some embodiments, the PtuB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns L and M. In some embodiments, the PtuB polypeptide comprises the amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95%, homology to similar domain regions in a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns L and M. In some embodiments, the PtuB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2- 2507, columns L and M. In some embodiments, the PtuB polypeptide comprises the amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95%, identity to similar domain regions in a sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns L and M. In some embodiments, the PtuB polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 15, rows 2-2507, columns L and M.

[00731] In some embodiments, the PtuB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns L and N. In some embodiments, the PtuB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95%, homology to similar domain regions in a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns L and N. In some embodiments, the PtuB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns L and N. In some embodiments, the PtuB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95%, identity to similar domain regions in a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns L and N. In some embodiments, the PtuB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns L and N.

[00732] In some embodiments, the nucleic acid sequence of a ptuB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns L and N. In some embodiments, the nucleic acid sequence of a ptuB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns L and N. In some embodiments, the nucleic acid sequence of a ptuB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology within the nucleotide sequence encoding similar domain regions to regions with a sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns L and N. In some embodiments, the nucleic acid sequence of a ptuB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence encoding similar domain regions selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns L and N. In some embodiments, the ptuB gene homolog encodes a polypeptide comprising a HNH endonuclease. In some embodiments, the nucleic acid sequence of a ptuB gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 15, rows 2-2507, columns L and N.

[00733] A skilled artisan would appreciate that the terms a "functional portion of a Defense System VII component" or "functional fragment of Defense System VII component" or "functional portion of a Septu defense system component" or "functional fragment of Septu defense system component" refers to a functional portion of a Septu polynucleotide or polypeptide, as disclosed herein, which expression is sufficient to elicit an anti-phage activity alone or in combination with the at least one of the other Septu polynucleotides or polypeptides disclosed herein or functional portions thereof.

[00734] The terms "PtuA", "PtuB", "ptuA" and ^u ptuB also refer to functional PtuA, PtuB, ptuA and ptuB, homologs, which exhibit the desired activity (i.e., conferring phage resistance). Such homologs can be, for example, at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polypeptide sequences referenced in Table 15 rows 2-2507 columns H and I and L and M, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polynucleotide sequences referenced in Table 15 rows 2-2507 columns H and J and L and N, respectively. In some embodiments, such homologs comprise at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homology or identity within similar domain regions of the polypeptide sequences referenced in Table 15 rows 2-2507 columns H and I and L and M, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identity or homology within nucleotide sequences encoding similar domain regions to the polynucleotide sequences referenced in Table 15 rows 2-2507 columns H and J and L and N, respectively.

[00735] Table 15 presents embodiments of components of Defense System VII that may be found in a diverse array of bacteria and archaea genomes (referenced in Table 18). Table 15 presents embodiments of nucleic acid sequences encoding gene cassettes of Defense System VII (referenced in Table 18). [00736] The Lamassu Defense System

[00737] In some embodiments, a defense system disclosed herein comprises a Lamassu anti- phage defense system. (Table 16)

[00738] In some embodiments, a Lamassu defense system provides a host cell with resistance to entry of foreign nucleic acid invasion. In some embodiments, a host cell expressing a functional Lamassu defense system (Defense System VIII) provides the host cell resistance foreign nucleic acid invasion.

[00739] In some embodiments, a Lamassu defense system provides a host cell with resistance to at least one phage.

[00740] In some embodiments, a microbial cell comprising a Lamassu defense system protects the microbial cell from phage infection. In some embodiments, a microbial cell expressing a Lamassu defense system protects the microbial cell from phage infection. In some embodiments, a microbial cell expressing a functional Lamassu defense system protects the microbial cell from phage infection. In some embodiments, a bacterial cell comprising a Lamassu defense system protects the bacterial cell from phage infection. In some embodiments, a bacterial cell expressing a Lamassu defense system protects the bacterial cell from phage infection. In some embodiments, a bacterial cell expressing a functional Lamassu defense system protects the bacterial cell from phage infection.

[00741] In some embodiments, a Lamassu defense system provides a host cell with resistance to a plasmid.

[00742] As used herein, the term "a Lamassu anti-phage defense system" may be used interchangeably with the term "a Defense System VHI", having all the same meanings and qualities. A skilled artisan would appreciate that the term "Lamassu system" may be used interchangeably in some embodiments with "Lamassu defense system", "Lamassu the defense system", "Lamassu anti-phage system", and "Defense System VIIF', having all the same meanings and qualities.

[00743] In some embodiments, a Lamassu defense system (Defense System VIII) provides a host cell with resistance to plasmid transformation. In some embodiments, a host cell expressing a functional Lamassu defense system (Defense System Vffl) provides a host cells with resistance to plasmid transformation.

[00744] In some embodiments, a Lamassu defense system (Defense system VIII) provides a host cell with resistance to entry of conjugative elements. In some embodiments, a host cell expressing a function Lamassu defense system (Defense System VIII) provides the host cell resistance from entry of conjugative elements.

[00745] In some embodiments, a microbial species does not comprise an endogenous Defense System VIII. In some embodiments, a microbial species does not express an endogenous Defense System VIII. In some embodiments, a microbial species does not express an endogenous functional Defense System VIII.

[00746] In some embodiments, a bacterial species does not comprise an endogenous Defense System VIII. In some embodiments, a bacterial species does not express an endogenous Defense System VIII. In some embodiments, a bacterial species does not express an endogenous functional Defense System VIII.

[00747] A Lamassu defense system comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence encoding a LmuA polypeptide comprising a pfaml4130 domain or a DUF4297 domain or a combination thereof, and a LmuB polypeptide comprising a pfam02463 domain. In some embodiments, a Lamassu defense system comprises a nucleic acid construct comprising a nucleic acid sequence comprising a ImuA gene and a ImuB gene.

[00748] In some embodiments, a Lamassu defense system comprises, a LmuA polypeptide comprising a pfaml4130 domain or a DUF4297 domain or a combination thereof, and a LmuB polypeptide comprising a pfam02463 domain. In some embodiments, a Lamassu defense system comprises a LmuA polypeptide and a LmuB polypeptide.

[00749] In some embodiments, a Defense System VIII comprises a LmuA polypeptide comprising a pfaml4130 domain or a DUF4297 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 16 rows 2-698 columns H and I; or a LmuB polypeptide comprising a pfam02463 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 16 rows 2-698 columns L and M; or a combination thereof.

[00750] In some embodiments, a Defense System VIII comprises at least two different polypeptide components selected from a LmuA polypeptide comprising a pfaml4130 domain or a DUF4297 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 16 rows 2-698 column H and I; and a LmuB polypeptide comprising a pfam02463 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 16 rows 2-698 columns L and M.

[00751] In some embodiments, a Lamassu defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a LmuA polypeptide and a LmuB polypeptide. In some embodiments, a Lamassu defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a LmuA polypeptide and a LmuB polypeptide comprising a RecF/RecN/SMC N- terminal domain.

[00752] In some embodiments, a Lamassu defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a LmuB polypeptide comprising a RecF/RecN/SMC N-terminal domain.

[00753] In some embodiments, the Lamassu anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising ImuA and ImuB genes.

[00754] In some embodiments, a Lamassu (Defense System VIII) gene cassette comprises the nucleic acid sequence:

1 tgcatattta taattgtgtg ttgaggcgag tgttaatcta ttgcaaatag ttttgcaatt 61 ctccactagt caattatatc tcttgatatc catcttgata aaaaactttt aaagacactt 121 tctcatttgg gaggtgtctt tatttattgg tatcatagtt tttttatggg agctaataaa 181 agtaacataa gatccgctca tgcattctgt gtctgataat gaaaaaaatt aggtatttat 241 atttgatagt tcaaaatcta tattattgaa aacataataa aattttcctg ataaatagta 301 ccattttttt gaaaatcctg atatcatata aataagagag aggatatcag gaggagcgca 361 atgattgaaa ttgacaacgg gggagccatc gcactaaaag gatttaacta tcaaaaagct 421 tccatcatac ttgtaatgat tcataatttt gaaaaagata attttatagt catacctgaa 481 tcgcaagaag attttgaaat tcatcttgga caagatactt attttataca agtgaaagga 541 acaaaaaaac tttccatagg taagttgaag tcaaggccta gcggaaaagc ttcaatcata 601 gagaaaaatc tttctcctgg taatgttgga gatataagga aaatatttct ctgggatata 661 gcggagttaa caaaaaacga attgataagc caagaaggaa cgcttattcc tatgaaacac 721 agcctttcat tgaaacaaaa gacagagatt ataaatactc ttgatttaga tgaagaacag 781 aaaaatagaa tgaacaatca atatatatat ataacccctt ttccaaacga tataaatttg 841 gctttaacat ttttaaaagg agaaatggtt aatgaaaact tgctggtttc taacgatcga 901 gctaaattag ttttaggaga actatcattg gaaatagatc gtaaaagtga aatagtagtt 961 tctactgaaa gtgatgtaga aaggaaaaaa atcgacggga attatcttaa gcaggtattc 1021 attaatatta agcaaaaaga gatgtttgat gaaattttag ataatctctc tatcaacaca 1081 attatgaaaa aaaaagtaaa gaaggagaaa ttaagaatac cactcttgta tcaaaatatt 1141 aaagagcaaa cgaagcaaaa ggcagatatt aatttactta tgagggagaa tgatgagggt 1201 gctattaact atctcagaga tctattggta gagatagtgc cagatatgaa gcctacagaa 1261 ctatctattg ctttagcaat agactgtttt tgtgagttgg gagaataaaa tctatgataa 1321 taattgcttt ttctattctt gattttaaaa ataaagaagc acaaaatttt gactttaaag 1381 ctgggactaa tctaattgtt agtaaaggaa ataccaaagg taaatcaagt cttttaaaat 1441 caatgtatta tacattagga tttgatgtgc atcaatttcc tagtaactgg aacataaatt 1501 ttatgtattt ccaaatagaa gtcttaataa ataatgttaa atataatata actagacaaa 1561 aaaatatttt tagagtaagt gatgtagaag tacctttgaa tgtaaaagag tattcagagt 1621 ggcttcaaca taaacttgag attaaaatgc agttagctaa tactcatact aagcacttat 1681 acgaggcata ttcttcggca gtaattttac cattttacat agatcaagac gattcttggg 1741 atggcggaat ttatagaaat gtaactaata ctctgaatca atatactcgc ataccggcag 1801 atattttcaa aagtgttttt aatctctcca attacgaact tctggagttg caaaattcgc 1861 ttactaatta tagtaaagaa aagaatacgg tagtgtctac aataaagagt ttattaaatg 1921 ttttggaaga ttatagacat gaaaacgcag atgtccctac tgtttcaaaa attgataaaa 1981 tagccttaaa taaagatatc gatcgctact tgcagatgca aaatgaatta aatgaacaaa 2041 tagtaaaata taaaatgaag ctattaaaca agcaagaaat gttggattta caaaagcaag 2101 aattgtctga attagagcag cttttaaaaa tgaacaaaaa gagatataac tctattgaaa 2161 cagaatgtca atattgtcat tctaaattaa caaaagaaca atctttaaca agacttgatt 2221 tatcgaataa ttattttgaa atatcgcttt tgaaagagga aatagaaaaa gaagtagtaa 2281 aattgactaa tgaaattata atattcgaat cacaacaaaa ttctattgaa tctaaaattg 2341 atgaaattca tcgtaggatt caaaattcta aagatctact tacgattgat gattatgtaa 2401 aagcaactgc taaaaaagaa gcatcaaatg aattggaaag tttagttgat aaacaagttc 2461 tttctaaata taatttagaa gaaaaaatta aagtattaag aagggaaatt aataaactga 2521 agaaagagaa agaaagttta agagagatta ttgagcgaga ttacactgat ttggtatttg 2581 aaataaaaaa agtgttgaat gatttaaatg atacaaagct ggatttatct gaattaaatc 2641 tggatgaact taaatttctt gaatttaaga aaatatcggg gagtggtatg gataaaaata 2701 aaaaattttt agcttactat ttaatttatt ttagtttgtt gagaaagtat agctcttata 2761 taattccctt ttgtatggat tcgtttatta aaaatgaaat tacgggtgag actgcaaaaa 2821 agatgtttga agcaatagaa aaatattttt ttgacactaa tcagtctttc ttttcaatcg 2881 tttctgaaaa ccttaaacat ttagagtttg tagatagtta caataagatt aatgttgagg 2941 gtaagctgtt ggttagagat aaatatgatg agattgcttt gaaattcaaa tttgatagtt 3001 aaaattatta aagggccttg aatgacattt gatagttcaa actttcaaat gcctgaagag 3061 aaaaatgatt atccgaaaga aattaactca tatagaatta tgcacttaat attcttaatt 3121 ttttagtaga atactcaatc ctttgatttt ttttggaata taataacatt tttcatcaga 3181 aaacaacaag gggaaaagcc aatttcttta cagtaggagt tggctttatt gtgcagaaac 3241 taaattaaat attatatgtt ttttcgatct taaccatatg aaaggataaa taaacaaaga 3301 gttgattgac ttcgttcttc gcttcataga ttgaggagtt gattcaactt tccattct

(SEQ ID NO: 7; construct 13 of Table 4)

[00755] The coding regions for each of the ImuA and ImuB gene sequences within this embodiment of a Lamassu cassette (SEQ ID NO: 7) are as follows: nucleotides 361-1308 encode an embodiment of a LmuA polypeptide, and nucleotides 1314-3002 encode an embodiment of a LmuB polypeptide.

[00756] In some embodiments, a Defense System VIII comprising a LmuA polypeptide and a LmuB polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 7. In some embodiments, a Defense System VIII comprising a LmuA polypeptide and a LmuB polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 7. In some embodiments, a Defense System VIII comprising a LmuA polypeptide and a LmuB polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 7. In some embodiments, a Defense System VIII comprising a LmuA polypeptide and a LmuB polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 7. In some embodiments, a Defense System VIII comprising a LmuA polypeptide and a LmuB polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 7.

[00757] In some embodiments, a Lamassu (Defense System VIII) gene cassette comprises the nucleic acid sequence:

1 gaagatgcgg ttaacaaaat agaagagatt ttgttggtaa tgtgaccaat tttgtgatca 61 ctggttttgt atagtatagg aatagaaaaa taacaaccgt atcaaacgtt aatttgacac 121 ggtttctaca actatgccct cggagaggct cgaactcatg gccttcatcc tgtcaaagtg 181 taaatagaag tcgttagttt aacgtaagtc aaatcggaaa tcggcactat ttacggatac 241 cgttatatca acgtttgcag ctaaatagtt atacgtccgt cttgttttct attattaatt 301 aaagcgtgta gtaccgccat actgcaagat ataaaaccgt taattgtcat tttaggatcc 361 ttcacattca ttgattatta cgaagctgca ggaatggcta tgtaaacagt acatgtttgg 421 aaagaaatga agatgatagg agaaaatctt catgaaattt atcatcgagc gaattaaatg 481 gacgtatgta aaaggtgatg aacaacccac gatgaaaatt aaatacaagt aaacgagcca 541 cgctcgtcac tgggcgtggt tttaatgtgt gtaattggaa actgtatgta aaaaagaaat 601 taacaagttt gttagtactg gatgatttag gataaaaaat gaaatttata acaaattata 661 gcttaaaatt gatataatat gataagaagg atgttttgct attgtaattt aagaaacaag 721 aattttgaac agaaaaaatt cactatataa atgaaattgt aaaattgcct ttgggattta 781 aaggagggat ggctagtgga tataagttct tatcctagct tggaaactta tgaagcacgt 841 gagaatacag gttcaaggtc ttcaaacaga ttagctatgc aaattagttt tgctatgtgg 901 aagatttttg aattatatca aaatgaagat tttactgtgg ctatggattg tattgatgat 961 gtagtcatat ttaaaacatc aaatgaaaat ccaactattg tgacttatca attgaaaaca 1021 aaggatgcta ctacggggaa ctttgaactg agaaagctaa ttggtgataa tgtatttttg 1081 aaaatgtatg atcacattga aaaaatagat gcagatgttg aagaaatata tttaataact 1141 aacaatcctt tgaaatttag aaagaaaacg gttaatgcag aacggatttt atttgaaaaa 1201 ttagatgaag atataaaaga gttaattgaa gaaaatatgt ctcagagtaa agtttttgca 1261 gataaaggat tatcatctaa gtttatatat tctttggtag atatgtcttt tcataatcat 1321 agagaaatca gtcaatataa attaaattct ttattaatga aagaaaaaat agatattagt 1381 ataacagctg cagatgcact ttttaatgca ttgcaagata ttttaacaac taagcaaaat 1441 tatgagttta gtttacaaga tgaatttaat acggtactaa agaaaaaaag ttactcgaaa 1501 acggaattta catcactatt ggataactcg aaaaaaatta atgcctatgt tttatctttc 1561 gaggatattc gtaccaacta taaaagcaaa cctttaaagc tgaaagaaga aagtttatac 1621 aggagagcga tggctagtgt taaagaaaaa tgcaataaat ctcctaatat attacaaaat 1681 ataaatgaag atatttttca atatgctaaa gagcagattg atatcaatga cgaaataacg 1741 agaattgagc tagtcatact tttacaaagt gtttttgacg acaagataaa tgttgagtta 1801 tctaaagaag aaaaagaaat tctatatatg caaaatatcg aattagccct aagggaggga 1861 taaactcatg aataaaataa taattcgtaa gttatttata tttgatgtga ttgaaaaaaa 1921 agccaaaagt gtagattttg aagatggtat caatattgtt acaagtaaag gaaatcaact 1981 gggtaaatca actataatga aatctattta ttatacattg ggtgcagaag tgttttttgc 2041 cgacagatta aatgtaaaga gtaaaatcca tatgttagag acagacgtta atgataagaa 2101 atataccttt attagacatg gcgatgttgt tgtgataaaa gatggtaaag gaatttttaa 2161 gacgtcgaac gcttctgaat tatcatctaa gttgcatgat atatttggat ttagcgtttt 2221 tctagaagat aaacagaaaa aatatgtgat agctccacct gtatttcgtt acattcctta 2281 ttatattgac caagaccatg gttggacatc agaattgaaa tcttttgata aattaggtca 2341 attcgataaa aaaagcaggg atttattatt ttattatcat ttaaatattc ttgatgaaga 2401 ttatggagta aagttgaaag agaaaaaaga actagatgct tcaatgactg atttgaaaac 2461 taggaaaaaa gagattttag gcctactcgc atacataaga gagaatatta cagcttttaa 2521 tttagaaatg gatattacag cgttacaaat tcaaaagaga gaaatactta ataaatataa 2581 aaagtattca tatgatttga ataacatacg aagaaaaatt ttagaatatc aagaagaaat 2641 atttaaaatt gacaatgtaa ttgataattt aaatagtact ttgaaacaaa atgataaagt 2701 aagagaacat ataaaacatc aatttgatgt agagtgcccg tattgtaata atcattttga 2761 aatacaggcg aaagatatat taagaattaa ttataatatt gtagacttag aggcatcaaa 2821 attagaaatg ctagatataa aagaaaaatt attggggaaa atgaaaaaag tacaaaaaga 2881 gtatgaagat tatcaagcta cgttgaaagc tattgaagaa gaaaaagttg attcagaaaa 2941 tacacttgaa gacatactga aatttaaagg gttacaagaa actcaaaatc aactaaatac 3001 ggaacttgtc aaaaatactg gtgatataga agaaaagtca gaagacttaa aagaaataag 3061 acgagattta aaaaaatggc aggatgaaat agataaagtt aacagtaggt ataaggatat 3121 cttaaattta aatctaatta gatttaatac gaatgaacat gcactccctg aaaaatataa 3181 tattggaaaa aacctcaaag catctggtag cggtcaagtt cgagttaatt tagctagagt 3241 atattcattt ataaagcttc ttgaagaata taatcctaca ggattaaaat atccattagt 3301 aattgactct cctaaaggcg gagaacagag tactacaaat agtgaattga ttttaagatt 3361 gttgacggag aaagcgcaaa tttcaaatca aattatttta gctacaattg attttgaaag 3421 tttttataat ggagatacta aaaaattcaa cataatctct ttagaaaatg aaccttatca 3481 tttattatct gctgaagatt atcaaaataa tcaagtgata attgatgact ttgtttcttt 3541 atattttgaa gcaaatcaat aaatagaaat agtaaaagga cgctttaata cgaagcgtcc

3601 tatttaattt gaaggagccc tcaaacaggg aatcctt (SEQ ID NO: 8; construct 14 of Table 4).

[00758] The coding regions for each of the ImuA and ImuB gene sequences within this embodiment of a Lamassu cassette (SEQ ID NO: 8) are as follows: nucleotides 877-1863 encode an embodiment of a LmuA polypeptide, and nucleotides 1868-3562 encode an embodiment of a LmuB polypeptide.

[00759] In some embodiments, a Defense System VIII comprising a LmuA polypeptide and a LmuB polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 8. In some embodiments, a Defense System VIII comprising a LmuA polypeptide and a LmuB polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 8. In some embodiments, a Defense System VIII comprising a LmuA polypeptide and a LmuB polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 8. In some embodiments, a Defense System VIII comprising a LmuA polypeptide and a LmuB polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 8. In some embodiments, a Defense System VIII comprising a LmuA polypeptide and a LmuB polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 8.

[00760] In some embodiments, a construct comprising the Lamassu defense system encodes one component of the defense system, whereby multiple constructs, for example but not limited to, two constructs may be used to assemble the functional defense system. In some embodiments, the components of a Lamassu defense system comprise genes ImuA and ImuB. In some embodiments, the components of a Lamassu defense system consist of genes ImuA and ImuB. In some embodiments, the components of a Lamassu defense system comprise nucleic acid sequences encoding a LmuA polypeptide and a LmuB polypeptide. In some embodiments, the components of a Lamassu defense system consist of nucleic acid sequences encoding a LmuA polypeptide and a LmuB polypeptide.

[00761] In some embodiments, a construct comprising the Lamassu defense system encodes one component of the defense system, whereby a second construct may be used to assemble the functional defense system. In some embodiments, a construct comprising the Lamassu defense system encodes one component of the defense system, whereby additional constructs may be used to assemble the functional defense system. For example, in some embodiments each of LmuA and LmuB may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional Lamassu defense system.

[00762] In some embodiments, the components making up a functional Lamassu anti-phage defense system comprise a LmuA polypeptide and a LmuB polypeptide, each encoded by a ImuA and a ImuB gene, respectively.

[00763] In some embodiments, a ImuB gene encodes a polypeptide comprising a RecF/RecN/SMC N-terminal domain. In some embodiments, a LmuB polypeptide comprises a RecF/RecN/SMC N-terminal domain.

[00764] In some embodiments, a Lamassu defense system having an anti-phage activity comprises a nucleic acid encoding a LmuA polypeptide. In some embodiments, a Lamassu defense system having an anti-phage activity comprises a nucleic acid encoding a LmuA polypeptide and a LmuB polypeptide. In some embodiments, a Lamassu defense system having an anti-phage activity comprises a nucleic acid encoding a LmuB polypeptide.

[00765] In some embodiments, a Lamassu defense system having an anti-phage activity comprises a nucleic acid comprising a ImuA gene. In some embodiments, a Lamassu defense system having an anti-phage activity comprises a nucleic acid comprising a ImuA gene and a ImuB gene. In some embodiments, a Lamassu defense system having an anti-phage activity comprises a nucleic acid comprising ImuB gene.

[00766] In some embodiments, a Lamassu defense system having an anti-phage activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3' order of polypeptides encoded is LmuA and LmuB. In some embodiments the 5' to 3' order of polypeptides does not affect the anti-phage activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti-phage activity.

[00767] In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of nucleic acid sequences encoding LmuA and LmuB. [00768] In some embodiments, a Lamassu defense system having an anti-phage activity comprises a nucleic acid construct comprising genes in a set order. In some embodiment, the 5' to 3 ' order of genes is ImuA and ImuB. In some embodiment, the 5' to 3' order of genes in a Lamassu defense system is not ImuA and ImuB. In some embodiments the 5' to 3' order of genes does not affect the anti-phage activity. In some embodiments the 5' to 3' order of genes does affect the anti-phage activity.

[00769] In some embodiments, the 5' to 3 ' order of genes is random, for example any order of ImuA and ImuB.

[00770] In some embodiments, the Lamassu system (Defense System VIII) composition and order is as shown in Figure 3B.

[00771] In some embodiments, a Lamassu defense system having an anti-phage activity originates from a microbial genome, for example a bacterial or an archaeal genome (Table 16). A skilled artisan would appreciate that the Lamassu system is not present in the majority of bacteria and or archaea species.

[00772] In some embodiments, a functional Lamassu defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different microbial species. For example, the source of the nucleic acid sequence encoding a LmuA polypeptide may be one microbial species, while the source of the nucleic acid sequence encoding a LmuB polypeptide may be a different microbial species. In some embodiments, a functional Lamassu defense system comprises a non-naturally occurring combination of polypeptide components. In some embodiments, a functional Lamassu defense system comprises a combination of at least two polypeptides that do not naturally occur together.

[00773] In some embodiments, a functional Lamassu defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different bacterial species. For example, the source of the nucleic acid sequence encoding a LmuA polypeptide may be one bacterial species, while the source of the nucleic acid sequence encoding a LmuB polypeptide may be a different bacterial species.

[00774] In some embodiments, the source of the nucleic acid encoding a LmuA polypeptide and a LmuB polypeptide is the same. In some embodiments, the source of the nucleic acid encoding a LmuA polypeptide and a LmuB polypeptide is the not the same. In some embodiments, the source of the nucleic acid sequence of any of the components of a Lamassu defense system comprises any of the species listed in Table 16.

[00775] In some embodiments, a Lamassu defense system having an anti-phage activity comprises a nucleic acid construct comprising non-coding regions between the nucleic acid sequences encoding the polypeptides. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence not naturally occurring in the microbial species of origin. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence is the naturally occurring in the microbial species of origin.

[00776] In some embodiments, a Lamassu system disclosed herein comprises a multi-gene phage resistance system broadly distributed in microbial genomes, for example but not limited to bacteria and archaea. A skilled artisan would appreciate that the majority of bacteria and archaea do not comprise a Lamassu defense system.

[00777] According to some embodiments, the Lamassu defense system components are located in a gene cluster (a cassette of genes) in a microbial cell genome. According to some embodiments, the Lamassu system components are located in close proximity (e.g. positioned within 20 genes, 10 genes, 5 genes or less one from the other) in a genome of a prokaryotic cell. According to some embodiments the prokaryotic cell expresses an endogenous Lamassu defense system. According to some embodiments, the prokaryotic cell expresses an endogenous functional Lamassu defense system. According to some embodiments, the species of prokaryotic cell is selected from the group consisting of the species listed in Table 16.

[00778] According to some embodiments a prokaryotic cell expresses a non-endogenous Lamassu defense system. According to some embodiments, a prokaryotic cell expresses a non- endogenous functional Lamassu defense system. According to some embodiments, the species of prokaryotic cell expressing a non-endogenous functional Lamassu defense system is selected from the group consisting of the species listed in Table 16.

[00779] In some embodiments, Lamassu defense system components comprise LmuA and LmuB polypeptides. In some embodiments, Lamassu defense system components comprise functional portions of LmuA and LmuB polypeptides. In some embodiments, the Lamassu defense system functional components are encoded by ImuA and ImuB genes.

[00780] Non-limiting embodiments of endogenous Lamassu systems and the respective location of their components are provided in Table 16 herein. [00781] In some embodiments, the components of a Lamassu system may be identified by the presence of similar domains present within each component. In some embodiments, domains comprise pfam domains and or clusters of orthologous groups (COG) domains.

[00782] In some embodiments, the term "LmuA" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the ImuA gene. In some embodiments, the term "LmuA" refers to a LmuA polypeptide. In some embodiments, the ImuA gene encodes a polypeptide comprising a pfaml4130 domain. In some embodiments, the ImuA gene encodes a polypeptide comprising a DUF4297 domain. In some embodiments, the ImuA gene encodes a polypeptide comprising a pfaml4130 domain and a DUF4297 domain. In some embodiments, the LmuA polypeptide comprises a pfaml4130 domain. In some embodiments, the LmuA polypeptide comprises a DUF4297 domain. In some embodiments, the LmuA polypeptide comprises a pfaml4130 domain and a DUF4297domain.

[00783] In some embodiments, LmuA polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a LmuB polypeptide in a genome of a prokaryotic cell. In some embodiments, LmuA polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a LmuB polypeptide in a genome of a prokaryotic cell. In some embodiments, LmuA polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a LmuB polypeptide in a genome of a prokaryotic cell.

[00784] In some embodiments, LmuA and LmuB are encoded by genes positioned sequentially 5' to 3 ' in a genome of a prokaryotic cell. In some embodiments, LmuA and LmuB are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00785] In some embodiments, ImuA and ImuB genes are positioned sequentially 5' to 3 ' in a genome of a prokaryotic cell. In some embodiments, ImuA and ImuB, genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00786] As used herein, the term "LmuA" refers to the polynucleotide or expression product e.g., polypeptide encoded by the ImuA gene. In some embodiments, the term "LmuA" refers to a LmuA polypeptide. In some embodiments, the product of the ImuA gene comprises a pfaml4130 domain. In some embodiments, the ImuA gene encodes a DUF4297 domain. In some embodiments, the product of the ImuA gene comprises a pfaml4130 domain or a DUF4297 domain, or any combination thereof. In some embodiments, the product of the ImuA gene comprises a pfaml4130 domain and a DUF4297 domain. [00787] In some embodiments, LmuA polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a LmuB polypeptide in a genome of a prokaryotic cell. In some embodiments, LmuA polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a LmuB polypeptide in a genome of a prokaryotic cell. In some embodiments, LmuA polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a LmuB polypeptide in a genome of a prokaryotic cell.

[00788] In some embodiments, a LmuA polypeptide is about 361 amino acids long (median gene size).

[00789] In some embodiments, the LmuA polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns H and I. In some embodiments, the LmuA polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns H and I. In some embodiments, the LmuA polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 16, rows 2-698, columns H and I.

[00790] In some embodiments, the LmuA polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns H and I. In some embodiments, the LmuA polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns H and I.

[00791] In some embodiments, the LmuA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns H and I. In some embodiments, the LmuA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns H and I. In some embodiments, the LmuA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns H and I. In some embodiments, the LmuA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2- 698, columns H and I. In some embodiments, the LmuA polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2- 698, columns H and I.

[00792] In some embodiments, the LmuA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns H and J. In some embodiments, the LmuA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns H and J. In some embodiments, the LmuA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns H and J. In some embodiments, the LmuA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns H and J. In some embodiments, the LmuA polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns H and J.

[00793] In some embodiments, the nucleic acid sequence of a ImuA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns H and J. In some embodiments, the ImuA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns H and J. In some embodiments, the nucleic acid sequence of a ImuA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns H and J. In some embodiments, the ImuA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns H and J. In some embodiments, the nucleic acid sequence of a ImuA gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns H and J.

[00794] As used herein, the term "LmuB" refers to the polynucleotide or expression product e.g., polypeptide encoded by the ImuB gene. In some embodiments, the term "LmuB" refers to a LmuB polypeptide. In some embodiments, the product of the ImuB gene comprises a pfam02463 domain. In some embodiments, the ImuB gene encodes a RecF/RecN/SMC N- terminal domain.

[00795] In some embodiments, LmuB polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a LmuA polypeptide in a genome of a prokaryotic cell. In some embodiments, LmuB polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a LmuA polypeptide in a genome of a prokaryotic cell. In some embodiments, LmuB polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a LmuA polypeptide in a genome of a prokaryotic cell.

[00796] In some embodiments, a LmuB polypeptide is about 559 amino acids long (median gene size).

[00797] In some embodiments, the LmuB polypeptide comprises an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns L and M. In some embodiments, the LmuB polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns L and M. In some embodiments, a homologue of the LmuB polypeptide comprises a RecF/RecN/SMC N-terminal domain. In some embodiments, the LmuB polypeptide comprises an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns L and M. [00798] In some embodiments, the LmuB polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns L and M. In some embodiments, the LmuB polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns L and M.

[00799] In some embodiments, the LmuB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns L and M. In some embodiments, the LmuB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2- 698, columns L and M. In some embodiments, the LmuB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2-698, columns L and M. In some embodiments, the LmuB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2- 698, columns L and M. In some embodiments, the LmuB polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 16, rows 2- 698, columns L and M.

[00800] In some embodiments, the LmuB polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns L and N. In some embodiments, the LmuB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns L and N. In some embodiments, the LmuB polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns L and N. In some embodiments, the LmuB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns L and N. In some embodiments, the LmuB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns L and N.

[00801] In some embodiments, the nucleic acid sequence of a ImuB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns L and N. In some embodiments, the ImuB gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns L and N. In some embodiments, the nucleic acid sequence of a ImuB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns L and N. In some embodiments, the ImuB gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns L and N. In some embodiments, the ImuB gene homolog encodes a polypeptide comprising a RecF/RecN/SMC N-terminal domain. In some embodiments, the nucleic acid sequence of a ImuB gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 16, rows 2-698, columns L and N.

[00802] A skilled artisan would appreciate that the terms a "functional portion of a Defense System VIII component" or "functional fragment of Defense System VIII component" or "functional portion of a Lamassu defense system component" or "functional fragment of Lamassu defense system component" refers to a functional portion of a Lamassu polynucleotide or polypeptide, as disclosed herein, which expression is sufficient to elicit an anti-phage activity alone or in combination with the at least one of the other Lamassu polynucleotides or polypeptides disclosed herein or functional portions thereof.

[00803] The terms "LmuA", "LmuB", "ImuA" and "ImuB", also refer to functional LmuA, LmuB, ImuA and ImuB, homologs, which exhibit the desired activity {i.e., conferring phage resistance). Such homologs can be, for example, at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polypeptide sequences referenced in Table 16 rows 2-698 columns H and I and L and M, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polynucleotide sequences referenced in Table 16 rows 2-698 columns H and J and L and N, respectively, respectively. In some embodiments, such homologs comprise at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homology or identity within similar domain regions of the polypeptide sequences referenced in Table 16 rows 2-698 columns H and I and L and M, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identity or homology within nucleotide sequences encoding similar domain regions to the polynucleotide sequences referenced in Table 16 rows 2-698 columns H and J and L and N, respectively.

[00804] Table 16 presents embodiments of components of Defense System VIII that may be found in a diverse array of bacteria and archaea genomes (referenced in Table 18). Table 16 presents embodiments of nucleic acid sequences encoding gene cassettes of Defense System Vni (referenced in Table 18).

[00805] The Kiwa Defense System

[00806] In some embodiments, a defense system disclosed herein comprises a Kiwa anti- phage defense system. (Table 17)

[00807] In some embodiments, a Kiwa defense system provides a host cell with resistance to entry of foreign nucleic acid invasion. In some embodiments, a host cell expressing a functional Kiwa defense system (Defense System IX) provides the host cell resistance foreign nucleic acid invasion.

[00808] In some embodiments, a Kiwa defense system provides a host cell with resistance to at least one phage.

[00809] In some embodiments, a microbial cell comprising a Kiwa defense system protects the microbial cell from phage infection. In some embodiments, a microbial cell expressing a Kiwa defense system protects the microbial cell from phage infection. In some embodiments, a microbial cell expressing a functional Kiwa defense system protects the microbial cell from phage infection. In some embodiments, a bacterial cell comprising a Kiwa defense system protects the bacterial cell from phage infection. In some embodiments, a bacterial cell expressing a Kiwa defense system protects the bacterial cell from phage infection. In some embodiments, a bacterial cell expressing a functional Kiwa defense system protects the bacterial cell from phage infection.

[00810] In some embodiments, a Kiwa defense system provides a host cell with resistance to a plasmid.

[00811] As used herein, the term "a Kiwa anti-phage defense system" may be used interchangeably with the term "a Defense System IX", having all the same meanings and qualities. A skilled artisan would appreciate that the term "Kiwa system" may be used interchangeably in some embodiments with "Kiwa defense system", and "Kiwa the defense system", "Kiwa anti-phage system", having all the same meanings and qualities.

[00812] In some embodiments, a microbial species does not comprise an endogenous Defense System IX. In some embodiments, a microbial species does not express an endogenous Defense System IX. In some embodiments, a microbial species does not express an endogenous functional Defense System IX.

[00813] In some embodiments, a bacterial species does not comprise an endogenous Defense System IX. In some embodiments, a bacterial species does not express an endogenous Defense System IX. In some embodiments, a bacterial species does not express an endogenous functional Defense System IX.

[00814] A Kiwa defense system comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence encoding a KwaA polypeptide and a KwaB polypeptide comprising a pfaml6162 domain or a DUF4868 domain or a combination thereof. In some embodiments, a Kiwa defense system comprises, a nucleic acid construct comprising a nucleic acid sequence encoding a KwaA polypeptide and a KwaB polypeptide comprising a pfaml6162 domain or a DUF4868 domain or a combination thereof, wherein said KwaA polypeptide is encoded by a gene positioned within 5 genes of a gene encoding a KwaB polypeptide in the genome of a prokaryotic cell. In some embodiments, a Kiwa defense system comprises a nucleic acid construct comprising a nucleic acid sequence comprising a kwaA gene and a kwaB gene.

[00815] In some embodiments, a Kiwa defense system comprises, a KwaA polypeptide and a KwaB polypeptide comprising a pfaml6162 domain or a DUF4868 domain or a combination thereof. In some embodiments, a Kiwa defense system comprises, a KwaA polypeptide and a KwaB polypeptide comprising a pfaml6162 domain or a DUF4868 domain or a combination thereof, wherein said KwaA polypeptide is encoded by a gene positioned within 5 genes of a gene encoding a KwaB polypeptide in the genome of a prokaryotic cell. In some embodiments, a Kiwa defense system comprises KwaA polypeptide and a KwaB polypeptide.

[00816] A Kiwa defense system comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid sequence encoding a KwaA polypeptide and a KwaB polypeptide comprising a pfaml6162 domain or DUF4868 domain or a combination thereof. In some embodiments, a Kiwa defense system comprises a nucleic acid construct comprising a nucleic acid sequence encoding a KwaA polypeptide and a KwaB polypeptide.

[00817] In some embodiments, a Defense System IX comprises a KwaA polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 17 rows 2-935 columns H and I; or a KwaB polypeptide comprising a pfaml6162 domain or a DUF4868 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 17 rows 2-935 columns H and I; or a combination thereof.

[00818] In some embodiments, a Defense System IX comprises at least two different polypeptide components selected from a KwaA polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 17 rows 2-935 columns H and I; and a KwaB polypeptide comprising a pfaml6162 domain or a DUF4868 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 17 rows 2-935 columns H and I.

[00819] In some embodiments, a Kiwa defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a KwaA polypeptide and a KwaB polypeptide. In some embodiments, a Kiwa defense system having an anti-phage activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a kwaA gene and a kwaB gene.

[00820] In some embodiments, the Kiwa anti-phage defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising kwaA and kwaB genes.

[00821] In some embodiments, a Kiwa (Defense System IX) gene cassette comprises the nucleic acid sequence:

1 taatggtctt ccttccattg gtatctcgtg agtatacaag caatatcgaa tcggcaaata 61 tactcattag tatactcaca agcctgttga tgtgggttgg ttcaggttga cttcagttga 121 ggagaaaagc tggaaaagcc ttgcgtggcg cggatttcag gcataaaaaa agacctcagt 181 tgaggtctat ttacatactt ttggtgcgaa ggccggactc gaacatcgca actatcctta 241 tgatcttaat ggattaaaaa ttaccatatt ggtcatgata ccatcattga taccatcaga 301 cccgattgat gataatcgaa cagtaataaa atatgactaa acaatttatg cttcaacata 361 agattgaatg ctttgatcta ccattttaat gcagtggaaa aatttttaac acaatactta 421 agaaaaataa tttcatataa aaactacatt tcatttcata tagttaacac accaaaaaca 481 actgtatata aacccagtaa aaaatggtag aatcactatt gtgttcaatt gttgaacatt 541 tataatacat ttgtcggata ggggggtgtt tatgcaaagg aacacataca acaaagtagg 601 tctatacatc ctatctttag ctatgctttt tgtttttatt attatcctga ctgccaaaat 661 ccccttttgc ttcacttcgg attgtagctt cataggtttg aagaaacttg tattaacaaa 721 tattgttcct attgtttgct ttgtattttt tctatttagt atttattttt ataatagatt 781 aaaaaacata acaaaataca atggacaaga tagcgttaaa ataacatcat gtcaaagcga 841 aagctatgaa agtttaacat tcttagcaac atacattgta ccttttatgg ggtttagttt 901 tgaagacatg caaaagaata tagcatatct tttgcttgta gtagtaatag gcattatttt 961 tattaaaaca gacaagtatt atgcgaatcc aactttagct ctgtttggct ttaaactata 1021 cagggtaaat atactacacc caggaagtgg agaaacaaaa aatctgatag ctatttcaaa 1081 tgatgtatta aaagtggacg ataatgttta ttatagtttc tttgacgaat ttgtttttat 1141 agcaaggaaa aaaatatgac tactcagcag ttaaaagaaa aaatttcaaa aataattgat 1201 aactttagcg gaatcagggt tgtatttact actactgcta atgaactaaa gctttccaga 1261 attgaaggga gtgcattaaa tagcatagct gaagggttta ttgacaaaat caaagaagac 1321 attataaata atgaagatct cacctcaccc ttgctgtcca attttgatga tagaaaaaat 1381 gccttgttta aatttgatta cgaacaatat cctgaagaat ttaacaaaat cactcaggcc 1441 atcgctatcc ctcctaactc acaagattat tataaccctt taaataaatt cacagatgtg 1501 aaaggaatta taattttaat aagtggagat aacaaatgcc tggctcttta taaaaacaaa 1561 actaaccttg cagtattgag aaatagcaga aaaatgttta atttagtccc tgaccctgat 1621 ggatacttga aacaactccc taatgagata ttacggttag atttcaatta tgatctattt 1681 tcaattggtg aggattttta cattaaaaat cacaagactc ttgaaactca aatgaaattt 1741 catcaagtga ttgaagccca agcagttatt gctttaaatt ctttacggga ttcactacta 1801 attgaagaca tatcaggttt agaaaagagt tcgagagaaa tttcattcgc tagaaagttg 1861 gcaaaaatct ccaaacattc tcctgttttg gggaaaatag atactaaaac aattattgat 1921 tatgtatccc aacataaata tttatctgca atacttcaga ttaatgaagc gggagataag 1981 ttattaatta aaaccaagac atcacagaag catttcatta aactcatgag cgatgattat 2041 ttacaatcag atctaaccaa aataatatac atgagcatag caaaagacag attagatgaa 2101 tagaacttta agtagaagtg acaaatatta taaaccattc ttgaaatata tttgtcacta

2161 ttactaat (SEQ ID NO: 3; construct 2 in Table 4).

[00822] The coding regions for each of the kwaA and kwaB gene sequences within this embodiment of a Kiwa cassette (SEQ ID NO: 3) are as follows: nucleotides 572-1159 encode an embodiment of a KwaA polypeptide, and nucleotides 1156-2103 encode an embodiment of a KwaB polypeptide.

[00823] In some embodiments, a Defense System IX comprising a KwaA polypeptide and a KwaB polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 3. In some embodiments, a Defense System IX comprising a KwaA polypeptide and a KwaB polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 3. In some embodiments, a Defense System IX comprising a KwaA polypeptide and a KwaB polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 3. In some embodiments, a Defense System IX comprising a KwaA polypeptide and a KwaB polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 3. In some embodiments, a Defense System IX comprising a KwaA polypeptide and a KwaB polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 3.

[00824] In some embodiments, a construct comprising the Kiwa defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system. In some embodiments, the components of a Kiwa defense system comprise genes kwaA and kwaB. In some embodiments, the components of a Kiwa defense system consist of genes kwaA and kwaB. In some embodiments, the components of a Kiwa defense system comprise nucleic acid sequences encoding a KwaA polypeptide and a KwaB polypeptide. In some embodiments, the components of a Kiwa defense system consist of nucleic acid sequences encoding a KwaA polypeptide and a KwaB polypeptide.

[00825] In some embodiments, a construct comprising the Kiwa defense system encodes one component of the defense system, whereby a second construct may be used to assemble the functional defense system. In some embodiments, a construct comprising the Kiwa defense system encodes one component of the defense system, whereby additional constructs may be used to assemble the functional defense system. For example, in some embodiments each of KwaA and KwaB may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional Kiwa defense system.

[00826] In some embodiments, the components making up a functional Kiwa anti-phage defense system comprise a KwaA polypeptide and a KwaB polypeptide, each encoded by a kwaA and a kwaB gene, respectively.

[00827] In some embodiments, a Kiwa defense system having an anti-phage activity comprise a nucleic acid encoding a KwaA polypeptide. In some embodiments, a Kiwa defense system having an anti-phage activity comprise a nucleic acid encoding a KwaA polypeptide and a KwaB polypeptide.

[00828] In some embodiments, a Kiwa defense system having an anti-phage activity comprise a nucleic acid comprising a kwaA gene. In some embodiments, a Kiwa defense system having an anti-phage activity comprise a nucleic acid comprising a kwaA gene and a kwaB gene.

[00829] In some embodiments, a Kiwa defense system having an anti-phage activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3' order of polypeptides encoded is KwaA and KwaB. In some embodiments the 5' to 3' order of polypeptides does not affect the anti-phage activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti-phage activity.

[00830] In some embodiments, the 5' to 3' order of polypeptides is random, for example any order of KwaA and KwaB.

[00831] In some embodiments, a Kiwa defense system having an anti-phage activity comprises a nucleic acid construct comprising genes in a set order. In some embodiment, the 5' to 3' order of genes is kwaA and kwaB. In some embodiment, the 5' to 3' order of genes in a Kiwa defense system is not kwaA and kwaB. In some embodiments the 5' to 3' order of genes does not affect the anti-phage activity. In some embodiments the 5' to 3' order of genes does affect the anti-phage activity.

[00832] In some embodiments, the 5' to 3' order of genes is random, for example any order of kwaA and kwaB.

[00833] In some embodiments, the Kiwa system (Defense System IX) composition and order is as shown in Figure 3B.

[00834] In some embodiments, a Kiwa defense system having an anti-phage activity originates from a microbial genome, for example a bacterial or an archaeal genome (Table 17). A skilled artisan would appreciate that the Kiwa system is not present in the majority of bacteria and or archaea species.

[00835] In some embodiments, a functional Kiwa defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different microbial species. For example, the source of the nucleic acid sequence encoding a KwaA polypeptide may be one microbial species, while the source of the nucleic acid sequence encoding a KwaB polypeptide may be a different microbial species. In some embodiments, a functional Kiwa defense system comprises a non-naturally occurring combination of polypeptide components. In some embodiments, a functional Kiwa defense system comprises a combination of at least two polypeptides that do not naturally occur together.

[00836] In some embodiments, a functional Kiwa defense system comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different bacterial species. For example, the source of the nucleic acid sequence encoding a KwaA polypeptide may be one bacterial species, while the source of the nucleic acid sequence encoding a KwaB polypeptide may be a different bacterial species.

[00837] In some embodiments, the source of the nucleic acid encoding a KwaA polypeptide and a KwaB polypeptide is the same. In some embodiments, the source of the nucleic acid encoding a KwaA polypeptide and a KwaB polypeptide is the not the same. In some embodiments, the source of the nucleic acid sequence of any of the components of a Kiwa defense system comprises any of the species listed in Table 17.

[00838] In some embodiments, a Kiwa defense system having an anti-phage activity comprises a nucleic acid construct comprising non-coding regions between the nucleic acid sequences encoding the polypeptides. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence not naturally occurring in the microbial species of origin. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence is the naturally occurring in the microbial species of origin.

[00839] In some embodiments, a Kiwa system disclosed herein comprises a multi-gene phage resistance system broadly distributed in microbial genomes, for example but not limited to bacteria and archaea. According to some embodiments, the Kiwa system components are located in a gene cluster (a cassette of genes) in a microbial cell genome. According to some embodiments, the Kiwa system components are located in close proximity (e.g. positioned within 20 genes, 10 genes, 5 genes or less one from the other) in a genome of a prokaryotic cell. According to some embodiments the prokaryotic cell expresses an endogenous Kiwa defense system. According to some embodiments, the prokaryotic cell expresses an endogenous functional Kiwa defense system. According to some embodiments, the species of prokaryotic cell is selected from the group consisting of the species listed in Table 17. According to some embodiments a prokaryotic cell expresses a non-endogenous Kiwa defense system. According to some embodiments, a prokaryotic cell expresses a non-endogenous functional Kiwa defense system. According to some embodiments, the species of prokaryotic cell expressing a non- endogenous functional Kiwa defense system is selected from the group consisting of the species listed in Table 17.

[00840] In some embodiments, Kiwa defense system components comprise KwaA and KwaB polypeptides. In some embodiments, a Kiwa defense system components comprise functional portions of KwaA and KwaB polypeptides. In some embodiments, the Kiwa defense system components are encoded by kwaA and kwaB genes.

[00841] Non-limiting embodiments of endogenous Kiwa systems and the respective location of their components are provided in Table 17 herein.

[00842] In some embodiments, the components of a Kiwa system may be identified by the presence of similar domains present within each component. In some embodiments, domains comprise pfam domains and or clusters of orthologous groups (COG) domains.

[00843] In some embodiments, a Defense System IX comprises a membrane associated complex.

[00844] In some embodiments, the term "KwaA" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the kwaA gene. In some embodiments, the term "KwaA" refers to a KwaA polypeptide. In some embodiments, a KwaA polypeptide comprises transmembrane helices. In some embodiments, a kwaA gene encodes a polypeptide comprising transmembrane helices.

[00845] In some embodiments, KwaA polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a KwaB polypeptide in a genome of a prokaryotic cell. In some embodiments, KwaA polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a KwaB polypeptide in a genome of a prokaryotic cell. In some embodiments, KwaA polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a KwaB polypeptide in a genome of a prokaryotic cell. [00846] In some embodiments, KwaA and KwaB are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, KwaA and KwaB are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, nucleic acid encoding additional copies of KwaB is positions 3' of the nucleic acid sequence first encoding a KwaB polypeptide.

[00847] In some embodiments, kwaA and kwaB genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, kwaA and kwaB, genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00848] In some embodiments, a KwaA polypeptide is about 194 amino acids long (median gene size).

[00849] In some embodiments, the KwaA polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns H and I. In some embodiments, the KwaA polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions to a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns H and I. In some embodiments, a KwaA homolog comprises transmembrane helices. In some embodiments, the KwaA polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 17, rows 2-935, columns H and I.

[00850] In some embodiments, the KwaA polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns H and I. In some embodiments, the KwaA polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions to a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns H and I.

[00851] In some embodiments, the KwaA polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns H and I. In some embodiments, the KwaA polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns H and I.

[00852] In some embodiments, the KwaA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns H and I. In some embodiments, the KwaA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns H and I. In some embodiments, the KwaA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns H and I. In some embodiments, the KwaA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2- 935, columns H and I. In some embodiments, the KwaA polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2- 935, columns H and I.

[00853] In some embodiments, the KwaA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns H and J. In some embodiments, the KwaA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns H and J. In some embodiments, the KwaA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns H and J. In some embodiments, the KwaA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns H and J. In some embodiments, the KwaA polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns H and J.

[00854] In some embodiments, the nucleic acid sequence of a kwaA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns H and J. In some embodiments, the kwaA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns H and J. In some embodiments, the nucleic acid sequence of a kwaA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns H and J. In some embodiments, the kwaA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns H and J. In some embodiments, a kwaA gene homolog encodes a polypeptide comprising transmembrane helices. In some embodiments, the nucleic acid sequence of a kwaA gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns H and J.

[00855] As used herein, the term "KwaB " refers to the polynucleotide or expression product e.g., polypeptide encoded by the kwaB gene. In some embodiments, the term "KwaB" refers to a KwaB polypeptide. In some embodiments, the product of the kwaB gene comprises a pfaml6162 domain. In some embodiments, the product of the kwaB gene comprises a DUF4868 domain.

[00856] In some embodiments, KwaB polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding a KwaA polypeptide in a genome of a prokaryotic cell. In some embodiments, KwaB polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a KwaA polypeptide in a genome of a prokaryotic cell. In some embodiments, KwaB polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a KwaA polypeptide in a genome of a prokaryotic cell.

[00857] In some embodiments, KwaA and KwaB are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments KwaA and KwaB are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. [00858] In some embodiments, a KwaB polypeptide is about 315 amino acids long (median gene size).

[00859] In some embodiments, the KwaB polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns L and M. In some embodiments, the KwaB polypeptide comprises the amino acid sequence having at least 80% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns L and M. In some embodiments, the KwaB polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 17, rows 2-935, columns L and M.

[00860] In some embodiments, the KwaB polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns L and M. In some embodiments, the KwaB polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns L and M.

[00861] In some embodiments, the KwaB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns L and M. In some embodiments, the KwaB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2- 935, columns L and M. In some embodiments, the KwaB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2-935, columns L and M. In some embodiments, the KwaB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2- 935, columns L and M. In some embodiments, the KwaB polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 17, rows 2- 935, columns L and M.

[00862] In some embodiments, the KwaB polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns L and N. In some embodiments, the KwaB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns L and N. In some embodiments, the KwaB polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns L and N. In some embodiments, the KwaB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns L and N. In some embodiments, the KwaB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns L and N.

[00863] In some embodiments, the nucleic acid sequence of a kwaB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns L and N. In some embodiments, the kwaB gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns L and N. In some embodiments, the nucleic acid sequence of a kwaB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns L and N. In some embodiments, the kwaB gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns L and N. In some embodiments, the nucleic acid sequence of a kwaB gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 17, rows 2-935, columns L and N.

[00864] A skilled artisan would appreciate that the terms a "functional portion of a Defense System ΓΧ component" or "functional fragment of Defense System IX component" or "functional portion of a Kiwa defense system component" or "functional fragment of Kiwa defense system component" refers to a functional portion of a Kiwa polynucleotide or polypeptide, as disclosed herein, which expression is sufficient to elicit an anti-phage activity alone or in combination with the at least one of the other Kiwa polynucleotides or polypeptides disclosed herein or functional portions thereof.

[00865] The terms "KwaA", "KwaB", "/ raA" and "kwaB", also refer to functional KwaA, KwaB, kwaA and kwaB homologs, which exhibit the desired activity (i.e., conferring phage resistance). Such homologs can be, for example, at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polypeptide sequences referenced in Table 17 rows 2-935 columns H and I and L and M, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polynucleotide sequences referenced in Table 17 rows 2-935 columns H and J and L and N, respectively, respectively. In some embodiments, such homologs comprise at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homology or identity within similar domain regions of the polypeptide sequences referenced in Table 17 rows 2-935 columns H and I and L and M, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identity or homology within nucleotide sequences encoding similar domain regions to the polynucleotide sequences referenced in Table 17 rows 2-935 columns H and J and L and N, respectively.

[00866] Table 17 presents embodiments of components of Defense System IX that may be found in a diverse array of bacteria and archaea genomes (referenced in Table 18). Table 17 presents embodiments of nucleic acid sequences encoding gene cassettes of Defense System IX (referenced in Table 18).

[00867] The Wadjet Defense System

[00868] In some embodiments, a defense system disclosed herein comprises a Wadjet anti- plasmid defense system. (Table 11)

[00869] In some embodiments, a Wadjet defense system provides a host cell with resistance to entry of foreign nucleic acid invasion. In some embodiments, a host cell expressing a functional Wadjet defense system (Defense System Xa; Defense System Xb; or Defense System Xc) provides the host cell resistance foreign nucleic acid invasion.

[00870] In some embodiments, a Wadjet defense system provides a host cell with reduced efficiency of transformation of plasmids. In some embodiments, a Wadjet defense system provides a host cell with protective activity against plasmids.

[00871] In some embodiments, a Type I Wadjet defense system provides a host cell with reduced efficiency of transformation of plasmids. In some embodiments, a Wadjet Type I defense system provides a host cell with protective activity against plasmids. In some embodiments, a Type II Wadjet defense system provides a host cell with reduced efficiency of transformation of plasmids. In some embodiments, a Wadjet Type II defense system provides a host cell with protective activity against plasmids. In some embodiments, a Type III Wadjet defense system provides a host cell with reduced efficiency of transformation of plasmids. In some embodiments, a Wadjet Type III defense system provides a host cell with protective activity against plasmids.

[00872] In some embodiments, expression of a Wadjet Type I defense system in microbial cells protects the microbial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, expression of a Wadjet Type II defense system in a microbial cell protects the microbial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, expression of a Wadjet Type III defense system in a microbial cell protects the microbial cell from plasmid entry, reducing or eliminating plasmid transformation.

[00873] In some embodiments, expression of a Wadjet Type I defense system in bacterial cell protects the bacterial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, expression of a Wadjet Type Π defense system in bacteria protects the bacterial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, expression of a Wadjet Type III defense system in bacteria protects the bacterial cell from plasmid entry, reducing or eliminating plasmid transformation.

[00874] In some embodiments, a microbial cell comprising a Wadjet Type I defense system protects the microbial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, a microbial cell expressing a Wadjet Type I defense system protects the microbial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, a microbial cell expressing a functional Wadjet Type I defense system protects the microbial cell from plasmid entry, reducing or eliminating plasmid transformation.

[00875] In some embodiments, a bacterial cell comprising a Wadjet Type I defense system protects the bacterial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, a bacterial cell expressing a Wadjet Type I defense system protects the bacterial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, a bacterial cell expressing a functional Wadjet Type I defense system protects the bacterial cell from plasmid entry, reducing or eliminating plasmid transformation.

[00876] In some embodiments, a microbial cell comprising a Wadjet Type II defense system protects the microbial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, a microbial cell expressing a Wadjet Type II defense system protects the microbial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, a microbial cell expressing a functional Wadjet Type Π defense system protects the microbial cell from plasmid entry, reducing or eliminating plasmid transformation.

[00877] In some embodiments, a bacterial cell comprising a Wadjet Type II defense system protects the bacterial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, a bacterial cell expressing a Wadjet Type II defense system protects the bacterial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, a bacterial cell expressing a functional Wadjet Type II defense system protects the bacterial cell from plasmid entry, reducing or eliminating plasmid transformation.

[00878] In some embodiments, a microbial cell comprising a Wadjet Type III defense system protects the microbial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, a microbial cell expressing a Wadjet Type III defense system protects the microbial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, a microbial cell expressing a functional Wadjet Type III defense system protects the microbial cell from plasmid entry, reducing or eliminating plasmid transformation.

[00879] In some embodiments, a bacterial cell comprising a Wadjet Type III defense system protects the bacterial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, a bacterial cell expressing a Wadjet Type III defense system protects the bacterial cell from plasmid entry, reducing or eliminating plasmid transformation. In some embodiments, a bacterial cell expressing a functional Wadjet Type III defense system protects the bacterial cell from plasmid entry, reducing or eliminating plasmid transformation.

[00880] In some embodiments, a Wadjet defense system provides a host cell with resistance to at least one phage. In some embodiments, a Wadjet Type I defense system provides a host cell with resistance to at least one phage. In some embodiments, a Wadjet Type Π defense system provides a host cell with resistance to at least one phage. In some embodiments, a Wadjet Type ΠΙ defense system provides a host cell with resistance to at least one phage.

[00881] In some embodiments, a Wadjet defense system (Defense system Xa, Xb, or Xc) provides a host cell with resistance to entry of conjugative elements. In some embodiments, a host cell expressing a function Wadjet defense system (Defense System Xa, Xb, or Xc) provides the host cell resistance from entry of conjugative elements.

[00882] As used herein, the term "a Wadjet anti-plasmid defense system" may be used interchangeably with the term "a Defense System X", having all the same meanings and qualities. Further, in some embodiments, the term "a Wadjet Type I defense system" may be used interchangeably with the term "a Defense System Xa", having all the same meanings and qualities, and in some embodiments, the term "a Wadjet Type II defense system" may be used interchangeably with the term "a Defense System Xb", having all the same meanings and qualities, and in some embodiments, the term "a Wadjet Type III defense system" may be used interchangeably with the term "a Defense System Xc", having all the same meanings and qualities.

[00883] A skilled artisan would appreciate that the term "Wadjet system" may be used interchangeably in some embodiments with "Wadjet defense system", "Wadjet the defense system", "Wadjet defense system", "Wadjet anti-plasmid system", "Wadjet Type I defense system", "Wadjet Type II defense system", "Wadjet Type III defense system", "Defense System Xa", "Defense System Xb", and "Defense System Xc".

[00884] In some embodiments, a microbial species does not comprise an endogenous Defense System X. In some embodiments, a microbial species does not express an endogenous Defense System X. In some embodiments, a microbial species does not express an endogenous functional Defense System X.

[00885] In some embodiments, a bacterial species does not comprise an endogenous Defense System X. In some embodiments, a bacterial species does not express an endogenous Defense System X. In some embodiments, a bacterial species does not express an endogenous functional Defense System X.

[00886] In some embodiments, a microbial species does not comprise an endogenous Defense System Xa. In some embodiments, a microbial species does not express an endogenous Defense System Xa. In some embodiments, a microbial species does not express an endogenous functional Defense System Xa.

[00887] In some embodiments, a bacterial species does not comprise an endogenous Defense System Xa. In some embodiments, a bacterial species does not express an endogenous Defense System Xa. In some embodiments, a bacterial species does not express an endogenous functional Defense System Xa.

[00888] In some embodiments, a microbial species does not comprise an endogenous Defense System Xb. In some embodiments, a microbial species does not express an endogenous Defense System Xb. In some embodiments, a microbial species does not express an endogenous functional Defense System Xb.

[00889] In some embodiments, a bacterial species does not comprise an endogenous Defense System Xb. In some embodiments, a bacterial species does not express an endogenous Defense System Xb. In some embodiments, a bacterial species does not express an endogenous functional Defense System Xb.

[00890] In some embodiments, a microbial species does not comprise an endogenous Defense System Xc. In some embodiments, a microbial species does not express an endogenous Defense System Xc. In some embodiments, a microbial species does not express an endogenous functional Defense System Xc.

[00891] In some embodiments, a bacterial species does not comprise an endogenous Defense System Xc. In some embodiments, a bacterial species does not express an endogenous Defense System Xc. In some embodiments, a bacterial species does not express an endogenous functional Defense System Xc.

[00892] A Wadjet defense system (Defense System X) comprises, in some embodiments, a nucleic acid construct comprising a nucleic acid construct comprising a nucleic acid sequence encoding a JetA polypeptide comprising a pfaml 1855 domain or a DUF3375 domain or a pfam09660 domain or a DUF2397 domain or no known domain, or any combination thereof; a JetB polypeptide comprising a pfaml3835 domain or a DUF4194 domain or a pfam09661 domain or a DUF2398 domain or no known domain, or any combination thereof; a JetC polypeptide comprising a pfaml3555 domain or a pfaml3558 domain or a COG4913 domain or a COG1196 domain, or a combination thereof; and a JetD polypeptide comprising a pfaml 1795 domain or a DUF3322 domain or a pfam09983 domain or a DUF2220 domain or a pfaml 1796 domain or a DUF3323 domain or a pfam09664 domain or a DUF2399 domain or a COG4924 domain, or any combination thereof.

[00893] A Wadjet defense system (Defense System X) comprises, in some embodiments, a JetA polypeptide comprising a pfaml 1855 domain or a DUF3375 domain or a pfam09660 domain or a DUF2397 domain or no known domain, or any combination thereof; a JetB polypeptide comprising a pfaml3835 domain or a DUF4194 domain or a pfam09661 domain or a DUF2398 domain or no known domain, or any combination thereof; a JetC polypeptide comprising a pfaml3555 domain or a pfaml3558 domain or a COG4913 domain or a COG1196 domain, or a combination thereof; and a JetD polypeptide comprising a pfaml 1795 domain or a DUF3322 domain or a pfam09983 domain or a DUF2220 domain or a pfaml 1796 domain or a DUF3323 domain or a pfam09664 domain or a DUF2399 domain or a COG4924 domain, or any combination thereof.

[00894] In some embodiments, a Wadjet Type I defense system (Defense System Xa) comprises a nucleic acid construct comprising a nucleic acid construct comprising a nucleic acid sequence encoding a JetA polypeptide comprising a pfaml 1855 domain or a DUF3375 domain, or any combination thereof; a JetB polypeptide comprising a pfaml3835 domain or a DUF4194 domain, or any combination thereof; a JetC polypeptide comprising a pfaml3555 domain or a pfaml3558 domain or a COG4913 domain, or a combination thereof; and a JetD polypeptide comprising a pfaml 1795 domain or a DUF3322 domain or a pfam09983 domain or a DUF2220 domain or a COG4924 domain, or any combination thereof. In some embodiments, a Wadjet Type I defense system comprises a nucleic acid construct comprising a nucleic acid sequence comprising a jetA etB etC etD gene.

[00895] In some embodiments, a Wadjet Type I defense system (Defense System Xa) comprises a JetA polypeptide comprising a pfaml 1855 domain or a DUF3375 domain, or any combination thereof; a JetB polypeptide comprising a pfaml3835 domain or a DUF4194 domain, or any combination thereof; a JetC polypeptide comprising a pfaml3555 domain or a pfaml3558 domain or a COG4913 domain, or a combination thereof; and a JetD polypeptide comprising a pfaml 1795 domain or a DUF3322 domain or a pfam09983 domain or a DUF2220 domain or a COG4924 domain, or any combination thereof. In some embodiments, a Wadjet Type I defense system comprises a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide.

[00896] In some embodiments, a Defense System Xa comprises a JetA polypeptide comprising a pfaml 1855 domain or a DUF3375 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns J and K; or a JetB polypeptide comprising a pfaml 3835 domain or a DUF4194 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns N and O; or a JetC polypeptide comprising a pfaml 3555 domain or a pfaml3558 domain or a COG4913 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns R and S; or a JetD polypeptide comprising a pfaml 1795 domain or a DUF3322 domain or a pfam09983 domain or a DUF2220 domain or a COG4924 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns V and W; or any combination thereof.

[00897] In some embodiments, a Defense System Xa comprises at least two different polypeptide components selected from a JetA polypeptide comprising a pfaml 1855 domain or a DUF3375 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns J and K; a JetB polypeptide comprising a pfaml3835 domain or a DUF4194 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns N and O; a JetC polypeptide comprising a pfaml3555 domain or a pfaml3558 domain or a COG4913 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns R and S; and a JetD polypeptide comprising a pfaml 1795 domain or a DUF3322 domain or a pfam09983 domain or a DUF2220 domain or a COG4924 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns V and W. In some embodiments, a Defense System Xa comprises at least three different polypeptide components selected from a JetA polypeptide comprising a pfaml 1855 domain or a DUF3375 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns J and K; a JetB polypeptide comprising a pfaml3835 domain or a DUF4194 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns N and O; a JetC polypeptide comprising a pfaml3555 domain or a pfaml3558 domain or a COG4913 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns R and S; and a JetD polypeptide comprising a pfaml 1795 domain or a DUF3322 domain or a pfam09983 domain or a DUF2220 domain or a COG4924 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns V and W. In some embodiments, a Defense System Xa comprises four different polypeptide components selected from a JetA polypeptide comprising a pfaml 1855 domain or a DUF3375 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns J and K; a JetB polypeptide comprising a pfaml 3835 domain or a DUF4194 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns N and O; a JetC polypeptide comprising a pfaml3555 domain or a pfaml3558 domain or a COG4913 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns R and S; and a JetD polypeptide comprising a pfaml 1795 domain or a DUF3322 domain or a pfam09983 domain or a DUF2220 domain or a COG4924 domain or any combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2-2322 columns V and W.

[00898] In some embodiments, a Wadjet Type II defense system (Defense System Xb) comprises a nucleic acid construct comprising a nucleic acid construct comprising a nucleic acid sequence encoding a JetA ¹¹ polypeptide comprising a pfam09660 domain or a DUF2397 domain, or any combination thereof; a JetB ¹¹ polypeptide comprising a pfam09661 domain or a DUF2398 domain, or any combination thereof; a JetC ^u polypeptide comprising a pfaml3558 domain; and a JetD ¹¹ polypeptide comprising a pfam 11796 domain or a DUF3323 domain or a pfam09664 domain or a DUF2399 domain, or any combination thereof. In some embodiments, a Wadjet Type II defense system comprises a nucleic acid construct comprising a nucleic acid sequence comprising a jetA ^a ,jetE? ¹ ,jetC ¹ ,jet∑f gene.

[00899] In some embodiments, a Wadjet Type II defense system (Defense System Xb) comprises a JetA ^u polypeptide comprising a pfam09660 domain or a DUF2397 domain, or any combination thereof; a JetB ¹¹ polypeptide comprising a pfam09661 domain or a DUF2398 domain, or any combination thereof; a JetC ^u polypeptide comprising a pfaml3558 domain; and a JetD ¹¹ polypeptide comprising a pfaml 1796 domain or a DUF3323 domain or a pfam09664 domain or a DUF2399 domain, or any combination thereof. In some embodiments, a Wadjet Type II defense system comprises a JetA ¹¹ polypeptide, a JetB ¹¹ polypeptides, a JetC ¹¹ polypeptide, and a JetD ^u polypeptide.

[00900] In some embodiments, a Defense System Xb comprises a JetA ^u polypeptide comprising a pfam09660 domain or a DUF2397 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns J and K; or a JetB ¹¹ polypeptide comprising a pfam09661 domain or a DUF2398 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns N and O; or a JetC ¹¹ polypeptide comprising a pfaml3558 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns R and S; or a JetD ¹¹ polypeptide comprising a pfaml 1796 domain or a DUF3323 domain or a pfam09664 domain or a DUF2399 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns V and W; or any combination thereof.

[00901] In some embodiments, a Defense System Xb comprises at least two different polypeptide components selected from a JetA ^u polypeptide comprising a pfam09660 domain or a DUF2397 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323- 2844 columns J and K; a JetB ^u polypeptide comprising a pfam09661 domain or a DUF2398 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns N and O; a JetC ^u polypeptide comprising a pfaml3558 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns R and S; and a JetD ^u polypeptide comprising a pfaml 1796 domain or a DUF3323 domain or a pfam09664 domain or a DUF2399 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns V and W. In some embodiments, a Defense System Xb comprises at least three different polypeptide components selected from a JetA ¹¹ polypeptide comprising a pfam09660 domain or a DUF2397 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns J and K; a JetB ¹¹ polypeptide comprising a pfam09661 domain or a DUF2398 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns N and O; a JetC ^u polypeptide comprising a pfaml3558 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns R and S; and a JetD ¹¹ polypeptide comprising a pfaml 1796 domain or a DUF3323 domain or a pfam09664 domain or a DUF2399 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns V and W. In some embodiments, a Defense System Xb comprises four different polypeptide components selected from a JetA ^u polypeptide comprising a pfam09660 domain or a DUF2397 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns J and K; a JetB ¹¹ polypeptide comprising a pfam09661 domain or a DUF2398 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns N and O; a JetC ¹¹ polypeptide comprising a pfaml3558 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns R and S; and a JetD ¹¹ polypeptide comprising a pfaml 1796 domain or a DUF3323 domain or a pfam09664 domain or a DUF2399 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2323-2844 columns V and W.

[00902] In some embodiments, a Wadjet Type III defense system (Defense System Xc) comprises a nucleic acid construct comprising a nucleic acid construct comprising a nucleic acid sequence encoding a JetD ¹¹¹ polypeptide comprising a pfam09664 domain or a DUF2399 domain or a pfam09983 domain or a DUF2220 domain, or any combination thereof; a JetA ^m polypeptide comprising no known domain; a JetB ^m polypeptide comprising no known domain; and a JetC ¹¹¹ polypeptide comprising a COG1196 domain. In some embodiments, a Wadjet Type III defense system (Defense System Xc) comprises a nucleic acid construct comprising a nucleic acid construct comprising a nucleic acid sequence encoding a JetD ^m polypeptide comprising a pfam09664 domain or a DUF2399 domain or a pfam09983 domain or a DUF2220 domain, or any combination thereof; a JetA ^m polypeptide; a JetB ^m polypeptide; and a JetC ^m polypeptide comprising a COG 1196 domain, said JetA ^m polypeptide being encoded by a gene positioned within 5 genes of a gene encoding JetD ¹¹¹ and or JetC ^m in a genome of a prokaryote, and said JetB ^m polypeptide being encoded by a gene positioned within 5 genes of a gene encoding JetD ^m and or JetC ^m in the genome of the prokaryote. In some embodiments, a Wadjet Type III defense system comprises a nucleic acid construct comprising a nucleic acid sequence comprising a jetD ^m ,jetA ^m ,jetB ^m , and a jetC ¹¹ gene.

[00903] In some embodiments, a Wadjet Type III defense system (Defense System Xc) comprises a JetD ^m polypeptide comprising a pfam09664 domain or a DUF2399 domain or a pfam09983 domain or a DUF2220 domain, or any combination thereof; a JetA ^m polypeptide; a JetB ¹¹¹ polypeptide; and a JetC ^m polypeptide comprising a COG 1196 domain. In some embodiments, a Wadjet Type III defense system (Defense System Xc) comprises a JetD ^m polypeptide comprising a pfam09664 domain or a DUF2399 domain or a pfam09983 domain or a DUF2220 domain, or any combination thereof; a JetA ¹¹¹ polypeptide; a JetB ¹¹¹ polypeptide; and a JetC ^m polypeptide comprising a COG 1196 domain, said JetA ^m polypeptide being encoded by a gene positioned within 5 genes of a gene encoding JetD ¹¹¹ and or JetC ^m in a genome of a prokaryote, and said JetB ^m polypeptide being encoded by a gene positioned within 5 genes of a gene encoding JetD ^m and or JetC ^m in the genome of the prokaryote. In some embodiments, a Wadjet Type ΠΙ defense system comprises a JetD ¹¹¹ polypeptide, a JetA ^m polypeptide, a JetB ^m polypeptide, and a JetC ^m polypeptide.

[00904] In some embodiments, a Defense System Xc comprises a JetA ^m polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns J and K; or a JetB ¹¹¹ polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns N and O; or a JetC ^m polypeptide comprising a COG 1196 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns R and S; or a JetD ¹¹¹ polypeptide comprising a pfam09983 domain or a pfam09664 domain or a DUF2220 or a DUF2399 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns V and W; or any combination thereof.

[00905] In some embodiments, a Defense System Xc comprises at least two different polypeptide components selected from a JetA ¹¹¹ polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns J and K; a JetB ¹¹¹ polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845- 3174 columns N and O; a JetC ^m polypeptide comprising a COG1196 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns R and S; and a JetD ^m polypeptide comprising a pfam09983 domain or a pfam09664 domain or a DUF2220 or a DUF2399 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns V and W. In some embodiments, a Defense System Xc comprises at least three different polypeptide components selected from a JetA ^m polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845- 3174 columns J and K; a JetB ^m polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns N and O; a JetC ^m polypeptide comprising a COG1196 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns R and S; and a JetD ^m polypeptide comprising a pfam09983 domain or a pfam09664 domain or a DUF2220 or a DUF2399 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns V and W. In some embodiments, a Defense System Xc comprises four different polypeptide components selected from a JetA ^m polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns J and K; a JetB ^m polypeptide comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns N and O; a JetC ^m polypeptide comprising a COG 1196 domain or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845- 3174 columns R and S; and a JetD ¹¹¹ polypeptide comprising a pfam09983 domain or a pfam09664 domain or a DUF2220 or a DUF2399 domain or a combination thereof, or comprising an amino acid sequence having at least 80% identity to a sequence selected from the group referenced in Table 11 rows 2845-3174 columns V and W.

[00906] In some embodiments, a JetA ¹¹¹ polypeptide comprises identical domains as are present in JetA and JetA ¹¹ . In some embodiments, a JetA ^m polypeptide comprises homologous domains with domains present in JetA and JetA ¹¹ , wherein the amino acid sequences comprise at least 80% homology. In some embodiments, a JetB ¹¹¹ polypeptide comprises identical domains as are present in JetB and JetB ¹¹ . In some embodiments, a JetB ^m polypeptide comprises homologous domains with domains present in JetB and JetB ¹¹ , wherein the amino acid sequences comprise at least 80% homology.

[00907] In some embodiments, a Wadjet Type I defense system having an anti-plasmid activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide. In some embodiments, a Wadjet Type I defense system having an anti-plasmid activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a jetA gene, a jetB gene, a jetC gene, and a jetD gene.

[00908] In some embodiments, a Wadjet Type II defense system having an anti-plasmid activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a JetA ¹¹ polypeptide, a JetB ¹¹ polypeptide, a JetC ¹¹ polypeptide, and a JetD ¹¹ polypeptide. In some embodiments, a Wadjet Type II defense system having an anti-plasmid activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a jetA ¹¹ gene, a jetB ¹¹ gene, a jetC ¹ gene, and a jetD ¹¹ gene.

[00909] In some embodiments, a Wadjet Type III defense system having an anti-plasmid activity comprises a nucleic acid construct comprising a nucleic acid sequence encoding a JetA ^m polypeptide, a JetB ^m polypeptide, a JetC ^m polypeptide, and a JetD ^m polypeptide. In some embodiments, a Wadjet Type III defense system having an anti-plasmid activity comprises a nucleic acid construct comprising a nucleic acid sequence comprising a jetA ^m gene, a jetB ^m gene, a jetC ^m gene, and a jetD ¹¹¹ gene.

[00910] In some embodiments, the Wadjet Type I anti-plasmid defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising jetA, jetB, jetC, and jetD genes. In some embodiments, a construct comprising the Wadjet Type I defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system.

[00911] In some embodiments, a Wadjet Type I (Defense System Xa) gene cassette comprises the nucleic acid sequence:

1 gttgatcaag aaacaactta tagcgtgtag tttttgttgg ataaaatttt aaaagttatg

6 1 taatttgatg caggggaatt gaaacgtaat atagaaattt ataattataa ttatagagtt 12 1 aaatgatggt gcttaatgga agacgatgat agcgaaaaag gaggctgaaa tgaaaaaact 18 1 atttgaatgc attccggaaa attatttcaa tttgtttgct gggaaaaatc gggggtttta 24 1 tgctgaagtt gcttttttac tatatgaaca attccatatc aatcgagctg gtattttata 30 1 cagtttgatg aaagatgagg ttcaagaatt aatagaaacg aaagaagagt taggagaatg 36 1 tattgatata gaagatgaaa tagaagaaaa agagcaagac agtgctggga gagcaaatga 42 1 ggtgcttcga cgtttaaaga aacttaaatg gattgatgta gaagtacgtg atcaatttga 48 1 agagtttata gtgcttccag tgtattctag ccgtattttg gctgtgctaa aggaaatttg 54 1 tgaaaataga acaattgaat atcaaagata ttgttttacg acatatcaat tattaacagg 60 1 agtggaggcg gaggagcgcc cagcttcagc tattttggag tctgaaaaat atagtgagca 66 1 actttatgat gaattaacaa ttttactgca caatatgaaa aatcatatgg aaacaattgc 72 1 agctaaagat gatatacaac aagtgttaga gcatcatttt ggagaatata aaaaagatat 78 1 aattgataaa agttaccatc gtttaaggac atcggatcat gtgtcgagat atcgaaataa 84 1 aatattggag cgtatacaga cttggttttt agatgataaa ttcatgaaac gtgctgccga 90 1 agatgctgta gaaagtggat attctgctaa ctgggaagaa gcaatggatg gattaagtaa 96 1 gaaaatgtat agggttgaag aaatttatag taatttagat gaaatttgta atcaaattga 102 1 tgcacgccat tatcaatatt tacgagcagt tttagatcgt tctagatatt taagtactta 108 1 taatgacagt atcaattaca aaatatctta tattttagaa catatagggc aaatggacga 114 1 gaatatactc gattcttctc tgtttcgttt agtacagttg cggcaacttc aagaagcgtc 120 1 actgttatcc ccacgtaaga aaaaaggtgt atatgaacca gaacagcatg aggttaatga 126 1 aattagtgat gagatgcgag aggagctaaa ggctgaaaat ataagacgta tggaaaaggt 132 1 tatgaatcga aagaaaatcc aaaaatttgt gttagaagca atgaaggggc gtcaagagat 138 1 agagatgagt gaattgaatt tgcaaaatga ggatgacgct ttgtatttaa tttacgttta 144 1 tttgtatggt tatagtaagg gaactggata caagcttagt gaagagccac ctgaatttat 150 1 tacacaaaag gggtatacat tttctaatcg tacgataaaa cgagaaaatt agggggaagt 156 1 tatgcaaaat gtatcggaaa gagaaagaga agagatgggg attgttgtta attatttatt 162 1 ctcccataat tttttattga aagaatttga acgtgagaag tatcacctgg cagtacggaa 168 1 taaagatatt attaagcaat atttacaggt aattggttgg gattttattg tggatgaaaa 174 1 gcatgggtgt attgttattg tttcgccaca ttacgagcat cgtttgaaat tgaagaaaga 180 1 cgaaacgatt tggttgttag tattaagact tatttatgag gaaaagcgta gcgctctatc 186 1 tattagtcaa tatcccttta ccactcttca agaaatcaag gggaaatatg agacgtttcg 192 1 attaccgttt gtatcaaaaa caaaattacg tgaacttgtg cagattggaa agcaaaatca 198 1 acttttgaga ccaattgata atgacataga gtcggatgat tgtcgttttc agcttttcca 204 1 ttcatgcatt catgtgctgc aacaaggaga tttaaatgta ttgtatgaaa aaataaaatc 210 1 ttatagtgag ggtggggatc acagtgaaat ggatgaagaa actacgatta attaattggc 216 1 attattatag tgatgaaaca attttatttg gaaaacaaac agtgatatct ggacatacag 222 1 gagcagggaa atcgactgtt attgatgctt tacaagtcct atttatttcc gatgagcgga 2281 agattaaatt taattcagca gcatatgagg aggccaatcg tactttaatt aattatttgc 2341 gggggaagat aggtacagaa gaaaaacctt ttgtaagaga agggtatttt acaacatata 2401 ttgttgctga gttttatgat gagaaggcag gagagagttt tgtaattggt atttcaattg 2461 atgtatttaa agatgatgaa aaagtaaaag agtattttat tataccgaaa tctgagatta 2521 atatgatttc gttttttagt acaaaagacg agaaacgtta tgtggaaaag caagcagact 2581 tttgtaaaaa aataagagaa caatttccag aggctataat tgaaaaaagt tcaaatcaat 2641 atcaaaaggc tttattacaa cgttttggtg gattacatga aagatttgtt aaaacgtttg 2701 caagagcatt atcgtttaaa ccaatcgata acatgaaaga ttttgtatat aaaaatatat 2761 tggacgaaaa agaattaaaa atcgacgtta tgaggaatat ttttcaaaca catgaagaat 2821 tgcaaagaga attagaagaa ttaaaagaac gaaaggaaga gctggagcga atagataata 2881 tttatttgga atgtgtaaag ctggaagcgg atatttccat acaagaatat gttcttagag 2941 ggctagagta tttattaata caagaagaaa agagcatgtg taaaaaaagt attgaacaga 3001 gagaaaaaga attaagaaaa tgtgaatcag atcaaaaaaa gacagcggaa caaaaagagc 3061 atgctagaaa aaaagagact gagtatgaaa ttaagattaa ggatagtgct gaacaaaaaa 3121 gacaaaaaca attacaagaa caaatagctc aagcgaaaaa agaatgtggt gatttagagt 3181 gtaccaaaaa catatatgtt catagtttag caagagaaga aaaggatgtt tctagtcttt 3241 taaattatca aggtaatgaa tatttctctt taagcaagga cgagaagcat gcattggaaa 3301 taggaagaga ttgtctagcc ttcttgtcac ataatgatgg tactggaggg aatagggaag 3361 agcaaacatt aaataaactt ggagagagtt taaaaagaat tagtgggcgt ttttataaga 3421 gtacagcaga attggaacac agatctgctg aattgaaaac agaagagaaa gaattacttt 3481 ctgatataga gaatttaaaa agaaggaagc gtccttatcc catgtctgtt gaaaagttga 3541 agggattact agaaaaacat ttagaggatc aatcgaaggt atggattctt tgtgaagagt 3601 tagaaataaa aaatgataaa tggcgaaatg ccctagaagg gtatttgaat actcaaagat 3661 ttgatatttt ggtagaacca catatgtttg cgactgcact gtctatctac gaaaaggaaa 3721 agtggaatct tggtcttgaa ggtgttggac ttgttgatac tgaaaaagaa caaacatatt 3781 tagggaaagt tgagaagggt tctttagctg aagagatagt aggtggtaac ccaatagtac 3841 aggctcgaat tcatcattta ttaggtaggg ttataaaggc agacaatgaa caagaattac 3901 gaaagtataa aacagctgtt actgcgacat gtatgagtta tcaacgtctt gtagcacgcc 3961 aaattcctag aaaagtatat gaaaccccat atataggtgc acatgctatt caaaagcaat 4021 tagaaattaa agaagaaaac ttaaaggaaa ttcaaacaga actgcaaata gtaggatact 4081 atattaaaga ctttaagaaa tggattgaaa ttttagaaga taagcaatcg gattataaga 4141 attatatatt aaatttctca ttaaacgata gtatcttgga gtttaataag aacataaata 4201 aatggaagag tgaactaaat actcttgatt tgtcacgttt agaaagttta cgccaaaagt 4261 tgaaagagtg gaatggaaaa tataatcaat ttaatggaga agaaggtaga ctgtttgaac 4321 aaattgggaa ggtgaaggaa gaacttcaaa gagtgaatgc tgagttatgg aaaaaggaaa 4381 aggccgcaac agagatttta gagaagtgga aaaattggaa gtttgaatat agaatcgaat 4441 tattacaaga ggctgagcaa aggtacgagc aagctatttc tacaaataaa gcttatggtg 4501 ctataaaaaa taaatacgaa aataataaaa aagaaaatca aaataaatac gaagaaaaaa 4561 ggggttttct agaaagtgaa cgtaagtctt ataatgaagc gcgaactttc caaggaatta 4621 tacaggctaa agataataag cagtacgaag aagcgctccg gaaaattgca aacctcgata 4681 tcccaaagtt tgaacaagag atcaaggaaa cgttgcagca agctgaagag gaatttcagt 4741 ctcactttat ttacaagatg cgtgaggcta ttcaagcggc gcgtagagaa tttaatcaat 4801 tgaaccatgc gttaggaaga tttaaattcc gaaatgacac gtatcgattt gtaataaagc 4861 caagtgaaca atataaaaaa ttttatgatg taattatgga tgaaagagta cagccggaga 4921 tatctctatt tgattttggt gatgaagata gggcggagat tttaaaggac ttatttggta 4981 gattagtggt gggcgagtat ggtgaaaacg aagagtttgt ggactatcgt aattatctcg 5041 attttgattt aagcattaat aatgaaaatg gaacaagatt tatgtctaac ttattacgtg 5101 agcaatctgg tggagagacg caaacacctt tttatattgc catcctagca tcatttcaac 5161 acctttatcg aaataaaaat accattcgtt tagtagtgtt tgatgaggct tttaataaaa 5221 tggatgaaga gcggattcaa attagtttac gtcttattaa acagttggac ttgcaattaa 5281 ttgcagctgt gccagatgag aaaatggctc atatggcagc tgaggcagat acagctataa 5341 taattaaccg aatagggcat tcatgtttta ctgacatatt atcttatcca agggaggacg 5401 aggcaattgg attacaagag caagattctt tcagtcttat tgaataaata tgaaaatagt 5461 aaaactgctc atacaggtga gagaagtgct cagcgccctc aattttcatt tcggcaaaaa 5521 catgaacttt ctaaagcata taatgatgaa atggattata cgaaccgatt agaaattaat 5581 actgcattaa aggacttaat tcgtaaaaaa attattgaag tgaaatggga aaagtgggaa 5641 gagaatcgaa ttgctgaaaa ggtttattta cagtatgatt ttattccaca agcttataga 5701 gaagctggta tagaaccaaa aattgaaaag atgaatagga ttttaaaagt gttagaacca 5761 cttgctgttc attcatggga gtgggttcga caatggtata aagaagtaca acagtcgttt 5821 caaaataata aaacggcacg aattaattta aacgatgtta aaggatatga actacttgta

5881 aaagcacttt ctagattaga aggtttggaa gatagtatac cgaaaaggac ctttagccaa

5941 ttagtattcg gggatacaaa actttttgaa actacgatac aaaaccgatt attaataata

6001 tataaaaggt acggagatat agaatatgaa agtgataaag aatatttaga gagtattggg

6061 attttagaga atatccaacc tgtctatata aaaggaaatg ttgatattcg tgttagagga

6121 gagaagattg ctctcggttc ctttcctggt gggttcggtt taatggatga aacaataaaa

6181 gaactagaaa ttcagtatgt acacgatgaa agtataatgc ttattgaaaa catgaccaca

6241 tactatgaac aaattaaaaa aaataataat attttattta tctatacagg tgggtttcct

6301 aagaagaatg tacagcaatt gttaaaaaag ttgaatatat atttggaaaa tcatccagtt

6361 ccagtatatc actatggaga tctggactac ggaggaatcc aaatatttga gtacattaag

6421 cgttcgtttt tttcagggct tgagccgtat atgatggatg tagctaccta caggcaattt

6481 gtaaagtacg ggatggaatt tggtgaaggg tatgaagaaa aattactgaa gatgttagag

6541 aatgagcagt attctttatg gcatgagtta attaaagaaa tgcttaaaga aaagaagcgt

6601 gttgagcagg aagtgatagt tagaaacgta atttagtgta tttatataaa tttaaaaagg

6661 atgtctatag accaggataa cggtttatgg gcatttttta ttaggttttg tataaaagag

6721 atttagttag aggaaatgag atttaatatg ttttgtaaac gccataatat taacgcctga

6781 atttttttag gagaggaaag tagagtgttg gctttgtttt tcgtaattaa ctaagtaatg

6841 tgagaagttt tttatatggg gttatttata taattattaa gtgctagata atgaattgtt

6901 agtccatcct tattttggag gcatgttcta attaaataaa ctggttggat gtaataagtg

6961 aattcctggt aatttatcgt tggaaaaaaa tatatattat gtataattag tgtataaata

7021 aaattctctg aaatttgaaa ggtgataaaa (SEQ ID NO: 17; construct 59 of Table

4).

[00912] The coding regions for each of the jetA, jetB, jetC, and jetD gene sequences within this embodiment of a Wadjet Type I cassette (SEQ ID NO: 17) are as follows: nucleotides 146- 1552 encode an embodiment of a JetA polypeptide, nucleotides 1562-2155 encode an embodiment of a JetB polypeptide, nucleotides 2133-5447 encode an embodiment of a JetC polypeptide, and nucleotides 5551-6636 encode an embodiment of a JetD polypeptide.

[00913] In some embodiments, a Defense System Xa comprising a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 17. In some embodiments, a Defense System Xa comprising a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in SEQ ID NO: 17. In some embodiments, a Defense System Xa comprising a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 17. In some embodiments, a Defense System Xa comprising a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 17. In some embodiments, a Defense System Xa comprising a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 17.

[00914] In some embodiments, the Wadjet Type II anti-plasmid defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising jetA", jetB", jet"C, and je D genes. In some embodiments, a construct comprising the Wadjet Type II defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system.

[00915] In some embodiments, a Wadjet Type Π (Defense System Xb) gene cassette comprises the nucleic acid sequence:

1 tctttgggtt cctttacttt ttgtaaaaaa tttaattctt tgcctgaagt atttcgaaaa 61 actgaaagcc tttaaaaaga atttcaccaa tcagtttaat tacagaccaa gattacaata 121 aatttaaaac cattcgatgt caatgtttaa atggaaaaac gtaagtatag gaatccttag 181 ttcaatatta tacaatggga ataatagaca aaaaatagga tgatgatcca tggattcaac 241 aatgaaaaaa ataatagagg ccagttattt aacagccgac tccgcggcac actatcgaac 301 gattcttcgc tatttttatc accagcacga aagaatgaga gattttattg caccggaaga 361 gttattggaa catatgcgtt cgatacctgc cttcgcggac tttcaagagg accagctcca 421 ccagcaatta gcgcagcttg taaaatggaa taatttaatt gccaggcagg atatgacaaa 481 cgcaaaaaca attgaagaat ataaaaagaa acggttccgt tatcaatgta caccctacac 541 ggttgagatt gagagaatga ttgtgcaact agaaaaatta ggagatacgt tccaagggtc 601 gttagaacgc tcccaatttg atcgcctttt ccaagcaata accagccttc aaaatgaact 661 agagaatgac ctaaacaaat cggcagaaga atatatgcgg atttgggagg acgtatttcg 721 ctattttcaa acgattcgta ccagcactgc tgattatatt gcttatatta atagtgaaca 781 aaccgatcaa cgaatgcaaa cagaggcatt tctagtctat aaaaatcagt ttacaacata 841 tttgcgagat tttattgtat ccttgcaaaa aacatcgctg caaatccagc attcattatc 901 agaattaacc ttggaacggt tacagcattt ttttcaaaaa ttaatcgagc atcgcggggc 961 aattccccgt cttgaggatg tttcgtcatc tacaaacgat tggcttactg aatatgagga 1021 atattggttt tcattacggc agtggttttt agggtcggct gttcagcaaa gtgaactaga 1081 tatccttcag tggcagacca atgaaatgat tcgccggatg acaagatacg ttcagcgcat 1141 cggtgaaagg cagcagcatt ttcgcagccg aaaaaaggac tatctgcaat tatcaaaatg 1201 gtttgttgaa tgcagggata gtgaggaagc tcataaactt tcagcagttg tattcggctc 1261 gatgacgatt caacatctcc agcttgagga agcgaccact gaaaaccttc atgtcgatac 1321 atgggatgag gcaccgactg aattaacgat aaaaccgaga acggtccgct accgtgaaaa 1381 aacaaaaccg ggatcgttta actcgaatga acagaagaaa aaagagcagc gagaactcta 1441 tttaaaggaa agagaacaag agaaaaagtt aatcgaaaaa tatatgaccc aaggtaaaat 1501 tacgctttca gcactctcga cagttgaacc attcatccgc aaggttttgt taagctggat 1561 tgggaaatca atggcggcca aaaatcgcat ggtcaagact gattacgggc ttcacgtaaa 1621 ggtaatgctt gattatgaga aaactattac cttacaagct gaggatggca atttactaat 1681 gcctgatgcg acattcttgt ttgaggagac taggtgatga taatggaaca aacgcaatta 1741 ttcgatgaaa aggcaatcca aggaatggac atcttgtttc atcattactg gatcttacgt 1801 gccgaacaac ctgaatggta tcagctgatt cgtgagcggg agaaggtatt gcgccgctat 1861 cttgatgaaa agttcggcct gcggctaatt gttcatcaac attttattaa actggaaaaa 1921 attcctgttg aaccggaagg ctggatgggc atccaagatt tccaagagcc aatggactat 1981 gcgatttttt gctgcgcact tgccttttta gaggggaaag cagtggatga acagtttttg 2041 ctttccgaac tatgtcaaga gattcaagcc gattatcctg gagattttcc gcttgattgg 2101 acgctctata cccaccggaa atcattgata agagctgtaa aagttttgat ggaatttcag 2161 ctcatacgaa ccattgatgg ggatatcggc cgcttcgatc aaaatgaaga gcaggaagtt 2221 ttatatgaag ctagcaccta tagtcgatat ttcatgagaa catatccaga tgatttttcg 2281 agctatcagc actggagcga gttactaaaa gaagattgga aattgaacca agaggatgaa 2341 cgtaggaagc gggtgtaccg caagctgttc ttttcacctg gtttgcatcg gctagatcaa 2401 caggatcctg attttctcta tatccggaac tatcgtaacc gcttagcaga agatattgaa 2461 aagcacagtg agtataaact ccatgtctat aaaaatacgg catttttatc gattgcggag 2521 ccaaggcaat atcaacaggt ttttcctaat tccaaggcat ccactgacat tatccttcag 2581 ttgtcaaagt acattcatgg ggagcctgag cgcttcaaag caaacgaaaa tggtgaaata 2641 ctgatgacgg aaggtgagtt tgaacaagtt gtggatgatt tacggcagca atttggaaca 2701 ggctgggcaa agtattttcg cgatatgagt acaaaaggaa ttcgaacgga actgcttcgt 2761 gccatgaagg attggatgat ggcggaagtg gattcagaaa cttctcttat tcggattaag 2821 tcattaacag gggtcatgac gggggaatat ccgagtgatt ttcaaacagg aggaacagaa 2881 tgatgacaga ggcaaaatgg gtgatgaacc gtgcggggtt attgaatttt tggtattacg 2941 atgatgaaat ttttcctttc tcggatggaa agctactgct taggggaacg aacggctccg 3001 ggaaatctgt aaccatgcaa agcttcctgc ctgttttgtt agacgggaaa aaatcacctg 3061 accgactcga tccatttgga tctaaagccc gcagaatgga agattattta ctcggggaaa 3121 aagaggtggt cgatcgtgat gagcgtacag ggtatctttt tatcgaatat aaaaaggccg 3181 gcgtagagcg atacattaca actgggatcg ggatgcaagc caagcggcat aaaggaatta 3241 agtcttggta ttttgtgatt accgataatc gcagaattgg atatgatttt gaacttgcac 3301 attcgcaact aggagaccga gttccttttt ccgcaaagga actggaaaat cggatcggag 3361 agggcggcta tgttgttcat acccagcgcg aatatatgga gctggtgaat aaatatattt 3421 ttggtttcca atcaaatgaa gcttatgaag acttgatcaa gcttttaatc caattacgaa 3481 gtcctaaact ttcgaaggat tttaaaccga cagtgattta tgaaatatta gagtcggcct 3541 tgcctccttt gaccgatgat gagttaaggc atctatctga taccattgaa agtatggatc 3601 aaacccagca gcagctcgaa cagttggaac gggaatttgc ctctagcagc aggctggtta 3661 accagtatca ttcctataat caatatattt tggccgaacg ggcagggaag tggcaggatg 3721 ccttaaaaag gtacactgtt gctgaggaac atgtaaaagg tttaacagcc caagacgaag 3781 aattgactca agaaattaaa caagaagagg aacagaagca gcaatttgcc cagcagcaag 3841 aaattgcctt agaagaaaaa aagcggttgg agcgccatga ggtttggaat ctggaagagg 3901 ataagcgtaa gaaaatagaa aatacaaaat ctttaagtag tgaaataaat tccttacaaa 3961 agaaatggga ccacaaaaac agtcagtaca atcgtctatg gcaggagcgg gagcagagtc 4021 aaaaccagat aaggcagcat gaaagcggca tggaagattt attaggggag ctgcaatttg 4081 atgcggaaga ggctgctttt tcagagcatg aggttaacgt ccatgatttc gaacgtcatc 4141 aggaggagga gtttgatttt tccatctgga ttggtgagat tggcagtcat gaacaattac 4201 ttgcgaattt aaatcaatta gctgatgagg aaaatcgtct gtcagaagag cataaccggc 4261 tccaacggca atcctctgag aaaaagaaag aggtagatgc aatccgcaag aatctcgatc 4321 atttagccga ttggtttacg gaagagaagc aaaggttgga gcatcaggta tttacttgga 4381 ttgagcagca tccaaagctt attttttcaa atgaaagacg ccaagaaatc gcccgatcaa 4441 tcgaaggttt atatgaagaa aatcggtacg agcaagtgag ggaaaaactc cttgctgtgg 4501 ttaatgatta tattaccgat atcagtacga agaaaaagct catggagaca aaaatagaag 4561 ataaaaagca cgaattggaa gcagcacgag cagaattgca tcactggaag acattaaaaa 4621 tgccaaaccc ggatcgtgct aaggatacag aggcatttcg cttgcagctg ctagaagacg 4681 ggcaggcatt tattccgttt tatgcggccg ttgagttcca agatgatgtg accgaagaac 4741 agaaagagcg gattgaatct gcgttaaaac aaacgggcat attggacagc ttgatcactg 4801 aaaatgccct tgccccaacc catgatcggg taattcgtcc tgagccgcaa ttactcggat 4861 atacgttagc agattatttg cgtccggatt tagaggcaga cagtcttatt tcaaacaaac 4921 ttgttgatga aatattacgg agcatctccc ttgaacagga aggggcaggt tttcatgtgg 4981 atgtcgatgg atcatattca cttggttgtt tagtggggca tgcaccaaat gaagggccgt 5041 ctaaatatat cggccgctca tcccgcaaac gataccagca agagaaaatc aaagaatgtc 5101 aggaaaccat tgagcaactc caattagagt tagaggagct aaaggtgcaa ctcagtcaat 5161 acgaagagaa tctcctccaa gcagcacaat ggaagcagac catgccaaca gatcaggaac 5221 ttaatgactt gaatgttcag attgaaaaga ccggccatca attggaggag caaaaaaagg 5281 ttctttttca gctggatgaa cagtggaagc aagtacacgg tcacctccaa gtgattaaaa 5341 tacagctcca tcaagaaggc cgccagctaa atctttcttt aactaaagaa gtcttagggc 5401 aagcattaat ctcagctaaa aactatcgtg atcaactcta tagctttaaa gatctttttc 5461 aaaaatgttt atttgcccgg aaaagaatag aggatttaac tcatcgctta tttgaaatgg 5521 aaacggaact ggacgatctt aaaggggatc aaaatgtcaa ggaatcacag ttgcggaaag 5581 aaaaggctga aattgagtca attgagcaac agctgaagct aaaagggatc gaggaagtaa 5641 gacttcggat tcaacaagtg cagcaggagc taagggaagc aacagaaggc atcaatcatc 5701 tacttgaaac cattcctcag aagaaagcaa aacaagaaac ctgtcaaaat gaattagcag 5761 cagctaaaac aagtgcggaa ttctggtcaa atatggcgga cgaatgggaa cagatggtga 5821 gagcggatat cgcccgtggt tttgtagaag ttgttgaaat ggatcctgtt aaaatcgtta 5881 aacagctgga atccatttta ggaaaatatg accgttcgaa gctaaatgaa cagctaacaa 5941 agacgttcat caatgaacag atatttttaa cggagtacag gatgtttgaa tacccggaag 6001 agaccgagcg tccagagtgg ttttcgaagg aatggggcga atactatgaa ccatttatga 6061 atgaatggaa tcagcttcaa agccgccgtt taattctaat ggaatataaa ggccagcgtg 6121 tcagtccgta ttttgtgttc acatcactgg aaaaagagtt agaagaccaa aaaggttggc 6181 ttgatgaaca agaccgccaa ctctatgagg atattatcgt caatacagtt ggagtaatct 6241 tacgaaatcg aatcaaacgt gccgaaaaat gggtgagtga gatggacaaa atcatggaaa 6301 gccgtgataa ttcatctgga ttaacgttct cgattgcatg gaaaccatta acggccgaat 6361 cggaacaaga attggataca aaagacttgg ttaagctttt gcagcggaat agtaagtttt 6421 tgaacgagga tgatttaaat cggattacaa aacacttcca atcgagaata ggaaaagcga 6481 aggaattaat tcagttacgg aatgaaggat cgacgcttca tcaagtgtta aaagaagtgt 6541 tggattatcg gaagtggttc acttttgttc tttcatttaa acgtgtaaat gaaccgaaac 6601 gagaattgac gaacaatgcc ttctttaaat ttagcggcgg cgagaaggca atggcgatgt 6661 atattccgtt gtttacggcg gcctattcaa gatataaaga agcaggagag atggcgccgt 6721 atatcatttc actcgatgag gcctttgccg gggtcgatga gaataatatc cgtgacatgt 6781 ttgaagtggt ggaacagctt ggctttaact atataatgaa ctcacaagcc ttatggggag 6841 attatgacac catttcaagt ctatcaattt gcgagttagt acggccaaag aatgccgact 6901 ttgttactgt gattcgctat caatgggacg ggaaacagcg cacctttgtg gtggacgatg 6961 agcacgttga ggagctagtg acacatgatt gacaaagtac aggtgtttag ggacgaacca 7021 ggttttgtta aattgtttac cctatttaaa gaaaaatacc gttcaatcgg gagaatcggc 7081 ggcatggtga gtttggatgg cttttcctat gatgaggtgg aatcaattgc cggctttttg 7141 ggacagtctg ttgaagcgct ccttgaaaaa gggaaggttt cattactttc ttttgaaaaa 7201 gaattaccgt tgaccggttt tgcagagtat tcccttattg aattgcttga agaagtgctc 7261 ggggagtcga tacttactaa acatgaggaa agtggcattg aagaagagaa agaaaagagg 7321 tttttacaag agttatcttt tatatgtcct gagggaagtt ggtggtggga ctggattgag 7381 tcgaaaccgc cggattcccg gtggatttgg tcgctttata agcaggatgc ggttggttta 7441 atggaaaaat tcatcaccgt ttttaaagca tatcaagatc ttccctgtaa ggagaataag 7501 tatgaaagac tgccgctgtt tgcccaacga acaacgggaa atccacatat tttcgataat 7561 aatcaactaa ctgggaaatt gctcgtcaat tgcctgcagg tagatcaaca gcttaagggg 7621 cgacgcgtac cgggaatgcc gaaaacaaca gaggatctaa atgatttgct aggtttgtat 7681 ggtttgatga gggatgattt gtggagtttt gtttcctgcc gcggattact tgcggaaggt 7741 gaaatgggga ttcatcctgt ttggaaagcc gcagctgaaa ctgacacagt tctaaacgtt 7801 ccgcttaagg aattactgaa aataaaaaga atctggcccg ctgcaggaaa aaaggtttgg 7861 attgttgaaa attcaagtgt ttgttcgacg attgttgatg aggttgctga tgctcctgta 7921 atctgcaccc acgggcaatt tcgggctgcg agctggatat tgttggagtt attagtggaa 7981 gcgggctgtc acctttacta ttcgggtgac ctagatccgg aaggggtatc gatggcacag 8041 cggcttttcg atcgttatca gggtcatgta acttgttgga ggatggatgt tgaatcctat 8101 gataaaacca tttcagatga ggatatttct ggcaggcttt ctaaattgga gtcaataact 8161 gcacctgaac ttcttgaagt agtgaatgtc cttaaaatgc ggcaaaaagc gggctatcaa 8221 gaaggtttag ttgagcaact tgttcaggat attaaaaacg agtttaatgt gttactttag

8281 gttgaatcaa atatagtagg aatccagttg gatccccacc acaaaaagcg ctat (SEQ

ID NO: 18; construct 60 of Table 4).

[00916] The coding regions for each of the jetA", jetB", jetC", and jetD" gene sequences within this embodiment of a Wadjet Type II cassette (SEQ ID NO: 18) are as follows: nucleotides 230-1717 encode an embodiment of a JetA ^u polypeptide, nucleotides 1717-2883 encode an embodiment of a JetB ^u polypeptide, nucleotides 2883-6992 encode an embodiment of a JetC ¹¹ polypeptide, and nucleotides 6985-8280 encode an embodiment of a JetD ^u polypeptide.

[00917] In some embodiments, a Defense System Xb comprising a JetA ^u polypeptide, a JetB ¹¹ polypeptide, a JetC ¹¹ polypeptide, and a JetD ¹¹ polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 18. In some embodiments, a Defense System Xb comprising a JetA ^u polypeptide, a JetB ¹¹ polypeptide, a JetC ¹¹ polypeptide, and a JetD ¹¹ polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in

SEQ ID NO: 18. In some embodiments, a Defense System Xb comprising a JetA ^u polypeptide, a JetB ¹¹ polypeptide, a JetC ¹¹ polypeptide, and a JetD ¹¹ polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 18. In some embodiments, a Defense System Xb comprising a JetA ¹¹ polypeptide, a JetB ¹¹ polypeptide, a JetC ^u polypeptide, and a JetD ^u polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 18. In some embodiments, a Defense System Xb comprising a JetA ^u polypeptide, a JetB ^u polypeptide, a JetC ¹¹ polypeptide, and a JetD ^u polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 18.

[00918] In some embodiments, the Wadjet Type III anti-plasmid defense system comprises a nucleic acid construct comprising nucleic acid sequences encoding a cassette comprising jetA" ¹ , jetB ¹ ", jetC", and jetD ¹ " genes. In some embodiments, a construct comprising the Wadjet Type III defense system encodes one component of the defense system, whereby multiple constructs may be used to assemble the functional defense system.

[00919] In some embodiments, a Wadjet Type ΙΠ (Defense System Xc) gene cassette comprises the nucleic acid sequence:

1 ttccgatact ctttagccat aaagcgatga attctgctgt tccgccgaat atcgcaacgg

61 ttagtgcata tggtaaacct acgcctagtg cacggatttc agttggaaag agttctgctt

121 ttacattgcg ttaatcgatg tgtaaccagt aacgatgatg aggccgacca tcatgagtga

181 aaatgctacc atgggttcta tatccatcat ttttaaaact tggtggatat ggagggacct

241 ggtactgttt tggttttgtg atgtctgtgg gatttcttgc tagcttctgc atgatttgtc

301 ggtaagtcga tatattcgga gttgcggtcg atataattgg ataatcgttg atatattttt

361 taaaggtatg gcattcattg gtagaaagag tgatgcgagc ttatgttaca atggaaatag

421 cttgtaagta aggaagtgac agtatgaatg gtatacaatt tgttcaattg tatgtaatga

481 aaagtgctga aaagattgat gagttgtata taaaaaaaga acaaggtatc acaactctcc

541 ccattataaa gcagaccccg cgtaagatta taaaaacagc ggaacttctt tttagtgaag

601 aagaggtttc ggatgtttct actactatta caaaaaactt ttattcacct aatgtaagga

661 aaagagaaag tgatgtttta aagtggttaa cgatacatga aatgatagat tgtatagaac

721 gagggatttt aattaaggaa gttcgttttg agaaggatgg gaaaactgtg cattccattt

781 tctatcgaat ggggtacggt ttgtttacat atatggaaaa gaaacaacag ctagaaaagg

841 taagagagga agaggcttta cagcaatgga tgaagcgcaa gcagtctatg ccgaagtaca

901 taaatgagta tacggaaaga ttgtggcatg ttttgtgcaa tattgaaagt gatttgtctt

961 ctatagatga aaaacgttgg tcgtttcaga agacgttttt atttttagag tttttacttg

1021 ctacatataa aatgagttgt gaaaagcgta cgtttgattg gaaagagatt ggtgcggcgt

1081 attatgaagt gattggtggt tctaaaaagt ttgatcaaca taaaaaagag tttcttaata

1141 agctggaaga tttgttagat gctccgccgc attgtttagg tttagtgagc ttagggacag

1201 tgacgcctat ctttttttgc gggaatttat atgaaggtaa tacgcgttat gagtgtgaca

1261 cagtgcgttc tttaacggat ttagttgtat ttcgtcatgc gtataaaacg gatgcgaagg

1321 tgttatggct cgttgaaaat agagcggtat taacgaggat tgccgcagag gatgatttta

1381 tttcaagtac aggtagtctc gttatcggag tggatgggca attacgtagt gggcataaaa 1441 ggttgattca aagcgtattg gaccactcaa aatctattac gaaaattatt atttggacgg 1501 attatgatgg ggcaggagag attattagtg ataagttatt cgaactagtt gctccatatg 1561 aacagtatac aagatggatt tcttcagaag gtaaggcgtt aaataaagat gaatttgagc 1621 aatccgttcg tttacgcgaa agtgaacaag aagagagttt aggaggtgtg gatgcttgga 1681 aggaatggat cagtcagtaa tttcgatttt gcaaacagat ccgtcgcata tgggagtacg 1741 aaatgcgatg aaagatttaa ataaattatc aggtgttatt tcagagcttg gagagagtga 1801 gtattttaat gatccattga aaacgtatga gtttctacta ttattaaata ttttaaatga 1861 agaagcgctt ggattgacgt cttctattga agatgtgcgt acgttgaaat tccgttaccg 1921 taatatgtac ggcggggatc cgtcaattcg tttagagcat ttcattaata ttttagataa 1981 atatggatgg atctcaaaag ggaaaagcaa gattacgatg atggacgttg ggaagcgaat 2041 gattgatgtg ttaattcgcc tagcaaacga ttcgttagcg tattacatgc aagatgaaat 2101 aacgaggtct ttatatcaag caaaccgtga tgcggattta agtgaagcgt atgatgataa 2161 aggtgtatcg ggcggaaata aattagcgag tatgataaaa aatgtagaag aagcggtaga 2221 aagactgaaa gagagagaac tcgaatattt agcggaccgc tatgcgttgc cgcaagtgca 2281 gattattcat cgtttaatga atgaattaaa tgttcgtttt gaagaaaggt tccaaaagtt 2341 tcaaacgttt gaagaaagtc ttgtgttaga gcctcttgtg aaaagaggaa cgagcgttat 2401 gtttgaaggt tcacaggtta gtcttggaac gattaagaag attttacatt ttacacatat 2461 tcagcagtct acagtcggag cgaatattcg tcatgatgcg cttcgtcgtt ttattgaaaa 2521 ttgttttacg aagcaaaata tggaattgcc agatgcacat gaaattttaa gttttatgga 2581 gcaagaccgt agagaaggcg agagacaaga tgggttatgg atgccagtac agtttgcggc 2641 gccgttatca agtgctgcga tttctagtgg tattcagttt ttagaagagt acgagccata 2701 tacggatcat atagaagaag ttgtgcagga agaatatgaa gagatagaag aaatgtcaga 2761 agcagaagtg aagaagctaa tggcagatca gcagtggagt atgacgaaag agcaaattca 2821 aacggaacga ttagaagagt ttcttatgga acaagaagaa gtcgatatgg aagagcttgt 2881 gcttgaagcc ggttctaata cgtggggaga tgcggtaaat gcattaatcg cactgtcagc 2941 tttaaccgct aataataagg cggatattat cgataatcaa aatgtaaaag aaagaaacat 3001 agaaaaagaa tgggaatggg gcagtgacga tgataaaaga aaacgagttc gaagccgaga 3061 aaggaattaa tccgctcgcg aaattaggag aacttcggta catattgtct cgtgatgaag 3121 agcatacgtt tatgcaactt ttattttcat cttcagcgcg tatgagagca acaaattttg 3181 gattgcgccg caaagaagta atgaaaatgc ttgggttaaa tagtgaggat atagaagggt 3241 ttgagtcatt tgtaatgcga ataaatggtg cgctaagtgg ctattttcag tgtgtatatg 3301 atgagagacg tgatcaagtc attgtgatga tgcgagtacc agcaaaacaa gcgagagaag 3361 tattatcttc agaaagttta ggattactta tgtttatttt ctaccatcaa gaagtgttgc 3421 aaaatgaatt tacattattt aatcaattac ttagtgcgct tggacatgaa acgttgcaag 3481 cacgtagaaa agtacaaaca aatttagatc cacttttaaa aattggggct attacgaaat 3541 atgattctcc gtcccaagaa gaagcatatg cgttaactgc cattggaagt agaatgtttt 3601 cagattcgtt cttacatagg gcggctgagt ttagtcagtc acaacaactt catatggatg 3661 atgttttaaa attctttaag cgttataacg taggaggtgg agagacgata tgattccata 3721 ccgtatttct ttttctggta tacgtgatta taagccgaga acgatttctt taatggggaa 3781 gcgtgatcac attttaattt caggtgcaaa tggtgccggg aaatcgacgc tgacattttg 3841 ctggggcgct gttatggcgt ctacgaaagt aaatgtggaa gggcttcgtt cgaaaaatct 3901 tccagacaat agagtatggc gagcgaaaat tgaacttata tatgaaaatg atggatttgt 3961 agatgcagca agatttgtga gatttacgct tgatttagaa caagagccag gtcatccatt 4021 gaaaaaagaa tattatattg cagaaggcga tcgggtagat gagtgggagc aagaaacgcg 4081 tttctcatct tcagataagc attttaactt tagagagtat aaaagaatgc ttcttcaaaa 4141 atataaaatt gatccagatg cgttctattt aatttggtac caacaagatg taaatcaatt 4201 tgcagtgatg aagcctgaag agaggttccg tatttttagc gagatgacag gaattgaaag 4261 tattcaaaag tcttgggagt ctttcaaaga acaagaacgt gataaggaag cgattttgca 4321 aacggctcgt aataaccaaa ttcaatataa gttcgaactt gagcgttggg agaaagagaa 4381 aaatcgttat gaagatcaac aaagccgtat aaaacgaggg attctgcaat ataaaacagc 4441 gttatgtaca ctagaagatc attattatac agaacgtatg aagtataagg atgagctaga 4501 agatgtgaaa gagaatcttg atgagaagta tgaagaagct cagcaaggag aaaaacagtt 4561 tgcacaatta gaggcggagt tactagcgaa acaagctgag tttcaaagtg cagaaaaaga 4621 gcgtgaaatt gccgaggaac gacaactaca gtgcaaaaag gaaagtaaag ataaagagcg 4681 agaatggaat gcaatgaaag aagagataaa agacgtaaca gatcgcgtga aaaatatagg 4741 aattagtgaa gatgttgtaa gagcagaaaa gagtagtaaa gagcagcaat tgcaagaagc 4801 tgaaaaggaa aaggtatata cagagcagct tattagtgag acaagttata atttaaatga 4861 attaaggtca gaagttgcga agctagaagt gcaagtagat aatgatgaag cagctgtcgt 4921 ttctgcaaag aattacatag tgcaatataa gtctagtttc tatatggaag aaaagcatac 4981 aaaagtagaa agtatgatga gacagacgaa agatcttgtt gaaacggtga agaaagatct 5041 tcagcaaaaa tacgaagaga aaaagcagct agagctaaat cgttacgtca gtccgaggca 5101 agaagaagga cttagatact taagaaggga agggttacaa gcttatccgc ttcgagactt 5161 aatagaatta gaaggcgacg cagaatttcg tcatgaagat attttaaata caattaaata 5221 tgcgatcttc gtagaatcaa aagaattcag accaccgaat gatttgtatt acgtaccgtt 5281 gccactcatt gttccaactg aaagtgttat ttccttaccg cagtataagc tgagaattaa 5341 agaaggagac aacgaaaaac ttgtttctgt agcaatgaaa gctttatggt gggtaaaaca 5401 attctttaca ggtgagcagc catgtattca aaagaatagt ttaattgata taagaggatt 5461 ccgtggggaa caagaaaaaa cggaatacat tttaagtgaa aaagcaatta tgcaacgttt 5521 agaagagaca ggaaaatgga ttgaagaaca tgaaaaacag ctcatccaat atgagcgtga 5581 tattcaaaca ctggaagaaa aagaaagaaa acttcacgac attgtatata aactaagaga 5641 tgcagaagcc gttttacaaa aagctgccga acgcacattt agaatcgaac agttagggcg 5701 aaaaacggaa gagaaacaaa ggctagaaca ggaaatacaa aggctatatg caattaacca 5761 agaattgcat acgcgcatat ctcgcttaag agagcgtctt gaaacgttag aacagtacga 5821 aatgatatat gaagaactgc ataaggaaaa agaaaaaatt gcacatatgc aaaagcttga 5881 acaaattcat agagagttat tggatgagct caagagagta gtagagcaaa gagatatact 5941 ggatgagact tgtaatagat tggaaattga atgtaataaa gcgagtcaaa aaacgaaaca 6001 acaaaaacaa gaagtagaag aactacgcgc gtatattcag cgtttagaaa agaaaaaaca 6061 agatgttcaa gagcatttca taacgacaga agaaaaacta attagcatac aaagagaaaa 6121 ccaggatgcg aatgacacgt atggaaaatt attagagcaa ctaggttggg aaaaacaaat 6181 agaagagtgg tctgaagcga aagcactttc tcaaaaacaa agcgcagaga ttacactaga 6241 aggagcactc ggtgaaacag ttgatccact agcgccagaa aattacgcga agatgaaaga 6301 agaaaatgaa aaaagtaatg cagaactgca taacgcagaa caaattttga acgaacttcg 6361 cgaaaatata gcacttatga gagaacgtct cgaaacgacg atccaaatga atgctcataa 6421 aatccataaa aagtttgaac agtacatgga acaattccac ttcgaaggaa aagtagaatg 6481 gaacatggac acaaacaaac acggtgacat gcgttactat ctctacataa aagcgcgtaa 6541 aaaaggtcac cgtggcaaaa tggaagacat tagcgccaaa ggacgcggag gcaaagtagg 6601 aagcggcgta tcaggaggag aagaatccct ttcatctcta ctattcgcac tagccttact 6661 acaaacaatc gaagcatccc caggctacat catcctagac gaatacgaca gcgccctaga 6721 cgacagccga aaagaaaaag tcttcaccct attcgaagag gaactaaatc ggaaaatgat 6781 catcgtctca ccaaaaagtc atgatccaaa ctacttacaa cacttctcgc aagcattaac 6841 agttatgcac gatgcgagtg tgccggttag tcgaattttg cagattaaga gggcggtaga 6901 agaaactgaa actgtaatca aggataacta atttaaaacg tccatatcaa attttgatat 6961 ggacgtttta ttgctgttta atatggagat aaagaaaata aggatgtgat tgtaaa

(SEQ ID NO: 19; construct 61 of Table 4).

[00920] The coding regions for each of the jetA" ¹ , jetB" ¹ , jetC", and jetD ¹ " gene sequences within this embodiment of a Wadjet Type III cassette (SEQ ID NO: 19) are as follows: nucleotides 444-1700 encode an embodiment of a JetD ^m polypeptide, nucleotides 1676-3070 encode an embodiment of a JetA ¹¹¹ polypeptide, nucleotides 3030-3713 encode an embodiment of a JetB ^m polypeptide, and nucleotides 3710-6931 encode an embodiment of a JetC ^m polypeptide.

[00921] In some embodiments, a Defense System Xc comprising a JetA ^m polypeptide, a JetB ¹¹¹ polypeptide, a JetC ^m polypeptide, and a JetD ¹¹¹ polypeptide is encoded by the nucleic acid sequence set forth in SEQ ID NO: 19. In some embodiments, a Defense System Xc comprising a JetA ^m polypeptide, a JetB ^m polypeptide, a JetC ^m polypeptide, and a JetD ^m polypeptide, is encoded by a nucleic acid sequence having at least 80% homology to the sequence set forth in

SEQ ID NO: 19. In some embodiments, a Defense System Xc comprising a JetA ^m polypeptide, a JetB ¹¹¹ polypeptide, a JetC ^m polypeptide, and a JetD ¹¹¹ polypeptide, is encoded by a nucleic acid sequence having at least 85% homology, or 90% homology, or 95% homology, or 97% homology, or 98% homology, or 99% homology to the sequence set forth in SEQ ID NO: 19. In some embodiments, a Defense System Xc comprising a JetA ^m polypeptide, a JetB ^m polypeptide, a JetC ^m polypeptide, and a JetD ^m polypeptide, is encoded by a nucleic acid sequence having at least 80% identity to the sequence set forth in SEQ ID NO: 19. In some embodiments, a Defense System Xc comprising a JetA ^m polypeptide, a JetB ^m polypeptide, a JetC ¹¹¹ polypeptide, and a JetD ^m polypeptide, is encoded by a nucleic acid sequence having at least 85% identity, or 90% identity, or 95% identity, or 97% identity, or 98% identity, or 99% identity to the sequence set forth in SEQ ID NO: 19.

[00922] In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) comprise genes jetAJetBJetC, and jetD. In some embodiments, the components of a Wadjet Type I defense system consist of genes jetA, jetB, jetC, and jetD. In some embodiments, the components of a Wadjet Type I defense system comprise nucleic acid sequences encoding a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide. In some embodiments, the components of a Wadjet Type I defense system consist of nucleic acid sequences encoding a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide. In some embodiments, the components of a Wadjet Type I defense system comprise a jetB gene, a jetC gene, and a jetD gene. In some embodiments, the components of a Wadjet Type I defense system consist of a jetB gene, a jetC gene, and a jetD gene. In some embodiments, the components of a Wadjet Type I defense system comprise nucleic acid sequences encoding a JetB polypeptide, and a JetC polypeptide, and an MKsG polypeptide. In some embodiments, the components of a Wadjet Type I defense system consist of nucleic acid sequences encoding a JetB polypeptide, and a JetC polypeptide, and an MKsG polypeptide.

[00923] In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) comprise JetA, JetB, JetC, and JetD polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) consist of JetA, JetB, JetC, and JetD polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) comprise JetB, JetC, and JetD polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) consist of JetB, JetC, and JetD polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) comprise JetC, and JetD polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) consist of, and JetD polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) comprise a JetD polypeptide. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) consist of a JetD polypeptide. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) comprise JetA, JetC, and JetD polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) consist of JetA, JetC, and JetD polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) comprise JetA and JetD polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) consist of JetA and JetD polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) comprise JetA and JetC polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) consist of JetA and JetC polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) comprise JetB and JetC polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) consist of JetB and JetC polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) comprise JetB and JetD polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) consist of JetB and JetD polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) comprise JetB and JetC polypeptides. In some embodiments, the components of a Wadjet Type I defense system (Defense System Xa) consist of JetC and JetD polypeptides.

[00924] In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) comprise JetA ¹¹ , JetB ¹¹ , JetC ^u , and JetD ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) consist of JetA ^u , JetB ^u , JetC ¹¹ , and JetD ^u polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) comprise JetB ¹¹ , JetC ¹¹ , and JetD ^u polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) consist of JetB ^u , JetC ¹¹ , and JetD ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) comprise JetC ^u , and JetD ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) consist of, and JetD ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) comprise a JetD ^u polypeptide. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) consist of a JetD ^u polypeptide. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) comprise JetA ¹¹ , JetC ^u , and JetD ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) consist of JetA ^u , JetC ^u , and JetD ^u polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) comprise JetA ¹¹ and JetD ^u polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) consist of JetA ^u and JetD ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type Π defense system (Defense System Xb) comprise JetA ¹¹ and JetC ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) consist of JetA ^u and JetC ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type Π defense system (Defense System Xb) comprise JetB ^u and JetC ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) consist of JetB ¹¹ and JetC ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type Π defense system (Defense System Xb) comprise JetB ^u and JetD ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) consist of JetB ¹¹ and JetD ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type Π defense system (Defense System Xb) comprise JetB ^u and JetC ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type II defense system (Defense System Xb) consist of JetC ¹¹ and JetD ¹¹ polypeptides.

[00925] In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) comprise JetA ¹¹¹ , JetB ^m , JetC ¹¹¹ , and JetDi ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type ΠΙ defense system (Defense System Xc) consist of JetA ^m , JetBi ¹¹ , JetCi ¹¹ , and JetDi ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) comprise JetB ^m , JetC ¹¹¹ , and JetD ^m polypeptides. In some embodiments, the components of a Wadjet Type ΠΙ defense system (Defense System Xc) consist of JetB ^m , JetC ^m , and JetD ^m polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) comprise JetC ^m , and JetD ^m polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) consist of, and JetD ^m polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) comprise a JetD ^m polypeptide. In some embodiments, the components of a Wadjet Type ΠΙ defense system (Defense System Xc) consist of a JetD ^m polypeptide. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) comprise JetA ^m , JetC ^m , and JetD ¹¹¹ polypeptides. In some embodiments, the components of a Wadjet Type ΠΙ defense system (Defense System Xc) consist of JetA ¹¹¹ , JetC ¹¹¹ , and JetD ^m polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) comprise JetA ^m and JetD ^m polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) consist of JetA ^m and JetD ^m polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) comprise JetA ^m and JetC ¹¹¹ polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) consist of JetA ^m and JetC ^m polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) comprise JetB ^m and JetC ¹¹¹ polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) consist of JetB ^m and JetC ¹¹ polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) comprise JetB ^m and JetD ^m polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) consist of JetB ¹¹¹ and JetD ^m polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) comprise JetB ^m and JetC ¹¹¹ polypeptides. In some embodiments, the components of a Wadjet Type III defense system (Defense System Xc) consist of JetC ¹¹¹ and JetD ^m polypeptides.

[00926] In some embodiments, a Wadjet system Type I, Type II, or Type III, comprising a non-functional JetA/JetA ^u /JetA ^m polypeptide or lacking a JetA/JetA ^u /JetA ^m polypeptide has increased transformation efficiency. In some embodiments, a Wadjet system Type I, Type II, or Type III, comprising a non-functional JetC/JetC ^u /JetC ^m polypeptide or lacking a JetC/JetC ^u /JetC ^m polypeptide has increased transformation efficiency. In some embodiments, a Wadjet system Type I, Type II, or Type III, comprising a non-functional JetD/JetD ^u /JetD ^m polypeptide or lacking a JetD/JetD ^u /JetD ^m polypeptide has increased transformation efficiency.

[00927] In some embodiments, a construct comprising the Wadjet defense system encodes more than one component of the defense system but less than all of the components required for a functionally active defense system, whereby multiple constructs may be used to assemble the functional defense system. For example, in some embodiments each of jetA, jetB, jetC, and jetD may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional a Wadjet Type I defense system. In some embodiments each of jetA", jetB", jetC", and jetD" may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional a Type II Wadjet defense system. In some embodiments each of jetA" ¹ , jetB ¹ ", jetC", and jetD ¹ " may be encoded by nucleic acid sequences comprised in different constructs, wherein expression of the combination of constructs produces a functional a Type III Wadjet defense system.

[00928] In some embodiments, components of a Wadjet Type I defense system (Defense Systems Xa) may be encoded by a nucleic acid encoding 1, 2, 3, or 4 components of the Wadjet defense system as described herein. For example, in some embodiments, a construct comprises a nucleic acid comprising a jetA gene. In some embodiments, a construct comprises a nucleic acid comprising a jetA gene and a jetB gene. In some embodiments, a construct comprises a nucleic acid comprising a jetA gene and a jetC gene. In some embodiments, a construct comprises a nucleic acid comprising a jetA gene and a jetD gene. In some embodiments, a construct comprises a nucleic acid comprising a jetB gene. In some embodiments, a construct comprises a nucleic acid comprising a jetB gene and a jetC gene. In some embodiments, a construct comprises a nucleic acid comprising a jetB gene and a jetD gene. In some embodiments, a construct comprises a nucleic acid comprising a jetC gene. In some embodiments, a construct comprises a nucleic acid comprising a jetC gene and a jetD gene. In some embodiments, a construct comprises a nucleic acid comprising a jetD gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' e/A gene, a y ^' eiS gene, and a jetC gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eiA gene, a y ^' eiS gene, and a jetD gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' e/A gene, a y ^' eiC gene, and a jetD gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eiD gene, a y ^' eiS gene, and a jetC gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eiD gene, a y ^' eifi gene, a y ^' eiC gene, and a y ^' e/A gene.

[00929] In some embodiments, components of a Wadjet Type II defense system (Defense Systems Xb) may be encoded by a nucleic acid encoding 1, 2, 3, or 4 components of the Wadjet defense system as described herein. For example, in some embodiments, a construct comprises a nucleic acid comprising a jetA ^u gene. In some embodiments, a construct comprises a nucleic acid comprising a jetA" gene and a jetB " gene. In some embodiments, a construct comprises a nucleic acid comprising a jetA " gene and a jetD " gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eiS " gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eiS ¹¹ gene and a y ^' eiC ¹¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eifi ¹¹ gene and a y ^' eiD ¹¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eiC ¹¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a jetC " gene and a jetD " gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eiD " gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' e/A ¹¹ gene, a y ^' eiS ¹¹ gene, and a y ^' eiC ¹¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' e/A ¹¹ gene, a jetB " gene, and a jetD " gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eiA " gene, a y ^' eiC ¹¹ gene, and a y ^' eiZ) ¹¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eiZ) ¹¹ gene, a y ^' eifi ¹¹ gene, and a y ^' eiC ¹¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a jetD " gene, a y ^' eifi " gene, a y ^' ei C " gene, and a y ^' eiA " gene.

[00930] In some embodiments, components of a Wadjet Type III defense system (Defense Systems Xc) may be encoded by a nucleic acid encoding 1, 2, 3, or 4 components of the Wadjet defense system as described herein. For example, in some embodiments, a construct comprises a nucleic acid comprising a jetA '" gene. In some embodiments, a construct comprises a nucleic acid comprising a jetA " ¹ gene and a jetB ¹¹¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a jetA ¹ " gene and a jetC" gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eiA ¹¹¹ gene and a jetD" ¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a jetB" ¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eifi ¹¹¹ gene and a y ^' eiC ¹¹¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eifi ¹¹¹ gene and a jetD ¹ " gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eiC ¹¹¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' eiC ¹¹¹ gene and a jetD" ¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a jetD ¹ " gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' e/A ¹¹¹ gene, a jef'B gene, and a y ^' eiC ¹¹¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a y ^' e/A ¹¹¹ gene, a jetB" ¹ gene, and a jetD ¹ " gene. In some embodiments, a construct comprises a nucleic acid comprising a jetA ¹ " gene, a jetC" gene, and a jetD" ¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a jetD ¹ " gene, a y ^' eifi ¹¹¹ gene, and a y ^' eiC ¹¹¹ gene. In some embodiments, a construct comprises a nucleic acid comprising a jetD" ¹ gene, a y ^' eiS ¹¹¹ gene, a y ^' eiC ¹¹¹ gene, and a y ^' e/A ¹¹¹ gene.

[00931] In some embodiments, components of a Wadjet defense system (Defense System Xa, Xb, or Xc) may comprise a nucleic acid encoding 1, 2, 3, or 4 polypeptide components of the Wadjet defense system. For example, in some embodiments, a construct comprises a nucleic acid encoding a JetA or a JetA ^u or a JetA ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetA or a JetA ¹¹ or a JetA ^m polypeptide, respectively and a JetB or a JetB ^u or a JetB ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetA or a JetA ¹¹ or a JetA ^m polypeptide, respectively and a JetC or a JetC ^u or a JetC ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetA or a JetA ¹¹ or a JetA ^m polypeptide, respectively and a JetD or a JetD ^u or a JetD ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetB or a JetB ^u or a JetB ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetB or a JetB ¹¹ or a JetB ^m polypeptide, respectively and a JetC or a JetC ¹¹ or a JetC ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetB or a JetB ¹¹ or a JetB ^m polypeptide, respectively and a JetD or a JetD ¹¹ or a JetD ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetC or a JetC ¹¹ or a JetC ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetC or a JetC ¹¹ or a JetC ^m polypeptide, respectively and a JetD or a JetD ¹¹ or a JetD ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetD or a JetD ¹¹ or a JetD ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetA or a JetA ^u or a JetA ^m polypeptide, respectively, a JetB or a JetB ^u or a JetB ¹¹¹ polypeptide, respectively, and a JetC or a JetC ¹¹ or a JetC ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetA or a JetA ^u or a JetA ^m polypeptide, a JetB or a JetB ¹¹ or a JetB ^m polypeptide, respectively, and a JetD or a JetD ¹¹ or a JetD ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetA or a JetA ^u or a JetA ^m polypeptide, a JetC polypeptide, and a JetD or a JetD ^u or a JetD ^m polypeptide, respectively. In some embodiments, a construct comprises a nucleic acid encoding a JetD or a JetD ¹¹ or a JetD ^m polypeptide, respectively, a JetB or a JetB ^u or a JetB ¹¹¹ polypeptide, respectively, and a JetC or a JetC ¹¹ or a JetC ^m polypeptide, respectively.

[00932] In some embodiments, the components making up a functional Wadjet Type I anti- plasmid defense system comprise a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide, each encoded by a jetA, a jetB, a jetC, and a jetD gene, respectively.

[00933] In some embodiments, the components making up a functional Wadjet Type II anti- plasmid defense system comprise a JetA ¹¹ polypeptide, a JetB ^u polypeptide, a JetC ^u polypeptide, and a JetD ^u polypeptide, each encoded by a jetA ¹¹ , a jetB ¹¹ , a jetC ¹ , and a y ^' eiD ¹¹ gene, respectively [00934] In some embodiments, the components making up a functional Wadjet Type ΠΙ anti- plasmid defense system comprise a JetA ^m polypeptide, a JetB ^m polypeptide, a JetC ^m polypeptide, and a JetD ¹¹¹ polypeptide, each encoded by a jetA ^m , a jetB ^m , a y ^' eiC ^m , and a jetD ^m gene, respectively

[00935] In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid encoding a JetA or a JetA ¹¹ or a JetA ^m polypeptide, respectively. In some embodiments, a Wadjet defense system having an anti- plasmid activity (Defense System Xa, Xb, or Xc) comprise a nucleic acid encoding a JetA or a JetA ¹¹ or a JetA ^m polypeptide, respectively and a JetB or a JetB ¹¹ or a JetB ¹¹¹ polypeptide, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprise a nucleic acid encoding a JetA or a JetA ¹¹ or a JetA ^m polypeptide, respectively and a JetC or a JetC ¹¹ or a JetC ^m polypeptide, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprise a nucleic acid encoding a JetA or a JetA ¹¹ or a JetA ^m polypeptide, respectively and a JetD or a JetD ^u or a JetD ^m polypeptide, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprise a nucleic acid encoding a JetA or a JetA ¹¹ or a JetA ^m polypeptide, respectively, a JetB or a JetB ^u or a JetB ^m polypeptide, respectively, and a JetC or a JetC ¹¹ or a JetC ^m polypeptide, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprise a nucleic acid encoding a JetA or a JetA ¹¹ or a JetA ^m polypeptide, respectively, a JetB or a JetB ^u or a JetB ^m polypeptide, respectively, and a JetD or a JetD ¹¹ or a JetD ^m polypeptide, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprise a nucleic acid encoding a JetA or a JetA ¹¹ or a JetA ^m polypeptide, respectively, a JetC or a JetC ^u or a JetC ^m polypeptide, respectively, and a JetD or a JetD ¹¹ or a JetD ^m polypeptide, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprise a nucleic acid encoding a JetB or a JetB ¹¹ or a JetB ^m polypeptide, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprise a nucleic acid encoding a JetB or a JetB ¹¹ or a JetB ^m polypeptide, respectively and a JetC or a JetC ¹¹ or a JetC ^m polypeptide, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprise a nucleic acid encoding a JetB or a JetB ^Ά or a JetB ^m polypeptide, respectively and a JetD or a JetD ^u or a JetD ^m polypeptide, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprise a nucleic acid encoding a JetC or a JetC ¹¹ or a JetC ^m polypeptide, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprise a nucleic acid encoding a JetC or a JetC ^u or a JetC ^m polypeptide, respectively and a JetD or a JetD ¹¹ or a JetD ¹¹¹ polypeptide, respectively.

[00936] In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid comprising a jetA, jetA", or jetA" ¹ gene, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid comprising a jetA, jetA", or jetA ¹ " gene, respectively and a jetB, jetB", or jetB ^m gene, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid comprising a jetA, jetA", or jetA ¹ " gene, respectively and a jetC, jetC", or jetC" gene, respectively. In some embodiments, a Wadjet defense system having an anti- plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid comprising a jetA, jetA", or jetA ¹ " gene, respectively and a jetD, jetD", or jetD ¹ " gene, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid comprising a jetA, jetA", or jetA ¹ " gene, respectively, a jetB, jetB", or jetB ¹ " gene, respectively, and a jetC, jetC", or jetC" gene, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid comprising a jetA, jetA", or jetA ¹ " gene, respectively, a jetB, jetB", or jetB ¹ " gene, respectively, and a jetD, jetD", or jetD ¹ " gene, respectively gene. In some embodiments, a Wadjet defense system having an anti-plasmid activity comprise a nucleic acid comprising a jetA, jetA", or jetA ¹ " gene, respectively, a jetC, jetC, or jetC" gene, respectively, and a jetD gene. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid comprising a jetB, jetB ¹¹ , or jetB ¹ " gene, respectively. In some embodiments, a Wadjet defense system having an anti- plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid comprising a jetB, jetB", or jetB ¹ " gene, respectively and a jetC, jetC", or jetC" gene, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity comprise a nucleic acid comprising a jetB, jetB", or jetB ¹ " gene, respectively and a jetD, jetD", or jetD ¹ " gene, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid comprising a jetB, jetB", or jetB ¹ " gene, respectively, a jetD, jetD", or jetD ¹ " gene, respectively, and a jetC, jetC", or jetC" gene, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid comprising a jetC, jetC", or jetC" gene, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid comprising a jetC, jetC, or jetC" gene, respectively and a jetD, jetD", or jetD ¹ " gene, respectively. In some embodiments, a Wadjet defense system having an anti-plasmid activity (Defense System Xa, Xb, or Xc) comprises a nucleic acid comprising a jetD, jetD", or jetD ¹ " gene, respectively.

[00937] In some embodiments, a Wadjet Type I defense system having an anti-plasmid activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3' order of polypeptides encoded is JetA, JetB, JetC, and JetD. In some embodiments the 5' to 3' order of polypeptides does not affect the anti-plasmid activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti-plasmid activity.

[00938] In some embodiments, the 5' to 3' order of polypeptides is random comprising any order of JetA, JetB, JetC, and JetD. In some embodiments, for example but not limited to, the order is JetB, JetC, JetD, and JetA; or JetC, JetD, JetA, and JetB; or JetD, JetA, JetB, and JetC.

[00939] In some embodiments, a Wadjet Type I defense system having an anti-plasmid activity comprises a nucleic acid construct comprising genes in a set order. In some embodiment, the 5' to 3' order of genes is jetA, jetB, jetC, and jetD. In some embodiment, the 5' to 3' order of genes in a Wadjet defense system is not jetA, jetB, jetC, and jetD. In some embodiments the 5' to 3' order of genes does not affect the anti-plasmid activity. In some embodiments the 5' to 3' order of genes does affect the anti-plasmid activity. [00940] In some embodiments, the 5' to 3' order of genes is random, for example any order of jetA, jetB, jetC, and jetD. In some embodiments, for example but not limited to, the order is jetB, jetC, jetD, and jetA; or jetC, jetD, jetA, and jetB; or jetD, jetA, jetB, and jetC.

[00941] In some embodiments, a Wadjet Type II defense system having an anti-plasmid activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3' order of polypeptides encoded is JetA ¹¹ , JetB ¹¹ , JetC ¹¹ , and JetD ¹¹ . In some embodiments the 5' to 3' order of polypeptides does not affect the anti- plasmid activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti- plasmid activity.

[00942] In some embodiments, the 5' to 3' order of polypeptides is random comprising any order of JetA ¹¹ , JetB ¹¹ , JetC ¹¹ , and JetD". In some embodiments, for example but not limited to, the order is JetB", JetC", JetD", and JetA"; or JetC", JetD", JetA", and JetB"; or JetD", JetA", JetB", and JetC".

[00943] In some embodiments, a Wadjet Type II defense system having an anti-plasmid activity comprises a nucleic acid construct comprising genes in a set order. In some embodiment, the 5' to 3' order of genes is jetA ¹¹ , jetB ¹¹ , jetC ¹¹ , and jetD ¹¹ . In some embodiment, the 5' to 3' order of genes in a Wadjet defense system is not jetA ¹¹ , jetB ¹¹ , jetC ¹ , and jetD ¹¹ . In some embodiments the 5' to 3' order of genes does not affect the anti-plasmid activity. In some embodiments the 5' to 3' order of genes does affect the anti-plasmid activity.

[00944] In some embodiments, the 5' to 3' order of genes is random, for example any order of jetA ¹¹ , jetB ¹¹ , j etC , and jetD ¹¹ . In some embodiments, for example but not limited to, the order is jetB ¹¹ , jetC ⁿ , jetD ¹¹ , and jetA ⁿ ; or jetC ¹ , jetD ¹¹ , jetA ⁿ , and jetB ¹¹ ; or jetD ¹ , jetA ⁿ , jetB ⁿ , and jetC ⁿ .

[00945] In some embodiments, a Wadjet Type III defense system having an anti-plasmid activity comprises a nucleic acid construct comprising nucleic acids encoding polypeptides in a set order. In one embodiment, the 5' to 3' order of polypeptides encoded is JetA" ¹ , JetB" ¹ , JetC ¹ ", and JetD" ¹ . In some embodiments the 5' to 3' order of polypeptides does not affect the anti- plasmid activity. In some embodiments the 5' to 3' order of polypeptides does affect the anti- plasmid activity.

[00946] In some embodiments, the 5' to 3' order of polypeptides is random comprising any order of JetA" ¹ , JetB ¹ ", JetC ¹ ", and JetD" ¹ . In some embodiments, for example but not limited to, the order is JetB" ¹ , JetC", JetD ¹ ", and JetA" ¹ ; or JetC" ¹ , JetD ¹¹¹ , JetA ¹ ", and JetB ¹ "; or JetD ¹¹¹ , JetA ¹¹¹ , JetB ¹¹¹ , and JetC" ¹ . [00947] In some embodiments, a Wadjet Type I defense system having an anti-plasmid activity comprises a nucleic acid construct comprising genes in a set order. In some embodiment, the 5' to 3' order of genes is jetA ^m ,jetB ^m ,jet ⁿ , and jetD ^m . In some embodiment, the 5' to 3' order of genes in a Wadjet defense system is not jetA ^m , jetB ^m , jetC ^m , and jetD ^m . In some embodiments the 5' to 3' order of genes does not affect the anti-plasmid activity. In some embodiments the 5' to 3' order of genes does affect the anti-plasmid activity.

[00948] In some embodiments, the 5' to 3' order of genes is random, for example any order of jetA ^m , jetB ^m , jetC ^m , and jetD ^m . In some embodiments, for example but not limited to, the order is jetEP, jetc , jetA , and jetl ; or jeti , jetA , jetB , and jetC .

[00949] In some embodiments, the Wadjet Type I system (Defense System Xa) composition and order is as shown in Figure 7B. In some embodiments, the Wadjet Type II system (Defense System Xb) composition and order is as shown in Figure 7B. In some embodiments, the Wadjet Type ΠΙ system (Defense System Xc) composition and order is as shown in Figure 7B.

[00950] In some embodiments, a Wadjet Type I defense system having an anti-plasmid activity originates from a microbial genome, for example a bacterial or an archaeal genome (Table 11). In some embodiments, a Wadjet Type II defense system having an anti-plasmid activity originates from a microbial genome, for example a bacterial or an archaeal genome (Table 11). In some embodiments, a Wadjet Type ΠΙ defense system having an anti-plasmid activity originates from a microbial genome, for example a bacterial or an archaeal genome (Table 11).

[00951] A skilled artisan would appreciate that a Wadjet system (Defense Xa, Xb, Xc) is not present in the majority of bacteria and or archaea species.

[00952] In some embodiments, a functional Wadjet defense system (Defense System Xa, Xb, or Xc) comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different microbial species. For example, the source of the nucleic acid sequence encoding a JetA, a JetA ¹¹ , or a JetA ^m polypeptides, respectively polypeptide may be one microbial species, the source of the nucleic acid sequence encoding a JetB, a JetB ¹¹ , or a JetB ^m polypeptides, respectively may be a different microbial species, the source of the nucleic acid sequence encoding a JetC, a JetC ^u , or a JetC ^m polypeptides, respectively may be yet a different microbial species, and the source of the nucleic acid sequence encoding a JetD, a JetD ¹¹ , or a JetD ^m polypeptides, respectively may be still a different microbial species. In some embodiments, a functional Wadjet defense system (Defense System Xa, Xb, or Xc) comprises a non-naturally occurring combination of polypeptide components. In some embodiments, a functional Wadjet defense system (Defense System Xa, Xb, or Xc) comprises a combination of at least two polypeptides that do not naturally occur together. In some embodiments, a functional Wadjet defense system (Defense System Xa, Xb, or Xc) comprises a combination of at least three polypeptides that do not naturally occur together. In some embodiments, a functional Wadjet defense system (Defense System Xa, Xb, or Xc) comprises a combination of four polypeptides that do not naturally occur together.

[00953] In some embodiments, a functional Wadjet defense system (Defense System Xa, Xb, or Xc) comprises a construct comprising nucleic acid sequences encoding polypeptides, wherein the nucleic acid sequence encoding each polypeptide may originate from a different bacterial species. For example, the source of the nucleic acid sequence encoding a JetA, a JetA ^u , or a JetA ^m polypeptides, respectively may be one bacterial species, the source of the nucleic acid sequence encoding a JetB, a JetB ¹¹ , or a JetB ^m polypeptides, respectively may be a different bacterial species, the source of the nucleic acid sequence encoding a JetC, a JetC ¹¹ , or a JetC ^m polypeptides, respectively may be yet a different bacterial species, and the source of the nucleic acid sequence encoding a JetD, a JetD ¹¹ , or a JetD ^m polypeptides, respectively may be still a different bacterial species.

[00954] In some embodiments, the source of the nucleic acid encoding a JetA, a JetA ¹¹ , or a JetA ^m polypeptides, respectively, a JetB, a JetB ¹¹ , or a JetB ^m polypeptides, respectively, a JetC, a JetC ¹¹ , or a JetC ¹¹¹ polypeptides, respectively, and a JetD, a JetD ¹¹ , or a JetD ^m polypeptides, respectively is the same. In some embodiments, the source of the nucleic acid encoding a JetA, a JetA ¹¹ , or a JetA ^m polypeptides, respectively, a JetB, a JetB ¹¹ , or a JetB ¹¹¹ polypeptides, respectively, a JetC, a JetC ¹¹ , or a JetC ¹¹¹ polypeptides, respectively, and a JetD, a JetD ^u , or a JetD ^m polypeptides, respectively is the not the same. In some embodiments, the source of some of the components is the same, while the source of other components is not the same. In some embodiments, the source of the nucleic acid sequence of some of the components is same and the source of other of the components is different. For example, but not limited to the source of any of the nucleic acid sequences encoding JetA, a JetA ^u , or a JetA ^m polypeptides, respectively; JetB, a JetB ^u , or a JetB ¹¹¹ polypeptides, respectively; JetC, a JetC ¹¹ , or a JetC ^m polypeptides, respectively; and a JetD, a JetD ^u , or a JetD ^m polypeptides, respectively may be the same or different, having any combination thereof. In some embodiments, the source of the nucleic acid sequence of any of the components of a Wadjet defense system (Defense Systems Xa, Xb, or Xc) comprises any of the species listed in Table 11.

[00955] In some embodiments, a Wadjet defense system (Defense Systems Xa, Xb, or Xc) having an anti-plasmid activity comprises a nucleic acid construct comprising non-coding regions between the nucleic acid sequences encoding the polypeptides. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence not naturally occurring in the microbial species of origin. In some embodiments, the non-coding regions between the nucleic acid sequences comprises nucleic acid sequence is the naturally occurring in the microbial species of origin.

[00956] In some embodiments, a Wadjet system disclosed herein (Defense Systems Xa, Xb, or Xc) comprises a multi-gene phage resistance system broadly distributed in microbial genomes. According to some embodiments, the Wadjet system (Defense Systems Xa, Xb, or Xc) components are located in a gene cluster in a microbial cell genome. According to some embodiments, the Wadjet system (Defense Systems Xa, Xb, or Xc) components are located in close proximity (e.g. positioned within 20 genes, 10 genes, 5 genes or less one from the other) in a genome of a prokaryotic cell. According to some embodiments the prokaryotic cell expresses an endogenous Wadjet defense system (Defense Systems Xa, Xb, or Xc). According to some embodiments, the prokaryotic cell expresses an endogenous functional Wadjet defense system (Defense Systems Xa, Xb, or Xc). According to some embodiments, the species of prokaryotic cell is selected from the group consisting of the species listed in Table 11. According to some embodiments, a prokaryotic cell expresses a non-endogenous Wadjet defense system (Defense Systems Xa, Xb, or Xc). According to some embodiments, a prokaryotic cell expresses a non-endogenous functional Wadjet defense system (Defense Systems Xa, Xb, or Xc). According to some embodiments, the species of prokaryotic cell expressing a non-endogenous functional Wadjet defense system (Defense Systems Xa, Xb, or Xc) is selected from the group consisting of the species listed in Table 11.

[00957] In some embodiments, Wadjet Type I defense system components comprise JetA, JetB, JetC and JetD polypeptides. In some embodiments, Wadjet Type I defense system components comprise functional portions of JetA, JetB, JetC and JetD polypeptides. In some embodiments, the Wadjet Type I defense system components are encoded by jetA, jetB, jetC and jetD genes. In some embodiments, Wadjet Type I defense system components comprise JetB, JetC and JetD polypeptides.

[00958] In some embodiments, Wadjet Type II defense system components comprise JetA ¹¹ , JetB ¹¹ , JetC ¹¹ and JetD ¹¹ polypeptides. In some embodiments, Wadjet Type II defense system components comprise functional portions of JetA ¹¹ , JetB ¹¹ , JetC ^u and JetD ^u polypeptides. In some embodiments, the Wadjet Type II defense system components are encoded

jetC ⁿ and jetD ⁿ genes.

[00959] In some embodiments, Wadjet Type III defense system components comprise JetA ^m , JetB ¹¹¹ , JetC ^m and JetD ^m polypeptides. In some embodiments, Wadjet Type ΠΙ defense system components comprise functional portions of JetA ¹¹¹ , JetB ^m , JetC ^m and JetD ¹¹¹ polypeptides. In some embodiments, the Wadjet Type III defense system components are encoded by jetA ^m , jetBT etC and jetJ genes.

[00960] Non-limiting embodiments of endogenous Wadjet systems (Defense Systems Xa, Xb, and Xc) and the respective location of their components are provided in Table 11 herein.

[00961] In some embodiments, the components of a Wadjet system may be identified by the presence of similar domains present within each component. In some embodiments, domains comprise pfam domains and or clusters of orthologous groups (COG) domains.

[00962] In some embodiments, the term "JetA" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the jetA gene, comprising variants jetA, jetA ¹¹ and jetA ¹¹¹ ' associated with Defense Systems Xa, Xb, and Xc, respectively. In some embodiments, the terms "jetA ", "jetA" and "jetA"' ' may be used interchangeably. In some embodiments, the term "JetA" refers to a JetA polypeptide or a JetA ¹¹ polypeptide or a JetA ^m polypeptide (Figure 7B). In some embodiments, the terms JetA, JetA ¹¹ , and JetA ^m may be used interchangeably.

[00963] A skilled artisan would recognize that each Defense System X (Xa, Xb, and Xc) comprises a JetA polypeptide (A), a JetB polypeptide (B), a Jet C polypeptide (C), and a JetD polypeptide (C), wherein the polypeptides are encoded by a jetA gene, a jetB gene, a jetC gene, or a jetD gene, and variants thereof.

[00964] In some embodiments, the jetA gene encodes a polypeptide comprising a pfaml l855 domain. In some embodiments, the jetA gene encodes a polypeptide comprising a DUF3375 domain. In some embodiments, the jetA gene encodes a polypeptide comprising a pfam09660 domain. In some embodiments, the jetA gene encodes a polypeptide comprising a DUF2397 domain. In some embodiments, the jetA gene encodes a polypeptide comprising no known domain. In some embodiments, the jetA gene encodes a polypeptide comprising a pfaml l855 domain, or a DUF3375 domain, or a pfam09660 domain, or a DUF2397 domain, or any combination thereof. In some embodiments, the jetA gene encodes a polypeptide comprising a pfaml l855 domain and a DUF3375 domain. In some embodiments, a jetA gene encodes a polypeptide comprising a pfam09660 domain and a DUF2397 domain.

[00965] In some embodiments, the jetA gene encodes a polypeptide comprising a member of the MukF-like family. MukF appears to play a role in chromosome partitioning during cell division. MukF has been described as a member of the kleisin family, which includes proteins that commonly mediate the interaction between SMCs and other accessory proteins.

[00966] In some embodiments, JetA polypeptide is encoded by a gene positioned within 5-60 genes of a gene encoding a JetB, JetC, and or JetD polypeptide in a genome of a prokaryotic cell. In some embodiments, JetA polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a JetB, JetC, and or JetD polypeptide in a genome of a prokaryotic cell. In some embodiments, JetA polypeptide is encoded by a gene positioned within 5 genes upstream (5') and downstream (3') to a gene encoding a JetB, JetC, and or JetD polypeptide, or any combination thereof, in a genome of a prokaryotic cell.

[00967] In some embodiments, JetA and JetB are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, JetA and JetB are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, JetA, JetB, and JetC are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, JetA, JetB, and JetC are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, JetA, JetB, JetC, and JetD are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, JetA, JetB, JetC, and JetD are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, JetD, JetA JetB, and JetC are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, JetD, JetA, JetB, and JetC are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00968] In some embodiments, jetA and jetB genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, jetA, and jetB, genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, jetA, jetB, and jetC genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, jetA, jetB, and jetC genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, jetA, jetB, jetC, and jetD genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, jetA, jetB, jetC, and jetD genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, jetD, jetA, jetB, and jetC genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, jetD, jetD, jetB, and jetC genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00969] In some embodiments, a JetA polypeptide is about 488 amino acids long (median gene size).

[00970] In some embodiments, the JetA polypeptide comprises the amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns J and K. In some embodiments, the JetA polypeptide comprises the amino acid sequence having at least 80% homology to similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns J and K. In some embodiments, the JetA polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 11, rows 2-3174, columns J and K. In some embodiments, a homolog of a JetA polypeptide comprises a member of the MukF-like family. In some embodiments, the JetA polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns J and K. In some embodiments, the JetA polypeptide comprises the amino acid sequence having at least 80% identity to similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns J and K. In some embodiments, the JetA polypeptide comprises a homolog of a polypeptide having the amino acid sequences set forth in the polypeptides referenced in Table 11, rows 2-3174, columns J and K.

[00971] In some embodiments, the JetA polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns J and K. In some embodiments, the JetA polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns J and K.

[00972] In some embodiments, an JetA polypeptide comprises a MukF-like domain. In some embodiments, an JetA polypeptide comprises a MukF-like activity.

[00973] In some embodiments, the JetA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, column J and K. In some embodiments, the JetA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns J and K. In some embodiments, the JetA polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns J and K. In some embodiments, the JetA polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2- 3174, columns J and K. In some embodiments, the JetA polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2- 3174, columns J and K.

[00974] In some embodiments, the JetA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns J and L. In some embodiments, the JetA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns J. and L In some embodiments, the JetA polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns J and L. In some embodiments, the JetA polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns J and L. In some embodiments, the JetA polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns J and L.

[00975] In some embodiments, the nucleic acid sequence of a jetA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns J and L. In some embodiments, the jetA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns J and L. In some embodiments, the nucleic acid sequence of a jetA gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns J and L. In some embodiments, the jetA gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns J and L. In some embodiments, the nucleic acid sequence of a jetA gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns J and L.

[00976] In some embodiments, the term "JetB" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the jetB gene, comprising variants jetB, jetB" and jetB ¹ "' associated with Defense Systems Xa, Xb, and Xc, respectively. In some embodiments, the terms "jetB", "jetB" and "jetB ¹ " ' may be used interchangeably. In some embodiments, the term "JetB" refers to a JetB polypeptide or a JetB ¹¹ polypeptide or a JetB ^m polypeptide (Figure 7B). In some embodiments, the terms JetB, JetB ¹¹ , and JetB ¹¹¹ may be used interchangeably.

[00977] In some embodiments, the product of the jetB gene comprises a pfaml3835 domain. In some embodiments, the product of the jetB gene comprises a DUF4194 domain. In some embodiments, the product of the jetB gene comprises a pfam09661 domain. In some embodiments, the product of the jetB gene comprises a DUF2398 domain. In some embodiments, the product of the jetB gene comprises a pfaml3835 domain and a DUF4194 domain. In some embodiments, the product of the jetB gene comprises a pfam09661 domain and a DUF2398 domain. In some embodiments, the product of the jetB gene comprises a pfaml3835 domain, or a DUF4194 domain, or pfam09661 domain, or a DUF2398 domain, or any combination thereof. In some embodiments, the product of the jetB gene comprises a pfaml3835 domain, a DUF4194 domain, a pfam09661 domain, and a DUF2398 domain. In some embodiments, the jetB gene encodes a member of MukE-like family.

[00978] In some embodiments, JetB polypeptide is encoded by a gene positioned within 5-60 genes of a gene encoding a JetA, a JetC, and or a JetD polypeptide in a genome of a prokaryotic cell. In some embodiments, JetB polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding a JetA, JetC, and or a JetD polypeptide in a genome of a prokaryotic cell.

[00979] In some embodiments, JetB and JetC are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments JetB and JetC are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, JetB and JetD are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments JetB and JetD are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, JetB and JetA are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments JetB and JetA are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell. In some embodiments, JetB, JetC, and JetD are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, JetB, JetC, and JetD are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00980] In some embodiments, JetB polypeptide is encoded by a gene positioned within 5 genes upstream or downstream to a gene encoding jetA, jetC, and or jetD, in a genome of a prokaryotic cell. In some embodiments, JetB polypeptide is encoded by a gene positioned within 5 genes upstream or downstream to a gene encoding jetA in a genome of a prokaryotic cell. In some embodiments, JetB polypeptide is encoded by a gene positioned within 5 genes upstream or downstream to a gene encoding jetD in a genome of a prokaryotic cell. In some embodiments, JetB polypeptide is encoded by a gene positioned within 5 genes upstream or downstream to a gene encoding jetC in a genome of a prokaryotic cell.

[00981] In some embodiments, a JetB polypeptide is about 247 amino acids long (median gene size).

[00982] In some embodiments, the JetB polypeptide comprises an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns N and O. In some embodiments, the JetB polypeptide comprises an amino acid sequence having at least 80% homology to similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns N and O. In some embodiments, a homolog of the JetB polypeptide comprises a MukE-like family member. In some embodiments, the JetB polypeptide comprises an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns N and O. In some embodiments, the JetB polypeptide comprises an amino acid sequence having at least 80% identity to similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns N and O. In some embodiments, a JetB homolog comprises an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns N and O.

[00983] In some embodiments, a JetB polypeptide homolog comprises a MukE-like domain. In some embodiments, a JetB polypeptide homolog comprises a MukE-like activity.

[00984] In some embodiments, the JetB polypeptide comprises the amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns N and O. In some embodiments, the JetB polypeptide comprises the amino acid sequence having at least 80% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns N and O.

[00985] In some embodiments, the JetB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns N and O. In some embodiments, the JetB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns N and O. In some embodiments, the JetB polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns N and O. In some embodiments, the JetB polypeptide comprises the amino acid sequence having at least 80%, 85%, 90%, 95% identity within similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2- 3174, columns N and O. In some embodiments, the JetB polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2- 3174, columns N and O.

[00986] In some embodiments, the JetB polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns N and P. In some embodiments, the JetB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns N and P. In some embodiments, the JetB polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns N and P. In some embodiments, the JetB polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns N and P. In some embodiments, the JetB polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns N and P.

[00987] In some embodiments, the nucleic acid sequence of a jetB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns N and P. In some embodiments, the jetB gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns N and P. In some embodiments, the nucleic acid sequence of a jetB gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns N and P. In some embodiments, the jetB gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns N and P. In some embodiments, the nucleic acid sequence of a jetB gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns N and P.

[00988] In some embodiments, the term "JetC" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the jetC gene, comprising variants jetC, jetC" and jetC" ¹ ' associated with Defense Systems Xa, Xb, and Xc, respectively. In some embodiments, the terms "jetC", "jetC" and "jetC" ' may be used interchangeably. In some embodiments, the term "JetC" refers to a JetC polypeptide or a JetC ¹¹ polypeptide or a JetC ^m polypeptide (Figure 7B). In some embodiments, the terms JetC, JetC ¹¹ , and JetC ¹¹¹ may be used interchangeably.

[00989] In some embodiments, the product of a jetC gene comprises a pfaml3555 domain. In some embodiments, the product of a jetC gene comprises a pfaml3558 domain. In some embodiments, the product of a jetC gene comprises a COG4913 domain. In some embodiments, the product of a jetC gene comprises a COGl 196 domain. In some embodiments, the product of a jetC gene comprises a pfaml555 domain or a pfaml3558 domain or a COG4913 domain, or a COGl 196 domain, or a combination thereof. In some embodiments, the product of a jetC gene comprises a pfaml555 domain and a pfaml3558 domain. In some embodiments, the product of a jetC gene comprises a pfaml555 domain, a pfaml3558 domain, and a COG4913 domain. In some embodiments, the product of a jetC gene comprises a pfaml555 domain and a COG4913 domain. In some embodiments, the product of a jetC gene comprises a pfaml3558 domain and a COG4913 domain. In some embodiments, the product of a jetC gene comprises a MukB-like family member. MukB appears to be functionally related to the structural maintenance of chromosomes (SMC) proteins. MukB is also known as the E. coli condesin, a structural maintenance of chromosomes (SMC)-like protein, which forms a complex with MukE and the kleisin MukF. MukB is known to be able to mediate knotting of a DNA ring, an intramolecular reaction. In some embodiments, the product of a jetC gene comprises an ATP binding domain. In some embodiments, the product of a jetC gene comprises an exonuclease SbcC domain. In some embodiments, the product of a jetC gene comprises a MukB-like family member, or an ATP binding domain or an exonuclease SbcC domain, or a combination thereof. In some embodiments, the product of a jetC gene comprises a MukB-like family member and an ATP binding domain. In some embodiments, the product of a jetC gene comprises a MukB-like family member and an exonuclease SbcC domain. In some embodiments, the product of a jetC gene comprises an ATP binding domain and an exonuclease SbcC domain. In some embodiments, the product of a jetC gene comprises a MukB-lrke family member, an ATP binding domain and an exonuclease SbcC domain.

[00990] In some embodiments, JetC polypeptide is encoded by a gene positioned within 5-60 genes of a gene encoding JetA, and/or JetB and/or JetD in a genome of a prokaryotic cell. In some embodiments, JetC polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding JetA, and/or JetB and/or JetD in a genome of a prokaryotic cell. In some embodiments, JetC polypeptide is encoded by a gene positioned within 5 genes upstream and downstream to a gene encoding JetA, and/or JetB and/or JetD in a genome of a prokaryotic cell.

[00991] In some embodiments, JetC and JetD are encoded by genes positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, JetC and JetD are encoded by genes positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00992] In some embodiments, jetC and jetD genes are positioned sequentially 5' to 3' in a genome of a prokaryotic cell. In some embodiments, jetC and jetD genes are positioned contiguously 5' to 3' in a genome of a prokaryotic cell.

[00993] In some embodiments, a JetC polypeptide is about 1476 amino acids long (median gene size).

[00994] In some embodiments, the JetC polypeptide comprises an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns R and S. In some embodiments, the JetC polypeptide comprises an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns R and S. In some embodiments, the JetC polypeptide comprises an amino acid sequence having at least 80% homology to similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns R and S. In some embodiments, the JetC polypeptide comprises an amino acid sequence having at least 80% identity to similar domain regions a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns R and S. In some embodiments, an JetC homolog comprises an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2- 3174, columns R and S.

[00995] In some embodiments, an JetC polypeptide homolog comprises an ATP binding domain. In some embodiments, an JetC polypeptide homolog comprises an exonuclease SbcC activity. In some embodiments, an JetC polypeptide homolog comprises an MukB like activity.

[00996] In some embodiments, the JetC polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of SEQ ID NOs: In some embodiments, the JetC polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns R and S. In some embodiments, a JetC homolog comprises an ATP binding domain. In some embodiments, a JetC homolog comprises an exonuclease SbcC activity. In some embodiments, a JetC homolog comprises a member of the MukB -like family. In some embodiments, a JetC homolog comprises an ATP binding domain, or an exonuclease SbcC activity, or a member of the MukB- like family, or any combination thereof. In some embodiments, a JetC homolog comprises an ATP binding domain and an exonuclease SbcC activity. In some embodiments, a JetC homolog comprises an ATP binding domain and a member of the MukB -like family. In some embodiments, a JetC homolog comprises an exonuclease SbcC activity and a member of the MukB-like family. In some embodiments, a JetC homolog comprises an ATP binding domain, and an exonuclease SbcC activity, and a member of the MukB-like family.

[00997] In some embodiments, the JetC polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns R and S. In some embodiments, the JetC polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2- 3174, columns R and S. In some embodiments, the JetC polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2- 3174, columns R and S.

[00998] In some embodiments, the JetC polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns R and T. In some embodiments, the JetC polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns R and T. In some embodiments, the JetC polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns R and T. In some embodiments, the JetC polypeptide comprises the amino acid sequence encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within similar domain regions within a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns R and T. In some embodiments, the JetC polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns R and T.

[00999] In some embodiments, the nucleic acid sequence of a jetC gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, column N. In some embodiments, the jetC gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% homology within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns R and T. In some embodiments, the nucleic acid sequence of a jetC gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns R and T. In some embodiments, the jetC gene comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95% identity within encoded similar domain regions in comparison with nucleotide sequence encoding these domain within a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns R and T. In some embodiments, the nucleic acid sequence of a jetC gene comprises a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns R and T. [001000] In some embodiments, the jetC gene homolog encodes a polypeptide comprising an ATP binding domain. In some embodiments, a jetC gene homolog encodes a polypeptide comprising an exonuclease SbcC activity. In some embodiments, a jetC gene homolog encodes a polypeptide comprising a member of the MukB-like family. In some embodiments, a JetC homolog jetC gene homolog encodes a polypeptide comprising ATP binding domain, or an exonuclease SbcC activity, or a member of the MukB-like family, or any combination thereof. In some embodiments, a jetC gene homolog encodes a polypeptide comprising an ATP binding domain and an exonuclease SbcC activity. In some embodiments, a jetC gene homolog encodes a polypeptide comprising an ATP binding domain and a member of the MukB-like family. In some embodiments, a jetC gene homolog encodes a polypeptide comprising an exonuclease SbcC activity and a member of the MukB-like family. In some embodiments, a jetC gene homolog encodes a polypeptide comprising an ATP binding domain, and an exonuclease SbcC activity, and a member of the MukB-like family.

[001001] In some embodiments, the term "JetD" refers to the polynucleotide or expression product e.g., the polypeptide encoded by the jetD gene, comprising variants jetD, jetD" and jetD" ¹ ' associated with Defense Systems Xa, Xb, and Xc, respectively. In some embodiments, the terms "jetD", "jetD" and "jetD"' ' may be used interchangeably. In some embodiments, the term "JetD" refers to a JetD polypeptide or a JetD ¹¹ polypeptide or a JetD ^m polypeptide (Figure 7B). In some embodiments, the terms JetD, JetD ¹¹ , and JetD ^m may be used interchangeably.

[001002] In some embodiments, the product of the jetD gene comprises a pfaml 1795 domain. In some embodiments, the product of the jetD gene comprises a DUF3322 domain. In some embodiments, the product of the jetD gene comprises a pfam09983 domain. In some embodiments, the product of the jetD gene comprises a DUF2220 domain. In some embodiments, the product of the jetD gene comprises a pfaml 1796 domain. In some embodiments, the product of the jetD gene comprises a DUF3323 domain. In some embodiments, the product of the jetD gene comprises a pfam09664 domain. In some embodiments, the product of the jetD gene comprises a DUF2399 domain. In some embodiments, the product of the jetD gene comprises a COG4924 domain. In some embodiments, the product of the jetD gene comprises a pfaml 1795 domain, or a DUF3322 domain, or a pfam09983 domain, or a DUF2220 domain, or a pfaml 1796 domain, or a DUF3323 domain, or a pfam09664 domain, or DUF2399 domain, or a COG4924 domain, or any combination thereof. In some embodiments, the product of the jetD gene comprises a pfaml 1795 domain and a DUF3322 domain. In some embodiments, the product of the jetD gene comprises a pfam09983 and a DUF2220 domain. In some embodiments, the product of the jetD gene comprises a pfaml 1796 domain and a DUF3323 domain. In some embodiments, the product of the jetD gene comprises a pfam09664 domain and DUF2399 domain. In some embodiments, the product of the jetD gene comprises a pfaml 1796 domain and a DUF3323 domain, and a pfam09664 domain, and a DUF2399 domain. In some embodiments, the product of the jetD gene comprises a pfaml 1795 domain and a DUF3322 domain, and a pfam09983 domain, and a DUF2220 domain. In some embodiments, the product of the jetD gene comprises a pfaml 1795 domain and a DUF3322 domain, and a pfam09983 domain, and a DUF2220 domain, and a COG4924 domain.

[001003] In some embodiments, a JetD polypeptide comprises a pfaml 1795 domain. In some embodiments, a JetD polypeptide comprises a DUF3322 domain. In some embodiments, a JetD polypeptide comprises a pfam09983 domain. In some embodiments, a JetD polypeptide comprises a DUF2220 domain. In some embodiments, a JetD polypeptide comprises a pfaml 1796 domain. In some embodiments, a JetD polypeptide comprises a DUF3323 domain. In some embodiments, a JetD polypeptide comprises a pfam09664 domain. In some embodiments, a JetD polypeptide comprises a DUF2399 domain. In some embodiments, a JetD polypeptide comprises a COG4924 domain. In some embodiments, a JetD polypeptide comprises a pfaml 1795 domain, or a DUF3322 domain, or a pfam09983 domain, or a DUF2220 domain, or a pfaml 1796 domain, or a DUF3323 domain, or a pfam09664 domain, or DUF2399 domain, or a COG4924 domain, or any combination thereof. In some embodiments, a JetD polypeptide comprises a pfaml 1795 domain and a DUF3322 domain. In some embodiments, a JetD polypeptide comprises a pfam09983 and a DUF2220 domain. In some embodiments, a JetD polypeptide comprises a pfaml 1796 domain and a DUF3323 domain. In some embodiments, a JetD polypeptide comprises a pfam09664 domain and DUF2399 domain. In some embodiments, a JetD polypeptide comprises a pfaml 1796 domain and a DUF3323 domain, and a pfam09664 domain, and a DUF2399 domain. In some embodiments, a JetD polypeptide comprises a pfaml 1795 domain and a DUF3322 domain, and a pfam09983 domain, and a DUF2220 domain. In some embodiments, a JetD polypeptide comprises a pfaml 1795 domain and a DUF3322 domain, and a pfam09983 domain, and a DUF2220 domain, and a COG4924 domain.

[001004] In some embodiments, a JetD polypeptide is encoded by a gene positioned within 5- 60 genes of a gene encoding JetA, and/or JetB and/or JetC in a genome of a prokaryotic cell. In some embodiments, a JetD polypeptide is encoded by a gene positioned within 5 genes upstream (5') or downstream (3') to a gene encoding JetA, and/or JetB and/or JetC in a genome of a prokaryotic cell. In some embodiments, JetD polypeptide is encoded by a gene positioned within 5 genes upstream or downstream to a gene encoding JetA, and/or JetB and JetC in a genome of a prokaryotic cell.

[001005] In some embodiments, a JetD polypeptide is about 347 amino acids long (median gene size).

[001006] In some embodiments, the JetD polypeptide comprises an amino acid sequence having at least 80% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns V and W. In some embodiments, the JetD polypeptide comprises an amino acid sequence having at least 80% homology to similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns V and W. In some embodiments, a JetD polypeptide homologue comprises a topoisomerase IV/VI activity. In some embodiments, the JetD polypeptide comprises an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns V and W. In some embodiments, the JetD polypeptide comprises an amino acid sequence having at least 80% identity to similar domain regions within a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns V and W. In some embodiments, an JetD homolog comprises an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns V and W.

[001007] In some embodiments, a JetD polypeptide homolog comprises a topoisomerase IV/VI domain. In some embodiments, a JetD polypeptide homolog comprises a topoisomerase IV/VI structural domain. In some embodiments, a JetD polypeptide homolog comprises a topoisomerase IV/VI activity.

[001008] In some embodiments, the JetD polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95% homology to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns V and W. In some embodiments, the JetD polypeptide comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95% identity to a sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns V and W. In some embodiments, the JetD polypeptide comprises an amino acid sequence selected from the group consisting of the polypeptides referenced in Table 11, rows 2-3174, columns V and W.

[001009] In some embodiments, the JetD polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns V and X. In some embodiments, the JetD polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns V and X. In some embodiments, the JetD polypeptide comprises an amino acid sequence encoded from a nucleic acid sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns V and X.

[001010] In some embodiments, the jetD gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% homology to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns V and X. In some embodiments, a mksG gene homolog encodes a polypeptide comprising a topoisomerase IV/VI activity. In some embodiments, the jetD gene comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, or at least 95% identity to a sequence selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns V and X. In some embodiments, the nucleic acid sequence of the jetD gene is selected from the group consisting of the polynucleotides referenced in Table 11, rows 2-3174, columns V and X.

[001011] A skilled artisan would appreciate that the terms a "functional portion of a Defense System X component" or "functional fragment of Defense System X component" or "functional portion of a Wadjet defense system component" or "functional fragment of Wadjet defense system component" refers to a functional portion of a Wadjet polynucleotide or polypeptide, as disclosed herein, which expression is sufficient to elicit an anti-plasmid transformation efficiency activity alone or in combination with the at least one of the other Wadjet polynucleotides or polypeptides disclosed herein or functional portions thereof.

[001012] The terms "JetA", "JetB", "JetC", "JetD", "JetA"", "JetB"", "JetC"", "JetD"", "JetA^", "JetB^", "JetC^", "JetD^", "jetA", "jetB", "jetC' jetD , jetA*", "jetB^, "jetC" "jet&, jetA ^m ", "jetBf", "jetC ⁱⁿ " and "jetD^ also refer to functional homologs, which exhibit the desired activity (i.e., conferring decreased efficiency of plasmid transformation). Such homologs can be, for example, at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polypeptide sequences referenced in Table 11 rows 2-3174 columns J and K, N and O, R and S and V and W, respectively, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polynucleotide sequences referenced in Table 11 rows 2-3174 columns J and L, N and P, R and T and V and X. In some embodiments, such homologs comprise at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % homology or identity within similar domain regions of the polypeptide sequences referenced in Table 11 rows 2-3174 columns J and K, N and O, R and S and V and W, or 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identity or homology within nucleotide sequences encoding similar domain regions to the polynucleotide sequences referenced in Table 11 rows 2-3174 columns J and L, N and P, R and T and V and X.

[001013] Table 11 presents embodiments of components of Defense System X (Xa, Xb, and Xc) that may be found in a diverse array of bacteria and archaea genomes (referenced in Table 18). Table 11 presents embodiments of nucleic acid sequences encoding gene cassettes of Defense System X (Xa, Xb, and Xc; referenced in Table 18).

[001014] Defense System components, nucleic acid sequences thereof, and amino acid sequences thereof

[001015] Defense System components, nucleic acid sequences thereof, amino acid sequences thereof, and gene cassette nucleotide sequences thereof are presented below in Table 18.

[001016] Table 18: Defense Systems: Components and Gene Cassettes - polypeptide and nucleotide sequences thereof

Defense System Component Composition Table References

Defense System la ZorA polypeptides Table 8; Rows 2-1174; ZORYA Type I Column J "ZorA

protein accession" and Column K "PRT SEQ ID NO:"

Defense System la ZorB polypeptides Table 8; Rows 2-1174; ZORYA Type I Column N "ZorB

protein accession" and Column 0 "PRT SEQ ID NO:"

Defense System la ZorC polypeptides Table 8; Rows 2-1174; ZORYA Type I Column R "ZorC

protein accession" and Column S "PRT SEQ ID NO:"

Defense System la ZorD polypeptides Table 8; Rows 2-1174; ZORYA Type I Column V "ZorD

protein accession" and Column W "PRT SEQ ID NO:"

Defense System la ZorA polynucleotides Table 8; Rows 2-1174; ZORYA Type I Column J "ZorA

protein accession" and Column L "DNA SEQ ID NO:"

Defense System la ZorB polynucleotides Table 8; Rows 2-1174; ZORYA Type I ColumnN "ZorB

protein accession" and Column P "DNA SEQ ID NO:"

Defense System la ZorC polynucleotides Table 8; Rows 2-1174; ZORYA Type I ColumnR "ZorC

protein accession" and Column T "DNA SEQ ID NO:"

Defense System la ZorD polynucleotides Table 8; Rows 2-1174; ZORYA Type I ColumnV "ZorD

protein accession" and Column X "DNA SEQ ID NO:"

Defense System la Gene Cassette polynucleotides Table 8; Rows 2-1174; ZORYA Type I Column G

"genomic_accession" with Start in Column AD "Genomic Start Point" and End in Column AE "Genomic End Point"

Defense System lb ZorA polypeptides Table 8; Rows 1175-1830; ZORYA Type II Column J "ZorA protein accession" and

Column K "PRT SEQ ID NO:"

Defense System lb ZorB polypeptides Table 8; Rows 1175-1830; ZORYA Type I ColumnN "ZorB

protein accession" and Column 0 "PRT SEQ ID NO:"

Defense System lb ZorE polypeptides Table 8; Rows 1175-1830; ZORYA Type I Column Z "ZorE

protein accession" and Column AA "PRT SEQ ID NO:"

Defense System lb ZorA polynucleotides Table 8; Rows 1175-1830; ZORYA Type I Column J "ZorA

protein accession" and Column L "DNA SEQ ID NO:"

Defense System lb ZorB polynucleotides Table 8; Rows 1175-1830; ZORYA Type I Column N"ZorB

protein accession" and Column P "DNA SEQ ID NO:"

Defense System lb ZorE polynucleotides Table 8; Rows 1175-1830; ZORYA Type I ColumnZ "ZorE

protein accession" and Column AB "DNA SEQ ID NO:"

Defense System lb Gene Cassette polynucleotides Table 8; Rows 1175-1830; ZORYA Type I Column G

"genomic_accession" with Start in Column AD "Genomic Start Point" and End in Column AE "Genomic End Point"

Defense System II ThsA polypeptides Table 9; Rows 2-2100;

Thoeris Column I "ThsA

protein accession" and Column J "PRT SEQ ID NO:"

Defense System II ThsB polypeptides Table 9; Rows 2-2100;

Thoeris Column M "ThsB ¹

protein accession" and Column N "PRT SEQ ID NO:", Column Q "ThsB" protein accession" and Column R "PRT SEQ ID NO:", Column U "ThsB ^m protein accession" and Column V "PRT SEQ ID NO:", Column Y "ThsB ^iv protein_accession" and Column Z "PRT SEQ ID

NO:", and Column AC "ThsB ^v

protein accession" and Column AD "PRT SEQ ID NO:"

Defense System II thsA polynucleotides Table 9; Rows 2-2100;

Thoeris Column I "ThsA

protein accession" and Column K "DNA SEQ ID NO:"

Defense System II thsB polynucleotides Table 9; Rows 2-2100;

Thoeris Column M "ThsB ¹

protein accession" and Column O "DNA SEQ ID NO:", Column Q "ThsB" protein accession" and Column S "DNA SEQ ID NO:", Column U "ThsB ^m protein accession" and Column W "DNA SEQ ID NO:", Column Y "ThsB ^iv protein accession" and Column AA "DNA SEQ ID NO:", and Column AC "ThsB ^v

protein accession" and Column AE "DNA SEQ ID NO:"

Defense System II Gene Cassette polynucleotides Table 9; Rows 2-2100;

Thoeris Column G

"genomic_accession" with Start in Column AG "Genomic Start Point" and End in Column AH "Genomic End Point"

Defense System Ilia DruA polypeptides Table 10; Rows 2-123; Druantia Type I Column J "DruA

protein accession" and Column K "PRT SEQ ID NO:"

Defense System Ilia DruB polypeptides Table 10; Rows 2-123; Druantia Type I Column N "DruB

protein accession" and Column O "PRT SEQ ID NO:"

Defense System Ilia DruC polypeptides Table 10; Rows 2-123; Druantia Type I Column R "DruC

protein accession" and Column S "PRT SEQ ID NO:"

Defense System Ilia DruD polypeptides Table 10; Rows 2-123; Druantia Type I Column V "DruD

protein accession" and Column W "PRT SEQ ID NO:"

Defense System Ilia DruE polypeptides Table 10; Rows 2-123; Druantia Type I Column Z "DruE

protein accession" and Column AA "PRT SEQ ID NO:"

Defense System Ilia druA polynucleotides Table 10; Rows 2-123; Druantia Type I Column J "DruA

protein accession" and Column L "DNA SEQ ID NO:"

Defense System Ilia druB polynucleotides Table 10; Rows 2-123; Druantia Type I Column N "DruB

protein accession" and Column P "DNA SEQ ID NO:"

Defense System Ilia druC polynucleotides Table 10; Rows 2-123; Druantia Type I Column R "DruC

protein accession" and Column T "DNA SEQ ID NO:"

Defense System Ilia druD polynucleotides Table 10; Rows 2-123; Druantia Type I Column V "DruD

protein accession" and Column X "DNA SEQ ID NO:"

Defense System Ilia druE polynucleotides Table 10; Rows 2-123; Druantia Type I Column Z "DruE

protein accession" and Column AB "DNA SEQ ID NO:"

Defense System Ilia Gene Cassette polynucleotides Table 10; Rows 2-123; Druantia Type I Column G

"genomic_accession" with Start in Column AT "Genomic Start Point" and End in Column AU "Genomic End Point"

Defense System Illb DruM polypeptides Table 10; Rows 124-295; Druantia Type II Column AD "DruM

protein accession" and Column AE "PRT SEQ ID NO:"

Defense System Illb DruF polypeptides Table 10; Rows 124-295; Druantia Type II Column AH "DruF

protein accession" and Column AI "PRT SEQ ID NO:"

Defense System Illb DruG polypeptides Table 10; Rows 124-295; Druantia Type II Column AL "DruG

protein accession" and Column AM "PRT SEQ ID NO:"

Defense System Illb DruE polypeptides Table 10; Rows 124-295; Druantia Type II Column Z "DruE

protein accession" and Column AA "PRT SEQ ID NO:"

Defense System Illb druM polynucleotides Table 10; Rows 124-295; Druantia Type II Column AD "DruM

protein accession" and Column AF "DNA SEQ ID NO:"

Defense System Illb druF polynucleotides Table 10; Rows 124-295; Druantia Type II Column AH "DruF

protein accession" and Column AJ "DNA SEQ ID NO:"

Defense System Illb druG polynucleotides Table 10; Rows 124-295; Druantia Type II Column AL "DruG

protein accession" and Column AN "DNA SEQ ID NO:"

Defense System Illb druE polynucleotides Table 10; Rows 124-295; Druantia Type II Column Z "DruE

protein accession" and Column AB "DNA SEQ ID NO:"

Defense System Illb Gene Cassette polynucleotides Table 10; Rows 124-295; Druantia Type II Column G

"genomic_accession" with Start in Column AT "Genomic Start Point" and End in Column AU "Genomic End Point"

Defense System IIIc DruH polypeptides Table 10; Rows 296-1343; Druantia Type III Column AP "DruH

protein accession" and Column AQ "PRT SEQ ID NO:"

Defense System IIIc DruE polypeptides Table 10; Rows 296-1343; Druantia Type III Column Z "DruE

protein accession" and Column AA "PRT SEQ ID NO:"

Defense System IIIc druH polynucleotides Table 10; Rows 296-1343; Druantia Type III Column AP "DruH

protein accession" and Column AR "DNA SEQ ID NO:"

Defense System IIIc druE polynucleotides Table 10; Rows 296-1343; Druantia Type III Column Z "DruE

protein accession" and Column AB "DNA SEQ ID NO:"

Defense System IIIc Gene Cassette polynucleotides Table 10; Rows 296-1343; Druantia Type III Column G

"genomic_accession" with Start in Column AT "Genomic Start Point" and End in Column AU

"Genomic End Point"

Defense System IV HamA polypeptides Table 12; Rows 2-1782;

Hachiman Column H "HamA

protein accession" and Column I "PRT SEQ ID NO:"

Defense System IV HamB polypeptides Table 12; Rows 2-1782;

Hachiman Column L "HamB

protein accession" and Column M "PRT SEQ ID NO:"

Defense System IV hamA polynucleotides Table 12; Rows 2-1782;

Hachiman Column H "HamA

protein accession" and Column J "DNA SEQ ID NO:"

Defense System IV hamB polynucleotides Table 12; Rows 2-1782;

Hachiman Column L "HamB

protein accession" and Column N "DNA SEQ ID NO:"

Defense System IV Gene Cassette polynucleotides Table 12; Rows 2-1782;

Hachiman Column G

"genomic_accession" with Start in Column P "Genomic Start Point" and End in Column Q "Genomic End Point"

Defense System V SduA polypeptides Table 13; Rows 2-1247;

Shedu Column H "SduA

protein accession" and Column I "PRT SEQ ID NO:"

Defense System V sduA polynucleotides Table 13; Rows 2-1247;

Shedu Column H "SduA

protein accession" and Column J "DNA SEQ ID NO:"

Defense System V Gene Cassette polynucleotides Table 13; Rows 2-1782;

Shedu Column G

"genomic_accession" with Start in Column L "Genomic Start Point" and End in

Column M "Genomic End Point"

Defense System VI GajA polypeptides Table 14; Rows 2-4599;

Gabija Column H "GajA

protein accession" and Column I "PRT SEQ ID NO:"

Defense System VI GajB polypeptides Table 14; Rows 2-4599;

Gabija Column L "GajB

protein accession" and Column M "PRT SEQ ID NO:"

Defense System VI gajA polynucleotides Table 14; Rows 2-4599;

Gabija Column H "GajA

protein accession" and Column J "DNA SEQ ID NO:"

Defense System VI gajB polynucleotides Table 14; Rows 2-4599;

Gabija Column L "GajB

protein accession" and Column N "DNA SEQ ID NO:"

Defense System VI Gene Cassette polynucleotides Table 14; Rows 2-4599;

Gabija Column G

"genomic_accession" with Start in Column P "Genomic Start Point" and End in Column Q "Genomic End Point"

Defense System VII PtuA polypeptides Table 15; Rows 2-2507;

Septu Column H "PtuA

protein accession" and Column I "PRT SEQ ID NO:"

Defense System VII PtuB polypeptides Table 15; Rows 2-2507;

Septu Column L "PtuB

protein accession" and Column M "PRT SEQ ID NO:"

Defense System VII ptuA polynucleotides Table 15; Rows 2-2507;

Septu Column H "PtuA

protein accession" and Column J "DNA SEQ ID NO:"

Defense System VII ptuB polynucleotides Table 15; Rows 2-2507;

Septu Column L "PtuB

protein accession" and Column N "DNA SEQ ID NO:"

Defense System VII Gene Cassette polynucleotides Table 15; Rows 2-2507;

Septu Column G "genomic_accession" with

Start in Column P "Genomic

Start Point" and End in

Column Q "Genomic End

Point"

Defense System VIII LmuA polypeptides Table 16; Rows 2-698;

Lamussa Column H "LmuA

protein accession" and Column I "PRT SEQ ID NO:"

Defense System VIII LmuB polypeptides Table 16; Rows 2-698;

Lamussa Column L "LmuB

protein accession" and Column M "PRT SEQ ID NO:"

Defense System VIII ImuA polynucleotides Table 16; Rows 2-698;

Lamussa Column H "LmuA

protein accession" and Column J "DNA SEQ ID NO:"

Defense System VIII ImuB polynucleotides Table 16; Rows 2-698;

Lamussa ColumnL "LmuB

protein accession" and Column N "DNA SEQ ID NO:"

Defense System VIII Gene Cassette polynucleotides Table 16; Rows 2-698;

Lamussa Column G

"genomic_accession" with Start in Column P "Genomic Start Point" and End in Column Q "Genomic End Point"

Defense System IX KwaA polypeptides Table 17; Rows 2-935;

Kiwa Column H "KwaA

protein accession" and Column I "PRT SEQ ID NO:"

Defense System IX KwaB polypeptides Table 17; Rows 2-935;

Kiwa Column L "KwaB

protein accession" and Column M "PRT SEQ ID NO:"

Defense System IX kwaA polynucleotides Table 17; Rows 2-935;

Kiwa Column H "KwaA

protein accession" and Column J "DNA SEQ ID NO:"

Defense System IX kwaB polynucleotides Table 17; Rows 2-935;

Kiwa Column L "KwaB

protein accession" and Column N "DNA SEQ ID NO:" Defense System IX Gene Cassette polynucleotides Table 17; Rows 2-935; Kiwa Column G

"genomic_accession" with Start in Column P "Genomic Start Point" and End in Column Q "Genomic End Point"

Defense System Xa JetA polypeptides Table 11 ; Rows 2-2322; Wadjet type I Column J "JetA

protein accession" and Column K "PRT SEQ ID NO:"

Defense System Xa JetB polypeptides Table 11 ; Rows 2-2322; Wadjet type I Column N "JetB

protein accession" and Column 0 "PRT SEQ ID NO:"

Defense System Xa JetC polypeptides Table 11 ; Rows 2-2322; Wadjet type I Column R "JetC

protein accession" and Column s "DNA SEQ ID NO:"

Defense System Xa JetD polypeptides Table 11 ; Rows 2-2322; Wadjet type I Column V "JetD

protein accession" and Column W "PRT SEQ ID NO:"

Defense System Xa jetA polynucleotides Table 11 ; Rows 2-2322; Wadjet type I Column J "JetA

protein accession" and Column L "DNA SEQ ID NO:"

Defense System Xa jetB polynucleotides Table 11 ; Rows 2-2322; Wadjet type I Column N "JetB

protein accession" and Column P "DNA SEQ ID NO:"

Defense System Xa jetC polynucleotides Table 11 ; Rows 2-2322; Wadjet type I Column R "JetC

protein accession" and Column T "DNA SEQ ID NO:"

Defense System Xa jetD polynucleotides Table 11 ; Rows 2-2322; Wadjet type I Column V "JetD

protein accession" and Column X "DNA SEQ ID NO:"

Defense System Xa Gene Cassette polynucleotides Table 11 ; Rows 2-2322; Wadjet type I Column G

"genomic_accession" with Start in Column Z "Genomic Start Point" and End in Column AA "Genomic End

Point"

Defense System Xb JetA ¹¹ polypeptides Table 11 ; Rows 2323-2844; Wadjet type II Column J "JetA

protein accession" and Column K "PRT SEQ ID NO:"

Defense System Xb JetB" polypeptides Table 11 ; Rows 2323-2844; Wadjet type II Column N "JetB

protein accession" and Column 0 "DNA SEQ ID NO:"

Defense System Xb JetC ¹¹ polypeptides Table 11 ; Rows 2323-2844; Wadjet type II Column R "JetC

protein accession" and Column s "PRT SEQ ID NO:"

Defense System Xb JetD ¹¹ polypeptides Table 11 ; Rows 2323-2844; Wadjet type II Column V "JetD

protein accession" and Column W "PRT SEQ ID NO:"

Defense System Xb jetA ¹¹ polynucleotides Table 11 ; Rows 2323-2844; Wadjet type II Column J "JetA

protein accession" and Column L "DNA SEQ ID NO:"

Defense System Xb jetB ¹¹ polynucleotides Table 11 ; Rows 2323-2844; Wadjet type II Column N "JetB

protein accession" and Column P "DNA SEQ ID NO:"

Defense System Xb jet polynucleotides Table 11 ; Rows 2323-2844; Wadjet type II Column R "JetC

protein accession" and Column T "DNA SEQ ID NO:"

Defense System Xb jetD ¹¹ polynucleotides Table 11 ; Rows 2323-2844; Wadjet type II Column V "JetD

protein accession" and Column X "DNA SEQ ID NO:"

Defense System Xb Gene Cassette polynucleotides Table 11 ; Rows 2323-2844; Wadjet type II Column G

"genomic_accession" with Start in Column Z "Genomic Start Point" and End in Column AA "Genomic End Point"

Defense System Xc JetA ¹¹¹ polypeptides Table 11 ; Rows 2845-3174; Wadjet type III Column J "JetA

protein accession" and Column K "PRT SEQ ID

NO:"

Defense System Xc JetB ¹¹¹ polypeptides Table 11 ; Rows 2845-3174; Wadjet type III Column N "JetB

protein accession" and Column 0 "PRT SEQ ID NO:"

Defense System Xc JetC ¹¹¹ polypeptides Table 11 ; Rows 2845-3174; Wadjet type III Column R "JetC

protein accession" and Column s "PRT SEQ ID NO:"

Defense System Xc JetD ¹¹¹ polypeptides Table 11 ; Rows 2845-3174; Wadjet type III Column V "JetD

protein accession" and Column W "PRT SEQ ID NO:"

Defense System Xc jetA ¹¹¹ polynucleotides Table 11 ; Rows 2845-3174; Wadjet type III Column J "JetA

protein accession" and Column L "DNA SEQ ID NO:"

Defense System Xc jetB ¹¹¹ polynucleotides Table 11 ; Rows 2845-3174; Wadjet type III Column N "JetB

protein accession" and Column P "DNA SEQ ID NO:"

Defense System Xc jetC ^m polynucleotides Table 11 ; Rows 2845-3174; Wadjet type III Column R "JetC

protein accession" and Column T "DNA SEQ ID NO:"

Defense System Xc jetD ¹¹¹ polynucleotides Table 11 ; Rows 2845-3174; Wadjet type III Column V "JetD

protein accession" and Column X "DNA SEQ ID NO:"

Defense System Xc Gene Cassette polynucleotides Table 11 ; Rows 2845-3174; Wadjet type III Column G

"genomic_accession" with Start in Column Z "Genomic Start Point" and End in Column AA "Genomic End Point"

[001017] Table 18 lists embodiments of the components of each Defense System and embodiments gene cassettes encoding the Defense Systems. Provided are the Sequence Numbers comprising the polypeptide and polynucleotide sequences, or explicit Reference to the Accession numbers provided in Tables 8-17, respectively for each Defense System, from which the skilled artisan can access the polypeptide and polynucleotide sequences. While Table 18 highlights polypeptide components of defense systems and the genes sequences that encode them, in some embodiments, defense system components include non-coding RNA and/or regulatory nucleic acid sequences.

[001018] Using the Reference locations provided in Table 18 and the "protein accession" numbers provided in Tables 8-17, one can reach both the amino acid and the nucleotide sequences of a Defense System component. For example, to access the polypeptide (amino acid) sequence of a component, a skilled artisan would find the Defense System and component of interest in Table 18. Next, they would use the Reference information provided in Table 18 to identify the series of accession numbers that encompass the polypeptide sequence of the component. Following that, the skilled artisan would query the NCBI "Protein" database: https://www.ncbi.nlm.nih.gov/protein, and enter the accession number provided for a component, for example but not limited to "ABS66238.1" (Table 8, row 2, column J), which would send them to https://www.ncbi.nlm.nih.gOv/protein/CEP95570.l, wherein the amino acid sequence of the component is disclosed on this page, as follows: MTVLKGLGRCVLFWTIIFGIFGVLYWLLPVVDMSALWGGTARAFSGDFSTVGTQPYA FALAFALFATAVGFASAFLILHVGPIGWRLRRLRLRIAGTGDMEGFARTYDATRALME RDRLISHAWKQFDTVLVHRPDERIIRSTARAHAFFNLGMAREKYFGLKMMGALPGYF VGIGLLLTFAGLVLALNKAAM A VNS SD AAGMQG ATRELLQV ATFKFATS IAGLG AS IA LSLLFRIYTILMEGFFIGFCETVEDRVRYLSAQQIAAESRDFAAEQTDQLKSINSADFFA RMGQELTPGMSRMFETALDKVMSPVTTSIDQAVHRLADSSQSGMSEMLTRFTDSVQN GAGAELRGLAETLRGMQGAM VGVQQGLTGS GEDFGRRMS D A AENLNRLVTD AGAR LGEGTDQSRAVLMDAVTAMRETFEQANRKVDEGLGAAAGGASARLEEVMGRVLGS LEAQVGGFRESLSGFQEKMAGQLDETRVRVSAAQAEATDAVAQASAQAARALQDGL ADALVRINGEIERFVVAMRASEVTLAAQAKAMMDATDKSRQVADAFSRTAQDVRAA SVPLAQSGERIAGATEKLGEAAGRSVAVLDKSQEEARRLAQALTGHVSNLDQVWRSY SARFEAVDEALGKAFERLTRGTDEQQDRIATFVRDVDVTFKEAVDTLAGCIGGLKDNT EEMVEAVDDLKRALRVEAAE (SEQ ID NO: 1).

[001019] Similarly, to access the nucleotide (nucleic acid) sequence of a component, a skilled artisan would find the Defense System and component of interest in Table 18. Next, they would use the Reference information provided in Table 18 to identify the series of accession numbers that encompass the nucleotide sequence of the component. Following that, the skilled artisan would query the NCBI "Identical Protein Groups" database https://www.ncbi.nlm.nih.gov/ipg, and enter the accession number provided for a component, for example but not limited to

ABS66238.1" (Table 8, row 2, column J), which would send them to https://www.ncbi.nlm.nih.gov/ipg ?term=ABS66238.1, wherein any of the links under "CDS

Region in Nucleotide" leads to the nucleotide sequence:

ORIGIN

1 atgacggtct tgaagggttt ggggcgctgc gttctttttt ggacaatcat attcggcatc 61 ttcggcgtct tgtactggct ccttcctgtc gtcgacatga gcgcgctctg gggcgggacg

121 gcgcgcgcct tcagcggtga tttttccacc gtcggcaccc agccctatgc tttcgccctg

181 gccttcgccc tgttcgccac ggcggtcggc ttcgcctccg ctttcctcat cctgcatgtg

241 ggtccgatcg ggtggaggct gcggcgcctg cgattgcgta tcgcgggcac gggggacatg

301 gaaggcttcg ccagaaccta tgacgccacg cgcgcgctca tggagcgcga tcgactgatc

361 agccatgcgt ggaagcagtt cgacaccgtg ctcgttcatc ggccggatga acgcatcatc

421 cgcagcaccg cccgtgccca cgcctttttc aatctgggca tggcgcggga gaagtatttc

481 ggcctgaaga tgatgggcgc gctgccgggc tatttcgtcg gcatcggtct tctgctcacc

541 ttcgccggcc tcgtgctggc gctcaacaag gcggccatgg ccgtcaacag ctcggatgcc

601 gccggaatgc agggcgcgac gcgcgaactg cttcaggtgg cgaccttcaa gtttgccacc

661 tccatcgccg gccttggtgc ctccatcgcg ctctcgctgc tgttccgcat ctataccatc

721 ctgatggaag gcttcttcat cggcttctgc gagacggtgg aggaccgggt gcgctatctg

781 tcggcacagc agatcgcggc cgagagccgg gattttgccg ccgaacagac cgatcagctc

841 aagtcgatca acagcgccga cttcttcgcg cgcatggggc aggagctgac gccgggcatg

901 tcccgcatgt tcgagacggc gctcgacaag gtcatgtcgc cggtgaccac cagcatcgac

961 caggcggtcc ataggctcgc cgacagcagc cagagcggca tgtccgagat gctgacgcgc 1021 ttcaccgatt cggtgcagaa cggggccggg gccgagttgc gcgggctcgc cgagacgctc 1081 cggggcatgc agggtgccat ggtgggcgtg cagcaggggc tgaccgggtc cggcgaggat 1141 ttcggccggc gcatgtcgga tgccgcggaa aacctcaacc gcctcgtcac cgacgccggc 1201 gcacgcctgg gtgaaggcac ggaccagagc cgcgcggtcc tcatggatgc ggtcaccgcc 1261 atgcgggaga ccttcgagca agccaatcgc aaggtggacg agggtctcgg cgccgcggcg 1321 ggcggggctt cggcgcggct ggaggaggtc atggggcggg tgctcggcag cctcgaagcc 1381 caggtgggcg gctttcgcga gagcctgtcc ggcttccagg agaagatggc cggccagctc 1441 gatgagaccc gggtccgcgt ctccgccgcc caggcggagg cgaccgatgc cgtcgcccag 1501 gcctcggccc aggcggcgcg cgcgctccag gacgggcttg cggatgcgct cgtgcgcatc 1561 aacggcgaga tcgagcgttt cgtcgtcgcc atgcgggcca gcgaggtgac gctggcggcg 1621 caggccaagg cgatgatgga cgccaccgac aagtcgcgcc aggtggccga tgccttcagc 1681 cgcactgcgc aggatgtgcg cgcggctagc gtaccgctgg cccaatcggg cgagcgcatc 1741 gcgggggcga ccgagaagct cggcgaggcc gccggccggt cggtggcggt cctcgacaag 1801 agccaggagg aggcgcggcg gctggcccag gcgctgaccg gccatgtctc caacctcgat 1861 caggtctggc gcagctattc ggcccgcttc gaggcggtcg acgaggcgct gggcaaggcg 1921 ttcgagcgcc tgacgcgcgg aaccgacgag cagcaggacc ggatcgccac tttcgttcgc 1981 gacgtggacg tgaccttcaa ggaagcggtg gatacgctgg ccggctgcat cggcggcctg 2041 aaggacaata ccgaggagat ggtggaggcg gtggacgacc tgaaacgcgc gctgcgcgtc 2101 gaggccgcgg aatga (SEQ ID NO: 2).

Defense Systems & Combination of Defense Systems

[001020] Described above are non-limiting examples of defense systems, wherein each system comprises components that together make-up a defense system, wherein in some embodiments each component is encoded by a different gene. In some embodiments, the combination of components that make-up a Defense System, for example the components that make-up each of Defense Systems Ia-Xc disclosed above, may include components comprising nucleic acid sequences or amino acid sequences derived from different species (different donor species). In some embodiments, the combination of components that make-up a Defense System, for example the components that make-up each of Defense Systems Ia-Xc, may include homologs of the genes and/or polypeptides identified in donor species. In some embodiments, the combination of components that make-up a Defense System, for example the components that make-up each of Defense Systems Ia-Xc, differs from the combination of components found in donor species. In some embodiments, the components of a Defense System, for example the components that make-up each of Defense Systems Ia-Xc, comprises less than all the components found in donor species. In some embodiments, the components of a Defense System, for example the components that make-up each of Defense Systems Ia-Xc, comprises duplications of the components found in donor species, or multiple copies of one or more components found in a donor species. In some embodiments, the components of a Defense System, for example the components that make-up each of Defense Systems Ia-Xc, comprise functional portions of the components found in donor species, wherein a functional component comprise less than the full length of the components present in a donor species. In some embodiments, the order of components encoded on the nucleic acid sequence comprised within a construct comprising a Defense System, for example the order of the components the make-up each of Defense Systems Ia-Xc, differs from the order of the components found encoded on the nucleic acid sequences in donor species.

[001021] In some embodiments each Defense Systems la, lb, Π, III, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc comprising a nucleic acid construct comprising a nucleic acid sequence encoding the polypeptide components as disclosed herein, further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof.

[001022] In some embodiments, a construct further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence. In some embodiment, the nucleic acid sequence of the regulatory element is from the same species as at least one component of the Defense System. In some embodiment, the nucleic acid sequence of the regulatory element is not from the same species as any of the components of the Defense System. In some embodiment, the nucleic acid sequence of the regulatory element is not from the donor species of the Defense System. In some embodiment, when a host cell comprises a Defense System, the nucleic acid sequence of the regulatory element is from the host species.

[001023] In some embodiments, cis-acting regulatory elements include those that direct constitutive expression of a nucleic acid sequence. In some embodiments, cis-acting regulatory elements comprise those that direct inducible expression of the nucleic acid sequence only under certain conditions.

[001024] According to some embodiments, the cis-acting regulatory element is heterologous to the genes encoding the components of a system. In some embodiments, the cis-acting regulatory element is heterologous to Defense System la genes zorA, zorB, zorC, and zorD. In some embodiments, the cis-acting regulatory element is heterologous to Defense System lb genes zorA, zorB, and zorE. In some embodiments, the cis-acting regulatory element is heterologous to Defense System II genes thsA and thsB. In some embodiments, the cis-acting regulatory element is heterologous to Defense System Ilia genes druA, druB, druC, druD, and druE. In some embodiments, the cis-acting regulatory element is heterologous to Defense System Illb genes druM, druF, druG, and druE. In some embodiments, the cis-acting regulatory element is heterologous to Defense System IIIc genes druH and druE. In some embodiments, the cis- acting regulatory element is heterologous to Defense System IV genes hamA and hamB. In some embodiments, the cis-acting regulatory element is heterologous to Defense System V component sduA. In some embodiments, the cis-acting regulatory element is heterologous to Defense System VI genes gajA and gajB. In some embodiments, the cis-acting regulatory element is heterologous to Defense System VII genes ptuA and ptuB. In some embodiments, the cis-acting regulatory element is heterologous to Defense System VIII genes ImuA and ImuB. In some embodiments, the cis-acting regulatory element is heterologous to Defense System IX genes kwaA and kwaB. In some embodiments, the cis-acting regulatory element is heterologous to Defense System Xa genes jetA, jetB, jetC, and jetD. In some embodiments, the cis-acting regulatory element is heterologous to Defense System Xb genes jetA", jetB", jetC, and jetD". In some embodiments, the cis-acting regulatory element is heterologous to Defense System Xc genes jetA , jetB ⁱ , jetC , and jetD ⁱ .

[001025] According to some embodiments, the nucleic acid construct includes a promoter sequence for directing transcription of the nucleic acid sequence in a host cell in a constitutive or inducible manner. In some embodiments, a promoter is a constitutive promoter. In some embodiments, a promoter is an inducible or regulatable promoter.

[001026] Constitutive promoters suitable for use with some embodiments of the Defense System constructs disclosed herein are promoter sequences which are active under most environmental conditions and most types of cells such as the cytomegalovirus (CMV) and Rous sarcoma virus (RSV). Inducible promoters suitable for use with some embodiments of Defense System constructs disclosed herein, include for example but not limited to the tetracycline- inducible promoter (Zabala M, et al., Cancer Res. 2004, 64(8): 2799-804) or pathogen-inducible promoters. Such promoters include those from pathogenesis-related proteins (PR proteins), which are induced following infection by a pathogen.

[001027] According to some embodiments, the promoter is bacterial nucleic acid (e.g., expression) construct.

[001028] A skilled artisan would appreciate that bacterial promoter encompasses any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of a coding sequence into mRNA. A promoter can have a transcription initiation region, which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site and a transcription initiation site. A bacterial promoter can also have a second domain called an operator, which can overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein can bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression can occur in the absence of negative regulatory elements, such as the operator. In addition, positive regulation can be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5') to the RNA polymerase binding sequence.

[001029] A non-limiting example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in Escherichia coli (Raibaud et al. (1984) Annu. Rev. Genet. 18: 173). Regulated expression can therefore be either positive or negative, thereby either enhancing or reducing transcription. Other examples of positive and negative regulatory elements are well known in the art. Various promoters that can be included in the protein expression system include, but are not limited to, a T7/LacO hybrid promoter, a trp promoter, a T7 promoter, a lac promoter, and a bacteriophage lambda promoter. Any suitable promoter can be used with the Defense systems disclosed herein, including the native promoter or a heterologous promoter. Heterologous promoters can be constitutively active or inducible. A non-limiting example of a heterologous promoter is given in U.S. Pat. No. 6,242,194 to Kullen and Klaenhammer.

[001030] Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (lac) (Chang et al. (1987) Nature 198: 1056), and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (trp) (Goeddel et al. (1980) Nucleic Acids Res. 8:4057; Yelverton et al. (1981) Nucleic Acids Res. 9:731; U.S. Pat. No. 4,738,921; EPO Publication Nos. 36,776 and 121,775). The beta-lactamase (bla) promoter system (Weissmann, (1981) "The Cloning of Interferon and Other Mistakes," in Interferon 3 (ed. I. Gresser); bacteriophage lambda PL (Shimatake et al. (1981) Nature 292: 128); the arabinose-inducible araB promoter (U.S. Pat. No. 5,028,530); and T5 (U.S. Pat. No. 4,689,406) promoter systems also provide useful promoter sequences. See also Balbas (2001) Mol. Biotech. 19:251-267, where E. coli expression systems are discussed.

[001031] In addition, synthetic promoters that do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or phage promoter can be joined with the operon sequences of another bacterial or phage promoter, creating a synthetic hybrid promoter (U.S. Pat. No. 4,551,433). For example, the tac (Amann et al. (1983) Gene 25: 167; de Boer et al. (1983) Proc. Natl. Acad. Sci. 80:21) and trc (Brosius et al. (1985) J. Biol. Chem. 260:3539-3541) promoters are hybrid trp-lac promoters comprised of both trp promoter and lac operon sequences that are regulated by the lac repressor. The tac promoter has the additional feature of being an inducible regulatory sequence. Thus, for example, expression of a coding sequence operably linked to the tac promoter can be induced in a cell culture by adding isopropyl-l-thio-P-D-galactoside (IPTG). Furthermore, bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The phage T7 RNA polymerase/promoter system is an example of a coupled promoter system (Studier et al. (1986) J. Mol. Biol. 189:113; Tabor et al. (1985) Proc. Natl. Acad. Sci. 82: 1074). In addition, a hybrid promoter can also be comprised of a phage promoter and an E. coli operator region (EPO Publication No. 267,851).

[001032] The nucleic acid construct can additionally contain a nucleic acid sequence encoding the repressor (or inducer) for that promoter. For example, an inducible construct can regulate transcription from the Lac operator (LacO) by expressing the nucleotide sequence encoding the Lacl repressor protein. Other examples include the use of the lexA gene to regulate expression of pRecA, and the use of trpO to regulate ptrp. Alleles of such genes that increase the extent of repression (e.g., laclq) or that modify the manner of induction (e.g., lambda CI857, rendering lambda pL thermo-inducible, or lambda CI+, rendering lambda pL chemo-inducible) can be employed.

[001033] In the construction of the construct, in some embodiments, the promoter is positioned approximately the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

[001034] According to some embodiments, the nucleic acid construct includes a promoter sequence for directing transcription of the nucleic acid sequence in the cell in a constitutive or inducible manner. In some embodiments, the expression of a Defense System disclosed herein can be transient or consistent, episomal or integrated into the chromosome of a host cell. According to some embodiments, the expression is on a transmissible genetic element.

[001035] The nucleic acid construct of some embodiments of a Defense System disclosed herein may further include additional sequences which render this construct suitable for replication and integration in prokaryotes, eukaryotes, or preferably both (e.g., shuttle vectors).

[001036] In some embodiments, the construct comprises a recombination element for integrating the polynucleotide into a genome of a cell transfected with the construct.

[001037] A skilled artisan would appreciate that the term "recombination element" encompasses a nucleic acid sequence that allows the integration of the polynucleotide in the genome of a cell (e.g. bacteria) transfected with the construct.

[001038] In some embodiments, a construct may also contain a transcription and translation initiation sequence, transcription and translation terminator and a polyadenylation signal. By way of example, such constructs will typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3' LTR or a portion thereof.

[001039] In some embodiments, a construct further comprises a transmissible element for directing transfer of said nucleic acid sequence from one cell to another. In some embodiments, a Defense System la or the Defense System la component(s) is on a transmissible genetic element. In some embodiments, a Defense System lb or the Defense System lb component(s) is on a transmissible genetic element. In some embodiments, a Defense System Ilia or the Defense System Ilia component(s) is on a transmissible genetic element. In some embodiments, a Defense System Illb or the Defense System Illb component(s) is on a transmissible genetic element. In some embodiments, a Defense System IIIc or the Defense System Hie component(s) is on a transmissible genetic element. In some embodiments, a Defense System IV or the Defense System IV component(s) is on a transmissible genetic element. In some embodiments, a Defense System V or the Defense System V component(s) is on a transmissible genetic element. In some embodiments, a Defense System VI or the Defense System VI component(s) is on a transmissible genetic element. In some embodiments, a Defense System VII or the Defense System VII component(s) is on a transmissible genetic element. In some embodiments, a Defense System VIII or the Defense System VIII component(s) is on a transmissible genetic element. In some embodiments, a Defense System IX or the Defense System IX component(s) is on a transmissible genetic element. In some embodiments, a Defense System Xa or the Defense System Xa component(s) is on a transmissible genetic element. In some embodiments, a Defense System Xb or the Defense System Xb component(s) is on a transmissible genetic element. In some embodiments, a Defense System Xc or the Defense System Xc component(s) is on a transmissible genetic element.

[001040] In some embodiments, a transmissible genetic element comprises the construct of a Defense System disclosed herein. In some embodiments, a transmissible genetic element comprises the construct of Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, a transmissible genetic element comprises the construct of Defense System la. In some embodiments, a transmissible genetic element comprises the construct of Defense System lb. In some embodiments, a transmissible genetic element comprises the construct of Defense System Π. In some embodiments, a transmissible genetic element comprises the construct of Defense System Ilia. In some embodiments, a transmissible genetic element comprises the construct of Defense System nib. In some embodiments, a transmissible genetic element comprises the construct of Defense System Hie. In some embodiments, a transmissible genetic element comprises the construct of Defense System IV. In some embodiments, a transmissible genetic element comprises the construct of Defense System V. In some embodiments, a transmissible genetic element comprises the construct of Defense System VI. In some embodiments, a transmissible genetic element comprises the construct of Defense System VII. In some embodiments, a transmissible genetic element comprises the construct of Defense System VIII. In some embodiments, a transmissible genetic element comprises the construct of Defense System IX. In some embodiments, a transmissible genetic element comprises the construct of Defense System Xa. In some embodiments, a transmissible genetic element comprises the construct of Defense System Xb. In some embodiments, a transmissible genetic element comprises the construct of Defense System Xc.

[001041] A skilled artisan would appreciate that the term "transmissible element" or "transmissible genetic element", which are interchangeably used, encompasses a polynucleotide that allows the transfer of the nucleic acid sequence from one cell to another, e.g. from one bacteria to another.

[001042] According to some embodiments, a transmissible genetic element comprises a conjugative genetic element or mobilizable genetic element. In some embodiments, a transmissible genetic element comprises a conjugative genetic element. In some embodiments, a transmissible genetic element comprises a mobilizable genetic element. The skilled artisan would appreciate that a "conjugative plasmid" encompasses a plasmid that is transferred from one cell (e.g. bacteria) to another during conjugation, and the term "mobilizable element" encompasses a transposon, which is a DNA sequence that can change its position within the genome.

[001043] In some embodiments, a nucleic acid construct disclosed herein, comprises an expression vector. In some embodiments, an "expression vector" or a "vector", used interchangeably herein, comprises and expresses the Defense System components from a single or a plurality of constructs (i.e. construct). In some embodiments, expression comprises transient expression. In some embodiments, expression comprises constituitive expression. In some embodiments, expression is from an episomal nucleic acid sequence. In some embodiments, expression is from a nucleic acid sequence integrated into the chromosome of the cell. According to specific embodiments, the expression is on a transmissible genetic element.

[001044] According to some embodiments, a construct further comprises a recombination element for integrating the nucleic acid sequence into a genome of cell transfected with the construct. A skilled artisan would appreciate that the term "recombination element" encompasses a polynucleotide that allows the integration of the nucleic acid sequence in the genome of a cell (e.g. bacteria) transfected with the construct.

[001045] In addition, typical constructs may also, in certain embodiments, contain a transcription and translation initiation sequence, transcription and translation terminator and a polyadenylation signal. By way of example, such constructs will typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3' LTR or a portion thereof.

[001046] According to some embodiment, the nucleic acid construct comprises a plurality of cloning sites for ligating a nucleic acid sequence of a Defense System, such that it is under transcriptional regulation of the regulatory elements.

[001047] Selectable marker genes that ensure maintenance of a construct in a host cell can also be included in the construct. In some embodiments, selectable markers include those which confer resistance to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline (Davies et al. (1978) Annu. Rev. Microbiol. 32:469). Selectable markers can also allow a cell to grow on minimal medium, or in the presence of toxic metabolite and can include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.

[001048] Other than containing the necessary elements for the transcription and translation of the inserted coding sequence, the expression construct of some embodiments of Defense system can also include sequences engineered to enhance stability, production, purification, yield or toxicity of the expressed polypeptide. Where appropriate, the nucleic acid sequences may be optimized for increased expression in the transformed organism. For example, the nucleic acid sequences can be synthesized using preferred codons for improved expression.

[001049] Various methods known within the art can be used to introduce the construct of some embodiments of a Defense System disclosed herein into cells. Such methods are generally described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992), in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989), Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich. (1995), Vega et al., Gene Targeting, CRC Press, Ann Arbor Mich. (1995), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston Mass. (1988) and Gilboa et at. [Biotechniques 4 (6): 504-512, 1986] and include, for example, stable or transient transfection, natural or induced transformation, lipofection, electroporation and infection with recombinant viral vectors. In addition, see U.S. Pat. Nos. 5,464,764 and 5,487,992 for positive-negative selection methods.

[001050] Some methods of introducing a construct or constructs into bacterial cells include for example conventional transformation or transfection techniques, or by phage-mediated infection. A skilled artisan would appreciate that the terms "transformation", "transduction", "conjugation", and "protoplast fusion" are intended to encompass a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a cell, such as calcium chloride co-precipitation. A skilled artisan would appreciate that introduction of a construct or constructs into a bacterial cell, may in certain embodiments, result in expression of a polypeptide or polypeptides encoded by the the construct or constructs.

[001051] Introduction of nucleic acids by phage infection offers several advantages over other methods such as transformation, since higher transfection efficiency can be obtained due to the infectious nature of phages. These methods are especially useful for rendering bacteria more sensitive to phage attack for antibiotics purposes as further described hereinbelow.

[001052] It will be appreciated that a Defense System polypeptide(s) can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. Thus, according to some embodiments, disclosed herein are isolated polypeptides of each of the Defense systems' components and functional fragments thereof as described herein. In some embodiments, a polypeptide component of a Defense System can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression, to confer resistance. In some embodiments, at least two different polypeptide components of a Defense System can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression, to confer resistance. In some embodiments, at least three different polypeptide components of a Defense System can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression, to confer resistance. In some embodiments, at least four polypeptide components of a Defense System can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression, to confer resistance. In some embodiments, at least five different polypeptide components of a Defense System can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression, to confer resistance. In some embodiments, multiple polypeptide components of a Defense System can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression, to confer resistance.

[001053] In some embodiments, a Defense System la polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense system la's components and functional fragments thereof as described herein. In some embodiments, a Defense System lb polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense system Ib's components and functional fragments thereof as described herein. In some embodiments, Defense System II polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense system IPs components and functional fragments thereof as described herein. In some embodiments, Defense System Ilia polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense system Ilia's components and functional fragments thereof as described herein. In some embodiments, Defense System nib polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense system Illb's components and functional fragments thereof as described herein. In some embodiments, Defense System Hie polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense system nic's components and functional fragments thereof as described herein. In some embodiments, Defense System rV polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense system rV components and functional fragments thereof as described herein. In some embodiments, Defense System V polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense System V components and functional fragments thereof as described herein. In some embodiments, Defense System VI polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense system VPs components and functional fragments thereof as described herein. In some embodiments, Defense System VII polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense system VIPs components and functional fragments thereof as described herein. In some embodiments, Defense System VIII polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense system VIII's components and functional fragments thereof as described herein. In some embodiments, Defense System IX polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense system IX' s components and functional fragments thereof as described herein. In some embodiments, a Defense System Xa polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense System Xa's components and functional fragments thereof as described herein. In some embodiments, a Defense System Xb polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense System Xb's components and functional fragments thereof as described herein. In some embodiments, a Defense System Xc polypeptides can be introduced directly into the cell (e.g., bacterial cell) and not via recombinant expression to confer resistance. In some embodiments, disclosed herein are isolated polypeptides of each of the Defense System Xc's components and functional fragments thereof as described herein.

[001054] In some embodiments, at least one Defense System component is on a transmissible genetic element. In some embodiments, more than one Defense System component, from the same Defense system, is on a transmissible genetic element. In some embodiments, two Defense System components, from the same Defense system, are on a transmissible genetic element. In some embodiments, three Defense System components, from the same Defense system, are on a transmissible genetic element. In some embodiments, four Defense System components, from the same Defense system, are on a transmissible genetic element. In some embodiments, five Defense System components, from the same Defense system, are on a transmissible genetic element. In some embodiments, all of the Defense System components from a single Defense system are on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001055] In some embodiments, at least one Defense System la component is on a transmissible genetic element. In some embodiments, more than one Defense System la component, is on a transmissible genetic element. In some embodiments, two Defense System la components, are on a transmissible genetic element. In some embodiments, three Defense System la components, are on a transmissible genetic element. In some embodiments, four Defense System la components, are on a transmissible genetic element. In some embodiments, all of the Defense System la components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System la is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001056] In some embodiments, at least one Defense System lb component is on a transmissible genetic element. In some embodiments, more than one Defense System lb component, is on a transmissible genetic element. In some embodiments, two Defense System lb components, are on a transmissible genetic element. In some embodiments, three Defense System lb components, are on a transmissible genetic element. In some embodiments, all of the Defense System lb components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System lb is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001057] In some embodiments, at least one Defense System II component is on a transmissible genetic element. In some embodiments, more than one Defense System II component, is on a transmissible genetic element. In some embodiments, two Defense System II components, are on a transmissible genetic element. In some embodiments, all of the Defense System II components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System Π is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001058] In some embodiments, at least one Defense System Ilia component is on a transmissible genetic element. In some embodiments, more than one Defense System Ilia component, is on a transmissible genetic element. In some embodiments, two Defense System Ilia components, are on a transmissible genetic element. In some embodiments, three Defense System Ilia components, are on a transmissible genetic element. In some embodiments, four Defense System Ilia components, are on a transmissible genetic element. In some embodiments, five Defense System Ilia components, are on a transmissible genetic element. In some embodiments, all of the Defense System Ilia components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System Ilia is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001059] In some embodiments, at least one Defense System Illb component is on a transmissible genetic element. In some embodiments, more than one Defense System nib component, is on a transmissible genetic element. In some embodiments, two Defense System Illb components, are on a transmissible genetic element. In some embodiments, three Defense System Illb components, are on a transmissible genetic element. In some embodiments, four Defense System Illb components, are on a transmissible genetic element. In some embodiments, five Defense System Illb components, are on a transmissible genetic element. In some embodiments, all of the Defense System Illb components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System Illb is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001060] In some embodiments, at least one Defense System IIIc component is on a transmissible genetic element. In some embodiments, more than one Defense System IIIc component, is on a transmissible genetic element. In some embodiments, two Defense System IIIc components, are on a transmissible genetic element. In some embodiments, three Defense System IIIc components, are on a transmissible genetic element. In some embodiments, four Defense System IIIc components, are on a transmissible genetic element. In some embodiments, five Defense System Hie components, are on a transmissible genetic element. In some embodiments, all of the Defense System Hie components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System IIIc is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001061] In some embodiments, at least one Defense System IV component is on a transmissible genetic element. In some embodiments, more than one Defense System IV component, is on a transmissible genetic element. In some embodiments, two Defense System IV components, are on a transmissible genetic element. In some embodiments, all of the Defense System IV components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System IV is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001062] In some embodiments, at least one Defense System V component is on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System V is on a transmissible genetic element. In some embodiments, all of the Defense System V components are on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001063] In some embodiments, at least one Defense System VI component is on a transmissible genetic element. In some embodiments, more than one Defense System VI component, is on a transmissible genetic element. In some embodiments, two Defense System

VI components, are on a transmissible genetic element. In some embodiments, all of the Defense System VI components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System VI is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001064] In some embodiments, at least one Defense System VII component is on a transmissible genetic element. In some embodiments, more than one Defense System VII component, is on a transmissible genetic element. In some embodiments, two Defense System

VII components, are on a transmissible genetic element. In some embodiments, all of the Defense System VII components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System VII is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001065] In some embodiments, at least one Defense System VIII component is on a transmissible genetic element. In some embodiments, more than one Defense System VIII component, is on a transmissible genetic element. In some embodiments, two Defense System Vni components, are on a transmissible genetic element. In some embodiments, all of the Defense System VIII components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense VIII is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001066] In some embodiments, at least one Defense System IX component is on a transmissible genetic element. In some embodiments, more than one Defense System IX component, is on a transmissible genetic element. In some embodiments, two Defense System IX components, are on a transmissible genetic element. In some embodiments, all of the Defense System IX components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System IX is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001067] In some embodiments, at least one Defense System Xa component is on a transmissible genetic element. In some embodiments, more than one Defense System Xa component, is on a transmissible genetic element. In some embodiments, two Defense System Xa components, are on a transmissible genetic element. In some embodiments, three Defense System Xa components, are on a transmissible genetic element. In some embodiments, four Defense System Xa components, are on a transmissible genetic element. In some embodiments, all of the Defense System Xa components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System Xa is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001068] In some embodiments, at least one Defense System Xb component is on a transmissible genetic element. In some embodiments, more than one Defense System Xb component, is on a transmissible genetic element. In some embodiments, two Defense System Xb components, are on a transmissible genetic element. In some embodiments, three Defense System Xb components, are on a transmissible genetic element. In some embodiments, four Defense System Xb components, are on a transmissible genetic element. In some embodiments, all of the Defense System Xb components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System Xb is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001069] In some embodiments, at least one Defense System Xc component is on a transmissible genetic element. In some embodiments, more than one Defense System Xc component, is on a transmissible genetic element. In some embodiments, two Defense System Xc components, are on a transmissible genetic element. In some embodiments, three Defense System Xc components, are on a transmissible genetic element. In some embodiments, four Defense System Xc components, are on a transmissible genetic element. In some embodiments, all of the Defense System Xc components are on a transmissible genetic element. In some embodiments, the nucleic acid construct of Defense System Xc is on a transmissible genetic element. In some embodiments, the components are on the same transmissible genetic element. In some embodiments, the components are on different transmissible elements. In some embodiments, the order of the components on a transmissible genetic element is as found in a donor species. In some embodiments, the order of the components on a transmissible genetic element differs from the order found in a donor species.

[001070] In some embodiments, a construct disclosed herein, further comprises an element providing episomal maintenance of said construct within a cell transfected with said construct.

[001071] In some embodiments, a Defense System construct comprising a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence. In some embodiments, a Defense System construct comprising a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc further comprises a transmissible element for directing transfer of said nucleic acid sequence from one cell to another. In some embodiments, a Defense System construct comprising a Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc further comprises a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct. In some embodiments, a Defense System construct comprising a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc further comprises an element providing episomal maintenance of said construct within a cell transfected with said construct. In some embodiments, a Defense System construct comprising a Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc further comprises any combination of a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof.

[001072] In some embodiments, a defense system described herein comprises a combination of Defense Systems. In some embodiments, a defense system described herein comprises a combination of Defense Systems (Ia)-(Xc). In some embodiments, the combination of Defense Systems, for example but not limited to the combination of Defense Systems (Ia)-(Xc), provides advantageous properties including (1) resistance to a broader range of phages or (2) resistance to at least one phage and reduced transformation efficiency of plasmids or (3) both resistance to a broader range of phages and reduced transformation efficiency.

[001073] A skilled artisan would appreciate that the terms "anti-phage activity" or "resistant to infection by at least one phage" or "resistance to at least one phage" or "anti-phage defense" encompasses an activity provided by a Defense system to a host cell, for example but not limited to bacterial cell expressing a functional Defense System disclosed herein, wherein said bacterial cell then comprises an increased resistance to infection by at least one phage in comparison to bacteria of the same species under the same developmental stage (e.g. culture state) which does not express an endogenous functional Defense System. Resistance to infection, may be determined by for example but not limited to bacterial viability, phage lysogeny, phage genomic replication, or phage genomic degradation. The phage can be a lytic phage or a temperate (lysogenic) phage described herein. In some embodiments, the increase in resistance is at least 1.5 fold, at least 2 fold, at least 3 fold, at least 5 fold, at least 10 fold, or at least 20 fold as compared to same bacterial host in the absence of the functional Defense System.

[001074] In some embodiments, the increase in resistance is by at least 5 %, by at least a 10 %, at least 20 %, at least 30 %, at least 40 %, at least 50 %, at least 60 %, at least 70 %, at least 80 %, at least 90 % or more than 100 % as compared to same host bacteria in the absence of the functional Defense System.

[001075] Assays for testing phage resistance are well known in the art and are further described hereinbelow.

[001076] A skilled artisan would appreciate that the terms "anti-plasmid activity" or "defense against plasmid transformation" or "reduced transformation by a plasmid" or "anti-plasmid defense" or "plasmid resistance" encompasses an activity provided by a Defense System to a host cell, for example but not limited to bacterial cell expressing a functional Defense System disclosed herein, wherein the bacterial cell then comprises a decreased efficiency of transformation by at least one plasmid in comparison to bacteria of the same species under the same developmental stage (e.g. culture state) which does not express a functional Defense System. Decreased efficiency of plasmid transformation, may be determined by for example but not limited to a transformation efficiency assay comparing bacteria comprising a Defense System with those not comprising the Defense System. The plasmid may be an episomal plasmid. In some embodiments, the decreased transformation efficiency is at least 1.5 fold, at least 2 fold, at least 3 fold, at least 5 fold, at least 10 fold, or at least 20 fold as compared to same bacterial host in the absence of the functional Defense System.

[001077] In some embodiments, the decreased transformation efficiency is by at least 5 %, by at least a 10 %, at least 20 %, at least 30 %, at least 40 %, at least 50 %, at least 60 %, at least 70 %, at least 80 %, at least 90 % or more than 100 % as compared to same host bacteria in the absence of the functional Defense System.

[001078] A skilled artisan would appreciate that the term "donor species" may in certain embodiments, encompass the bacterial or archaeal species in which a Defense System was identified and sequenced. The skilled artisan would also appreciate that the term "host cell" may in certain embodiments, encompass bacterial or archaeal or eukaryotic cell in which a Defense System has been introduced. In some embodiments, the host cell does not endogenously comprise the Defense System introduced. In some embodiments, the host cell does not endogenously comprise a functional version of the Defense System introduced. In some embodiments, the host cell comprises the Defense System introduced but it is not functional in the host cell. In some embodiments, the host cell does not endogenously express the Defense System introduced. In some embodiments, the host cell does not endogenously express a functional version of the Defense System introduced.

[001079] Regardless of the method of introduction, in some embodiments provided herein are cells, for example but not limited to bacterial cells, which comprise a heterologous functional defense system, or components thereof. In some embodiments, the method of introduction is conjugation.

[001080] In some embodiments, the isolated cell is transformed or transfected with the described nucleic acid construct or nucleic acid construct Defense System, or a combination thereof.

[001081] In some embodiments, in some embodiments a combination of Defense Systems comprises a combination of the nucleic acid constructs comprising each Defense System. In some embodiments a combination of Defense systems comprises a combination of the nucleic acid constructs comprising a functional Defense System selected from Defense System la, lb, II, Ilia, Illb, nic, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments two defense systems are combined. In some embodiments 2-17 defense systems are combined. In some embodiments 2-5 defense systems are combined. In some embodiments 2-10 defense systems are combined. In some embodiments 5-10 defense systems are combined. In some embodiments 10-17 defense systems are combined. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 defense systems are combined. In some embodiments 2-40 defense systems are combined. In soeme embodiments, multiple copies of the same Defense System are combined. In some embodiments, the combination comprises all different Defense Systems. In some embodiments a combination of Defense systems comprises any combination of the nucleic acid constructs comprising a functional Defense System selected from Defense System la, lb, II, nia, Illb, nic, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc.

[001082] In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with any combination of Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 1-16 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 1 defense system selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 2 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 3 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 4 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 5 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 6 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 7 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 8 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 9 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 10 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 11 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 12 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 13 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 14 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 15 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System la comprises a combination of Defense System la with 16 defense systems selected from Defense Systems lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc.

[001083] In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with any combination of Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System la with 1-16 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System la with 1 defense system selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 2 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 3 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 4 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 5 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 6 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 7 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 8 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 9 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 10 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 11 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 12 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 13 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 14 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 15 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System lb comprises a combination of Defense System lb with 16 defense systems selected from Defense Systems la, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc.

[001084] In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System II with any combination of Defense Systems la, lb, Ilia, nib, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Π comprises a combination of Defense System Π with 1-16 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System Π with 1 defense system selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System II with 2 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System Π with 3 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System Π with 4 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System Π with 5 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System Π with 6 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System Π with 7 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System Π with 8 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System Π with 9 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System II with 10 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System Π with 11 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System II with 12 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System Π with 13 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System II with 14 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System Π with 15 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System II comprises a combination of Defense System II with 16 defense systems selected from Defense Systems la, lb, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. [001085] In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with any combination of Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 1-16 defense systems selected from Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 1 defense system selected from Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 2 defense systems selected from Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 3 defense systems selected from Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 4 defense systems selected from Defense Systems la, lb, Π, Illb, Hie, IV, V, VI, VII, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 5 defense systems selected from Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 6 defense systems selected from Defense Systems la, lb, Π, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 7 defense systems selected from Defense Systems la, lb, II, Illb, nic, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 8 defense systems selected from Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 9 defense systems selected from Defense Systems la, lb, II, Illb, nic, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 10 defense systems selected from Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 11 defense systems selected from Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 12 defense systems selected from Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 13 defense systems selected from Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 14 defense systems selected from Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 15 defense systems selected from Defense Systems la, lb, II, nib, IIIc, IV, V, VI, VII, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Ilia comprises a combination of Defense System Ilia with 16 defense systems selected from Defense Systems la, lb, II, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc.

[001086] In some embodiments, a combination comprising a Defense System nib comprises a combination of Defense System Illb with any combination of Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System nib comprises a combination of Defense System nib with 1-16 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VH, VHI, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System Illb with 1 defense system selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VH, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System Illb with 2 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VH, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System nib with 3 defense systems selected from Defense Systems la, lb, Π, Ilia, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System Illb with 4 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VH, VHI, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System nib with 5 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System Illb with 6 defense systems selected from Defense Systems la, lb, Π, Ilia, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System nib comprises a combination of Defense System nib with 7 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System nib with 8 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System nib with 9 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System fflb with 10 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System fflb comprises a combination of Defense System Illb with 11 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VH, Vffl, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System fflb with 12 defense systems selected from Defense Systems la, lb, Π, Ilia, IIIc, IV, V, VI, VII, Vffl, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System Illb with 13 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VII, Vffl, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System Illb with 14 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Illb comprises a combination of Defense System Illb with 15 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System fflb comprises a combination of Defense System Illb with 16 defense systems selected from Defense Systems la, lb, II, Ilia, IIIc, IV, V, VI, VII, Vffl, IX, Xa, Xb, and Xc.

[001087] In some embodiments, a combination comprising a Defense System IIIc comprises a combination of Defense System IIIc with any combination of Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Hie comprises a combination of Defense System IIIc with 1-16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IIIc comprises a combination of Defense System Hie with 1 defense system selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IIIc comprises a combination of Defense System IIIc with 2 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Hie comprises a combination of Defense System Hie with 3 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IIIc comprises a combination of Defense System IIIc with 4 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IIIc comprises a combination of Defense System IIIc with 5 defense systems selected from Defense Systems la, lb, Π, nia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IIIc comprises a combination of Defense System IIIc with 6 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IIIc comprises a combination of Defense System IIIc with 7 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Hie comprises a combination of Defense System Hie with 8 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IIIc comprises a combination of Defense System IIIc with 9 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Hie comprises a combination of Defense System IIIc with 10 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Hie comprises a combination of Defense System Hie with 11 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IIIc comprises a combination of Defense System IIIc with 12 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IIIc comprises a combination of Defense System Hie with 13 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Hie comprises a combination of Defense System IIIc with 14 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IIIc comprises a combination of Defense System IIIc with 15 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IIIc comprises a combination of Defense System Hie with 16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc.

[001088] In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with any combination of Defense Systems la, lb, II, Ilia, Illb, Hie, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 1-16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 1 defense system selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 2 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 3 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 4 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 5 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 6 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 7 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 8 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 9 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 10 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 11 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 12 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 13 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 14 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, Hie, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 15 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IV comprises a combination of Defense System IV with 16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, V, VI, VII, VIII, IX, Xa, Xb, and Xc.

[001089] In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with any combination of Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with 1-16 defense systems selected from Defense Systems la, lb, Π, Ilia, Illb, Hie, IV, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with 1 defense system selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with 2 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, Hie, IV, VI, VII, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System

V comprises a combination of Defense System V with 3 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with 4 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, Hie, IV, VI, VII, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System

V comprises a combination of Defense System V with 5 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with 6 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, Hie, IV, VI, VII, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System

V comprises a combination of Defense System V with 7 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with 8 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, Hie, IV, VI, VII, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System

V comprises a combination of Defense System V with 9 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with 10 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, VII, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System

V comprises a combination of Defense System V with 11 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with 12 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, VII, Vin, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with 13 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with 14 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with 15 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System V comprises a combination of Defense System V with 16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, nic, IV, VI, VII, VIII, IX, Xa, Xb, and Xc.

[001090] In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with any combination of Defense Systems la, lb, II, Ilia, Illb, Hie, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 1-16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 1 defense system selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 2 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 3 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 4 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 5 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 6 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 7 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 8 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 9 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 10 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 11 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 12 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, Vn, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 13 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 14 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, Hie, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 15 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VI comprises a combination of Defense System VI with 16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VII, VIII, IX, Xa, Xb, and Xc.

[001091] In some embodiments, a combination comprising a Defense System VII comprises a combination of Defense System VII with any combination of Defense Systems la, lb, Π, Ilia, Illb, IIIc, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VII comprises a combination of Defense System VII with 1-16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VII comprises a combination of Defense System VII with 1 defense system selected from Defense Systems la, lb, II, Ilia, nib, IIIc, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VII comprises a combination of Defense System VII with 2 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VII comprises a combination of Defense System VII with 3 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, nic, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VII comprises a combination of Defense System VII with 4 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, nic, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VII comprises a combination of Defense System VII with 5 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Vn comprises a combination of Defense System VII with 6 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VII comprises a combination of Defense System VII with 7 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VII comprises a combination of Defense System VII with 8 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, nic, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VII comprises a combination of Defense System VII with 9 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, nic, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VH comprises a combination of Defense System VII with 10 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VH comprises a combination of Defense System VH with 11 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VH comprises a combination of Defense System VH with 12 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VII comprises a combination of Defense System VII with 13 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, nic, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VH comprises a combination of Defense System VII with 14 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, nic, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VH comprises a combination of Defense System VII with 15 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vni, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System Vn comprises a combination of Defense System VII with 16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VIII, IX, Xa, Xb, and Xc.

[001092] In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with any combination of Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 1-16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 1 defense system selected from Defense Systems la, lb, Π, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System Vni with 2 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, Hie, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 3 defense systems selected from Defense Systems la, lb, Π, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 4 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 5 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 6 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System Vni with 7 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, Hie, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 8 defense systems selected from Defense Systems la, lb, Π, Ilia, Illb, nic, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 9 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 10 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 11 defense systems selected from Defense Systems la, lb, Π, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System Vni with 12 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 13 defense systems selected from Defense Systems la, lb, Π, Ilia, Illb, nic, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 14 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 15 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System VIII comprises a combination of Defense System VIII with 16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, IX, Xa, Xb, and Xc.

[001093] In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with any combination of Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 1-16 defense systems selected from Defense Systems la, lb, Π, Ilia, Illb, Hie, IV, VI, V, VI, VII, Vni, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 1 defense system selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 2 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 3 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 4 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 5 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vn, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 6 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 7 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 8 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 9 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 10 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vn, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 11 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 12 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 13 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 14 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 15 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vn, VIII, Xa, Xb, and Xc. In some embodiments, a combination comprising a Defense System IX comprises a combination of Defense System IX with 16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, Xa, Xb, and Xc.

[001094] In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with any combination of Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 1-16 defense systems selected from Defense Systems la, lb, Π, Ilia, Illb, Hie, IV, VI, V, VI, VII, Vni, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 1 defense system selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 2 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vn, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 3 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, nic, IV, VI, V, VI, VII, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 4 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 5 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vn, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 6 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 7 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vn, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 8 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, Hie, IV, VI, V, VI, VII, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 9 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 10 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vn, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 11 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 12 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vn, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 13 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, nic, IV, VI, V, VI, VII, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 14 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 15 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vn, VIII, IX, Xa, and Xc. In some embodiments, a combination comprising a Defense System Xb comprises a combination of Defense System Xb with 16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xc.

[001095] In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with any combination of Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 1-16 defense systems selected from Defense Systems la, lb, Π, Ilia, Illb, Hie, IV, VI, V, VI, VII, Vni, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 1 defense system selected from Defense Systems la, lb, II, Ilia, nib, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 2 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 3 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, nic, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 4 defense systems selected from Defense Systems la, lb, Π, Ilia, nib, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 5 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vn, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 6 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 7 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 8 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, nic, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 9 defense systems selected from Defense Systems la, lb, Π, Ilia, nib, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 10 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vn, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 11 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 12 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 13 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, Hie, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 14 defense systems selected from Defense Systems la, lb, Π, Ilia, nib, IIIc, IV, VI, V, VI, VII, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 15 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, Vn, VIII, IX, Xa, and Xb. In some embodiments, a combination comprising a Defense System Xc comprises a combination of Defense System Xc with 16 defense systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, VI, V, VI, VH, VIII, IX, Xa, and Xb. [001096] In some embodiments, a combination of Defense Systems disclosed herein above, does not naturally occur in nature. In some embodiments, a combination of Defense Systems disclosed herein above, does not naturally occur in a host cell. In some embodiments, a combination of Defense Systems disclosed herein above, does not naturally occur in bacterial cell. In some embodiments, a combination of Defense Systems disclosed herein above, does not naturally occur in an archaeal cell. In some embodiments, a combination of Defense Systems disclosed herein above, does not naturally occur in a eukaryotic cell. In some embodiments, a combination of Defense Systems disclosed herein above, does not naturally occur in a species disclosed in Tables 6-19C. In some embodiments, a combination of Defense Systems disclosed herein above, does not naturally occur in a host cell.

[001097] In some embodiments, a combination of Defense Systems disclosed herein above, is not expressed together in nature. In some embodiments, a combination of Defense Systems disclosed herein above, is not naturally expressed in a host cell. In some embodiments, a combination of Defense Systems disclosed herein above, is not naturally expressed in bacterial cell. In some embodiments, a combination of Defense Systems disclosed herein above, is not naturally expressed in an archaeal cell. In some embodiments, a combination of Defense Systems disclosed herein above, is not naturally expressed in a eukaryotic cell. In some embodiments, a combination of Defense Systems disclosed herein above, is not naturally expressed in a species disclosed in Tables 6-17.

[001098] In some embodiments, a combination of functional Defense Systems disclosed herein above, does not naturally occur in nature. In some embodiments, a combination of functional Defense Systems disclosed herein above, does not naturally occur in a host cell. In some embodiments, a combination of functional Defense Systems disclosed herein above, does not naturally occur in bacterial cell. In some embodiments, a combination of functional Defense Systems disclosed herein above, does not naturally occur in an archaeal cell. In some embodiments, a combination of functional Defense Systems disclosed herein above, does not naturally occur in a eukaryotic cell. In some embodiments, a combination of functional Defense Systems disclosed herein above, does not naturally occur in a species disclosed in Tables 6-19C. In some embodiments, a combination of functional Defense Systems disclosed herein above, does not naturally occur in a host cell.

[001099] In some embodiments, a cell comprising a combination of Defense Systems disclosed herein above, does not naturally occur in nature. In some embodiments, a cell comprising a combination of functional Defense Systems disclosed herein above, does not naturally occur in nature.

[001100] In some embodiments, a nucleic acid constructs, comprised in a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, encodes a polycistronic mRNA comprising said nucleic acid sequences. In some embodiments, a nucleic acid constructs, comprised in a Defense System la, lb, II, Ilia, nib, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, encodes a polycistronic mRNA comprising said nucleic acid sequences encoding said polypeptides. In some embodiments, a nucleic acid constructs, comprised in a Defense System la, lb, II, Ilia, Illb, nic, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, encodes a polycistronic mRNA comprising said nucleic acid sequences encoding components or functional portions thereof, of a Defense System.

[001101] Various construct schemes can be utilized to express few genes from a single nucleic acid construct. In some embodiments, the construct encodes a polycistronic mRNA comprising the nucleic acid sequences. In some embodiments, the nucleic acid sequences can be co- transcribed as a polycistronic message from a single promoter sequence of the nucleic acid construct. To enable co-translation of all the genes from a single polycistronic message, the different nucleic acid sequence segments can be transcriptionally fused via linker sequence including an internal ribosome entry site (IRES) sequence, which enables the translation of the nucleic acid sequence segment downstream of the IRES sequence. In this case, a transcribed polycistronic RNA molecule including the coding sequences of different combinations of the nucleic acid sequences, for example as disclosed herein, will be translated from both the capped 5' end and the internal IRES sequence of the polycistronic RNA molecule.

[001102] In some embodiments, each two nucleic acid sequence segments can be translationally fused via protease recognition site cleavable by a protease expressed by the cell to be transformed with the nucleic acid construct. In this case, a chimeric polypeptide translated will be cleaved by the cell expressed protease.

[001103] In some embodiments, the nucleic acid construct can include at least two Cis acting regulatory elements each being for separately expressing a distinct nucleic acid sequence. These at least two Cis acting regulatory elements can be identical or distinct.

[001104] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System disclosed herein. In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising two components of a Defense System disclosed herein. In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising three components of a Defense System disclosed herein. In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising four components of a Defense System disclosed herein. In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising five components of a Defense System disclosed herein.

[001105] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System la or a Defense System lb, said component selected from the group consisting of a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, a ZorD polypeptide, and a ZorE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising two components of a Defense System la or a Defense System lb, said component selected from the group consisting of a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, a ZorD polypeptide, and a ZorE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising three components of a Defense System la or a Defense System lb, said component selected from the group consisting of a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, a ZorD polypeptide, and a ZorE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising four components of a Defense System la or a Defense System lb, said component selected from the group consisting of a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, a ZorD polypeptide, and a ZorE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising greater than four components of a Defense System la or a Defense System lb, said component selected from the group consisting of a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, a ZorD polypeptide, and a ZorE polypeptide.

[001106] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System Π, said component selected from the group consisting of a ThsA polypeptide and a ThsB polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising two components of a Defense System Π, said component selected from the group consisting of a ThsA polypeptide and a ThsB polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising more than two components of a Defense System Π, said component selected from the group consisting of a ThsA polypeptide and a ThsB polypeptide.

[001107] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System Ilia, said component selected from the group consisting of a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising two components of a Defense System Ilia, said component selected from the group consisting of a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising three components of a Defense System Ilia, said component selected from the group consisting of a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising four components of a Defense System Ilia, said component selected from the group consisting of a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising five components of a Defense System Ilia, said component selected from the group consisting of a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising more than five components of a Defense System Ilia, said component selected from the group consisting of a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide.

[001108] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System Illb, said component selected from the group consisting of a DruM polypeptide, a DruF polypeptide, a DruG polypeptide, a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising two components of a Defense System Illb, said component selected from the group consisting of a DruM polypeptide, a DruF polypeptide, a DruG polypeptide, a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising three components of a Defense System Illb, said component selected from the group consisting of a DruM polypeptide, a DruF polypeptide, a DruG polypeptide, a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising four components of a Defense System Illb, said component selected from the group consisting of a DruM polypeptide, a DruF polypeptide, a DruG polypeptide, a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising five components of a Defense System Illb, said component selected from the group consisting of a DruM polypeptide, a DruF polypeptide, a DruG polypeptide, a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising more than five components of a Defense System nib, said component selected from the group consisting of a DruM polypeptide, a DruF polypeptide, a DruG polypeptide, a DruE polypeptide.

[001109] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System IIIc, said component selected from the group consisting of a DruH polypeptide a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising two components of a Defense System IIIc, said component selected from the group consisting of a DruH polypeptide a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising three components of a Defense System IIIc, said component selected from the group consisting of a DruH polypeptide a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising four components of a Defense System IIIc, said component selected from the group consisting of a DruH polypeptide a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising five components of a Defense System IIIc, said component selected from the group consisting of a DruH polypeptide a DruE polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising more than five components of a Defense System IIIc, said component selected from the group consisting of a DruH polypeptide a DruE polypeptide.

[001110] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System IV, said component selected from the group consisting of a HamA polypeptide and a HamB polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising two components of a Defense System IV, said component selected from the group consisting of a HamA polypeptide and a HamB polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising more than two components of a Defense System IV, said component selected from the group consisting of a HamA polypeptide and a HamB polypeptide.

[001111] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System V, said component selected from the group consisting of a SduA polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising more than one component of a Defense System V, said component selected from the group consisting of a SduA polypeptide.

[001112] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System VI, said component selected from the group consisting of a GajA polypeptide and a GajB polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising two components of a Defense System VI, said component selected from the group consisting of a GajA polypeptide and a GajB polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising more than two components of a Defense System VI, said component selected from the group consisting of a GajA polypeptide and a GajB polypeptide.

[001113] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System VII, said component selected from the group consisting of a PtuA polypeptide and a PtuB polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising two components of a Defense System VII, said component selected from the group consisting of a PtuA polypeptide and a PtuB polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising more than two components of a Defense System VII, said component selected from the group consisting of a PtuA polypeptide and a PtuB polypeptide.

[001114] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System VIII, said component selected from the group consisting of a LmuA polypeptide and a LmuB polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising two components of a Defense System VIII, said component selected from the group consisting of a LmuA polypeptide and a LmuB polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising more than two components of a Defense System VIII, said component selected from the group consisting of a LmuA polypeptide and a LmuB polypeptide.

[001115] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System IX, said component selected from the group consisting of a KwaA polypeptide and a KwaB polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising two components of a Defense System IX, said component selected from the group consisting of a KwaA polypeptide and a KwaB polypeptide. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising more than two components of a Defense System IX, said component selected from the group consisting of a KwaA polypeptide and a KwaB polypeptide.

[001116] In some embodiments, disclosed herein is an isolated polypeptide comprising an amino acid sequence comprising one component of a Defense System Xa or a Defense System Xb or a Defense System Xc, said component selected from the group consisting of a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide, and variants thereof. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising two components of a Defense System Xa or a Defense System Xb or a Defense System Xc, said component selected from the group consisting of a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide, and variants thereof. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising three components of a Defense System Xa or a Defense System Xb or a Defense System Xc, said component selected from the group consisting of a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide, and variants thereof. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising four components of a Defense System Xa or a Defense System Xb or a Defense System Xc, said component selected from the group consisting of a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide, and variants thereof. In some embodiments, is an isolated polypeptide comprising an amino acid sequence comprising more than four components of a Defense System Xa or a Defense System Xb or a Defense System Xc, said component selected from the group consisting of a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, and a JetD polypeptide, and variants thereof. [001117] In some embodiments, the isolated polypeptide comprising an amino acid sequence of a Defense System has an anti-phage activity. In some embodiments, the isolated polypeptide comprising an amino acid sequence of a Defense System has an anti-plasmid activity. In some embodiments, the isolated polypeptide comprising an amino acid sequence of a Defense System has an anti-phage activity and an anti-plasmid activity. In some embodiments, the anti-phage activity is against at least one phage. In some embodiments, the anti-phage activity is against more than one phage.

[001118] In some embodiments, any one of said constructs disclosed herein, comprises multiple nucleic acid sequences, each sequence encoding at least one of said polypeptides. In some embodiments, any one of said constructs disclosed herein, comprises multiple nucleic acid sequences, each sequence encoding at least a functional portion of one of said polypeptides. In some embodiments, any one of said constructs disclosed herein, comprises multiple nucleic acid sequences, each sequence encoding at least one component of a Defense System. In some embodiments, any one of said constructs disclosed herein, comprises multiple nucleic acid sequences, each sequence encoding at least one functional component of a Defense System. In some embodiments, any one of said constructs disclosed herein, comprises multiple nucleic acid sequences, each sequence encoding at least one functional portion of a component of a Defense System.

[001119] As used herein, the terms designating a polypeptide, for example the terms "ZorA", "ZorB", "ZorC", "ZorD", "ZorE", "ThsA", "ThsB", "DruA", "DruB", "DruC", "DruD", "DruE", DruM", "DruF", "DruG", "DruH", "HamA", "HamB", "SduA", "GajA", "GajB", "PtuA", "PtuB", "LmuA", "LmuB", "KwaA", "KwaB", "JetA", "JetB", "JetC", "JetD", "JetA"", "JetB"", "JetC"", "JetD"", "JetAi"", "JetB" ¹ ", "JetC"", and "JetD" ¹ ", in some embodiments comprise full length polypeptides, respectively. In some embodiments, the terms designating a polypeptide, for example the terms "ZorA", "ZorB", "ZorC", "ZorD", "ZorE", "ThsA", "ThsB", "DruA", "DruB", "DruC", "DruD", "DruE", DruM", "DruF", "DruG", "DruH", "HamA", "HamB", "SduA", "GajA", "GajB", "PtuA", "PtuB", "LmuA", "LmuB", "KwaA", "KwaB", "JetA", "JetB", "JetC", "JetD", "JetA"", "JetB"", "JetC"", "JetD"", "JetAi"", "JetB" ¹ ", "JetC" ¹ ", and "JetD ¹ "", comprise a fragment of the full length polypeptide, wherein the fragment maintains the activity as disclosed herein.

[001120] Similarly, the terms designating a gene, for example the terms "zorA ", "zorB", "zorC", "zorD", "zorE", "thsA ", "thsB", "druA ", "druB", "druC", "druD", "druE", "druM", "druF", "druG", "druH", "hamA ", "hamB", "sduA ", "gajA ", "gajB", "ptuA ", "ptuB", "ImuA ", "ImuB", "kwaA ", "kwaB", "jetA ", "jetB ", "jetC", "jetD ", "jetA ⁿ ", "jetB' ¹ ", "jetC ¹ ", "jetD ¹¹ ", "jetA ", "jetB™", "jetC ^m ", and "jetD ^m ", in some embodiments comprise a full length gene, respectively. In some embodiments, the terms designating a gene, for example the terms "zorA ", "zorB", "zorC", "zorD", "zorE", "thsA ", "thsB", "druA ", "druB", "druC", "druD", "druE", "druM", "druF", "druG", "druH", "hamA ", "hamB", "sduA ", "gajA ", "gajB", "ptuA ", "ptuB", "ImuA ", "ImuB", "kwaA ", "kwaB", "jetA ", "jetB", "jetC", "jetD", "jetA' ¹ ", "jetB ¹¹ ", "jetC ¹ ", "jetD' ¹ ", "jetA' ¹¹ ", "jetB ", "jetC' ¹ ", and "jetD ^m ", comprise a fragment of the full length gene, wherein the fragment encodes a polypeptide, respectively, comprising the activity as disclosed herein.

[001121] In some embodiments, a construct comprising the nucleic acid sequence encoding the ZorA polypeptide, the ZorB polypeptide, the ZorC polypeptide, and the ZorD polypeptide, comprises a nucleic acid sequence having at least 80% homology with the sequence referenced in Table 8 rows 2-1174 columns G, AD, and AE or the sequence set forth in SEQ ID NO: 14, or comprises nucleic acid sequences having at least 80% homology to at least one of each of the sequences referenced in Table 8 rows 2-1830 columns J and L (encoding ZorA polypeptide), in Table 8 rows 2-1830 columns N and P (encoding ZorB polypeptide), in Table 8 rows 2-1174 columns R and T (encoding ZorC polypeptide), and in Table 8 rows 2-1174 columns V and X (encoding ZorD polypeptide).

[001122] In some embodiments, a construct comprising the nucleic acid sequence encoding the ZorA polypeptide, the ZorB polypeptide, and the ZorE polypeptide comprises a nucleic acid sequence having at least 80% homology to the sequence referenced in Table 8 rows 1175-1830 columns G, ADand AE, or the sequence set forth in SEQ ID NO: 15, or comprises nucleic acid sequences having at least 80% homology to the sequences referenced in Table 8 rows 2-1830 columns J and L (encoding ZorA polypeptide), in Table 8 rows 2-1830 columns N and P (encoding ZorB polypeptide), and in Table 8 rows 1175-1830 columns Z and AB (encoding ZorE polypeptide).

[001123] In some embodiments, a construct comprising the nucleic acid sequence encoding the ThsA polypeptide and the ThsB polypeptide comprises a nucleic acid sequence having at least 80% homology with the sequence referenced in Table 9 rows 2-2100 columns G, AG and AH, or the sequence set forth in SEQ ID NO: 10 or SEQ ID NO: 11, or comprises nucleic acid sequences having at least 80% homology to at least one of each of the sequences referenced in Table 9 rows 2-2100 columns I and K (encoding ThsA polypeptide) and the sequences referenced in Table 9 rows 2-2100 columns M and O, Q and S, U and W, Y and AA, and AC and AE (encoding ThsB polypeptide).

[001124] In some embodiments, a construct comprising the nucleic acid sequence encoding the DruA polypeptide, the DruB polypeptide, the DruC polypeptide, the DruD polypeptide, and the DruE polypeptide comprises a nucleic acid sequence having at least 80% homology with the sequences referenced in Table 10 rows 2-123 columns G, AT, and AU or the sequence set forth in SEQ ID NO: 16, or comprises nucleic acid sequences having at least 80% homology to at least one of each of the sequences referenced in Table 10 rows 2-123 columns J and L (encoding DruA polypeptide), referenced in Table 10 rows 2-123 columns N and P (encoding DruB polypeptide), referenced in Table 10 rows 2-123 columns R and T (encoding DruC polypeptide), referenced in Table 10 rows 2-123 columns V and X (encoding DruD polypeptide), and referenced in Table 10 rows 2-1343 columns Z and AB (encoding DruE polypeptide).

[001125] In some embodiments, a construct comprising the nucleic acid sequence encoding the DruM polypeptide, the DruF polypeptide, the DruG polypeptide, and the DruE polypeptide, comprises a nucleic acid sequence having at least 80% homology with the sequence referenced in Table 10 rows 124-295 columns G, AT, and AU, or comprises nucleic acid sequences having at least 80% homology to at least one of each of the sequences referenced in Table 10 rowsl24- 295 columns AD and AF (encoding DruM polypeptide), referenced in Table 10 rows 124-295 columns AH and AJ (encoding DruF polypeptide), referenced in Table 10 rows 124-295 columns AL and AN (encoding DruG polypeptide), and referenced in Table 10 rows2-1343 columns Z andAB (encoding DruE polypeptide).

[001126] In some embodiments, a construct comprising the nucleic acid sequence encoding the DruH polypeptide and the DruE polypeptide, comprises a nucleic acid sequence having at least 80% homology with the sequence referenced in Table 10 rows 296-1343 columns G, AT, and AU, or comprises nucleic acid sequences having at least 80% homology to at least one of each of the sequences referenced in Table 10 rows 296-1343 columnd AP and AR (encoding DruH polypeptide) and referenced in Table 10 rows 2-1343 columns Z and AB (encoding DruE polypeptide).

[001127] In some embodiments, a construct comprising the nucleic acid sequence encoding the HamA polypeptide and the HamB polypeptide comprises a nucleic acid sequence having at least 80% homology with the sequences referenced in Table 12 rows 2-1782 columns G, P, and Q or the sequence set forth in SEQ ID NO: 4, or comprises nucleic acid sequences having at least 80% homology to at least one of each of the sequences referenced in Table 12 rows 2-1782 column H and J (encoding HamA polypeptide) and referenced in Table 12 rows 2-1782 columnL and N (encoding HamB polypeptide).

[001128] In some embodiments, a construct comprising the nucleic acid sequence encoding the SduA polypeptide comprises a nucleic acid sequence having at least 80% homology with the sequences referenced in Table 13 rows 2-1247 columns H and J or columns G, L, and M, or the sequences set forth in SEQ ID NO: 9.

[001129] In some embodiments, a construct comprising the nucleic acid sequence encoding the GajA polypeptide and the GajB polypeptide comprises a nucleic acid sequence having at least 80% homology with the sequences referenced in Table 14 rows 2-4599 columns G, P, and Q, or the sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 6, or comprises nucleic acid sequences having at least 80% homology to at least one of each of sequences referenced in Table 14 rows 2-45-99 columns H and K (encoding GajA polypeptide) and referenced in Table 14 rows 2-45- 99 columns L and N (encoding GajB polypeptide).

[001130] In some embodiments, a construct comprising the nucleic acid sequence encoding the PtuA polypeptide and the PtuB polypeptide comprises a nucleic acid sequence having at least 80% homology with the sequences referenced in Table 15 rows 2-2507 columns G, P and Q or the sequence set forth in SEQ ID NO: 12 or SEQ ID NO: 13, or comprises nucleic acid sequences having at least 80% homology to at least one of each of the sequences referenced in Table 15 rows 2-2507 columns H and J (encoding PtuA polypeptide) and referenced in Table 15 rows 2-2507 columns L and N (encoding PtuB polypeptide).

[001131] In some embodiments, a construct comprising the nucleic acid sequence encoding the LmuA polypeptide and the LmuB polypeptide comprises a nucleic acid sequence having at least 80% homology with the sequences referenced in Table 16 rows 2-698 columns G, P, and Q, or the sequence set forth in SEQ ID NO: 7 or SEQ ID NO: 8, or comprises nucleic acid sequences having at least 80% homology to at least one of each of the sequences referenced in Table 16 rows 2-698column H (encoding LmuA polypeptide) and sequences referenced in Tablel6 rows 2-698column J (encoding LmuB polypeptide).

[001132] In some embodiments, a construct comprising the nucleic acid sequence encoding the KwaA polypeptide and the KwaB polypeptide comprises a nucleic acid sequence having at least 80% homology with the sequences referenced in Table 17 rows 2-935 columns G, P, and Q, or the sequence set forth in SEQ ID NO: 3, or comprises nucleic acid sequences having at least 80% homology to at least one of each of the sequences referenced in Table 17 rows 2-935 columns H and J (encoding KwaA polypeptide) and referenced in Table 17 rows 2-935 columns L and N (encoding KwaB polypeptide).

[001133] In some embodiments, a construct comprising the nucleic acid sequence encoding the JetA polypeptide, the JetB polypeptide, the JetC polypeptide, and the JetD comprises a nucleic acid sequence having at least 80% homology with the sequences referenced in Table 11 rows 2- 2322 columns G, Z, and AA, or the sequence set forth in SEQ ID NO: 17, or comprises nucleic acid sequences having at least 80% homology to at least one of each of the sequences referenced in Table 11 rows 2-2322 columns J and L (encoding JetA polypeptide), referenced in Table 11 rows 2-2322 columns N and P (encoding JetB polypeptide), referenced in Table 11 rows 2-2322 columns R and T (encoding JetC polypeptide) and referenced in Table 11 rows 2- 2322 columns V and X (encoding JetD polypeptide);

[001134] In some embodiments, a construct comprising the nucleic acid sequence encoding the JetA ¹¹ polypeptide, the JetB ^Ά polypeptide, the JetC ¹¹ polypeptide, and the JetD ¹¹ comprises a nucleic acid sequence having at least 80% homology with the sequences referenced in Table 11 rows 2323-2844 columns G, Z, and AA, or the sequence set forth in SEQ ID NO: 18 or comprises nucleic acid sequences having at least 80% homology to at least one of each of the sequences referenced in Table 11 rows 2323-2844 columns J and L (encoding JetA ^Ά polypeptide), referenced in Table 11 rows 2323-2844 columns N and P (encoding JetB ¹¹ polypeptide), referenced in Table 11 rows 2323-2844 columns R and T (encoding JetC ¹¹ polypeptide) and referenced in Table 11 rows 2323-2844 columns V and X (encoding JetD ^Ά polypeptide);

[001135] In some embodiments, a construct comprising the nucleic acid sequence encoding the JetA ^m polypeptide, the JetB ¹¹¹ polypeptide, the JetC ^m polypeptide, and the JetD ^m comprises a nucleic acid sequence having at least 80% homology with the sequences set forth in Table 11 rows 2845-3174 columns G, Z, and AA, or the sequence set forth in SEQ ID NO: 19 or comprises nucleic acid sequences having at least 80% homology to at least one of each of the sequences referenced in Table 11 rows 2845-3174 columns J and L (encoding JetA ^m polypeptide), referenced in Table 11 rows 2845-3174 columns N and P (encoding JetB ^m polypeptide), referenced in Table 11 rows 2845-3174 columns R and T (encoding JetC ^m polypeptide) and referenced in Table 11 rows 2845-3174 columns V and X (encoding JetD ^m polypeptide).

[001136] In some embodiments, a construct comprising a nucleic acid sequence comprises multiple copies of a nucleic acid sequence encoding a component of the Defense System. In some embodiments, a construct comprising a nucleic acid sequence comprises multiple copies of a nucleic acid sequence encoding two components of the Defense System. In some embodiments, a construct comprising a nucleic acid sequence comprises multiple copies of a nucleic acid sequence encoding three components of the Defense System. In some embodiments, a construct comprising a nucleic acid sequence comprises multiple copies of a nucleic acid sequence encoding four components of the Defense System. In some embodiments, a construct comprising a nucleic acid sequence comprises multiple copies of a nucleic acid sequence encoding five components of the Defense System. In some embodiments, a construct comprising a nucleic acid sequence comprises multiple copies of a nucleic acid sequence encoding more than components of the Defense System. In some embodiments, multiple copies comprise more than one copy. In some embodiments, multiple copies comprise 2 copies. In some embodiments, multiple copies comprise 2-10 copies. In some embodiments, multiple copies comprise 3 copies, 4 copies, 5 copies, 6 copies, 7 copies, 8 copies, 9 copies, or 10 copies.

[001137] In some embodiments, a Defense System disclosed herein provides a host cell with resistance to a foreign nucleic acid invasion. In some embodiments, a Defense System disclosed herein provides a bacterial cell with resistance to a foreign nucleic acid invasion. In some embodiments, a Defense System disclosed herein provides a bactieral cell with protection to foreign nucleic acid invasion.

[001138] In some embodiments, a method disclosed herein protects a host cell from foreign nucleic acid invasion, said method comprising a step of introducing into the host cell at least one defense system described herein. In some embodiments, a method disclosed herein protects a host cell from foreign nucleic acid invasion, said method comprising a step of introducing into the host cell at least one function defense system described herein. In some embodiments, a method disclosed herein protects a bacterial cell from foreign nucleic acid invasion, said method comprising a step of introducing into the bacterial cell at least one defense system described herein. In some embodiments, a method disclosed herein protects a bacterial cell from foreign nucleic acid invasion, said method comprising a step of introducing into the bacterial cell at least one function defense system described herein. [001139] In some embodiments, protecting a host cell from foreign nucleic acid invasion comprises protecting from phage infection, protecting from plasmid transformation, or protection from conjugative element entry, or any combination thereof. In some embodiments, protecting a bacterial cell from foreign nucleic acid invasion comprises protecting from phage infection, protecting from plasmid transformation, or protection from conjugative element entry, or any combination thereof. In some embodiments, protection from phage infection comprises protection from at least one phage infection.

[001140] In some embodiments, a nucleic acid construct comprising any one of the defesne systems described herein or any combination thereof, provides a host cell with resistance to foreign nucleic acid invasion. In some embodiments, a nucleic acid construct comprising any one of the defesne systems described herein or any combination thereof, provides protection from foreign nucleic acid invasion to a host cells.

[001141] In some embodiments, a nucleic acid construct comprising any one of the defesne systems described herein or any combination thereof, provides a bacterial cell with resistance to foreign nucleic acid invasion. In some embodiments, a nucleic acid construct comprising any one of the defesne systems described herein or any combination thereof, provides protection from foreign nucleic acid invasion to a bacterial cells.

[001142] In some embodiments, a Defense System disclosed herein provides a host cell with resistance to at least one phage. In some embodiments, a Defense System disclosed herein provides a host cell with resistance to a plasmid. In some embodiments, a Defense System disclosed herein provides a host cell with resistance to a combination of at least one phage and a plasmid.

[001143] In some embodiments, a Defense System selected from a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, provides a host cell with resistance to at least one phage. In some embodiments, a Defense selected from a Defense System la, lb, II, Ilia, Illb, Hie, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, provides a host cell with resistance to a plasmid. In some embodiments, a Defense System selected from a Defense System la, lb, II, Ilia, Illb, Hie, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, provides a host cell with resistance to a combination of at least one phage and a plasmid.

[001144] In some embodiments, a defense system comprising a combination of Defense Systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, provides a host cell with resistance to at least one phage. In some embodiments, a defense system comprising a combination of Defense Systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, provides a host cell with resistance to a plasmid. In some embodiments, a defense system comprising a combination of Defense Systems selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, provides a host cell with resistance to a combination of at least one phage and a plasmid.

[001145] In some embodiments, resistance is to at least one phage. In some embodiments, resistance to at least one phage comprises resistance to more than one phage. In some embodiments, resistance is to phage comprises resistance to phages from different families (See for example Figures 3B and 3C, and Figure 5D).

[001146] A skilled artisan would appreciate that the term "phage" or "bacteriophage" refers to a virus that selectively infects one or more bacterial species. Many phages are specific to a particular genus or species or strain of bacteria. In some embodiments, a phage or a bacteriophage selectively infects one or more archaeal species. Many phages are specific to a particular genus or species or strain of archaea.

[001147] In some embodiments, the phage genome can be ssDNA, dsDNA, ssRNA, or dsRNA. In some embodiments, the phage genome is linear. In some embodiments, the phage genome is circular. In some embodiments, the phage is virulent to bacteria. In some embodiments, the phage is virulent to archaea. In some embodiments, the phage is virulent to bacteria and archaea.

[001148] In some embodiments, the phage is a lytic phage. In some embodiments, the phage is temperate (also referred to as lysogenic). In some embodiments, the phage is a lytic phage selected from the group consisting of Nf, SP82G and SPOl. In some embodiments, the phage is Nf. In some embodiments, the phage is SPOl. In some embodiments, the phage is a temperate phage selected from the group consisting of phi3T and phil05. In some embodiments, the phage is phi3T.

[001149] In some embodiments, phage as disclosed herein include, but are not limited to, phages that belong to any of the following virus families: Caudavirales, Corticoviridae, Cystoviridae, Inoviridae, Leviviridae, Microviridae, Myoviridae, Podoviridae, Siphoviridae, or Tectiviridae. In some embodiments, the phage is a podovirus, a myovirus or a siphovirus phage. In some embodiments, the phage is a T7 or a lambda- vir phage. In some embodiments, a phage comprises phage that infect bacteria that are pathogenic to plants and/or animals (including humans).

[001150] In some embodiments, the resistance of a host cell comprising a defense system against a phage is improved as compared to a host cell of the same species, which does not include a defense system disclosed herein.

[001151] Assays for testing phage resistance are well known in the art. Thus, for example, the lysogenic activity of a phage can be assessed by PCR or DNA sequencing. The DNA replication activity of a phage can be assessed e.g. by DNA sequencing or Southern blot analysis.

[001152] The lytic activity of a phage can be assessed e.g. by optical density, plaque assay or living dye indicators. The lytic activity of a phage can be measured indirectly by following the decrease in optical density of the bacterial cultures owing to lysis. This method involves introduction of phage into a fluid bacterial culture medium. After a period of incubation, the phage lyses the bacteria in the broth culture resulting in a clearing of the fluid medium resulting in decrease in optical density.

[001153] Another method, known as the plaque assay, introduces phage into a few milliliters of soft agar along with some bacterial host cells. This soft agar mixture is laid over a hard agar base (seeded-agar overlay). The phage adsorbs onto the host bacterial cells, infect and lyse the cells, and then begin the process anew with other bacterial cells in the vicinity. After 6 - 24 hours, zones of clearing on the plate, known as plaques, are observable within the lawn of bacterial growth on the plate. Each plaque represents a single infective phage particle in the original sample.

[001154] Yet another method is the one-step phage growth curve which allows determining the production of progeny virions by cells as a function of time after infection. The assay is based on the fact that cells in the culture are infected simultaneously with a low number of phages so that no cell can be infected with more than one phage. At various time intervals, samples are removed for a plaque assay allowing quantitative determination of the number of phages present in the medium.

[001155] Other methods use for example redox chemistry, employing cell respiration as a universal reporter. During active growth of bacteria, cellular respiration reduces a dye (e.g., tetrazolium dye) and produces a color change that can be measured in an automated fashion. On the other hand, successful phage infection and subsequent growth of the phage in its host bacterium results in reduced bacterial growth and respiration and a concomitant reduction in color.

[001156] Thus, nucleic acid sequences encoding a Defense System component(s) or functional fragments thereof, and the polypeptides and nucleic acid constructs disclosed herein can be used in conferring phage resistance thereby protecting bacteria from phage infection.

[001157] In some embodiments, "conferring phage resistance" refers to the level of phage infection and/or multiplication in the e.g. bacteria containing a functional Defense System as disclosed herein, that does not cause a deleterious effect to the bacteria e.g., growth arrest or death.

[001158] In some embodiments, the phage has about 10-10,000 times lower efficiency of plaquing on bacteria containing a functional Defense System. In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System ([EOP] = 10 ^"2 ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001159] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System la ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001160] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System la ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001161] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System la ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001162] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System lb ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001163] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System II ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001164] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System III (Type I, Type II, and Type III) ([EOP] = 10 ^"2 ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^{" 4} ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001165] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System rV ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001166] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System V ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001167] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System VI ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001168] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System VII ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001169] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System VIII ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001170] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System ΓΧ ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001171] In some embodiments, the phage has about 100-100,000 times lower efficiency of

_2

plaquing on bacteria containing a functional Defense System Xa ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001172] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System Xb ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001173] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a functional Defense System Xc ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours.

[001174] In some embodiments, the phage has about 100-100,000 times lower efficiency of plaquing on bacteria containing a combination of functional Defense Systems ([EOP] = 10 ^" ), about 1000 times lower EOP (EOP = 10 ^"3 ), 10,000 times lower EOP (EOP = 10 ^"4 ), or 100,000 times lower EOP (EOP=10 ⁵ ). In some embodiments, the level of phage multiplication in a culture is measured after about 6-14 hours incubation of the culture, e.g., after about 12 hours, after about 9 hours, after about 8 hours after about 7 hours, or after about 6 hours. In some embodiments, the combination of Defense Systems comprises any combination of Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc as described herein.

[001175] In some embodiments, a Defense System provides resistance is to a plasmid. In some embodiments, the resistance of a host cell comprising a defense system against a phage is improved as compared to a host cell of the same species, which does not include a defense system disclosed herein. In some embodiments, a plasmid comprises an episomal plasmid. In some embodiments, a plasmid comprises an integrative plasmid. In some embodiments, resistance to a plasmid comprises decrease transformation efficiency of the plasmid. In some embodiments, resistance to a plasmid comprises decrease transformation efficiency of the episomal plasmid.

[001176] In some embodiments, a nucleic acid sequences encoding a Defense System component(s) or functional fragments thereof, and the polypeptides and nucleic acid constructs disclosed herein can be used in protecting bacteria from conjugative elements. In some embodiments, disclosed herein is a method of protecting bacteria from conjugative elements, the method comprising the step of introducing into the bacteria a defense system selected from Defense Systems Ia-Xc, or a combination thereof. In some embodiments, disclosed herein is a method of protecting bacteria from conjugative elements, the method comprising the step of introducing into the bacteria a functional defense system selected from Defense Systems Ia-Xc, or a combination thereof. In some embodiments, disclosed herein is a method of protecting bacteria from conjugative elements, the method comprising the step of introducing into the bacteria at least one component of a defense systems selected from Defense Systems Ia-Xc, or a combination thereof.

[001177] A skilled artisan would appreciate that a method protecting bacteria from conjugative elements, would in some embodiments, encompass a reduction in the horizontal gene transfer between bacteria. The steps of conjugation known in the art comprise an initial step of cell-to- cell contact during mating pair formation, followed by a transfer of gene(s)/genetic elements in three steps. The DNA is nicked at the origin of transfer, wherein the nicking enzyme binds covalently to one of the DNA strands. The nucleoprotein filament is then coupled to the type 4 secretion system (T4SS) and transferred to the recipient cell. Finally, the element is replicated in the original and novel hosts leading to double stranded DNA molecules in each cell. (Cury et al. (2017) Nucleic Acids Res. Sep 6; 45(15): 8943-8956).

[001178] In some embodiments, a method of protecting bacteria from conjugative elements inhibits or reduces cell-to-cell contact or mating pair formation. In some embodiments, a method of protecting bacteria from conjugative elements inhibits or reduces nicking of the DNA strand. In some embodiments, a method of protecting bacteria from conjugative elements inhibits or reduces transfer of the DNA into the recipient cell. In some embodiments, a method of protecting bacteria from conjugative elements inhibits or reduces replication of the element in the novel host comprising a defense system described herein, a combination thereof, of at least one element thereof. In some embodiments, the conjugative element comprises a plasmid. In some embodiments, the conjugative element comprises a transposon.

[001179] In some embodiments, there is provided an article of manufacture or a kit identified for providing bacterial resistance, or plasmid transformation, or bacterial resistance and plasmid transformation to a microbial cell, for example but not limited to bacteria, comprising a defense system disclosed herein. In some embodiments, the article of manufacture or kit is for use producing bacteria resistant to at least one phage, wherein the bacteria do not naturally comprise the defense system. In some embodiments, the article of manufacture or kit is for use producing bacteria resistant to plasmid transformation, wherein the bacteria do not naturally comprise the defense system. In some embodiments, the article of manufacture or kit is for use producing bacteria resistant to at least one phage and resistant to plasmid transformation, wherein the bacteria do not naturally comprise the defense system.

[001180] In some embodiments, the defense system comprises at least 2 Defense Systems, wherein the bacteria do not naturally comprise the at least 2 Defense Systems. In some embodiments, the defense system comprises any of Defense Systems Ia-Xc or a combination thereof, wherein the bacteria do not naturally comprise the Defense System or combination of systems. In some embodiments, the defense system comprises a combination of Defense systems selected from Defense Systems Ia-Xc, wherein the bacteria do not naturally comprise the combination of Defense Systems present in the article of manufacture or the kit.

[001181] In some embodiments, a Defense System described herein is packaged in a container. In some embodiments, different Defense Systems are packaged in separate containers. In some embodiments, different Defense Systems are packaged in the same containers. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 different Defense Systems are packaged in the same containers. In some embodiments, the different Defense Systems are in a co-formulation. In some embodiments, different Defense Systems are packaged in transportable containers.

[001182] In some embodiments, a container comprising a Defense Systems described herein comprises lyophilized components of said Defense System. In some embodiments, a container comprising at least two Defense Systems described herein comprises lyophilized components of said Defense Systems. In some embodiments, a container comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 Defense Systems described herein comprises lyophilized components of said Defense Systems. In some embodiments, Defense Systems comonents are co-formulated and lyophilized and stored in a container.

[001183] In some embodiments, a container comprising a Defense Systems described herein comprises spray-dried components of said Defense System. In some embodiments, a container comprising at least two Defense Systems described herein comprises spray-dried components of said Defense Systems. In some embodiments, a container comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 Defense Systems described herein comprises spray-dried components of said Defense Systems. In some embodiments, Defense Systems comonents are co-formulated and spray-dried and stored in a container.

[001184] In some embodiments, a container comprising a Defense Systems described herein comprises components of said Defense System in a liquid formulation. In some embodiments, a container comprising at least two Defense Systems described herein comprises components of said Defense Systems in a liquid formulation. In some embodiments, a container comprising at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 Defense Systems described herein comprises components of said Defense Systems in a liquid formulation. In some embodiments, Defense Systems components are co-formulated and stored in a container in a liquid formulation.

[001185] In some embodiments, a Defense system stored in a container comprises a full complement of components. In some embodiments, a Defense system stored in a container comprises less than a full complement of components. In some embodiments, a Defense system stored in a container comprises at least one component of the Defense system. In some embodiments, a Defense system stored in a container comprises at least 1, 2, 3, 4, or 5 component of the Defense system. In some embodiments, a Defense system stored in a container comprises between about 1-10 component of the Defense system. In some embodiments, a Defense system stored in a container comprises more than components of the Defense system. In some embodiments, a Defense system stored in a container comprises different numbers of components of different Defense systems. For example but not limited to, in some embodiments a container comprises a full complement of components of one Defense System and less than a full complement of components of another Defense system.

Methods of Use of a Defense System or Combinations thereof

[001186] Defense systems have been described in detail above, as has the combination of Defense Systems each comprising a nucleic acid construct. In some embodiments, methods of use a defense system disclosed herein comprises use of a single Defense System comprising a nucleic acid construct, selected from Defense Systems la, lb, II, Ilia, Ilia, Ilia, IV, V, VI, VII, Vni, IX, Xa, Xb, and Xc. In some embodiments, methods of use of a defense system comprises use of a combination of Defense Systems comprising nucleic acid constructs selected from Defense systems la, lb, II, nia, nia, Ilia, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, as disclosed herein.

[001187] Methods of use of a defense system described herein include but are not limited to, methods of protecting bacteria from phage infection, methods of protecting bacteria from plasmid transformation, methods of protecting bacteria from conjugative elements, methods of protecting bacteria from any combination of phage infection, conjugative elements, and plasmid transformation, methods of producing bacteria resistant to phage infection; methods of producing bacteria resistant to plasmids; methods of producing bacteria protected from conjugative elements, methods of producing bacteria resistant to phage infection, conjugative elements, or plasmids, or any combination thereof; and methods of making a food, a food additive, a feed, a nutritional supplement, a probiotic supplement, a personal care product, a health care product, and/or a veterinary product.

[001188] In some embodiments, a method of use described herein comprises a method of protecting a host cell from foreign nucleic acid invasion. , a method of use described herein comprises a method of protecting a bacterial cell from foreign nucleic acid invasion.

[001189] In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises introducing into the host cells at least one defense system described herein. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises introducing into the host cells a combination of defense systems described herein. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises introducing into the host cells at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 defense system described herein.

[001190] In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises introducing into the host cells at least one functional defense system described herein. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises introducing into the host cells a combination of functional defense systems described herein. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises introducing into the host cells at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 functional defense system described herein. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises introducing into the host cells at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 functional and nonfunctional defense system described herein.

[001191] In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises introducing into the bacterial cells at least one defense system described herein. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises introducing into the bacterial cells a combination of defense systems described herein. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises introducing into the bacterial cells at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 defense system described herein. [001192] In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises introducing into the bacterial cells at least one functional defense system described herein. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises introducing into the bacterial cells a combination of functional defense systems described herein. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises introducing into the bacterial cells at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 functional defense system described herein. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises introducing into the bacterial cells at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 functional and non-functional defense system described herein.

[001193] In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises protecting said host cell from phage infection. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises protecting said host cell from at least one phage infection. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises protecting said host cell from more than one phage infection. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises protecting said host cell from plasmid transformation. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises protecting said host cell from at least one plasmid transformation. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises protecting said host cell from more than one plasmid transformation. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises protecting said host cell from entry of conjugative elements. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises protecting said host cell from entry of at least one conjugative element. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises protecting said host cell from entry of more than one conjugative elements. In some embodiments, a method of protecting a host cell from foreign nucleic acid invasion comprises protecting said host cell from any combination of phage infection, plamisd transformation, and entry of conjugative elements.

[001194] In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises protecting said bacterial cell from phage infection. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises protecting said bacterial cell from at least one phage infection. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises protecting said bacterial cell from more than one phage infection. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises protecting said bacterial cell from plasmid transformation. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises protecting said bacterial cell from at least one plasmid transformation. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises protecting said bacterial cell from more than one plasmid transformation. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises protecting said bacterial cell from entry of conjugative elements. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises protecting said bacterial cell from entry of at least one conjugative element. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises protecting said bacterial cell from entry of more than one conjugative elements. In some embodiments, a method of protecting a bacterial cell from foreign nucleic acid invasion comprises protecting said bacterial cell from any combination of phage infection, plamisd transformation, and entry of conjugative elements.

[001195] In some embodiments, a method disclosed herein comprises the use of a defense system described herein, for protecting bacteria from phage infection. In some embodiments, a method disclosed herein comprises a method of protecting bacteria from plasmid transformation. In some embodiments, a method disclosed herein comprises a method of protecting bacteria from conjugative elements. In some embodiments, a method disclosed herein comprises a method of protecting bacteria from phage infection, and/or conjugative elements, and/or plasmid transformation. In some embodiments, a method disclosed herein comprises a method of producing bacteria resistant to phage infection. In some embodiments, a method disclosed herein comprises a method of producing bacteria resistant to plasmids. In some embodiments, a method disclosed herein comprises a method of producing bacteria resistant to conjugative elements. In some embodiments, a method disclosed herein comprises a method of producing bacteria resistant to phage infection, and/o conjugative elements, and/or plasmids.

[001196] In some embodiments, a method disclosed herein comprises a method of making a food. In some embodiments, a method disclosed herein comprises a method of making a food additive. In some embodiments, a method disclosed herein comprises a method of making a feed. In some embodiments, a method disclosed herein comprises a method of making a nutritional supplement. In some embodiments, a method disclosed herein comprises a method of making a probiotic supplement. In some embodiments, a method disclosed herein comprises a method of making a personal care product. In some embodiments, a method disclosed herein comprises a method of making a health care product. In some embodiments, a method disclosed herein comprises a method of making a veterinary product.

[001197] In some embodiments, disclosed herein is a method of protecting bacteria from phage infection, said method comprising the step of introducing into bacteria a defense system comprising at least one of a Defense System la, a Defense System lb, a Defense System II, a Defense System Ilia, a Defense System nib, a Defense System IIIc, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, or a Defense System Xc, wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method results in the bacteria being resistant to at least one phage, or being resistant to a plasmid, or being resistant to at least one phage and a plasmid.

[001198] In some embodiments, disclosed herein is a method of protecting bacteria from plasmid transformation, said method comprising the step of introducing into bacteria a defense system comprising at least one of a Defense System la, a Defense System lb, a Defense System II, a Defense System Ilia, a Defense System Illb, a Defense System IIIc, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, or a Defense System Xc, wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method results in the bacteria being resistant to at least one phage, or being resistant to a plasmid, or being resistant to at least one phage and a plasmid.

[001199] In some embodiments, disclosed herein is a method of protecting bacteria from conjugative elements, said method comprising the step of introducing into bacteria a defense system comprising at least one of a Defense System la, a Defense System lb, a Defense System II, a Defense System Ilia, a Defense System nib, a Defense System IIIc, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, or a Defense System Xc, wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method results in the bacteria being resistant to at least one conjugative elements.

[001200] In some embodiments, disclosed herein is a method of protecting bacteria from any combination of phage infection, conjugative elements, and plasmid transformation, said method comprising the step of introducing into bacteria a defense system comprising at least one of a Defense System la, a Defense System lb, a Defense System Π, a Defense System Ilia, a Defense System nib, a Defense System Hie, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, or a Defense System Xc, wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method results in the bacteria being resistant to at least one phage, or being resistant to a plasmid, or being resistant to a conjugative element, or being resistant to a combination of at least one phage, a conjugative element, and a plasmid.

[001201] In some embodiments, disclosed herein is a method of producing bacteria resistant to phage infection, said method comprising the step of introducing into bacteria a defense system comprising at least one of a Defense System la, a Defense System lb, a Defense System II, a Defense System Ilia, a Defense System nib, a Defense System Hie, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, or a Defense System Xc, wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method produces bacteria resistant to at least one phage.

[001202] In some embodiments, disclosed herein is a method of producing bacteria resistant to plasmid transformation, said method comprising the step of introducing into bacteria a defense system comprising at least one of a Defense System la, a Defense System lb, a Defense System II, a Defense System Ilia, a Defense System Illb, a Defense System IIIc, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, or a Defense System Xc, wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method produces bacteria resistant to a plasmid transformation.

[001203] In some embodiments, disclosed herein is a method of producing bacteria resistant to conjugative elements, said method comprising the step of introducing into bacteria a defense system comprising at least one of a Defense System la, a Defense System lb, a Defense System II, a Defense System Ilia, a Defense System nib, a Defense System IIIc, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, or a Defense System Xc, wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method produces bacteria resistant to conjugative elements.

[001204] In some embodiments, disclosed herein is a method of producing bacteria resistant to any combination of phage infection, conjugative elements, and plasmid transformation, said method comprising the step of introducing into bacteria a defense system comprising at least one of a Defense System la, a Defense System lb, a Defense System II, a Defense System Ilia, a Defense System Illb, a Defense System Hie, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, or a Defense System Xc, wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method produces bacteria resistant to any combination of phage infection, conjugative elements, and plasmid transformation.

[001205] In some embodiments, the defense system used in a method disclosed herein comprises one of a Defense System la, a Defense System lb, a Defense System II, a Defense System Ilia, a Defense System Illb, a Defense System Hie, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, and a Defense System Xc. In some embodiments, the defense system used in a method disclosed herein comprises a combination of Defense Systems selected from a Defense System la, a Defense System lb, a Defense System II, a Defense System Ilia, a Defense System Illb, a Defense System Hie, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, and a Defense System Xc. In some embodiments, the defense system used in a method disclosed herein comprises between 2- 5 Defense Systems selected from a Defense System la, a Defense System lb, a Defense System II, a Defense System III, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, and a Defense System Xc. In some embodiments, the defense system used in a method disclosed herein comprises between 2-10 Defense Systems selected from a Defense System la, a Defense System lb, a Defense System II, a Defense System Ilia, a Defense System Illb, a Defense System Hie, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, and a Defense System Xc. In some embodiments, the defense system used in a method disclosed herein comprises between 10-20 Defense Systems selected from a Defense System la, a Defense System lb, a Defense System Π, a Defense System Ilia, a Defense System nib, a Defense System Hie, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, and a Defense System Xc.

[001206] In some embodiments, the defense system used in a method disclosed herein comprises a combination of Defense Systems, as described in detail herein, selected from a Defense System la, a Defense System lb, a Defense System Π, a Defense System Ilia, a Defense System nib, a Defense System Hie, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, and a Defense System Xc.

[001207] In some embodiments, disclosed herein is a method of protecting bacteria from phage infection, said method comprising the step of introducing into bacteria a defense systems comprising a combination of Defense Systems, said combination comprising any combination of a Defense System la, a Defense System lb, a Defense System II, a Defense System Ilia, a Defense System nib, a Defense System Hie, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, or a Defense System Xc, wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method results in the bacteria being resistant to at least one phage.

[001208] In some embodiments, disclosed herein is a method of protecting bacteria from plasmid transformation, said method comprising the step of introducing into bacteria a defense systems comprising a combination of Defense Systems, said combination comprising any combination of a Defense System la, a Defense System lb, a Defense System Π, a Defense System Ilia, a Defense System Illb, a Defense System Hie, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, or a Defense System Xc, wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method results in the bacteria being resistant to a plasmid transformation.

[001209] In some embodiments, disclosed herein is a method of protecting bacteria from conjugative elements, said method comprising the step of introducing into bacteria a defense systems comprising a combination of Defense Systems, said combination comprising any combination of a Defense System la, a Defense System lb, a Defense System Π, a Defense System Ilia, a Defense System Illb, a Defense System Hie, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, or a Defense System Xc, wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method results in the bacteria being resistant to conjugative elements.

[001210] In some embodiments, disclosed herein is a method of protecting bacteria from any combination of phage infection, conjugative elements, and plasmid transformation, said method comprising the step of introducing into bacteria a defense systems comprising a combination of Defense Systems, said combination comprising any combination of a Defense System la, a Defense System lb, a Defense System II, a Defense System Ilia, a Defense System Illb, a Defense System IIIc, a Defense System IV, a Defense System V, a Defense System VI, a Defense System VII, a Defense System VIII, a Defense System IX, a Defense System Xa, a Defense System Xb, or a Defense System Xc, wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method results in the bacteria being resistant to any combination of phage infection, conjugative elements, and plasmid transformation.

[001211] In some embodiments, a method of protecting bacteria from phage infection produces bacteria resistant to phage infection. In some embodiments, the method of protecting bacteria from plasmid transformation produces bacteria having reduced transformation efficiency of a plasmid. In some embodiments, the method of protecting bacteria from conjugative elements produces bacteria resistant to horizontal gene transfer. In some embodiments, the method of protecting bacteria from phage infection, and/or conjugative elements, and/or plasmid transformation, produces bacteria resistant to phage infection, resistant to horizontal gene transfer, and having reduced transformation efficiency of a plasmid. [001212] In some embodiments, a method of protecting bacteria from phage infection produces bacteria resistant to at least one phage. In some embodiments, a method of protecting bacteria from plasmid transformation produces bacteria resistant to plasmid transformation. In some embodiments, a method of protecting bacteria from phage infection and plasmid transformation produces bacteria resistant to at least one phage and resistant to entry of a plasmid.

[001213] In some embodiments, provided herein is a method of protecting bacteria from phage infection, the method comprising introducing into the bacteria a defense system having an anti- phage activity, the system comprising at least one component selected from the group consisting of the components of the defense system, thereby protecting the bacteria from phage infection. In some embodiments, a method of protecting bacteria from phage infection comprises introducing into the bacteria a defense system comprising a Defense System selected from a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, wherein said defense system comprises an anti-phage activity, the system comprising at least one component of said Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, said at least one component selected from the group consisting of the components of the Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, respectively, thereby protecting the bacteria from phage infection. In some embodiments, a method of protecting bacteria from phage infection comprises introducing into the bacteria a defense system comprising a combination of Defense Systems selected from Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, wherein said defense system comprises an anti-phage activity, the system comprising at least one component of each of said Defense Systems in combination, said at least one component selected from the group consisting of the components of the Defense Systems la, lb, Π, Ilia, fflb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, respectively, thereby protecting the bacteria from phage infection.

[001214] In some embodiments, an at least one component comprises the components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, required for a functional Defense System, wherein said function comprises an anti-phage activity. In some embodiments, an at least one component comprises the components of the cassette of genes making up a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises two components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises three components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, Vni, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises four components of a Defense System la, lb, II, Ilia, nib, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises five components of a Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, a component comprises the full-length component. In some embodiments, a component comprises a functional portion of the component. In some embodiments, a component comprises a component homolog.

[001215] In some embodiments, provided herein is a method of protecting bacteria from plasmid transformation, the method comprising introducing into the bacteria a defense system having an anti-plasmid activity, the system comprising at least one component selected from the group consisting of the components of the defense system, thereby protecting the bacteria from plasmid transformation. In some embodiments, a method of protecting bacteria from plasmid transformation comprises introducing into the bacteria a defense system comprising a Defense System selected from a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, wherein said defense system comprises an anti-plasmid activity, the system comprising at least one component of said Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, Vn, Vni, IX, Xa, Xb, or Xc, said at least one component selected from the group consisting of the components of the Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, respectively, thereby protecting the bacteria from plasmid transformation. In some embodiments, a method of protecting bacteria from plasmid transformation comprises introducing into the bacteria a defense system comprising a combination of Defense Systems selected from Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, wherein said defense system comprises an anti-plasmid activity, the system comprising at least one component of each of said Defense Systems in combination, said at least one component selected from the group consisting of the components of the Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, respectively, thereby protecting the bacteria from plasmid transformation.

[001216] In some embodiments, an at least one component comprises the components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, required for a functional Defense System, wherein said function comprises an anti-plasmid activity. In some embodiments, an at least one component comprises the components of the cassette of genes making up a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises two components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises three components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, Vni, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises four components of a Defense System la, lb, II, Ilia, nib, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises five components of a Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, a component comprises the full-length component. In some embodiments, a component comprises a functional portion of the component. In some embodiments, a component comprises a component homolog.

[001217] In some embodiments, provided herein is a method of protecting bacteria from conjugative elements, the method comprising introducing into the bacteria a defense system having an anti-conjugation activity, the system comprising at least one component selected from the group consisting of the components of the defense system, thereby protecting the bacteria from conjugation. In some embodiments, a method of protecting bacteria from conjugative elements comprises introducing into the bacteria a defense system comprising a Defense System selected from a Defense System la, lb, II, nia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, wherein said defense system comprises an anti-conjugation activity, the system comprising at least one component of said Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, Vn, Vni, IX, Xa, Xb, or Xc, said at least one component selected from the group consisting of the components of the Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, respectively, thereby protecting the bacteria from conjugation. In some embodiments, a method of protecting bacteria from conjugative elements comprises introducing into the bacteria a defense system comprising a combination of Defense Systems selected from Defense System la, lb, II, nia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, wherein said defense system comprises an anti-conjugation activity, the system comprising at least one component of each of said Defense Systems in combination, said at least one component selected from the group consisting of the components of the Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, respectively, thereby protecting the bacteria from conjugation.

[001218] In some embodiments, an at least one component comprises the components of a Defense System la, lb, II, nia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, required for a functional Defense System, wherein said function comprises an anti-conjugation activity. In some embodiments, an at least one component comprises the components of the cassette of genes making up a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises two components of a Defense System la, lb, II, Ilia, Illb, nic, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises three components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, Vni, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises four components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises five components of a Defense System la, lb, II, Ilia, Illb, nic, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, a component comprises the full-length component. In some embodiments, a component comprises a functional portion of the component. In some embodiments, a component comprises a component homolog.

[001219] In some embodiments, provided herein is a method of protecting bacteria from any combination of phage infection, conjugative elements, and plasmid transformation, the method comprising introducing into the bacteria a defense system having an anti-phage, anti- conjugation, and/or anti-plasmid activity, the system comprising at least one component selected from the group consisting of the components of the defense system, thereby protecting the bacteria from phage infection, conjugative elements, and plasmid transformation. In some embodiments, a method of protecting bacteria from phage infection, conjugative elements, and plasmid transformation comprises introducing into the bacteria a defense system comprising a Defense System selected from a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, wherein said defense system comprises an anti-phage, anti-conjugation, and/or anti-plasmid activity, the system comprising at least one component of said Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, said at least one component selected from the group consisting of the components of the Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, respectively, thereby protecting the bacteria from phage infection, conjugative elements, and/or plasmid transformation. In some embodiments, a method of protecting bacteria from phage infection, conjugative elements, and plasmid transformation comprises introducing into the bacteria a defense system comprising a combination of Defense Systems selected from Defense System la, lb, II, Ilia, Illb, Hie, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, wherein said defense system comprises an anti-phage, anti- conjugation, and anti-plasmid activity, the system comprising at least one component of each of said Defense Systems in combination, said at least one component selected from the group consisting of the components of the Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, Vni, IX, Xa, Xb, or Xc, respectively, thereby protecting the bacteria from phage infection, bacterial conjugation, and/or plasmid transformation.

[001220] In some embodiments, an at least one component comprises the components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, required for a functional Defense System, wherein said function comprises an anti-phage, anti-conjugation, and/or anti-plasmid activity. In some embodiments, an at least one component comprises the components of the cassette of genes making up a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises two components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises three components of a Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises four components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises five components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, a component comprises the full-length component. In some embodiments, a component comprises a functional portion of the component. In some embodiments, a component comprises a component homolog.

[001221] The components of Defense Systems la, lb, II, Ilia, nib, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc have been described in detail above, as has the combination of these Defense systems. Methods of protecting bacteria comprising introducing into the bacteria a defense system comprising at least one components of a Defense System selected from Defense Systems la, lb, II, nia, Illb, nic, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, or a combination of Defense Systems thereof, comprises use of the components of the Defense Systems as described in detail above, and in Tables 6-18. The detailed description of the Defense Systems and components thereof, and combinations thereof, as described above, are incorporated in full in the method of use of protecting bacteria described herein. Briefly, a non-limiting description of Defense Systems and their components includes Defense Systems la, lb, Π, Ilia, Illb, Hie, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc and components thereof, including but are not limited to methods of protecting bacteria comprising introducing into the bacteria a defense system comprising at least one components of a Defense System selected from Defense Systems la, lb, II, Ilia, Illb, nic, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, or a combination of Defense Systems thereof, wherein in some embodiments:

[001222] a Defense System la comprises a nucleic acid construct comprising a nucleic acid sequence encoding a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, a ZorC polypeptide comprising a pfaml5611 domain, and a ZorD polypeptide comprising a pfam00176 domain or a pfam00271 domain or a combination thereof;

[001223] a Defense System lb comprises a nucleic acid construct comprising a nucleic acid sequence encoding a ZorA polypeptide comprising a pfam01618 domain, a ZorB polypeptide comprising a pfaml3677 domain or a pfam00691 domain or a combination thereof, and a ZorE polypeptide comprising a pfam01844 domain or a COG3183 domain or a combination thereof;

[001224] a Defense System II comprises a nucleic acid construct comprising a nucleic acid sequence encoding a ThsA polypeptide comprising a pfaml3289 domain or a pfaml4519 domain or a combination thereof, and a KwaB polypeptide comprising a pfaml3676 domain or a pfam08937 domain or a pfam08357 domain, or a combination thereof;

[001225] a Defense System Ilia comprises a nucleic acid construct comprising a nucleic acid sequence encoding a DruA polypeptide comprising a DUF4338 domain or a pfaml4236 domain or a combination thereof, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof;

[001226] a Defense System Ilia comprises a nucleic acid construct comprising a nucleic acid sequence encoding a DruA polypeptide comprising a DUF4338 domain or a pfam 14236 domain or a combination thereof, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, said DruB polypeptide encoded by a gene positioned within 5 genes of a gene encoding DruA, DruD, and or DruE, and said DruC polypeptide encoded by a gene positioned within 5 genes of a gene encoding DruA, DruD, and or DruE;

[001227] a Defense System nib comprises a nucleic acid construct comprising a nucleic acid sequence encoding a DruM polypeptide comprising a pfam00145 domain or a COG0270 or a combination thereof, a DruF polypeptide, a DruG polypeptide, and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof;

[001228] a Defense System nib comprises a nucleic acid construct comprising a nucleic acid sequence encoding a DruM polypeptide comprising a pfam00145 domain or a COG0270 or a combination thereof, a DruF polypeptide, a DruG polypeptide, and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, said DruF polypeptide encoded by a gene positioned within 5 genes of a gene encoding DruM and or DruE, and said DruG polypeptide encoded by a gene positioned within 5 genes of a gene encoding DruM and or DruE;

[001229] a Defense System IIIc comprises a nucleic acid construct comprising a nucleic acid sequence encoding a DruH polypeptide and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof;

[001230] a Defense System Hie comprises a nucleic acid construct comprising a nucleic acid sequence encoding a DruH polypeptide and a DruE polypeptide comprising a pfam00270 domain or a pfam00271 domain or a pfam09369 domain or a DUF1998 domain or any combination thereof, said DruH polypeptide encoded by a gene positioned within 5 genes of a gene encoding DruE;

[001231] a Defense System IV comprises a nucleic acid construct comprising a nucleic acid sequence encoding a HamA polypeptide comprising a pfam08878 domain or a DUF1837 domain or a combination thereof, and a HamB polypeptide comprising COG1204 domain or a pfam00270 domain or a pfam00271 domain or any combination thereof;

[001232] a Defense System V comprises a nucleic acid construct comprising a nucleic acid sequence encoding a SduA polypeptide comprising a pfaml4082 domain or a pfam01939 domain or a combination thereof;

[001233] a Defense System VI comprises a nucleic acid construct comprising a nucleic acid sequence encoding a GajA polypeptide comprising a pfaml3175 domain or a COG3593 domain or a combination thereof, and a GajB polypeptide comprising a pfam04257 domain or a pfam00580 domain or a pfaml3361 domain or a combination thereof;

[001234] a Defense System VII comprises a nucleic acid construct comprising a nucleic acid sequence encoding a PtuA polypeptide comprising a pfaml3304 domain or a pfam02463 domain or a combination thereof, and a PtuB polypeptide comprising pfaml3395 domain or a pfam 01844 domain or a combination thereof;

[001235] a Defense System VIII comprises a nucleic acid construct comprising a nucleic acid sequence encoding a LmuA polypeptide comprising a pfaml4130 domain or a DUF4297 domain or a combination thereof, and a LmuB polypeptide comprising a pfam02463 domain;

[001236] a Defense System IX comprises a nucleic acid construct comprising a nucleic acid sequence encoding a KwaA polypeptide and a KwaB polypeptide comprising a pfaml6162 domain or a DUF4868 domain or a combination thereof;

[001237] a Defense System IX comprises a nucleic acid construct comprising a nucleic acid sequence encoding a KwaA polypeptide and a KwaB polypeptide comprising a pfaml6162 domain or a DUF4868 domain or a combination thereof, said KwaA polypeptide encoded by a gene positioned within 5 genes of a gene encoding KwaB;

[001238] a Defense System Xa comprises a nucleic acid construct comprising a nucleic acid sequence encoding a JetA polypeptide comprising a pfaml 1855 domain or a DUF3375 domain or any combination thereof, a JetB polypeptide comprising a pfam 13835 domain or a DUF4194 domain or any combination thereof, a JetC polypeptide comprising a pfaml 3555 domain or a pfaml3558 domain or a COG4913 domain or a combination thereof, and a JetD polypeptide comprising a pfaml 1795 domain or a DUF3322 domain or a pfam09983 domain or a DUF2220 domain or a COG4924 domain or any combination thereof;

[001239] a Defense System Xb comprises a nucleic acid construct comprising a nucleic acid sequence encoding a JetA ¹¹ polypeptide comprising a pfam09660 domain or a DUF2397 domain or any combination thereof, a JetB ¹¹ polypeptide comprising a pfam09661 domain or a DUF2398 domain or any combination thereof, a JetC ¹¹ polypeptide comprising a pfaml3558 domain, and a JetD ¹¹ polypeptide comprising a pfaml 1796 domain or a DUF3323 domain or a pfam09664 domain or a DUF2399 domain or any combination thereof;

[001240] a Defense System Xc comprises a nucleic acid construct comprising a nucleic acid sequence encoding a JetA ^m polypeptide, a JetB ¹¹¹ polypeptide, a JetC ^m polypeptide comprising a COG 1196 domain, a JetD ^m polypeptide comprising a pfam09983 domain or a pfam09664 domain, or a DUF2220 domain, or a DUF2399 domain, or a combination thereof; or

[001241] a Defense System Xc comprises a nucleic acid construct comprising a nucleic acid sequence encoding a JetA ^m polypeptide, a JetB ¹¹¹ polypeptide, a JetC ^m polypeptide comprising a COG 1196 domain, a JetD ^m polypeptide comprising a pfam09983 domain or a pfam09664 domain, or a DUF2220 domain, or a DUF2399 domain, or a combination thereof, said JetA ¹¹¹ polypeptide and a JetB ^m polypeptide each encoded by a gene positioned within 5 genes of a gene encoding JetC ^m polypeptide or a JetD ^m polypeptide;

[001242] wherein each nucleic acid construct of each Defense System Ia-Xc further comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof; wherein said method results in protecting bacteria comprising the bacteria being resistant to at least one phage, or the bacteria having reduced efficacy of plasmid transformation, or a combination thereof.

[001243] In some embodiments, the bacteria do not express an endogenous version of the defense system being introduced. In some embodiments, the bacteria do not express a functional endogenous version of the defense system being introduced.

[001244] In some embodiments, the bacteria do not express an endogenous version of the Defense System la. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System la. In some embodiments, the bacteria do not express an endogenous version of the Defense System lb. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System lb. In some embodiments, the bacteria do not express an endogenous version of the Defense System Π. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System Π. In some embodiments, the bacteria do not express an endogenous version of the Defense System Ilia. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System Ilia. In some embodiments, the bacteria do not express an endogenous version of the Defense System Illb. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System Illb. In some embodiments, the bacteria do not express an endogenous version of the Defense System IIIc. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System IIIc. In some embodiments, the bacteria do not express an endogenous version of the Defense System IV. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System IV. In some embodiments, the bacteria do not express an endogenous version of the Defense System V. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System V. In some embodiments, the bacteria do not express an endogenous version of the Defense System VI. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System VI. In some embodiments, the bacteria do not express an endogenous version of the Defense System VII. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System VII. In some embodiments, the bacteria do not express an endogenous version of the Defense System VIII. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System VIII. In some embodiments, the bacteria do not express an endogenous version of the Defense System IX. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System IX. In some embodiments, the bacteria do not express an endogenous version of the Defense System Xa. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System Xa. In some embodiments, the bacteria do not express an endogenous version of the Defense System Xb. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System Xb. In some embodiments, the bacteria do not express an endogenous version of the Defense System Xc. In some embodiments, the bacteria do not express a functional endogenous version of the Defense System Xc.

[001245] In some embodiments, the bacteria do not express an endogenous version of the combination of Defense Systems selected from combinations disclosed herein above, of any of Defense Systems Ia-Xc. In some embodiments, the bacteria do not express a functional endogenous version of the combination of Defense Systems selected from combinations disclosed herein above, of any of Defense Systems Ia-Xc.

[001246] A skilled artisan would appreciate that various modalities may be used to introduce or express a defense system comprising a Defense System Ia-Xc or a combination thereof, or the components of a Defense System Ia-Xc, in the bacteria.

[001247] In some embodiments, the method is effected by expressing in the bacteria, an isolated nucleic acid sequence(s), nucleic acid construct or construct or alternatively introducing the component polypeptides of a Defense System or a combination of Defense Systems, as described herein, to confer protection. In some embodiments, protection comprises an anti- phage activity. In some embodiments, protection comprises an anti-plasmid activity. In some embodiments, protection comprises a combination of an anti-phage activity and an anti-plasmid activity. Alternatively, or additionally, the defense system comprising a Defense System or a combination of Defense Systems, is introduced into the bacteria via transmissible genetic element in a process of bacterial conjugation.

[001248] In some embodiments, there is provided a method of protecting bacteria from phage infection, or plasmid transformation, or phage infection and plasmid transformation, the method comprising introducing into the bacteria a defense system having an anti-phage activity, or an anti-plasmid activity, or an anti-phage activity and an anti-plasmid activity, wherein said bacteria is a first bacteria and said introducing into said bacteria said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, comprises contacting said first bacteria with a second bacteria expressing said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc on a transmissible genetic element.

[001249] In some embodiments, a transmissible genetic element comprises a defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described herein in detail above. In some embodiments, the transmissible genetic element comprises a conjugative genetic element or a mobilized genetic element. In some embodiments, a transmissible genetic element comprises a plasmid or a transposon.

[001250] A skilled artisan would appreciate that the phrase "bacterial conjugation" encompasses a direct transfer of genetic material between bacterial cells by cell-to-cell contact or by bridge-like connection between the cells. During conjugation the donor bacterium provides a transmissible genetic element, typically a plasmid or a transposon. The transfer of the transmissible genetic element takes advantage of the complementary nature of double stranded DNA. Thus, one strand of the transmissible genetic element is transferred, and the other remains in the original bacteria. Both strands have the complementary stranded added so that each bacterium ends up with a complete transmissible element.

[001251] According to some embodiments, contacting a first bacteria with second bacteria comprise the step of incubating the bacterial cell (e.g., first bacteria) with a substance or cell (e.g., second bacteria) such that the substance or a substance contained in the cell affects the bacterial cell resistance to phage infection, or to plasmid transformation, or to phage infection and plasmid transformation. [001252] In some embodiments, the first bacteria and the second bacteria are non-identical.

[001253] In some embodiments, the first bacteria do not express an endogenous defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc. In some embodiments, the first bacteria do not express an endogenous functional defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc.

[001254] In some embodiments, the first bacteria is a commercially valuable bacteria such as those used for fermentation as described above. Thus, following the above teachings, in some embodiments, there is provided isolated bacteria comprising a nucleic acid sequence encoding a defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, said system having an anti-phage activity and a transmissible genetic element expressing the defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, wherein the isolated bacteria does not express an endogenous functional defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc.

[001255] In some embodiments, the first bacteria is a commercially valuable bacteria such as those used for fermentation as described above. Thus, following the above teachings, in some embodiments, there is provided isolated bacteria comprising a nucleic acid sequence encoding a defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, said system having an anti-plasmid activity and a transmissible genetic element expressing the defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, wherein the isolated bacteria does not express an endogenous functional defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc.

[001256] In some embodiments, the first bacteria is a commercially valuable bacteria such as those used for fermentation as described above. Thus, following the above teachings, in some embodiments, there is provided isolated bacteria comprising a nucleic acid sequence encoding a defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, said system having an anti-phage activity and anti-plasmid activity, and a transmissible genetic element expressing the defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, wherein the isolated bacteria does not express an endogenous functional defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc.

[001257] In some embodiments, a cell comprises a host cell. In some embodiments, a host cell comprises bacteria. In some embodiments, a cell comprises bacteria. In some embodiments, a host cell comprises a microbial cell. In some embodiments, a cell comprises a microbial cell. In some embodiments, the cell is an isolated cell. In some embodiments, bacteria are isolated bacteria. In some embodiments, a cell comprises isolated microbial cells. In some embodiments, the cell is a microbial cell such as bacteria, e.g., Gram-positive or Gram-negative bacteria. In some embodiments, the bacteria comprise Gram-negative bacteria or Negativicutes that stain negative in Gram stain. In some embodiments, a host cell comprises gram-positive bacteria, gram-negative bacteria, or archaea.

[001258] In some embodiments, Gram-negative bacteria comprise Acinetobacter calcoaceticus, Actinobacillus actinomycetemcomitans, Aeromonas hydrophila, Alcaligenes xylosoxidans, Bacteroides, Bacteroides fragilis, Bartonella bacilliformis, Bordetella spp., Borrelia burgdorferi, Branhamella catarrhalis, Brucella spp., Campylobacter spp., Chalmydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Chromobacterium violaceum, Citrobacter spp., Eikenella corrodens, Enterobacter aerogenes, Escherichia coli, Flavobacterium meningosepticum, Fusobacterium spp., Haemophilus influenzae, Haemophilus spp., Helicobacter pylori, Klebsiella spp., Legionella spp., Leptospira spp., Moraxella catarrhalis, Morganella morganii, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Pasteurella multocida, Plesiomonas shigelloides, Prevotella spp., Proteus spp., Providencia rettgeri, Pseudomonas aeruginosa, Pseudomonas spp., Rickettsia prowazekii, Rickettsia rickettsii, Rochalimaea spp., Salmonella spp., Salmonella typhi, Serratia marcescens, Shigella spp., Treponema carateum, Treponema pallidum, Treponema pallidum endemicum, Treponema pertenue, Veillonella spp., Vibrio cholerae, Vibrio vulnificus, Yersinia enterocolitica, Yersinia pestis. [001259] In some embodiments, the bacteria comprise gammaproteobacteria (e.g. Escherichia coli, pseudomonas, vibrio and klebsiella) or Firmicutes (belonging to class Negativicutes that stain negative in Gram stain).

[001260] In some embodiments, Gram-positive bacteria comprise Actinomyces spp., Bacillus anthracis, Bifidobacterium spp., Clostridium botulinum, Clostridium perfringens, Clostridium spp., Clostridium tetani, Corynebacterium diphtheriae, Corynebacterium jeikeium, Enterococcus faecalis, Enterococcus faecium, Erysipelothrix rhusiopathiae, Eubacterium spp., Gardnerella vaginalis, Gemella morbillorum, Leuconostoc spp., Mycobacterium abcessus, Mycobacterium avium complex, Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium haemophilium, Mycobacterium kansasii, Mycobacterium leprae, Mycobacterium marinum, Mycobacterium scrofulaceum, Mycobacterium smegmatis, Mycobacterium terrae, Mycobacterium tuberculosis, Mycobacterium ulcerans, Nocardia spp., Peptococcus niger, Peptostreptococcus spp., Proprionibacterium spp., Staphylococcus aureus, Staphylococcus auricularis, Staphylococcus capitis, Staphylococcus cohnii, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdanensis, Staphylococcus saccharolyticus, Staphylococcus saprophyticus, Staphylococcus schleiferi, Staphylococcus similans, Staphylococcus warneri, Staphylococcus xylosus, Streptococcus agalactiae (group B streptococcus), Streptococcus anginosus, Streptococcus bovis, Streptococcus canis, Streptococcus equi, Streptococcus milleri, Streptococcus mitior, Streptococcus mutans, Streptococcus pneumoniae, Streptococcus pyogenes (group A streptococcus), Streptococcus salivarius, Streptococcus sanguis.

[001261] In some embodiments the bacteria is a species selected from the group consisting of Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Agrobacterium, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Rickettsia, Shewanella, Serratia, Enterobacter, Proteus, Providencia, Brochothrix, and Brevibacterium.

[001262] In some embodiments, there is provided herein a cell (e.g., bacteria) expressing at least one component of a defense system. In some embodiments, the cell is genetically modified. In some embodiments, the cell comprises an isolated cell. The components of defense systems comprising a Defense System Ia-Xc and combinations thereof, have been described in detail above. In some embodiments, polypeptide components of these systems include but are not limited to ZorA, ZorB, ZorC, ZorD, ZorE (Defense System la and lb); ThsA and ThsB (Defense System II); DruA, DruB, DruC, DruD, DruE, DruH, DruM, DruG, DruF (Defense Systems nia, Illb, IIIc); HamA and HamB (Defense System IV); SduA (Defense System V); GajA and GajB (Defense System VI); PtuA and PtuB (Defense System VII); LmuA and LmuB (Defense System VIII); KwaA and KwaB (Defense System IX); and JetA, JetB, JetC, and JetD, and variants thereof (Defense Systems Xa, Xb, Xc). In some embodiments, polynucleotide (e.g., gene) components, include but are not limited to zorA, zorB, zorC, zorD, zorE (Defense Systems la, lb); thsA and thsB (Defense System II); druA, druB, druC, druD, druE, druF, druG, druH, druM (Defense Systems nia, Illb, IIIc); hamA and hamB (Defense System IV); sduA (Defense System V); gajA and gajB (Defense System VI); ptuA and ptuB (Defense System VII); ImuA and ImuB (Defense System VIII); kwaA and kwaB (Defense System IX); and jetA, jetB, jetC, and jetD and variants thereof (Defense Systems Xa, Xb, Xc).

[001263] In some embodiments, a cell is genetically modified to express at least 2, at least 3, or at least 4 of the components of an anti-nucleic acid defense system comprising a Defense System of Ia-Xc, or a combination thereof. In some embodiments, the cell is genetically modified to express a functional anti-nucleic acid defense system. In some embodiments, the cell is genetically modified to express the components necessary for a functional anti-nucleic acid defense system. In some embodiments, the cell is genetically modified to expression any combination of components of a Defense System la, any combination of components of a Defense System lb, any combination of components of a Defense System II, any combination of components of a Defense System nia, any combination of components of a Defense System Illb, any combination of components of a Defense System IIIc, any combination of components of a Defense System IV, any combination of components of a Defense System V, any combination of components of a Defense System VI, any combination of components of a Defense System VII, any combination of components of a Defense System VIII, any combination of components of a Defense System IX, any combination of components of a Defense System Xa, any combination of components of a Defense System Xb, or any combination of components of a Defense System Xc. In some embodiments, a cell is genetically modified to express all of the components of a Defense System.

[001264] In some embodiments, a cell is genetically modified to express at least 2, 3, 4, or 5 components of a Defense System or combination of Defense systems, as described herein. In some embodiments, a cell is genetically modified to express at least 2, 3, 4, or 5 functional components of a Defense System or combination of Defense systems, as described herein, wherein the cell comprises the anti-phage, or anti-plasmid, or anti-phage and anti-plasmid resistance provide by each of the functional Defense Systems.

[001265] In some embodiments, a cell that has been genetically modified to express a defense system comprising a Defense System of Ia-Xc or a combination thereof, has an anti-phage activity. In some embodiments, a cell that has been genetically modified to express a defense system comprising a Defense System of Ia-Xc or a combination thereof, has an anti-plasmid activity. In some embodiments, a cell that has been genetically modified to express a defense system comprising a Defense System of Ia-Xc or a combination thereof, has an anti-phage activity and an anti-plasmid activity.

[001266] In some embodiments, a cell (e.g., bacterial cell) does not express an endogenous defense system comprising any one of Defense Systems Ia-Xc, or any combination thereof. In some embodiments, the cell expressing a defense system described herein (e.g., bacterial cell expressing a Defense System of Ia-Xc, or any combination thereof) does not endogenously express the defense system comprising any one ofa theDefense Systems of Ia-Xc, or any combination thereof.

[001267] In some embodiments, the cell expressing a defense system (e.g., bacterial cell) is resistant to infection by at least one phage. In some embodiments the cell is resistant to at least one lytic phage. In some embodiments, the cell is resistant to at least one temperate (also referred as lysogenic) phage. In some embodiments, the cell is resistant to phage lysogeny. In some embodiments, the cell is resistant to phage DNA replication. In some embodiments, the cell is resistant to plasmid transformation. In some embodiments, the cell is resistant to infection by at least one phage and is resistant to plasmid transformation.

[001268] Phage contamination is now considered to be a main cause of slow fermentation or complete starter failure. The lack of bacteria which survive adequately can result in milk products which do not have a desirable taste. Thus, a goal of scientists working to produce better milk products lies in providing bacteria which have all the characteristics associated with production of a good flavor and which are able to resist infection by phages.

[001269] In some embodiments, the bacteria may be useful in the manufacture of dairy and fermentation processing such as, but not limited to, milk-derived products, such as cheeses, yogurt, fermented milk products, sour milks, and buttermilk. In some embodiments, the bacteria are useful as a part of the starter culture in the manufacture of dairy and fermentation processing. In some embodiments, the starter culture is a food grade starter culture.

[001270] A bacterium traditionally used in the production of milk products is S. thermophilus. It is particularly employed in the production of yogurt, mozzarella and Swiss type cheeses. One problem with S. thermophilus is that it is extremely sensitive to phage infection.

[001271] In some embodiments, the bacteria are lactic acid bacteria. A skilled artisan would appreciate that the term "lactic acid bacteria" encompasses Gram positive, microaerophillic or anaerobic bacteria which ferment sugar with the production of acids including lactic acid as the predominantly produced acid, acetic acid, formic acid and propionic acid.

[001272] In some embodiments, bacteria used in methods disclosed herein, are selected from a species selected from the group of the industrially most useful lactic acid bacteria comprising Lactococcus species, Streptococcus species, Lactobacillus species, Leuconostoc species, Oenococcus species, Pediococcus species, Bifidobacterium species, and Propionibacterium species. In some embodiments, bacteria protected in a method of protecting bacteria from phage infection compises bacteria selected from a Lactococcus species, a Streptococcus species, a Lactobacillus species, a Leuconostoc species, a Oenococcus species, a Pediococcus species, a Bifidobacterium, and a Propionibacterium species. In some embodiments a method of protecting bacteria from phage infection compises protecting a Lactococcus species of bacteria. In some embodiments a method of protecting bacteria from phage infection compises protecting a Streptococcus species of bacteria. In some embodiments a method of protecting bacteria from phage infection compises protecting a Lactobacillus species of bacteria. In some embodiments a method of protecting bacteria from phage infection compises protecting a Leuconostoc species of bacteria. In some embodiments a method of protecting bacteria from phage infection compises protecting a Oenococcus species of bacteria. In some embodiments a method of protecting bacteria from phage infection compises protecting a Pediococcus species of bacteria. In some embodiments a method of protecting bacteria from phage infection compises protecting a Bifidobacterium of bacteria. In some embodiments a method of protecting bacteria from phage infection compises protecting a Propionibacterium species of bacteria.

[001273] In some embodiments, bacteria protected in a method of protecting bacteria from plasmid transformation compises bacteria selected from a Lactococcus species, a Streptococcus species, a Lactobacillus species, a Leuconostoc species, a Oenococcus species, a Pediococcus species, a Bifidobacterium species, and a Propionibacterium species. In some embodiments, bacteria protected in a method of protecting bacteria from plasmid transformation compises bacteria selected from a Lactococcus species, a Streptococcus species, a Lactobacillus species, a Leuconostoc species, a Oenococcus species, a Pediococcus species, a Bifidobacterium, and a Propionibacterium species. In some embodiments a method of protecting bacteria from plasmid transformation compises protecting a Lactococcus species of bacteria. In some embodiments a method of protecting bacteria from plasmid transformation compises protecting a Streptococcus species of bacteria. In some embodiments a method of protecting bacteria from plasmid transformation compises protecting a Lactobacillus species of bacteria. In some embodiments a method of protecting bacteria from plasmid transformation compises protecting a Leuconostoc species of bacteria. In some embodiments a method of protecting bacteria from plasmid transformation compises protecting a Oenococcus species of bacteria. In some embodiments a method of protecting bacteria from plasmid transformation compises protecting a Pediococcus species of bacteria. In some embodiments a method of protecting bacteria from plasmid transformation compises protecting a Bifidobacterium of bacteria. In some embodiments a method of protecting bacteria from plasmid transformation compises protecting a Propionibacterium species of bacteria.

[001274] In some embodiments, bacteria protected in a method of protecting bacteria from phage infection and plasmid transformation compises bacteria selected from a Lactococcus species, a Streptococcus species, a Lactobacillus species, a Leuconostoc species, a Oenococcus species, a Pediococcus species, a Bifidobacterium species, and a Propionibacterium species. In some embodiments, bacteria protected in a method of protecting bacteria from phage infection and plasmid transformation compises bacteria selected from a Lactococcus species, a Streptococcus species, a Lactobacillus species, a Leuconostoc species, a Oenococcus species, a Pediococcus species, a Bifidobacterium, and a Propionibacterium species. In some embodiments a method of protecting bacteria from phage infection and plasmid transformation compises protecting a Lactococcus species of bacteria. In some embodiments a method of protecting bacteria from phage infection and plasmid transformation compises protecting a Streptococcus species of bacteria. In some embodiments a method of protecting bacteria from phage infection and plasmid transformation compises protecting a Lactobacillus species of bacteria. In some embodiments a method of protecting bacteria from phage infection and plasmid transformation compises protecting a Leuconostoc species of bacteria. In some embodiments a method of protecting bacteria from phage infection and plasmid transformation compises protecting a Oenococcus species of bacteria. In some embodiments a method of protecting bacteria from phage infection and plasmid transformation compises protecting a Pediococcus species of bacteria. In some embodiments a method of protecting bacteria from phage infection and plasmid transformation compises protecting a Bifidobacterium of bacteria. In some embodiments a method of protecting bacteria from phage infection and plasmid transformation compises protecting a Propionibacterium species of bacteria.

[001275] In some embodiments, a host cell comprises a defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc. In some embodiments, a cell comprises a defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc. In some embodiments, bacteria comprise a defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc.

[001276] In some embodiments, a cell comprises a transmissible genetic element comprising a defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc. In some embodiments, bacteria comprise a transmissible genetic element comprising a defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc.

[001277] In some embodiments, an expression vector comprises a defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc. In some embodiments, a cell comprises an expression vector comprising a defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc. In some embodiments, bacteria comprise an expression vector comprising a defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc. In some embodiments, an expression vector comprises multiple vectors each comprising a construct comprising a Defense System selected from la-Xc. In some embodiments, an expression vector comprises multiple vectors each encoding a polypeptide component or functional portion of a polypeptide component of a Defense System la-Xc construct.

[001278] In some embodiments, a cell comprising a defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as disclosed herein, is resistant to at least one phage. In some embodiments, a cell comprising a defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as disclosed herein, is resistant to plasmid transformation. In some embodiments, a cell comprising a defense system comprising a Defense System selected from Defense Systems Ia- Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as disclosed herein, is resistant to at least one phage and is resistant to plasmid transformation.

[001279] In some embodiments, a cell comprising a transmissible element comprising a defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as disclosed herein, is resistant to at least one phage. In some embodiments, a cell comprising a transmissible element comprising comprising a defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as disclosed herein, is resistant to plasmid transformation. In some embodiments, a cell comprising a transmissible element comprising a defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as disclosed herein, is resistant to at least one phage and is resistant to plasmid transformation.

[001280] In some embodiments, a cell comprising an expression vector comprising a defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as disclosed herein, is resistant to at least one phage. In some embodiments, a cell comprising an expression vector comprising a defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as disclosed herein, is resistant to plasmid transformation. In some embodiments, a cell comprising an expression vector comprising a defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as disclosed herein, is resistant to at least one phage and is resistant to plasmid transformation.

[001281] Cultures, and starter cultures, in particular are used extensively in the food industry in the manufacture of fermented products including milk products (e.g., yogurt, buttermilk, and cheese), meat products, bakery products, wine, and vegetable products. The preparation of cultures is labor intensive, occupying much space and equipment, and there is a considerable risk of contamination with spoilage bacteria and/or phages during the propagation steps. The failure of bacterial cultures due to phage infection and multiplication is a major problem with the industrial use of bacterial cultures. There are many different types of phages and new strains continue to emerge. Indeed, despite advances in culture development, there is a continuing need to improve cultures for use in industry.

[001282] In some embodiments, there is provided a method of preparing a food, the method comprising adding to the food at least one defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, thereby preparing the food. In some embodiments, a food comprises an alcoholic beverage.

[001283] In some embodiments, an alcoholic beverage comprises a wine or a sake. In some embodiments, provided herein is a method of preparing an alcoholic beverage, the method comprising adding to the alcoholic beverage at least on defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, thereby preparing the alcoholic beverage. In some embodiments, provided herein is a method of preparing a wine, the method comprising adding to the wine at least on defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, thereby preparing the wine. In some embodiments, provided herein is a method of preparing a sake, the method comprising adding to the sake at least on defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, thereby preparing the sake.

[001284] In some embodiments, a food comprises a dairy product. In some embodiments, a dairy product comprises a milk product, a sour milk, a buttermilk, a milk, a cheese, a yogurt, viili, yakult, or casein. In some embodiments, a food comprises natto.

[001285] In some embodiments, provided herein is a method of preparing a dairy product, the method comprising adding to the dairy product at least on defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, thereby preparing the dairy product. In some embodiments, provided herein is a method of preparing a milk product, the method comprising adding to the milk product at least on defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, thereby preparing the milk product. In some embodiments, provided herein is a method of preparing milk, the method comprising adding to the milk at least on defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the milk. In some embodiments, provided herein is a method of preparing a sour milk, the method comprising adding to the sour milk at least on defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the sour milk. In some embodiments, provided herein is a method of preparing a butter milk, the method comprising adding to the butter milk at least on defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the butter milk. In some embodiments, provided herein is a method of preparing a cheese, the method comprising adding to the cheese at least on defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the cheese. In some embodiments, provided herein is a method of preparing a yogurt the method comprising adding to the yogurt at least on defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the yogurt. In some embodiments, provided herein is a method of preparing a viili the method comprising adding to the viili at least on defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the viili. In some embodiments, provided herein is a method of preparing a yakult the method comprising adding to the yakult at least on defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the yakult. In some embodiments, provided herein is a method of preparing a casein, the method comprising adding to the casein at least on defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the casein.

[001286] In some embodiments, provided herein is a method of preparing a natto, the method comprising adding to the natto at least on defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the natto.

[001287] In some embodiments, there is provided a method of preparing a food additive, the method comprising adding to the food additive, at least one defense system components, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the food additive.

[001288] In some embodiments, there is provided a method of preparing a feed, the method comprising adding to the feed at least one defense system components, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the feed.

[001289] In some embodiments, there is provided a method of preparing a nutritional supplement, the method comprising adding to the nutritional supplement at least one defense system components, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the nutritional supplement.

[001290] In some embodiments, there is provided a method of preparing a probiotic supplement, the method comprising adding to the probiotic supplement, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the probiotic supplement.

[001291] In some embodiments, there is provided a method of preparing a health care product, the method comprising adding to the health care product at least one defense system components, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the health care product. In some embodiments, a health care product comprises an antibiotic.

[001292] In some embodiments, there is provided a method of preparing an antibiotic, the method comprising adding to the antibiotic, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the antibiotic. In some embodiments, an antibiotic comprises a polymyxin, a colistin, or a bacitracin.

[001293] In some embodiments, there is provided a method of preparing a polymyxin, the method comprising adding to the polymyxin, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the polymyxin. In some embodiments, there is provided a method of preparing colistin, the method comprising adding to the colistin, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the colistin. In some embodiments, there is provided a method of preparing a bacitracin, the method comprising adding to the bacitraicin, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the bacitraicin.

[001294] In some embodiments, there is provided a method of preparing a personal care product, the method comprising adding to the personal care product at least one defense system components, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing the personal care product.

[001295] In some embodiments, there is provided a method of preparing a veterinary product, the method comprising adding to the veterinary product at least one defense system components, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing veterinary product.

[001296] In some embodiments, there is provided a method of preparing a L-glutamine, the method comprising adding to the L-glutamine at least one defense system components, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing L- glutamine.

[001297] In some embodiments, there is provided a method of preparing acetone, the method comprising adding to the acetone at least one defense system components, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, thereby preparing acetone.

[001298] In some embodiments, there is provided a method of preparing butanol, the method comprising adding to the butanol at least one defense system components, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, thereby preparing butanol.

[001299] Thus, following the above teachings, in some embodiments, there is provided a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in details herein. In some embodiments, a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001300] In some embodiments, there is provided a starter culture comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a started culture comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a starter culture comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001301] In some embodiments, there is provided a food comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a food comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a food comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001302] In some embodiments, a food comprises a dairy product. In some embodiments, a food comprises an alcoholic beverage. In some embodiments, a food comprises a natto.

[001303] In some embodiments, there is provided a dairy product comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a dairy product comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a dairy product comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001304] In some embodiments, there is provided a milk comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a milk comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a milk comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001305] In some embodiments, there is provided a milk product comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a milk product comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a milk product comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001306] In some embodiments, there is provided a sour milk comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a sour milk comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a sour milk comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001307] In some embodiments, there is provided a butter milk comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a butter milk comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a butter milk comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001308] In some embodiments, there is provided a cheese comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a cheese comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a cheese comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001309] In some embodiments, there is provided a yogurt comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a yogurt comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a yogurt comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001310] In some embodiments, there is provided a viili comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a viili comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a viili comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001311] In some embodiments, there is provided a yakult comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a yakult comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a yakult comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001312] In some embodiments, there is provided a casein comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a casein comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a casein comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001313] In some embodiments, there is provided an alcoholic beverage comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, an alcoholic beverage comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided an alcoholic beverage comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia- Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, an alcoholic beverage comprises a wine or a sake. In some embodiments, there is provided a wine comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a wine comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a wine comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems la-Xc or a combination of functional Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, there is provided a sake comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, a sake comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, there is provided a sake comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia- Xc or a combination of functional Defense Systems selected from Defense Systems la-Xc, as described in detail herein.

[001314] In some embodiments, there is provided a natto comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, a natto comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, there is provided a natto comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems la-Xc or a combination of functional Defense Systems selected from Defense Systems la-Xc, as described in detail herein.

[001315] In some embodiments, there is provided a food additive comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, a food additive comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, there is provided a food additive comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems la-Xc or a combination of functional Defense Systems selected from Defense Systems la-Xc, as described in detail herein.

[001316] In some embodiments, there is provided feed comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, feed comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, there is provided feed comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems la-Xc or a combination of functional Defense Systems selected from Defense Systems la-Xc, as described in detail herein.

[001317] In some embodiments, there is provided a nutritional supplement comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, a nutritional supplement comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, there is provided a nutritional supplement comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems la-Xc or a combination of functional Defense Systems selected from Defense Systems la-Xc, as described in detail herein.

[001318] In some embodiments, there is provided a probiotic supplement comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, a probiotic supplement comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, there is provided a probiotic supplement comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia- Xc or a combination of functional Defense Systems selected from Defense Systems la-Xc, as described in detail herein.

[001319] In some embodiments, there is provided a health care product comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a health care product comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a health care product comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia- Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001320] In some embodiments, a health care product comprises an antibiotic. In some embodiments, there is provided an antibiotic comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia- Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, an antibiotic comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided an antibiotic comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001321] In some embodiments, an antibiotic comprises a polymyxin, a colistin, or a bacitracin. In some embodiments, there is provided a polymyxin comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a polymyxin comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a polymyxin comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001322] In some embodiments, there is provided a colistin comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a colistin comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a colistin comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001323] In some embodiments, there is provided a bacitracin comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a bacitracin comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a bacitracin comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001324] In some embodiments, there is provided a personal care product comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a personal care product comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a personal care product comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia- Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001325] In some embodiments, there is provided a veterinary product comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, a veterinary product comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, there is provided a veterinary product comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia- Xc or a combination of functional Defense Systems selected from Defense Systems la-Xc, as described in detail herein.

[001326] In some embodiments, there is provided a L-glutamine comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, a L-glutamine comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, there is provided a L-glutamine comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems la-Xc or a combination of functional Defense Systems selected from Defense Systems la-Xc, as described in detail herein.

[001327] In some embodiments, there is provided an acetone comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, an acetone comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems la-Xc or a combination of Defense Systems selected from Defense Systems la-Xc, as described in detail herein. In some embodiments, there is provided an acetone comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems la-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001328] In some embodiments, there is provided butanol comprising at least one components of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, a butanol comprises at least one functional component of a defense system, said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein. In some embodiments, there is provided a butanol comprising a functional defense system, said defense system comprising a functional Defense System selected from Defense Systems Ia-Xc or a combination of functional Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein.

[001329] In some embodiments, the nucleic acid construct of the Defense Systems Ia-Xb comprises a regulatory element operably linked to said construct comprising a cis-acting regulatory element for directing expression of said nucleic acid sequence, or a transmissible element for directing transfer of said nucleic acid sequence from one cell to another, or a recombination element for integrating said nucleic acid sequence into a genome of a cell transfected with said construct, or an element providing episomal maintenance of said construct within a cell transfected with said construct, or any combination thereof.

[001330] In some embodiments, a method of preparing a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product, comprises adding to the food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product at least one component selected from the group consisting of the components of the defense system, thereby preparing a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product. In some embodiments, a method of preparing a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product comprises introducing into the bacteria a defense system comprising a Defense System selected from a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, wherein said defense system comprises an anti-phage activity, or an anti-plasmid activity, or an anti-phage and an anti-plasmid activity, the system comprising at least one component of said Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, said at least one component selected from the group consisting of the components of the Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, Vni, IX, Xa, Xb, or Xc, respectively, thereby preparing the food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product.

[001331] In some embodiments, a method of preparing a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product comprises introducing into the bacteria a defense system comprising a combination of Defense Systems selected from Defense System la, lb, Π, nia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, and Xc, wherein said defense system comprises an anti-phage activity, an anti- plasmid activity, or an anti-phage and an anti-plasmid activity, the system comprising at least one component of each of said Defense Systems in a combination, said at least one component selected from the group consisting of the components of the Defense Systems la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, respectively, thereby preparing a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product.

[001332] In some embodiments, an at least one component comprises the components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, required for a functional Defense System, wherein said function comprises an anti-phage activity, an anti- plasmid activity, or an anti-phage and an anti-plasmid activity. In some embodiments, an at least one component comprises the components of the cassette of genes making up a Defense System la, lb, II, Ilia, nib, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises two components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises three components of a Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises four components of a Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises five components of a Defense System la, lb, II, Ilia, Illb, nic, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, a component comprises the full-length component. In some embodiments, a component comprises a functional portion of the component. In some embodiments, a component comprises a component homolog. Defense System components, nucleic acid sequences thereof, and amino acid sequences thereof are presented herein in Table 18. [001333] In some embodiments, for a method of use disclosed herein, the at least one defense system component is comprised in cell (e.g. bacteria) genetically modified to express the component.

[001334] In some embodiments, there is provided a method of preparing a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product, the method comprising adding to the food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product a cell comprising a defense system disclosed herein, thereby preparing the food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product. In some embodiments, said use comprises use of an isolated cell comprising a defense system disclosed herein.

[001335] In some embodiments, there is provided a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product comprising the cell comprising a defense system disclosed herein.

[001336] In some embodiments, there is provided a method of preparing a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product comprising adding to the food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product bacteria which expresses on a transmissible genetic element at least one component of a defense system disclosed herein, wherein said defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc, as described in detail herein, thereby preparing the food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product.

[001337] In some embodiments, an at least one component comprises the components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, required for a functional Defense System, wherein said function comprises an anti-phage activity, an anti- plasmid activity, or an anti-phage and an anti-plasmid activity. In some embodiments, an at least one component comprises the components of the cassette of genes making up a Defense System la, lb, II, Ilia, nib, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises two components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises three components of a Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises four components of a Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises five components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, a component comprises the full-length component. In some embodiments, a component comprises a functional portion of the component. In some embodiments, a component comprises a component homolog. Defense System components, nucleic acid sequences thereof, and amino acid sequences thereof are presented herein in Table 18.

[001338] In some embodiments, there is provided a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product comprising bacteria which expresses on a transmissible genetic element at least one component of a defense system comprising a Defense System selected from Defense Systems Ia-Xc or a combination of Defense Systems selected from Defense Systems Ia-Xc.

[001339] In some embodiments, an at least one component comprises the components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc, required for a functional Defense System, wherein said function comprises an anti-phage activity, an anti- plasmid activity, or an anti-phage and an anti-plasmid activity. In some embodiments, an at least one component comprises the components of the cassette of genes making up a Defense System la, lb, II, Ilia, nib, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises two components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises three components of a Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises four components of a Defense System la, lb, Π, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, an at least one component comprises five components of a Defense System la, lb, II, Ilia, Illb, IIIc, IV, V, VI, VII, VIII, IX, Xa, Xb, or Xc. In some embodiments, a component comprises the full-length component. In some embodiments, a component comprises a functional portion of the component. In some embodiments, a component comprises a component homolog. Defense System components, nucleic acid sequences thereof, and amino acid sequences thereof are presented herein in Table 18.

[001340] In some embodiments, a food or feed disclosed herein, comprises a dairy product. In some embodiments, a food additive comprises an additive to be added to a dairy product or to an ingredient used to prepare a dairy product.

[001341] The preparation of starter cultures of such bacteria, and methods of fermenting substrates, particularly food substrates such as milk, can be carried out in accordance with known techniques, including but not limited to those described in Mayra-Makinen and Bigret (1993) Lactic Acid Bacteria; Salminen and vonWright eds. Marcel Dekker, Inc. New York. 65- 96; Sandine (1996) Dairy Starter Cultures Cogan and Accolas eds. VCH Publishers, New York. 191-206; Gilliland (1985) Bacterial Starter Cultures for Food. CRC Press, Boca Raton, Fla.

[001342] The term "fermenting" refers to the energy-yielding, metabolic breakdown of organic compounds by microorganisms that generally proceeds under anaerobic conditions and with the evolution of gas.

[001343] Products produced by fermentation which have been known to experience phage infection, and the corresponding infected fermentation bacteria, include cheddar and cottage cheese (Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris), yogurt (Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus), Swiss cheese (S. thermophilus, Lactobacillus lactis, Lactobacillus helveticus), blue cheese (Leuconostoc cremoris), Italian cheese (L. bulgaricus, S. thermophilus), viili (Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis biovar diacetylactis, Leuconostoc cremoris), yakult (Lactobacillus casei), casein (Lactococcus lactis subsp. cremoris), natto (Bacillus subtilis var. natto), wine (Leuconostoc oenos), sake (Leuconostoc mesenteroides), polymyxin (Bacillus polymyxa), colistin (Bacillus colistrium), bacitracin (Bacillus licheniformis), L-glutamic acid (Brevibacterium lactofermentum, Microbacterium ammoniaphilum), and acetone and butanol (Clostridium acetobutylicum, Clostridium saccharoperbutylacetonicum).

[001344] In some embodiments, provided herein are bacteria resistant to phage infection, said bacteria including but not limited to Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, S. thermophilus, Lactobacillus lactis, Lactobacillus helveticus, Leuconostoc cremoris, L. bulgaricus, S. thermophilus, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis biovar diacetylactis, Leuconostoc cremoris, Lactobacillus casei, Lactococcus lactis subsp. cremoris, Bacillus subtilis var. natto, Leuconostoc oenos, Leuconostoc mesenteroides, polymyxin Bacillus polymyxa, Bacillus colistrium, Bacillus licheniformis, L- Brevibacterium lactofermentum, Microbacterium ammoniaphilum, and acetone and butanol Clostridium acetobutylicum, Clostridium saccharoperbutylacetonicum.

[001345] In some embodiments, provided here are starter cultures comprising bacteria resistant to phage infection, said bacteria including but not limited to Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, S. thermophilus, Lactobacillus lactis, Lactobacillus helveticus, Leuconostoc cremoris, L. bulgaricus, S. thermophilus, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis biovar diacetylactis, Leuconostoc cremoris, Lactobacillus casei, Lactococcus lactis subsp. cremoris, Bacillus subtilis var. natto, Leuconostoc oenos, Leuconostoc mesenteroides, polymyxin Bacillus polymyxa, Bacillus colistrium, Bacillus licheniformis, L- Brevibacterium lactofermentum, Microbacterium ammoniaphilum, and acetone and butanol Clostridium acetobutylicum, Clostridium saccharoperbutylacetonicum.

[001346] In some embodiments, a method of protecting a bacteria from phage infection, comprises protecting bacteria selected from Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, S. thermophilus, Lactobacillus lactis, Lactobacillus helveticus, Leuconostoc cremoris, L. bulgaricus, S. thermophilus, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis biovar diacetylactis, Leuconostoc cremoris, Lactobacillus casei, Lactococcus lactis subsp. cremoris, Bacillus subtilis var. natto, Leuconostoc oenos, Leuconostoc mesenteroides, polymyxin Bacillus polymyxa, Bacillus colistrium, Bacillus licheniformis, L- Brevibacterium lactofermentum, Microbacterium ammoniaphilum, and acetone and butanol Clostridium acetobutylicum, and Clostridium saccharoperbutylacetonicum.

[001347] In some embodiments, a method of protecting a bacteria from plasmid transformation, comprises protecting bacteria selected from Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, S. thermophilus, Lactobacillus lactis, Lactobacillus helveticus, Leuconostoc cremoris, L. bulgaricus, S. thermophilus, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis biovar diacetylactis, Leuconostoc cremoris, Lactobacillus casei, Lactococcus lactis subsp. cremoris, Bacillus subtilis var. natto, Leuconostoc oenos, Leuconostoc mesenteroides, polymyxin Bacillus polymyxa, Bacillus colistrium, Bacillus licheniformis, L- Brevibacterium lactofermentum, Microbacterium ammoniaphilum, and acetone and butanol Clostridium acetobutylicum, and Clostridium saccharoperbutylacetonicum.

[001348] In some embodiments, a method of protecting a bacteria from phage infection and plasmid transformation, comprises protecting bacteria selected from Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, S. thermophilus, Lactobacillus lactis, Lactobacillus helveticus, Leuconostoc cremoris, L. bulgaricus, S. thermophilus, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis biovar diacetylactis, Leuconostoc cremoris, Lactobacillus casei, Lactococcus lactis subsp. cremoris, Bacillus subtilis var. natto, Leuconostoc oenos, Leuconostoc mesenteroides, polymyxin Bacillus polymyxa, Bacillus colistrium, Bacillus licheniformis, L- Brevibacterium lactofermentum, Microbacterium ammoniaphilum, and acetone and butanol Clostridium acetobutylicum, and Clostridium saccharoperbutylacetonicum.

[001349] In some embodiments, a cell comprising a defense system described herein, comprises a Lactococcus lactis subsp. Lactis cell, a Lactococcus lactis subsp. cremoris cell, a Lactobacillus delbrueckii subsp. bulgaricus cell, a Streptococcus thermophilus cell, a S. thermophilus cell, a Lactobacillus lactis cell, a Lactobacillus helveticus cell, a Leuconostoc cremoris cell, a L. bulgaricus cell, a S. thermophilus cell, a Lactococcus lactis subsp. cremoris cell, a Lactococcus lactis subsp. lactis biovar diacetylactis cell, a Leuconostoc cremoris cell, a Lactobacillus case cell, a, Lactococcus lactis subsp. cremoris cell, a Bacillus subtilis var. natto cell, a Leuconostoc oenos cell, a Leuconostoc mesenteroides cell, a polymyxin Bacillus polymyxa cell, a Bacillus colistrium cell, a Bacillus licheniformis cell, a L- Brevibacterium lactofermentum cell, a Microbacterium ammoniaphilum cell, a Clostridium acetobutylicum cell, anda Clostridium saccharoperbutylacetonicum cell

[001350] As exemplified herein below in Examples 1-8, transformation of bacteria with a defense system confers either phage resistance or plasmid resistance to the bacteria. For example, but not limited to the results presented in Figures 3B, 3C, 3D, 3E, 5D, and 7C. These results suggest that the use of anti-defense system as a method to induce phage sensitivity.

[001351] In some embodiments, addition of nucleic acid sequences to the genome of a bacteria provides phage resistance. In some embodiments, addition of a nucleic acid construct, as disclosed herein, to the genome of a bacteria provides phage resistance. In some embodiments, addition of a nucleic acid construct, as disclosed herein, to the genome of a bacteria comprising Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, S. thermophilus, Lactobacillus lactis, Lactobacillus helveticus, Leuconostoc cremoris, L. bulgaricus, S. thermophilus, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. lactis biovar diacetylactis, Leuconostoc cremoris, Lactobacillus casei, Lactococcus lactis subsp. cremoris, Bacillus subtilis var. natto, Leuconostoc oenos, Leuconostoc mesenteroides, polymyxin Bacillus polymyxa, Bacillus colistrium, Bacillus licheniformis, L- Brevibacterium lactofermentum, Microbacterium ammoniaphilum, and acetone and butanol Clostridium acetobutylicum, Clostridium saccharoperbutylacetonicum, provides phage resistance to the bacteria.

[001352] As used herein, "inducing phage sensitivity" refers to an increase of at least 5 % in bacterial susceptibility towards a phage, as compared to same in the absence of the defense system agent, as may be manifested e.g. in growth arrest, death or prevention of lysogeny. According to a specific embodiment, the increase is in at least 10%, 20 %, 30 %, 40 % or even higher say, 50 %, 60 %, 70 %, 80 %, 90 % or more than 100 %.

Methods of Identifying Defense Systems

[001353] Disclosed herein, in some embodiments is a computational approach to identify new defense systems localized in the vicinity of annotated defense systems.

[001354] In some embodiments, there is provided a method for identifying a defense system in a prokaryotic cell, comprising the steps of:

(a) selecting, in-silico, a gene located in close proximity to a known defense-related gene family present in a plurality of prokaryotic genomes;

(b) analyzing, in-silico, the DNA upstream and downstream of said gene; and

(c) identifying, in-silico, a cassette of genes within the upstream and downstream DNA analyzed in step (b) comprising said gene of step (a), wherein said cassette of genes has conserved synteny in said plurality of prokaryotic genomes.

[001355] In some embodiments, a method for identifying a defense system comprises the steps of:

(a) in-silico selecting a gene in location proximity to an annotated defense system of a plurality of prokaryotic genomes; and

(b) in-silico selecting a cassette of genes comprising said gene with conserved synteny in said plurality of prokaryotic genomes.

[001356] In some embodiments, the defense system comprises an anti-phage defense system. In some embodiments, the defense system comprises an anti-plasmid defense system. In some embodiments, the defense system comprises an anti-phage defense system and an anti-plasmid defense system. [001357] In some embodiments, a gene in location proximity comprises a gene positioned within less than 10 genes upstream (5') or 10 genes downstream (3') to the annotated defense system. In some embodiments, the location proximity is positioned within 10 genes upstream or downstream to said annotated defense system in said prokaryotic genome.

[001358] Annotated defense systems are disclosed in scientific papers and databases known to the skilled in the art (see e.g. Makarova et al. J Bacteriol. 2011 Nov; 193(21): 6039-6056; Swarts et al. Nature (2014) 507, 258-261; and Goldfarb et al. EMBO J. (2015) 34, 169-83]. Non-limiting examples of annotated defense systems that can be used with some embodiments of the methods for identifying defense systems include, but are not limited to surface modifications to prevent adsorption of phages, restriction-modification (R/M) systems, infection (Abi) mechanisms, the CRISPR/Cas adaptive defense system, the prokaryotic argonaute and the BREX system.

[001359] In some embodiments, the annotated defense system is selected from the group consisting of a restriction-modification (R/M) system, an infection (Abi) system, a CRISPR/Cas adaptive defense system, a prokaryotic argonaute and a BREX system.

[001360] In some embodiments, the plurality comprises at least 2. In some embodiments, the plurality comprises at least 5, at least 10, at least 20, at least 50, at least 100 or at least 500.

[001361] A skilled artisan would appreciate that the term "conserved synteny" encompasses a conserved gene order in the genomes of different species.

[001362] In some embodiments, the method for identifying a defense system further comprises a step of validating a defensive effect of the selected (identified) cassette of genes.

[001363] Validating a defensive effect may be effected in any method known in the art.

[001364] In some embodiments, validating the defensive effect is effected by genetically modifying a prokaryotic cell to express the selected cassette of genes and subjecting the prokaryotic cell to phage infection or plasmid transformation, wherein a decrease in phage or plasmid sensitivity below a predetermined threshold as compared to a prokaryotic cell of the same origin not genetically modified to express the selected cassette of genes is indicative of a defensive effect.

[001365] In some embodiments, validating the defensive effect is effected by contacting a prokaryotic cell with an agent capable of downregulating expression and/or activity of at least one gene of the selected cassette of genes in a prokaryotic cell and subjecting the prokaryotic cell to phage infection or plasmid transformation, wherein an increase in phage or plasmid sensitivity above a predetermined threshold as compared to a prokaryotic cell of the same origin not contacted with the agent is indicative of a defensive effect.

[001366] In some embodiments, the decrease/increase below or above a predetermined threshold is statistically significant.

[001367] In some embodiments, the predetermined threshold is at least at least 1.5 fold, at least 2 fold, at least 3 fold, at least 5 fold, at least 10 fold, or at least 20 fold. In some embodiments, the predetermined threshold is at least 2 %, at least 5 %, at least 10 %, at least 20 %, at least 30 %, at least 40 %, at least 50 %, at least 60 %, at least 70 %, at least 80 %, at least 90 %, e.g., 100 %, at least 200 %, at least 300 %, at least 400 %, at least 500 %, at least 600 %.

[001368] A non-limiting example of a method of identifying a defense system, which can be used according to embodiments disclosed herein, is described at least in the Materials and Methods hereinbelow, Example 1, Example 2, and in Figure 1, which is to be understood as forming an integral part of the present section.

[001369] Once selected, the identified cassette of genes comprising said gene with conserved synteny in said plurality of prokaryotic genomes can be cloned or synthesized.

[001370] The gene(s) can be ligated into expression constructs and used in a variety of applications e.g., for conferring phage resistance in for example, but not limited to the food, feed, medical and veterinary industries.

[001371] In some embodiments, an identified cassette of gene confers phage resistance to a starter culture. In some embodiments, an identified cassette of gene confers phage resistance to a food product. In some embodiments, a food product comprises a dairy product, an alcoholic beverage, or a natto. In some embodiments, an identified cassette of gene confers phage resistance to a dairy product. In some embodiments, an identified cassette of gene confers phage resistance to an alcoholic beverage. In some embodiments, an identified cassette of gene confers phage resistance to a natto.

[001372] In some embodiments, an identified cassette of gene confers phage resistance to a milk product. In some embodiments, an identified cassette of gene confers phage resistance to milk. In some embodiments, an identified cassette of gene confers phage resistance to a sour milk. In some embodiments, an identified cassette of gene confers phage resistance to a milk butter milk. In some embodiments, an identified cassette of gene confers phage resistance to a cheese. In some embodiments, an identified cassette of gene confers phage resistance to a yogurt. In some embodiments, an identified cassette of gene confers phage resistance to a viili. In some embodiments, an identified cassette of gene confers phage resistance to yakult. In some embodiments, an identified cassette of gene confers phage resistance to a casein. In some embodiments, an identified cassette of gene confers phage resistance to a wine. In some embodiments, an identified cassette of gene confers phage resistance to a sake. In some embodiments, an identified cassette of gene confers phage resistance to a food additive. In some embodiments, an identified cassette of gene confers phage resistance to a feed. In some embodiments, an identified cassette of gene confers phage resistance to a nutritional supplement. In some embodiments, an identified cassette of gene confers phage resistance to a probiotic supplement. In some embodiments, an identified cassette of gene confers phage resistance to a health care product. In some embodiments, an identified cassette of gene confers phage resistance to an antibiotic. In some embodiments, an identified cassette of gene confers phage resistance to polymyxin. In some embodiments, an identified cassette of gene confers phage resistance to a colistin. In some embodiments, an identified cassette of gene confers phage resistance to a bacitracin. In some embodiments, an identified cassette of gene confers phage resistance to a personal care product. In some embodiments, an identified cassette of gene confers phage resistance to a veterinary product.

Antagonists of Defense Systems and Methods of Use Thereof

[001373] In some embodiments, there is provided an antagonist of a defense system disclosed herein, an "anti-defense system agent". A skilled artisan would appreciate that the terms "anti- defense system agent" and "anti-Defense System agent" and "agent" may in some embodiments, be used interchangeably having all the same elements and qualities. In some embodiments, an anti-defense system agent may antagonize more than one Defense System function. In some embodiments, an anti-defense system agent may antagonize more than one Defense System function, selected from Defense systems Ia-Xc. In some embodiments, an anti- Defense System agent may antagonize more than one Defense System. In some embodiments, an anti-Defense System agent may antagonize more than one Defense System selected from Defense systems Ia-Xc.

[001374] In some embodiments, an anti-Defense System agent is capable of down regulating expression and/or activity of at least one Defense System component. In some embodiments, an anti-Defense System agent is capable of down regulating expression and/or activity of at least one Defense System component, wherein said Defense System is selected from Defense Systems Ia-Xc. [001375] In some embodiments, the anti-defense system agent is directed against a defense system component comprising an enzyme activity, for example but not limited to a HamB polypeptide, a SduA polypeptide, a GajA polypeptide, a GajB polypeptide, a PtuA polypeptide, a PtuB polypeptide, a LmuB polypeptide, a ZorD polypeptide, a ZorE polypeptide, a DruE polypeptide, a DruM polypeptide, or a JetC polypeptide. For example, the anti-defense agent may interfere with the expression of an active defense system component or, for example in its DNA methyltransferase function, helicase function, exonuclease function, or endonuclease function. For example, in some embodiments, a methylase activity may be inhibited by the use of common inhibitors of such an enzyme e.g., 5-Azacytidine, Decitabine Zebularine, RG108, Hydralazine hydrochloride, and Psammaplin A.

[001376] In some embodiments, an at least one component comprises a component selected from Defense Systems la, lb, II, Ilia, Illb, IIIc, IN, V, VI, VII, VIII, IX, Xa, Xb, and Xc. In some embodiments, a component comprises a functional component. In some embodiments, a component comprises an essential component. In some embodiments, a component comprises the full-length component. In some embodiments, a component comprises a functional portion of the component.

[001377] The components of defense systems comprising a Defense System Ia-Xc and combinations thereof, have been described in detail above. In some embodiments, polypeptide components of these systems include but are not limited to ZorA, ZorB, ZorC, ZorD, ZorE (Defense System la and lb); ThsA and ThsB (Defense System II); DruA, DruB, DruC, DruD, DruE, DruH, DruM, DruG, DruF (Defense Systems Ilia, Illb, IIIc); HamA and HamB (Defense System IN); SduA (Defense System V); GajA and GajB (Defense System VI); PtuA and PtuB (Defense System VII); LmuA and LmuB (Defense System VIII); KwaA and KwaB (Defense System IX); and JetA, JetB, JetC, and JetD, and variants thereof (Defense Systems Xa, Xb, Xc). In some embodiments, polynucleotide (e.g., gene) components, include but are not limited to zorA, zorB, zorC, zorD, zorE (Defense Systems la, lb); thsA and thsB (Defense System II); druA, druB, druC, druD, druE, druF, druG, druH, druM (Defense Systems Ilia, Illb, IIIc); hamA and hamB (Defense System IN); sduA (Defense System V); gajA and gajB (Defense System VI); ptuA and ptuB (Defense System VII); ImuA and ImuB (Defense System VIII); kwaA and kwaB (Defense System IX); and jetA, jetB, jetC, and jetD and variants thereof (Defense Systems Xa, Xb, Xc). In some embodiments, a component comprises a component homolog. Defense System components, nucleic acid sequences thereof, and amino acid sequences thereof are presented herein in Table 18.

[001378] In some embodiments, a Defense System described herein comprises at least two different polypeptide components. The polypeptide components of the Defense Systems described herein, and the nucleic acids encoding them are described in detail above, and in Tables 8-18. In some embodiments, a Defense System described herein comprises at least three different polypeptide components. In some embodiments, a Defense System described herein comprises at least four different polypeptide components. In some embodiments, a Defense System described herein comprises at least five different polypeptide components. In some embodiments, a Defense System described herein comprises multiple polypeptide components, wherein the components comprise different polypeptides. In some embodiments, a Defense System described herein comprises multiple polypeptide components, wherein the components comprise different polypeptides and duplications of a same polypeptide. In some embodiments, components comprising duplication of a same polypeptide comprise homologues of that polypeptide.

[001379] In some embodiments, a Defense System comprising at least two different polypeptide components provides a functional defense activity (protection from foreign nucleic acid) for a cell. In some embodiments, a Defense System described herein comprises at least three different polypeptide components provides a functional defense activity (protection from foreign nucleic acid) for a cell. In some embodiments, a Defense System described herein comprises at least four different polypeptide components provides a functional defense activity (protection from foreign nucleic acid) for a cell. In some embodiments, a Defense System described herein comprises at least five different polypeptide components provides a functional defense activity (protection from foreign nucleic acid) for a cell. In some embodiments, a Defense System described herein comprises multiple polypeptide components, wherein the components comprise different polypeptides, and wherein the Defense System provides a functional defense activity (protection from foreign nucleic acid) for a cell. In some embodiments, a Defense System described herein comprises multiple polypeptide components, wherein the components comprise different polypeptides and duplications of a same polypeptide, wherein said Defense System provides a functional defense activity (protection from foreign nucleic acid) for a cell. In some embodiments, components comprising duplication of a same polypeptide comprise homologues of that polypeptide.

[001380] In some embodiments, an agent is capable of down regulating expression and/or activity of at least two components of a defense system. In some embodiments, an agent is capable of down regulating at least one components of at least two different Defense Systems. In some embodiments, an agent is capable of down regulating expression and/or activity of at least two components of a Defense System. In some embodiments, an agent is capable of down regulating at least two components of the same Defense System. In some embodiments, an agent is capable of down regulating expression and/or activity of at least two components of a Defense System selected from the components of Defense Systems Ia-Xc.

[001381] In some embodiments, an agent is capable of down regulating expression and/or activity of 1-40 components of a defense system. In some embodiments, an agent is capable of down regulating expression and/or activity of 1-4 components of a defense system. In some embodiments, an agent is capable of down regulating expression and/or activity of 1-5 components of a defense system. In some embodiments, an agent is capable of down regulating expression and/or activity of 1-10 components of a defense system. In some embodiments, an agent is capable of down regulating expression and/or activity of 10-20 components of a defense system. In some embodiments, an agent is capable of down regulating expression and/or activity of 20-30 components of a defense system. In some embodiments, an agent is capable of down regulating expression and/or activity of 30-40 components of a defense system. In some embodiments, an agent is capable of down regulating expression and/or activity of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, or 43 components of a defense system. In some embodiments, an agent is capable of down regulating at least one components of at least two different Defense Systems. In some embodiments, an agent is capable of down regulating expression and/or activity of at least two components of a Defense System. In some embodiments, an agent is capable of down regulating at least two components of the same Defense System. In some embodiments, an agent is capable of down regulating expression and/or activity of at least two components of a Defense System selected from the components of Defense Systems Ia-Xc.

[001382] A skilled artisan would recognize that the phrase "anti-Defense agent" encompasses an agent capable of specifically inhibiting the expression of a target Defense System gene (at the DNA or RNA level) or alternatively specifically impairing the functionality of the target Defense System protein. In some embodiments, an agent is capable of specifically inhibiting the expression of a target Defense System component (at the DNA or RNA level) or alternatively specifically impairing the functionality of the target Defense System component polypeptide.

[001383] In some embodiments, the anti-Defense system agent is directed against one of the Defense System components. In some embodiments, the anti-Defense System agent is directed against multiple components of a Defense System. In some embodiments, the anti-Defense System agent is directed against at least 2 components of a Defense System. In some embodiments, the anti-Defense System agent is directed against at least 3 components of a Defense System. In some embodiments, the anti-Defense System agent is directed against at least 4 components of a Defense System. In some embodiments, the anti-Defense System agent is directed against at least 5 components of a Defense System.

[001384] In some embodiments, the anti-Defense system agent is directed against any of the components disclosed in Table 18. In some embodiments, the anti-Defense system agent is directed against any combination of the components disclosed in Table 18. In some embodiments, the combination of components may be from a same Defense System selected from Defense Systems Ia-Xc. In some embodiments, the combination of components may be from different Defense Systems selected from Defense Systems Ia-Xc. In some embodiments, the combination of components may be from the same and different Defense Systems selected from Defense Systems Ia-Xc.

[001385] In some embodiments, the agent is directed against all of the components of a single Defense System. In some embodiments, the agent is directed against all of the essential components of a single Defense System. In some embodiments, the agent is directed against all of the components of a single Defense System selected from Defense Systems Ia-Xc. In some embodiments, the agent is directed against all of the essential components of a single Defense System, selected from Defense Systems Ia-Xc.

[001386] Down regulation of a Defense System can be effected on the genomic and/or the transcript level using a variety of molecules that interfere with transcription and/or translation (e.g., RNA silencing agents), or on the protein level using e.g., aptamers, small molecules and inhibitory peptides, antagonists, enzymes that cleave the polypeptide and the like.

[001387] In some embodiments the anti-Defense System agent is selected from the group consisting of a nucleic acid suitable for silencing expression, aptamers, small molecules and inhibitory peptides.

[001388] A skilled artisan would appreciate that the phrase "nucleic acid suitable for silencing expression" refers to regulatory mechanisms mediated by nucleic acid molecules, which result in the inhibition or "silencing" of the expression of a corresponding protein-coding gene.

[001389] Methods for qualifying efficacy and detecting inhibition or "silencing" of the expression of a corresponding protein-coding gene are well known in the art and include, but are not limited to, DNA sequencing, electrophoresis, an enzyme-based mismatch detection assay and hybridization assay such as PCR, RT-PCR, RNase protection, in-situ hybridization, primer extension, Southern blot, Northern Blot and dot blot analysis. Inhibition or "silencing" of the expression of a specific protein-coding gene can also be determined at the protein level using e.g. chromatography, electrophoretic methods, immunodetection assays such as ELISA and Western blot analysis or immunohistochemistry. In addition, one ordinarily skilled in the art can readily design a knock-in/knock-out construct including positive and/or negative selection markers for efficiently selecting transformed cells that e.g. underwent a homologous recombination event with the construct.

[001390] In some embodiments, downregulation can be achieved by DNA silencing.

[001391] Methods of introducing nucleic acid alterations to a gene of interest are well known in the art [see for example Menke D. Genesis (2013) 51: - 618; Capecchi, Science (1989) 244: 1288-1292; Santiago et al. Proc Natl Acad Sci USA (2008) 105:5809-5814; International Patent Application Nos. WO 2014085593, WO 2009071334 and WO 2011146121; US Patent Nos. 8771945, 8586526, 6774279 and UP Patent Application Publication Nos. 20030232410, 20050026157, US20060014264; the contents of which are incorporated by reference in their entireties] and include targeted homologous recombination, site specific recombinases, PB transposases and genome editing by engineered nucleases.

[001392] Non-limiting examples of DNA silencing agents that can be used In some embodiments include: the "Hit and run" or "in-out" strategy; the "double-replacement" or "tag and exchange" strategy; site-specific recombinases such as, but not limited to, ere recombinase and Flp recombinase; genome editing using engineered endonucleases such as, but not limited to, meganucleases, Zinc finger nucleases (ZFNs), transcription-activator like effector nucleases (TALENs) and CRISPR/Cas system; transposases; and genome editing using recombinant adeno-associated virus (rAAV) platform.

[001393] It will be appreciated that the agent can be a mutagen that causes random mutations and the cells exhibiting downregulation of the expression level and/or activity of a component or components of a Defense System disclosed herein, for example but not limited to the components and Defense Systems disclosed in Table 18. The mutagens may be, but are not limited to, genetic, chemical or radiation agents.

[001394] Downregulation can also be achieved by RNA silencing.

[001395] In certain embodiments, the RNA silencing agent is capable of preventing complete processing (e.g., the full translation and/or expression) of an mRNA molecule through a post- transcriptional silencing mechanism. RNA silencing agents include non-coding RNA molecules, for example RNA duplexes comprising paired strands, as well as precursor RNAs from which such small non-coding RNAs can be generated. Exemplary RNA silencing agents include dsRNAs such as siRNAs, miRNAs and shRNAs.

[001396] In some embodiments, the RNA silencing agent is capable of inducing RNA interference. In some embodiments, the RNA silencing agent is capable of mediating translational repression.

[001397] In some embodiments, the RNA silencing agent is specific to the target RNA of a component of a Defense System disclosed herein, and does not cross inhibit or silence other targets or a splice variant which exhibits 99 % or less global homology to the target gene, e.g., less than 98 %, 97 %, 96 %, 95 %, 94 %, 93 %, 92 %, 91 %, 90 %, 89 %, 88 %, 87 %, 86 %, 85 %, 84 %, 83 %, 82 %, 81 % global homology to the target gene; as determined by PCR, Western blot, Immunohistochemistry and/or flow cytometry.

[001398] Non-limiting examples of RNA silencing agents that can be used in some embodiments include but are not limited to antisense, DsRNA, siRNA, shRNA, miRNA and miRNA mimics.

[001399] Numerous methods are known in the art for gene silencing particularly in prokaryotes; examples include but are not limited to U.S. Patent Application 20040053289 which teaches the use of si hybrids to down-regulate prokaryotic genes, and U.S. Patent Application PCT/US09/69258 which teaches the use of CRISPR to downregulate prokaryotic genes.

[001400] In some embodiments, the inhibition can be carried out at the protein level which interferes with protein activity, such as by the use of aptamers. Various methods are known in the art which can be used to design protein specific aptamers. The skilled artisan can employ SELEX (Systematic Evolution of Ligands by Exponential Enrichment) for efficient selection as described in Stoltenburg R, Reinemann C, and Strehlitz B (Biomolecular engineering (2007) 24(4):381-403).

[001401] In some embodiments, a small molecule, peptides or antibodies can be used which interfere with the Defense System component(s) protein function (e.g., catalytic or interaction).

[001402] In some embodiments, an anti-Defense agent comprises any molecule which binds to and/or cleaves a Defense System component gene or component polypeptide. Such molecules can be, for example, a small molecule, antagonists, or inhibitory peptide.

[001403] It will be appreciated that a non-functional analogue of at least a catalytic or binding portion of a Defense System polypeptide component can be also used as an anti-Defense System agent.

[001404] In some embodiments, there is provided a method of inducing phage sensitivity in bacteria, the method comprising introducing the agent disclosed herein into bacteria, which expresses a defense system having an anti-phage activity, said system comprising at least one component selected from the group consisting of said component polypeptides of said Defense System, thereby inducing sensitivity of the bacteria to phage infection.

[001405] In some embodiments, there is provided a method of killing bacteria, the method comprising introducing into bacteria, which expresses a defense system having an anti-phage activity, as described herein, an anti-defense system agent capable of down regulating expression and/or activity of a component polypeptide of the defense system, thereby killing the bacteria.

[001406] In another embodiment, there is provided an isolated anti-defense system agent capable of down regulating expression and/or activity of at least two defense system components. In some embodiments, the bacteria express the at least one Defense System component for which the anti-Defense System agent is directed against.

[001407] In some embodiments, the method further comprises infecting said bacteria with a phage.

[001408] Specifically, introducing an anti-Defense System agent is effected such that the positioning of the anti-Defense System agent is in direct or indirect contact with the bacterial cell. In some embodiments, both applying the anti-Defense System agent or agents disclosed herein to a desirable surface and/or directly to the bacterial cells. In some embodiments, the surface is comprised in a biological tissue, such as for example, mammalian tissues e.g. the skin.

[001409] It will be appreciated that the bacteria may be comprised inside a particular organism, (e.g. intracellularly or extracellularly) for example inside a mammalian body or inside a plant. In this case, the introducing may be effected by administering the anti-Defense System agent per se or by transfecting the cells of the organism with the anti-Defense System agents. [001410] In some embodiments, introducing with an anti-Defense System agent is effected in- vivo. In some embodiments, introducing with an anti-Defense System agent is effected ex-vivo. In some embodiments, introducing with an anti-Defense System agent is effected in- vitro.

[001411] In some embodiments, there is provided isolated bacteria generated by introducing into bacteria an anti-Defense System agent as described above. In some embodiments, there is provided isolated bacteria generated by introducing into the bacteria an anti-Defense System agent in-vitro or ex-vivo.

[001412] Thus, following the above teachings there is provided isolated bacteria comprising the anti-Defense System agent.

[001413] According to some embodiments, a Defense System or an anti-Defense System agent is provided in a formulation suitable for cell penetration that enhances intracellular delivery of the system or the agent.

[001414] Any suitable penetrating agent for enhancing penetration of a Defense System or its components or an anti-Defense System agent to cell (e.g., bacteria) may be used, as known by those of skill in the art. Examples include but are not limited to:

[001415] Phages - Phages offer several advantages including lateral infection, higher efficiency of transformation, and targeting to, and propagation in, specific bacteria.

[001416] Cell-Penetrating Peptides (CPPs) - CPPs, for example TAT (transcription activator from HrV-1) are short peptides (<40 amino acids), with the ability to gain access to the interior of almost any cell. They are highly cationic and usually rich in arginine and lysine amino acids. They have the exceptional property of carrying into the cells a wide variety of covalently and noncovalently conjugated cargoes such as proteins, oligonucleotides, and even 200 nm liposomes. Protocols for producing CPPs-cargos conjugates and for infecting cells with such conjugates can be found, for example L. Theodore et al. [The Journal of Neuroscience, (1995) 15(11): 7158-7167], Fawell S, et al. [Proc Natl Acad Sci USA, (1994) 91:664-668], and Jing Bian et al. [Circulation Research. (2007) 100: 1626-1633].

[001417] The expression level and/or activity level of the Defense System components expressed in the cells of some embodiments can be determined using methods known in the arts, e.g. but not limited to selectable marker gene, Northern blot analysis, PCR analysis, DNA sequencing, RNA sequencing, Western blot analysis or Immunohistochemistry.

[001418] In some embodiments, there is provided a method of treating bacterial infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the anti-Defense System agent, thereby treating the bacterial infection in the subject. In some embodiments, there is provided the agent, for use in the treatment of bacterial infection in a subject in need thereof.

[001419] A skilled artisan would appreciate that the term "treating" encompasses in some embodiments, curing, reversing, attenuating, alleviating, minimizing, suppressing or halting the deleterious effects of a pathogen infection. Those of skill in the art will understand that various methodologies and assays can be used to assess the development of the pathology, and similarly, various methodologies and assays may be used to assess the reversal, attenuation, alleviation or suppression of the pathology.

[001420] In some embodiments, a "subject in need thereof includes but is not limited to mammals. In some embodiments, the subject comprises a human being of any gender and at any age which suffer from pathogen infection.

[001421] The anti-Defense System agent may be used alone or together with additional antimicrobial agents (e.g. phage therapy, antibiotic and/or additional anti-microbial peptides).

[001422] In some embodiments, a method disclosed herein further comprises administering to the subject a phage therapy and/or an antibiotic. In some embodiments, the uses further comprise a phage therapy and/or an antibiotic.

[001423] In some embodiments, antibiotics include, but are not limited to aminoglycoside antibiotics, cephalosporins, quinolone antibiotics, macrolide antibiotics, penicillin, sulfonamides, tetracyclines and carbapenems. It will be appreciated that since the agents disclosed herein, enhance the anti-bacterial effect of the antibiotic, doses of the antibiotic may be lower (e.g. 20 % lower, 30 % lower, 40 % lower, 50 % lower, 60 % lower, 70 % lower, 80 % lower or even 90 % lower) than those currently in use.

[001424] In the context of manufacturing of food products and especially fermented products in the food industry, an anti-Defense System agent can be used to eliminate spoilage bacteria or the end product from traces of used bacteria.

[001425] Thus, in some embodiments, there is provided a method of preparing a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product, the method comprising adding to the food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product the anti-Defense System agent, thereby preparing the food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product.

[001426] Following the above teachings there is provided a food, food additive, feed, nutritional supplement, probiotic supplement, personal care product, health care product and veterinary product comprising the anti-Defense System agent.

[001427] The nucleic acid sequences, constructs, transmissible elements, polypeptides and cells comprising the Defense System components or the anti-Defense System agent of some embodiments, can be administered to a starter culture, a fermentation vat or an organism per se, or in a composition where it is mixed with suitable carriers or exeipients.

[001428] The phrase "pharmaceutical composition" as used herein refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and exeipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

[001429] Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases.

[001430] Herein, the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of exeipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

[001431] As used herein the term "active ingredient" refers to any one of the component polypeptides or polynucleotides of a Defense System, an anti-Defense System agent, or cells generated according to the methods disclosed herein, accountable for the biological effect.

[001432] Techniques for formulation and administration of drugs may be found in the latest edition of "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, which is herein fully incorporated by reference and are further described herein below.

[001433] It will be appreciated that the polypeptides, polynucleotides, nucleic acid construct(s) or other agents can be provided to the individual with additional active agents to achieve an improved therapeutic effect as compared to treatment with each agent by itself.

[001434] In some embodiments, additional agents include phage therapy and antibiotics (e.g. rifampicin, chloramphenicol and spectinomycin).

[001435] In some embodiments, the composition further comprises a phage. [001436] Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, intraperitoneal, intranasal, or intraocular injections.

[001437] Conventional approaches for drug delivery to the central nervous system (CNS) include: neurosurgical strategies (e.g., intracerebral injection or intracerebroventricular infusion); molecular manipulation of the agent (e.g., production of a chimeric fusion protein that comprises a transport peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB) in an attempt to exploit one of the endogenous transport pathways of the BBB; pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers); and the transitory disruption of the integrity of the BBB by hyperosmotic disruption (resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide). However, each of these strategies has limitations, such as the inherent risks associated with an invasive surgical procedure, a size limitation imposed by a limitation inherent in the endogenous transport systems, potentially undesirable biological side effects associated with the systemic administration of a chimeric molecule comprised of a carrier motif that could be active outside of the CNS, and the possible risk of brain damage within regions of the brain where the BBB is disrupted, which renders it a suboptimal delivery method.

[001438] Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a tissue region of a patient.

[001439] Pharmaceutical compositions may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

[001440] Pharmaceutical compositions for use in accordance with the disclosure herein, may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. [001441] For injection, the active ingredients may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[001442] For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[001443] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[001444] Pharmaceutical compositions, which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.

[001445] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[001446] For administration by nasal inhalation, the active ingredients for use according to the disclosure herein are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[001447] The preparations described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

[001448] Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.

[001449] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water based solution, before use.

[001450] The preparation may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.

[001451] The preparation may also be formulated as a topical composition, such as a spray, a cream, a mouthwash, a wipe, a foam, a soap, an oil, a solution, a lotion, an ointment, a paste, a gel and a patch. [001452] Pharmaceutical compositions suitable for use in context include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients effective to prevent, alleviate or ameliorate symptoms of disease (e.g., bacterial infection) or prolong the survival of the subject being treated.

[001453] Determination of a therapeutically effective amount is well within the capability of those skilled in the art.

[001454] For any preparation used in the methods disclosed herein, the therapeutically effective amount or dose can be estimated initially from in vitro assays. For example, a dose can be formulated in animal models and such information can be used to more accurately determine useful doses in humans.

[001455] Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. [See e.g., Fingl, et al., (1975) "The Pharmacological Basis of Therapeutics", Ch. l p.l].

[001456] Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.

[001457] The amount of a composition to be administered will, of course, be dependent on e.g. the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

[001458] Compositions of some embodiments, may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above.

[001459] In some embodiments, there is provided an article of manufacture or a kit identified for treating bacterial infection comprising the anti-Defense System agent; and a phage and/or an antibiotic. In some embodiments, the anti-Defense System agent and the phage and/or the antibiotic are packaged in separate containers. In some embodiments, the anti-Defense System agent and the phage and/or the antibiotic are in co-formulation.

[001460] In some embodiments, there is provided a method of screening for identifying phage useful for infecting bacteria, the method comprising:

(a) contacting a phage with bacteria expressing a Defense System; and

(b) determining deleterious effects induced in said bacteria, wherein an increase in deleterious effects of said bacteria in the presence of said phage compared to deleterious effects in the absence of said phage is indicative of a phage useful for infecting said bacteria.

[001461] In some embodiments, the method comprising further isolating the phage, characterizing it in terms of sequencing and compatibility with phages species and the ability to infect different bacterial species.

Use of a Defense System or Components Thereof, for Gene Editing

[001462] In some embodiments, disclosed herein is a method of gene editing, the method comprising contacting a nucleic acid sequence with a defense system component, as described herein, wherein said contact edits a gene sequence within the nucleic acid. In some embodiments, said editing comprises deleting a gene, deleting a portion of a gene, deleting upstream regulatory sequences of a gene, deleting downstream regulatory sequences of a gene, deleting upstream and downstream regulatory sequences of a gene, repairing a gene sequence, replacing a gene, replacing a part of a gene, replacing an upstream sequence of a gene, replacing a downstream sequence of a gene, replacing an upstream and a downstream sequence of a gene, modifying a gene sequence, modifying a sequence upstream of a gene, modifying a sequence downstream of a gene, modifying a sequence upstream and downstream of a gene, or a combination thereof.

[001463] In some embodiments, use of a defense system component, as described herein, for gene editing provides greater precision in editing a nucleotide sequence. In some embodiments, gene editing provides greater precision of cutting the nucleotide sequence at a cleavage site. In some embodiments, gene editing comprising cutting the nucleic acid sequence at a specific cleavage site. In some embodiments, gene editing comprising cutting the nucleic acid sequence based on the modification of nucleotides within the nucleic acid. In some embodiments, gene editing comprising inhibition of cutting the nucleic acid sequence based on the modification of nucleotides within the nucleic acid. In some embodiments, cleavage comprises cleavage of the phosphodiester bond within a nucleotide sequence. In some embodiments, cleavage is ATP dependent.

[001464] In some embodiments, use of a defense system component, as described herein, for gene editing provides separation of two annealed nucleic acid strands. In some embodiments, gene editing comprises separation of double stranded DNA. In some embodiments, gene editing comprises separation of double stranded RNA. In some embodiments, gene editing comprises separation of a double stranded RNA-DNA hybrid. In some embodiments, separation uses energy derived from ATP hydrolysis. In some embodiments, separation of a double stranded sequence is based on the specific sequence of the double stranded sequence. In some embodiments, separation of a double stranded sequence is based on the methylation pattern within the double stranded sequence. In some embodiments, separation of a double stranded sequence is based on the modification pattern within the double stranded sequence.

[001465] In some embodiments, use of a defense system component, as described herein, for gene editing provides unwinding of a double stranded nucleic acid sequence one base at a time. In some embodiments, unwinding is of a double stranded DNA. In some embodiments, unwinding is of a double stranded RNA. In some embodiments, unwinding is of a hybrid double stranded RNA-DNA. In some embodiments, unwinding uses energy derived from ATP hydrolysis. In some embodiments, unwinding of a double stranded sequence is based on the specific sequence of the double stranded sequence. In some embodiments, unwinding of a double stranded sequence is based on the methylation pattern within the double stranded sequence. In some embodiments, unwinding of a double stranded sequence is based on the modification pattern within the double stranded sequence.

[001466] In some embodiments, use of a defense system component, as described herein, for gene editing provides cleaving nucleotides one at a time from the end of a polynucleotide chain. In some embodiments, the polynucleotide change comprises DNA. In some embodiments, the polynucleotide chain comprises RNA. In some embodiments, the polynucleotide chain comprises a hybrid RNA-DNA construct. In some embodiments, cleavage is based on the specific sequence of the double stranded sequence. In some embodiments, cleavage is based on the methylation pattern within the double stranded sequence. In some embodiments, cleavage is based on the modification pattern within the double stranded sequence.

[001467] In some embodiments, use of a defense system component, as described herein, for gene editing provides overwinding or underwinding of DNA. In some embodiments, the overwinding or underwinding comprises cleavage of the phosphate backbone of one of the DNA strands. In some embodiments, the overwinding or underwinding comprises cleavage of the phosphagen backbone of both of the DNA strands. In some embodiments, overwinding or underwinding is based on the specific sequence of the double stranded sequence. In some embodiments, overwinding or underwinding is based on the methylation pattern within the double stranded sequence. In some embodiments, overwinding or underwinding is based on the modification pattern within the double stranded sequence.

[001468] In some embodiments, modifications comprise methylation and acetylation. In some embodiments, methylation comprises methylation of adenine bases. In some embodiments, methylation comprises methylation of cytosine bases.

[001469] In some embodiments, gene editing comprises cutting the nucleic acid sequence based on the methylation pattern of the nucleic acid. In some embodiments, gene editing comprising cutting the nucleic acid sequence based on the lack of methylation of the nucleic acid. In some embodiments, gene editing comprises inhibition of cutting the nucleic acid sequence based on the methylation pattern of the nucleic acid. In some embodiments, gene editing comprising inhibition of cutting the nucleic acid sequence based on the lack of methylation of the nucleic acid.

[001470] A skilled artisan would appreciate that the terms "cutting" and "cleaving" may be used interchangeably in some embodiments, having all the qualities and meanings.

[001471] In some embodiments, cutting a nucleic acid sequence comprises cleavage of a single stranded nucleic acid. In some embodiments, cutting a nucleic acid sequence comprises cleavage of a double stranded nucleic acid. In some embodiments, cutting a nucleic acid sequence comprises cleavage of a DNA molecule. In some embodiments, cutting a nucleic acid sequence comprises cleavage of an RNA molecule.

[001472] In some embodiments, cutting a nucleic acid sequence comprises recognizing a specific nucleotide sequence. In some embodiments, cutting a nucleic acid sequence comprises recognizing a specific pattern of methylation of a nucleotide sequence. In some embodiments, editing comprising inhibiting cleavage of a nucleic acid sequence, wherein said inhibition of cleavage comprises recognizing a specific pattern of methylation of the nucleotide sequence.

[001473] In some embodiments, the nucleotide sequence being edited is comprised in a cell. In some embodiments, the nucleotide sequence being edited is not comprised within a cell. In some embodiments, editing of a nucleotide sequence within a cell, comprises genetically engineering the cell.

[001474] In some embodiments, genetic engineering of a cell comprises deleting a gene, deleting a portion of a gene, deleting upstream regulatory sequences of a gene, deleting downstream regulatory sequences of a gene, deleting upstream and downstream regulatory sequences of a gene, repairing a gene sequence, replacing a gene, replacing a part of a gene, replacing an upstream sequence of a gene, replacing a downstream sequence of a gene, replacing an upstream and a downstream sequence of a gene, modifying a gene sequence, modifying a sequence upstream of a gene, modifying a sequence downstream of a gene, modifying a sequence upstream and downstream of a gene, or a combination thereof, within the cell.

[001475] In some embodiments, a cell comprises a eukaryotic cell. In some embodiments, a cell comprises a prokaryotic cell. In some embodiments, a cell comprises a plant cell. In some embodiments, a cell comprises a yeast cell. In some embodiments, a cell comprises a protozoa cell.

[001476] In some embodiments, genetic engineering of a cell provides cells useful in treating a disease.

[001477] In some embodiments, genetic engineering of a plant cell provides for improved plant growth. In some embodiments, genetic engineering of a plant cell provides for improved plant growth under adverse conditions, including but not limited to extreme heat, extreme cold, drought, high salt content, lack of nutrients, or any combination thereof. In some embodiments, genetic engineering of a plant cell provides for higher crop yield. In some embodiments, genetic engineering of a plant cell provides for higher crop yield under adverse conditions, including but not limited to extreme heat, extreme cold, drought, high salt content, lack of nutrients, or any combination thereof.

[001478] In some embodiments, gene editing provides improved identification and validation of therapeutic agents. In some embodiments, gene editing provides improved development and production of animal models of human disease. In some embodiments, uses of gene editing leading to improvements comprises performing the work in a shorter amount of time and with more precision.

[001479] In some embodiments, a method of gene editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a defense system as described herein, thereby editing the nucleic acid sequence. In some embodiments, a method of cutting a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a defense system as described herein, thereby cutting the nucleic acid sequence.

[001480] Components of defense systems have been described in detail here (Tables 7-17 and 18).

[001481] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System la, said component comprising a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, or a ZorD polypeptide, thereby editing the nucleic acid sequence.

[001482] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System lb, said component comprising a ZorA polypeptide, a ZorB polypeptide, or a ZorD polypeptide, thereby editing the nucleic acid sequence.

[001483] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System Π, said component comprising a ThsA polypeptide or a ThsB polypeptide, thereby editing the nucleic acid sequence.

[001484] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System Ilia, said component comprising a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, or a DruE polypeptide, thereby editing the nucleic acid sequence.

[001485] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System Illb, said component comprising a DruM polypeptide, a DruF polypeptide, a DruG polypeptide, or a DruE polypeptide, thereby editing the nucleic acid sequence.

[001486] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System IIIc, said component comprising a DruH polypeptide, or a DruE polypeptide, thereby editing the nucleic acid sequence.

[001487] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System IV, said component comprising a HamA polypeptide or a HamB polypeptide, thereby editing the nucleic acid sequence.

[001488] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System V, said component comprising a SduA polypeptide, thereby editing the nucleic acid sequence.

[001489] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System VI, said component comprising a GajA polypeptide or a GajB polypeptide, thereby editing the nucleic acid sequence.

[001490] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System VII, said component comprising a PtuA polypeptide or a PtuB polypeptide, thereby editing the nucleic acid sequence.

[001491] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System VIII, said component comprising a LmuA polypeptide or a LmuB polypeptide, thereby editing the nucleic acid sequence.

[001492] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System IX, said component comprising a KwaA polypeptide or a KwaB polypeptide, thereby editing the nucleic acid sequence.

[001493] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System Xa, said component comprising a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, or a JetD polypeptide, thereby editing the nucleic acid sequence.

[001494] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System Xb, said component comprising a JetA ^u polypeptide, a JetB ¹¹ polypeptide, a JetC ¹¹ polypeptide, or a JetD ^u polypeptide, thereby editing the nucleic acid sequence.

[001495] In some embodiments, a method of editing a nucleic acid sequence comprises contacting the nucleic acid sequence with a component of a Defense System Xc, said component comprising a JetA ^m polypeptide, a JetB ¹¹¹ polypeptide, a JetC ^m polypeptide, or a JetD ¹¹ polypeptide, thereby editing the nucleic acid sequence.

[001496] In some embodiments, a method of editing a nucleic acid sequence comprises editing said sequence within a cell. One skilled in the art would appreciate that a method of editing a nucleic acid sequence within a cell comprises in some embodiments, expressing a component of a defense system in the cell. Genes encoding the components of defense systems described herein, have been described in detail (Tables 7-17 and 18).

[001497] In some embodiments, contacting the nucleic acid sequence with the defense system component can be performed by any in vitro conditions including for example, adding a defense system polypeptide to a naked nucleic acid sequence, adding a defense system polypeptide to a cell expressing the nucleic acid sequence, or introducing a defense system gene nucleotide sequence into a cell and expressing the gene sequence, such that the defense system component is in or comes into direct contact with the nucleic acid sequence to be edited.

[001498] The contacting may be effected with at least 1, at least 2, at least 3, or at least 4 defense system components.

[001499] In some embodiments, the contacting is effected with a ZorA, ZorB, ZorC, or ZorD polypeptide, or any combination thereof. In some embodiments, the contacting is effected with a ZorA, ZorB, or ZorE polypeptide, or any combination thereof. In some embodiments, the contacting is effected with a ThsA or a ThsB polypeptide, or any combination thereof. In some embodiments, the contacting is effected with a DruA, DruB, DruC, DruD, or DruE polypeptide, or any combination thereof. In some embodiments, the contacting is effected with a DruM, DruF, DruG, or DruE polypeptide, or any combination thereof. In some embodiments, the contacting is effected with a DruH or a DruE polypeptide, or any combination thereof. In some embodiments, the contacting is effected with a HamA or a HamB polypeptide, or any combination thereof. In some embodiments, the contacting is affected with a SduA polypeptide, or any combination thereof. In some embodiments, the contacting is effected with a GajA or a GajB polypeptide, or any combination thereof. In some embodiments, the contacting is effected with a PtuA or a PtuB polypeptide, or any combination thereof. In some embodiments, the contacting is affected with a Lmu or a LmuB polypeptide, or any combination thereof. In some embodiments, the contacting is effected with a KwaA or a KwaB polypeptide, or any combination thereof. In some embodiments, the contacting is effected with a JetA, JetB, JetC, or JetD polypeptide, or any combination thereof. In some embodiments, the contacting is effected with a JetA ¹¹ , JetB ¹¹ , JetC ¹¹ , or JetD ¹¹ polypeptide, or any combination thereof. In some embodiments, the contacting is effected with a JetA ¹¹¹ , JetB ^m , JetC ¹¹¹ , or JetD ^m polypeptide, or any combination thereof.

[001500] In some embodiments, the nucleic acid sequence being edited is comprised in a cell. In some embodiments, the nucleic acid sequence being edited is comprised in a cell that is not expressing an endogenous defense system or components thereof. In some embodiments, the nucleic acid sequence being edited is comprised in a cell that is not expressing an endogenous functional defense system or components thereof.

[001501] In some embodiments, the nucleic acid sequence being edited is not comprised in a cell expressing an endogenous defense system or components thereof. In some embodiments, the nucleic acid sequence being edited is not comprised in a cell expressing an endogenous functional defense system or components thereof.

[001502] In some embodiments, wherein the nucleic acid being edited is comprised in a cell expressing a component polypeptide of a defense system, the method further comprises introducing into the cell an agent capable of downregulating expression and/or activity of the expressed component polypeptide.

[001503] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System la within said cell, said component comprising a ZorA polypeptide, a ZorB polypeptide, a ZorC polypeptide, or a ZorD polypeptide, thereby editing the nucleic acid sequence.

[001504] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System lb within said cell, said component comprising a ZorA polypeptide, a ZorB polypeptide, or a ZorD polypeptide, thereby editing the nucleic acid sequence.

[001505] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System II within said cell, said component comprising a ThsA polypeptide or a ThsB polypeptide, thereby editing the nucleic acid sequence. [001506] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System Ilia within said cell, said component comprising a DruA polypeptide, a DruB polypeptide, a DruC polypeptide, a DruD polypeptide, or a DruE polypeptide, thereby editing the nucleic acid sequence.

[001507] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System Illb within said cell, said component comprising a DruM polypeptide, a DruF polypeptide, a DruG polypeptide, or a DruE polypeptide, thereby editing the nucleic acid sequence.

[001508] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System IIIc within said cell, said component comprising a DruH polypeptide, or a DruE polypeptide, thereby editing the nucleic acid sequence.

[001509] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System IV within said cell, said component comprising a HamA polypeptide or a HamB polypeptide, thereby editing the nucleic acid sequence.

[001510] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System V within said cell, said component comprising a SduA polypeptide, thereby editing the nucleic acid sequence.

[001511] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System VI within said cell, said component comprising a GajA polypeptide or a GajB polypeptide, thereby editing the nucleic acid sequence.

[001512] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System VII within said cell, said component comprising a PtuA polypeptide or a PtuB polypeptide, thereby editing the nucleic acid sequence.

[001513] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System VIII within said cell, said component comprising a LmuA polypeptide or a LmuB polypeptide, thereby editing the nucleic acid sequence.

[001514] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System IX within said cell, said component comprising a KwaA polypeptide or a KwaB polypeptide, thereby editing the nucleic acid sequence.

[001515] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System Xa within said cell, said component comprising a JetA polypeptide, a JetB polypeptide, a JetC polypeptide, or a JetD polypeptide, thereby editing the nucleic acid sequence.

[001516] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System Xb within said cell, said component comprising a JetA ¹¹ polypeptide, a JetB ¹¹ polypeptide, a JetC ¹¹ polypeptide, or a JetD ^u polypeptide, thereby editing the nucleic acid sequence.

[001517] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a component of a Defense System Xc within said cell, said component comprising a JetA ^m polypeptide, a JetB ^m polypeptide, a JetC ^m polypeptide, or a JetD ^u polypeptide, thereby editing the nucleic acid sequence.

[001518] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System la within said cell, said gene comprising a zorA gene, a zorB gene, a zorC gene, or a zorD gene, thereby editing the nucleic acid sequence.

[001519] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System lb within said cell, said gene comprising a zorA gene, a zorB gene, or a zorD gene, thereby editing the nucleic acid sequence.

[001520] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System II within said cell, said gene comprising a thsA gene or a thsB gene, thereby editing the nucleic acid sequence.

[001521] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System Ilia within said cell, said gene comprising a druA gene, a rafi gene, a ra gene, a draZ) polypeptide, or a dmE gene, thereby editing the nucleic acid sequence.

[001522] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System Illb within said cell, said gene comprising a druM gene, a druF gene, a druG gene, or a dmE gene, thereby editing the nucleic acid sequence.

[001523] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System IIIc within said cell, said gene comprising a druH gene, or a raE gene, thereby editing the nucleic acid sequence.

[001524] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System IV within said cell, said gene comprising a hamA gene or a hamB gene, thereby editing the nucleic acid sequence.

[001525] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System V within said cell, said gene comprising a sduA gene, thereby editing the nucleic acid sequence.

[001526] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System VI within said cell, said gene comprising a gajA gene or a gene, thereby editing the nucleic acid sequence.

[001527] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System VII within said cell, said gene comprising a ptuA gene or a /?ίαβ gene, thereby editing the nucleic acid sequence.

[001528] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System VIII within said cell, said gene comprising a ImuA gene or a ImuB gene, thereby editing the nucleic acid sequence.

[001529] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System IX within said cell, said gene comprising a kwaA gene or a fcwafi gene, thereby editing the nucleic acid sequence.

[001530] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System Xa within said cell, said gene comprising a jetA gene, a y ^' eifi gene, a y ^' eiC gene, or a y ^' eiZ) gene, thereby editing the nucleic acid sequence.

[001531] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System Xb within said cell, said gene comprising a jetA" gene, a y ^' eiS" gene, a y ^' eiC ¹¹ gene, or a jetD" gene, thereby editing the nucleic acid sequence.

[001532] In some embodiments, a method of editing a nucleic acid sequence within a cell comprises expressing a gene encoding a component of a Defense System Xc within said cell, said gene comprising a jetA ¹ " gene, a jetB" ¹ gene, a jetC" gene, or a y ^' eiZ) ¹¹ gene, thereby editing the nucleic acid sequence.

[001533] In some embodiments, the nucleic acid sequence being editing is not comprised in a cell expressing the defense system component. In some embodiments, the nucleic acid sequence being editing is not comprised in a cell expression a defense system polypeptide component comprising a ZorA, ZorB, ZorC, ZorD, ZorE, ThsA, ThsB, DruA, DruB, DruC, DruD, DruE, DruM, DruF, DruG, DruH, HamA, HamB, SduA, GajA, GajB, PtuA, PtuB, LmuA, LmuB, KwaA, KwaB, JetA, JetB, JetC, JetD, JetA", JetB", JetC", JetD", JetAi", JetB ¹ ", JetC ¹ ", or JetD ¹ " polypeptide.

[001534] In some embodiments, the nucleic acid sequence being editing is not comprised in a cell expressing a defense system gene encoding the polypeptide component, said gene comprising a zorA, zorB, zorC, zorD, zorE, thsA, thsB, druA, druB, druC, druD, druE, druM, druF, druG, druH, hamA, hamB, sduA, gajA, gajB, ptuA, ptuB, ImuA, ImuB, kwaA, kwaB, jetA, jetB, jetC, jetD, jetA ⁿ , jetB ¹¹ , jetC ⁿ , jetD ¹¹ , jetA ^m , jetB ^m , jetC ^m , or jetD ^m gene.

[001535] In some embodiments, the nucleic acid sequence being editing is not comprised in a cell expressing a functional defense system component. In some embodiments, the nucleic acid sequence being editing is not comprised in a cell expression a functional defense system polypeptide component comprising a ZorA, ZorB, ZorC, ZorD, ZorE, ThsA, ThsB, DruA, DruB, DruC, DruD, DruE, DruM, DruF, DruG, DruH, HamA, HamB, SduA, GajA, GajB, PtuA, PtuB, LmuA, LmuB, KwaA, KwaB, JetA, JetB, JetC, JetD, JetA", JetB ¹¹ , JetC ¹¹ , JetD ¹¹ , JetAi", JetB" ¹ , JetC" ¹ , or JetD ¹ "

[001536] In some embodiments, the nucleic acid sequence being editing is not comprised in a cell expressing a functional defense system gene encoding the polypeptide component, said gene comprising a zorA, zorB, zorC, zorD, zorE, thsA, thsB, druA, druB, druC, druD, druE, druM, druF, druG, druH, hamA, hamB, sduA, gajA, gajB, ptuA, ptuB, ImuA, ImuB, kwaA, kwaB, jetA, jetB, jetC, jetD, jetA ⁿ , jetB ⁿ , jetC ⁿ , jetD ¹¹ , jetA ¹¹¹ , jetB ¹¹¹ , jetC ^m , or jetD ^m gene.

[001537] In some embodiments, there is provided a method of cloning an expression product of interest, the method comprising:

[001538] (a) introducing into a nucleic acid construct a polynucleotide encoding the expression product of interest and a defense system component comprising a nucleic acid cleavage activity, or an unwinding activity; and [001539] (b) further introducing into said nucleic acid construct an additional at least one component of the defense system, thereby cloning the expression product of interest.

[001540] In some embodiments, step (b) comprises introducing into said nucleic acid construct any other component of the defense system. In some embodiments, step (b) comprises introducing into said nucleic acid construct all other component of the defense system. In some embodiments, step (b) comprises introducing into said nucleic acid construct component of the defense system to form a functional defense system. According to some embodiments the cell does not express an endogenous defense system. In some embodiments, the nucleic acid sequence being edited is not comprised in a cell expressing an endogenous functional version of the defense system.

[001541] In a non-limited example, in some embodiments, there is provided a method of cloning an expression product of interest, the method comprising:

[001542] (a) introducing into a nucleic acid construct a polynucleotide encoding the expression product of interest and a DruM; and

[001543] (b) introducing into said nucleic acid construct a Druantia (Type II) system component selected from the group consisting of: a DruF polypeptide; a DruG polypeptide; and a DruE polypeptide; or any combination thereof, thereby cloning the expression product of interest.

[001544] According to some embodiments the cell does not express an endogenous Druantia system. In some embodiments, the nucleic acid sequence being edited is not comprised in a cell expressing an endogenous functional Druantia (Type II) system.

[001545] As used herein the term "about" refers to ± 10 %

[001546] As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.

[001547] Throughout this application, various embodiments are disclosed that may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[001548] Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases "ranging/ranges between" a first indicate number and a second indicate number and "ranging/ranges from" a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.

[001549] As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

[001550] When reference is made to particular sequence listings, such reference is to be understood to also encompass sequences that substantially correspond to its complementary sequence as including minor sequence variations, resulting from, e.g., sequencing errors, cloning errors, or other alterations resulting in base substitution, base deletion or base addition, provided that the frequency of such variations is less than 1 in 50 nucleotides, alternatively, less than 1 in 100 nucleotides, alternatively, less than 1 in 200 nucleotides, alternatively, less than 1 in 500 nucleotides, alternatively, less than 1 in 1000 nucleotides, alternatively, less than 1 in 5,000 nucleotides, alternatively, less than 1 in 10,000 nucleotides.

EXAMPLES

[001551] Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments in a non-limiting fashion.

[001552] Generally, the nomenclature used herein, and the laboratory procedures utilized, include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); "Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley-Liss, N. Y. (1994), Third Edition; "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); "nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985); "Transcription and Translation" Hames, B. D., and Higgins S. J., eds. (1984); "Animal Cell Culture" Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.

Materials and Methods

[001553] Computational prediction of defense systems

[001554] A set of gene families known to participate in defense: A set of pfams and COGs that are known to participate in anti-phage defense was compiled based on the gene families present in Table S 10 from Makarova et al. (2011) Defense islands in bacterial and archaeal genomes and prediction of novel defense systems. J Bacteriol.193: 6039-56, with the addition of pfams/COGs present in the BREX (Goldfarb T, et al.(2015) BREX is a novel phage resistance system widespread in microbial genomes. EMBO J. EMBO Press; 34: 169-83) and DISARM (Ofir G, et al. (2017) DISARM is a widespread bacterial defense system with broad anti-phage activities. Nat Microbiology 2017 doi: 10.1038/s41564-017-0051-0). This set is found in Table 1.

[001555] Table 1: Known Defense-associated gene families

¹ Makarova et al. J Bacteriol. 2011 Nov; 193(21): 6039-6056 al. (2011) Cas2

Domain of unknown function

(DUF2357) (often fused to

Makarova et recB-like nuclease domain GI:

pfam09823 al. (2011) new_system 218891088) 69.1% 0.52

Makarova et Putative addiction module

pfam09720 _l al. (2011 ) TA component 81.8% 0.44

Makarova et CRISPR-associated protein

pfam09709 _l al. (2011) CRISPR (Cas_Csdl) 97.4% 0.27

Makarova et CRISPR-associated protein

pfam09707 _l al. (2011) CRISPR (Cas_Cas2CT1978) 98.3% 0.16

Makarova et CRISPR-associated protein

pfam09706 al. (2011) CRISPR (Cas_CXXC_CXXC) 99.4% 0.33

Makarova et CRISPR-associated protein

pfam09704 _l al. (2011) CRISPR (Cas_Cas5) 99.2% 0.25

Makarova et CRISPR-associated protein

pfam09703 al. (2011 ) CRISPR (Cas_Csa4) 100.0% 0.58

Makarova et CRISPR-associated protein pfam09702 al. (2011) CRISPR (Cas_Csa5) 71.1% 0.72

Makarova et CRISPR-associated protein pfam09701 _l al. (2011) CRISPR (Cas_Cmr5) 99.5% 0.69

Makarova et CRISPR-associated protein pfam09700 _l al. (2011) CRISPR (Cas_Cmr3) 98.2% 0.65

Makarova et CRISPR-associated protein pfam09670 _l al. (2011) CRISPR (Cas_Cas02710) 89.8% 0.76

Type II restriction

Makarova et endonuclease

pfam09665 al. (2011) RM (RE_Alw26IDE) 97.4% 0.18

Makarova et CRISPR-associated protein pfam09659 _l al. (2011) CRISPR (Cas_Csm6) 78.8% 0.13

Makarova et CRISPR-associated protein pfam < 20 pfam < 20 pfam09658 _l al. (2011) CRISPR (Cas_Csx9) members members

Makarova et CRISPR-associated protein pfam09657 al. (2011) CRISPR Csx8 (Cas_Csx8) 99.2% 0.33

Makarova et Putative CRISPR-associated pfam09652 _l al. (2011) CRISPR protein (Cas_VVA1548) 94.5% 0.86

Makarova et CRISPR-associated protein pfam09651 _l al. (2011) CRISPR (Cas_APE2256) 93.0% 0.76

Makarova et CRISPR-associated protein pfam09623 al. (2011) CRISPR NE0113 (Cas_NE0113) 89.2% 0.79

Makarova et CRISPR-associated protein pfam09620 _l al. (2011) CRISPR (Cas_csx3) 91.4% 0.82

Makarova et CRISPR-associated protein pfam09618 _l al. (2011) CRISPR (Cas_Csy4) 98.3% 0.21

Makarova et CRISPR-associated protein pfam09617 ! al. (2011) CRISPR GSU0053 (Cas_GSU0053) 95.9% 0.47

Makarova et CRISPR-associated protein pfam09615 ! al. (2011) CRISPR (Cas_Csy3) 99.7% 0.21

Makarova et CRISPR-associated protein pfam09614 ! al. (2011) CRISPR (Cas_Csy2) 99.8% 0.19

Makarova et CRISPR-associated protein pfam09611 ! al. (2011) CRISPR (Cas_Csyl) 98.6% 0.17

CRISPR-associated protein,

Makarova et GSU0054 family

pfam09609 al. (2011) CRISPR (Cas_GSU0054) 95.0% 0.47

Makarova et

pfam09573 ₁ al. (2011) RM Taql restriction endonuclease 85.5% 0.51

Makarova et

pfam09572 _l al. (2011) RM XamI restriction endonuclease 92.3% 0.36

Makarova et

pfam09571 _l al. (2011) RM Xcyl restriction endonuclease 91.0% 0.51 pfam09569 1 Makarova et RM Seal restriction endonuclease 97.7% 0.33 al. (2011)

Makarova et

pfam09568 al. (2011) RM Mjal restriction endonuclease 85.0% 0.34

Makarova et NgoFVII restriction

pfam09565 _l al. (2011) RM endonuclease 95.1% 0.42

Makarova et

pfam09563 ! al. (2011) RM LlaJI restriction endonuclease 94.0% 0.45

Makarova et

pfam09559 ! al. (2011) CRISPR Cas6 Crispr 80.0% 0.40

Makarova et Haelll restriction

pfam09556 _l al. (2011) RM endonuclease 97.1% 0.34

Makarova et BpulOI restriction

pfam09549 ! al. (2011) RM endonuclease 96.1% 0.50

Makarova et CRISPR-associated protein pfam < 20 pfam < 20 pfam09530 ! al. (2011) CRISPR (cas_TM1812) members members

Makarova et

pfam09520 ! al. (2011) RM Mjall restriction endonuclease 89.7% 0.41

Makarova et Eco29kI restriction

pfam09517 ! al. (2011) RM endonuclease 95.5% 0.32

Makarova et CfrBI restriction

pfam09516 ! al. (2011) RM endonuclease 95.5% 0.16

Makarova et

pfam09491 ! al. (2011) RM Alwl restriction endonuclease 90.5% 0.28

Makarova et CRISPR-associated protein pfam09485 ! al. (2011) CRISPR Cse2 (CRISPR_cse2) 99.6% 0.16

Makarova et CRISPR-associated protein pfam09484 ! al. (2011) CRISPR TM1802 (cas_TM1802) 93.0% 0.51

Makarova et CRISPR-associated protein pfam09481 ! al. (2011) CRISPR Csel (CRISPR_csel) 98.4% 0.17

Makarova et CRISPR-associated (Cas)

pfam09455 ! al. (2011) CRISPR DxTHG family 91.5% 0.71

Contains a number of Zn- binding domains; Domain of

unknown function

Makarova et (DUF1998); DISARM

pfam09369 al. (2011) new RM system: DrmB 66.2% 0.26

Makarova et

pfam09344 ! al. (2011) CRISPR CT1975-like protein 99.3% 0.17

Makarova et Restriction endonuclease

pfam09233 ! al. (2011) RM EcoRV 91.6% 0.39

Makarova et Restriction endonuclease

pfam09225 ! al. (2011) RM PvuII 99.5% 0.16

Makarova et Restriction endonuclease

pfam0921 ! al. (2011) RM EcoRII, N-terminal 98.0% 0.25

Makarova et Restriction endonuclease

pfam09208 ! al. (2011) RM Mspl 96.7% 0.69

Makarova et Restriction endonuclease

pfam09195 ! al. (2011) RM BgUI 69.2% 0.41

Makarova et Restriction endonuclease

pfam09194 ! al. (2011) RM Bsobl 93.8% 0.50

Makarova et

pfam09019 ! al. (2011) RM EcoRII C terminal 97.7% 0.17

COG1517 contains RecB

family nuclease and wHTH;

Makarova et Domain of unknown function pfam09002 al. (2011) new_system (DUF1887) 46.1% 0.50

Makarova et HicA; Domain of unknown pfam08972 ! al. (2011) TA function (DUF1902) 73.2% 0.47

Makarova et Same as DUF3387; which is al. (2011), fused to RM (GI:

Goldfarb et "new system", 209527353); Putative inner pfam08849 1 al. (2015) BREX membrane protein 95.2% 0.39 (DUF1819); pdb: 3BHW;

BrxA - Unknown function

Same as COG2253, AbiG;

Domain of unknown function

(DUF1814); Nucleotidyl

Makarova et transferase AbiEii toxin, Type pfam08843 al. (2011) new Abi IV TA system 70.1% 0.20

Makarova et

pfam08808 al. (2011) TA RES domain 66.6% 0.14

Makarova et

pfam08798 _l al. (2011) CRISPR CRISPR associated protein 98.6% 0.18

Makarova et HEPN;Nucleotidyltransferase pfam08780 ! al. (2011) TA substrate binding protein like 91.2% 0.32

Makarova et

al. (2011), Domain of unknown function

Goldfarb et new_RM, (DUF1788); BrxB - Unknown pfam08747 al. (2015) BREX function 97.9% 0.45

PglZ domain, Alkaline

Makarova et phosphatase clan. BREX

pfam08665 al. (2011) "new system" system: PglZ 69.4% 0.45

Makarova et

pfam08463 ! al. (2011) RM EcoEI R protein C-terminal 97.3% 0.28 toxin component, HicA

family ; YcfA-like protein;

Makarova et HicA toxin of bacterial toxin- pfam07927 al. (2011) TA antitoxin 89.7% 0.24

Makarova et

pfam07805 _l al. (2011) TA HipA-like N-terminal domain 57.3% 0.24

Makarova et

pfam07804 ! al. (2011) TA HipA-like C-terminal domain 56.2% 0.24

Makarova et

pfam07751 ! al. (2011) Abi Abi-like protein 66.3% 0.17

Makarova et Eco57I restriction

pfam07669 ! al. (2011) RM endonuclease 74.2% 0.29

Protein of unknown function

Makarova et (DUF1419) linked to

pfam07215 al. (2011) new_RM methylase COG0827 88.1% 0.53

Makarova et BsuBI/PstI restriction

pfam06616 ! al. (2011) RM endonuclease C-terminus 81.7% 0.34

Makarova et

pfam06414 ! al. (2011) TA Zeta toxin 35.1% 0.27

Toxin component, RelE

Makarova et family Protein of unknown

pfam06296 al. (2011) TA function (DUF1044) 90.5% 0.13

Same as COG2856; Domain

Makarova et of unknown function

pfam06114 al. (2011) TA (DUF955) 48.5% 0.16

Makarova et Archaeal PaREPl/PaREP8

pfam05942 ! al. (2011) TA family 70.7% 0.34

Makarova et

pfam05534 ! al. (2011) TA HicB family 76.4% 0.21

Plasmid stabilisation system

Makarova et protein;ParE toxin of type II pfam05016 al. (2011) TA toxin-antitoxin system, parDE 77.4% 0.18

Makarova et Type III restriction enzyme, pfam04851 _l al. (2011) RM res subunit 55.5% 0.16

Makarova et DpnII restriction

pfam04556 ! al. (2011) RM endonuclease 93.8% 0.19

Makarova et Restriction endonuclease

pfam04555 ! al. (2011) RM Xhol 90.0% 0.39

Makarova et

pfam04149 ! al. (2011) TA DUF397, see our TA paper 51.5% 0.12 SpoVT / AbrB like domain;

Makarova et Antidote-toxin recognition

pfam04014 1 al. (2011) TA MazE, bacterial antitoxin 77.3% 0.16

Makarova et

pfam03787 1 al. (2011) CRISPR RAMP superfamily 98.4% 0.44

Makarova et HicB family; Uncharacterized pfam < 20 pfam < 20 pfam03681 1 al. (2011) TA protein family (UPF0150) members members

Makarova et

pfam03230 1 al. (2011) RM Antirestriction protein 57.8% 0.14

Makarova et Restriction endonuclease

pfam02963 1 al. (2011) RM EcoRI 61.6% 0.40

Makarova et Restriction endonuclease

pfam02923 1 al. (2011) RM BamHI 97.4% 0.47

Makarova et Antitoxin Phd_YefM, type II pfam02604 1 al. (2011) TA toxin-antitoxin system 90.5% 0.13

Makarova et Domain of unknown function pfam01930 1 al. (2011) CRISPR DUF83 90.5% 0.37

Makarova et Nucleotidyltransferase

pfam01909 ! al. (2011) TA domain, COG 1669 47.6% 0.26

Makarova et CRISPR associated protein

pfam01867 1 al. (2011) CRISPR Casl 97.4% 0.26

Makarova et

pfam01850 1 al. (2011) TA PIN domain 76.0% 0.11

Makarova et

pfam01845 1 al. (2011) TA CcdB protein 89.4% 0.15

Type I restriction

Makarova et modification DNA specificity pfam01420 1 al. (2011) RM domain 91.8% 0.20

Ofir et al. DISARM- Putative PD-(D/E)XK family pfaml4390 1 (2017) associated member, (DUF4420) 98.9% 0.42

PglX - Adenine-specific

methylase; DrmMI - Superfamily SSF5335 (S-

Goldfarb et adenosyl-L-mefhionine- al. (2015) ² , dependent

Ofir et al. BREX, methyltransferases) ;

pfaml3659 1 (2017) ³ DISARM Mefhyltransferase domain 63.3% 0.21

Histidine kinase-, DNA

Ofir et al. DISARM- gyrase B-, and HSP90-like

pfaml3589 1 (2017) associated ATPase 33.5% 0.21

Ofir et al. DISARM- UvrD-like helicase C-terminal pfaml3361 1 (2017) associated domain 50.2% 0.08

Protein of unknown function

(DUF4007); BrxP -

Goldfarb et Phosphoadenosine

pfaml3182 1 al. (2015) BREX phosphosulfate reductase 94.9% 0.31

BrxC/PglY, BrxD - ATP

Goldfarb et binding; P-loop Domain of

pfaml0923 1 al. (2015) BREX unknown function (DUF2791) 93.1% 0.28

BrxC/PglY - ATP binding;

Goldfarb et Protein of unknown function pfam04465 1 al. (2015) BREX (DUF499) 93.1% 0.50

Ofir et al. DISARM- DNA mismatch endonuclease pfam03852 1 (2017) associated Vsr 93.0% 0.18

Goldfarb et DNA methylase; PglXI - pfam01555 1 al. (2015) BREX Adenine-specific methylase 64.4% 0.20

² Goldfarb T, et al. (2015) BREX is a novel phage resistance system widespread in microbial genomes. EMBO J. EM BO Press; 34: 169-83

³ Submitted Phosphoadenosine

phosphosulfate reductase

family; BrxP -

Goldfarb et Phosphoadenosine

pfam01507 al. (2015) BREX phosphosulfate reductase 62.9% 0.07

Ofir et al. DISARM- UvrD/REP helicase N- pfam00580 _l (2017) associated terminal domain 47.4% 0.09

Ofir et al. DrmA; Helicase conserved C- pfatn00271 ! (2017) DISARM terminal domain 39.0% 0.10

Ofir et al. DrmD ; SNF2 family N- pfam00176 ! (2017) DISARM terminal domain 46.8% 0.23

Ofir et al. DrmMII; C-5 cytosine- pfam00145 ! (2017) DISARM specific DNA mefhylase 72.5% 0.19

ATPase family associated

i Ofir et al. DISARM- with various cellular activities pfam00004 (2017) associated (AAA) 30.1% 0.07

Makarova et Uncharacterized conserved

COG5654 ! al. (2011) TA protein

Makarova et Uncharacterized conserved

COG5642 ! al. (2011) TA protein

Makarova et Uncharacterized protein

COG4861 ! al. (2011) Abi conserved in bacteria

Makarova et

COG5611 al. (2011) TA PIN domain

Makarova et Uncharacterized protein

COG4849 al. (2011) Abi conserved in bacteria

Makarova et Uncharacterized conserved

COG5606 al. (2011) TA small protein

Abortive infection

Makarova et bacteriophage resistance

COG4823 al. (2011) Abi protein

Predicted nucleic-acid-

Makarova et binding protein, contains PIN

COG5573 al. (2011) TA domain

Predicted nuclease of

i Makarova et restriction endonuclease-like

COG4804 al. (2011) new_system fold

Makarova et CRISPR system related

COG5551 ! al. (2011) CRISPR protein, RAMP superfamily

Makarova et Uncharacterized conserved

COG4748 al. (2011) RM protein

Superfamily II helicase or

Makarova et inactivated derivatives, fused

COG5519 al. (2011) new_system to primase

Makarova et Uncharacterized protein

COG4737 al. (2011) TA conserved in bacteria

Predicted transcription

Makarova et regulator containing HTH

COG5499 al. (2011) TA domain

Makarova et Predicted DNA-binding

COG4 10 al. (2011) TA protein with an HTH domain

RecB-family nuclease domain

Makarova et (see TIGR01784), linked to

COG5464 al. (2011) new_RM COG 1479

Makarova et Wobble nucleotide-excising

COG4694 al. (2011) Abi tRNase

Makarova et Transcription regulator of the

COG5450 al. (2011) TA Arc/MetJ class

Makarova et

COG4691 al. (2011) TA Plasmid stability protein

Makarova et Predicted transcriptional

COG5340 al. (2011) Abi regulator Makarova et Uncharacterized protein

COG4683 _l al. (2011) TA conserved in bacteria

Makarova et Uncharacterized protein

COG5304 _l al. (2011) TA conserved in bacteria

Makarova et Uncharacterized protein

COG4680 _l al. (2011) TA conserved in bacteria

Post-segregation antitoxin (ccd killing mechanism

Makarova et protein) encoded by the F

COG5302 al. (2011) TA plasmid

Makarova et

COG4679 _l al. (2011) TA Phage-related protein

Makarova et Uncharacterized protein

COG4951 _l al. (2011) RM conserved in bacteria

Makarova et DNA methylase, see

COG4646 _l al. (2011) new_system COG0553

Makarova et Predicted

COG4914 _l al. (2011) Abi nucleotidyltransferase

Makarova et Endonuclease, Uma2 family

COG4636 _l al. (2011) TA (restriction endonuclease fold)

Makarova et

COG4889 _l al. (2011) RM Predicted helicase

PIN family nuclease, potential

Makarova et toxin-antitoxin system

COG4634 al. (2011) TA component

Makarova et Virulence-associated protein

COG4456 _l al. (2011) TA or related protein

Makarova et Uncharacterized protein

COG4453 _l al. (2011) TA conserved in bacteria

Makarova et Uncharacterized protein

COG4423 al. (2011) TA conserved in bacteria

PIN domain nuclease, a

Makarova et component of toxin-antitoxin

COG4374 al. (2011) TA system (PIN domain)

Makarova et CRISPR-associated protein,

COG4343 , al. (2011) CRISPR RecB family exonuclease

Makarova et McrBC 5-methylcytosine

COG4268 _l al. (2011) RM restriction system component

Makarova et

COG4227 _l al. (2011) new_system Antirestriction protein

Makarova et Predicted nuclease of the

COG4226 _l al. (2011) TA RNAse H fold, HicB family

Makarova et Mrr restriction endonuclease

COG4127 _l al. (2011) new RM domain

Antitoxin (DNA binding

Makarova et domain) of toxin-antitoxin

COG4118 al. (2011) TA stability system

Makarova et Uncharacterized protein

COG4115 _l al. (2011) TA conserved in bacteria

Makarova et Predicted nucleic acid-binding

COG4113 _l al. (2011) TA protein, contains PIN domain

Type I site-specific restriction-modification

Makarova et system, R (restriction) subunit

COG4096 al. (2011) RM or related helicase

Makarova et Uncharacterized protein

COG4006 _l al. (2011) CRISPR conserved in archaea

Makarova et Predicted ATP-binding

COG3950 _l al. (2011) new_system protein involved in virulence

Makarova et

COG3943 _l al. (2011) new TA Virulence protein

Makarova et Predicted transcriptional

COG3905 _l al. (2011) TA regulator Predicted HKD family

Makarova et nuclease; type III restriction

COG3886 al. (2011) RM protein res subunit

Makarova et Uncharacterized conserved

COG3832 ! al. (2011) TA protein

PIN domain nuclease, a

Makarova et component of toxin-antitoxin

COG3744 al. (2011) TA system (PIN domain)

Makarova et Uncharacterized protein

COG3742 _l al. (2011) TA conserved in bacteria

Makarova et Uncharacterized protein

COG3692 _l al. (2011) TA conserved in bacteria

Makarova et Plasmid stabilization system

COG3668 ! al. (2011) TA protein

Makarova et Uncharacterized protein

COG3657 ₁ al. (2011) TA conserved in bacteria

Makarova et Prophage maintenance system

COG3654 _l al. (2011) TA killer protein

Makarova et CRISPR system related

COG3649 _l al. (2011) CRISPR protein

Makarova et Predicted transcriptional

COG3636 ! al. (2011) TA regulator

Predicted transcriptional regulators containing the

Makarova et CopG/Arc/MeLl DNA-binding

COG3609 al. (2011) TA domain

Makarova et RecA-family ATPase , fused

COG3598 _l al. (2011) new_system to TOPRIM

Makarova et

COG3587 _l al. (2011) RM Restriction endonuclease

Some protein fused to domains similar to N terminal regions found in type I restriction enzyme R (HSDR)

Makarova et proteins and RloF (gi:

COG3586 al. (2011) new_system 93006430)

Toxin module HipA, protein

Makarova et kinase of phosphatidylinositol

COG3550 al. (2011) TA 3/4-kinase superfamily

Makarova et Plasmid maintenance system

COG3549 _l al. (2011 ) TA killer protein

Makarova et Uncharacterized protein

COG3514 ! al. (2011) TA conserved in bacteria

Predicted CRISPR-associated nuclease, contains

Makarova et McrA/HNH-nuclease and

COG3513 al. (2011) CRISPR RuvC-like nuclease domain

Makarova et CRISPR-associated protein,

COG3512 al. (2011) CRISPR Cas2 homolog

Makarova et Uncharacterized; often fused

COG3472 ₁ al. (2011) new_system to COG 1479

Makarova et Predicted restriction

COG3440 _l al. (2011) RM endonuclease

Makarova et Uncharacterized conserved

COG3410 _l al. (2011) Abi protein

Makarova et Adenine-specific DNA

COG3392 ! al. (2011) RM methylase

Predicted nuclease of restriction endonuclease-like

Makarova et fold; associated with

COG3372 al. (2011) new_RM COG1061 (RM)

Makarova et Retron-type reverse

COG3344 al. (2011) Abi transcriptase Makarova et CRISPR system related

COG3337 _l al. (2011) CRISPR protein

Makarova et

COG3311 _l al. (2011) TA HTH MerR SF

Makarova et Predicted restriction

COG3183 _l al. (2011) RM endonuclease

Makarova et

COG3177 al. (2011 ) TA Fic family protein

Makarova et Plasmid maintenance system

COG3093 _l al. (2011) TA antidote protein

Makarova et DNA-damage-inducible

COG3077 _l al. (2011) TA protein J

Makarova et Uncharacterized protein

COG3041 al. (2011) TA conserved in bacteria

Makarova et Predicted transcriptional

COG2944 _l al. (2011) TA regulator

Makarova et Uncharacterized protein

COG2929 ₁ al. (2011) TA conserved in bacteria

Makarova et

COG2886 ! al. (2011) TA Uncharacterized small protein

Makarova et Uncharacterized protein

COG2880 _l al. (2011) TA conserved in archaea

Predicted transcriptional regulator containing an HTH domain and diverged ATP-

Makarova et binding domain (Schlafen-

COG2865 al. (2011) new_system like)

Makarova et

COG2856 _l al. (2011) TA Predicted Zn peptidase

Makarova et Very-short-patch-repair

COG2852 al. (2011) RM endonuclease

Makarova et Predicted type IV restriction

COG2810 _l al. (2011) RM endonuclease

Makarova et Predicted archaeal

COG2521 _l al. (2011) new_RM methyltransferase

Makarova et Uncharacterized conserved

COG2445 al. (2011 ) TA protein

Makarova et Uncharacterized conserved

COG2442 _l al. (2011) TA protein

Makarova et Predicted nucleic acid-binding

COG2405 _l al. (2011) TA protein, contains PIN domain

Makarova et Predicted nucleic acid-binding

COG2402 al. (2011) TA protein, contains PIN domain

Makarova et Uncharacterized conserved

COG2361 _l al. (2011) TA protein

Toxin-antitoxin addiction module toxin component l Makarova et

COG2337 al. (2011) TA MazF (an endoRNAse)

Toxin-antitoxin addiction i Makarova et module antitoxin component

COG2336 al. (2011) TA MazE

Makarova et Predicted HD superfamily

COG2254 _l al. (2011) CRISPR hydrolase, possibly a nuclease

Makarova et Uncharacterized conserved

COG2253 _l al. (2011) Abi protein

Makarova et

COG2250 ₁ al. (2011) TA HEPN domain

Makarova et Adenine specific DNA

COG2189 ! al. (2011) RM methylase Mod

Makarova et Protein involved in cell

COG2184 ! al. (2011) TA division

Makarova et Antitoxin (DNA-binding

COG2161 al. (2011) TA domain) of toxin-antitoxin stability system

Cytotoxic translational

Makarova et repressor of toxin-antitoxin

COG2026 al. (2011) TA stability system

Makarova et Transcriptional regulator

COG2002 ₁ al. (2011) TA AbrB

Uncharacterized conserved protein related to C-terminal

Makarova et domain of eukaryotic

COG 1895 al. (2011) TA chaperone, SACSIN

Makarova et CRISPR system related

COG1857 al. (2011) CRISPR protein

Makarova et Predicted nucleic acid-binding

COG 1848 al. (2011) TA protein, contains PIN domain

Makarova et Endonuclease, HJR/Mrr/RecB

COG 1787 al. (2011) RM family

Makarova et CRISPR system related

COG 1769 ₁ al. (2011) CRISPR protein, RAMP superfamily

Makarova et Predicted antitoxin, copG

COG 1753 _l al. (2011) TA family

Makarova et Adenine-specific DNA al. (2011), methylase containing a Zn- Goldfarb et ribbon; PglXI - Adenine-

COG 1743 al. (2015) RM, BREX specific methylase

Predicted RNA binding

Makarova et protein (dsRBD-like fold),

COG 1724 al. (2011) TA HicA family

Makarova et

COG1715 ₁ al. (2011) RM Restriction endonuclease

Makarova et Predicted

COG 1708 _l al. (2011) TA nucleotidyltransferase

Makarova et Contains PD_(D/E)xK

COG 1700 _l al. (2011) new_RM nuclease odmain, DUF524

Makarova et CRISPR system related

COG1688 al. (2011) CRISPR protein, RAMP superfamily

Makarova et

COG 1669 al. (2011) TA Nucleotidyltransferase

Makarova et CRISPR system related

COG 1604 al. (2011) CRISPR protein, RAMP superfamily

Makarova et Predicted nuclease of the

COG1598 al. (2011) TA RNAse H fold, HicB family

Makarova et CRISPR system related

COG1583 al. (2011) CRISPR protein, RAMP superfamily

Makarova et Predicted nucleic acid-binding

COG1569 al. (2011) TA protein, contains PIN domain

Makarova et CRISPR system related

COG1567 ! al. (2011) CRISPR protein. RAMP superfamily

Makarova et CRISPR-associated protein

COG1518 al. (2011) CRISPR Casl

Makarova et CRISPR system related

COG1517 al. (2011) CRISPR protein

Makarova et Predicted nucleic acid-binding

COG1487 al. (2011) TA protein, contains PIN domain

RloF-like, possible RM

Makarova et component (contains HNH-

COG 1479 al. (2011) new_system type nuclease domain)

Makarova et Predicted transcriptional

COG 1476 al. (2011) TA regulator, xre family

Stage 0 sporulation protein J

Makarova et (antagonist of Soj); contains

COG1475 al. (2011) new_system ParB-like nuclease domain

COG1468 1 Makarova et CRISPR CRISPR-associated protein al. (2011) Cas4 (RecB family

exonuclease)

Argonaute homolog,

Makarova et implicated in RNA

COG 1431 al. (2011) pAgo metabolism

Makarova et CRISPR system related

COG1421 ₁ al. (2011) CRISPR protein

Makarova et Restriction endonuclease,

COG1403 ! al. (2011) RM McrA/HNH family

Makarova et GTPase subunit of restriction

COG1401 _l al. (2011) RM endonuclease

Makarova et Predicted transcriptional

COG1396 al. (2011) TA regulator, xre family

Makarova et CRISPR system related

COG 1367 ₁ al. (2011) CRISPR protein, RAMP superfamily

Makarova et Predicted CRISPR-associated

COG1353 _l al. (2011) CRISPR polymerase

Makarova et CRISPR-associated protein

COG 1343 _l al. (2011) CRISPR Cas2

Makarova et CRISPR system related

COG1337 al. (2011) CRISPR protein, RAMP superfamily

Makarova et CRISPR system related

COG1336 al. (2011) CRISPR protein, RAMP superfamily

Makarova et CRISPR system related

COG1332 ! al. (2011) CRISPR protein, RAMP superfamily

Makarova et CRISPR-associated helicase

COG 1203 _l al. (2011) CRISPR Cas3

Makarova et Superfamily I DNA/RNA

COG1112 _l al. (2011) new_system helicase

Makarova et

COG 1106 ! al. (2011) Abi Predicted ATPase

Makarova et DNA or RNA helicase of

COG 1061 ! al. (2011) RM superfamily II

Makarova et

al. (2011), Type II restriction enzyme, Goldfarb et methylase subunit; PglX -

COG 1002 al. (2015) RM, BREX Adenine-specific methylase

Transcriptional regulator, CopG/Arc/MeU family

Makarova et (DNA-binding and a metal-

COG0864 al. (2011 ) TA binding domains)

Makarova et

al. (2011), DNA modification methylase; Goldfarb et PglXI - Adenine-specific

COG0863 al. (2015) RM, BREX methylase

Makarova et Adenine-specific DNA

COG0827 ! al. (2011) RM methylase

Makarova et Restriction endonuclease S

COG0732 ! al. (2011) RM subunit

Transcriptional regulator i Makarova et containing HTH domain,

COG0640 al. (2011) TA ArsR family

Type I site-specific restriction-modification

Makarova et system, R (restriction) subunit

COG0610 al. (2011) RM or related helicase

Makarova et

COG0338 al. (2011) RM Site-specific DNA methylase

Type I restriction-

Makarova et modification system al. (2011), methyltransferase subunit; Goldfarb et PglX - Adenine-specific

COG0286 1 al. (2015) RM, BREX methylase Makarova et

al. (2011),

Ofir et al. RM, Dcm, Site-specific DNA-

COG0270 (2017) DISARM cytosine methylase; DrmMII

Goldfarb et

COG4930 _l al. (2015) BREX BrxL - Lon-like protease

Ofir et al. DISARM- DNA-binding transcriptional

COG3655 (2017) associated regulator, XRE family

Ofir et al. DISARM- Serine protease, subtilisin

COG 1404 _l (2017) associated family

ATP-dependent helicase

YprA, contains C-terminal

Ofir et al. DISARM- metal-binding DUF1998

COG 1205 (2017) associated domain

Goldfarb et

COG1201 ! al. (2015) BREX BrxHI - Lhr-like helicase

Goldfarb et BrxHII - DNA/RNA

al. (2015), helicases; DrmD; HepA,

Ofir et al. BREX, Superfamily II DNA or RNA

COG0553 (2017) DISARM helicase, SNF2 family

Goldfarb et PglW - Serine/threonine

COG0515 ! al. (2015) BREX protein kinase

Ofir et al. DISARM- UvrD, Superfamily I DNA or

COG0210 ! (2017) associated RNA helicase

Goldfarb et BrxP - Phosphoadenosine

COG0175 ! al. (2015) BREX phosphosulfate reductase

Ofir et al.

pfaml3091 2 (2017) DISARM DrmC; PLD-like domain 44.2% 0.14 known

system

found in CRISPR associated protein pfam01881 2 round 1 CRISPR Cas6 92.3% 0.44 known

system

found in CRISPR-associated negative pfam01905 2 round 1 CRISPR auto-regulator DevR/Csa2 99.3% 0.41

Protein of unknown function

known DUF104. Probably a new

system antitoxin; the associated gene found in is a PIN-domain protein,

pfam01954 2 round 1 TA known toxin 89.8% 0.59 known

system

found in Uncharacterized ACR,

pfam02697 2 round 1 TA COG1753 89.6% 0.42 known

system

found in Restriction endonuclease

pfam02980 2 round 1 RM Fokl, catalytic domain 74.4% 0.63 known

system

found in Restriction endonuclease

pfam02981 2 round 1 RM Fokl, recognition domain 75.0% 0.64 known

system

found in

round 1,

putative

system

found in Protein of unknown function pfam03235 2 round 1 RM DUF262 78.8% 0.38 known

pfatn03683 2 system TA predicted 88.3% 0.54 found in

round 1

known

system Bacterial antitoxin of ParD

found in toxin-antitoxin type II system pfam03693 2 round 1 TA and RHH 88.1% 0.19 known

system

found in Protein of unknown function pfam03750 2 round 1 CRISPR (DUF310) 99.9% 0.26 known

system

found in Protein of unknown function pfam04255 2 round 1 TA (DUF433) 69.0% 0.36 known

system

found in Ribonuclease toxin, BrnT, of pfam04365 2 round 1 TA type II toxin-antitoxin system 91.1% 0.33 known

system

found in PD-(D/E)XK nuclease

pfam04411 2 round 1 RM superfamily 84.0% 0.57 known

system HigAB; RelE-like toxin of

found in type II toxin-antitoxin system pfam05015 2 round 1 TA HigB 96.9% 0.26 known

system

found in CRISPR-associated protein pfam05107 2 round 1 CRISPR Cas7 98.5% 0.41 known

system

found in

pfam05168 2 round 1 TA HEPN domain 84.9% 0.36 known

system

found in

pfam05315 2 round 1 RM ICEA Protein 98.7% 0.17 known

system

found in Archaeal protein of unknown pfam06023 2 round 1 CRISPR function (DUF911) 93.9% 0.71 known

system CbeA_antitoxin, type IV,

found in cytoskeleton bundling- pfam06154 2 round 1 TA enhancing factor A 97.2% 0.11 known

system

found in Tsp45I type II restriction

pfam06300 2 round 1 RM enzyme 97.1% 0.33 known

system

found in RM, System

round 1, around

putative anchors

system pfam06634,

found in COG1483, Protein of unknown function pfam06634 2 round 1 pfaml2635 (DUF1156) 95.5% 0.66 known

system

found in CbtA_toxin of type IV toxin- pfam06755 2 round 1 TA antitoxin system 96.6% 0.12 pfam07362 2 known TA Post-segregation antitoxin 94.5% 0.15 system CcdA

found in

round 1

known

system

found in

round 1,

putative

system

found in Protein of unknown function pfam07510 2 round 1 RM (DUF1524) 72.8% 0.29 known

system

found in Rv0623-like transcription

pfam07704 2 round 1 TA factor 99.3% 0.05 known

system

found in CfrlOI/Bse634I restriction

pfam07832 2 round 1 RM endonuclease 100.0% 0.57 known

system

found in Domain of unknown function pfam08870 2 round 1 DND (DUF1832) 96.1% 0.52 known

system

found in

pfam08998 2 round 1 TA Bacterial epsilon antitoxin 92.0% 0.22 known

system

found in

pfam09015 2 round 1 RM NgoMIV restriction enzyme 98.1% 0.34 known

system

found in

pfam09126 2 round 1 RM Restriction endonuclease Nael 95.9% 0.50 known

system

found in Restriction endonuclease

pfam09226 2 round 1 RM Hindi 97.1% 0.47 known

system

found in Restriction endonuclease

pfam09254 2 round 1 RM Fokl, C terminal 78.3% 0.73 known

system

found in

pfam09386 2 round 1 TA Antitoxin ParD 92.1% 0.58 known

system

found in ApaLI-like restriction

pfam09499 2 round 1 RM endonuclease 99.1% 0.10 known

system

found in Hindlll restriction

pfam09518 2 round 1 RM endonuclease 84.8% 0.46 known

system

found in HindVP restriction

pfam09519 2 round 1 RM endonuclease 93.8% 0.56 known

system

found in NgoPII restriction

pfam09521 2 round 1 RM endonuclease 96.4% 0.18 known

system

found in

pfam09545 2 round 1 RM AccI restriction endonuclease 95.2% 0.68 known

system

found in Eco47II restriction

pfam09553 2 round 1 RM endonuclease 97.6% 0.36 known

system

found in

pfam09554 2 round 1 RM Haell restriction endonuclease 97.5% 0.33 known

system

found in Hpall restriction

pfam09561 2 round 1 RM endonuclease 82.0% 0.33 known

system

found in NgoBV restriction

pfam09564 2 round 1 RM endonuclease 99.6% 0.13 known

system

found in

pfam09566 2 round 1 RM Sacl restriction endonuclease 95.8% 0.41 known

system

found in

pfam09570 2 round 1 RM Sinl restriction endonuclease 95.1% 0.49 known

system

found in CRISPR-associated protein pfam09711 2 round 1 CRISPR (Cas_Csn2) 98.9% 0.15 known

system

found in Protein of unknown function pfam09722 2 round 1 TA (DUF2384) 92.7% 0.16 known

system

found in

pfam09907 2 round 1 TA HigAB 97.8% 0.18 known

system

found in

pfam09946 2 round 1 TA predicted 97.9% 0.16 known

system putative toxin has a

found in nucleotidyl transferase

pfam09952 2 round 1 TA domain 94.2% 0.13 known

system

found in McrBC 5-mefhylcytosine

pfaml0117 2 round 1 RM restriction system component 75.9% 0.40 known

system

found in Protein of unknown function pfaml0884 2 round 1 TA (DUF2683) 80.7% 0.44 known

system

found in Protein of unknown function pfaml0959 2 round 1 TA (DUF2761) 91.3% 0.33 known

system R.HinPlI restriction

pfaml l463 2 found in RM endonuclease 90.9% 0.36 round 1

known

system

found in Restriction endonuclease

pfaml l564 2 round 1 RM BpuJI - N terminal 100.0% 0.58 known

system

found in contains PIN domain. Two

pfaml l848 2 round 1 TA small proteins 95.9% 0.54 known

system

found in Domain of unknown function pfaml l867 2 round 1 RM (DUF3387) 86.9% 0.37 known

system

found in Domain of unknown function pfaml2102 2 round 1 RM (DUF3578) 46.0% 0.23 known

system

found in CopG antitoxin of type II

pfaml2441 2 round 1 TA toxin-antitoxin system 89.9% 0.46 known

system

found in

pfaml2469 2 round 1 CRISPR CRISPR-associated protein 98.2% 0.70 known

system Type III

found in restriction/modification

pfaml2564 2 round 1 RM enzyme methylation subunit 95.3% 0.25 known

system

found in Protein of unknown function pfaml2676 2 round 1 TA (DUF3796) 96.5% 0.08 known

system

found in maybe a type IIG gene;

pfaml3156 2 round 1 RM Restriction endonuclease 82.5% 0.19 known

system

found in Putative ATP-dependent Lon pfaml3337 2 round 1 BREX protease 91.8% 0.56 known

system

found in

pfaml3391 2 round 1 RM HNH_2, HNH endonuclease 75.3% 0.36 known

system

found in

pfaml3395 2 round 1 CRISPR HNH endonuclease 85.4% 0.34 known

system

found in Domain of unknown function pfaml3643 2 round 1 RM (DUF4145) 70.9% 0.44 known

system

found in Toxin YafO, type II toxin- pfaml3957 2 round 1 TA antitoxin system 79.6% 0.11 known

system

found in DndB, DNA-sulfur

pfaml4072 2 round 1 DND modification-associated 86.1% 0.44 known Domain of unknown function pfaml4076 2 system TA (DUF4258) 78.5% 0.38 found in

round 1

known

system

found in Domain of unknown function pfaml4335 2 round 1 RM (DUF4391) 92.8% 0.54 known

system

found in

pfaml4338 2 round 1 RM Mrr N-terminal domain 87.8% 0.27 known

system

found in Nearby gene is HigA

pfaml4350 2 round 1 TA antitoxin 71.2% 0.39 known

system

found in

pfaml4355 2 round 1 Abi Abortive infection C-terminus 73.1% 0.41 known

system

found in Domain of unknown function pfaml4367 2 round 1 TA (DUF4411) 98.0% 0.17 known

system

found in BrnA antitoxin of type II

pfaml4384 2 round 1 TA toxin-antitoxin system 88.9% 0.26 known

system

found in

pfaml4487 2 round 1 TA pmen type TA system 88.7% 0.22 known

system

found in Type II restriction

pfaml4511 2 round 1 RM endonuclease EcoO109I 95.1% 0.42 known tgiA

system (deazaguanine

found in tRNA CI domain of tRNA- guanine pfaml4809 2 round 1 modification) transglycosylase dimerisation 81.1% 0.57 known

system

found in

pfaml5514 2 round 1 RM Restriction endonuclease Thai 95.1% 0.33 known

system

found in Mval/Bcnl restriction

pfaml5515 2 round 1 RM endonuclease family 95.0% 0.44 known

system

found in Motility quorum-sensing

pfaml5723 2 round 1 TA regulator, toxin of Mqs A 81.1% 0.19 known

system

found in Bacterial toxin of type II

pfaml5738 2 round 1 TA toxin-antitoxin system, YafQ 87.0% 0.22 known

system

found in Domain of unknown function pfaml6277 2 round 1 TA (DUF4926) 87.5% 0.22 known

system Lon Protease; Phospholipase found in D-like domain at C-terminus pfaml6565 2 round 1 BREX of MIT 85.5% 0.74 pfaml6592 2 known CRISPR REC lobe of CRISPR- 98.0% 0.17 system associated endonuclease Cas9

found in

round 1

known

system

found in Bridge helix of CRISPR- pfaml6593 2 round 1 CRISPR associated endonuclease Cas9 97.8% 0.14 known

system PAM-interacting domain of found in CRISPR-associated

pfaml6595 2 round 1 CRISPR endonuclease Cas9 99.4% 0.14 known

system

found in PIN domain; Ribbon-helix- pfaml6762 2 round 1 TA helix domain 96.6% 0.38 known

system

found in CRISPR-associated protein pfaml6813 2 round 1 CRISPR Csn2 subfamily St 98.8% 0.28 known

system

found in Fokl; Type-2 restriction

pfaml6902 2 round 1 RM enzyme D3 domain 73.5% 0.62 known

system

found in HipAB; Cell translocating

pfaml6948 2 round 1 TA kinase A N-terminus 73.9% 0.56 known

system

found in

pfam02384 2 round 1 RM N-6 DNA Methylase 79.5% 0.31 putative

system single-gene

found in "system" of

pfam01541 2 round 1 pfaml4267 GIY-YIG catalytic domain 38.0% 0.12 putative

system

found in ZorA; MotA/TolQ/ExbB

pfam01618 2 round 1 Zorya proton channel family 66.5% 0.06 putative

system single-gene

found in "system" of Protein of unknown function pfam01863 2 round 1 COG1451 DUF45 62.3% 0.18 putative

system

found in

pfam00691 2 round 1 Zorya ZorB; OmpA family 60.7% 0.06

System

around

putative anchors

system pfam06634, Chitobiase/beta- found in COG1483, hexosaminidase C-terminal pfam03174 2 round 1 pfaml2635 domain 41.9% 0.24 putative

system single-gene

found in "system" of

pfam04383 2 round 1 pfam04383 KilA-N domain 43.1% 0.31 putative

system

found in ZorD (in some cases);

pfam04471 2 round 1 Zorya Restriction endonuclease 66.7% 0.31 putative

system single-gene

found in "system" of Protein of unknown function pfam06250 2 round 1 COG4804 (DUF1016) 55.6% 0.42 putative

system

found in HamA; Domain of unknown pfam08878 2 round 1 Hachiman function (DUF1837) 89.5% 0.48 putative

system System

found in around anchor

pfam09414 2 round 1 pfaml2476 RNA ligase 34.5% 0.39 putative

system JetD; Uncharacterized protein found in conserved in bacteria C- pfam09983 2 round 1 Wadjet term(DUF2220) 87.5% 0.45 putative

system LmuB; Uncharacterized

found in protein conserved in bacteria pfaml0088 2 round 1 Lamassu (DUF2326) 57.3% 0.52 putative

system JetD; Uncharacterized protein found in conserved in bacteria N-term pfaml l795 2 round 1 Wadjet (DUF3322) 95.3% 0.40 putative

system

found in JetA; Protein of unknown

pfaml l855 2 round 1 Wadjet function (DUF3375) 97.6% 0.31 putative

system System

found in around anchor Protein of unknown function pfaml2476 2 round 1 pfaml2476 (DUF3696) 89.0% 0.45

System

around

putative anchors

system pfam06634,

found in COG1483, Protein of unknown function pfaml2635 2 round 1 pfaml2635 (DUF3780) 98.8% 0.69

System

putative around

system anchors

found in pfam06634, Domain of unknown function pfaml3020 2 round 1 COG1483 (DUF3883) 52.6% 0.41 putative

system Septu+System

found in around anchor

pfaml3175 2 round 1 pfaml2476 PtuA; AAA ATPase domain 73.9% 0.37 putative

system System

found in around anchor

pfaml3208 2 round 1 pfaml3208 TerB N-terminal domain 89.6% 0.29 putative

system Septu+System PtuA; AAA domain, putative found in around anchor AbiEii toxin, Type IV TA

pfaml3304 2 round 1 pfaml2476 system 63.8% 0.33 putative

system

found in

pfaml3476 2 round 1 Septu PtuA; AAA domain 47.1% 0.24 putative

system ZorB; Membrane MotB of

found in proton-channel complex

pfaml3677 2 round 1 Zorya MotA/MotB 92.5% 0.04 putative

system

found in JetB; Domain of unknown

pfaml3835 2 round 1 Wadjet function (DUF4194) 98.0% 0.32 putative

system single-gene

found in "system" of Domain of unknown function pfaml3910 2 round 1 pfaml3910 (DUF4209) 69.0% 0.34 putative

system

found in LmuA; Domain of unknown pfaml4130 2 round 1 Lamassu function (DUF4297) 74.8% 0.45 putative

system single-gene

found in "system" of Domain of unknown function pfaml4267 2 round 1 pfaml4267 (DUF4357) 78.8% 0.60 putative

system

found in Septu- Protein of unknown function pfaml4491 2 round 1 associated (DUF4435) 92.4% 0.29 putative

system

found in

pfaml5611 2 round 1 Zorya ZorC; EH_Signature domain 98.3% 0.55 putative

system System

found in around anchor

pfaml5615 2 round 1 pfaml3208 TerB-C domain 92.1% 0.29

System

putative around

system anchors

found in pfam06634, exists in subtypes; WYL

pfaml3280 2 round 1 COG1483 domain 57.6% 0.19 known

system

found in RM, System

round 1, around

putative anchors

system pfam06634,

found in COG1483, Predicted ATPase, AAA+

COG1483 2 round 1 pfaml2635 superfamily

putative

system LmuB; SbcC, DNA repair

found in exonuclease SbcCD ATPase

COG0419 2 round 1 Lamassu subunit

Vsr accompanying C

known methylase, auxilary to RM;

system G:T-mismatch repair DNA

found in endonuclease, very short

COG3727 2 round 1 RM patch repair protein

putative

system

found in ZorA; Methyl-accepting

COG0840 2 round 1 Zorya chemotaxis protein

putative

system

found in LmuB; Smc, Chromosome

COG 1196 2 round 1 Lamassu segregation ATPase

putative

system

found in Lamassu- Replicative superfamily II

COG 1204 2 round 1 associated helicase

COG1360 2 putative Zorya ZorB; Flagellar motor protein system MotB

found in

round 1

putative

system single-gene

found in "system" of Predicted metal-dependent

COG1451 2 round 1 COG1451 hydrolase

System

putative around Predicted DNA-binding

system anchors transcriptional regulator

found in pfam06634, YafY, contains an HTH and

COG2378 2 round 1 COG1483 WYL domains

putative ZorB; Outer membrane

system protein OmpA and related

found in peptidoglycan-associated

COG2885 2 round 1 Zorya (lipo)proteins

putative

system JetC; Uncharacterized protein,

found in contains a C-terminal ATPase

COG4913 2 round 1 Wadjet domain

putative

system

found in

COG4924 2 round 1 Wadjet JetD; Uncharacterized protein

putative

system System

found in around anchor

COG4938 2 round 1 pfaml2476 Predicted ATPase

putative LmuB; Uncharacterized

system protein YydD, contains

found in DUF2326 domain

COG5293 2 round 1 Lamassu (pfaml0088)

[001556] Identification of pfams enriched near defense genes: The genome sequences, gene annotations and taxonomy annotations of all publicly available sequenced bacterial and archaeal genomes were downloaded from the NCBI FTP site (ftp .ncbi.nih.gov/genomes/genbank/bacteria/ and ftp .ncbi.nih.gov/genomes/genbank/archaea/, respectively) on April 2016. pfam annotations for bacterial and archaeal genes were obtained from the Integrated Microbial Genomes (IMG) database (Markowitz VM, et al. (2012) IMG: the Integrated Microbial Genomes database and comparative analysis system, nucleic Acids Res. Oxford University Press;40: Dl 15-22) on December 2015, and cross-referenced to the genes in the genomes downloaded from NCBI using the locus_tag Genbank field. All pfams annotated in at least 20 genes ("members") across the analyzed genomes (14,083 pfams) were scanned. For each pfam, the number of member genes for which a gene having an annotation of a known defense gene family (Table 1) was present in proximity (up to ten genes upstream and ten genes downstream) was recorded. The fraction of defense-associated members out of total members ("defense score") was calculated per pfam. A second score ("defense context variability score") was calculated for each pfam as follows: for each member gene occurring with at least one defense gene in proximity, a list of the proximal defense genes was recorded, and the fraction of unique lists out of total number of lists for that pfam represents the score (for example: if pfamX is found within 20 genes in our set, with 15 of them having Cas9 nearby and 5 having type I R-M nearby, the number of unique lists is 2, and the "defense context variability score" is 2/20 = 0.1). Pfams with defense score >= 65% and defense context variability score >= 0.1 were taken for further analysis. This list was supplemented with 35 non-pfam gene families that were predicted to be associated with defense by Makarova et al. (2011) ibid, as well as 23 pfams that were predicted in the same study but did not pass the thresholds above (Table 2).

[001557] Table 2: Scanned Families

Defense Variability

Family score score Family source Classification

pf ami 0802 65.4% 0.82 Prediction cycle 1 Likely mobilome

pf ami 0657 96.4% 0.15 Prediction cycle 1 Likely non-defense function pfam09226 94.3% 0.30 Prediction cycle 1 Known system

pf ami 4809 70.3% 0.58 Prediction cycle 1 Likely known system

pfaml l572 92.1% 0.23 Prediction cycle 1 Likely non-defense function pfaml4455 67.4% 0.79 Prediction cycle 1 Likely mobilome

pfam07832 100.0% 0.53 Prediction cycle 1 Known system

pf ami 0959 84.8% 0.31 Prediction cycle 1 Likely known system

Possibly belongs to a new defense pfam04033 85.7% 0.77 Prediction cycle 1 system

pfam09629 70.9% 0.26 Prediction cycle 1 Likely mobilome

pfam01304 74.6% 0.41 Prediction cycle 1 Likely non-defense function

Possibly belongs to a new defense pfaml l536 75.0% 0.60 Prediction cycle 1 system

pfam09545 80.6% 0.70 Prediction cycle 1 Known system

pfaml l564 100.0% 0.48 Prediction cycle 1 Known system

pfam09566 95.8% 0.38 Prediction cycle 1 Known system

pf ami 6902 69.9% 0.45 Prediction cycle 1 Known system

pf ami 2942 78.2% 0.13 Prediction cycle 1 Likely non-defense function pfam02981 71.6% 0.46 Prediction cycle 1 Known system

pf ami 6992 86.5% 0.18 Prediction cycle 1 Likely non-defense function pfam02980 71.1% 0.44 Prediction cycle 1 Known system

pf ami 2962 67.0% 0.34 Prediction cycle 1 Likely mobilome

pfam09518 76.8% 0.43 Prediction cycle 1 Known system

pf ami 0473 78.3% 0.18 Prediction cycle 1 Likely mobilome

pf ami 4466 84.6% 0.28 Prediction cycle 1 Likely mobilome

pfaml4456 78.3% 0.34 Prediction cycle 1 Likely mobilome

pf ami 0876 66.7% 0.40 Prediction cycle 1 Likely mobilome

pfam09543 67.9% 0.24 Prediction cycle 1 Likely non-defense function pfam09254 76.1% 0.58 Prediction cycle 1 Known system pfam09973 65.5% 0.23 Prediction cycle 1 Likely non-defense function pfam09570 92.3% 0.42 Prediction cycle 1 Known system

pfaml5514 95.1% 0.29 Prediction cycle 1 Known system

pfam08078 66.7% 0.36 Prediction cycle 1 Likely non-defense function pfam09519 93.2% 0.45 Prediction cycle 1 Known system

pfam09554 97.5% 0.29 Prediction cycle 1 Known system

pfaml l428 67.7% 0.13 Prediction cycle 1 Likely non-defense function pfaml6813 98.8% 0.20 Prediction cycle 1 Known system

pfam09895 71.4% 0.18 Prediction cycle 1 Likely non-defense function pfaml l463 88.2% 0.26 Prediction cycle 1 Known system

pfam09436 84.7% 0.28 Prediction cycle 1 Likely mobilome

pfaml0884 75.6% 0.40 Prediction cycle 1 Known system

pf ami 0907 85.1% 0.15 Prediction cycle 1 Likely mobilome

pf ami 2963 67.1% 0.32 Prediction cycle 1 Likely mobilome

pfaml6827 81.6% 0.37 Prediction cycle 1 Likely non-defense function pfam09871 66.0% 0.16 Prediction cycle 1 Likely non-defense function

Possibly belongs to a new defense pfaml2635 94.7% 0.55 Prediction cycle 1 system

pfam09126 95.5% 0.40 Prediction cycle 1 Known system

pfam06023 93.9% 0.69 Prediction cycle 1 Known system

pfaml l645 67.2% 0.21 Prediction cycle 1 Likely non-defense function pf ami 2959 87.7% 0.48 Prediction cycle 1 Likely mobilome

pfam06300 95.0% 0.26 Prediction cycle 1 Known system

pf ami 6948 68.6% 0.49 Prediction cycle 1 Known system

pfam09386 91.1% 0.52 Prediction cycle 1 Known system

pfam09466 89.4% 0.23 Prediction cycle 1 Likely mobilome

pfaml6468 92.3% 0.28 Prediction cycle 1 Likely mobilome

pfam09015 98.1% 0.29 Prediction cycle 1 Known system

Possibly belongs to a new defense pfam09544 81.4% 0.19 Prediction cycle 1 system

pfam05315 98.1% 0.13 Prediction cycle 1 Known system

pfaml l426 66.1% 0.36 Prediction cycle 1 Likely mobilome

pfam09553 97.3% 0.29 Prediction cycle 1 Known system

pf ami 4462 81.4% 0.53 Prediction cycle 1 Likely non-defense function pf ami 2960 90.8% 0.46 Prediction cycle 1 Likely mobilome

pf ami 2997 80.4% 0.17 Prediction cycle 1 Likely non-defense function pfam09521 95.3% 0.15 Prediction cycle 1 Known system

pfam07015 69.5% 0.61 Prediction cycle 1 Likely mobilome

pf ami 4457 71.2% 0.51 Prediction cycle 1 Likely mobilome

pfam08998 91.0% 0.19 Prediction cycle 1 Known system

pfaml4511 93.2% 0.34 Prediction cycle 1 Known system

pfam09946 97.7% 0.12 Prediction cycle 1 Likely known system pfaml0398 93.2% 0.26 Prediction cycle 1 Likely non-defense function pf ami 6762 96.4% 0.33 Prediction cycle 1 Known system

pfam03513 68.1% 0.29 Prediction cycle 1 Likely non-defense function pfam07820 68.8% 0.41 Prediction cycle 1 Likely mobilome

pfaml l320 69.8% 0.27 Prediction cycle 1 Likely non-defense function pfaml6565 81.7% 0.61 Prediction cycle 1 Known system

pfaml l341 67.9% 0.27 Prediction cycle 1 Likely non-defense function pfam09561 80.1% 0.25 Prediction cycle 1 Known system

pfaml4386 71.5% 0.45 Prediction cycle 1 Likely mobilome

pfaml4192 89.7% 0.30 Prediction cycle 1 Likely mobilome

pfaml2617 73.3% 0.24 Prediction cycle 1 Likely non-defense function pf ami 4203 88.3% 0.37 Prediction cycle 1 Likely mobilome

pfam07550 67.6% 0.12 Prediction cycle 1 Likely non-defense function pfaml5515 93.8% 0.37 Prediction cycle 1 Known system

pfaml4101 76.9% 0.11 Prediction cycle 1 Likely non-defense function pf ami 6509 79.5% 0.34 Prediction cycle 1 Likely mobilome

pfam08950 65.4% 0.12 Prediction cycle 1 Likely non-defense function pfam09274 70.3% 0.39 Prediction cycle 1 Likely mobilome

pfam07764 78.8% 0.19 Prediction cycle 1 Likely mobilome

pfaml l083 80.5% 0.11 Prediction cycle 1 Likely mobilome

pf ami 2957 68.2% 0.48 Prediction cycle 1 Likely mobilome

pfaml4194 73.8% 0.29 Prediction cycle 1 Likely mobilome

pf ami 4461 67.1% 0.35 Prediction cycle 1 Likely mobilome

pf ami 2599 72.6% 0.55 Prediction cycle 1 Likely mobilome

pf ami 6734 66.7% 0.39 Prediction cycle 1 Likely non-defense function pf ami 4452 85.5% 0.47 Prediction cycle 1 Likely non-defense function pfaml4193 80.3% 0.31 Prediction cycle 1 Likely mobilome

pfaml4195 77.6% 0.39 Prediction cycle 1 Likely mobilome

pfam02697 88.4% 0.38 Prediction cycle 1 Known system

pfaml4217 67.9% 0.30 Prediction cycle 1 Likely non-defense function

Possibly belongs to a new defense pfaml5611 92.5% 0.41 Prediction cycle 1 system

Possibly belongs to a new defense pfaml3910 65.1% 0.27 Prediction cycle 1 system

pfaml2958 67.2% 0.29 Prediction cycle 1 Likely mobilome

Possibly belongs to a new defense pfaml4130 66.5% 0.35 Prediction cycle 1 system

pf ami 4460 65.9% 0.30 Prediction cycle 1 Likely mobilome

pfam05626 83.4% 0.23 Prediction cycle 1 Uncertain

pf ami 2664 72.1% 0.17 Prediction cycle 1 Likely mobilome

pfaml6560 73.7% 0.11 Prediction cycle 1 Likely mobilome

pfam04796 69.8% 0.42 Prediction cycle 1 Likely mobilome

pf ami 4271 66.0% 0.15 Prediction cycle 1 Likely non-defense function pfam08870 92.8% 0.32 Prediction cycle 1 Known system pf ami 1211 65.2% 0.29 Prediction cycle 1 Likely mobilome pf ami 2469 97.8% 0.67 Prediction cycle 1 Known system

pfam05037 74.5% 0.21 Prediction cycle 1 Likely mobilome

pfam06666 78.2% 0.32 Prediction cycle 1 Likely mobilome

pfam06868 67.3% 0.30 Prediction cycle 1 Likely mobilome

pfam08989 73.7% 0.28 Prediction cycle 1 Uncertain

pfam04411 69.9% 0.54 Prediction cycle 1 Likely known system

pfaml l225 73.4% 0.16 Prediction cycle 1 Likely non-defense function pfaml4350 68.9% 0.31 Prediction cycle 1 Known system

Possibly belongs to a new defense pfaml4335 91.7% 0.45 Prediction cycle 1 system

Possibly belongs to a new defense pf ami 2476 72.9% 0.41 Prediction cycle 1 system

pf ami 2750 77.7% 0.31 Prediction cycle 1 Likely mobilome

pfaml2564 94.5% 0.19 Prediction cycle 1 Known system

pfaml4198 70.8% 0.44 Prediction cycle 1 Likely mobilome

pfaml3872 71.6% 0.45 Prediction cycle 1 Likely mobilome

Possibly belongs to a new defense pfam06634 91.9% 0.50 Prediction cycle 1 system

pfaml3871 72.8% 0.46 Prediction cycle 1 Likely mobilome

pfaml4283 81.6% 0.35 Prediction cycle 1 Likely mobilome

pfaml0987 70.9% 0.14 Prediction cycle 1 Likely non-defense function

Possibly belongs to a new defense pfam08878 86.8% 0.38 Prediction cycle 1 system

Possibly belongs to a new defense pf ami 3208 83.0% 0.24 Prediction cycle 1 system

pfam09509 68.3% 0.39 Prediction cycle 1 Likely known system

pfaml2358 70.0% 0.34 Prediction cycle 1 Likely mobilome

pf ami 5723 76.6% 0.17 Prediction cycle 1 Known system

Possibly belongs to a new defense pfaml0980 78.5% 0.22 Prediction cycle 1 system

Possibly belongs to a new defense pfaml5615 85.9% 0.23 Prediction cycle 1 system

pfam08775 70.6% 0.23 Prediction cycle 1 Likely mobilome

Possibly belongs to a new defense pfam08814 70.1% 0.48 Prediction cycle 1 system

pfaml l848 82.8% 0.53 Prediction cycle 1 Likely known system

pf ami 2441 81.8% 0.42 Prediction cycle 1 Known system

Possibly belongs to a new defense pf ami 4267 72.7% 0.54 Prediction cycle 1 system

pf ami 4065 65.4% 0.14 Prediction cycle 1 Likely mobilome

pfaml3101 70.3% 0.25 Prediction cycle 1 Likely mobilome

pfam01905 99.0% 0.37 Prediction cycle 1 Known system

pfaml3351 67.1% 0.25 Prediction cycle 1 Likely mobilome

pfaml3337 89.2% 0.44 Prediction cycle 1 Known system

pfaml l l03 68.9% 0.36 Prediction cycle 1 Likely non-defense function pfaml2083 85.2% 0.20 Prediction cycle 1 Likely mobilome pfam09035 73.8% 0.17 Prediction cycle 1 Likely mobilome

pf ami 3707 93.3% 0.26 Prediction cycle 1 Likely known system

pfam07638 67.4% 0.17 Prediction cycle 1 Likely non-defense function

Possibly belongs to a new defense pfam08869 72.6% 0.43 Prediction cycle 1 system

pfaml4355 67.4% 0.33 Prediction cycle 1 Known system

pfam03750 99.9% 0.25 Prediction cycle 1 Known system

pfam06892 71.1% 0.12 Prediction cycle 1 Likely mobilome

pf ami 4076 73.9% 0.33 Prediction cycle 1 Likely known system

pfam07515 77.4% 0.20 Prediction cycle 1 Likely mobilome

pfam02920 67.7% 0.17 Prediction cycle 1 Likely mobilome

pfaml0134 72.8% 0.34 Prediction cycle 1 Likely mobilome

pfaml l HO 71.2% 0.13 Prediction cycle 1 Likely non-defense function pfam01881 90.7% 0.40 Prediction cycle 1 Known system

pf ami 4072 80.6% 0.31 Prediction cycle 1 Known system

pfaml0552 72.0% 0.11 Prediction cycle 1 Likely mobilome

pfam09952 92.9% 0.11 Prediction cycle 1 Known system

pfam06290 87.1% 0.12 Prediction cycle 1 Likely mobilome

pf ami 6277 85.0% 0.19 Prediction cycle 1 Likely known system

pfaml4367 97.4% 0.14 Prediction cycle 1 Known system

pfam03683 85.0% 0.46 Prediction cycle 1 Known system

pf ami 5937 96.2% 0.14 Prediction cycle 1 Likely mobilome

pfaml3156 79.4% 0.16 Prediction cycle 1 Likely known system

pfam06952 84.0% 0.12 Prediction cycle 1 Likely mobilome

pfam06953 78.6% 0.10 Prediction cycle 1 Likely non-defense function pf ami 4487 82.1% 0.18 Prediction cycle 1 Known system

pfam05107 98.5% 0.35 Prediction cycle 1 Known system

pfaml3711 92.8% 0.32 Prediction cycle 1 Likely mobilome

pfaml0554 73.2% 0.12 Prediction cycle 1 Likely mobilome

pfam07514 76.0% 0.21 Prediction cycle 1 Likely mobilome

pfam05284 73.1% 0.36 Prediction cycle 1 Likely mobilome

pfaml3154 68.0% 0.28 Prediction cycle 1 Likely mobilome

pf ami 4261 66.3% 0.35 Prediction cycle 1 Likely mobilome

pfam07128 96.0% 0.13 Prediction cycle 1 Likely mobilome

pfam08273 79.8% 0.13 Prediction cycle 1 Likely mobilome

pfaml3395 81.0% 0.25 Prediction cycle 1 Known system

pfam06406 79.1% 0.16 Prediction cycle 1 Likely mobilome

pfaml4338 84.2% 0.23 Prediction cycle 1 Known system

pfaml0117 65.1% 0.35 Prediction cycle 1 Known system

pfaml3643 66.4% 0.35 Prediction cycle 1 Likely known system

pfam08401 69.4% 0.33 Prediction cycle 1 Likely mobilome

pfam09907 97.4% 0.14 Prediction cycle 1 Known system pfaml3148 68.0% 0.25 Prediction cycle 1 Uncertain

pfam07275 75.3% 0.14 Prediction cycle 1 Likely mobilome

pfaml5738 85.6% 0.18 Prediction cycle 1 Known system

pf ami 3708 75.2% 0.11 Prediction cycle 1 Uncertain

pfaml4384 84.4% 0.22 Prediction cycle 1 Known system

pfam07362 93.8% 0.12 Prediction cycle 1 Known system

pfam03288 70.3% 0.13 Prediction cycle 1 Likely mobilome

pfam05015 96.4% 0.21 Prediction cycle 1 Known system

pfaml3310 68.4% 0.36 Prediction cycle 1 Likely known system

pfaml l867 78.7% 0.29 Prediction cycle 1 Known system

pfam05168 82.0% 0.31 Prediction cycle 1 Likely known system

pfam04365 80.6% 0.28 Prediction cycle 1 Known system

pfaml3391 67.8% 0.28 Prediction cycle 1 Known system

pfaml3362 76.6% 0.19 Prediction cycle 1 Likely mobilome

pfam08706 65.4% 0.16 Prediction cycle 1 Likely mobilome

pfam08774 69.9% 0.11 Prediction cycle 1 Likely mobilome

pfam03693 86.8% 0.16 Prediction cycle 1 Known system

pfam04255 66.4% 0.32 Prediction cycle 1 Likely known system

pf ami 3744 87.2% 0.15 Prediction cycle 1 Known system

Possibly belongs to a new defense pfam06067 76.7% 0.15 Prediction cycle 1 system

pf ami 4657 67.2% 0.11 Prediction cycle 1 Likely mobilome

pfaml5919 75.6% 0.26 Prediction cycle 1 Likely non-defense function pfam04221 84.2% 0.18 Prediction cycle 1 Known system

pfam05973 78.5% 0.17 Prediction cycle 1 Known system

Possibly belongs to a new defense pfam03235 66.7% 0.28 Prediction cycle 1 system

Possibly belongs to a new defense pfaml3635 68.0% 0.19 Prediction cycle 1 system

pfaml l657 78.9% 0.37 Prediction cycle 1 Likely mobilome

pf ami 4662 72.0% 0.53 Prediction cycle 1 Likely non-defense function pfam04313 90.7% 0.23 Prediction cycle 1 Known system

pfam08130 65.0% 0.31 Prediction cycle 1 Likely non-defense function pfam09116 94.7% 0.39 Prediction cycle 1 Likely mobilome

pfam04582 85.1% 0.19 Prediction cycle 1 Likely mobilome

pfam04875 79.3% 0.26 Prediction cycle 1 Likely mobilome

pfaml l592 68.2% 0.31 Prediction cycle 1 Likely non-defense function pfam09552 92.7% 0.47 Prediction cycle 1 Known system

pf ami 0892 93.8% 0.29 Prediction cycle 1 Likely mobilome

pfam09567 72.7% 0.53 Prediction cycle 1 Known system

pfam02691 78.6% 0.12 Prediction cycle 1 Likely non-defense function pfam08046 78.9% 0.10 Prediction cycle 1 Likely non-defense function pfaml l570 71.0% 0.24 Prediction cycle 1 Likely non-defense function pfaml0083 81.9% 0.19 Prediction cycle 1 Likely mobilome pfam02048 68.5% 0.44 Prediction cycle 1 Likely non-defense function

Possibly belongs to a new defense pfaml3604 66.3% 0.10 Prediction cycle 1 system

pfaml l770 73.5% 0.32 Prediction cycle 1 Likely non-defense function

Possibly belongs to a new defense pfam06709 86.8% 0.36 Prediction cycle 1 system

pf ami 6790 84.2% 0.50 Prediction cycle 1 Likely mobilome

pfam04604 65.0% 0.13 Prediction cycle 1 Likely non-defense function pfaml2113 66.1% 0.17 Prediction cycle 1 Likely mobilome

pf ami 4459 66.7% 0.68 Prediction cycle 1 Likely mobilome

pf ami 2703 88.5% 0.28 Prediction cycle 1 Known system

pfam02384 77.6% 0.22 Prediction cycle 1 Known system

pfaml6848 80.2% 0.15 Prediction cycle 1 Likely non-defense function pfaml l056 76.2% 0.31 Prediction cycle 1 Likely mobilome

pfam07339 95.1% 0.36 Prediction cycle 1 Likely mobilome

pfaml4562 96.9% 0.39 Prediction cycle 1 Known system

pfam09185 82.9% 0.14 Prediction cycle 1 Likely non-defense function pf ami 2493 82.3% 0.32 Prediction cycle 1 Likely mobilome

pfaml6831 68.0% 0.28 Prediction cycle 1 Likely non-defense function pfam01818 75.0% 0.50 Prediction cycle 1 Likely mobilome

pfaml l554 67.2% 0.69 Prediction cycle 1 Likely mobilome

pfam09504 97.8% 0.34 Prediction cycle 1 Known system

pf ami 6243 100.0% 0.22 Prediction cycle 1 Likely mobilome

pf ami 6280 90.9% 0.34 Prediction cycle 1 Likely known system

pfam09020 98.5% 0.14 Prediction cycle 1 Likely mobilome

pfam09562 80.0% 0.55 Prediction cycle 1 Known system

Possibly belongs to a new defense pfam07154 75.5% 0.45 Prediction cycle 1 system

pfam06443 77.1% 0.12 Prediction cycle 1 Likely non-defense function pfam03295 100.0% 0.50 Prediction cycle 1 Likely mobilome

pfaml3128 68.4% 0.15 Prediction cycle 1 Likely mobilome

pfaml l504 74.8% 0.18 Prediction cycle 1 Likely non-defense function pfaml2136 98.2% 0.14 Prediction cycle 1 Likely non-defense function pfam07042 74.7% 0.50 Prediction cycle 1 Likely mobilome

Prediction cycle 1 +

pfaml l459 87.6% 0.24 Makarova et al. (2011) ⁴ Likely known system

Prediction cycle 1 +

pfaml l726 79.5% 0.12 Makarova et al. (2011) Likely mobilome

Prediction cycle 1 +

pfam01954 87.5% 0.54 Makarova et al. (2011) Known system

Prediction cycle 1 +

pfam03428 86.2% 0.26 Makarova et al. (2011) Likely mobilome

pfam06924 91.9% 0.19 Prediction cycle 1 + Likely mobilome Makarova et al. J Bacteriol. 2011 Nov; 193(21): 6039-6056 Makarova et al. (2011)

Prediction cycle 1 +

pfam07183 77.6% 0.59 Makarova et al. (2011) Likely mobilome

Prediction cycle 1 +

pfaml l800 84.5% 0.26 Makarova et al. (2011) Likely mobilome

Prediction cycle 1 +

pfam09722 90.4% 0.12 Makarova et al. (2011) Known system

Prediction cycle 1 + Possibly belongs to a new defense pfaml l994 72.6% 0.39 Makarova et al. (2011) system

Prediction cycle 1 +

pfaml2101 84.6% 0.19 Makarova et al. (2011) Likely mobilome

Prediction cycle 1 +

pfam08900 90.5% 0.17 Makarova et al. (2011) Likely mobilome

Prediction cycle 1 +

pf ami 0074 83.5% 0.24 Makarova et al. (2011) Likely mobilome

Prediction cycle 1 +

pfaml lOOO 71.8% 0.22 Makarova et al. (2011) Likely mobilome

Prediction cycle 1 +

pfaml l284 86.2% 0.21 Makarova et al. (2011) Likely mobilome

Prediction cycle 1 +

pfaml l358 95.8% 0.17 Makarova et al. (2011) Likely mobilome

Prediction cycle 1 +

pfaml l679 93.3% 0.18 Makarova et al. (2011) Likely mobilome

Prediction cycle 1 +

pfaml2553 86.9% 0.19 Makarova et al. (2011) Likely mobilome

COG4688 Makarova et al. (2011) Likely mobilome

COG4190 Makarova et al. (2011) Likely known system

COG5428 Makarova et al. (2011) Likely known system

COG3756 Makarova et al. (2011) Likely mobilome

COG4185 Makarova et al. (2011) Likely non-defense function

COG4854 Makarova et al. (2011) Likely non-defense function

COG5532 Makarova et al. (2011) Likely mobilome

COG5545 Makarova et al. (2011) Likely mobilome

COG5658 Makarova et al. (2011) Likely non-defense function pfam01724 64.0% 0.34 Makarova et al. (2011) Likely non-defense function pfam03432 62.3% 0.27 Makarova et al. (2011) Likely mobilome

pfam09588 40.7% 0.25 Makarova et al. (2011) Likely mobilome

pfaml l238 37.1% 0.10 Makarova et al. (2011) Likely non-defense function

Possibly belongs to a new defense

COG1205 Makarova et al. (2011) system

Possibly belongs to a new defense

COG4913 Makarova et al. (2011) system

Possibly belongs to a new defense

COG4924 Makarova et al. (2011) system

Possibly belongs to a new defense pfam04383 32.4% 0.28 Makarova et al. (2011) system

COG1112 Makarova et al. (2011) Uncertain

COG1373 Makarova et al. (2011) Uncertain COG2865 Makarova et al. (2011) Uncertain

COG3598 Makarova et al. (2011) Likely mobilome

pf ami 0543 55.9% 0.26 Makarova et al. (2011) Uncertain

pfaml l l85 50.8% 0.35 Makarova et al. (2011) Uncertain

pfam09823 69.1% 0.52 Makarova et al. (2011) Likely known system

COG5519 Makarova et al. (2011) Likely mobilome

pfaml0711 29.6% 0.18 Makarova et al. (2011) Likely mobilome

Possibly belongs to a new defense

COG1483 Makarova et al. (2011) system

Possibly belongs to a new defense

COG3586 Makarova et al. (2011) system

Possibly belongs to a new defense

COG3950 Makarova et al. (2011) system

Possibly belongs to a new defense

COG4804 Makarova et al. (2011) system

pfam01541 31.4% 0.10 Makarova et al. (2011) Uncertain

COG 1475 Makarova et al. (2011) Likely mobilome

COG0507 Makarova et al. (2011) Likely non-defense function

Possibly belongs to a new defense

COG0553 Makarova et al. (2011) system

COG1192 Makarova et al. (2011) Likely mobilome

Possibly belongs to a new defense

COG1451 Makarova et al. (2011) system

COG3727 Makarova et al. (2011) Known system

pfam01464 22.2% 0.10 Makarova et al. (2011) Likely mobilome

pfam02876 60.9% 0.01 Makarova et al. (2011) Likely non-defense function pfam03837 33.5% 0.12 Makarova et al. (2011) Likely mobilome

pfam08861 30.3% 0.09 Makarova et al. (2011) Likely known system

pfam09199 92.0% 0.00 Makarova et al. (2011) Likely non-defense function

Possibly belongs to a new defense pfam09954 21.0% 0.31 Makarova et al. (2011) system

COG3505 Makarova et al. (2011) Likely mobilome

COG3843 Makarova et al. (2011) Likely mobilome

COG4227 Makarova et al. (2011) Likely mobilome

COG4646 Makarova et al. (2011) Likely mobilome

COG4930 Makarova et al. (2011) Known system

COG5489 Makarova et al. (2011) Likely mobilome

pfam07895 42.0% 0.03 Makarova et al. (2011) Likely non-defense function pfam08849 95.2% 0.39 Makarova et al. (2011) Known system

pfam09002 46.1% 0.50 Makarova et al. (2011) Known system

pfaml l l98 80.0% 0.14 Makarova et al. (2011) Likely mobilome

pfaml l455 97.1% 0.10 Makarova et al. (2011) Known system

pfaml l985 22.7% 0.18 Makarova et al. (2011) Likely mobilome

COG1479 Makarova et al. (2011) Known system

COG3472 Makarova et al. (2011) Known system Possibly belongs to a new defense pf ami 0923 93.1% 0.28 Makarova et al. (2011) system

pf ami 2495 85.7% 0.17 Prediction cycle 2 Likely non-defense function pfam04787 100.0% 1.00 Prediction cycle 2 Likely mobilome

pfaml5541 69.0% 0.40 Prediction cycle 2 Likely mobilome

pfam04778 68.8% 0.36 Prediction cycle 2 Likely non-defense function pfam07199 69.7% 0.26 Prediction cycle 2 Likely non-defense function pf ami 0790 68.4% 0.65 Prediction cycle 2 Likely mobilome

pfam09131 79.5% 0.19 Prediction cycle 2 Likely non-defense function pf ami 6445 66.7% 0.19 Prediction cycle 2 Likely non-defense function pfaml l519 69.0% 0.28 Prediction cycle 2 Likely non-defense function pfaml l516 95.3% 0.17 Prediction cycle 2 Likely non-defense function pf ami 6904 76.5% 0.10 Prediction cycle 2 Likely non-defense function pfam07046 90.4% 0.11 Prediction cycle 2 Likely non-defense function pfaml6436 86.8% 0.11 Prediction cycle 2 Likely non-defense function pf ami 4590 72.2% 0.15 Prediction cycle 2 Likely non-defense function pf ami 2772 69.8% 0.22 Prediction cycle 2 Likely non-defense function pfaml l263 98.3% 0.10 Prediction cycle 2 Likely non-defense function pfaml0913 69.7% 0.11 Prediction cycle 2 Likely mobilome

pf ami 6390 68.8% 0.13 Prediction cycle 2 Uncertain

pfaml6847 65.0% 0.38 Prediction cycle 2 Likely non-defense function pfaml l565 92.0% 0.11 Prediction cycle 2 Likely non-defense function pfam03857 65.7% 0.52 Prediction cycle 2 Likely non-defense function pf ami 3497 92.2% 0.19 Prediction cycle 2 Likely mobilome

pfam08048 85.3% 0.33 Prediction cycle 2 Likely mobilome

pfam09264 83.5% 0.11 Prediction cycle 2 Likely non-defense function pfam05946 72.9% 0.13 Prediction cycle 2 Likely non-defense function pfam09930 97.8% 0.16 Prediction cycle 2 Likely non-defense function pfaml6163 68.5% 0.68 Prediction cycle 2 Likely non-defense function pf ami 6754 75.7% 0.29 Prediction cycle 2 Known system

Possibly belongs to a new defense pfaml6416 65.2% 0.48 Prediction cycle 2 system

pfam06613 82.2% 0.36 Prediction cycle 2 Likely mobilome

pf ami 6479 88.9% 0.11 Prediction cycle 2 Likely non-defense function pfam05969 65.3% 0.40 Prediction cycle 2 Likely non-defense function pfaml5538 66.0% 0.10 Prediction cycle 2 Likely non-defense function pfaml0865 68.9% 0.41 Prediction cycle 2 Likely non-defense function pfam07828 85.5% 0.12 Prediction cycle 2 Likely non-defense function pfaml l580 85.6% 0.10 Prediction cycle 2 Likely non-defense function pfam08017 68.3% 0.10 Prediction cycle 2 Likely non-defense function pfam05265 88.7% 0.12 Prediction cycle 2 Likely mobilome

pf ami 3009 66.7% 0.53 Prediction cycle 2 Likely mobilome

pfam09016 65.9% 0.19 Prediction cycle 2 Likely non-defense function pf ami 0726 67.3% 0.29 Prediction cycle 2 Likely non-defense function pfaml0130 69.0% 0.71 Prediction cycle 2 Known system

pfaml0616 78.4% 0.10 Prediction cycle 2 Likely non-defense function pfaml3314 69.8% 0.11 Prediction cycle 2 Likely non-defense function

Possibly belongs to a new defense pfam04485 65.1% 0.35 Prediction cycle 2 system

pfaml2655 65.6% 0.12 Prediction cycle 2 Likely non-defense function pf ami 3079 69.0% 0.11 Prediction cycle 2 Likely non-defense function pf ami 4275 67.6% 0.13 Prediction cycle 2 Likely non-defense function pfaml l686 70.8% 0.11 Prediction cycle 2 Likely non-defense function pfaml l397 67.0% 0.13 Prediction cycle 2 Likely non-defense function

Possibly belongs to a new defense pfaml l796 65.0% 0.59 Prediction cycle 2 system

pfam09000 66.3% 0.28 Prediction cycle 2 Likely non-defense function pfaml4453 65.8% 0.12 Prediction cycle 2 Likely non-defense function pfaml3651 85.8% 0.46 Prediction cycle 2 Known system

pfaml l l73 66.6% 0.11 Prediction cycle 2 Likely non-defense function

Possibly belongs to a new defense pfaml6162 70.6% 0.46 Prediction cycle 2 system

pf ami 2975 68.1% 0.11 Prediction cycle 2 Likely non-defense function pfaml4133 71.1% 0.18 Prediction cycle 2 Likely non-defense function pf ami 6082 65.4% 0.15 Prediction cycle 2 Likely mobilome

pf ami 6223 66.3% 0.11 Prediction cycle 2 Likely non-defense function pf ami 2545 65.6% 0.11 Prediction cycle 2 Likely non-defense function

Possibly belongs to a new defense pfam09664 67.9% 0.50 Prediction cycle 2 system

pfaml l813 79.5% 0.10 Prediction cycle 2 Likely non-defense function pfaml l l49 69.5% 0.52 Prediction cycle 2 Likely mobilome

Possibly belongs to a new defense pf ami 6263 76.4% 0.35 Prediction cycle 2 system

pfaml2119 72.8% 0.11 Prediction cycle 2 Likely non-defense function pf ami 0893 91.7% 0.13 Prediction cycle 2 Likely mobilome

pf ami 4790 67.2% 0.11 Prediction cycle 2 Likely non-defense function

Possibly belongs to a new defense pfaml2668 68.0% 0.38 Prediction cycle 2 system

Possibly belongs to a new defense pf ami 4082 65.3% 0.57 Prediction cycle 2 system

pfam06698 79.9% 0.12 Prediction cycle 2 Likely non-defense function pfam07509 65.6% 0.12 Prediction cycle 2 Likely non-defense function pfam07323 77.8% 0.12 Prediction cycle 2 Likely non-defense function pfam09919 98.4% 0.11 Prediction cycle 2 Likely non-defense function pf ami 6930 85.1% 0.11 Prediction cycle 2 Likely non-defense function pfaml4113 71.7% 0.14 Prediction cycle 2 Likely non-defense function

Possibly belongs to a new defense pfaml3151 65.5% 0.40 Prediction cycle 2 system pf ami 4328 71.3% 0.13 Prediction cycle 2 Likely non-defense function pfam07511 68.4% 0.23 Prediction cycle 2 Likely mobilome

Possibly belongs to a new defense pf ami 4281 71.4% 0.59 Prediction cycle 2 system

pfaml4584 79.8% 0.12 Prediction cycle 2 Likely non-defense function pfaml l047 78.1% 0.11 Prediction cycle 2 Likely non-defense function pfaml l660 70.4% 0.20 Prediction cycle 2 Likely mobilome

pfaml l l90 67.1% 0.20 Prediction cycle 2 Likely mobilome

pfaml4103 97.7% 0.39 Prediction cycle 2 Likely known system

pfam09686 68.6% 0.20 Prediction cycle 2 Likely mobilome

pfaml5978 75.8% 0.25 Prediction cycle 2 Likely mobilome

Possibly belongs to a new defense pfam09376 67.6% 0.33 Prediction cycle 2 system

pf ami 2602 69.9% 0.18 Prediction cycle 2 Likely mobilome

pfam07455 91.6% 0.11 Prediction cycle 2 Likely mobilome

pf ami 6452 82.1% 0.13 Prediction cycle 2 Likely mobilome

pfaml l072 75.0% 0.20 Prediction cycle 2 Likely mobilome

pfaml4253 69.7% 0.30 Prediction cycle 2 Known system

pf ami 5731 83.3% 0.28 Prediction cycle 2 Known system

Possibly belongs to a new defense pfam05419 65.3% 0.43 Prediction cycle 2 system

pf ami 2870 65.4% 0.18 Prediction cycle 2 Likely non-defense function pf ami 0723 78.2% 0.20 Prediction cycle 2 Likely mobilome

pf ami 4302 67.0% 0.10 Prediction cycle 2 Likely non-defense function pf ami 4348 69.7% 0.23 Prediction cycle 2 Likely mobilome

pf ami 0049 75.1% 0.51 Prediction cycle 2 Likely known system

pfaml3814 65.5% 0.25 Prediction cycle 2 Likely mobilome

pfaml2834 67.9% 0.27 Prediction cycle 2 Likely mobilome

pfam09937 66.2% 0.10 Prediction cycle 2 Likely non-defense function

Possibly belongs to a new defense pfam08937 67.8% 0.33 Prediction cycle 2 system

Possibly belongs to a new defense pfam09903 65.6% 0.26 Prediction cycle 2 system

pfam02521 90.4% 0.11 Prediction cycle 2 Likely non-defense function pfaml2835 70.7% 0.31 Prediction cycle 2 Likely mobilome

pfam02387 75.9% 0.20 Prediction cycle 2 Likely mobilome

Possibly belongs to a new defense pfaml3784 65.1% 0.47 Prediction cycle 2 system

pfam09848 65.6% 0.45 Prediction cycle 2 Known system

pf ami 2950 67.4% 0.39 Prediction cycle 2 Known system

pfaml3166 75.6% 0.39 Prediction cycle 2 Known system

Possibly belongs to a new defense pfaml3555 70.4% 0.27 Prediction cycle 2 system

pfam01927 65.2% 0.19 Prediction cycle 2 Likely known system

pfam06006 93.4% 0.14 Prediction cycle 2 Likely mobilome pfam06174 98.7% 0.10 Prediction cycle 2 Likely mobilome pfaml l398 85.9% 0.10 Prediction cycle 2 Likely non-defense function pfaml2686 65.4% 0.32 Prediction cycle 2 Likely mobilome

pfam03596 70.8% 0.12 Prediction cycle 2 Likely non-defense function pfam06527 68.3% 0.31 Prediction cycle 2 Likely mobilome

pfam07799 70.7% 0.12 Prediction cycle 2 Likely mobilome

pf ami 3470 67.0% 0.43 Prediction cycle 2 Known system

pfaml3588 68.3% 0.37 Prediction cycle 2 Known system

pfam05713 65.0% 0.39 Prediction cycle 2 Likely mobilome

pfam05272 68.0% 0.17 Prediction cycle 2 Uncertain

Possibly belongs to a new defense pf ami 3749 69.0% 0.43 Prediction cycle 2 system

pfaml3657 69.5% 0.30 Prediction cycle 2 Known system

Possibly belongs to a new defense pfam04326 65.1% 0.39 Prediction cycle 2 system

pfam06769 96.5% 0.12 Prediction cycle 2 Known system

pfam02498 66.8% 0.17 Prediction cycle 2 Likely mobilome

Possibly belongs to a new defense pfaml3173 68.3% 0.26 Prediction cycle 2 system

pfam05685 67.2% 0.27 Prediction cycle 2 Uncertain

Possibly belongs to a new defense pfaml3538 66.9% 0.13 Prediction cycle 2 system

pfam01402 67.6% 0.12 Prediction cycle 2 Likely non-defense function pf ami 2705 76.4% 0.10 Prediction cycle 2 Likely non-defense function

Possibly belongs to a new defense pfaml3175 73.9% 0.37 Prediction cycle 2 system

Possibly belongs to a new defense pfaml3304 63.8% 0.33 Prediction cycle 2 system

[001558] From genes to systems: Each of the putative defense-related gene families was used as an anchor to search for multi-gene systems, as follows. The protein coding sequences for neighboring genes (+/-10 genes) for all family members were clustered based on sequence homology (for example, if pfamY is found within 50 genomes in our set, the 20 neighboring genes in each genome, plus the pfamY gene in each genome, were taken - altogether 50*21 = 1050 genes to be clustered). Clustering was done with OrthoMCL software v2.0.9 (Li L, Stoeckert CJ, Roos DS.(2003) OrthoMCL: identification of ortholog groups for eukaryotic genomes. Genome Res.13: 2178-89) with blastp parameters [-F 'm S' -v 100000 -b 100000 -e le-5 -m 8] and with mcl v 12.068 downloaded from http://micans.org/mcl/ (Enright AJ, Van Dongen S, Ouzounis CA.(2002) An efficient algorithm for large-scale detection of protein families, nucleic Acids Res.30: 1575-84; van Dongen S, Abreu-Goodger C. (2012) Using MCL to Extract Clusters from Networks. Methods in molecular biology (Clifton, NJ). pp. 281-295) with inflation value of 1.1. When the number of blastp hits for a given anchor pfam was too large and prohibitive for OrthoMCL to generate clusters (>75 million blastp hits), a subset of genomes, containing only bacterial and archaeal genomes annotated as "complete" (rather than "draft") was used for clustering.

[001559] To detect the most prevalent genes around the anchor pfam, only the 10% largest clusters ("frequent clusters") were considered. For the sake of cluster size calculation, genes originating from the same species (derived from the strain name in the NCBI annotation) were counted as one gene, to prevent organisms for which many strains have been sequenced from inflating the cluster size. An edge between cluster(i) and cluster(j) was defined if a gene from cluster(j) followed a gene from cluster(i) in a given genome with no other genes belonging to frequent clusters found in between, with edge weight ("thickness") defined as the number of such adjacency cases. Again, edge weights were adjusted such that multiple appearances of a cluster pair originating from the same species were recorded as a single appearance. Only the 10% thickest edges were retained for further analysis. In each genome, the maximal "path" that included the anchor pfam gene and was composed of the retained (largest) clusters and the retained (thickest) edges was recorded. Such a "path", representing a set of genes appearing in a conserved order in multiple genomes, was considered a candidate multi-gene system. Infrequent variations on the gene order and composition of common systems were merged into the common system if they shared at least 50% of their clusters and had less than 25% appearances than the common system. Only systems with five or more appearances from different species were further analyzed.

[001560] The domains within the gene members of each system were analyzed bioinformatically using the tools HHpred (Soding J, Biegert A, Lupas AN. (2005) The HHpred interactive server for protein homology detection and structure prediction, nucleic Acids Res.33: W244-W248; Alva V, Nam S-Z, Soding J, Lupas AN, I. S, S. C, et al. (2016) The MPI bioinformatics Toolkit as an integrative platform for advanced protein sequence and structure analysis, nucleic Acids Res. Oxford University Press; 44: W410-W415), Phyre2 (Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. (2015) The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc. Nature Research; 10: 845-858), PSI-BLAST (Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, nucleic Acids Res.25: 3389-402), and NCBI's Conserved Domain Database (CDD) (Marchler-Bauer A, Lu S, Anderson JB, Chitsaz F, Derbyshire MK, DeWeese-Scott C, et al. (2011) CDD: a Conserved Domain Database for the functional annotation of proteins, nucleic Acids Res. 39: D225- D229). The systems were then manually filtered, based on this analysis, to remove (i) known defense systems whose domains did not appear in our initial set of gene families known to participate in defense; (ii) systems likely representing mobile genetic elements ("mobilome") and; (iii) systems likely participating in non-defensive functions or house-keeping systems (Table 2).

[001561] A second cycle of prediction was then performed, expanding the set of "positive" gene families from Table 1 to include the gene families participating in the candidate new defense systems, as well as the gene families participating in known defense systems that were previously missing from our set and detected in the first round. All pfams were again scanned and the same thresholds were applied (defense score 65%, context variability score 0.1). New pfams retrieved from the second cycle were analyzed as above to generate and annotate multi- gene systems.

[001562] Candidate new systems were further prioritized to select instances for experimental validations. Systems tagged as "questionable", due to uncertainty whether they represent defense genes or mobile genetic elements, were filtered out (Table 3). Systems existing in only a narrow range of organisms, as well as systems that were not found in organisms phylogenetically close either to E. coli or B. subtilis, were not tested experimentally (Table 3).

[001563] Table 3: Candidate Defense Systems

Included /

Excluded from

Number experimental

Anchor protein families of genes? study Reason for exclusion pfam04033 1 Excluded Archaea specific pfaml l536 2 Excluded Thermococcus specific pfaml2635;pfam06634;COG1483 3-4 Included - pfam09544 3-4 Excluded Myxococcales specific pfaml5611 ;COG0553 3-4 Included - pfaml3910 1 Included - pfaml4130 2 Included -

No locus that is a standalone gene, always pfaml4335 1-2 Excluded within R-M systems pfaml2476;pfam03235 3 Included - pfam08878 2 included - pf ami 3208 ;pf ami 5615 ;pf ami 0923 3 Included - pfaml0980 7 Included - pfam08814;pfam08869 2 Excluded Cyanobacteria specific pf ami 4267 1 Included -

Loci in Bacillus are in phage/mobilome pfam06067 1-2 Excluded context

pfaml3635;pfaml3173 1 Included - pfaml3604;pfaml3538 1 Included - pfam06709 1 Excluded Vibrio specific pfam07154 1 Excluded Cyanobacteria specific

Not found in

pfaml l994 3 Excluded bacillus/coli

COG1205 2-5 Included -

COG4913;COG4924;pfaml 1796;pfa

m09664;pfaml3555 3-4 Included - pfam04383 1 Included -

COG3586 1 Included -

COG3950 2 Included -

COG4804 1 Included -

COG1451 1 Included -

No appropriate locus that is a stand-alone gene, always comes with other genes + already exists in pfam09954 1 Excluded BEST7003

pfaml6416;pfam05419 2-4 Excluded Cyanobacteria specific pfam04485 4 Excluded Cyanobacteria specific pfaml6162 2 Included -

Loci in Bacillus are in phage/mobilome pf ami 6263 1 Excluded context

pfaml2668;pfaml3151 2 Included - pf ami 4082 1 Included - pf ami 4281 1 Included - pfam09376 3 Included - pfam08937 2 Included - pfam09903 1 Included - pfaml3784 1 Included - pf ami 3749 ;pfam04326 1 Included - pfaml3175;pfaml3304 2 included -

[001564] Phylogenetic distribution analysis of new systems: For each validated defense system, several loci including the locus that was experimentally verified were taken as seeds for psi-Blast. psi-Blast version 2.5.0 of BLAST+ (Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, nucleic Acids Res. ;25: 3389^402; Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. (2009) BLAST+: architecture and applications. BMC Bioinformatics. 10: 421. doi:10.1186/1471-2105-10-421) with parameters [- num_iterations 10 -max_hsps 1 -max_target_seqs 100000 -evalue le-10] was performed for each protein of each system, against all microbial genomes downloaded from NCBI on April 2016. When the hits of all proteins of a system were found closely localized on a genome, spanning no more than 150% of the length of the original system, this genome was recorded as containing the system. For the Druantia and Wadjet systems, -evalue le-5 was used to enable detection of distant homologs. For systems with 4 or 5 genes (Zorya type I, Druantia types I and II, Wadjet), systems were reported if at least 3 of their genes were identified. For the Druantia system, systems with hits to the DruE protein were retained if the DruE size was >1300aa. For the Thoeris system, multiple thsB genes near the thsA gene were recorded if they were within 10 kb of genomic DNA around the identified thsA. Phylum for each genome was obtained using the JGI taxonomy server (https://taxonomy.jgi-psf.org/).

[001565] Experimental validation of defense systems

[001566] Cloning of the systems into E. coli MG1655 and/or B. subtilis BEST7003

[001567] A cloning shuttle vector for large fragments was constructed as previously described (Ofir G, Melamed S, Sberro H, Silverman S, Doron S, Yaakov G, Mukamel Z, Sorek R. (2017) DISARM, a novel bacterial defense system with broad anti-phage activities, submitted). The vector contains a pi 5a origin of replication and ampicillin resistance for plasmid propagation in E. coli, and amyE integration cassette with spectinomycin resistance for genomic integration into B. subtilis. The backbone of this vector was amplified using primers OGO309 +OGO310, adding to it a BamHI restriction site and a terminator site upstream to the insert cloning site. The multiple cloning site of plasmid pBSIC (Radeck J, Kraft K, Battels J, Cikovic T, Diirr F, Emenegger J, Kelterborn S, Sauer C, Fritz G, Gebhard S, Mascher T. (2013) The Bacillus BioBrick Box: generation and evaluation of essential genetic building blocks for standardized work with Bacillus subtilis. J Biol Eng. BioMed Central; 7: 29. doi: 10.1186/1754-1611-7-29), received from BGSC (accession ECE257), was amplified using primers OG0311 +OG0312. Both fragments were digested using Ascl and BamHI, ligated using T4 ligase and transformed into E. coli, resulting in plasmid pSGl-rfp.

[001568] The loci of most systems were commercially synthesized by Genscript and cloned, also by Genscript, directly into pSGl-rfp between the Ascl and Notl sites of the multiple cloning site (Table 4: "Cloning method" column).

[001569] Table 4: Loci for Candidate Systems [001570] In one case (the Type I Wadjet system) the DNA was synthesized by Gen9 (Boston, MA) with synonymous modifications to optimize GC content. In case the donor strains were readily available the system was not synthesized but instead was directly amplified from the genomic DNA of the donor strain using KAPA HiFi HotStart ReadyMix (Kapa Biosystems KK2601) with primers as detailed in Table 5.

[001571] Table 5: Primers

SEQ ID OSM332 GTTGCCGCCGGGCGTTTTTTATGGCGCG

NO: 39 CCTATCAAGCCCCCTCATTTCA

SEQ ID OSM340 atcctagaagcttatcgaattcgcggccgcTTCGTTACTT C.N. 29 to lift from strain, use with OSM341 NO: 40 CTGGGATGGG

SEQ ID OSM341 gttgccgccgggcgttttttatggcgcgccTGAAAAAGA

NO: 41 CTCCTCCGTATTTG

SEQ ID OSM365 atcctagaagcttatcgaattcgcggccgcTAACTGGAC C.N. 34 to lift from strain, use with OSM366 NO: 42 AGTGCTCTTGG

SEQ ID OSM366 gttgccgccgggcgttttttatggcgcgccATGCCGATA

NO: 43 GAAGATATTGCG

SEQ ID OSM342 atcctagaagcttatcgaattcgcggccgcTTCCGATAC C.N. 61 to lift from strain, use with OSM343a NO: 44 TCTTTAGCCATAA

SEQ ID OSM343a gttgccgccgggcgttttttatggcgcgccACAATCACA

NO: 45 TCCTTATTTTCTT

SEQ ID OSM343b atcctagaagcttatcgaattcgcggccgcATCTTTTTGA C.N. 18 to lift from strain, use with OSM344 NO: 46 ATAGTTTCAATGATG

SEQ ID OSM344 gttgccgccgggcgttttttatggcgcgccAGTGTGGTA

NO: 47 TGGAGATTAGC

SEQ ID OSM359 atcctagaagcttatcgaattcgcggccgcGTGCTTAGA C.N. 57 to lift fragment 1 from Genscript plasmid, use NO: 48 TACGAAGGG with OSM360

SEQ ID OSM360 TAGCTCATTCTCTACAAAATCC

NO: 49

SEQ ID OSM361 TCGATAGAGGATTTTGTAGAG C.N. 57 to lift fragment 2 from Genscript plasmid, use NO: 50 with OSM362

SEQ ID OSM362 TTTTTGACGACCGTCTGAA

NO: 51

SEQ ID OSM363 AGTTTTGCTATTTTCAGAC C.N. 57 to lift fragment 3 from Genscript plasmid, use NO: 52 with OSM364

SEQ ID OSM364 gttgccgccgggcgttttttatggcgcgccTGGTTATGG

NO: 53 TTAGTATTATCTAAATT

SEQ ID OSM402 TAGAGCAAATACCTGATCTGG C.N. 55 to lift fragment 1 from strain, use with OSM371 NO: 54

SEQ ID OSM371 GTTGCCGCCGGGCGTTTTTTATGGCGCG

NO: 55 CCAGCGGTAAGTTTTATAGAAAAT

SEQ ID OSM403 TCTCTTAGATCCAGATCAGG C.N. 55 to lift fragment 2 from strain, use with OSM370 NO: 56

SEQ ID OSM370 ATCCTAGAAGCTTATCGAATTCGCGGCC

NO: 57 GCAGGGGGGATATAGATTTATATATAA

T

SEQ ID OSM335 ATCCTAGAAGCTTATCGAATTCGCGGCC C.N. 25 to lift from strain, use with OSM336 NO: 58 GCACAAGATACATCACATTGAAGG

SEQ ID OSM336 GTTGCCGCCGGGCGTTTTTTATGGCGCG

NO: 59 CCCAATATATGCGATATACGCAAAAAC

SEQ ID OSM329 ATCCTAGAAGCTTATCGAATTCGCGGCC C.N. 64 to lift from strain, use with OSM330 NO: 60 GCACAAATGGGCAGAGAGAG

SEQ ID OSM330 GTTGCCGCCGGGCGTTTTTTATGGCGCG

NO: 61 CCGATATTTCATTTTCTTCTTCCTCTCAC

SEQ ID OSM420 ATCCTAGAAGCTTATCGAATTCGCGGCC C.N. 66 to lift from strain, use with OSM421 NO: 62 GCGGTGAATGTAAAAATATTGATACAG

SEQ ID OSM421 GTTGCCGCCGGGCGTTTTTTATGGCGCG

NO: 63 CCAATTTAGTCCTCCTGGGG

SEQ ID OSM31 tgagttgattgcagtccagttac C.N. 59 to lift fragment 1 from Gen9 construct, use with NO: 64 OSM32

SEQ ID OSM32 GTTACCACCTACTATCTCTTCAGC

NO: 65

SEQ ID OSM33 TCTTTAGCTGAAGAGATAGTAGGTG C.N. 59 to lift fragment 2 from Gen9 construct, use with NO: 66 OSM34 SEQ ID OSM34 tatggaggtcaggtatgatttaaatg

NO: 67

SEQ ID OG0242 catcactgaccatttaaatcatacctgacctccataCGAATG pl5-pDR110 backbone for C.N. 59, use with OSM28 NO: 68 GCGATTTTCGTTCGTG

SEQ ID OSM28 gcttgactccagcgtaactggactgcaatcaactcaCGATC

NO: 69 AGACCAGTTTTTAAT

SEQ ID OSM386 ATCCTAGAAGCTTATCGAATTC C.N. 56 to lift fragment 1 from Genscript plasmid, use NO: 70 with OSM387

SEQ ID OSM387 ATGTCATTCATAGCCAGAGC

NO: 71

SEQ ID OSM388 AGATTTTAATGCTCTGGCTA C.N. 56 to lift fragment 2 from Genscript plasmid, use NO: 72 with OSM389

SEQ ID OSM389 CTCATCTTCTGATAATGGTCC

NO: 73

SEQ ID OSM390 CAGCCGAACGGACCATT C.N. 56 to lift fragment 3 from Genscript plasmid, use NO: 74 with OSM391

SEQ ID OSM391 GTTGCCGCCGGGCGT

NO: 75

SEQ ID OLA489 ATCCTAGAAGCTTATCGAATTCGCGGCC C.N. 51 to lift from strain, use with OLA490 NO: 76 GCACCTGCCTTCCTTTGATACAATTC

SEQ ID OLA490 GTTGCCGCCGGGCGTTTTTTATGGCGCG

NO: 77 CCTCAATTTATTGCTTTATTCATTGTGAC

TG

[001572] For long systems (> 10000 bases) when the donor strain was not available, the system was commercially synthesized in overlapping fragments (Table 4, "Cloning method" column). Systems amplified from genomic DNA or ordered as overlapping fragments were cloned into pSGl-rfp between the AscI and NotI sites using NEBuilder HiFI DNA Assembly cloning kit (NEB E5520S). The full list of sources used for cloning the systems into our model organisms is found in Table 4, including accessions of all strains ordered.

[001573] Transformation to B. subtilis was performed using MC medium as previously described (Wilson GA, Bott KF. (1968) Nutritional factors influencing the development of competence in the Bacillus subtilis transformation system. J Bacteriol. 95: 1439^49). MC medium was composed of 80 mM K ₂ HP0 ₄ , 30 mM KH ₂ P0 ₄ , 2% Glucose, 30 mM Trisodium citrate, 22 μ§/ιη1 Ferric ammonium citrate, 0.1% Casein Hydrolysate (CAA), 0.2% potassium glutamate. From an overnight starter of bacteria, 10 μΐ were diluted in 1 ml of MC medium supplemented with 10 μΐ 1M MgS0 ₄ . After 3 hours of incubation (37 °C, 200 rpm), 300 μΐ was transferred to a new 15 ml tube and -200 ng of plasmid DNA was added. The tube was incubated for another 3 hours (37 °C, 200 rpm), and the entire reaction was plated on LB agar plates supplemented with 100 μg/ml spectinomycin and incubated overnight at 30 °C.

[001574] For systems to be tested on E. coli, the cloned vector was transformed into E. coli MG1655 cells (ATCC 47076), and the resulting transformants were verified by PCR. For systems to be tested in B. subtilis, the cloned vector was transformed into B. subtilis BEST7003 cells. The system was integrated into the amyE locus, and resulting transformants were screened on starch plates for amylase-deficient phenotype. Whole-genome sequencing was then applied to all transformed B. subtilis and E. coli clones as described in (Ofir G, Melamed S, Sberro H, Silverman S, Doron S, Yaakov G, Mukamel Z, Sorek R. (2017) DISARM, a novel bacterial defense system with broad anti-phage activities, ibid) to verify system's integrity and lack of mutations.

[001575] As a negative control for transformation into B. subtilis, a transformant with an empty plasmid, containing only the spectinomycin resistance gene in the amyE locus, was used. As a negative control for transformation into E. coli, the wild-type E. coli MG1655 carrying an empty plasmid was used.

[001576] For strains with gene deletions and point mutations, plasmids containing systems with these deletions/mutations were commercially synthesized by Genscript. The mutated systems were transformed into B. subtilis and E. coli as described above, and clones used were fully sequenced to verify proper integration and sequence of the mutated systems.

[001577] Phage strains, cultivation, and plaque assay

[001578] The following B. subtilis phages were obtained from the Bacillus Genetic Stock Center (BGSC): SPOl (BGSCID 1P4), phi3T (BGSCID 1L1), SPp (BGSCID 1L5), SPR (BGSCID 1L56), phil05 (BGSCID 1L11), rhol4 (BGSCID 1L15), and SPP1 (BGSCID 1P7). Phage phi29 was obtained from the DSMZ (DSM 5546). Phages SBSphiJ and SBSphiC were isolated by us from mixed soil and leaves samples on B. subtilis BEST7003. For this, soil and leaves samples were added to a log phase B. subtilis BEST7003 culture and incubated overnight to enrich for B. subtilis phages. The enriched sample was centrifuged and filtered through 0.2 μηι filters, and the filtered supernatant was used to perform double layer plaque assays as described in Kropinski et al. (Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP. Enumeration of Bacteriophages by Double Agar Overlay Plaque Assay. In: Clokie MRJ, Kropinski AM, editors. Bacteriophages: Methods and protocols. NY: Humana Press; 2009. pp. 69-76). Single plaques that appeared after overnight incubation were picked, re-isolated 3 times, and amplified as described below.

[001579] E. coli phages (T4, T7, lambda-vir) were kindly provided by U. Qimron. Phages SECphil7, SECphil8 and SECphi27 were isolated as described in Wommack et al. (Wommack KE, Williamson KE, Helton RR, Bench SR, Winget DM. Methods for the Isolation of Viruses from Environmental Samples. In: Clokie MRJ, Kropinski AM, editors. Bacteriophages: Methods and protocols. NY: Humana Press; 2009. pp. 3-14) from sewage samples on E. coli MG1655. 0.2 μιη filtered concentrated sewage samples were used to perform double layer plaque assays, individual plaques were picked, re-isolated 3 times, and amplified as described below.

[001580] All phages isolated by us were Illumina sequenced following a library prep using the Nextera protocol (Baym M, Kryazhimskiy S, Lieberman TD, Chung H, Desai MM, Kishony R. (2015) Inexpensive multiplexed library preparation for megabase- sized genomes. PLoS One. 10: e0128036) and assembled using SPAdes v. 3.10.1 using the -careful and -cov-cutoff auto modifiers (Bankevich et al. (2012) A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing. J Comput Biol.;19: 455^177. doi: 10.1089/cmb.2012.0021). Assembled genomes and raw reads were deposited in the European Nucleotide Archive (ENA) under study accession PRJEB23070. Phage classification was done according to sequence homology to the closest known similar phage. Phage SECphil7 (ENA ERS 1981053) has a 5,538 bp genome and its closest relative is Coliphage WA3 (GenBank DQ079897.1, 66% coverage, 81% identity), indicating it is an ssDNA phage of the Microviridae family. Phage SECphil8 (ENA ERS 1981054) has a 44,798 bp genome and its closest relative is Escherichia phage Gluttony (GenBank KX534336.1, 92% coverage, 93% identity), indicating it is a member of the Siphoviridae family. Phage SECphi27 (ENA ERS1981055) has a 51,811 bp genome, and its closest relative is Escherichia phage vB_Eco_swan01 (GenBank LT841304.1, 91% coverage, 98% identity), indicating it is a member of the Siphoviridae family. Phage SBSphiJ (ENA ERS 1981056) has a 156,875 bp genome, and its closest relative is Bacillus phage Grass (GenBank KF669652.1, 91% coverage, 95% identity), indicating it is a member of the family Myoviridae. Phage SBSphiC (ENA ERS1981057) has a 144,651 bp genome, and its closest relative is Bacillus phage SP10 (GenBank AB605730.1, 94% coverage, 90% identity), indicating it is a member of the Myoviridae family. Siphoviridae and Myoviridae phage morphologies were verified by electron microscopy (EM). For the EM experiments, phage lysates were blotted onto copper grids, stained using uranyl acetate 2%, and visualized in FEI Tecnai T12 transmitting electron microscope.

[001581] Phages were propagated on either E. coli MG1655 or B. subtilis BEST7003 using the plate lysate method as previously described (Fortier L-C, Moineau S. (2009) Phage production and maintenance of stocks, including expected stock lifetimes. Methods Mol Biol. 501: 203- 19). Lysate titer was determined using the small drop plaque assay method as previously described (Mazzocco A, Waddell TE, Lingohr E, Johnson RP. (2009) Enumeration of bacteriophages using the small drop plaque assay system. [Internet]. Methods in molecular biology (Clifton, N.J.). pp. 81-5). Bacteria were mixed with MMB agar (LB + 0.1 mM MnCl ₂ + 5 mM MgCl ₂ + 5 mM CaCl ₂ + 0.5% agar), and serial dilutions of phage lysate in MMB were dropped on top of them. After the drops dried up, plates were incubated at room temperature overnight. Efficiency of plating (EOP) was measured by performing small drop plaque assay with the same phage lysate on control bacteria and bacteria containing the candidate defense system, and comparing the ratio of plaque formation.

[001582] To determine the number of infective centers during infection with T7 phage of control bacteria and bacteria containing type I or type II Zorya (Defense Systems la and lb, respectively), a modified version of the technique described in (Sing et al., (19909) J. Gen. Microbiol. 136:807-1815) as used. Zorya-lacking E. coli MG1655 or Zorya-containing cells were infected with T7 phage at MOI 0.05 and incubated for 10 min at 37°C to allow adsorption. Cells with adsorbed phages were then centrifuged (1 min, 14,000 rpm) at 4°C, washed once with ice-cold MMB medium, and resuspended in 200 mlice-cold MMB medium. Then, 100 ml aliquots of 10-fold dilutions of resuspended phage-infected cells were mixed with 100 ml of a Zorya-lacking E. coli MG1655 culture grown to O.D. 0.3. The mixture was plated using the double agar over-lay method and infection centers (plaques) were counted after overnight incubation in room temperature.

[001583] For the liquid culture infection with T7 phage, overnight cultures of Zorya-lacking E. coli MG1655 or Zorya-containing cells were diluted 1: 100 in MMB medium. 180 ml volumes of the diluted culture were dispersed into wells in a 96 -well plate and grown at 37°C with vigorous shaking until early log phase (O.D.600 0.3). 20 mlofT7 phage lysate were added at multiplicities of infection 0.05, 0.5 and 5 in three replicates. Optical density measurements at a wavelength of 600 nm were taken every 15 min using a TEC AN Infinite 200 plate reader in a 96-well plate.

[001584] Transformation efficiency assay

[001585] Transformation was performed using the MC medium as described above. To test plasmid transformation efficiency, the episomal Bacillus plasmid pHCMC05 was used (Titok M., Chapuis J, Selezneva Y., Lagodich A., Prokulevich V., Ehrlich S., Janniere L. (2003) Bacillus subtilis soil isolates: plasmid replicon analysis and construction of a new theta- replicating vector. Plasmid. 49: 53-62). Transformation efficiency was calculated by dividing the number of transformants that grew on LB plates containing 5 μg/ml chloramphenicol by the live count on LB plates.

[001586] DNA-seq and RNA-seq

[001587] DNA was extracted from bacteria using Qiagen DNeasy blood and tissue kit (Qiagen 69504). DNA libraries were constructed using the Nextera library preparation protocol as previously published (Baym M, Kryazhimskiy S, Lieberman TD, Chung H, Desai MM, Kishony R. (2015) Inexpensive multiplexed library preparation for megabase- sized genomes. PLoS One. 10: e0128036). RNA-seq was performed with the NEBNext Ultra Directional RNA Library Prep Kit (NEB, E7420) according to the manufacturer's instructions with modifications as previously described (Dar D, Shamir M, Mellin JR, Koutero M, Stern-Ginossar N, Cossart P, Sorek R. (2016) Term-seq reveals abundant ribo-regulation of antibiotics resistance in bacteria. Science. 352: aad9822-aad9822). Prior to library preparation, equal amounts of extracted RNA from 3-7 strain samples were pooled together and processed as a single library. All libraries were sequenced using the Illumina NextSeq500. The sequencing reads were aligned to the reference genomes of B. subtilis BEST7003 (Genbank: AP012496) and E. coli MG1655 (Genbank: NC_000913), and to the plasmid sequence of each system, using Novoalign 3.02.02 (Novocraft Technologies Sdn Bhd, http://www.novocraft.com) with the default parameters and [-r Random]. The coverage along the reference genomes was calculated, to check if each system exists in the genome (DNA-seq) or expressed (RNA-seq). The pooled RNA library was sequenced to a depth of 5 million reads per sample and later aligned to the reference genomes as described.

EXAMPLE 1

Identification of New Bacterial Defense Systems

[001588] Objective: To comprehensively identify new defense systems enriched within defense islands, in an attempt to systematically map the arsenal of defense systems that are at the disposal of bacteria and archaea in their fight against phages. Anti-phage defense systems were found to be frequently physically clustered in bacterial and archaeal genomes such that, for example, genes comprising restriction enzymes commonly reside in the vicinity of genes comprising infection systems and other phage resistance systems. The observation that defense systems are clustered in genomic "defense islands" has led to the suggestion that genes of unknown function residing within such defense islands may also participate in anti-phage defense.

[001589] Methods: The first step in this discovery effort was to identify gene families that are enriched near known defense systems in the microbial pan-genome (Figure 1A). For this, 14,083 protein families (pfams) were analyzed in >45,000 available bacterial and archaeal genomes (overall comprising >120 million genes). Each pfam represents a set of genes sharing a common protein domain. For each pfam, the prevalence of its member genes to reside in the vicinity (10 genes from each side) of one or more known defense genes was calculated (Figure IB). Pfams were selected that had at least 65% of their member genes found next to defense genes, and that their member genes appeared in diverse defense contexts in different genomes (at least 10% variability; Figure IB). These thresholds were selected as they capture the majority of pfams that comprise known defense systems (Figures 1A-1C; Table 1). The resulting set of 277 candidate pfams was supplemented by 58 additional gene families that were previously predicted to be associated with known defense systems (Makarova KS, Wolf YI, Snir S, Koonin E V. (2011) Defense islands in bacterial and archaeal genomes and prediction of novel defense systems. J Bacteriol. 193: 6039-56), altogether yielding a list of 335 candidate gene families (Table 2).

[001590] To check whether the defense-associated pfams belong to multi-gene systems, each such pfam was used as an anchor around which commonly associated genes were searched for (Figure 1A). For this, all the neighboring genes (10 genes from each side) from all the genomes in which members of the anchor pfam occurred were collected, and these genes were clustered based on sequence homology. Cassettes of gene clusters were then searched for that showed conserved order across multiple different genomes, marking such cassettes as candidate multi- gene systems (Figure 1A).

[001591] Results: The gene annotations in the resulting candidate systems were manually inspected in order to filter out likely false predictions. It was found that 39% of the cases represented non-defense, mobile genetic elements that are known to co-localize to defense islands (Table 2). Additionally, 30% of the resulting candidate defense systems found represented known defense systems whose pfams were not included in the original set of known defense pfams, and 17% belonged to operons probably performing metabolic functions or other functions not associated with defense (Figures 2A and 2B).

[001592] The remaining systems possibly represent putative new defense systems. To expand the predictions with new pfams that may be specifically enriched next to the putative new defense systems, a second prediction cycle was performed, this time adding the members of the predicted new systems to the positive defense pfam set (Figure 1A).

[001593] Altogether, 41 candidate single-gene or multi-gene systems were retrieved from this analysis (Table 3). This set of systems was further filtered to remove systems that were largely confined to a specific clade (e.g., systems appearing only in cyanobacteria or only in actinobacteria), resulting in a set of 28 candidate systems that showed broad phylogenetic distribution.

EXAMPLE 2

Verification of New Bacterial Defense Systems

[001594] Objective: To experimentally verify the candidate defense systems identified in Example 1, as having defense system activity.

[001595] Methods: Two bacteria strains were selected for verification of candidate defense systems, Escherichia coli str. MG1655 and Bacillus subtilis str. BEST7003. These bacteria were utilized as models to experimentally examine whether the predicted systems confer defense against phage (Figure 3A). None of the candidate new systems are naturally present in the genomes of these two bacteria. For each candidate system, source organisms were selected from which the system was taken and heterologously cloned into one of the model organisms. To increase the probability that the cloned system would be compatible and functionally expressed within the receiving bacterium, systems were selected from mesophilic organisms as close phylogenetically as possible to E. coli or to B. subtilis, and included the upstream and downstream intergenic regions so that promoters, terminators or other regulatory sequences would be preserved. Where possible at least two instances of each system were used (from two different source genomes), to account for the possibility that some systems may not be active in their source organism. The DNA of each system, spanning the predicted genes and the intergenic spaces, was synthesized or amplified from the source genome (donor species) and cloned either to E. coli (on a plasmid) or to B. subtilis (genomically integrated). As a control, the procedure was repeated with 5 known defense systems (instances of types I, II and III R-M systems, type III toxin/antitoxin system and an infection gene of the AbiH family) for which source organisms were similarly selected and cloning was performed into B. subtilis, as well a 6 ^th control comprised of the recently discovered DISARM defense system.

[001596] Results: Altogether, heterologously cloning of 61 representative instances of the 28 candidate new systems was attempted, and successful cloning was verified by whole genome sequencing (Table 4). For 27 of these 28 systems there was at least one candidate locus for which cloning was successful, and RNA-seq of the transformants showed that for 26 of the systems, at least one of the candidates was expressed in the receiving E. coli or B. subtilis strain.

[001597] The engineered bacteria were then challenged by an array of phages consisting of 10 B. subtilis and 6 E. coli phages, spanning the three major families of tailed dsDNA phages (myo-, sipho- and podo-phages), as well as one ssDNA phage infecting E. coli (Figures 3B, 3C, and 3D). Measuring phage efficiency of plating (EOP) on system-containing bacteria vs. control cells, it was found that 9 of the 26 tested systems (35%) showed protection from infection by at least one phage (Figures 3B, 3C, 3D, 3E, and 3F). In comparison, three of the six positive control systems showed defense, with the remaining 3 showing no protection against the 10 B. subtilis phages tested.

[001598] The 9 verified new systems were named after protective deities from various world mythologies. These defense systems are comprised of between 1 and 5 genes and span between 2 and 12 kb of genomic DNA (Table 6; Table 7).

[001599] Table 6: Composition of Defense Systems Reported

[001600] Table 7: Verified Defense Systems

JetD pfaml l795 Unknown functions 347 Topoisomerase VI

(DUF3322)- predicted by pfam09983 structural

(DUF2220) / similarities pfaml l796

(DUF3323)- pfam09664

(DUF2399)

[001601] W lere possible, system consistency was verified by testing for phage resistance in systems where individual genes were deleted (Figure 3G). We found between several hundreds and several thousand representations of each of the defense systems in sequenced microbial genomes, usually with broad phylogenetic distribution (Figure 3H; Tables 8-17). Most systems were detected in >10 taxonomic phyla, and 7 of them appear in archaea (Figure 3H).

[001602] Some of the systems seem to target a specific class of phages (e.g., the Thoeris system appears to specifically protect from myophages), while others, such as the Hachiman system, provide broader defense (Figure 3B). The genes comprising the new systems encode many protein domains that are commonly present in antiviral systems such as CRISPR-Cas and RNAi, including helicases, nucleases, and nucleic acid binding domains, in addition to many domains of unknown function and also atypical domains as described herein. Three of the systems contain membrane-associated proteins as predicted by the presence of multiple transmembrane helices. Further functional analyses was performed for a selected set of systems.

EXAMPLE 3

Genomic Identification and Analysis of the ZORYA System

[001603] Objective: Identify the candidate defense system based on the enrichment of the anchor pfam 15611.

[001604] Method: ZORYA was one of the systems identified in the first round of prediction. The anchor gene family for ZORYA was pfaml5611. This pfam had a defense score of 0.98 and a diversity score of 0.55.

[001605] Cloning of ZORYA into E. coli MG1655 - A cloning vector for large fragments was constructed by assembling the pl5a origin of replication (ori) from pACYCDuet-1 and the amyE integration cassette from plasmid pDRHO (see https://www(dot)ncbi(dot)nlm(dot)nm(dot)gov/pmc/articles/PMC 3814332/#pgen.l003892.s005 ). The pl5a ori was amplified using primers OG0174+OG0175 (a list of all primers is provided in Table 5). The amyE integration cassette was amplified using primers OG0176 + OG0185. The two fragments were assembled and transformed into E. coli cells using Gibson assembly cloning kit (NEB E5510S), and assembled plasmids were verified by restriction pattern and full sequencing.

[001606] The backbone of the above described vector was amplified using primers OGO309 + OG0310, adding to it a BamHI restriction site and a terminator site. The multiple cloning site of plasmid pBSIC (received from the BGSC) was amplified using primers OG0311 +OG0312. Both fragments were digested using Ascl and BamHI, ligated using T4 ligase and transformed into E. coli, resulting in plasmid pSGl-rfp. The plasmid was digestion verified and fully sequenced.

[001607] A representative ZORYA operon (locus) from E. coli E24377A (RefSeq accession NC_009801, coordinates 298890-307639 of the reverse strand, SEQ ID NO: XXXX) was commercially synthesized (GenScript) directly into pSGl-rfp between the Ascl and Notl sites of the multiple cloning site. The cloned vector was transformed into E. coli MG1655 cells, and the resulting transformants were verified by PCR and whole genome sequencing.

[001608] Phage cultivation and plaque assays have been described above.

[001609] For analysis in solid cultures, Zorya-containing cells (Defense System la or Defense System lb) were infected with T7 phage at MOI 0.05 and were incubated for 10 min at 37 °C to allow phage adsorption (Figure 4G). Cells with adsorbed phages were then centrifuged and washed to eliminate unabsorbed phages. These T7-infected cells were mixed together with E. coli MG1655 cells that lacked a Zorya defense system, and the mixture was plated using an agar overlay method. Phage bursts from successful infections were visualized as a single infection center on a lawn from the T7-sensitive E. coli strain, enabling an evaluation of the number of phages that have adsorbed and completed a successful infection cycle. For analysis in liquid cultures, T7 infection in liquid cultures of E. coli cells containing type I (Figure 4H) and type II (Figure 41) Zorya. Bacteria were infected at t= 0 at multiplicities of infection (MOI) of 0.05, 0.5 and 5.

[001610] Results: The Zorya system (named after a diety from the Slavic mythology) was identified based on the enrichment of the anchor pfaml5611, representing a domain of unknown function, within defense islands. Pfaml5611-containing gene clusters were previously reported as genomically associated with tellurium- and stress-resistance genes.

[001611] The computational analysis found this pfam to be part of a 4-gene system, zorABCD comprising ZorA, ZorB, ZorC, and ZorD polypeptides. Overall the ZORYA gene system encompasses ~9kb of DNA, with pfaml5611 being the third gene in the system (zorC; Figures 3C, and Figures 4A and 4B; Table 6). Initially 262 appearances of the ZORYA system were found in the dataset that was used in the automatic prediction.

[001612] A representative ZORYA operon from E. coli E24377A was cloned into E. coli MG1655 (Figure 4C), which does not contain an endogenous ZORYA system. The correct insertion of the system into the E. coli MG1655 genome was verified by whole genome sequencing.

[001613] In the next step, the E. coli MG1655 containing the ZORYA system (type I) was challenged with phage from three families of the dsDNA tail phages Caudavirales: T4 of Myoviridae, T7 of the Podoviridae, and Lambda of the Siphoviridae. T4 and T7 are obligatory lytic phages, while Lambda is a temperate phage. In addition to the wild-type Lambda phage (lambda-wt), a mutant that is an obligatory lytic phage was also used (lambda-vir). The results showed that the type I ZORYA system provided protection against T7 phage (2-3 orders of magnitude), and lambda-vir phage (at least 2 orders of magnitude), manifested by reduction in plaque formation on the ZORYA-containing strains (Figure 3E). Further analysis showed that the type I ZORYA system provided 10-10000-fold protection against infection by T7, SECphi27, and lambda-vir phages (Figures 3C and 3F). Further searches based on homologies to the first two genes in the system, zorA and zorB, revealed a second type of ZORYA, comprised of the 3 genes zorABE. (Figures 4D and 4E). A Type II Zorya system was cloned from E. coli ATCC8739 into E. coli MG1655 and yielded 10,000-fold defense against T7 and 10-fold against the ssDNA phage SECphil7 (Figure 3C and Figures 4B and 4C).

[001614] The first two genes of the Zorya system, zorA and zorB, contain protein domains sharing sequence homology with motA and motB, respectively (Figure 4B). MotA and MotB are inner membrane proteins that are part of the flagellar motor of bacteria. They assemble into a MotAB complex, which forms the stator of the flagellar motor (the static part within which the flagellar rotor swivels). The MotAB complex also forms the proton channel that provides the energy for flagellar rotation, coupling transport of protons into the cell with the rotation (Figure 4F). While zorB shares the same size and domain organization with motB (including the pfaml3677 and pfam00691 domains), zorA contains, in addition to the MotA domain (pfam01618), also a long C-terminal helical domain that is sometime identified as a "methyl- accepting chemotaxis domain" (COG0840). In addition to these two genes, Type I Zorya contains zorC, a gene of unknown function, and zorD, which is a large gene (encoding a ~1200aa polypeptide) comprising a helicase domain. Type II Zorya lacks zorC and zorD and instead contains zorE, a smaller gene comprising an HNH-endonuclease domain.

[001615] Analysis of the Zorya Defense Systems was performed by performing phage infection of Zorya Defense System-containing bacteria cells (Defense System la or Defense System lb) in solid and liquid cultures. Three replicates of cells containing type I Zorya, type II Zorya or no Zorya defense system are shown in Figures 4G-4I; data represent, for each replicate, the number of derived infection centers as a fraction from the average number of infection centers derived from Zorya-lacking ("No Zorya") cells (see Methods). The results show that in cells containing a type I Zorya defense system, only an average of 17% of infection events lead to successful phage progeny, while in cells containing a type Π Zorya defense system, 6% of the infected cells yield successful phage bursts. (Figures 4G) For liquid culture infection, shown are three replicates for each MOI, with each curve showing an individual replicate. The delayed collapse of Zorya-containing cultures suggests that most of the infected Zorya-containing cells undergo abortive infection, while a minority of cells produces viable phage progeny, which eventually accumulate to a high MOI leading to a culture collapse.

[001616] Conclusion: The Zorya defense system was identified in 1829 instances within 1663 sequenced bacterial genomes belonging to 12 phyla, marking this system as prevalent in at least 3% of sequenced bacteria (Table 8).

[001617] Table 8: ZORYA Defense System and Components Thereof

[001618] This table is presented in landscape orientation. Due to the number of columns, the table has been split into parts. Part A includes the first set of columns and therefore should be place to the left of subsequent parts (Part B and where relevant Part C). To avoid any doubt, the rows of the table in each part line up once the tables are placed together.

Table 8 (Part A)

Table 8 (Part B)

Table 8 (Part C)

[001619] The ZORYA system was not found in archaea. The system is present mainly in Proteobacteria and is markedly under-represented in Gram positive bacteria (Firmicutes and Actinobacteria), suggesting that its functionality depends on the double membrane organization of Gram negative bacteria (Table 8).

[001620] The gene composition of the Zorya system may point to several hypotheses as to its mechanism of action: It is possible that the system has adopted the MotAB proton channel to achieve depolarization of membrane potential upon phage infection. Possibly, ZorC, ZorD and ZorE may be involved in the sensing and inactivation of phage DNA, and if phage inactivation fails, the ZorAB proton channel opens up, leading to membrane depolarization and cell death. Under this hypothesis Zorya may be a conditional abortive infection system.

[001621] Interestingly, although Zorya-containing cells that were infected by phage T7 did not yield phage progeny in greater than 80% of infection events, infection of Zorya-containing cells in liquid cultures led to an eventual culture collapse, suggesting that Zorya-mediated defense involves death or metabolic arrest of the infected cell (Figures 4G-4I).

[001622] A second, more far-fetched hypothesis as to the function of Zorya may be that ZorAB localizes to the flagellar motor and alters the activity of the flagella in response to phage infection, presumably to evade infection or to avoid infection spreading.

EXAMPLE 4

Analysis of the Type I ZORYA System Components

[001623] Objective: To analyze the functionality of the Type I ZORYA system.

[001624] Methods: In order to study the four gene components of the ZORYA type I system, functionality was analyzed with mutated forms of each of the genes of the Type I ZORYA. Deletion mutants were made and the cloned vectors comprising specific gene deletions were transformed into E. coli MG1655 cells. Similarly, point mutations were generated and vectors comprising the point mutation constructs were transformed into E. coli MG1655 cells.

[001625] Results: All four genes in the system appear to be essential for its functionality, as deletion of each of the genes resulted in loss of protection from phage infection (Figure 4J). Moreover, the activity of the ZorAB proton channel appears to be necessary for the system's functionality, as point mutations in residues predicted to be critical for proton translocation through the channel (either ZorA: T147A/S 184A or ZorB:D26N) yielded a non-functional system (Figure 4J). Similarly, point mutations inactivating the Walker B motif of the helicase domain of ZorD, predicted to prevent ATP hydrolysis, resulted in loss of protection from phage infection.

EXAMPLE 5

Genomic Identification and Analysis of the Thoeris System

[001626] Objective: Identify the candidate defense system based on the enrichment of the anchor pfam08937 (TIR domain).

[001627] Methods: The Thoeris system was one of the systems identified in the first round of prediction. The Thoeris (Egyptian protective deity of childbirth and fertility) defense system is a two-gene system that was detected based on the enrichment of pfam08937 (TIR domain) next to defense genes (Figure 3B and Figure 5A). The Thoeris system in some embodiments, is termed the SIR2-TIR system. The TIR domain was previously reported as associated with prokaryotic argonaute genes.

[001628] Genomic identification and analysis of Thoeris (SIR2-TIR) systems - The anchor genes family for SIR2-TIR was pfam08937, a TIR-like domain (also annotated as DUF1863). It had a defense score of 0.68 and a diversity score of 0.33. It produced several subsystems, one of which was the SIR2-TIR subsystem with a defense score of 0.58 and diversity score of 0.91. It is composed of a SIR2-domain gene, with one or more TIR-domain genes in the immediate vicinity of +/- 5 genes from the SIR2 gene. Initially 78 appearances were found in the dataset that was used in the automatic prediction. Later, by manual expansion using the most up-to-date IMG dataset, and via homologs of the SIR2 gene, additional 1162 appearances were found, totaling in 1240 appearances in microbial genomes. The genes domains, properties and environment were explored using known bioinformatics tools.

[001629] Cloning of SIR2-TIR into B. subtilis BES7003-

A cloning vector for large fragments was constructed by assembling the pl5a origin of replication (ori) from pACYCDuet-1 and the amyE integration cassette from plasmid pDRHO (see

https ://www(dot)ncbi(dot)nlm(dot)nih(dot)gov/pmc/articles/PMC3814 332/#pgen.1003892. s005 ). The pi 5a ori was amplified using primers OG0174+OG0175 (a list of all primers is provided in Table 5). The amyE integration cassette was amplified using primers OG0176+OG0185. The two fragments were assembled and transformed into E. coli cells using Gibson assembly cloning kit (NEB E5510S), and assembled plasmids were verified by restriction pattern and full sequencing.

[001630] The backbone of the above described vector was amplified using primers OGO309+OGO310, adding to it a BamHI restriction site and a terminator site. The multiple cloning site of plasmid pBSIC (received from the BGSC) was amplified using primers OG0311+OG0312. Both fragments were digested using Ascl and BamHI, ligated using T4 ligase and transformed into E. coli, resulting in plasmid pSGl-rfp. The plasmid was digestion verified and fully sequenced.

[001631] The SIR2-TIR locus of Bacillus cereus MSX-D12 (RefSeq accession AHEQ01000050, coordinates 16453-19685 of the forward strand, SEQ ID NO: XXXXX) was commercially synthesized (GenScript) directly into pSGl-rfp between the Ascl and Notl sites of the multiple cloning site. The cloned vector was transformed into B/ subtilis BEST7003 [SD1] cells, and the resulting transformants were verified by PCR and whole genome sequencing.

[001632] Phage cultivation and plaque assay— In the initial studies, phi3T, SPOl, phi29 and phil05 phages were obtained from the Bacillus Genetic Stock Center (BGSC). Phages were propagated on B. subtilis BEST7003 using the plate lysate method as described by Fortier & Moineau (Fortier and Moineau (2009) Phage Production and Maintenance of Stocks, Including Expected Stock Lifetimes. In: Clokie M.R., Kropinski A.M. (eds) Bacteriophages. Methods in Molecular Biology™, vol 501. Humana Press)

[001633] Lysate titer was determined using the small drop plaque assay method as described by Mazzocco et al. (Mazzocco et al., 2009 ibid). Efficiency of plating (EOP) was measured by performing small drop plaque assay with the same phage lysate concentrations on control bacteria and bacteria containing the SIR2-TIR system and comparing the ratio of plaque formation. Follow-up experiments included plaque assays testing the EOP against JER, Chloro, SpBeta, SPR, phil05, rhol4, and SPP1.

[001634] Results: Thoeris (Egyptian protective deity of childbirth and fertility) is a system that was detected based on the enrichment of pfam08937 (TIR domain) next to known defense genes (Figure 5A). This domain was previously reported as associated with prokaryotic argonaute genes. The pfam08937 (DUF1863) domain was found to be significantly associated with known defense systems (defense score of 0.68). pfam08937 is a protein domain of unknown function, which was found to have structural homology with the TIR-domain (TIR = Toll-Interleukin receptor). TIR domains are known to be involved in bacterial immune system evasion in animals and plants.

[001635] As defense systems are frequently encoded by multiple genes working in concert that are co-localized in the genome (i.e. defense islands), the genetic context of the pfam08937- containing genes was analyzed. It was found that there is a subsystem in which upstream of the genes with a pfam08937 domain there is a gene with a SIR2 domain (pfaml3289). Also, in many cases there was more than one TIR-domain gene in proximity (Figure 5A). The defense score of this subsystem was 0.58, raising the hypothesis that these two (or more) genes together form an anti-phage defense system, denoted herein as SIR2-TIR. The SIR2 gene (pfaml3289) encodes a protein with a median size of 483 amino acids. The TIR genes can have one of two pfams, pfam08937 or pfaml3676 or pfam 08357. They encode proteins with a median size of 202 amino acids.

[001636] The first gene in the Thoeris system, denoted thsA, has NAD-binding domain that is sometimes annotated as a sirtuin (SIR2)-like domain or Macro domain. The second gene was denoted thsB, and contains the TIR domain, and can appear in one or more copies (Figure 5A). In some versions of the Thoeris system, ThsA polypeptide has a multi-transmembrane N- terminal domain.

[001637] Two instances of this system, one from Bacillus cereus MSX-D12 (SEQ ID NO: 10; where ThsA is predicted to be cytoplasmic) and the other from Bacillus amyloliquefaciens Y2 (SEQ ID NO: 11; where ThsA is predicted to be membrane-associated) (Figure 5B), were engineered into B. subtilis BEST7003, which does not contain an endogenous Thoeris defense system. The correct insertion of the system into the B. subtilis BEST7003 genome was verified by whole genome sequencing. The Thoeris system containing B. subtilis BEST7003 strains were challenged with multiple phages spanning the three families of the dsDNA tailed phages Caudavirales, as detailed above in the methods. The mycophages and podophages are obligatory lytic phages, while the siphophages are temperate.

[001638] The cloned systems were found to confer defense against myophages (Figures 3B and 3E, and Figures 5C and 5D). As the 3 tested myophages are very different from each other and share little gene homologies, it is possible that the Thoeris system is sensing or targeting a general feature in the biology of myophages rather than a specific sequence or genome modification. Both Thoeris genes, thsA and thsB, are essential in the system as deletion of either of them rendered the system inactive (Figure 5C). [001639] Interestingly, the TIR domain (acronym for Toll-Interleukin Receptor) is an important component of the innate immune systems of mammals, plants and invertebrates, where it mainly serves as a connector domain that transfers the immune signal once a molecular pattern of an offensive pathogen is sensed. In animals this domain frequently forms the intracellular portion of membrane-bound Toll-like receptors, whereas in plants it is often connected to intracellular R genes and can also be involved in direct recognition of pathogens. The findings presented here mark a common role for TIR domains in innate immunity across the three domains of life, and implies that the ancestry of this important component of eukaryotic innate immune systems may have stemmed from prokaryotic defense against phages.

[001640] The Thoeris system is broadly distributed in bacteria and archaea, and can be detected in at least 4% of the sequenced genomes we analyzed (2070 genomes; Table 9; Figure 3H).

[001641] Table 9: The Thoeris Defense System and Components Thereof

[001642] This table is presented in landscape orientation. Due to the number of columns, the table has been split into parts. Part A includes the first set of columns and therefore should be place to the left of subsequent parts (Part B and where relevant Part C). To avoid any doubt, the rows of the table in each part line up once the tables are placed together.

_{| | 1 |bkhldii 13319 B} A0 ₉₁₃₆₂₁ A _P 0 ₁ 4 _{5791 P RPE67 B RPE6775} 8 ₇₉₆₇₅ 8 ₇₉₆ GCA0008 ₂ 88 _751tt roeoacerauroera s _p ...._ 663

| _{| | | 1bdi 1332l B} AQ ₇ 4 ₇ 0 ₂₁ A _P 0 ₁ 4 _{6271 P} O _{l7 P} O _{l7 15} 00 ₆ 8 _{6 15} 00 ₆ 8 ₆ GCA00 ₁₅ 4 ₇ 8 _951tt roeoacerasseuomonas s _p s...._

| _{| |blbi 13326 E} N _Z 8 ₃₂₅ 0 ₁ A _P M _P 0 ₁ 00000 _{31 P} O _R37 C O _{R37 155} 8 _{92 1292} 0 ₃ 4 GCA000 ₃₇₂₆ 4 _51tttt roeoaceraauoacer crescenus..._

| _{| |bhbiii 13329 E} Q _B 0 ₇₅₅ 0 ₁ ATDO0 ₁ 00004 _{91 P} HD _IP 04 _S HD _IP 04 4 ₂ 8 ₉₉ 4 4 ₂ 8 ₉₉ 4 GCA00044 ₅ 08 _51tt roeoacera _p n _g oum s _p ...._

| _{| |bdi 13} 3 ^3l _EPJ 8 ₂₁ 8 ₉₁ AT _L O0 ₁ 0000 _{351 P} C _FII6 4 _P C _FII6 4 ₉₁₁₂ 4 _{2 9112} 4 ₂ GCA0004 _162351tt roeoaceraseuomonas s _p ...._

| _{| |bhbhhiiii} ¹³³³³ _EPR1 4 ₅₂₇₁ AUDA0 ₁ 000 _{1591 P IP26 S IP26} 4 ₂ 0 _{233 13} 4 ₆₇₉ 0 GCA0004 _219251ttt roeoacera _p n _g oum cnaense..._

_{I 1} ^| _{| |hlii} ¹³³³⁵ _E QM ₉₁₆ 04 ₁ AU _PS 0 ₁ 0000 _{151 Fsi S SI 12} 80 ₁₃ 44 ₅₇₇ GCA0004 _557252tt rmcuesa _py ococcus aureus..._

| _{| |hlii} ¹³³³ 8 _EPZ 04 ₉₆ 0 ₁ AU _P T0 ₁ 0000 _{161 F S13} 0 _{S S13} 0 ₁₂ 80 ₁₃ 44 ₅₇ 8 GCA00044 ₃₂ 4 _51tt rmcuesa _py ococcus aureus..._

| _{| |hlii} ¹³³ 4 ^l _EPZ 0 ₆₆₇₁₁ AU _P U0 ₁ 0000 _{151 F S123 S S123 12} 80 ₁₃ 44 ₅₇₉ GCA00044 _32651tt rmcuesa _py ococcus aureus..._

| _{| |hlii} ¹³³ 44 _EPZ 0 ₃₆ 8 ₆₁ AU _P V0 ₁ 0000 _{161 F Sl} OO _{S Sl} OO ₁₂ 80 ₁₃ 44 ₅ 80 GCA00044 _31251tt rmcuesa _py ococcus aureus..._

| _{| | | 1hlii} ¹³³ 4 ⁷ _EPZ11 4 ₉₅₁ AU _P W0 ₁ 0000 _{161 FS9} 4 _{S S9} 4 ₁₂ 80 ₁₃ 44 ₅ 8 ₁ GCA00044 ₃₂ 8 _51tt rmcuesa _py ococcus aureus..._

- ^| _{| |bll fiii} ¹³³⁵ 0 _E QC ₆ 0 ₁ 01 ¹ AVA _B 0 ₁ 00000 _{11 F} MTCC 8 _{711 L} MTCC 8 _{711 1613 1366} 0 ₅₂ GCA0004 _775151ttt rmcuesacoacusermenum..._

| _{| |ld dffliiiiiii} ¹³³⁵² _E QG ₂ 00 ⁷⁵¹ AV _I U0 ₁ 0000 _{721 F} DA000 _{65 P} DA000 _{65 1} 4 _{96 1151319} GCA00044 ₉₉ 4 _52ttt rmcuese _p ocosrumce..._

| _{| | | 1ld dffliiiiiii} ¹³³⁵ 4 _E QK ²²⁹⁹⁵¹ AVMW0 ₁ 0000 _{331 FP71 P P71 1} 4 _{96 1151} 4 ₃₆ GCA0004 _521252ttt rmcuese _p ocosrumce..._

| _{| |bb biiii} ¹³³⁵⁶ ET ^R9 4 ⁹²⁵¹ AVO _E 0 ₁ 0000 _{231 P} C _I7 8 A C _I7 8 ₁₃ 4 ₃ 0 ₇₃ GCA000 _5166152tttt roeoaceracneoaceraumann..._

| _{| |bbhliiii} ^{13362 E} Q ^L 8 ⁹² 4 ⁵¹ AVO _I 0 ₁ 0000 _{151 P} V _P2 00 ₇ 0 ₉₅ V V _P2 00 ₇ 0 _{95 123} 8 ₁₉₃ GCA0004 ₅ 4 _1651ttt roeoaceraro _p araaemo _y cus--..._

| _{| |bii} ^{13365 ER} H ⁷³²¹⁶¹ AV _SR 0 ₁ 000008 _{1 P E} GDH _P2 0 _{S E} GDH _P2 0 _1357297 GCA0004 _656152ttt roeoaceraerraa marcescens--..._

| _{| |hii} ^{13367 ER} T ⁶²⁵⁶²¹ AWXA0 ₁ 00000 _{31 F B} V ₃ C ₁₆₁ M _B V ₃ C _{161 1111} 4 ₅ 4 ₁₁₁₁ 4 ₅ 4 GCA0004 ₇ 8 _9651t rmcuese _g as _p aera s _p --...._

| _{| |hliiii} ^{13369 ER} T ⁶¹⁵⁵ 4 ¹ AWX _B 0 ₁ 000008 _{1 F B} V ₃ C _{26 P B} V ₃ C _{26 111113} 4 ₁₁₁₁₁₃ 4 GCA0004 ₇ 8 ₉ 8 _51tt rmcuese _p on _p us s _p ...._

| _{| |hliiii} ^{13372 ER} T ⁵ 84 ³⁶¹ AWX _B 0 ₁ 00004 _{61 F B} V ₃ C _{26 P B} V ₃ C _{26 111113} 4 ₁₁₁₁₁₃ 4 GCA0004 ₇ 8 ₉ 8 _51tt rmcuese _p on _p us s _p ...._

_{| 1} ^| _{| |bddii} ¹³³⁷ 4 ^ER T ¹⁹¹⁶ 8 ² AXDX0 ₂ 0000 ₃₉ ¹ _{PSJ3 P SJ3 13} 88 ₇₆ 0 GCA0004 ₇ 88 _652ttt roeoaceraseuomonas _p ua..._

| _{| |bdii} ^{13379 ESR699} 8 ²¹ AX _ZJ 0 ₁ 000 ₁ 00 ¹ _P V _RFP A0 _{5 P} V _RFP A0 _{5 1} 408 ₁₉₃ GCA0004 _963251tt roeoaceraseuomonas aeru _g nosa..._

| _{| | fliii} ¹³³ 8 ^{2 K} A ^J 84 ⁷⁵¹¹ AYO _L 0 ₁ 00004 ⁵¹ _F NY _{9 E} NY _{9 1351 1} 400808 GCA000 ₆ 48 _1951tt rmcuesnerococcusaecas..._

| _{| | fliii} ¹³³ 8 ^{5 K} A ^J 8 ²²²⁵¹ AYO _L 0 ¹ 000 ¹¹ 0 ¹ _F NY _{9 E} NY _{9 1351 1} 400808 GCA000 ₆ 48 _1951tt rmcuesnerococcusaecas..._

| _{| |bhdbli} ¹³³ 8 ^{7 E} TD8 ² 0 ³²¹ AYQA0 ¹ 0000 ⁵⁷¹ _{P R B6 1} 0 _{61 1} 4 ₁₅₁₆₂ GCA000 ₅ 0 ₆ 4 _252tttt roeoaceraooacer ca _p suaus..._

| _{| |bli} ¹³³ 8 ^{9 ESZ} 88 ⁷ 08 ¹ AY ^S C0 ¹ 00000 ³¹ _{P B} CAC _I A ₁ 4H _{2 1} 4 ₁₉ 8 _{76 1} 4 ₁₉ 8 ₇₆ GCA000 ₅ 0 _31951ttt roeoaceraasomonas s _p ...._ <

| ^| _|bdiii ^{13392 E} T ^J9932 0 ¹ A ^ZK M0 ¹ 0000 ²²¹ _F ATCC ₃₃ 0 _{99 E} ATCC ₃₃ 0 _{99 3551} 8 ₁₁₆₁₉ 0 ₂ GCA000 ₅₁ 04 _251ttt rmcuesuacerum noaum..._

b _iii A _tttttgg re _g aacer acnom _y ceemcomans

b ^{i 1339} 4 ^K Y ^K739 40 ¹ _{P S} A ₂₁ 4 _{9 S} A ₂₁ 4 _{9 1} 4 ₃ 4 ₂₆₃ GCA 00 _15962251t ^t _tt roeoacera sero _yp e e sr...

| ^| _|hblii ^{13397 E} T0 ⁹ 8 ⁹³²¹ A ^Z XX0 ¹ 0000 ²⁵¹ _F M _S X _{33 L} M _S X _{33 936596 936596} GCA000 _5129951 ^t rmcuesacnoanaeroacuum s _p ...._

| ^| _|llki ⁱ _ii ¹³³⁹⁹ GA ^E27 4 ⁷ 0 ^{1 B} AUT0 ¹ 0000 ⁵²¹ _{F J} CM ₉₁ 40 _{B J} CM ₉₁ 40 ₁₂₇ 8 _{91 123697} 0 GCA000 ₅₁₃ 0 ₉₅₁ ^t rmcuesacus waoenss..._

b _hbl ⁱ _iiii ¹³ 40 ¹ GAM0 ^{27951 BBPI} 0 ¹ 0000 ^{991 P} N _BR C ₁₅₁ 00 _S N _BR C ₁₅₁ 00 ₂ 8 _{213 1219} 04 ₉ GCA 000 ₇ 8 ₇₇₁₅₁ ^tt roeoacera _p n _g omonas _p ara _p aucmos...

| ^| _| ^b _{dll bh} ⁱ _ii ¹³ 404 CA ^E3 0 ⁹ 8 ^{21 B} X4 ⁷ 0 ²⁵ 0 ^{1 P} _RB5 0 _{B RB5} 0 ₂₅₇₃₁ 0 GCA000 _1956751 ^tt _tt roeoaceraoreearoncse _p ca..._

| ^| _| ^b _hlhl ⁱ _ii ¹³ 40 ⁷ CC ^P1 8 ⁵²³¹ CA ^L M0 ¹ 00 ¹¹ 8 ^{71 P} _R A8 _{S R} A8 40 ₃₂ 4 ₁₁₁ 8 ₁₅₇ GCA000 _3557251 ^tt _ttt roeoaceraenoro _p omonas mao _p a..._

| ^| _| ^b _{hbl bffl} ⁱ _iiiii ¹³ 4 ¹ 0 CD ^Z53 0 ⁶³¹ CC ^RK 0 ¹ 0000 ¹ 4 ^{1 P} N ₃₂₃₆₅₆ GCA000 ₉ 8 ₅₉₇₅₁ ^tt roeoaceraeorzoum _g ae _g aev ocnas...._

| ^| _| ⁱⁱ _i ¹³ 4 ¹² C ^EF522971 CCXC0 ¹ 000004 ^{1 F} M ₁ 4 _{L 1363 1363} GCA0008 ₂ 04 ₂₅₁ ^t _t rmcuesacococcus _g arveae..._

| ^| _| ⁱⁱ _i ¹³ 4 ¹ 4 C ^J D ⁵⁹⁵² 4 ¹ C ^K YA0 ¹ 0000 ^{151 F} _S M _R U ₂ 0 ₁ 4 _{S 1313 1313} GCA00 _11133651 ^t _tt rmcuesre _p ococcus _p neumonae..._

| ^| _|ll ⁱⁱ _i ¹³ 4 ^{16 EEL} 0 ⁹⁵²⁷¹ CM000 ^{7261 F} _B D _R DC4 _{B B} D _R DC4 _{1396 52697} 8 GCA000 _1611151 ^t rmcueseracus cereuser--..._

| ^| _|ll ⁱⁱ _i ¹³ 4 ¹ S ^EEL 84 ⁷ 8 ²¹ CM000 ⁷ 40 ^{1 F} AH ₁₂₇ ² _B AH _{1272 1396 526993} GCA000 _1613951 ^t rmcuesacus cereus..._

| ^| _|ll ⁱⁱ _i ¹³ 4 ^{2l EEL9} 0 ¹¹ 4 ¹ CM000 ⁷ 4 ^{11 F} AH ¹²⁷³ _B AH _{1273 1396 52699} 4 GCA00000 ₃₉₅₅₁ ^t rmcuesacus cereus..._

| ^| | _ld ⁱⁱ _ii ¹³ 4 ² 4 ^EF H ⁹²⁷¹⁹¹ CM000 ^{9551 F} ATCC ⁵³⁵¹⁶ _F ATCC _{53516 126} 0 ₅₂₅₂ 8 ₂ GCA000 _1596951 ^t rmcuesne _g oa ma _g na..._

| ^{| |ii} _{ii i} ¹³ 4 ^{26 EFR921711} CM00 ¹ 048 ^{1 F FSLS} 4 ³⁷ 8 _{L FSL S} 4 ₃₇ 8 ₁₆ 4 _{2 7} 0 ₂ 4 ₅₆ GCA000 ₁ 8 ₃ 88 ₅₁ ^t _t rmcuesserannocua--..._

| ^{| |b} _{d fl} ^{i 13} 4 ² 8 ^EIK629271 CM00 ^{15131 P SS1} 0 ¹ _{P SSl} O _{l 1} 0 ₃ 8 ₉₂ 4 GCA000 _2636752 ^tt roeoaceraseuomonasuorescens..._

| ^{| |b} _h ⁱ _iii ¹³ 4 ^3l A ^BB 40 ⁹⁶⁹¹ C ^P 000 ¹ 0 ^{92 P} XC ^L2 T XC _{L2 39765 317} 0 ₂₅ GCA0000 ₁₂₆ 0 ₅₁ ^tt roeoaceraomcros _p ra cruno _g ena--..._

| ^{| |b} _{hdf fd} ⁱ _i ¹³ 4 ³⁵ A ^B D ⁶ 880 ⁹¹ C ^P 000 ^{2671 P} D ^S M ¹⁵²³⁶ _R T ₁₁ 8 ₁₉₂ 84 _{3 33} 8 ₉₆₉ GCA0000 ₁₃₆ 0 ₅₁ ^tt roeoaceraooeraxerrreucens..._

| ^{| 1 | |bll} _hbll ⁱⁱ _iii ¹³ 4 ³⁷ A ^BR91 4 ⁶ 0 ¹ C ^P 000 ^{2691 P} M _J M ₃₇₅₂ 8 _{6 3752} 8 ₆ GCA0000 ₁₃₆₂₅₁ ^tt _tt roeoaceraarseeannoacerum s _p arsee...._

| ^{| |b} _hll ^{i 13} 440 A ^BI 4 ² 0 ³⁶¹ C ^P 000444 ^{1 P} M ^R7 _S M _{R7 6} 048 _{1 6} 048 ₁ GCA0000 ₁ 4 ₆₆₅₁ ^tt roeoaceraewanea s _p --...._ b _lll ^b _ii ⁱ A ⁵ _t ^t cnoacus _p euro _p neumonae serovar sr.

b ^{i 13} 44 ³ A ^B N ⁷ 4 ²⁷¹¹ C ^P 000 ^{5691 P L2} 0 _L2 0 4 ₁₆₂₆₉ GCA 0000 ₁₅ 88 ₅₁ ^tt roeoacera...

^{| 1| | |h} _h ^ld _i ^{i 13} 44 ⁶ A ^B 0 ³⁵ 4 ⁶⁶¹ C ^P 000 ⁶ 0 ^{91 E} C ⁵ M C ⁵ ₃₉₁₅₂ 40 ₂ 880 GCA0000 ₁₆₁₂₅₁ ^t _t ur ^y arcaeoaeanococcus mar _p aus..._ | ^{| |b} _hdbh ^{dii 13} 448 A ^BP732 0 ⁹¹ C ^P 000 ^{6651 P} ATCC ¹⁷ 0 ²⁵ _R ATCC ¹⁷ 0 ²⁵ ₁ 0 _{63 3} 4 ₉₁ 0 ₂ GCA0000 ₁₆ 40 ₅₁ ^tt _t roeoaceraooacer s _p aeroes..._

o o

o

< o o o o

670

Table 9 (Part C)

[001643] The TIR domain gene, thsB, has a strong tendency (35%) to appear in multiple copies clustered around the thsA gene (Figure 5A). Such duplication is typical to specificity- conferring genes in defense systems (such as the S subunit in type I R-M systems), where duplication followed by diversification serves for multiple specificities of the system. It is therefore possible that the TIR domain gene is responsible for identification of specific phage patterns, with multiple TIR domain genes serving for recognition of different phage components. Under this hypothesis, it is tempting to suggest that Thoeris is the prokaryotic ancestral form of pathogen-associated molecular pattern (PAMP) receptors.

[001644] A recent study showed that TIR domains can have enzymatic NAD+ hydrolase activities. In animal neurons, NAD+ hydrolase activity of the SARM1 TIR domain-containing gene leads to NAD+ depletion and generation of ADP-ribose and cyclic ADP-ribose that form signaling molecules regulating axonal degeneration. An E99A point mutation in the B. amyloliquefaciens Y2 KwaB protein, which aligns with the catalytic residue in the SARM1 NAD-cleaving TIR domain (Figure 5E) abolished the protective activity of Thoeris (Figure 5C). Moreover, point mutations in the ThsA NAD binding site predicted to abolish NAD binding also resulted in system inactivation (ThsA:N112A and ThsA:D100A/N115A for the B. cereus and B. amyloliquefaciens systems, respectively). These results mark NAD+ binding and hydrolysis as essential for the anti-phage activity of the Thoeris system.

EXAMPLE 6

Genomic Identification and Analysis of the Druantia System

[001645] Objective: Identify the candidate defense system based on the enrichment of the anchor COG1205.

[001646] Methods: As above

[001647] Results: Another system worthwhile of a brief discussion is the Druantia system (named after a deity from the Gallic mythology). This system is characterized by a very large protein (~1800-2 lOOaa) containing a DUF1998 (a domain of unknown function), as well as a helicase signature and a Walker A/B motif suggestive of ATP utilization. This polypeptide, named DruE, is encoded by a very large gene, named druE.

[001648] The druE gene is typically preceded by a set of highly variable genes with no recognizable domains or function prediction - either 3 genes sized 350-600aa each (Type I; druB, druC, and druD), or two genes sized 700aa-900aa (Type II; druX, druY), or a single large gene of 1000-1200aa (Type ΠΙ; druF) (Figures 6A and 6B). The system is in some cases also preceded by a gene druA, annotated as DUF4338, comprising yet another domain of unknown function; and Type II systems are also associated with a cytosine methylase (Figure 6A). In at least one instance, druA was downstream (3') of the druE gene. (Figure 6A- second embodiment of a Type I Druantia system)

[001649] A Type I system (Figure 6B) cloned from E. coli UMEA 4076-1 into E. coli MG1655 rendered the engineered strain resistant against 4 of the 6 phages tested, and by serially deleting each of the 4 genes in this system, it was verified that all 4 are essential for its activity (Figure 6C). Notably, DUF1998-containing genes are among the components of the recently reported DISARM and Dpd defense systems, where their function is also unknown. The sheer size of the Druantia system (12kb of genomic DNA) was unexpected and surprising, suggesting a complex function, and the near-complete absence of recognizable domains in its encoded polypeptides is suggestive of a new mode of defense not shared by prokaryotic defense systems whose mechanism are currently understood.

[001650] Elements of the Druantia system (Types I, II, and III, are presented in Table 10.

[001651] Table 10: The Druantia Defense System and Components Thereof

[001652] This table is presented in landscape orientation. Due to the number of columns, the table has been split into parts. Part A includes the first set of columns and therefore should be place to the left of subsequent parts (Part B and where relevant Part C). To avoid any doubt, the rows of the table in each part line up once the tables are placed together.

Table 10 (Part A)

Table 10 (Part B)

827

828

829

830

831

832

835

836

837

838

839

842

843

844

845

Table 10 (Part C)

Table 10 (Part D)

AN AO AP AQ AR AS AT AU

322 CUA18546.1 25120 28349 1065 2356943 23662831

323 CBW22537.1 25122 28351 1065 2371910 2381250

324 EYA28062.1 25124 28353 1065 293528 302868

325 EYA33840.1 25126 28355 1037 163999 173255

326 EXY44319.1 25128 28357 1052 187 9488

327 EYB10317.1 25130 28359 1065 1271019 1280359

328 EXZ67957.1 25132 28361 1037 20085 29341

329 EXY49047.1 25134 28363 1065 152 9492

330 EXY53776.1 25136 28365 1065 152 9492

331 EDS16319.1 25138 28367 1065 257362 266699

332 KXT38968.1 25140 28369 1065 23341 32678

333 EGW44031.1 25142 28371 1115 780950 790461

334 EEA03716.1 25144 28373 1107 62115 71698

335 KVM07645.1 25146 28375 1046 33574 42969

336 KVM11422.1 25148 28377 1046 33574 42969

337 KVM41743.1 25150 28379 1046 33574 42969

338 KVU39939.1 25152 28381 247 370491 377497

339 KVX50940.1 25154 28383 1046 44196 53591

340 CDH43329.1 25156 28385 655 4045 12202

341 KPA18786.1 25158 28387 1131 595 10180

342 AIY12567.1 25160 28389 1006 1117511 1126448

343 EYF08671.1 25162 28391 1135 53327 62186

344 KQM35754.1 25164 28393 995 5095 13992

345 ALD78155.1 25166 28395 212 3535505 3542469

346 KPR54497.1 25168 28397 1099 99 9732

347 KLV49874.1 25170 28399 1204 585396 595495

348 KLV71166.1 25172 28401 1099 3121291 3130924

349 BA081223.1 25174 28403 1185 1467812 1477691

350 ALB51924.1 25176 28405 581 3364334 3372410

351 AGE87744.1 25178 28407 581 3364989 3373065

352 KJR98716.1 25180 28409 1125 158922 168526

353 KLE94550.1 25182 28411 1099 34358 43990

354 KLF52639.1 25184 28413 1095 284140 293760

355 KLW28644.1 25186 28415 1099 100681 110313

356 KLW04618.1 25188 28417 1099 307954 317586

357 KLQ05989.1 25190 28419 978 81311 90573

358 KJI56237.1 25192 28421 978 146027 155289

359 KLP80554.1 25194 28423 736 56455 64988

360 KLW09756.1 25196 28425 1098 216709 226328

361 KLW05114.1 25198 28427 1098 663448 673067

362 KUQ64465.1 25200 28429 1098 9538

363 KUQ79075.1 25202 28431 736 8452

364 KPS33775.1 25204 28433 1098 80541 90160

AN AO AP AQ AR AS AT AU

365 ESL79956.1 25206 28435 981 2192087 22013551

366 KLW78404.1 25208 28437 736 3877717 3886250

367 KFC20757.1 25210 28439 1007 9124 18004

368 AKQ40860.1 25212 28441 1098 94495 103750

369 EDL49428.1 25214 28443 1099 20106 29358

370 KDM84273.1 25216 28445 978 6814 16064

371 CDU40544.1 25218 28447 1096 393610 403257

372 KHJ28073.1 25220 28449 1096 77599 87246

373 KHI41603.1 25222 28451 978 158488 167738

374 KHH60356.1 25224 28453 1096 25725 35372

375 KHH50449.1 25226 28455 1096 78872 88519

376 KHI22271.1 25228 28457 978 6097 15347

377 KHH70906.1 25230 28459 1096 36388 46035

378 KIG29579.1 25232 28461 978 23204 32454

379 AJE58951.1 25234 28463 1112 4932802 4942497

380 KIY28286.1 25236 28465 978 14480 23730

381 KIZ10080.1 25238 28467 978 13870 23120

382 KJJ46597.1 25240 28469 978 70937 80187

383 KJW55358.1 25242 28471 978 141103 150353

384 KJW51708.1 25244 28473 978 107073 116323

385 KLG52822.1 25246 28475 978 104422 113672

386 KLX28161.1 25248 28477 1096 4718573 4728220

387 KNF16924.1 25250 28479 978 6097 15347

388 KNF21006.1 25252 28481 978 104562 113812

389 KNF39647.1 25254 28483 978 6770 16020

390 KNG41000.1 25256 28485 978 150782 160032

391 KNZ99176.1 25258 28487 1096 44216 53863

392 KOZ12890.1 25260 28489 978 82598 91848

393 KOZ62952.1 25262 28491 978 13754 23004

394 KOZ92097.1 25264 28493 978 37881 47131

395 KOZ11136.1 25266 28495 978 13756 23006

396 KOZ14878.1 25268 28497 978 252679 261929

397 KOZ33113.1 25270 28499 978 79917 89167

398 KOZ23285.1 25272 28501 978 351820 361070

399 KOZ33453.1 25274 28503 978 13754 23004

400 KOZ38041.1 25276 28505 978 13755 23005

401 KOZ50107.1 25278 28507 978 351727 360977

402 KOZ47197.1 25280 28509 978 13752 23002

403 KOZ49679.1 25282 28511 978 351882 361132

404 KOZ66206.1 25284 28513 978 71615 80865

405 KOZ69711.1 25286 28515 978 351658 360908

406 KOZ74971.1 25288 28517 978 21854 31104

407 KOZ84785.1 25290 28519 978 70890 80140

AN AO AP AQ AR AS AT AU

408 KOZ80260.1 25292 28521 978 70889 80139

409 KOZ97703.1 25294 28523 978 140404 149654

410 CTS44167.1 25296 28525 847 218 9124

411 KPH47387.1 25298 28527 978 2323 11573

412 KPH46214.1 25300 28529 978 252468 261718

413 KPH35166.1 25302 28531 978 351816 361066

414 KPH38566.1 25304 28533 978 82601 91851

415 KP074476.1 25306 28535 978 13791 23041

416 KPP03701.1 25308 28537 978 104692 113942

417 KPP08800.1 25310 28539 978 105621 114871

418 KPP18159.1 25312 28541 978 353473 362723

419 KPP24073.1 25314 28543 978 13790 23040

420 KPP34586.1 25316 28545 978 13790 23040

421 KPP39156.1 25318 28547 978 13790 23040

422 KPP49344.1 25320 28549 978 13791 23041

423 KPP10373.1 25322 28551 978 13791 23041

424 KPP42095.1 25324 28553 978 13789 23039

425 KPP53665.1 25326 28555 978 353543 362793

426 KUH02057.1 25328 28557 978 17180 26430

427 KUH15975.1 25330 28559 734 973 9534

428 KUR31969.1 25332 28561 1096 1385 11032

429 ALZ66919.1 25334 28563 734 2305792 2314353

430 KUT20785.1 25336 28565 1096 48863 58510

431 KUT66045.1 25338 28567 734 37927 46488

432 KUS25251.1 25340 28569 1096 36024 45671

433 KUS40200.1 25342 28571 978 12399 21649

434 KUT25862.1 25344 28573 978 18618 27868

435 KUT18409.1 25346 28575 303 18302 25527

436 KUU15387.1 25348 28577 1096 48864 58511

437 KUT50335.1 25350 28579 978 22067 31317

438 KUX11802.1 25352 28581 1096 21668 31315

439 KUU59476.1 25354 28583 1096 34340 43987

440 KUU32878.1 25356 28585 978 18302 27552

441 KUU24019.1 25358 28587 978 12402 21652

442 KUV88045.1 25360 28589 978 12596 21846

443 KUW19172.1 25362 28591 978 93523 102773

444 KUW69121.1 25364 28593 978 50756 60006

445 KUW47144.1 25366 28595 978 18299 27549

446 KUT58152.1 25368 28597 1096 75379 85026

447 KUX52806.1 25370 28599 1096 12564 22211

448 KUX36551.1 25372 28601 1096 44479 54126

449 AMG81877.1 25374 28603 978 4045570 4054820

450 KXG88716.1 25376 28605 1112 36249 45944

AN AO AP AO. A AS AT AU

494 ENB03533.1 254641 286931 228 1250 8293

495 ERD09265.1 25466 28695 978 14046 23296

496 EKK37395.1 25468 28697 978 13796 23046

497 ELW28318.1 25470 28699 978 13976 23226

498 KDT83307.1 25472 28701 1119 16955 26628

499 KEK80771.1 25474 28703 1119 51355 61028

500 KEL07352.1 25476 28705 1119 15020 24693

501 KEK94608.1 25478 28707 1119 17085 26758

502 EKK36705.1 25480 28709 978 13809 23059

503 EKI06061.1 25482 28711 978 70939 80189

504 EIL64996.1 25484 28713 734 48987 57548

505 EKI02733.1 25486 28715 978 71504 80754

506 KEL97938.1 25488 28717 1119 5160 14833

507 KEM08516.1 25490 28719 1119 17042 26715

508 KEM49611.1 25492 28721 978 17146 26396

509 KEN01217.1 25494 28723 648 970 9273

510 KEM09156.1 25496 28725 648 1056 9359

511 KEM25600.1 25498 28727 648 1069 9372

512 KEM85725.1 25500 28729 1119 16764 26437

513 KEN65097.1 25502 28731 1119 4411 14084

514 ELW21806.1 25504 28733 978 23163 32413

515 EKK71768.1 25506 28735 738 72931 81461

516 EKK61090.1 25508 28737 978 13790 23040

517 EKK52334.1 25510 28739 978 13792 23042

518 EKK87668.1 25512 28741 978 81736 90986

519 EKV85100.1 25514 28743 978 13804 23054

520 EKV70654.1 25516 28745 978 13802 23052

521 EKW05773.1 25518 28747 978 79877 89127

522 EKW03271.1 25520 28749 978 13798 23048

523 ESD10540.1 25522 28751 1104 4185 13813

524 ESA83484.1 25524 28753 1112 48996 58691

525 ESD19200.1 25526 28755 399 7559

526 ESD45642.1 25528 28757 1112 48833 58528

527 ESD61125.1 25530 28759 589 18577 26703

528 ESD71192.1 25532 28761 1104 20331 29959

529 ESD92013.1 25534 28763 1112 60634 70329

530 ESD92685.1 25536 28765 1112 1234 10929

531 EKW04268.1 25538 28767 978 13806 23056

532 EKW19025.1 25540 28769 978 13808 23058

533 EIN33838.1 25542 28771 982 13788 23050

534 EKW08488.1 25544 28773 978 13808 23058

535 ELW29952.1 25546 28775 978 2439 11689

536 EKW22422.1 25548 28777 233 55 7070

AN AO AP AO. AR AS AT AU

537 EKW74795.1 255501 287791 978 13790 23040

538 EKY34592.1 25552 28781 978 13806 23056

539 EKW38125.1 25554 28783 978 13800 23050

540 EKW51347.1 25556 28785 978 13792 23042

541 EKW70676.1 25558 28787 978 79810 89060

542 EKW68014.1 25560 28789 982 14005 23267

543 EKW71372.1 25562 28791 978 10852 20102

544 EKY34709.1 25564 28793 1117 416 10083

545 EKW75843.1 25566 28795 978 13959 23209

546 ELW46372.1 25568 28797 978 13998 23248

547 EKW96657.1 25570 28799 978 79287 88537

548 EKW96261.1 25572 28801 978 13993 23243

549 ELV31250.1 25574 28803 978 30317 39567

550 ELV35524.1 25576 28805 978 30154 39404

551 ELV44384.1 25578 28807 978 842 10092

552 ELW27708.1 25580 28809 978 13946 23196

553 ELV47168.1 25582 28811 978 13933 23183

554 ELW24263.1 25584 28813 1119 4040 13713

555 ELV62897.1 25586 28815 978 19714 28964

556 ETJ70883.1 25588 28817 1129 37993 47697

557 ELV63260.1 25590 28819 978 4590 13840

558 ACA79489.1 25592 28821 1119 4256022 4265695

559 ETJ79054.1 25594 28823 287 15819 22996

560 ERB88975.1 25596 28825 978 13919 23169

561 ERD08337.1 25598 28827 978 14296 23546

562 ERD05021.1 25600 28829 978 14116 23366

563 ERD20748.1 25602 28831 978 14235 23485

564 ERD22951.1 25604 28833 978 14065 23315

565 ERB79217.1 25606 28835 978 81295 90545

566 ERD23992.1 25608 28837 978 13981 23231

567 ERD35316.1 25610 28839 978 14139 23389

568 ERD37185.1 25612 28841 978 14019 23269

569 ERD26786.1 25614 28843 1119 19748 29421

570 ERD52931.1 25616 28845 978 14048 23298

571 ERD40232.1 25618 28847 978 14087 23337

572 ERD45129.1 25620 28849 978 14048 23298

573 ERB91861.1 25622 28851 978 81300 90550

574 ERCOO 104.1 25624 28853 978 81417 90667

575 ERC08312.1 25626 28855 978 14059 23309

576 ERC07682.1 25628 28857 978 13951 23201

577 ERC15339.1 25630 28859 978 13964 23214

578 ERC23446.1 25632 28861 359 7395

579 ERC10660.1 25634 28863 978 13969 23219

AN AO AP AQ AR AS AT AU

623 EKJ05365.1 25722 28951 978 30254 39504

624 EKI92954.1 25724 28953 978 116536 125786

625 EKJ00853.1 25726 28955 978 27618 36868

626 EIP72927.1 25728 28957 978 13800 23050

627 EKJ19826.1 25730 28959 978 13802 23052

628 EKJ20863.1 25732 28961 978 13806 23056

629 EKJ36028.1 25734 28963 978 13806 23056

630 EKJ47664.1 25736 28965 978 13808 23058

631 EKJ36500.1 25738 28967 978 13802 23052

632 EIP38854.1 25740 28969 978 79651 88901

633 EIO92502.1 25742 28971 978 30370 39620

634 EI087495.1 25744 28973 978 30410 39660

635 EIP27285.1 25746 28975 978 858 10108

636 EIP10340.1 25748 28977 978 13800 23050

637 EIP33943.1 25750 28979 978 13798 23048

638 EIP40273.1 25752 28981 978 13804 23054

639 EIP48989.1 25754 28983 978 13794 23044

640 EIP35348.1 25756 28985 978 30343 39593

641 EIP50031.1 25758 28987 978 30347 39597

642 EKI03042.1 25760 28989 978 13596 22846

643 EST65290.1 25762 28991 734 297776 306337

644 EMX76367.1 25764 28993 191 49211 56397

645 EMX78113.1 25766 28995 443 53674 61616

646 EKH36316.1 25768 28997 978 13812 23062

647 EIN15910.1 25770 28999 978 13808 23058

648 EKH25287.1 25772 29001 978 332440 341690

649 EKH13353.1 25774 29003 978 13810 23060

650 EIN16633.1 25776 29005 978 384 9634

651 EIN33028.1 25778 29007 978 392 9642

652 EKH48831.1 25780 29009 978 13808 23058

653 EKJ48108.1 25782 29011 978 13813 23063

654 EFI22363.1 25784 29013 580 393643 401742

655 EFF02930.1 25786 29015 580 394852 402951

656 EQN36979.1 25788 29017 1096 424617 434264

657 EQQ54037.1 25790 29019 1096 103333 112980

658 EQQ62152.1 25792 29021 1096 309247 316458

659 EQQ82444.1 25794 29023 1096 390614 400261

660 EQR15649.1 25796 29025 1096 438811 448458

661 EQR29833.1 25798 29027 1096 391018 400665

662 EQR56341.1 25800 29029 1096 391165 400812

663 EQR70530.1 25802 29031 1096 553783 563430

664 EQR73387.1 25804 29033 1096 4977594 4987241

665 ESP12227.1 25806 29035 1119 351091 360764

AN AO AP AQ AR AS AT AU

666 EQR98264.1 25808 29037 1096 2757793 27674401

667 EQS19619.1 25810 29039 1096 427754 437401

668 EQS44553.1 25812 29041 1096 3133555 3143202

669 EQS43787.1 25814 29043 1096 1053884 1063531

670 ERA63200.1 25816 29045 1096 388536 398183

671 EQS73533.1 25818 29047 1096 430980 440627

672 EQS83532.1 25820 29049 1096 426028 435675

673 EQT06518.1 25822 29051 1096 102775 112422

674 EQT31740.1 25824 29053 1119 352526 362199

675 EQT33090.1 25826 29055 1096 3599701 3609348

676 EQT84559.1 25828 29057 1119 636062 645735

677 EQU07295.1 25830 29059 1096 262560 272207

678 EQU46107.1 25832 29061 847 2189631 2198531

679 EQU56270.1 25834 29063 1096 388758 398405

680 EQU82065.1 25836 29065 1096 4855064 4864711

681 EQN74805.1 25838 29067 1096 658360 668007

682 EQV15998.1 25840 29069 516 393529 401436

683 EQO01911.1 25842 29071 1096 430981 440628

684 EQ057393.1 25844 29073 1119 624054 633727

685 EQO66404.1 25846 29075 1119 1181503 1191176

686 EQ074549.1 25848 29077 1096 3758553 3768200

687 EQP20053.1 25850 29079 1096 388587 398234

688 EQP30925.1 25852 29081 1096 388774 398421

689 EQP87866.1 25854 29083 1096 3466364 3476011

690 EQV39984.1 25856 29085 1096 73576 83223

691 EQV77953.1 25858 29087 1096 2087647 2097294

692 EQV75317.1 25860 29089 1096 4273553 4283200

693 EQV93984.1 25862 29091 1096 3719713 3729360

694 EOX00082.1 25864 29093 1096 390270 399917

695 EOW11794.1 25866 29095 660 1242010 1250349

696 ELF04267.1 25868 29097 1096 558868 568515

697 ELI36531.1 25870 29099 1096 36436 46083

698 ELI49201.1 25872 29101 1119 4408 14081

699 EOW43091.1 25874 29103 1096 709076 718723

700 ELI49521.1 25876 29105 1096 29428 39075

701 EOW53695.1 25878 29107 362 410393 417840

702 EOW53660.1 25880 29109 362 460969 468416

703 EOW60867.1 25882 29111 1096 64416 74063

704 ELG97962.1 25884 29113 717 2669732 2678242

705 ELH03273.1 25886 29115 1096 560405 570052

706 ELF28433.1 25888 29117 1119 2025589 2035262

707 EU30966.1 25890 29119 1096 40359 50006

708 EOW72674.1 25892 29121 894 398221 407262

AN AO AP AQ AR AS AT AU

709 ELC68672.1 25894 29123 1096 435063 4447101

710 ELC04769.1 25896 29125 1096 390301 399948

711 EOV27242.1 25898 29127 1096 64489 74136

712 ELH63191.1 25900 29129 1119 392427 402100

713 ELD00701.1 25902 29131 1096 695401 705048

714 ELD16726.1 25904 29133 1096 2591525 2601172

715 EOV39941.1 25906 29135 1096 1942871 1952518

716 EOX13559.1 25908 29137 894 1232970 1242011

717 ELD74208.1 25910 29139 1096 3687026 3696673

718 ELC51201.1 25912 29141 1096 61006 70653

719 ELC65366.1 25914 29143 1096 410891 420538

720 ELG08156.1 25916 29145 1119 1535102 1544775

721 ELE06289.1 25918 29147 221 439185 445994

722 ELE13900.1 25920 29149 1096 2561123 2570770

723 EOV54809.1 25922 29151 1096 91839 101486

724 ELE75377.1 25924 29153 1096 655020 664667

725 EU61314.1 25926 29155 1096 36434 46081

726 ELE76411.1 25928 29157 1096 390340 399987

727 EGI23326.1 25930 29159 1112 73149 82844

728 EIF87147.1 25932 29161 1119 451385 461058

729 KDG67766.1 25934 29163 380 3753850 3761349

730 EFK89792.1 25936 29165 1112 30388 40083

731 EFK27049.1 25938 29167 978 7440 16690

732 EFI89546.1 25940 29169 295 155 7399

733 EFJ72999.1 25942 29171 1112 22606 32301

734 EKH61409.1 25944 29173 978 13807 23057

735 EKJ52944.1 25946 29175 978 13796 23046

736 EMS03601.1 25948 29177 1119 11246 20919

737 KDM81020.1 25950 29179 978 156383 165633

738 AHY73975.1 25952 29181 1119 5408661 5418334

739 AHG 12156.1 25954 29183 1119 5408663 5418336

740 EYZ76663.1 25956 29185 978 104414 113664

741 EYW98551.1 25958 29187 978 140023 149273

742 EYV59036.1 25960 29189 978 140415 149665

743 EZE90568.1 25962 29191 978 7566 16816

744 EYV46018.1 25964 29193 978 106704 115954

745 EYV44257.1 25966 29195 978 139248 148498

746 EYV24874.1 25968 29197 978 140321 149571

747 EYV22944.1 25970 29199 978 8920 18170

748 EYV18169.1 25972 29201 978 106497 115747

749 EYV20079.1 25974 29203 978 7135 16385

750 EYV16483.1 25976 29205 978 139329 148579

751 EYZ14530.1 25978 29207 978 6648 15898

AN AO AP AQ A AS AT AU

752 EZQ47393.1 25980 292091 978 302436 3116861

753 EZQ50283.1 25982 29211 978 351950 361200

754 EFX13463.1 25984 29213 978 293415 302665

755 EFX18240.1 25986 29215 978 293366 302616

756 KKF77972.1 25988 29217 978 14601 23851

757 KKF80704.1 25990 29219 978 13870 23120

758 KKY44755.1 25992 29221 978 3452 12702

759 ALH93946.1 25994 29223 978 5197926 5207176

760 KRQ04868.1 25996 29225 978 284710 293960

761 EYZ52259.1 25998 29227 978 351745 360995

762 EYZ38308.1 26000 29229 978 351772 361022

763 EYZ37415.1 26002 29231 978 13749 22999

764 EYZ36218.1 26004 29233 978 351747 360997

765 EYX13627.1 26006 29235 978 13750 23000

766 EYX12328.1 26008 29237 978 351786 361036

767 EYX02203.1 26010 29239 978 13747 22997

768 EZD85329.1 26012 29241 978 80155 89405

769 EZE88805.1 26014 29243 978 14613 23863

770 EYV70455.1 26016 29245 978 129736 138986

771 EZE89448.1 26018 29247 978 251411 260661

772 EYV67647.1 26020 29249 978 302523 311773

773 EYX70059.1 26022 29251 978 250164 259414

774 EYX57444.1 26024 29253 978 351787 361037

775 EYX54549.1 26026 29255 978 351787 361037

776 EYX48135.1 26028 29257 978 351787 361037

777 EYX44882.1 26030 29259 978 351787 361037

778 EYX43992.1 26032 29261 978 13749 22999

779 EYX33005.1 26034 29263 978 351787 361037

780 EYX30697.1 26036 29265 978 351787 361037

781 EYX27760.1 26038 29267 978 13749 22999

782 EYW85333.1 26040 29269 978 351787 361037

783 EYW83366.1 26042 29271 978 351787 361037

784 EYW75520.1 26044 29273 978 13748 22998

785 EYW71150.1 26046 29275 978 13748 22998

786 EYW67180.1 26048 29277 978 351652 360902

787 EYW64049.1 26050 29279 978 351651 360901

788 EYW57177.1 26052 29281 978 351652 360902

789 EYW49141.1 26054 29283 978 13748 22998

790 EYW49454.1 26056 29285 978 13748 22998

791 EYW43049.1 26058 29287 978 351652 360902

792 EYW39161.1 26060 29289 978 13748 22998

793 EYW34610.1 26062 29291 978 13749 22999

794 EYW25813.1 26064 29293 978 351733 360983

AN AO AP AQ AR AS AT AU

795 EYW27181.1 26066 29295 978 79670 88920

796 EYW24510.1 26068 29297 978 80111 89361

797 EYW09906.1 26070 29299 978 351749 360999

798 EYW13501.1 26072 29301 978 80139 89389

799 EZF08561.1 26074 29303 978 351749 360999

800 EYW07432.1 26076 29305 978 13749 22999

801 EZF05482.1 26078 29307 978 351681 360931

802 EDZ88246.1 26080 29309 978 3701544 3710794

803 EDZ83804.1 26082 29311 978 2581794 2591044

804 EDU68764.1 26084 29313 978 75340 84590

805 EDU54287.1 26086 29315 978 83808 93058

806 ACI36184.1 26088 29317 978 5437955 5447205

807 EDU34142.1 26090 29319 978 82700 91950

808 EDZ77846.1 26092 29321 978 2713466 2722716

809 EDU76195.1 26094 29323 978 115023 124273

810 EDU82677.1 26096 29325 978 313683 322933

811 EDU87436.1 26098 29327 978 115901 125151

812 EDU97874.1 26100 29329 978 80068 89318

813 AAG59483.1 26102 29331 1117 5393893 5403560

814 AIG71773.1 26104 29333 978 5413191 5422441

815 EZA89752.1 26106 29335 978 351745 360995

816 EZB05975.1 26108 29337 978 351787 361037

817 EZB04404.1 26110 29339 978 351787 361037

818 EZB11566.1 26112 29341 978 351878 361128

819 EYV89286.1 26114 29343 978 351787 361037

820 EZB20621.1 26116 29345 978 351787 361037

821 EZB18142.1 26118 29347 978 79602 88852

822 EZB30350.1 26120 29349 978 351749 360999

823 EFX08674.1 26122 29351 978 287972 297222

824 EZB32014.1 26124 29353 978 13750 23000

825 EZB41523.1 26126 29355 978 13747 22997

826 EZB46984.1 26128 29357 978 13747 22997

827 EZB48637.1 26130 29359 978 14769 24019

828 EZB48353.1 26132 29361 488 7782

829 EZB52649.1 26134 29363 714 20977 29436

830 EZB74689.1 26136 29365 978 14053 23303

831 EZB73673.1 26138 29367 978 13126 22376

832 EZB87910.1 26140 29369 978 14311 23561

833 EZB80136.1 26142 29371 978 351521 360771

834 EZB81694.1 26144 29373 978 13944 23194

835 EZB95443.1 26146 29375 978 146895 156145

836 EZC17286.1 26148 29377 596 351887 359991

837 EZC37646.1 26150 29379 978 351954 361204

AN AO AP AQ AR AS AT AU

838 EZC28523.1 26152 29381 978 79400 88650

839 EZC43982.1 26154 29383 978 251669 260919

840 EZC48749.1 26156 29385 978 351852 361102

841 EZC62956.1 26158 29387 978 63484 72734

842 EZC70421.1 26160 29389 978 14637 23887

843 EZC77661.1 26162 29391 978 14037 23287

844 EZC64796.1 26164 29393 978 352100 361350

845 EZC83413.1 26166 29395 978 14468 23718

846 EZC90332.1 26168 29397 978 13966 23216

847 EZC92770.1 26170 29399 978 14435 23685

848 EZC86952.1 26172 29401 978 13396 22646

849 EZD00268.1 26174 29403 978 82072 91322

850 EYV84724.1 26176 29405 978 352019 361269

851 EZD08969.1 26178 29407 978 351981 361231

852 EZD17520.1 26180 29409 978 352026 361276

853 EZD15758.1 26182 29411 978 351390 360640

854 EZD19489.1 26184 29413 978 351929 361179

855 EZD75268.1 26186 29415 978 13749 22999

856 BAB38682.1 26188 29417 1117 5363890 5373557

857 AIF96933.1 26190 29419 1117 5389312 5398979

858 AJA29435.1 26192 29421 1117 5354079 5363746

859 ACT75063.1 26194 29423 1117 5393599 5403266

860 EEC29561.1 26196 29425 978 1424935 1434185

861 EYZ63881.1 26198 29427 978 12253 21503

862 EFX22733.1 26200 29429 280 7159

863 ADD59518.1 26202 29431 1119 5202149 5211822

864 ENC26728.1 26204 29433 1096 30243 39890

865 ENA10895.1 26206 29435 1096 68021 77668

866 EMZ79274.1 26208 29437 630 79591 87840

867 ENG24752.1 26210 29439 580 361 8460

868 ENG35038.1 26212 29441 580 308 8407

869 ENG38630.1 26214 29443 580 299 8398

870 END33528.1 26216 29445 580 225 8324

871 ENE04445.1 26218 29447 580 299 8398

872 ENG47568.1 26220 29449 648 74 8377

873 ENG50953.1 26222 29451 580 274 8373

874 ENG56304.1 26224 29453 580 275 8374

875 ENG57263.1 26226 29455 580 248 8347

876 ENH40673.1 26228 29457 580 249 8348

877 ENG66729.1 26230 29459 580 341 8440

878 ENG74276.1 26232 29461 648 133 8436

879 EST67461.1 26234 29463 978 52346 61596

AN AO AP AQ AR AS AT AU

880 EST67375.1 26236 29465 978 26084 35334

881 EIN65415.1 26238 29467 515 15190 23051

882 ELV75968.1 26240 29469 978 13903 23153

883 ELV90963.1 26242 29471 1119 4036 13709

884 EIN69804.1 26244 29473 978 13804 23054

885 EIN85520.1 26246 29475 978 13808 23058

886 ELV76554.1 26248 29477 978 22913 32163

887 ELV98806.1 26250 29479 1119 13633 23306

EIN94345.1 26252 29481 982 80889 90151

889 EKH63850.1 26254 29483 978 13810 23060

890 EIN88191.1 26256 29485 978 30257 39507

891 EIN89776.1 26258 29487 978 116447 125697

892 EIO09773.1 26260 29489 978 13804 23054

893 EIN49113.1 26262 29491 978 30335 39585

894 EIO07042.1 26264 29493 978 13806 23056

895 EIO07418.1 26266 29495 978 13802 23052

896 EI011194.1 26268 29497 978 13808 23058

897 EKH20918.1 26270 29499 978 13807 23057

898 ELW23233.1 26272 29501 978 4450 13700

899 EKI33365.1 26274 29503 1119 328 10001

900 EI024462.1 26276 29505 233 60 7075

901 EKH71762.1 26278 29507 978 13807 23057

902 EI049153.1 26280 29509 978 13808 23058

903 EKH87902.1 26282 29511 978 13810 23060

904 ELV91643.1 26284 29513 978 30222 39472

905 ELV93151.1 26286 29515 978 6984 16234

906 EKH83462.1 26288 29517 978 13812 23062

907 EIN52367.1 26290 29519 978 13804 23054

908 EKH07682.1 26292 29521 978 369039 378289

909 ELW12425.1 26294 29523 978 13985 23235

910 EIN68647.1 26296 29525 978 13804 23054

911 ACB20170.1 26298 29527 1119 4912969 4922642

912 ERE14329.1 26300 29529 978 82268 91518

913 ERC65824.1 26302 29531 978 80921 90171

914 ERC74188.1 26304 29533 287 14108 21285

915 ERC92369.1 26306 29535 978 4611 13861

916 EG 128994.1 26308 29537 1119 296390 306063

917 EKH95567.1 26310 29539 978 13812 23062

918 EI046356.1 26312 29541 978 245564 254814

919 EIO79510.1 26314 29543 978 7053 16303

920 EI065811.1 26316 29545 978 13799 23055

921 EIO79102.1 26318 29547 982 81173 90435

922 EI063487.1 26320 29549 978 254421 263671

AN AO AP AQ AR AS AT AU

923 EI069659.1 26322 29551 978 14347 23597

924 EIP05663.1 26324 29553 978 11135 20385

925 EIP03387.1 26326 29555 375 7442

926 ERE42062.1 26328 29557 978 80488 89738

927 ERE45410.1 26330 29559 978 80936 90186

928 KDG81461.1 26332 29561 1096 4589703 4599350

929 KDG84324.1 26334 29563 1096 577940 587587

930 ERB08805.1 26336 29565 1119 3410757 3420430

931 ERB13351.1 26338 29567 1119 312752 322425

932 EQX93206.1 26340 29569 1096 1299123 1308770

933 EQY50265.1 26342 29571 333 972500 979858

934 ERB23700.1 26344 29573 580 575397 583496

935 EQY93866.1 26346 29575 580 381918 390017

936 EQZ08531.1 26348 29577 1096 4369199 4378846

937 EQZ94052.1 26350 29579 1096 413548 423195

938 ERA40554.1 26352 29581 1096 440488 450135

939 CAR16063.1 26354 29583 1112 5111725 5121420

940 AFJ31994.1 26356 29585 1117 5251667 5261334

941 KWW01507.1 26358 29587 1096 161157 170801

942 CAQ90579.1 26360 29589 1112 3162768 3172460

943 EGC09237.1 26362 29591 1096 152611 162258

944 EOW71261.1 26364 29593 894 3729077 3738118

945 AJY69763.1 26366 29595 1141 2031423 2041104

946 EDL62311.1 26368 29597 1176 180740 190521

947 EOD77323.1 26370 29599 1172 615 10570

948 KJS14045.1 26372 29601 1149 1372 10961

949 EAQ32829.1 26374 29603 1113 307409 317059

950 KXS34468.1 26376 29605 1113 44606 54256

951 CDG80808.1 26378 29607 1090 170928 180527

952 KMK41964.1 26380 29609 1095 35196 44816

953 KMV95473.1 26382 29611 1117 1146551 1156230

954 EYT05882.1 26384 29613 1117 319260 328939

955 KGK50932.1 26386 29615 1095 410829 420449

956 KHE28070.1 26388 29617 1099 5171646 5181278

957 KHF57367.1 26390 29619 1095 316218 325838

958 KHQ22240.1 26392 29621 1095 2386538 2396158

959 KLZ78428.1 26394 29623 1095 5093831 5103451

960 KMB09548.1 26396 29625 1095 318671 328291

961 KMG65748.1 26398 29627 1117 5116317 5125996

962 KMG69377.1 26400 29629 1095 565524 575144

963 KMH23799.1 26402 29631 1095 5137914 5147534

964 KMH84529.1 26404 29633 1095 1291264 1300884

AN AO AP AQ AR AS AT AU

965 KMX40525.1 26406 29635 1095 315214 3248341

966 ALH86087.1 26408 29637 1095 3020287 3029907

967 KRR31028.1 26410 29639 978 49625 58887

968 ALQ84489.1 26412 29641 1095 2158397 2168017

969 ALQ89984.1 26414 29643 1095 2150002 2159622

970 KSX16170.1 26416 29645 1095 8524 18144

971 KSX18602.1 26418 29647 1095 8564 18184

972 KSX52403.1 26420 29649 1095 137974 147594

973 ALP76745.1 26422 29651 1095 840774 850394

974 KSZ32506.1 26424 29653 1095 26187 35807

975 KUF65063.1 26426 29655 1008 109 9468

976 KUG47426.1 26428 29657 1095 20414 30034

977 KX023871.1 26430 29659 1095 14263 23883

978 KYM26277.1 26432 29661 1095 41531 51151

979 ERN57702.1 26434 29663 983 10160 19444

980 EWE85119.1 26436 29665 1095 328445 338065

981 ESL33174.1 26438 29667 1095 5034330 5043950

982 KDK59887.1 26440 29669 1095 315804 325424

983 CDK69437.1 26442 29671 1096 45317 54964

984 EMH91691.1 26444 29673 1095 9198 18818

985 EOZ63296.1 26446 29675 1095 5980 15600

986 EOY67007.1 26448 29677 1095 5980 15600

987 ESN46752.1 26450 29679 1117 360085 369764

988 EWF66267.1 26452 29681 1095 4867354 4876974

989 ESM58758.1 26454 29683 286 1837389 1844582

990 KDL89511.1 26456 29685 1117 324473 334152

991 AIX83031.1 26458 29687 1095 1046321 1055941

992 AIG86150.1 26460 29689 983 2966500 2975784

993 EKB81086.1 26462 29691 1095 363340 372960

994 ESM10102.1 26464 29693 1095 362779 372399

995 EP098435.1 26466 29695 1095 8713 18333

996 EPA89974.1 26468 29697 1095 25993 35613

997 EJI89218.1 26470 29699 997 541259 550532

998 KDE37041.1 26472 29701 1095 322666 332267

999 CAH16733.1 26474 29703 1130 2836365 2846089

1000 KTD65147.1 26476 29705 1129 286299 296026

1001 ETX11656.1 26478 29707 1143 71478 81199

1002 ESY80721.1 26480 29709 1033 45837 54964

1003 ESY66318.1 26482 29711 1047 196269 205519

1004 ESY44730.1 26484 29713 1088 453521 462897

1005 KQU80075.1 26486 29715 1774 218186 229640

1006 EMS40058.1 26488 29717 1141 3688 13384

1007 EMS40204.1 26490 29719 1141 172603 182299

AN AO AP AQ AR AS AT AU

1008 KQQ15549.1 26492 29721 1141 42064 51757

1009 KQO59080.1 26494 29723 1161 65935 75509

1010 KQO90880.1 26496 29725 1161 25635 35221

1011 EFV81024.1 26498 29727 1115 1071595 1080026

1012 EHJ60590.1 26500 29729 1099 90561 99810

1013 AIT79633.1 26502 29731 1099 1555853 1565102

1014 CCA92391.1 26504 29733 1099 1584078 1593321

1015 KTS15499.1 26506 29735 978 42898 52160

1016 KTS86095.1 26508 29737 978 116960 126222

1017 EFM21231.1 26510 29739 1117 215561 225243

1018 KGA41247.1 26512 29741 1098 133311 142924

1019 ACX87466.1 26514 29743 1097 1819036 1828646

1020 EAU47587.1 26516 29745 964 2465108 2474018

1021 EAS45762.1 26518 29747 1124 716356 725945

1022 KJM66694.1 26520 29749 1104 103727 113355

1023 KMK11834.1 26522 29751 1104 56209 65837

1024 KMK24778.1 26524 29753 1104 35136 44764

1025 KXU56725.1 26526 29755 1044 4561 13774

1026 EGW47199.1 26528 29757 292 245464 254742

1027 KSX98965.1 26530 29759 1012 140775 150099

1028 KTF11892.1 26532 29761 1090 229654 239236

1029 KGB84629.1 26534 29763 1099 215 9832

1030 KHE32030.1 26536 29765 1019 23646 32926

1031 KOJ75583.1 26538 29767 1111 16183 25846

1032 KRV15978.1 26540 29769 1036 3295 12626

1033 KSD09759.1 26542 29771 1109 5385 15042

1034 KSD19547.1 26544 29773 1036 60524 69855

1035 KSG03395.1 26546 29775 1036 438855 448186

1036 KSG67482.1 26548 29777 1111 15322 24985

1037 KSE90722.1 26550 29779 1036 21419 30732

1038 KSF67272.1 26552 29781 1111 15322 24985

1039 KSG19247.1 26554 29783 1036 1688 11019

1040 KSG75426.1 26556 29785 1036 22047 31378

1041 KSG85748.1 26558 29787 1036 21450 30781

1042 KSH39447.1 26560 29789 1036 194095 203426

1043 KSH60514.1 26562 29791 1036 22047 31378

1044 KSI22085.1 26564 29793 1036 22046 31377

1045 KSI51646.1 26566 29795 1109 518066 527723

1046 KSI82064.1 26568 29797 1111 199155 208818

1047 KSI99556.1 26570 29799 1036 449321 458652

1048 KSJ34445.1 26572 29801 1111 21403 31066

1049 KSK63576.1 26574 29803 1109 573017 582674

1050 KSL54235.1 26576 29805 1036 24722 34053

AN AO AP AQ AR AS AT AU

1051 KSM73158.1 26578 29807 1111 23541 33204

1052 KSM79531.1 26580 29809 1036 22039 31370

1053 KSN72845.1 26582 29811 1036 24722 34053

1054 KSO70094.1 26584 29813 1036 8292 17605

1055 KSQ54942.1 26586 29815 1036 31335 40666

1056 KSQ13844.1 26588 29817 1036 443745 453076

1057 KSK33231.1 26590 29819 1036 61118 70449

1058 KSL81229.1 26592 29821 1036 194095 203426

1059 KSL64952.1 26594 29823 1036 22039 31370

1060 KSM29109.1 26596 29825 1111 42134 51797

1061 KSN07703.1 26598 29827 1111 378604 388267

1062 KSN22463.1 26600 29829 1111 16138 25801

1063 KSN45780.1 26602 29831 1036 438815 448146

1064 KSO16560.1 26604 29833 1111 15322 24985

1065 KS084936.1 26606 29835 1036 605 9936

1066 KS099159.1 26608 29837 1111 23415 33078

1067 KSQ29951.1 26610 29839 1036 438855 448186

1068 KSR12022.1 26612 29841 1036 3385 12716

1069 KSR96744.1 26614 29843 1036 518449 527756

1070 KSS25556.1 26616 29845 1028 203854 213146

1071 KSS39722.1 26618 29847 1099 12270 21887

1072 KSR72710.1 26620 29849 1036 194095 203426

1073 KSS45915.1 26622 29851 1109 472018 481675

1074 ALY37666.1 26624 29853 1111 4647649 4657312

1075 ALY62762.1 26626 29855 1111 5985465 5995128

1076 KXC98082.1 26628 29857 1036 73491 82822

1077 KXC86337.1 26630 29859 1036 478140 487471

1078 KXD25984.1 26632 29861 1036 24577 33908

1079 KXD09025.1 26634 29863 1036 84962 94293

1080 KXD14448.1 26636 29865 1036 47987 57318

1081 KXD23305.1 26638 29867 1036 24766 34097

1082 KXC87753.1 26640 29869 1036 84679 94010

1083 KXF38232.1 26642 29871 1036 73251 82582

1084 KXF47447.1 26644 29873 1036 84960 94291

1085 KXF43394.1 26646 29875 1036 84964 94295

1086 KY095527.1 26648 29877 1111 13894 23557

1087 KAJ18078.1 26650 29879 970 68033 77166

1088 ERY57592.1 26652 29881 1115 1472487 1482055

1089 ERY65606.1 26654 29883 1115 3001215 3010783

1090 ERV59834.1 26656 29885 1115 3014713 3024281

1091 ERY33375.1 26658 29887 1115 276729 286297

1092 ERY37452.1 26660 29889 1115 303965 313533

1093 ERY30830.1 26662 29891 1115 323839 333407

AN AO AP AQ AR AS AT AU

1094 ERW68207.1 26664 29893 1115 321053 3306211

1095 ERW13881.1 26666 29895 1115 438293 447861

1096 ERV79733.1 26668 29897 1115 316993 326561

1097 ETV52348.1 26670 29899 1115 387845 395610

1098 ERU88469.1 26672 29901 1115 308446 318014

1099 ERU86604.1 26674 29903 1115 308446 318014

1100 KEA15334.1 26676 29905 1140 772974 782617

1101 ERZ32987.1 26678 29907 1115 332366 341934

1102 GAA19669.1 26680 29909 970 5052470 5061603

1103 EME92222.1 26682 29911 1111 15085 24748

1104 EYU00120.1 26684 29913 1111 198162 207825

1105 EOT13872.1 26686 29915 1028 4956028 4965320

1106 ETU84933.1 26688 29917 1115 527654 537213

1107 ERX16724.1 26690 29919 1115 629489 639057

1108 EWH25348.1 26692 29921 1140 1491323 1500966

1109 GAD64770.1 26694 29923 1115 16216 25769

1110 GAD61322.1 26696 29925 1116 202461 212017

1111 EZQ18205.1 26698 29927 1099 419637 429263

1112 AM073921.1 26700 29929 1111 445996 455662

1113 KPW38787.1 26702 29931 1158 36556 46279

1114 KQB53692.1 26704 29933 1111 1406 11069

1115 EZI30290.1 26706 29935 1099 22889 32461

1116 KIR22317.1 26708 29937 1099 33962 43528

1117 KJH86852.1 26710 29939 1029 114387 123676

1118 KWV84208.1 26712 29941 1029 9497 18786

1119 EFQ63351.1 26714 29943 634 3228353 3236566

1120 KMM97952.1 26716 29945 1111 145121 154784

1121 ENY78085.1 26718 29947 1043 45721 55116

1122 ENA27916.1 26720 29949 1116 122129 131384

1123 EWC41654.1 26722 29951 1140 1199767 1208507

1124 EMD98965.1 26724 29953 1027 61976 71271

1125 KPB88881.1 26726 29955 794 33409 40166

1126 KFD13680.1 26728 29957 1099 44083 53715

1127 ACE91185.1 26730 29959 1074 2221342 2230688

1128 KKZ86595.1 26732 29961 1140 262183 271712

1129 KQU05107.1 26734 29963 1079 513 9877

1130 CCF21880.1 26736 29965 911 4095719 4104474

1131 KQZ63425.1 26738 29967 1079 733975 743234

1132 KIV64826.1 26740 29969 1133 375717 385216

1133 KQB14223.1 26742 29971 1033 23685 32821

1134 KQB14198.1 26744 29973 1033 23685 32821

1135 ETX15682.1 26746 29975 1055 1000 10241

1136 KJS41397.1 26748 29977 1042 38507 47619

AN AO AP AQ AR AS AT AU

1265 CED48958.1 27006 30235 1099 3782745 37923771

1266 CDW00039.1 27008 30237 1099 1754437 1764069

1267 CDV01787.1 27010 30239 1099 1788427 1798059

1268 CEA40519.1 27012 30241 1099 1783442 1793074

1269 CEB13673.1 27014 30243 1099 1753084 1762716

1270 CEA18908.1 27016 30245 1099 1854428 1864060

1271 CDY92812.1 27018 30247 1099 1752529 1762161

1272 CEA88154.1 27020 30249 1099 1506435 1516067

1273 AK082198.1 27022 30251 1099 4482333 4491965

1274 CAR62301.1 27024 30253 1099 4477563 4487195

1275 ESF93195.1 27026 30255 1099 11502 21134

1276 AAV80043.1 27028 30257 1099 4482333 4491965

1277 EPE40531.1 27030 30259 1099 85913 95545

1278 EPE40313.1 27032 30261 1099 85780 95412

1279 EPE40095.1 27034 30263 1099 85905 95537

1280 KSB43364.1 27036 30265 1099 156994 166626

1281 ELX27349.1 27038 30267 1099 65113 74745

1282 EHC78170.1 27040 30269 77 221 6787

1283 ESF47593.1 27042 30271 1099 172275 181907

1284 CUS01662.1 27044 30273 1099 4951384 4961016

1285 CUS00367.1 27046 30275 944 4759655 4768822

1286 CUS00368.1 27048 30277 944 4851124 4860291

1287 CUS00366.1 27050 30279 1099 5018293 5027925

1288 CBY96200.1 27052 30281 944 85 9252

1289 EDZ29008.1 27054 30283 285 63002 70192

1290 KNM15296.1 27056 30285 1099 282369 292001

1291 KNM69141.1 27058 30287 1099 343834 353466

AN AO AP AQ AR AS AT AU

1292 KN058855.1 27060 30289 1099 206734 216366

1293 KNW78916.1 27062 30291 1099 1907 11539

1294 KTZ77424.1 27064 30293 1099 96532 106164

1295 KUC23740.1 27066 30295 1099 171297 180929

1296 ESF03067.1 27068 30297 1099 120111 129743

1297 KMJ09050.1 27070 30299 1099 529831 539463

1298 CVG51486.1 27072 30301 1099 238999 248631

1299 CVB32240.1 27074 30303 1099 239061 248693

1300 EZQ69786.1 27076 30305 1099 90156 99788

1301 EFE97639.1 27078 30307 482 743953 751819

1302 KFK98827.1 27080 30309 1095 286734 296378

1303 KFK92330.1 27082 30311 1095 1654 11298

1304 ABK48268.1 27084 30313 1180 2437310 2447236

1305 AFJ48529.1 27086 30315 263 3585169 3592293

1306 GAB81434.1 27088 30317 269 178785 185928

1307 ACP25984.1 27090 30319 1083 2298324 2307700

1308 CAN98361.1 27092 30321 1152 11387949 11397690

1309 EPR18397.1 27094 30323 1038 2646 9729

1310 KKW93258.1 27096 30325 1099 135724 144994

1311 CCW17774.1 27098 30327 1098 7698 15633

1312 KER36315.1 27100 30329 1064 2812 11959

1313 KQM97529.1 27102 30331 1002 1512 10520

1314 KPV39945.1 27104 30333 499 46068 53818

1315 KQW61500.1 27106 30335 1187 77355 87231

1316 KLE23445.1 27108 30337 1121 177407 186987

1317 EDL70290.1 27110 30339 1125 191775 201360

1318 KHD25448.1 27112 30341 1169 189282 199238

1319 KFE26106.1 27114 30343 1118 33695 43271

1320 KFD94236.1 27116 30345 1118 12302 21878

1321 EJH60536.1 27118 30347 1102 68538 78157

1322 EMQ54781.1 27120 30349 1118 244112 253688

1323 KNA52261.1 27122 30351 1118 12538 22114

1324 GAD79747.1 27124 30353 1169 25836 35781

1325 KNY42356.1 27126 30355 1125 111138 120729

1326 KHF16001.1 27128 30357 1121 3364 12944

1327 KOF25302.1 27130 30359 1121 11973 21559

1328 KHT39220.1 27132 30361 1102 105669 115288

1329 KYN85118.1 27134 30363 1118 68509 78085

1330 EKM24798.1 27136 30365 1169 448059 458009

1331 CDU08195.1 27138 30367 1102 291331 300963

1332 CAV18547.1 27140 30369 1124 1498484 1508125

1333 KWU01491.1 27142 30371 1119 60437 70011

AN AO AP AQ AR AS AT AU AV

1334 K0013423.1 27144 30373 1125 88330 97921

1335 CNI05770.1 27146 30375 1100 395449 405084

1336 COJ 58416.1 27148 30377 1100 455230 464865

1337 CQJ21073.1 27150 30379 1117 22700 32382

1338 CFR01913.1 27152 30381 1100 235368 245003

1339 CNH31670.1 27154 30383 1100 474426 484061

1340 CFV22965.1 27156 30385 1100 113536 ¹ 123171

1341 KFE39719.1 27158 30387 1100 4143 13778

1342 AKA39097.1 27160 30389 1100 2710693 2720328

1343 EH 51571.1 27162 30391 944 252227 261394

EXAMPLE 7

Genomic Identification and Analysis of an Anti-Pasmid System

[001653] Objective: Some of the putative defense systems experimentally tested did not show any anti-phage activity despite being strongly associated with known defense genes. It was reasoned that some of these systems may defend against other forms of foreign nucleic acid. The objective in this case was to analyze a candidate defense system, which we hereby denote Wadjet (god protector of ancient Egypt) for further experimentation.

[001654] Methods: To test this hypothesis, the Wadjet system was selected for further experimentation. The selected candidate system is a 4-gene system, jetA, jetB, jetC, and jetC, that is common in microbial genomes and is very frequently found next to defense genes (Figure 7A). Three different types of the Wadjet system were cloned from three separate BacUlus species into B. subtUis BEST7003 (Figure 7B).

[001655] Results: While none of these systems provided protection against any of the 10 BacUlus phages in the array tested (data not shown), all three consistently and significantly reduced transformation efficiency of the episomal plasmid pHCMC05 (Figure 7C). These results suggest that this may be a defense system specifically targeting foreign plasmids.

[001656] Three different domain compositions were identified, each encoding a different set of pfams, but all with common sequence signatures marking them as three types of Wadjet (Figure 7B). While the pfam domains of Wadjet genes are mostly defined as "domains of unknown function", structural modeling using Phyre2 showed structural homology between JetA, JetB and JetC and genes belonging to the housekeeping condensin system MukF, MukE and MukB, respectively. Bacterial condensins are chromosome-organizing complexes that are responsible for DNA condensation and accurate segregation during replication, and mutations in the housekeeping condensins lead to severe defects in chromosome segregation and viability. Several versions of housekeeping codensins appear in bacterial genomes: SMC, MukBEF and MksBEF; the Wadjet system was previously noted as a distant homolog of the MksBEF system described in P. aeruginosa.

[001657] While the domain organization of the jetABC genes may lead to the hypothesis that Wadjet is an alternative condensin system involved in bacterial chromosome maintenance, the data herein presented imply that its role is defensive. This system is highly enriched within defense islands, undergoes extensive horizontal gene transfer, and is only sporadically found within strains of the same species, all of which is inconsistent with a core, essential role in chromosome maintenance. The Wadjet system may have adapted from a MukBEF condensin ancestor to become a defense system. Possibly, the system identifies foreign plasmids and uses its condensin properties to interfere with proper plasmid segregation into daughter cells. Notably, plasmid transformation in B. subtilis takes place via the natural competence of this organism, during which the plasmid DNA is transformed to the cell through dedicated transporters as single- stranded DNA (ssDNA). It is possible that the Wadjet system protects against rampant natural transformation or, alternatively, may specifically target ssDNA phages. However, as no ssDNA phage was reported for B. subtilis, it could not be tested whether ssDNA phages are specifically blocked by the Wadjet systems we cloned in B. subtilis BEST7003.

[001658] The Wadjet system is broadly spread in bacterial and archaeal genomes (found in -6% of the genomes that were studied), where it presents high sequence diversity (Table 11; Figure 3H). Deletion of each of the four genes in Type I Wadjet from B. cereus Ql abolished its activity and restored plasmid transformation, indicating that each of the genes is essential for anti-plasmid defense (Figure 7C). Moreover, point mutations E59K/K60E in JetB, predicted to disrupt the MukE-MukF-like protein-protein interactions, resulted in loss of protective activity against plasmids (data not shown), and so has the E1025Q mutation in the Walker-B motif of JetC that is predicted to abolish ATPase activity. The JetD gene, which has no homology to genes in the Muk system has a putative topoisomerase VI domain based on structural predictions; a point mutation JetD:E226A, predicted to diminish binding of the topoisomerase VI domain to DNA, also abolished the protective activity of the system.

[001659] Table 11: The Wadjet Defense System and Components Thereof

[001660] This table is presented in landscape orientation. Due to the number of columns, the table has been split into parts. Part A includes the first set of columns and therefore should be place to the left of subsequent parts (Part B and where relevant Part C). To avoid any doubt, the rows of the table in each part line up once the tables are placed together. Table 11 (Part A)

Table 11 (Part B)

00 00 O

00 O

σι σι σι

oo σι

> 8 >

TabI 11 (Part C)

1136

1137

EXAMPLE 8

Genomic Identification and Analysis of Additional Defense System

[001661] Objective: To identify additional Defense Systems

[001662] Methods: As above for Examples 1-7, wherein anchor protein families used in the searches were as follows:

• for the Hachiman Family: pfam08878;

• for the Gabija Family: pfaml3175, pfaml3304;

• for the Kiwa Family: pfaml6162;

• for the Lamassu Family: pfaml4130;

• for the Shedu Family: pfaml4082;

• for the Septu Family: COG3950; and

• for the Wadjet Family: COG4913, COG4924, pfaml 1796, pfam09664, pfaml3555.

[001663] Results: each of these systems was validated by introducing the system constructs into an appropriate bacterial host. The Hachiman, Shedu, Gabija, Septu, and Lamassu candidate Defense Systems were each individually engineered into B. subtilis BEST7003, which does not contain the respective defense systems identified. The correct insertion of the system into the B. subtilis BEST7003 genome was verified by whole genome sequencing. The defense system containing B. subtilis BEST7003 strains were challenged with multiple phages spanning the three families Myoviridae, Siphoviridae, and Podoviridae. The cloned systems were found to confer defense against myophages (Figure 3B), with different fold protection to all or a subset of the phage provided as shown.

[001664] The Kiwa candidate Defense System was engineered into a host E. coli (E. coli

MG1655; correct insertion checked by whole genome sequencing), wherein it was shown to provide protection against viruses in the Siphoviridae family (Figure 3C).

[001665] The Hachiman, Shedu, Gabija, Septu, and Lamassu candidate Defense Systems were broadly distributed in bacteria and archaea (Tables 12-17; Figure 3H).

[001666] Table 12: The Hachiman Defense System and Components Thereof

This table is presented in landscape orientation. Due to the number of columns, the table has been split into parts. Part A includes the first set of columns and therefore should be place to the left of subsequent parts (Part B and where relevant Part C). To avoid any doubt, the rows of the table in each part line up once the tables are placed together. Table 12 (Part A)

Table 12 (Part B)

_{8133828011666130093123160775575 KXP5557} .

6 _{02162 1166633011Q69392162 45 47 557 5 KX 557} .

_{600620 1163013221677 5474 5575 5 KXR744 5574} .

3 _{086366918 1066301908166 574 54 5577 55} A _H W _{44 557} .

_{11362 1066 11693011211168577 557 57 KPU5 557} .

_{116290 116868130198910168055 7 55 5 EP} A _{5 55} .

_{1| 116028 11686833021} 0 _{96331682575 55 5 EP7 55} .

_{91120 868 11686830236091116845 555 5 ERN 554} .

_{1800 138 113368302S93231686544 557 55 E} A _{5 55} .

_{103019 1068 1168689302S28116887744 55 57 EL57 55} .

_{3081 3038 10616913029S96316907757 55 5 E} M _{47 55} .

_{219 23310 116933031S3828169274577774 55 5 EN7 55} .

_{608166 10616930338021697 577 555 5 E} W _{D57 554} .

_{836 8319 10669303033316967544 557 55 E} W _{E7 55} .

_{89000 82 1168699303Q8681698475 55 57 EZ75 55} .

_{89013 838 116866013039239801660047 5 5 EZR 5} .

_{3080 30063 1061660330116316602774 5 54 KDL45 5} .

_{1389 130619 116866030300166044 55 54 KDL577 54} .

_{1| 11 1| 1| 11 | | 1| 2119212821166030696216606575577457545KDL75} .

_{33096 32621 11686609302231660875 5 547 KEF45 5} .

_{9260 9293 116611309} G _{8901166107774 5 54} A _{I5 5} .

_{282881 2820 1168661330102063166125454 5 55} A _{IT 5} .

_{1| 1| 1| | | 1|9829191168661303} G _{6291661 4554 45545555KK5554} .

_{89136 8861 116866130630166164 57 555 KHF57 5} .

_{281932 292 102661930192166187774 5 557 KII57 5} .

_{89132 88 11686621309 C} 0 _{88116620457 5 55E44 5} .

_{629992 1166233061291662245 5774 5 5 KKJ774 5} .

_{11 11 1| 11 11 | | 1| 62099831166230639362166247574555KKY754} .

_{3322 3290 11686623068306166264577 57 55 KLZ5 5} .

_{2310 2381366293063631662854545 5 57 K} M _{B75 5} .

_{309629 3061 106166313069801663055 5 5 K} M _{D444 5} .

_{89109 883 11686633301} G _{802891663244 5 57 K} M ₅ .

_{330962 32668 11686633033316016637 55 57 K} M _{H 54} .

₃₃₁₁ ³ _{326860 11686633002816636} ⁵ _{57 575 K} M _{H45 5} .

6 _{3663 1061663930632316638} 5 ⁷⁷⁷ _{5 5 577 K} M _{H5 5} .

a ³³¹¹³ _{326860 1168661309618961660} ⁵ _{54 57 K} M _{H 54} .

³³⁰⁸²³ _{3268 1168663308182166254 54 5 K} M _{H747 54} .

1 _{160 116630838301166} ⁷⁵⁴⁴⁷ _{774 545 5} A _{LH4 544 111} .

⁶⁰ ₁ ⁶⁸ _{11663082131666} ⁵⁵ _{774 547 55 KPR45 54} .

2 ¹⁶²⁸ _{11669308 CQ289081668} ⁵ 4 ⁷⁷⁵ _{74 54 57T 54} .

^{1089 1099} _{116613089Q86321660} ⁷⁵⁴⁴ _{77 55 5} A _{L7 55} .

^{1892 196} _{116633091Q932331662} ⁷⁷⁷⁴⁴ _{77 55 5} A _{L 55} . o

_{3091889991904554555 KJL4575451154} .

_{328186 32209389130219244 545 55 K} V _{K47 545 1155} .

_{32103 28339893Q139197 5455 55 KL45 5454 1165} .

_{21638 2126369890021196444 5457 555} A _{IR5 545 1157} .

_{310160 3102189989621119874 545 557} A _{BN4 545 1185} .

_{39808 39026961899} G _{363919605777 54 55} A _{Z7 54 1195} .

_{39203 3680963901 C2022019625 54 55DX 54 1205} .

1 _6219996903 G _{8893196 754 7 545 55} A _{D5 544 1215} .

6 _{8289096906891966 444 4 547 555 KRP47 54 1225} .

_{1683310 168023196990} O _{130101968 54 557 EH 54 1235} .

_{28808 288091909813190744 547 55 KFI44 547 1254} .

_{2060631 20168939119257 547 55 547 1255}

_{16630 16609913 C39291955454 5475 55} A _{Y7 5474 1265} .

_{16639 166008991 C22196454 5477 555} A _{X557 547 1257} .

1 _{1101109699919111198 545 57 547 557} A _{LU5 547 1285} .

_{32983 3012998191930211980 54 55 EPD7 54 1295} .

9 _{13983921283031982 4 54 55 KRN 54 1305} .

8 _{9989233180198 47 545 55 KRN5 544 1315} .

| _{11111 863 8629989228312198655774 547 555 KJL 54 1325} .

_{23009 23198992600619885447 54 557 E} A _{T5 54 1335} .

_{388 321299192963119904457444 54 55 ET} M _{77 54 1354} .

_{19631 19280993931220199257 54 55 E} M _{Z57 54 1355} .

_{12238 868399933} G _{1939199 545 55 KF7 544 1365} .

2 _{2289993Q606231996 5775 547 555 E} A _{54 1357} .

_{8883 812999993C012199847 54 557 K} V _{74 54 1385} .

_{319 3112901939Q0911900477 55 55 K} V _{55 55 1395} .

_{6961 6629090391S699319027 55 554 K} V _{7 55 1054} .

1 _{| 111 1293 12619093S0001904757 555 554 K} V _{77 554 1154} .

_{6961 66290909S382319067 557 5545 K} V _{5 55 1254} .

_{1293 12619099S38619084757 55 5547 K} V _{55 55 1354} .

1 _{6961 6629091199S80119107 55 554 K5 1} V _{55 5544} .

1 _{1293 126191391S8081912 14757 55 555 K} V _{54 55545} .

_{6961 662909193S9191917 555 555 K} V _{54 554 1654} .

| _{1293 1261919S91811916} ⁴⁷ _{57 557 5555 K} V _{5 55 1547} .

6 ⁹⁶¹ _{662909199S90611918} ⁷ _{55 5557 K} V _{7 55 1854} .

a ¹²⁹³ _{126192199S90611920} ⁴⁷ _{57 55 555 K} V _{5 55 1954} .

⁶⁹⁶¹ _{66290923961S1361922} ⁷ _{55 55 K} V _{44 55 1055} .

¹²⁹³ _{126192963S10192} ⁴⁷ _{57 555 55 K} V _{447 554 1155} .

s ⁶⁹⁶¹ ₆₆₂ ⁹⁰ _{9296200181926} ⁷ _{557 555 KV} T _{55 1255} .

¹²⁹³ ₁ 2 ⁶¹ _{9299620021928} ⁴⁷⁵⁷ _{55 557 KV} T _{5 55 1355} . | ²³²⁹ _{9319693311930 55 55 K} V _{U74 55 1554} .

^{1260 1229} _93391361932 ⁴⁴⁴⁷ _{55 557 KV} T _{545 55 1555} . o 8 s I I ∞ 3 § § 3 3 £ 1 1 3 3 3 3 3 3 3 3 3 3 z

Έ

5 5 s ∞ m § 1 i s a i s s § m § § § § § § § § m

[001667] Table 13: The Shedu Defense System and Components Thereof

[001668] This table is presented in landscape orientation. Due to the number of columns, the table has been split into parts. Part A includes the first set of columns and therefore should be place to the left of subsequent parts (Part B and where relevant Part C). To avoid any doubt, the rows of the table in each part line up once the tables are placed together.

Table 13 (Part A)

Table 13 (Part B)

[001669] Table 14: The Gabija Defense System and Components Thereof

[001670] This table is presented in landscape orientation. Due to the number of columns, the table has been split into parts. Part A includes the first set of columns and therefore should be place to the left of subsequent parts (Part B and where relevant Part C). To avoid any doubt, the rows of the table in each part line up once the tables are placed together.

Table 14 (Part A)

Table 14 (Part B)

_{11111| 11 | I 1| 11220636226662339l 619} O _{Q6201339061975745E44744} .

_{1| 1| 11 11 | I 1| 1139329338l3393619} O _{0919133926196445747ER574} .

ε _ττ

_{169699 161339 6199} O _{0911339 6198757 754 ER54 744} .

_{28316 298339 6201} G _{222313396 62007775 774} AM _{7 74} .

_{1| 1| 11 | I 1| 113233996203860211339862024474ENE 74} .

_{11 1| 1| 11 | | 11 11300132636301620} G _{226130062047445} A _D547444 .

_{16 1266303 620} O _{16131302 62064454 7447 ER4 744} .

_{1| 1| 11 11 | I 11 1113218306209} O _{S2031306208444577454E757444} .

_{11 11 11 1| | | 11 11232662322230621l} O _{S381306621074757474E457744} .

_{11 11 11 | | 11 1| 1|3133096213} O _{S2921308621275445744E74744} .

_{1| 1| 1| 11 | I 1| 1120222089l31l 621} O _{S8136213106215557445E 7444} .

_{1| 11 11 1| | | 1| 1| 9816l 980206313621} O _{S3981312621647447E75744} .

_{1| 11 11 11 | I 1| 119839308316219} G _{18101316218577547454} A _N57444 .

_{1| 11 1| 1| | I 1| 119838936331622l} G _{21131316622057547474} A _N7744 .

_{11 11 1| 11 | | 1| 112016919333196223} O _{218613186222474744ET4744} .

_{1| 1| 11 | | 11 11366321622} O _{699132062277445EY457444} .

_{1| 11 11 | | 1| 11366323622} O _{221322622677447EZ745744} .

_{3222 3189832 6229} O _{032132 6228744 7454 ET44 7444} .

_{199862 19961032 6231} O _{280901326 623054 7474 ET 744} .

_{1| 11 11 11 11 1|06202663296233} O _{961328623245744744 ET444744} .

_{1| 11 1| 11 | | 1| 1181893 l 8199833l 623} O _{62133062347445ET7777444} .

_{11 11 11 1| | I 1| 1| 102192101613333623} O _{691613326236577447E} W ₇₇₄₄ .

_{31338 3091933 6239} O _{80208133 623844 7454 E} W ₇₄₄₄ .

₂₁₈₉₉ ³ _{21893833 621} O _{681336 62055 74744 ET774 7444} .

₁ ^| _{11 1| 11 | I 1| 110} 3 ²⁰ _3999339623 O _831313386224 ⁵ _{457444ET77444} .

a ₁ ¹ _{1| 1| 11 11} ²⁸ _{23893l 62901130 62} ⁷⁷⁷ _{5744445 EP} A _75744444 .

₁ ^| _{1| 11 11 | 1 11 11} ²³ _{233362C1060132626} ⁵⁷ _{57744447EP574444} .

¹¹⁰³¹ ₁ ² _{3 629C82913 628 75 744544 EP57 744444} .

^61820860 _{3 621C683136 620} ⁵⁷ _{744745 EP54 74445} .

2 ⁸³ _{39 623C88138 622} ⁴ _{74445 EP575 74445} .

¹¹ 1 ¹ _{1| 11 | | 1| 11} ^18308110 _{3l 6226213062} ⁴⁵ _{745455EPD55745454} .

^{11 1|} _{11 1| 1| 1|} ^29902630l _{3362268132626} ⁴ _{745457 EPD4574545} . o

^{11 1|} _{11 | I 11} ^39636122 ₃₆₂₉ G _683013628 ⁷⁵ _{745545KE5 745445} . z

Έ

-

_{||||| 3} 0 ₁ 8 ₃₆ 09 _l3 8 _666lS 8 ₂₁₃ 8 ₆₇ 4 ₇₇₅₇ 4 _E M ₇ 4 ₅₇₅₁ 09 ₂ .

₃₁ 900 ₃₁₆₁₁ 8 ₃ 89 _6663S 8 ₃ 9 ₁₃ 88 ₆₆₆₂₅ 4 _{5 75} 4 _E M _{57 75} 4 ₁ 09 ₃ .

₁₁ 8 ₂ 98 ₁₁ 90 ₃ 8 ₃ 8 _{61 666S} 8 ₆ 880 ₁₃ 8 ₆ 0 _{77 7} 4 _{5 E} M _{7 1} 094.

1 _{111 || 2226} 0 ₁ 0 ₂₂₂₂ 09 ₁₃ 8 _{63 666S21} 08 ₁₃ 8 _{62 7} 4 _{7 E} N _{7 7 1} 09 ₅ .

1 _{1111 61} 9 ₆ 080 ₁₃ 8 _6S311 8 ₁₁₃ 8 _{6 5} 4 _{75 E} N ₇ 4 ₁ 09 ₆ .

1 _{||| || 1 1} 09 ₆₁₆₃ 8 _{6 661} C ₆₆₆ 9 ₁₃ 8 _{66 66} 0 _{5 7} 4 ₇₇ 4 ₇ D _{I5 7} 4 _{7 1} 09 ₇ .

10 ₆ 0 ₁ 0 ₁ 9 ₃ 8 ₆ 9 ₆₆₃ CC ₆ 8 ₁₃ 8 ₆ 8 ₆₆₂ 4 ₅₅ 4 _{77 7} 4 ₇ W ₇₅ 4 ₇ 4 _{7 1} 098.

1 _{1| 1 | 1 2} 0 ₁ 0 ₂ 0 ₃₂₂ 9 ₃ 8 _{l 66} G ₂ 8 ₁ 0 ₂₁₃ 80 ₆₆ 4 _{557 77} 4 ₇₅ A _{Z 77} 4 ₇ 4 ₁ 099.

1 _{|33 163} 8 _{3 66S} Q ₁ 0 ₂₃₆₁₃ 8 _{2 666 5} 4 _{77 77} 4 _{77 E 77} 4 _{7 11} 00.

₃₁ 8 ₆ 0 ₃₁₂₃ 8 ₆₆ 9 ₆ 99 ₁₃ 8 ₆₆ 84444 _{75 775} 4 ₇ A _IL 4 _{5 77} 44 _{7 11} 0 ₁ .

9 ₆ 9889 ₆₆ 0 ₃ 8 ₆₆ 8 ₁ 089 ₆₁₃ 8 ₆ 4 ₇ 4 _{77 777} 4 AMA4 _{77 11} 0 ₂ .

6 ₁ 0 ₆ 8 ₆₁₃ 88 ₃ 89 ₆₆ 8 ₃₂ 0 ₁₂₃ 88 ₆₆ 8 ₂ 4 ₇ 44 ₇₇ 4 AHA4 _{5 77} 4 ₁₁ 0 ₃ .

0 ₂ 9 ₁ 00 ₂ 9 ₃ 0 ₃ 88 _{1 66} 8 ₂₆₂₁₁₃ 880 _{55 55 7} 4 ₅ AHA4 _{7 11} 04.

1 _{2 6} 8 ₁₃ 88 _{3 66} 8 G89 ₃ 8 ₁₃ 88 _{2 777} 4 _{5 7} 4 ₇ AD _{5 7 11} 0 ₅ .

₂₆₆ 0 _{1 261} 89 ₁₃ 88 _SS 8 ₃ 8 ₁₃ 88 _{7 75 E57 7} 4 ₁₁ 0 ₆ .

| _{| 11 | 11 2} 8 _{36 213} 88 ₆₆ 9 _1SS 0 ₁₃ 88 _{6 66} 90 ₇ 4 ₅ 4 ₇₇ 4 _{E5777 7} 4 ₁₁ 0 ₇ .

₁ 99 ₁₂ 8 ₃ 889 ₆₆ 9 _3S1 09 ₆₁₃ 888 ₆₆ 9 ₂ 4 ₇ 44 _{57 7} 4 _E T4 ₇ 4 ₁₁ 08.

8 ₃₆₃ 09 ₃ 09 ₃ 89 _{1 66} 9 _SS1 08 ₆₁₃ 890 ₆₆ 9 _{7 7} 4 _{5 E} 4 ₇ 44 ₁₁ 09.

₃₆₃ 8 _{22 36} 0 ₁₆₃ 89 _{3 66} 9 _S1 900 ₁₁₃ 89 _{27 7} 4 _{7 E} U _{7 111} 0.

₁₂ 99 ₁₂₆₂₃ 89 ₆₆ 99 _S2 88 ₁₃ 89 ₅ 4 _{55 75} 4 _E U ₇ 4 ₇ 4 ₁₁₁₁ .

1 _{111 | 11 2} 0989 ₂ 09 ₃₆₃ 89 ₆ 0 _1S31 88 ₆₁₃ 89 _{6 6} 00 ₅ 44 _{5 77} 4 _{7 E} U ₇ 4 _{7 1112} .

₆ 8 ₁ 8 _{3 6} 8 ₃ 98 ₃ 899 ₆ 0 ₃ 00 ₁₃ 898 ₆ 0 _{275 7} 4 ₇ A _I N ₅₇ 4 ₇ 4 _{7 1113} .

₆ 8 _{3 36} 9 ₃ 90 _{1 6} 0G8 ₁ 9 ₁₂₁₃ 900 ₆ 0 _{75 7} 4 _{75 KP 7} 4 ₇ 4 ₁₁₁ 4.

₁₃₂ 8 _{3 1313223} 90 _{3 6} 0G8 ₁₁₃₁₃ 90 _{2 6} 0 _{65 7} 4 _{77 KP7 7} 4 _{7 1115} .

₁₂ 00 _{2 116} 09 ₁₃ 90 ₆ 09G8909 ₁₃ 90 ₆ 08 _{5 75} 4 _{7 KP} 4 ₇ 44 _{7 1116} .

1 _{11| 11 6} 0 ₁ 0 ₂ 00 ₃ 90 ₆₁₁₃ 8 ₁₁₃ 90 _{6 61} 0 _{7 77} 4 _{7 KEI5} 4 ₇ 4 _{7 1117} .

₃ 88 ₃ 9 ₃ 8 ₆ 0 ₃ 909 _613S613313 908 ₆₁₂₇ 44 ₇ 4 _{7 E} V _{7 7} 4 _{7 111} 8.

₃ 88 ₁ 0 ₃ 8 ₃₆₃ 9 _{11 61S2} 9 ₃₁₃ 9 ₁ 0 ₆₁ 44 _{5 7} 4 _{75 E} W4 _{5 7} 4 ₇ 4 ₁₁₁ 9.

₁₁ ¹³⁶¹ ₁ 0 ₆ 0 ₃ 9 _{13 61S636213} 9 _{12 61677 7} 4 _{77 EZ7 7} 4 _{7 112} 0.

a ¹ 0 ⁶¹ 9 ₁ 0 ₂ 0 ₂₃ 9 _{1 61} 9 _S6 0 ₁₃ 9 _{1 61} 8 ₁₁₂₁ ⁵ _{7 75} 4 _{7 E} Y _{577 7} 44 ₇ .

¹² 8 ² ₁₂ 0 ₃ 9 _{1 621S13313} 9 _{16 62} 0 ⁷⁷ 4 _{55 77} 4 _{7 E} Y _{57 7} 4 _{7 1122} .

⁶¹ 9 ⁶ 8 ₃ 9 ₂₃ 9 ₁ 9 _623S663 9 ₃₁₃ 9 ₁ 8 ₆₂₂ ⁵ _{5 7} 4 _{7 E} Y ₇ 4 _{7 1123} .

¹⁶ 89 ₁₃ 89 ₃ 9 _{21 62S326} 9 ₁₃ 9 ₂ 0 ₆₂ ⁵⁷ ₅ 4 ₇ 4 _{75 E} Y _{5 7} 4 ₇ 4 ₁₁₂ 4.

9 ¹⁶ 9 ¹ ₃ 9 _{23 62S} 8080 ₁₃ 9 _{22 626} ⁷ ₇ 5 ⁷⁵ ₇ 4 _{77 E} W _{5 7} 4 _{7 1125} .

1 ¹ 8 ³ ₃ 9 _{2 62} 9 _S 8 ₂ 0 ₁₃ 9 _{2 62} 8 ⁵ 4 4 ⁷ 4 ⁷ ₇₅ 4 _{7 EZ} 4 _{7 7} 44 _{7 1126} .

³³ 00 ³³ 98 ¹ ₃ 9 _{2 631} O0900 ₁₃ 9 _{26 63} 0 ⁵⁷⁵ ₇₇ 4 _{7 B} A _{5 7} 4 _{7 1127} .

²³¹² 0 ^{2 23} 08 ²³ ₃ 9 ₂ 9 ₆₃₃ 9 ₁ 8 ₁₁₃ 9 ₂ 8 ₆₃₂ ⁷⁵ ₇ 4 ₇ AH _{B5 7} 4 _{7 112} 8.

en m /l <n o o /l /l m o ■a- m m ■a- ■a- ¹ 0 ^{6 66} ₃ 9 _{31 63} 90 ₂₂₁₃ 9 ₃ 0 ₆₃ ⁵ 44 ⁵ ₇ 4 _{75 E} TD _{7 7} 4 ₇ 4 ₁₁₂ 9. m o en en o -n ■a- o ■a- in m m σι o i-n -n ■a- ■a- m m m m m m m m 99 ^{6 2} 08 ₃ 9 _{33 6321} 0 ₃₁₃ 9 _{32 636} ⁵ 4 ₇ 4 _{77 E} T _{E5 7} 4 _{7 113} 0. m o

288 ²²⁶ 0 ⁶ ₃ 9 _{3 63} 98 ₃ 0 ₆ 9 ₁₃ 9 _{3 63} 8 ^{755 7} ₇₅ 4 _{7 E} T _{I 7} 44 _{7 1131} . z

en <n

■a-

Έ

en m <n m m ■a- <n <n <n o m ■a- ■a- o o m m m m <n <n m <n <a- o o m m m

m m m m m m m m m

o o ■a-

<n

- ■a- ■a- ■a- ■a-

₁ 9 ₂₃₁ 9 ₂₃₆₃ 099Q ₂ 9 ₆₁ 98 _77575766 8 _{3 B} A _7575766 8 _2213775 .

18880998 ₁₆₂₁ 980 ₅ 4 4 _{7 7566} 8 _K MM ₇₅ 4 ₇₅₆₆ 8 ₂₁₇₅₇ 4 ₅ 4.

1 _{| 11} 98 ₁₁₆ 98 ₃ 0 ₂₆₃ 8 ₆₁ 98 _{25 57 7566} 8 _K M ₇₅₆₆ 8 _{6 2177755} .

| _{111 1} 0 ₃ 0 ₆ 8980 ₁₁₁₁ 98 ₅ 4 _{5 75566} 89 _K M4 _{5 75} 4 ₆₆ 88 ₂₁₆₇₇₅ .

1 _{1| 3} 9980 ₆₁ 9 ₁ 98 _{655 75766} 9 _{1 K} M _{57 7566} 90 ₂₁₇₇₅₇ .

1 _{| 1 | 1 2} 98 _{2 263} 0 ₂ 9890 ₁ 8 ₆ 9 ₁ 988 _{5 7566} 9 _{3 K} M _{7 7566} 9 _{2 21} 8 ₇₇₅ .

| _{|| 11 6126 26} 99 ₁ O80 ₃ 0 ₁ 990 ₅ 4 ₇₅₆₆ 9 _K M _{5 7566} 9 ₂₁ 9 ₇₅₇ 4 ₅ .

| _{11 221} 99 ₃ O880 ₃₁ 99 ₂ 4 ₇₅₆₆ 9 _K M4 ₇₅₆₆ 9 _{6 216} 0 ₇₇₇ .

| ₁₁₁₆ 9 ₁ 8990 ₁₂₁ 99 ₅ 4 ₇ 4 ₇₅₅₆₆ 99 _K M _P 4 _{5 75} 4 ₆₆ 98 ₂₁₆₁₇₇ .

1 _{11 1} 8 ₃ 0 ₁ 899 ₆₁ 8 ₃₁ 99 ₆₅ 44 _{5 75766} 80 _{1 K} M _{P7 7566} 800 ₂₁₆₂ .

| _{| 1 | 1 213} 88 _{2 211} 9990 ₂₃₂₂₁ 9984 _{55 7566} 80 ₃ A _{KP 7566} 80 _{2 2163} .

1 ₁₁₁ 9 ₆ 0 9 ₂ 9 ₂₆ 00 ₁₃₂₁₁₆ 000 ₅ 4 _{7 766} 80 A _KP 4 _{7 766} 80 ₂₁₆₅ 44.

| _{1 | 1 1611} 8 ₆ 00 ₃ C88 ₃₂₁₆ 00 _{25 766} 80DT4 ₇₆₆ 80 _{6 21675} .

1 _{| 1 | 1 3} 09 ₃ 0 ₃₂ 0 ₆ 00 C ₃₂₂₁₆ 00 ₇ 4 ₇ 4 ₇₅₆₆ 809DT44 ₇ 4 ₆₆ 808 ₂₁₆₆ .

| ₁₁₁₁₃ 0 _l 0 ₃₃₆ 00 C ₂₁ 908 ₁₆ 00 _{6 5} 4 ₅ 4 ₇₇₆₆ 8 ₁₁ DT ₇₆₆ 8 ₁ 0 ₂₁₆₇ .

| _{11 | 13} 9 ₃₂ 00 ₆₆ 009 C89 ₂₁₆ 008 _{5 5} 4 ₇₆₆ 8 ₁₃ DT ₅ 4 ₇₆₆ 8 _{12 216} 8.

1 _{1| | 13} 9000 ₂₆ 0 ₁₁ C ₃₂ 8 ₁₆ 0 ₁ 0 ₅ 4 _{57 766} 8 ₁ DT ₇ 4 ₇₆₆ 8 _{1 216} 9 ₅ 4.

| _111|3 9 ₃₁ 00 ₆₃₆ 0 ₁₃ C ₃ 90 ₆₁₁₆ 0 _{12 5 5 766} 8 ₁ DT ₇₆₆ 8 _{16 21} 0 ₇₇ .

1 _{| 1 | 1 3} 90 ₃₁ 8 ₃₆ 0 ₁ C99 ₁₃₆₁₆ 0 ₁ 444 ₇₅₆₆ 8 ₁ 9DT ₇ 4 ₆₆ 8 ₁ 8 ₂₁₁₇ .

1 _1||2 09 ₃₁ 099 ₆ 0 ₁ C ₁₂₁₁₆ 0 _{16 77 77 7766} 8 _21PR 4 _{5 766} 8 ₂ 0 ₂₁₂₇ .

| _{| 1 | 1 33 311226} 0 ₁ 9 C ₆₆ 0 ₃ 0 ₁₆ 0 ₁ 84 ₅ 4 ₇₆₆ 8 _{23RL 766} 8 _{22 2137} .

| _{1| | 1} 8 ₁₃₂₃₃ 809 ₁₆ 0 ₂₁ G ₁₂ 98 ₁₆ 0 ₂ 044 ₇₆₆ 8 ₂ A _{P5 766} 8 _{2 215} 4 ₇ 4.

1 _{1 | 1 3} 98 _{3 3} 9 ₆₆ 0 ₂₃ CC ₆ 0 ₁₆ 0 ₂₂ 4 ₅ 444 _{75 766} 8 ₂ H ₇ 4 _{7 766} 8 _{26 21775} .

1 _{11 | 1} 909 ₂₂ 0 ₆₆ 0 ₂ CC ₃ 8 ₃₃₁₆ 0 _{2 5 7566} 8 ₂ 9N4 ₇ 4 ₆₆ 8 ₂ 8 ₂₁₆₇ .

1 _{11 | 1 2} 9 ₆ 9 _{1 26} 0 ₆ 0 ₂ CC89 ₂₁₆ 0 ₂₆₅ 4 ₇₇₆₆ 8 ₃₁ N _{55 766} 8 ₃ 0 ₂₁₇₇ .

1 _{11 | 1 2} 9 ₆ 9 _{1 26} 0 ₆ 0 ₂ 9 CC9 ₂₂₁₆ 0 ₂ 8 ₅ 4 ₇₆₆ 8 ₃₃ N _{77 766} 8 _{32 21} 8 ₇ .

| _{| | 1123 3} 0 ₆ 0 ₃₁ CC ₃₃₁₁₆ 0 ₃ 0 _{7757 766} 8 ₃ N4 _{5 766} 8 _{3 21} 9 ₅ 4 ₇ .

1 _{| 11| 2} 980 ₂₆₁₆₆ 0 ₃₃ CC ₆₃₁ 0 ₂₁₆ 0 _{3277 766} 8 ₃ N ₇₆₆ 8 _{36 21} 80 ₇ .

| _{| 111} 8 _3l 8 ₁ 0 ₆ 0 ₃ CC9 ₁ 9 ₁ 9 ₁₆ 0 ₃ 4 _{755 7566} 8 ₃ 9N ₇ 4 ₆₆ 8 ₃ 8 ₂₁ 8 ₁ .

1 _{1| || 2} 9 ₆ 8 ₂₆ 0 ₆ 0 ₃ CC0 ₃ 9 ₁₆ 0 ₃₆ ⁵ ₅ 4 ₇₇₆₆ 8 ₁ 4 ₅ 4 ₇₆₆ 80 ₂₁ 8 ₂ 44.

o

1 _{11 | 1 1} 8 ³³ ₁ 90 ₃₆ 0 ₃ 9 C8 ₆₃₁₆ 0 ₃ 8 ⁵ 4 ₇₆₆ 8 ₃ DH4 _{5 766} 8 _{2 21} 8 ₃ 44.

a ¹ _{1 | 1} 0 ² ₆ 0 ₁₆₆ 8 C8 ₆₆₆₁₆ 00 ₆₆ 8 ₂₁ 8 4 ⁵ ₇ 44 ₅ DH4 ₇ 4444.

1 _{1 | 1} ^| ₃ 999 ₆ 0 ₃ CG ₁ 0 ₃₁₆ 0 ₂ ⁷⁵⁵ 4 ₇ 4 ₆₆ 8 _E 44 ₇ 4 ₆₆ 8 _{6 21} 84 ₇ 4 ₅ .

1 _|36 0 CQ ₆ 9 ₃ 9 ₃₁₆ 0 4 ⁷ 4 ⁷⁵ 4 ₅ 44 ₇ 4 ₅₆₆ 89 _{F 7} 44 ₆₆ 88 ₂₁ 8 ₆ 44.

en ^{| 1} ₁₁ ^621l ₂₆₂₆ 09 ₁₂ 0 ₁₆ 0 ₆ ⁷ ₇ ⁵ ₇ 4 ₇₆₆ 8 _{1 K} MU _{7 7} 4 ₆₆ 80 ₂₁ 8 ₅₅₇ .

1 ¹ ₁₁ ³ 9 ² 900 ₃ 9 ₂ 1 ²¹⁶ ₆ 090 ₆₂₁₆ 084 ₇ 4 ₇ 4 ₆₆ 8 _{3 K} MV ₅ 4 ₆₆ 8 _{2 21} 88 ₅₅ .

1 ¹ _{| 1} ¹² 99 ³³ 8 ₁ ² 9 ⁶ 0 ¹¹ ₆ 0 _l 0 ₂ 0 ₁₆ 00 ₇₅₆₆ 8 _K MV ₅ 4 ₇₅₆₆ 8 ₂₁ 89 ₅₅₅ 4.

1 ¹ _1| ⁶ 08 ⁶ 0 ⁶ 0 ₆ 0 ₃ 09 ₆₂₁₆ 0 ₂ 4 ⁷⁷ ₇₅₆₆ 8 _K MV _{5 7566} 8 _{6 21} 90 ₅₇₅ .

| ¹ ₁₁ ^{222 21} 8 ⁶⁶ ₆ 0 ₂ 9 ₂₁₆ 0 ⁵⁵⁵⁵ ₇₅₅₆₆ 89 _K MW4 _{7 75} 4 ₆₆ 88 ₂₁ 9 ₁₅₅ . | ^| _|| ¹⁶³ 9 ¹⁶³³ 90 ₆ 0 ₁ 99 ₆₁₆ 0 ₆ ⁷⁵ ₇₅₇₆₆ 8 _{61 K} MW _{7 7566} 8 ₆ 0 ₂₁ 9 ₂ . | ^| ₁₁ ^{3332 3} 0 ¹³ ₆ 09 ₂ 9 ₆ 0 ₆₁₆ 08 ⁷⁷ ₇₅₆₆ 8 _{63 K} MW ₇₅₆₆ 8 _{62 21} 9 ₃ . o z

Έ

o o o

o o o o o

-

_{1360023211169 C} O _{6928169674761N574602637757757} .

_{28681 2808699 C6216984 7463} MV _{547 7462 2638775775} .

_{328 28982691 C868169055 756JY77 756 263977557754} .

2 _{68693 C939961692 545 4574 756JT 7566 26077577754} .

6 _{302369 C0169 54 547 75569JN5547 75468 2617757754} .

_{89106869 C80916964 5 757661} M _{Y54 75660 26277774} .

_{80268639699 C} 0 _{966231698 75 75663J 75662 26377774} .

_{2806 28336961 C82101696074 766} M _{X7 766 2677577444} .

_{309 312066963 C0911696257 766I} W _{45 7666 267777745} .

_{613289696 C30816967 575 75669JU45 74668 26677774} .

_{22290 18311696 C01816966 7761} M _{T55 760 2677777747} .

_{6682 62896969 C91161696877 763JN7 762 2687777774} .

_{221 182691 C22316904547 776} M _{T57 776 269777577744} .

1 _{2 2168693 C8169255574 776IZ5747 7766 26077777775} .

_{19662 18969 C6616957 77569} M _{X555 77468 2617777775} .

_{3023 2636169 C998116964 777681} M _{U7 77680 26277775} .

9 _{21639699 C1601698 447 4 77683TD47 77682 26377775} .

_{20331 1993366981 C680169805 768} M _{T47 768 2677577454} .

| _{| 1113611 39386983 C13916982 47 768JL74 7686 267777755} .

_{291 226698 C} G _{2889116985554 75689K 74688 26677775} .

_{63189282698 C62169865 5 77691IR444 7690 26777757} .

_{309 312036989 C} OG _{68191698854 76935 7692 26877775} .

_{1899 11226991 C0921699055 769} M _{U55 769 2697757745} .

| _{| 111 110621896993 C} O _{191816992 7 769J7 7696 266077777} .

_{1280 12099699 C} O _{C831699455 75699544 74698 26617777} .

_{9192 8801699 C133621699645 776801} MV _{76800 266277} .

_{2806 28336999 CC9891699874 76803K57 76802 266377} .

8 _{16133001 C68321000 57 55 77 680NP4 77 680 26675744} .

1 _{21 6630003 C} G _{1881002 757 77680J55 776806 2667775} .

9 _{1162600 C099100 44} ⁴ _{4 7756809TE77 774680877} .

8 _{196300 C} O _{02681006 5} 5 ⁵⁴ _{5 7776811} A _{7 776810 266777} .

a _{| 11} ⁹⁶¹⁰ _{30096813 C6210086812 577 777} MV _{477 777} .

8 ¹⁶ _{133011 C101381010} ⁵⁷ _{55 77 681NP 77 681 26697574} .

| ^| _11| ¹¹⁰⁶² ₁₈ ⁹ _{013 C} O _{18331012 7 77681P5 776816 2607777} .

1 ₁₁ ⁹³¹ _{01 CC3930101} ⁴⁴⁴ ₄ 5 ⁴⁴ _{7756819K7 7746818 261777} .

1 ¹ _{| ||} ^{896 1993} _{01 C} O _3221016 ⁵ _{7776821D47 776820 262777} .

| ¹ _{1 | 1} ⁶²²³⁹ _{019 C9901018} ^{47 474} _{776823TF47 776822 263777} .

3 ¹⁶⁹⁹³ _{021 C6021020} ^{57 45} _{77 682NP57 77 682 26757474} .

1 ^| ₁₁₁ ⁹²⁹⁸⁶ _{023 C86111022} ^{77 755} ₇₇₆₈₂ M _{Z4 776826 2677775} . o

| _{1 |} ^{189 10l} _{02 C} O _6129102 ⁷⁴⁵⁷ _{7756829B4 7746828 266777} .

-

_{111612268016881801655747091 KX} A _{44409023757547} .

| _{11 3 801921981 80187574093 K} W _{Z540922387575 4} .

| _{||128 8011231 8010 4509 K} W _{Z447509239755754 4} .

| _{1 || 31 801333361 801247509 K} W _{Z550962075775 44} .

_{13333 128806 1036 801S611 801555099 B} A _{7445409821 75 75 44} .

1 _{1|| 339688 339096 801Q691 801674570961 B} A _{747509602277 44} .

1 _{| || 669029 660 8019Q3221 80187754450963 B} A _{44509622377 44} .

1 _{1| 1 622 6160 8016l381 8016045544096 B} A _{T47709627574 444} .

1 _{11 || 20089 2009 80163S20811 8016257475096 B} A _{409662777 445} .

| _{| 1 | 1 61236 6130 8016S3861 801674750969 B} A _{57409682677 44} .

| _{1||336192906 8016S331 80166 57 5777091 B} A _{44709027777 447} .

| _{11 | 1336193092 80169S3381 80168 57 577093 B} A _{44092287777 44} .

1 _{1| 1 11323 11691 801l28811 80107445709} AM _{D570929775774 44} .

1 _{11| 1161 1160688 80132811 8012447709} AM _{D5770962077777 45} .

1 _{111111020228 801661 801 44 44775099 B} A _{R57574098217777 45} .

| _{|68232 801091 8016 4454 44557770981 B} A _{R577709802277 45} .

| _{111 236 2389 80192631 80184754770983 KXB77709822377 45} .

| _{|| | 1 161289 160 8018128301 80180575098 KXB709827574 454} .

| _{| 1 | 1 11298 11166 8018332361 8018254098 KXU709862777 455} .

1 _{111 96802 801891 801875 550989 KXB5444409882677 45} .

1 _{111 2038 200381 801806961 80186444470991} AM _{E50990277 457} .

1 _{11 | 1 698 2926 80189C33991 8018840993 KX509922877 45} .

1 _{1| 11 698 2926 80191C166281 801904099 KX099297574 45} .

1 _{1111 698 2926 80193C16911 801924099 KX50996260777 4} .

1 _{111|29 30 8019C169281 8019 777750999 KX4099826177 4} .

1 _{11 | 1 698 2926 8019C3221 80196471001 KX55100026277 4} .

| _{11169 80199C9301 80198 451003 KX75100226377 4} .

| _{| 111 13 13936 80201C91001 8020045755100 KX4100267574 44} .

| _{| 1129l 319 80203C9811 80202 77100 KX55100626777 45} .

en ^| _{| 11 13 13936 80200211 8020457} ⁷ _{751009 KXD554100826677 4} .

| _{1111 1} ¹⁶⁹ _{169 8020109931 802067} ⁵ _{74471011 KXD10102677 47} .

a ^| _{| 1 | 1} ^21013l _{2092l 802091013C89661 80208101226857 KX57 4} .

1 _{1| 1} ²⁸⁸⁰⁹³ _{28803 802119831 80210} ⁴ ₅₄₁₀₁ AM _{F551012697574 4} .

1 _{11 ||} ¹⁶²³² _{16060 80213} G _{038611 80212} ⁴⁴ ₄₄₁₀₁ AM _{101620777 47} .

en ^{| 1} ₁₁ ²²¹¹ _{181 80211911 8021} ⁵ ₅ ⁷ _{51019 KXF77410182177 47} .

1 ¹ _|| ²⁸⁸ ₂ 6 ³ ₈₀₂₁ G _{3801 80216} ⁵⁷⁷⁷ ₅₇ ⁵⁴ ₇₁₀₂₁ AM _{5410202277 47} .

1 ₁₁ ^1661268 ₁ ⁶ _{8021909011 80218} ⁵⁷⁷⁴⁵ ₁₀₂₃ AM _{H410222377 47} .

| ¹ _{| 1} ^{388102 38363} _{802219931 80220} ⁴ _{102 KXF5710227574 474} .

1 ^| ₁₁ ^10806063 _{8022388111 80222} ^{4 474} ₁₀₂ AM _{H510262777 475} .

1 ¹ ₁₁ ^{1896 18088} _{802213601 8022} ⁵⁴⁵⁵⁷ ₅₁₀₂₉ AM _{J4410282677 47} . o ¹¹ ₁₁ ^{192236 191891} _{8022111 80226} ⁴⁵ ₇₁₀₃₁ AM _{J4471030277 477} .

1 ¹ ₁₁ ^{182616 182108} _{8022969931 80228} ⁴⁵ ₁₀₃₃ AM _{J510322877 47} . z

Έ

-

[001671] Table 15: The Septu Defense System and Components Thereof

[001672] This table is presented in landscape orientation. Due to the number of columns, the table has been split into parts. Part A includes the first set of columns and therefore should be place to the left of subsequent parts (Part B and where relevant Part C). To avoid any doubt, the rows of the table in each part line up once the tables are placed together.

Table 15 (Part A)

_{1 | 1 |bhlb} C _S6361 C _S O ₁ 00000 ₃₁₁ 8 _{i L22} 9 ₁ GCD ₇₇ W _J A V ₅ 4 ₅ A ₁₆₃₆ eoacoe _ir ..._

_{1 1 | 1 |bhlb} C ₆₂₃₆₁ C0 ₁ 00000 _{11i L2261} GC _RZ5 WNT V ₅₇₅ A ₁₆₃₇ eoacoe _ir ..._

_{1 | | 1bhlb} C _S C9 ₃ 89 ₁ C0 ₁ 0000 ₁ 0 _{1 621i L221} GC ₇ W _R D ₅ V ₅₇₇₅ A ₁₆₃ 8 eoacoe _ir ..._

_{1 | | 1 |bhlb} C9 ₁ CO0 ₁ 00000 _{2112i L22} 8 ₁ GC _RZ7757 W _B A ₅ V ₅₇₅ A ₁₆₃ 9 eoacoe _ir ..._

_{1 | 11 |bhlb} C _S C999 ₁ C _S 0 ₁ 00000 ₁₁ 8 _{i L22} 89 ₁ GC ₇ 4W _R 4 ₅₅ V ₅₅ A ₁₆ 04 eoacoe _ir ..._

₁ ^| _{| 1 |bhlb} C _S C89 ₂₁ C0 ₁ 00000 _{21 136i L23} 0 ₃₁ GC ₇₇ W _RJ 4 V ₅₅ A ₁₆₁ 4 eoacoe _ir ..._

₁ ^| _{1 |bhlb} C _S 0 ₂₂₁ C0 ₁ 00000 ₆₁₆ 00 _{i L23} 0 ₁ GCD ₅ 4W _R W 4 V ₅₅₅ A ₁₆₂ 4 eoacoe _ir ..._

₁ ¹ _|bhlb C0 ₂ 0 ₁ C0 ₁ 00000 _{211i L2311} GC _RZ7 4WNX A ₅ 4 V ₅₅₅ A ₁₆₃ 4 eoacoe _ir ..._

₁ ^| _{11 |bhlb} C _S 88 ¹ COO0 ₁ 0000 ₁₃₁₁ 8 _{i L2311} GCA ₇ 4 ₅ W A4 V ₅₇₅ A ₁₆ 44 eoacoe _ir ..._

₁ ^| _{1 | 1bhlb} C _S 9 ¹ 9 ¹ C _S 0 ₁ 00000 ₁₁₂ 9 _{i L23231} GCD4 ⁷ W _I A V ₅₅ A ₁₆ 4 ₅ eoacoe _ir ..._

₁ ¹ _{11 |bhlb} C _S ¹ 08 ¹²¹ CO0 ₁ 00000 ₁₁ 8 _{i L232} 9 ₁ GCAW _K 4 A ₅ V ₅₅ A ₁₆₆ 4 eoacoe _ir ..._

₁ ^| 1 _{| 1bhlb} C9998 ¹ CO0 ₁ 00000 _{211i L2331} GC ^RZ7 W W A ₅ V ₅ 4 ₅ A ₁₆ 4 ₇ eoacoe _ir ..._

₁ ^{| |} _{1 |bhlb} C ^S 8 ³⁶³¹ CQC0 ₁ 00000 ₁₂ 9 _{i L231} GC ^B7 W4 A ₇ V ₅₅₅₅ A ₁₆ 84 eoacoe _ir ..._

₁ ^| _{1 |bhlb} C ³ 8 ³¹ C0 ₁ 00000 ₃ ¹ G8 _{i L231} GC ^RZ 44WNN _P V ₅₅₇₅ A ₁₆ 94 eoacoe _ir ..._

₁ ^{1 |} _{1 |bhlb} C ^S C ²⁶² 0 ¹ CQ0 ₁ 0000 ²¹ ₂₁ 9 _{i L23611} GC4W _P 4 A V ₅₅ A ₁₆ 0 ₅ eoacoe _ir ..._

(J ₁ ^{| 1} _{| 1bhlb} C ^S3161 C _S O _l OOOOO ^ll _{31i L236} 9 ₁ GCD4 ⁷ W _K A V ₅₅ A ₁₆₁₅ eoacoe _ir ..._

₁ ^{| 1} _|bhlb C ^S1 98 ³⁶¹ C _S CO ^l OOOOO ^ll _{i L2} 0 ₁ GCDW V ₅ 4 ₅₅ A ₁₆₂₅ eoacoe _ir ..._

₁ ^{1 |} _{1 |bhlb} C ^S C ⁶⁶¹ 8 ¹ CQ0 ¹ 0000 ¹³¹ 8 _{1i L221} GC4WD A4 V ₅ 4 ₅₅ A ₁₆₃₅ eoacoe _ir ..._

₁ ^| _|bhlb C ^S 9 ⁶¹ C0 ¹ 00000 ¹ 8 _{i L2331} GCD ⁵ 4 ⁵ W ^R V ⁷ 4 ₇ 4 V ₅ 4 ₅ A ₁₆₅ 4 eoacoe _ir ..._

₁ ^{| 1} _{| |bhlb} C ^S 9 ⁶³²¹ C ^S QO ^l OOOOO ^ll G _{116226i L231} GCD ⁵ W M V ₅ 4 ₅₅ A ₁₆₅₅ eoacoe _ir ..._

₁ ^{| |} _{1 |bhlb} C ^S21 C ^S 0 ¹ 00000 ²¹ G ₁₆ 0 _{i L231} GCD4 ⁵ 4 ⁵ W ^B _P V ₅ 44 ₅ A ₁₆₆₅ eoacoe _ir ..._

₁ ^{| |} _{| 1bhlb} C999 ¹ COG0 ¹ 00000 ¹ 9 _{i L231} GC ^RZ7 4W4 A ₅ V ₅ 4 ₅₅ A ₁₆₅₇ eoacoe _ir ..._

₁ ¹ _{1 |hlbb} 0 ²¹ _{623i L2631} GC C ^S11 080 ¹ CO ¹ 0000DW ^R M 4 V ₅ 4 ₅ A ₁₆ 8 ₅ eoacoe _ir ..._

₁ ^{| |} _{1 |bhlb} C ^S622231 C ^S 0 ¹ 00000 ²¹ _l O _{i L261} GCDW ^F A V ₅ 4 ₅₅ A ₁₆ 9 ₅ oe _ir eoac..._

_{1 1} ¹¹ _| ^b _hlb C ^S26 0 ¹³¹ C ^S O ^l OOOOO ^ll _{i L261} GCDW ^E V ₅ 4 ₇₅ A ₁₆₆ 0 eoacoe _ir ..._

₁ ^{| |} _{1 |} ^b _hlb C8 ³¹ C ^S 0 ¹ 00000 ²¹ G ₁₁₆ 0 _{2i L2} 89 ₁ GC ^RZ7 4 ⁵ WN M ₅ V ₅ 4 ₅ A ₁ eoacoe _i ..._

o o o o o o o o o o o o o o o o o o o o o o o o o _661r

o o o o o o o o o o o o o o o o o o

₁ ^{| |} _{1 |} ^b _hlb C98 ³ 8 ¹ CO0 ¹ 00000 ³¹ ₁ 80 _{i L2} 9 ₁₁ GC ^RZ7 W ^R A V ₅ 4 ₅ A ₁₆₆₂ eoacoe _ir ..._

₁ ^| _| ^b _hlb C ⁶ 0 ⁶¹ C0 ¹ 00000 ¹ _{i L211} GC ^RZ 4 ⁵ WN ^L 4 V ₅₅₅₅ A ₁₆₆₃ eoacoe _ir ..._

₁ ^{| 1} _| ^b _hlb C ^S 98 ³⁶²¹ C0 ¹ 000009 ¹ ₂ 00 _{i L22} 9 ₁ GC ^B W ^P W A V ₅₅₅ A ₁₆₆ 4 eoacoe _ir ..._

¹ ₁ ^{| |} _| ^b _hlb C ^S2 9 ⁶¹ C ^S G0 ¹ 00000 ²¹ _{i L21} GCD ⁵⁷ W V ₅₅₅₇₅ A ₁₆₆₅ eoacoe _ir ..._

₁ ^{1 | 1} _| ^b _hlb C ^S31 0 ¹ C ^S 0 ¹ 00000 ¹ _{36i L2} 8 ₃₁ GCD ⁷ 4WA4 4 ₅ V ₅₅₅ A eoacoe _ir ..._

₁ ¹¹ _| ^b _hlb C ^S C8 ¹³ 0 ¹ C0 ¹ 00000 ¹ ₆ 8 _{i L2} 9 ₁₁ GC ⁷ W ^RI5 ₇₅ V ₅₅₅ A ₁₆₆₇ eoacoe _ir ..._

₁ ^{1 | 1} ₁ ^b _hlb C ^S1 88 ¹¹ CO0 ¹ 0000 ¹³¹ _{663i L26} 0 ₁₁ GCA ⁷ WD 4 V ₅₅ A eoacoe _ir ..._

₁ ¹¹ _| ^b _hlb C ^S C ¹ 9 ² 8 ¹ CQO ^I OOOO ^I O ^I _{i L2631} GC4W ^I _PRL5 V ₅₅₅ A ₁₆₆ 9 eoacoe _ir ..._

₁ ^{| | 1} _| ^b _hlb C ^S C ³ 8 ²¹ C0 ¹ 0000 ² 8 ¹ ₂ 09 _{i L2661} GC ⁵ 4W ^P U A V ₅₅₅ A ₁₆ 0 ₇ eoacoe _ir ..._

₁ ^{| 1} _| ^b _hlb C ^S33311 CO ^l OOOOO ^ll ₂ ¹ _{i L2661} GC ^B7 W ^P X A4 V ₅₇₅ A ₁₆₁₇ eoacoe _ir ..._

< < ₁ ^{| 11} _| ^b _hlb C ^S2 8 ² 9 ¹ C0 ¹ 00000 ³¹²³¹ _{i L26} 8 ₃₁ GC ^B5 W ^PP A V ₅₅ A ₁₆₂₇ eoacoe _ir ..._

^{1 | 1} _| ^1b _hlb C ^S6 0 ³²³¹ CO0 ¹ 0000 ¹³¹²³² _{i L26} 9 ₁ GC ^B W ^P A V ₅₇₅ A ₁₆₃₇ eoacoe _ir ..._

^{1 | | 1} _| ^b() _hlb C ^S 9 ⁶³¹ C ^S 0 ¹ 00000 ⁶¹ 88 ^l _{i L2} 0 ₁ GCD ⁷ 4WN A4 V ₅₇₇₅ A ₁₆₇ 4 eoacoe _ir ..._

¹¹¹ _| ^b _hlb C ^S16 8 ¹ 0 ¹ C0 ¹ 00000 ¹³³ 0 _{i L2211} GCAWNU4 A V ₅₇₅ A ₁₆₇₅ eoacoe _ir ..._

^{1 | 11} _| ^b _hlb C9 ³ 9 ³¹ CO0 ¹ 00000 ³¹¹ 09 _{i L221} GC ^RZ5 W ^J V V ₅₇₅₅ A ₁₆₆₇ eoacoe _ir ..._

^{1 | | 1} _| ^b _hlb C ^S C89 ¹ CQ0 ¹ 0000 ¹ 9 ^{1 61} 9 ³ _{i L2} 8 ₃₁ GC ⁷⁵ 4W ^Z V ₅₇₅ A ₁₆₇₇ eoacoe _ir ..._ | ¹¹ _| ^b _hlb C ^S C98 ⁶¹ C0 ¹ 00000 ²¹ 9 ³ _{i L2} 89 ₁ GC4 ⁷ W ^RL 4 ⁵ V ₅₇₅ A ₁₆ 8 ₇ eoac aeoe _ir ..._ o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o

<

o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o

Table 15 (Part B)

_{111111 | | 1| 16898016186393C831618639277754BK4} .

8 _{362 8639} G _{039301 8639 7777 77445} AA ₄ .

_{11 11 1| | I 1| 12208012189863912911863967747} A _EE4 .

_{11 11 119980686399810186398 7447745} A _EE45 .

_{11 11 11 11190301902368601900186004474} A _EE444 .

_{11 11 11 11282882826832860300618602754} A _EE554 .

_{11 11 11 1181188308686039118607757745} A _EE5544 .

_{11 11 11 | I 13291069860} G _001614547EK5 .

_{1| 1| 11839281388860901615754} A _E M ₄₇ .

_{11 11 1| | | 1122822922603861l33828186104454} Α _ΕΗ4 .

_{11 1| 11 1|1983130l 86133921861244444} A _EH474 .

_{11 11 | | 1166193861} G _68390186145E M ₄₄ .

_{11 11 1| | | 1| 2086206090861} G _{693186164747E} M ₇₅₄ . _iz

_{1| 1| 11 118218038619} G _{081186185475554 EN454} .

_{28326 2611 8621} G _{662191 86207754 EN4} .

_{161 1623 8623} G _{60381 8622444444 EN74} .

_ZZL

_{11 11 11022900088620101862444 44545} A _EI5744 .

_{11 11 | I 11 636663226862162186264444447} A _EI574 .

_{11 11 | I 11 6686628886291933186285477544} A _EI54 .

_{11 1| 1| 11101339288631621863074774} A _EI5454 . _iz

_{11 11 11 1| 126809912660986336291863274} A _EI744 .

Z _LL

_{11 1| 11 113129823129l 86363186375545} A _EI45544 .

_{11 11 1| | I 1| 6392901639086362111863657547} A _EI74 .

_{1| 1| 11 | I 11231992118639} G _{Q168218638744E74} .

_{9802 831 861} G _{Q803861 860444 E44} .

_{11 11 11 1168806398863} G _{6318625444 EU54744} .

₁ ^| ₁₁₆₁₁₀ ⁹ _{916 86291 8655445} A _E M ₄₄₇₄₄₄ .

₁ ¹ _{1| 1} 1 ⁰⁹ _{9312 86} G ₁₉₁ ⁵ _{447 E} W ₄₇₄ .

a ₁ ¹ _{11 11 | I} 2 ⁶³²⁰ _{2610869Q13811} ⁷⁷ ₇₄₄₄₄ A _E4 .

₁ ¹ _{11 1| | | 11} ²⁶⁶⁰⁰⁹ _26313861 GG _89031860 ⁵ ₅₇₄₅ A ₅₄₅ .

1 ⁹ ₂₂₉ ⁹ _{863198081 862} ⁴⁴ _{45 EHB45} . m

¹¹ ₁ ^| _{11 | I} ⁸³ 6 ⁶¹ _{8601381 86} ⁵⁵⁴ ₅ ⁵ _455EHB5454 .

¹¹⁰⁸ _{86C001 866457 EH45545} .

¹¹ ₁ ¹ _{11 | | 11} ^16262116096 _86986691868 ⁴⁴⁴ ₄₅ A _ER445 .

en en σι o σι m m m m m ¹¹ 1 _{1| | I} ^16262116096 m _866l916131 ⁴⁴⁴ ₄ A _ER . m ο σι o cn cn cn o cn cn ¹ m o cn o cn o

8 ^{0 239} _{866308091 8662} ⁴⁷⁴ _{4 EHI54} . z

m en m σι m cn m cn m cn m m

mι σ mι e mn m m m m c mn cn m m m m m c mn σ σ mι ο ο o o o

Έ

en ο m o m m cn m m o o m

m o m m m o cn m

o o o o ο ο o o o o o en m m m m m m m σι σ

m m m m mι e mn σ mι

m ο o o O o en o m en o m cn o m cn o cn cn

₃₁ 988 ₂ 88 ₃₂₃₆ 9 ₁ 88 ₂ 88 _{322557 KFE577} 4 ₇₁₂ 0 ₂ .

₂ 98 _{12 2} 8 ₂ 0 88 ₂ 8 8 ₃₂₁ 9 ₁ 8 _{327775 KFE5} 4 ₇₇ 4 ₁₂ 0 ₃ .

₁₁₂ 98 ₁ 98 88 ₂ 89 8 ₃₂₆ 89 ₆₆₁ 8 ₃₂₆₅ 4 _{7577 KFE7 12} 04.

₁₂₂ 8 ₁ 00 ₂ 8 88 ₂ 9 ₁ 8 ₃₂ 99 ₃₁₁ 88 ₂ 90 8 ₃₂ 8 _{77 KFE} 4 _{57 12} 0 ₅ .

₃ 0 _{6 2} 0 88 ₂ 9 ₃ 8 ₃₂ 8 ₁ 0 ₃₆ 8 ₃₁ 88 ₂ 9 ₂ 8 ₃₂ 80 ₅₅₇ 4 _{5 KFF 12} 0 ₆ .

₁ 9 _{2 1} 9 ₁ 9 ₆₂ 88 ₂ 9 8 ₃₂ 8 ₃ 0 ₃ 8 ₃₁ 88 ₂ 9 8 ₃₂ 8 ₂ 4 _{555 KFF7} 4 ₁₂ 0 ₇ .

_{133166 132} 998 88 ₂ 9 8 ₃₂ 8 ₆₆₁₁₁ 88 ₂ 9 ₆ 8 ₃₂ 8 _{5575 KFF7} 4 ₁₂ 08.

9 ₂₃ 909 ₁ 88 ₂ 99 8 ₃₂ 8 ₆₁ 8 ₁ 88 ₂ 98 8 ₃₂ 8 ₆₅₇ 4 _{7 KFF} 4 _{5 12} 09.

₁₃₁₁ 9 _1312363 88 ₃ 0 ₁ 8 ₃₂ 898 ₆₆₁ 88 ₃ 00 8 ₃₂ 8844 _{KFF75 121} 0.

₃₃₃ 8 _{1 33132} 88 ₃ 0 ₃ 8 ₃₂ 9 ₁ 9 ₆₁ 88 ₃ 0 ₂ 8 ₃₂ 90 _{57 KFF57} 4 ₁₂₁₁ .

1 9 ₂₃ 88 ₃ 0 8 ₃₂ 9 ₃₂ 09 ₁ 88 ₃ 0 8 ₃₂ 9 ₂₅₅ A _IJ 444 ₁₂₁₂ .

0 ₃₃₁₃ 8 ₂ 8 88 ₃ 0 8 ₃₂ 9098 ₁ 88 ₃ 0 ₆ 8 ₃₂ 9 ₅ 4 _{5775 KFJ77} 4 ₁₂₁₃ .

₃₁ 8 ₃₁ 8 ₃₂ 88 ₃ 09 8 ₃₂ 9 ₁₁₁₂₁ 88 ₃ 08 8 ₃₂ 9 ₆₅ 44 ₇ 4 _{57 KFJ} 4 ₁₂₁ 4.

₆ 098 ₁ 88 ₃₁₁ 8 ₃₂ 99 ₃₆ 9 ₁ 88 ₃₁ 0 8 ₃₂ 98 _{77 577 KFJ75 1215} .

98 ₆₂ 9 9 ₆ 9 88 ₃₁₃ 8 ₃₃ 0 ₁ 888 ₁₁ 88 ₃₁₂ 8 ₃₃ 00 _{57 KFJ} 4 ₁₂₁₆ .

89 89 ₃₃₂ 9 88 ₃₁ 8 ₃₃ 0 ₃₁₁₂₁ 88 ₃₁ 8 ₃₃ 0 ₂₅ 4 ₅ 4 ₅ A _IL57 4 ₁₂₁₇ .

| _{|| |||1} 8 ₂ 09 ₁₃ 9 88 ₃₁ 8 ₃₃ 0880 ₃₁ 88 ₃₁₆ 8 ₃₃ 0 _{5 55} 4 _{75 KFK7} 4 ₁₂₁ 8.

₁ 08 _{6 1} 09 88 ₃₁ 9 8 ₃₃ 08 ₁ 88 ₃₁ 8 8 ₃₃ 0 ₆ 4 ₇₅ 4 ₅₅ 4 ₇ A _IL7 4 _{55 121} 9.

, _τζ

₂₆₆ 8 _{2 26632} 9 ₂ 88 ₃₂₁ 8 ₃₃ 099 ₆₃₁ 88 ₃₂ 0 8 ₃₃ 08 ₅ 4 A _{IL75 122} 0.

₁ 8 ₁₂₆ 90 88 ₃₂₃ 8 ₃₃₁₁ 99 ₆₁ 88 ₃₂₂ 8 ₃₃₁ 0 ₇ 44 ₅₇₇ 4 A _IL 44 ₁₂₂₁ .

₃ 00 _{1 3} 00 ₂ 9 ₃ 88 ₃₂ 8 _3313361 88 ₃₂ 8 _3312575 4 ₅ A _I M ₇₅₅ 4 ₁₂₂₂ .

| _{||| 3} 00 ₆ 0 _{6 3} 00 ₆ 88 ₃₂ 8 ₃₃₁₃₆₁ 88 ₃₂₆ 8 ₃₃₁₅ 4 ₅ 4 ₇₅ A _I M ₇₅₇ 4 ₁₂₂₃ .

_{3626 336} 88 ₃₂ 9 8 _3313121 88 ₃₂ 8 8 _3316575 44 ₇ A _I M _{57 122} 4.

₂ 9 ₆₆ 9 ₂ 9 ₂ 88 ₃₃₁ 8 ₃₃₁ 999 ₁ 88 ₃₃ 0 8 ₃₃₁ 8 ₅ 4 ₅ 4 ₇₅ A _JK5 44 ₁₂₂₅ .

889 ₆ 88 ₃₃₃ 8 ₃₃₂₁ 00 ₁₁ 88 ₃₃₂ 8 ₃₃₂ 0 _{7 KF} X4 _{5 1226} .

69 ₆ 8 ₆₁ 88 ₃₃ 8 ₃₃₂₃ 0 ₂ 0 ₂₁ 88 ₃₃ 8 _{3322 5} 4 ₅₇₅ 4 _{5 KF} X ₇ 4 ₁₂₂₇ .

180 ₃ 9 ₁ 88 ₃₃ 8 ₃₃₂ 09 ₂ 0 ₁ 88 ₃₃₆ 8 _{332 5} 4 ⁵ ₅ 4 _{775 KF} X ₇ 4 ₁₂₂ 8.

₁ 8800 ₁ 8 ₆₁₆₁ 88 ₃₃ 9 8 ₃₃₂₂ 008 ₁ 88 ₃₃ 8 8 ₃₃₂₆ ⁷ _{7 KF} X _{5 122} 9.

a ⁶ 9 ² 98 ₆ 9 ₁ 0 ₆₃ 88 ₃₁ 8 ₃₃₂ 98 ₂ 9 ₃₁ 88 ₃ 0 8 ₃₃₂ 8 ₁₂₃ 0 ⁷ 4 _KFZ7 4.

¹⁶ 90 ₁₆₂₃ 9 88 ₃₃ 8 ₃₃₃₁ G8 ₁ 8 ₁ 88 ₃₂ 8 ₃₃₃ 04 ⁵ ₅ 4A _K 4 ₅ 4 ₁₂₃₁ .

²¹ 99 ⁶ 9 ₂₁ 9 ₃₂₂ 88 ₃ 8 _33336231 88 ₃ 8 ₃₃₃₂ 4 ₇ 4 ₅ A _I N ₇ 444 ₁₂₃₂ .

m

σι ¹ 90 ₃ 9 ² 88 ₃ 8 ₃₃₃ G ₂ 9 ₃₁ 88 ₃₆ 8 ₃₃₃ ⁵ 44 ₅₅₅ 4 _{75 K} A ₇₇ 44 ₁₂₃₃ .

¹⁶ 9 ²⁶⁶ ₁₆ 90 ³ 09 88 ₃ 9 8 ₃₃₃ G9 ₂₁ 88 ₃ 8 8 ₃₃₃₆ ⁵ 4 _{7 K} A4 ₇₅ 4 ₁₂₃ 4.

² 8 ¹ ₂ 9889 88 ₃₁ 8 ₃₃₃ 9G ₁₁₂₁ 88 ₃ 0 8 ₃₃₃ 8 ⁷⁷⁷ 4 ⁷⁷ _{5 K} A _{775 1235} .

^{122 12} 9 88 ₃₃ 8 ₃₃₁ G0 ₂₂₁₁ 88 ₃₂ 8 ₃₃ 0 ⁷ 4 ⁵⁷⁵⁵ ₅ 4A _L75 4 ₁₂₃₆ .

⁶¹ 809980 88 ₃ 8 ₃₃₃ G0 ₂ 0 ₁₂₁ 88 ₃ 8 ₃₃₂ ⁵⁵ ₅₅ 4 _KB5 44 ₁₂₃₇ .

m ■a- ■a- o o o <n <n m o <a- o o m o <n 8 ₃₃₃₃ 88 ₁ 88 ₃₆ 8 ₃₃ ^{16622 16} 88 ₃ 4 ⁷ 44 ⁷⁷ 4 ₅₇ 4 ₅ A _IP 4 ₅ 44 ₁₂₃ 8.

■a- σι ■a- m o o o ■a- o o ■a- ■a- m o

m ¹ 90 ³ 0 ⁶⁶ 88 ₃ 9 8 ₃₃ GC80 ₆₂₃₁ 88 ₃ 8 8 ₃₃₆ 4 ⁷ 4 ⁷⁷ ₅ 4 _{7 K5} 4 ₁₂₃ 9.

^{136631 13} 0 88 ₃₆₁ 8 ₃₃ 9G0 ₂ 9 ₁ 88 ₃₆ 0 8 ₃₃ 8 ⁷⁷⁵ 444 _K D4 ₅ 4 ₁₂ 04. z

Έ

m m o o m o ■a- m m ■a- m m m m m <a- m m

■a- ■a- o o m o

■a- <a- ■a- <a- ■a- <a- ■a- ■a- m m m m m m ■a- <a- ■a-

-

_{1099221080238869336818869283681 KJR57836801064} .

_{928689 886901261 8869 745 83683 KJR44 83682 1047} .

_{112201 10999 886961191 8869647 8368 KJR7 8368 108544} .

1 _{1633961292901 88698 444 4454 8368} A _{JY5 83686 10974} .

6 _{332611 88011061 8800 444 44577 83689} A _{JZ457 83688} .

6 _{336612 8803328131 8802 447 44457 83691} A _{JZ7 83690} .

6 _{3316116 880321 880 444 44575 83693} A _{JZ77774 83692} .

6 _{3336118 88011 8806 444 44577 8369} A _{JZ47447 836954} .

_{3 1800 8809S0661 88087447 8369 KJ557 836967} .

_{126 1321 8811S69081 88105777 83699 KJ47 83698} .

| _{113l 881381891 88127 8301 KJU47 830077} .

1 _{8 369 881831331 881 555775 8303 KJU74 830277} .

_{111668 108901 881011881 881677 830} A _K A _{7 8307574} .

_{962910 881908221 881877 830} A _K A _{57 8306777} .

_{263 263222 882100911 8820747457 8309} A _K A _{77 8308 120774} .

_{122 882300301 882247 8311 KJ} V _{77 8310 121774} .

_{81069 882281 8824 5475 8313 KJ} V _{45774 8312 122774} .

_{13089 1096 882} G _{8881 8826577 831} A _{N447 831 12375744} .

1 _{1| 1|1030 203 882960681 8828 457 831 KJ} W _{57 8316 1277744} .

0 _{29 203 883168311 8830 447 8319 KJ} W _{47 8318 127745} .

_{319 2963 8833160221 88324547 8321 KJX7 8320 126774} .

_{12888 123088 883091 883475 8323 KJX57774 8322 127747} .

_{12888 123088 8832831 8836477 832 KJX457 832 12875744} .

1 _{11111 90 6823 88390321 8838477 832 KJX447 8326 1297774} .

_{12888 123088 88161631 880474 8329 KJX774 8328 130774} .

_{12888 123088 8836261 882474 8331 KJX5774 8330 131774} .

_{12888 123088 8888121 884745 8333 KJ} W _{7744 8332 132774} .

_{12888 123088 8806661 8864747 833 KJX474 833 13375744} .

1 _{11| 1| 12888 123088 889801 888474 833 KJ} W _{75774 8336 1377744} .

_{3393 329 88110331 88057775 8339 KJX775 8338 137745} .

₁₂₈ ¹ _{122981 88301 8824775 831 KJX544475 830 13674744} .

| _| ³³ _{33 88261 88} 7 ⁵ _{57755 833 KJX554754 832 13747447} .

a ⁶⁸⁹ _{318 88 8309281 886 83 138} ⁴⁵ _{47757745 KJZ5757444} .

³⁰⁰⁹²¹ _{398860 889 888} ⁵ _{475 8375 836 139747744}

1 ⁹⁶⁰ _{61 886136131 8860} ⁴⁷ _{4777 839 KJZ57 838 10747444} .

9 ⁹ ₈₀ ³ _{8863381 8862} ⁷⁵⁵ _{747 831 KJZ4777 830 11757544} .

0 ⁶⁸¹¹⁰ _{8866361 8866} ^{5 475} _{77 83 KJZ477 83 1375575444} .

1 ^2306821198 _{8869 C} O _{168101 8868} ^{54 54} _{7 83D7 836 175775444} .

1 ^362232616 _{88109681 880} ^{45 4} _{77 839 KK} A _{577 838 17575445} .

^{39623 30} _{88320631 882} ⁷⁵⁴ _{77 8361 KK} A _{577 8360 167744} . o a a a a a a a s 3 a £ S a 3 a a ∞ a a a a a ∞ a S a a a a a ₁ ^{12888 123088} a _{88361 88} ⁴ _{775 8363 KK} A _{445774 8362 177447} . a

1 ¹³³⁹² _{88033011 886} ^{5447 577} _{777 836} A _{KB77 836 18757444} . en

σι

z

Έ

a

1 ■a- 3 3 3 3 3 1 § ∞ s s s s 3 8 3 3 3 3 3 ∞ 3 s § ¾ R a s § 3 ft

-

S a a ■a- a a a a

₆₁₂ 9 ₆₁₃ 0 ₂ 89 ₂₃ 9 C ₆₁₁ 89 ₂₃ 8 ₅₇₇ 8 _22RZ575 8 ₂₂₆₁₆ 94 ₇ 4 ₇ .

₁₂₃ 0 89 ₂₁ C _S1 9 ₆₃₁₁ 89 ₂ 04 8 ₂₂ 9 _B 4 8 ₂₂ 8 ₁₆ 8044.

_{1123 1112} 9 89 ₂₃ C _S C ₂ 8 ₁ 89 ₂₂₅₅ 44 8 ₂₃₁₇₇ 44 8 ₂₃ 0 ₁₆ 8 ₁ 44.

_{1122 111} 00 ₆ 89 ₂ C _S3 0 ₃ 9 ₁ 89 ₂ 4 ₇ 4 ₅ 8 ₂₃₃ D ₇ 44 8 _{232 16} 8 ₂ 44.

_{12663 12322} 89 ₂ C _S1 9 ₁ 89 ₂₆ 444 ₇ 8 ₂₃ D ₅₇₅ 4 8 _{23 16} 8 ₃ 4 ₅ 44.

_{1266 1232} 89 ₂ 9 C _S C8 ₆₁₆₁ 89 ₂ 8 ₅₇ 444 8 ₂₃₅ 4 8 _{236 16} 84 ₇ 44.

₁₂₆ 88 ₁₂₃ 89 ₂₁ C _S331 89 ₂ 0444 ₇₅ 8 ₂₃ 9A ₇₅ 4 ₅ 8 ₂₃ 8 ₁₆ 844 ₅ .

_{1266 12326} 89 ₂₃ C _S21 8 ₁ 89 ₂₂ 4 ₇ 4 ₅ 8 ₂₁ D ₅₅₅ 8 ₂ 04444.

₁₃ 0 _{33 12} 808 ₃ 89 ₂ C _S 80 ₆₁₂₁ 89 ₂₅₅₅ 8 _23B5 4 8 _{22 16} 84444 ₇ .

₁₂ 0 ₆ 0 ₁₂₃ 8 ₁ 9 89 ₂ C99 ₂₂₁ 89 ₂₆₅₅₇ 8 _2RZ75 8 ₂ 44 ₅ 444.

₂₂ 009 ₂₁ 9 ₂₆ 8 89 ₂ 9 C8 ₁₁ 8 ₁₁ 89 ₂ 8 ₅₅ 8 _2RZ5 8 _{26 16} 8944 ₇ 44.

₂₂₂ 9 ₃ 0 ₂₂ 0 ₆ 8 89 ₂₆₁ C _S6 0 ₂₁ 89 ₂₆ 0 ₇ 8 ₂ 9 _B5 4 8 ₂ 8 ₁₆ 904444.

₂₂₂ 99 ₁ 99 ₃ 8 89 ₂₆₃ 89 ₆₁ 89 ₂₆₂ 8 _{21 K} NX ₇ 4 8 ₂ 0 ₁₆ 9 ₁ 4 ₅ 4 ₅ .

₂₂ 0 ₃ 88 ₂₁ 9 ₁ 89 ₂₆ C ₆ 9 ₆₁ 89 ₂₆ 4 ₇₅ 8 _23RZ 4 ₇ 4 8 _{22 16} 9 ₂ 4 ₅ 4 ₅ .

_{11226 11} 00 ₁₂ 89 ₂₆ C _S 9 ₁ 8 ₁₁ 89 ₂₆₆ 4 ₇ 8 ₂ D4 8 _{2 16} 9 ₃ 4 ₅₅ 4 ₅ 4.

30 ₂₆₆ 89 ₂₆ 9 C _S C ₁ 0 ₁ 89 ₂₆ 8 4 ₇₇ 44 8 ₂ 4 ₅₇ 8 _{26 16} 94 ₅₇ 4 ₅ 4.

₂ 0 _{2 222} 0 89 ₂₁ C8 ₆₆₁ 89 ₂ 0 ₅ 4 ₅₅₅₇ 8 ₂ 9 _RZ5 4 ₇ 8 ₂ 8 ₁₆ 94 ₅ 4 ₅₅ .

₁₂₆ 0 ₁₂₃₁ 8 89 ₂₃ C _S1 98 ₁ 89 ₂₂₅₇ 4 ₇ 8 ₂₆₁ D ₅ 4 ₇ 8 ₂₆ 0 ₁₆ 9 ₆ 44.

| _{| 11111 6113} 8 ₆₁₁ 88 ₆ 89 ₂ C _S C98 ₂₁₁ 89 ₂ 4 ₇₅ 8 ₂₆₃₇₇ 4 8 _{262 16} 944 ₇ .

_{11221 111} 0 ₁ 0 89 ₂ C _S6313 8 ₁ 89 ₂₆₅₇₇ 8 ₂₆ D ₇ 8 _{26 16} 984 ₅ 44.

₂₂ 08 _{13 21} 9 ₂ 89 ₂ 9 C _S1 09 ₆₃₁ 89 ₂ 8 ₅₇₇ 8 ₂₆ A ₇ 8 _{266 16} 994 ₇ 4.

_{1266 1232} 89 ₂ 8 ₁ C _S21 8 ₁₁ 89 ₂ 80 ₅₇ 44 8 ₂₆ 9D4 8 ₂₆ 8 ₁ 0044 ₇ .

₁₂ 80 ₁₂₃₂ 8 89 ₂ 8 ₃ C _S C ₁₁₂₁₁ 89 ₂ 8 ₂₅₇₅ 8 ₂₁ 4 8 ₂ 0 ₁ 0 ₁ 4 ₇ 4 ₇₇ .

1 _1111112 89 ₂ 89 ₂ 8 C _S C0 ₃ 8 ₆₁ 89 ₂ 8 4 ₅ 44 4 ₅ 8 ₂₃₅ 4 8 _{22 1} 0 ₂ 4 ₇ 4 ₇₇ .

3 ₂₂ 8 ₃ 89 ₂ 8 C _S62231 89 ₂ 8 ₆ 44 ₅₅ 4 ₇ 8 _2B7 8 _{2 1} 0 ₃ 4 ₇₅ 4 ₇ 4 ₇ .

₃₆ 08 ₃₃₃₆ 89 ₂ 89 C _S2 8 ₁₆₁ 89 ₂ 88 ₅₅₅₅ 8 _2B5 8 _{26 1} 04 ₇₇ 4 ₇₇ 4.

_{11226 11} 00 ₁₃ 89 ₂ 9 ₁ C _S161 89 ₂ 90 ₅ 8 ₂ 9 _E 444 8 ₂ 8 ₁ 04 ₇ 4 ₇₇₅ .

1 ₃₂ 9 ₁ 00 89 ₂ 9 ₃ C _S C ₃₁₁₁₁ 89 ₂ 9 ₂₅₇ 8 ₂ 8 ₁ 4 8 ₂ 80 ₁ 0 ₆ 44 ₇ .

| ₁₁₁₁₁ 0 ₁ 8 ₂ 89 ₂ 9 CQ ₁₆₁ 0 ₁ 89 ₂ 9 ₅ 4 ₇ 4 ₅₇₅ 8 ₂ 8 ₃ T ₇ 4 8 ₂ 8 _{2 1} 044 ₇₇ .

_{16 12} 89 ₁ 89 ₂ 9 ₁₃₃₁ 89 ₂ 9 ₆ 4 ₇₇₇ 8 ₂ 8 _K NY ₇₅ 8 ₂ 8 ₁ 084 ₅ 44 ₇ . _{1 TTZ}

2 ₁ ³ 0 ₁ 8 89 ₂ 9998 ₁ 89 ₂ 98 ₅ 4 ₅ 4 8 ₂ 8 _K NY ₅₅₅ 8 ₂ 8 _{6 1} 094 ₇ 4 ₇ .

₁₃ 29 ³ ₁₃ 0 ₃ 89 ₃ 0 ₁₆₁ 9 ₁ 89 ₃ 00 ₇ 4 ₇₅₇ 8 ₂ 89 A _K V44 8 ₂ 88 ₁₁ 044 ₇ .

a 30 ³ 8 ¹ ₃ 0 ₃₂₂ 89 ₃ 0 ₃ 8 ₂ 9 ₁₆ 8 ₁ 89 ₃ 0 ₂ 8 ₂ 90 ₁₁₁ 444 ₅ 4 A _K V ₅ 4 ₇ 4 ₇ .

_ZZZ

| ³³²² ₁ 0 ₁ 9 89 ₃ 0O0 ₂ 8 ₁₁ 89 ₃ 0 ₅ 8 ₂ 9 _{3 K} A ₇ 4 8 ₂ 9 _{2 112} 44 ₇ . _{1 TTZ}

³⁶ 88 ⁶¹² ₃₆ 8 ₆₆₁₁ 89 ₃ 0909 ₁ 89 ₃ 0 ₆₇ 8 ₂ 9 A _K V ₇₇ 8 ₂ 9 ₁₁₃ 4 ₅ 44 ₇ .

² 8 ¹³⁶ ₂ 98 ₆ 0 89 ₃ 09OC ₆ 9 ₃₁₁ 89 ₃ 08 ⁷ ₇ 8 ₂ 9 _K7 8 ₂ 9 _{6 11} 4 ₇ 4 ₇ 4.

³²¹ 0 ³ ₃₁ 8 ⁶ 8 89 ₃₁₁ O89 ₂₁₁ 89 ₃₁ 0 ⁷⁵ 8 ₂ 99 _KE 4 8 ₂ 98 ₁₁ 44 ₇₅ .

18 ¹ 9 ¹¹⁶ 9 89 ₃₁₃ O8 ₂ 8 ₁ 89 ₃₁₂ ^{7 755} 8 ₃ 0 _{1 KE} 44 8 ₃ 00 ₁₁₆ 44 ₇ .

8 ¹³¹ 09 8 ¹¹¹⁶ 89 ₃₁ O80 ₆₁ 89 ₃₁ ⁷ ₅ 8 ₃ 0 _{3 KE} 4 ₅ 4 8 ₃ 0 _{2 11} 44 ₇₇ .

¹² 0 ^{31 11} 8 ²³ 89 ₃₁ O00 ₁ 89 ₃₁₆ ⁷⁵ ₇ 8 ₃ 0 _KE7 44 8 ₃ 0 ₁₁ 84 ₅ 44 ₇ .

_ZZZ

■a- <n σι o <n ■a- ¹ 909 ^{13 1} 8899 ⁶ 89 ₃₁ 9O9 ₆₆ 8 ₁₁ 89 ₃₁ 8 8 ₃ 0 _KE 8 ₃ 0 _{6 11} 94 ₇ 4 ₇ . ■a- <n o o o o o o o o o o o o σι o o o o o o o o o o o o o o o ■a- ■a- o 90 ³ 8 ⁶¹ 89 ₃₂₁ GO9 ₁₆ 0 ₃₁ 89 ₃₂ 0 ³ 8 ₃ 09 ⁷⁷⁷ A 8 ₃ 08 ₁₂ 044 ₇ .

³ 88 ³⁶ 0 89 ₃₂₃ G09 ₂₃ 8 ₁ 89 ₃₂₂ ⁵⁷⁵ 4 8 ₃₁₁ A4 8 ₃₁ 0 ₁₂₁ 44 ₇ . z

Έ

o <n m m m o m m o m m o ■a- m o m o o o m m o o o o o o o ■a- n ■a- ■a- ■a- o o o ■a- o o ■a- o o ■a- <n o ■a- o ■a- ■a- ■a- o o ■a- ■a- ■a- ■a- ■a- ■a- ■a- ■a- ■a- ■a- ■a-

-

[001673] Table 16: The Lamassu Defense System and Components Thereof

[001674] This table is presented in landscape orientation. Due to the number of columns, the table has been split into parts. Part A includes the first set of columns and therefore should be place to the left of subsequent parts (Part B and where relevant Part C). To avoid any doubt, the rows of the table in each part line up once the tables are placed together.

Table 16 (Part A)

Table 16 (Part B)

[001675] Table 17: The Kiwa Defense System and Components Thereof

[001676] This table is presented in landscape orientation. Due to the number of columns, the table has been split into parts. Part A includes the first set of columns and therefore should be place to the left of subsequent parts (Part B and where relevant Part C). To avoid any doubt, the rows of the table in each part line up once the tables are placed together.

Table 17 (Part A)

Table 17 (Part B)

[001677] Summary Examples 1-8

[001678] Examples 1-8 significantly expand the known arsenal of defense systems used by prokaryotes for protection against phages. This knowledge leads to broader understanding of the global defense capabilities of bacteria, and indeed with our results the content of defense islands now becomes much clearer (Figures 4A, 4D, 5A, 6A, 7A). However, the results do not yet expose the complete set of prokaryotic defense systems. Out of the 28 candidate systems tested, 10 were verified as anti-phage defense systems and an additional one showed protection against plasmids. The remaining 17, although not verified by the experiments, do not necessarily represent false predictions, as exemplified by the fact that only 50% of our positive control systems showed defense in the assays. Lack of activity could possibly stem from incompatibility of some tested systems with the recipient organism (E. coli or B. subtilis), or due to pseudogenization of some systems in their genome of origin. Some systems can be highly specific against a certain type of phages or foreign genetic element not represented in the phage set, while others may work in a specific condition not tested in the study. Clade- specific potential systems such as those found only in archaea or cyanobacteria (Table 3) were not tested in this study and can represent a more specialized defense arsenal unique only to a subset of organisms. Finally, some true systems may have been missed by falsely tagging them as belonging to the "mobilome" (Table 2), as mobile genetic elements have intimate evolutionary relationship with defense systems.

[001679] While certain features have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the disclosure presented herein.